Clustering O 0 0.00020599130948539823
of O 0 8.139979399857111e-06
missense O 0 6.756704533472657e-05
mutations O 0 1.277193587156944e-05
in O 0 5.94102584727807e-06
the O 0 4.41610136476811e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.999997615814209
telangiectasia I-Disease 1 1.0
gene O 0 5.9104007959831506e-05
in O 0 4.489894308790099e-06
a O 0 2.745516576396767e-05
sporadic B-Disease 1 0.9979451298713684
T I-Disease 1 0.9999994039535522
- I-Disease 1 0.9987290501594543
cell I-Disease 1 0.999358594417572
leukaemia I-Disease 1 0.9999904632568359
. O 0 2.758931259450037e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
telangiectasia I-Disease 1 1.0
( O 1 0.9940419793128967
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.255420892855909e-07
is O 0 8.841330156883487e-08
a O 0 3.615997741235333e-07
recessive B-Disease 0 6.738828687957721e-06
multi I-Disease 0 0.028206147253513336
- I-Disease 1 0.5971297025680542
system I-Disease 0 3.3483982406323776e-05
disorder I-Disease 0 0.1588025987148285
caused O 0 2.061054328805767e-05
by O 0 1.6198264063405077e-07
mutations O 0 1.8061507489619544e-07
in O 0 4.336619667810737e-07
the O 0 9.849640036918572e-07
ATM O 0 3.657202614704147e-05
gene O 0 2.2374661057256162e-06
at O 0 3.211996590835042e-05
11q22 O 0 0.0003162797656841576
- O 0 5.3540014050668105e-05
q23 O 0 0.00014152507355902344
( O 0 1.644986468818388e-06
ref O 0 5.8285593695472926e-05
. O 0 5.771902351625613e-07
3 O 0 4.138807526032906e-06
) O 0 3.1267381928046234e-06
. O 0 9.44774456002051e-06

The O 0 7.605459541082382e-05
risk O 0 6.093285992392339e-05
of O 0 2.0220601072651334e-05
cancer B-Disease 1 0.9962379932403564
, O 0 3.038517434106325e-06
especially O 0 3.6849583011644427e-06
lymphoid B-Disease 1 0.932813823223114
neoplasias I-Disease 1 0.5713526606559753
, O 0 2.127156221831683e-06
is O 0 7.866917144383478e-07
substantially O 0 5.155645339982584e-06
elevated O 0 0.0017750338884070516
in O 0 9.181729183183052e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.6622357179585379e-06
and O 0 2.729345283114526e-07
has O 0 7.394170324914739e-07
long O 0 8.756909437579452e-07
been O 0 5.970163670099282e-07
associated O 0 8.253970236182795e-07
with O 0 1.200093265651958e-06
chromosomal O 1 1.0
instability O 1 1.0
. O 0 0.00031093641882762313

By O 0 2.591427073639352e-05
analysing O 0 0.00029329454991966486
tumour B-Disease 1 1.0
DNA O 0 4.660550257540308e-05
from O 0 3.349320877532591e-06
patients O 0 9.572653425493627e-07
with O 0 3.238646684167179e-07
sporadic B-Disease 1 0.7788584232330322
T I-Disease 1 0.9999370574951172
- I-Disease 0 0.2058096081018448
cell I-Disease 1 0.9538209438323975
prolymphocytic I-Disease 1 0.9123480916023254
leukaemia I-Disease 1 0.9999977350234985
( O 0 2.3077880541677587e-05
T B-Disease 1 0.5741312503814697
- I-Disease 0 0.00012930540833622217
PLL I-Disease 0 0.0002674210991244763
) O 0 8.728164146987183e-08
, O 0 4.1298189756844295e-08
a O 0 1.1631509977405585e-07
rare O 0 3.5553907196117507e-07
clonal B-Disease 0 3.380156704224646e-05
malignancy I-Disease 0 5.187098213355057e-05
with O 0 1.231984043670309e-07
similarities O 0 4.3633480117932777e-07
to O 0 2.902240794355748e-07
a O 0 1.7428305000066757e-05
mature B-Disease 0 0.0003046188212465495
T I-Disease 1 0.8927517533302307
- I-Disease 0 0.0013399769086390734
cell I-Disease 0 0.011244275607168674
leukaemia I-Disease 1 0.9808972477912903
seen O 0 6.085974291636376e-06
in O 0 2.3602910914632957e-06
A B-Disease 1 0.9994114637374878
- I-Disease 1 0.7372811436653137
T I-Disease 1 0.6899963021278381
, O 0 7.407652447000146e-08
we O 0 1.3458495651264002e-08
demonstrate O 0 3.427203054684469e-08
a O 0 1.4150545268876158e-07
high O 0 3.6876826925436035e-07
frequency O 0 1.8765099696338439e-07
of O 0 4.202398145025654e-07
ATM O 0 3.009919419127982e-05
mutations O 0 3.3552707918715896e-06
in O 0 2.640639831952285e-05
T B-Disease 0 0.20367296040058136
- I-Disease 0 0.002274180995300412
PLL I-Disease 0 0.003870410844683647
. O 0 1.2343741218501236e-05

In O 0 1.526332926005125e-05
marked O 0 1.5455856555490755e-05
contrast O 0 2.3469469851988833e-06
to O 0 2.2520997333685955e-07
the O 0 8.933661206356192e-07
ATM O 0 2.410079468972981e-05
mutation O 0 1.4038887456990778e-06
pattern O 0 1.664465708017815e-05
in O 0 7.307410214707488e-06
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999986886978149
T I-Disease 1 0.9999986886978149
, O 0 3.2133513627741195e-07
the O 0 9.812065826508842e-08
most O 0 3.244229063170678e-08
frequent O 0 1.1926890408631152e-07
nucleotide O 0 5.858907456968154e-07
changes O 0 5.741226161148916e-08
in O 0 1.5058783731092262e-07
this O 0 3.8102106714177353e-07
leukaemia B-Disease 0 0.0007158591179177165
were O 0 2.2379397250915645e-06
missense O 0 4.4138781959190965e-05
mutations O 0 1.1828534297819715e-05
. O 0 2.203594340244308e-05

These O 0 4.2528613448666874e-06
clustered O 0 1.381698439217871e-05
in O 0 1.1570057267817901e-06
the O 0 7.14268480805913e-07
region O 0 6.57642317491991e-07
corresponding O 0 6.777278258596198e-07
to O 0 2.837547583567357e-07
the O 0 1.595054072822677e-06
kinase O 0 6.072106316423742e-06
domain O 0 1.4332637192637776e-06
, O 0 1.7104927962918737e-07
which O 0 1.0335674005546025e-07
is O 0 9.886797158742411e-08
highly O 0 2.0050694615747489e-07
conserved O 0 3.6539773873300874e-07
in O 0 5.988188149785856e-07
ATM O 0 6.742390542058274e-05
- O 0 6.78128844810999e-06
related O 0 7.974868481142039e-07
proteins O 0 2.484966614701989e-07
in O 0 9.37444838200463e-07
mouse O 0 5.419980880105868e-06
, O 0 4.591001356857305e-07
yeast O 0 3.3650508157734293e-06
and O 0 3.1195270366879413e-06
Drosophila O 0 0.00020744826178997755
. O 0 8.881452231435105e-06

The O 0 0.00021193687280174345
resulting O 0 0.00023204211902339011
amino O 0 7.887014362495393e-05
- O 0 6.680846126982942e-05
acid O 0 3.3434012038924266e-06
substitutions O 0 7.331200890803302e-07
are O 0 1.0640480496704185e-07
predicted O 0 1.6496666148668737e-06
to O 0 7.146160641013921e-08
interfere O 0 7.896735496615293e-07
with O 0 3.562820722891047e-07
ATP O 1 0.9856517314910889
binding O 0 2.0155307538516354e-06
or O 0 1.2879627320216969e-06
substrate O 0 2.2660982722300105e-05
recognition O 0 1.2405520465108566e-05
. O 0 1.7826734620030038e-05

Two O 0 1.742323729558848e-05
of O 0 1.3782043424725998e-05
seventeen O 0 7.479015766875818e-05
mutated O 0 0.0001806001819204539
T B-Disease 1 0.5083435773849487
- I-Disease 0 0.00010679576371330768
PLL I-Disease 0 0.00015335518401116133
samples O 0 4.442822501005139e-07
had O 0 6.29808653229702e-07
a O 0 1.5420464478665963e-06
previously O 0 5.563510512729408e-06
reported O 0 4.6206507249735296e-05
A B-Disease 1 0.9999967813491821
- I-Disease 1 0.9999961853027344
T I-Disease 1 0.999996542930603
allele O 0 8.01288042566739e-05
. O 0 1.3796588973491453e-05

In O 0 2.2466312657343224e-05
contrast O 0 5.3264384405338205e-06
, O 0 5.74663715724455e-07
no O 0 2.0492032604124688e-07
mutations O 0 3.514069817356358e-07
were O 0 5.291305456012196e-07
detected O 0 1.7680049495538697e-06
in O 0 2.345648510981846e-07
the O 0 5.961214242233837e-07
p53 O 0 3.426263219807879e-06
gene O 0 6.318227292467782e-07
, O 0 1.8022004155682225e-07
suggesting O 0 6.76493186801963e-07
that O 0 7.044393157684681e-08
this O 0 8.515621630067471e-07
tumour B-Disease 1 1.0
suppressor O 1 0.9999892711639404
is O 0 3.0208039447643387e-07
not O 0 6.301150534682165e-08
frequently O 0 1.444533666017378e-07
altered O 0 7.6441364171842e-07
in O 0 5.679827950189065e-07
this O 0 1.7689883407001616e-06
leukaemia B-Disease 1 0.9995142221450806
. O 0 2.2690608602715656e-05

Occasional O 0 6.268598372116685e-05
missense O 0 0.00011756778985727578
mutations O 0 1.1444162737461738e-05
in O 0 3.5277867027616594e-06
ATM O 0 8.305996743729338e-05
were O 0 1.046851821229211e-06
also O 0 5.005294383408909e-07
found O 0 4.013943737390946e-07
in O 0 2.8351178116281517e-06
tumour B-Disease 1 1.0
DNA O 0 0.00013665635196957737
from O 0 5.928528935328359e-06
patients O 0 1.8821820049197413e-06
with O 0 1.172306610897067e-06
B B-Disease 1 0.9642717838287354
- I-Disease 1 0.9126620292663574
cell I-Disease 1 0.9998428821563721
non I-Disease 1 0.9516052007675171
- I-Disease 1 0.9654873609542847
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.8317756652832031
( O 0 3.926396857423242e-06
B B-Disease 0 4.683700899477117e-05
- I-Disease 0 6.72226906317519e-06
NHL I-Disease 0 1.7842693296188372e-06
) O 0 1.1663323107313772e-07
and O 0 2.509041792109201e-07
a O 0 4.606760285241762e-06
B B-Disease 0 8.02612557890825e-05
- I-Disease 0 7.727171760052443e-05
NHL I-Disease 0 3.65054038411472e-05
cell O 0 0.00011472270853118971
line O 0 7.408132660202682e-05
. O 0 8.102973879431374e-06

The O 0 2.817936365318019e-05
evidence O 0 4.965764219377888e-06
of O 0 1.5986099697329337e-06
a O 0 1.6711319403839298e-06
significant O 0 9.88034685178718e-07
proportion O 0 2.3445243186870357e-06
of O 0 6.5028648350562435e-06
loss O 0 0.004327249713242054
- O 0 3.3931042707990855e-05
of O 0 6.817393114033621e-06
- O 0 5.057508587924531e-06
function O 0 1.2897569945380383e-07
mutations O 0 5.038599226736551e-08
and O 0 4.6446977819414315e-08
a O 0 4.98456870445807e-07
complete O 0 6.936805903023924e-07
absence O 0 2.5815722892730264e-06
of O 0 6.375097427735454e-07
the O 0 4.3706447172553453e-07
normal O 0 2.9697000059059064e-07
copy O 0 4.3787886738755333e-07
of O 0 3.2986108067234454e-07
ATM O 0 1.0645290785760153e-05
in O 0 1.390421715541379e-07
the O 0 2.948495421151165e-07
majority O 0 1.1397532517776199e-07
of O 0 2.6594943847157992e-06
mutated O 0 4.2960797145497054e-05
tumours B-Disease 1 0.9999998807907104
establishes O 0 2.5000013920362107e-05
somatic O 0 0.00013340156874619424
inactivation O 0 0.17305582761764526
of O 0 1.2234479527251096e-06
this O 0 9.56973522647786e-08
gene O 0 1.599447188027625e-07
in O 0 2.603589450700383e-07
the O 0 7.684923275519395e-07
pathogenesis O 0 6.221076182555407e-05
of O 0 3.4393026453471975e-06
sporadic B-Disease 0 0.0050752912648022175
T I-Disease 1 0.9934976100921631
- I-Disease 0 0.00047674259985797107
PLL I-Disease 0 0.00044472553418017924
and O 0 1.1916613118501118e-07
suggests O 0 2.3272792759598815e-07
that O 0 7.759954456787455e-08
ATM O 0 1.084517043636879e-05
acts O 0 1.3231501725385897e-06
as O 0 3.970680154452566e-06
a O 0 0.00012793215864803642
tumour B-Disease 1 1.0
suppressor O 1 0.9999971389770508
. O 0 5.9539146604947746e-05

As O 0 1.754818731569685e-05
constitutional O 0 7.376207122433698e-06
DNA O 0 6.091438081057277e-06
was O 0 1.1264525710430462e-05
not O 0 1.4561716454863927e-07
available O 0 9.780543308579581e-08
, O 0 2.5737696773830976e-07
a O 0 2.4178427793231094e-06
putative O 0 0.0002546883770264685
hereditary O 1 0.9999133348464966
predisposition O 1 0.9999456405639648
to O 0 5.2844177844235674e-05
T B-Disease 1 0.9998730421066284
- I-Disease 0 0.00032665650360286236
PLL I-Disease 0 0.0001305743062403053
will O 0 3.230354650440859e-08
require O 0 3.139051329981157e-08
further O 0 3.916020432370715e-07
investigation O 0 2.206170620411285e-06
. O 0 8.034489269448386e-07
. O 0 4.442667432158487e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0009271119488403201
kinase O 0 0.00023817922919988632
is O 0 8.037892484935583e-07
involved O 0 2.1193473287439701e-07
in O 0 1.0411096695861488e-07
the O 0 1.1672513977600829e-07
modulation O 0 6.608172498090426e-07
of O 0 2.2657749809695815e-07
the O 0 8.535362781003641e-07
Ca2 O 0 2.297074934176635e-05
+ O 0 7.251524948514998e-06
homeostasis O 0 3.707566065713763e-05
in O 0 7.487893071811413e-06
skeletal O 1 0.9999582767486572
muscle O 0 0.10403593629598618
cells O 0 0.00036294886376708746
. O 0 2.528191907913424e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9975554347038269
DM B-Disease 1 1.0
) O 0 2.149416832253337e-05
, O 0 1.5286299230865552e-06
the O 0 6.674892460978299e-07
most O 0 6.550722559950373e-07
prevalent O 0 0.01731913909316063
muscular B-Disease 1 0.9999991655349731
disorder I-Disease 1 0.9988932013511658
in O 0 3.216869799871347e-06
adults O 0 1.0188557553192368e-06
, O 0 1.2743993238473195e-06
is O 0 1.081944446923444e-06
caused O 0 2.7976237106486224e-05
by O 0 2.010754087677924e-06
( O 0 2.076240889437031e-06
CTG O 0 0.00013980967923998833
) O 0 4.2935545252476004e-07
n O 0 1.4367315088748e-06
- O 0 1.5694732837800984e-06
repeat O 0 5.723136382584926e-07
expansion O 0 6.704673864987853e-07
in O 0 7.969138948737964e-08
a O 0 3.0167475983944314e-07
gene O 0 1.4914601820237294e-07
encoding O 0 3.480390944332612e-07
a O 0 2.566274815762881e-06
protein O 0 6.573033260792727e-06
kinase O 0 7.152615580707788e-05
( O 0 1.2700829756795429e-05
DM B-Disease 1 0.9999998807907104
protein O 0 1.497225366620114e-05
kinase O 0 3.265427585574798e-05
; O 0 6.116330837357964e-07
DMPK O 0 6.11382638453506e-05
) O 0 7.330866225174759e-08
and O 0 4.261864461341247e-08
involves O 0 1.698972624808448e-07
changes O 0 8.034798071321347e-08
in O 0 5.611814799522108e-07
cytoarchitecture O 0 3.0271503419498913e-05
and O 0 2.506272721802816e-06
ion O 0 0.0002493727661203593
homeostasis O 0 0.0018989578820765018
. O 0 3.808272958849557e-05

To O 0 6.2627459556097165e-06
obtain O 0 4.970720056007849e-06
clues O 0 1.7687332729110494e-05
to O 0 4.424957182891376e-07
the O 0 6.959109555282339e-07
normal O 0 1.504339479652117e-06
biological O 0 3.315156163807842e-06
role O 0 2.659824076545192e-06
of O 0 5.199912720854627e-06
DMPK O 0 0.00024501766893081367
in O 0 6.497835443042277e-07
cellular O 0 1.3644949831359554e-05
ion O 0 7.962292329466436e-06
homeostasis O 0 2.3240098016685806e-05
, O 0 2.251721582524624e-07
we O 0 3.855270946928613e-08
have O 0 2.9652955646497503e-08
compared O 0 2.9268616685840243e-07
the O 0 1.6253197543392162e-07
resting O 0 2.3256513941305457e-06
[ O 0 4.294443272101489e-07
Ca2 O 0 1.6555546835661517e-06
+ O 0 6.597310289180314e-07
] O 0 3.3364023011017707e-07
i O 0 1.3996761083490128e-07
, O 0 4.128866137875775e-08
the O 0 1.2757669765051105e-07
amplitude O 0 2.1623732209263835e-06
and O 0 2.1930547688953084e-07
shape O 0 1.2655675618589157e-06
of O 0 3.1549993764201645e-06
depolarization O 0 9.787589806364849e-05
- O 0 1.977553438337054e-05
induced O 0 0.000103273632703349
Ca2 O 0 1.7026939531206153e-05
+ O 0 2.9190418899815995e-06
transients O 0 3.6061317132407567e-06
, O 0 1.6003718883439433e-07
and O 0 6.17300770500151e-08
the O 0 2.4156292965926696e-07
content O 0 1.8395762424461282e-07
of O 0 2.98760073746962e-06
ATP O 0 0.35405808687210083
- O 0 1.4502315025310963e-05
driven O 0 1.022216474666493e-05
ion O 0 6.2698991314391606e-06
pumps O 0 6.866852800158085e-06
in O 0 2.617301788632176e-06
cultured O 1 0.748499870300293
skeletal O 1 0.9998070597648621
muscle O 0 0.00021871742501389235
cells O 0 5.061213414592203e-06
of O 0 2.8342635687295115e-06
wild O 0 4.45797149950522e-06
- O 0 6.23717005510116e-06
type O 0 1.6437336398666957e-06
and O 0 9.681317578724702e-07
DMPK O 0 0.037089068442583084
[ O 0 1.4164672393235378e-05
- O 0 0.0001186811932711862
/ O 0 5.3045121603645384e-05
- O 0 4.066338806296699e-05
] O 0 8.320632332470268e-06
knockout O 0 0.00016170545131899416
mice O 0 7.418156747007743e-05
. O 0 1.284005611523753e-05

In O 0 9.251776646124199e-05
vitro O 0 0.0005366811528801918
- O 0 0.0003392779908608645
differentiated O 0 0.00010668746836017817
DMPK O 0 0.15424396097660065
[ O 0 4.5060231059323996e-05
- O 0 8.278431050712243e-05
/ O 0 4.3876782001461834e-05
- O 0 1.283000619878294e-05
] O 0 1.2547183132483042e-06
myotubes O 0 3.6691744753625244e-06
exhibit O 0 7.550685836577031e-07
a O 0 1.3186833029976697e-06
higher O 0 1.7478221252531512e-06
resting O 0 5.679244168277364e-06
[ O 0 1.1793655403380399e-06
Ca2 O 0 3.1556312478642212e-06
+ O 0 1.5271481288436917e-06
] O 0 7.851641612433014e-07
i O 0 2.543347648042982e-07
than O 0 3.9485779979031577e-08
do O 0 3.863824460381693e-08
wild O 0 5.959724944659683e-07
- O 0 5.193044216866838e-06
type O 0 2.687607093321276e-06
myotubes O 0 1.6091231373138726e-05
because O 0 6.21819680191038e-08
of O 0 1.9974848441961512e-07
an O 0 1.685345978330588e-07
altered O 0 3.1993405968933075e-07
open O 0 7.306854854505218e-07
probability O 0 5.868984658263798e-07
of O 0 2.9336599709495204e-06
voltage O 0 0.00021682462829630822
- O 0 5.429240445664618e-06
dependent O 0 1.7746860976330936e-06
l O 0 3.320620635349769e-06
- O 0 6.843095547992561e-07
type O 0 3.015277627582691e-07
Ca2 O 0 1.626271568966331e-06
+ O 0 2.8165666776658327e-07
and O 0 1.3868354642454506e-07
Na O 0 5.956888344371691e-06
+ O 0 1.0855596883629914e-06
channels O 0 1.604989165571169e-06
. O 0 3.902586740878178e-06

The O 0 5.047625018050894e-05
mutant O 0 0.0001030419662129134
myotubes O 0 0.00011930003529414535
exhibit O 0 5.692724243999692e-06
smaller O 0 8.854119073475886e-07
and O 0 5.641639404529997e-07
slower O 0 6.637664228037465e-06
Ca2 O 0 4.707657808467047e-06
+ O 0 7.262877943503554e-07
responses O 0 1.5408512865633384e-07
upon O 0 2.5131896563834744e-07
triggering O 0 3.460038442426594e-06
by O 0 1.8512763233502483e-07
acetylcholine O 0 4.516003627941245e-06
or O 0 6.302532256086124e-07
high O 0 2.4131453756126575e-05
external O 0 4.713290763902478e-05
K O 0 0.00012438144767656922
+ O 0 2.217607107013464e-05
. O 0 9.998233508667909e-06

In O 0 1.4222688150766771e-05
addition O 0 1.8563125649961876e-06
, O 0 4.166197697941243e-07
we O 0 6.780239658610299e-08
observed O 0 1.4592522745715542e-07
that O 0 3.9040944699308966e-08
these O 0 5.514399958883587e-08
Ca2 O 0 4.696079486166127e-06
+ O 0 1.8426786709824228e-06
transients O 0 2.025212779699359e-06
partially O 0 1.4554206018146942e-06
result O 0 1.806595264497446e-07
from O 0 1.3823486710862198e-07
an O 0 1.1230915220039606e-07
influx O 0 1.9677511886584398e-07
of O 0 3.455955095432728e-07
extracellular O 0 2.556967501732288e-06
Ca2 O 0 2.789114660117775e-06
+ O 0 8.134687732308521e-07
through O 0 2.0322211469192553e-07
the O 0 1.213532300425868e-06
l O 0 3.843512786261272e-06
- O 0 1.7143318018497666e-06
type O 0 1.299024120271497e-06
Ca2 O 0 8.017581421881914e-06
+ O 0 1.9906153738702415e-06
channel O 0 9.444285751669668e-06
. O 0 4.963074843544746e-06

Neither O 0 5.846032945555635e-05
the O 0 5.020908247388434e-06
content O 0 1.178624643216608e-06
nor O 0 9.948100796464132e-07
the O 0 4.225473730912199e-07
activity O 0 1.2316098718656576e-06
of O 0 1.3589567515737144e-06
Na O 0 2.8610775189008564e-05
+ O 0 4.484536020754604e-06
/ O 0 7.41496978662326e-06
K O 0 9.905244951369241e-06
+ O 0 3.364906433489523e-06
ATPase O 0 2.8452092010411434e-05
and O 0 2.3133591184887337e-06
sarcoplasmic O 0 9.197467443300411e-05
reticulum O 0 8.39537606225349e-05
Ca2 O 0 4.9130314437206835e-05
+ O 0 1.6936719475779682e-05
- O 0 1.1460654604888987e-05
ATPase O 0 2.342435618629679e-05
are O 0 6.613569780711259e-08
affected O 0 4.3420035922281386e-07
by O 0 1.5326310176533298e-06
DMPK O 0 0.001053493469953537
absence O 0 9.714356565382332e-05
. O 0 2.6726174837676808e-05

In O 0 2.2623884433414787e-05
conclusion O 0 8.645996786071919e-06
, O 0 8.399484840992955e-07
our O 0 4.104009008187859e-07
data O 0 7.433998803207942e-07
suggest O 0 5.733444936595333e-07
that O 0 2.670952881089761e-07
DMPK O 0 0.00014618979184888303
is O 0 2.787774917578645e-07
involved O 0 1.4712345830503182e-07
in O 0 2.839155399669835e-07
modulating O 0 5.186233465792611e-06
the O 0 1.618507781131484e-07
initial O 0 4.956577299708442e-07
events O 0 2.00163242425333e-07
of O 0 2.3617772058059927e-06
excitation O 0 0.0006742769037373364
- O 0 0.04283306002616882
contraction O 0 0.0992373451590538
coupling O 0 1.6206799045903608e-05
in O 0 4.424287908477709e-06
skeletal O 1 0.9321767091751099
muscle O 0 9.545986540615559e-05
. O 0 2.4510511593689444e-06
. O 0 1.0856916560442187e-05

Constitutional O 0 0.0031372373923659325
RB1 O 1 0.9991483688354492
- O 0 0.0004271138459444046
gene O 0 8.189274012693204e-06
mutations O 0 2.6527056888880907e-06
in O 0 1.7614094076634501e-06
patients O 0 9.65921230999811e-07
with O 0 3.7076492276355566e-07
isolated O 0 4.222312418278307e-05
unilateral B-Disease 0 0.0014581081923097372
retinoblastoma I-Disease 1 0.9992768168449402
. O 0 5.544401938095689e-05

In O 0 2.2583230020245537e-05
most O 0 1.6538583622605074e-06
patients O 0 8.642417697046767e-07
with O 0 1.1813800426807575e-07
isolated O 0 5.135055744176498e-06
unilateral B-Disease 0 0.0001506662229076028
retinoblastoma I-Disease 1 0.9987969398498535
, O 0 2.550795670686057e-06
tumor B-Disease 1 0.9630861878395081
development O 0 6.484693244601658e-07
is O 0 5.673407699191557e-08
initiated O 0 2.917592780704581e-07
by O 0 6.934531171509661e-08
somatic O 0 3.280504188296618e-06
inactivation O 0 0.00010623226262396201
of O 0 5.864927743459702e-07
both O 0 1.1082956064001337e-07
alleles O 0 5.213072995502444e-07
of O 0 3.19026253237098e-06
the O 0 3.6693669244414195e-05
RB1 O 0 0.0037725719157606363
gene O 0 1.7695634596748278e-05
. O 0 2.1592702978523448e-05

However O 0 2.112106085405685e-05
, O 0 1.263700710296689e-06
some O 0 8.741925938693385e-08
of O 0 3.57503608938714e-07
these O 0 1.4536878722992697e-07
patients O 0 6.584808147636068e-07
can O 0 1.5499890082537604e-07
transmit O 0 2.6643872843123972e-05
retinoblastoma B-Disease 1 0.999863862991333
predisposition O 1 0.9389557242393494
to O 0 2.002617065954837e-06
their O 0 2.5719148197822506e-06
offspring O 0 4.587843068293296e-05
. O 0 1.6991010852507316e-05

To O 0 4.311812062951503e-06
determine O 0 1.0091220019603497e-06
the O 0 8.392831318815297e-07
frequency O 0 2.3989514374989085e-06
and O 0 3.1827121915739554e-07
nature O 0 9.293418088418548e-07
of O 0 2.8702395411528414e-06
constitutional O 0 9.507967479294166e-05
RB1 O 1 0.7801260352134705
- O 0 1.0579042282188311e-05
gene O 0 5.546958163904492e-07
mutations O 0 3.4294990314265306e-07
in O 0 3.2590958198852604e-07
patients O 0 1.516609557938864e-07
with O 0 4.769831107864775e-08
isolated O 0 1.4500105862680357e-06
unilateral B-Disease 0 1.9500574126141146e-05
retinoblastoma I-Disease 0 0.018935635685920715
, O 0 2.578368594186031e-07
we O 0 3.906821177679376e-08
analyzed O 0 2.2895336826422863e-07
DNA O 0 7.007860745034122e-07
from O 0 1.8653116740097175e-06
peripheral O 0 0.04818394035100937
blood O 0 5.96726022195071e-05
and O 0 1.0081293112307321e-05
from O 0 0.0028484570793807507
tumor B-Disease 1 1.0
tissue O 1 0.9999985694885254
. O 0 0.00012054429680574685

The O 0 7.417802407871932e-05
analysis O 0 2.4191842385334894e-05
of O 0 3.092741462751292e-05
tumors B-Disease 1 0.9999994039535522
from O 0 2.0369941921671852e-05
54 O 0 2.205745295214001e-05
( O 0 1.0970610446747742e-06
71 O 0 7.758963874948677e-06
% O 0 3.856359853671165e-07
) O 0 9.90078063978217e-08
of O 0 5.152177209311049e-07
76 O 0 9.823364962358028e-06
informative O 0 1.633977717574453e-06
patients O 0 1.0376102181908209e-06
showed O 0 2.683887942112051e-06
loss O 0 4.1277667151007336e-06
of O 0 3.70693851436954e-06
constitutional O 0 2.4381342882406898e-05
heterozygosity O 0 0.0009217870538122952
( O 0 1.3294059499457944e-05
LOH O 1 0.9870600700378418
) O 0 4.6557320274587255e-06
at O 0 3.273852416896261e-05
intragenic O 0 0.00034558676998130977
loci O 0 8.416537457378581e-05
. O 0 2.9518218070734292e-05

Three O 0 1.527445601823274e-05
of O 0 8.367389455088414e-06
13 O 0 3.8407764805015177e-05
uninformative O 0 0.011023011989891529
patients O 0 5.464745754579781e-06
had O 0 1.4256569556891918e-05
constitutional O 0 7.757227285765111e-05
deletions O 0 0.00021360120445024222
. O 0 3.052952524740249e-05

For O 0 2.121517354680691e-05
39 O 0 3.677385757328011e-05
randomly O 0 8.127716682793107e-06
selected O 0 1.6077627151389606e-05
tumors B-Disease 1 0.9999998807907104
, O 0 1.9449891624390148e-05
SSCP O 1 0.9956051707267761
, O 0 7.012780770310201e-06
hetero O 0 0.0010064743692055345
- O 0 4.0175866161007434e-05
duplex O 0 0.00014347380783874542
analysis O 0 4.1227758629247546e-07
, O 0 9.577806281413359e-08
sequencing O 0 6.83345035668026e-07
, O 0 1.4629293332291127e-07
and O 0 9.256925181944098e-08
Southern O 0 4.380162579309399e-07
blot O 0 1.1286955668765586e-05
analysis O 0 5.768001187789196e-07
were O 0 1.8574623084077757e-07
used O 0 1.462802430296506e-07
to O 0 2.2636734797742974e-07
identify O 0 1.182213509309804e-06
mutations O 0 4.246508615324274e-05
. O 0 4.942051964462735e-05

Mutations O 0 5.232901094132103e-05
were O 0 4.343388809502358e-06
detected O 0 9.053288522409275e-06
in O 0 1.6958191508820164e-06
21 O 0 3.089806796197081e-06
( O 0 2.530568394831789e-07
91 O 0 3.044936647711438e-06
% O 0 3.5680400856108463e-07
) O 0 3.423032524096925e-07
of O 0 4.521390565059846e-06
23 O 0 0.04132026061415672
tumors B-Disease 1 1.0
with O 0 0.0643850788474083
LOH O 1 1.0
. O 0 0.0001035431123455055

In O 0 2.3356591555057094e-05
6 O 0 1.915534994623158e-05
( O 0 1.2934636970385327e-06
38 O 0 2.0139552816544892e-06
% O 0 2.82627496517307e-07
) O 0 1.342194480002945e-07
of O 0 1.3233369600129663e-06
16 O 0 0.00013167157885618508
tumors B-Disease 1 1.0
without O 0 3.8338490412570536e-05
LOH O 1 0.9999954700469971
, O 0 2.2710534608449962e-07
one O 0 6.100194127611758e-08
mutation O 0 1.0669541694596774e-07
was O 0 2.6442346552357776e-06
detected O 0 1.5614739368174924e-06
, O 0 1.1366162766535126e-07
and O 0 9.172456572059673e-08
in O 0 3.4128399306609936e-07
9 O 0 2.8249025945115136e-06
( O 0 3.97804541307778e-07
56 O 0 2.4120988655340625e-06
% O 0 3.328679269998247e-07
) O 0 1.7351339920423925e-07
of O 0 2.553799276938662e-06
the O 0 0.00011514728976180777
tumors B-Disease 1 1.0
without O 0 2.9939277737867087e-05
LOH O 1 0.9999481439590454
, O 0 1.5890142890384595e-07
both O 0 4.353521987354725e-08
mutations O 0 4.1435049524807255e-07
were O 0 2.3089971818990307e-06
found O 0 5.6364619922533166e-06
. O 0 9.952780601452105e-06

Thus O 0 1.5085593986441381e-05
, O 0 1.0332594229112146e-06
a O 0 4.666364361582964e-07
total O 0 5.009907795283652e-07
of O 0 6.695536853840167e-07
45 O 0 9.852983566815965e-07
mutations O 0 7.083005471031356e-07
were O 0 9.856536280494765e-07
identified O 0 1.5787263691890985e-06
in O 0 3.863014626404038e-06
tumors B-Disease 1 1.0
of O 0 0.0040251282043755054
36 O 0 0.000739321403671056
patients O 0 6.530545942950994e-05
. O 0 2.9933053156128153e-05

Thirty O 0 0.0002797323977574706
- O 0 4.0332604839932173e-05
nine O 0 2.6549203084869077e-06
of O 0 1.5585311530230683e-06
the O 0 6.589143026758393e-07
mutations O 0 1.1278586953267222e-06
- O 0 2.0667584976763465e-06
including O 0 1.3690741695882025e-07
34 O 0 6.124116680439329e-07
small O 0 1.1008817324409392e-07
mutations O 0 1.8977407023612614e-07
, O 0 1.4369902601174545e-07
2 O 0 2.5136927206403925e-07
large O 0 3.419860945541586e-07
structural O 0 3.504376581986435e-05
alterations O 0 1.4607195225835312e-05
, O 0 6.048037448636023e-07
and O 0 3.434244604250125e-07
hypermethylation O 0 5.193541801418178e-05
in O 0 2.4450512228213483e-06
3 O 0 3.127192030660808e-05
tumors O 1 1.0
- O 0 3.061538882320747e-05
were O 0 2.983558147207077e-07
not O 0 2.5542707504655482e-08
detected O 0 4.6184476332200575e-07
in O 0 1.0917938908505675e-07
the O 0 4.6625208938166907e-07
corresponding O 0 5.485689598572208e-06
peripheral O 0 0.026116451248526573
blood O 0 0.00030376671929843724
DNA O 0 0.0002654939016792923
. O 0 3.776148514589295e-05

In O 0 6.82842219248414e-05
6 O 0 6.514299457194284e-05
( O 0 2.412142748653423e-06
17 O 0 5.085346856503747e-06
% O 0 5.159296847523365e-07
) O 0 1.0804497208027897e-07
of O 0 2.551486204538378e-07
the O 0 6.58191993352375e-07
36 O 0 2.7025810140912654e-06
patients O 0 3.343910179864906e-07
, O 0 1.8079705910167831e-07
a O 0 2.7805316449303064e-07
mutation O 0 2.805238068503968e-07
was O 0 1.8715802525548497e-06
detected O 0 3.664991652385652e-07
in O 0 1.5456285495929478e-07
constitutional O 0 7.004159101597907e-07
DNA O 0 4.481371718156879e-07
, O 0 1.6080487341696426e-07
and O 0 7.642358923476422e-08
1 O 0 1.9891017188911064e-07
of O 0 1.6736026964281336e-07
these O 0 3.270478288186496e-08
mutations O 0 2.810824355492514e-07
is O 0 1.5948715770264243e-07
known O 0 3.0282484431154444e-07
to O 0 5.847519801704948e-08
be O 0 1.8026059933617944e-07
associated O 0 5.463529078042484e-07
with O 0 5.196380357119779e-07
reduced O 0 4.7059562348295e-05
expressivity O 0 0.0018643040675669909
. O 0 2.885406320274342e-05

The O 0 1.9398745280341245e-05
presence O 0 4.681372956838459e-06
of O 0 1.7772485989553388e-06
a O 0 1.07877212940366e-06
constitutional O 0 1.9314086330268765e-06
mutation O 0 1.0126534562004963e-06
was O 0 1.3517633306037169e-05
not O 0 1.287741326905234e-07
associated O 0 2.5176947815452877e-07
with O 0 2.7172443850531636e-08
an O 0 2.2443873604061082e-07
early O 0 1.2419681070241495e-06
age O 0 3.738553687071544e-06
at O 0 4.339627412264235e-05
treatment O 0 6.396025855792686e-05
. O 0 2.2700651243212633e-05

In O 0 2.9255797926452942e-05
1 O 0 2.528088225517422e-05
patient O 0 1.232581416843459e-05
, O 0 1.6156869833139353e-06
somatic O 0 0.00020526234584394842
mosaicism O 1 0.5875465869903564
was O 0 3.344619108247571e-05
demonstrated O 0 1.5498811762881815e-06
by O 0 1.5185692348040902e-07
molecular O 0 2.216364691776107e-06
analysis O 0 1.8747802243979095e-07
of O 0 5.322633569448953e-07
DNA O 0 1.5565615285595413e-06
and O 0 9.090005050893524e-07
RNA O 0 6.831438804510981e-05
from O 0 1.6402636902057566e-05
peripheral O 1 0.9573066234588623
blood O 0 0.007062200456857681
. O 0 2.8378059141687118e-05

In O 0 2.8129636120866053e-05
2 O 0 1.745084227877669e-05
patients O 0 1.60583738306741e-06
without O 0 3.8134388091748406e-07
a O 0 1.5220997511278256e-06
detectable O 0 1.549023909319658e-05
mutation O 0 1.481621666243882e-06
in O 0 2.816055712173693e-06
peripheral O 0 0.012861338444054127
blood O 0 1.0556044799159281e-05
, O 0 1.028377482725773e-06
mosaicism O 0 0.0057366942055523396
was O 0 1.5986914149834774e-05
suggested O 0 4.797669816980488e-07
because O 0 4.620989457748692e-08
1 O 0 2.2026166845989792e-07
of O 0 2.8084102154934953e-07
the O 0 8.307480356961605e-07
patients O 0 4.03663716497249e-06
showed O 0 0.0019573557656258345
multifocal O 1 0.9999995231628418
tumors B-Disease 1 1.0
and O 0 3.7256797895679483e-06
the O 0 1.3957001101516653e-06
other O 0 1.3536892140564305e-07
later O 0 2.2154599719215184e-06
developed O 0 3.556099954948877e-06
bilateral B-Disease 0 0.00015556557627860457
retinoblastoma I-Disease 1 0.9194329977035522
. O 0 4.94103878736496e-05

In O 0 3.3472613722551614e-05
conclusion O 0 2.30703972192714e-05
, O 0 2.0366110220493283e-06
our O 0 4.610860457887611e-07
results O 0 5.0715743782348e-07
emphasize O 0 3.3758658446458867e-07
that O 0 1.804425693308076e-07
the O 0 4.600753413797065e-07
manifestation O 0 2.7217392926104367e-05
and O 0 5.124637141307176e-07
transmissibility O 0 5.6230041082017124e-05
of O 0 1.862151407294732e-06
retinoblastoma B-Disease 0 4.554169572656974e-05
depend O 0 2.6438209488333086e-07
on O 0 8.592892868364288e-07
the O 0 2.1265346106247307e-07
nature O 0 1.5729780500350898e-07
of O 0 2.595475336875097e-07
the O 0 2.2234156915601488e-07
first O 0 3.925311773400608e-07
mutation O 0 2.1522869531054312e-07
, O 0 8.650088290096392e-08
its O 0 8.655056404904826e-08
time O 0 8.09861901984732e-08
in O 0 1.4963981698201678e-07
development O 0 5.597468089035829e-07
, O 0 9.790883837013098e-08
and O 0 3.887153710024904e-08
the O 0 1.101904700817613e-07
number O 0 1.0347864787263461e-07
and O 0 6.246845885016228e-08
types O 0 8.449403310351045e-08
of O 0 1.91266826732317e-06
cells O 0 4.268676093488466e-06
that O 0 2.836492285496206e-07
are O 0 1.694312743438786e-07
affected O 0 1.1101083146058954e-06
. O 0 1.1916833955183392e-06
. O 0 5.29972157892189e-06

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
of I-Disease 0 0.00018611941777635366
the I-Disease 0 2.6345929654780775e-05
fifth I-Disease 0 0.00014131321222521365
component I-Disease 0 5.2799764489464e-06
of I-Disease 0 2.8583624498423887e-06
complement I-Disease 0 9.29458656173665e-06
in O 0 1.2454939678718802e-05
man O 0 0.0003012613451573998
. O 0 2.8788674171664752e-05

I O 0 0.0059638721868395805
. O 0 0.0005456628859974444

Clinical O 1 0.8375565409660339
, O 0 4.7829838877078146e-05
immunochemical O 0 0.00944586843252182
, O 0 6.148840384412324e-06
and O 0 2.134288706656662e-06
family O 0 6.0148645388835575e-06
studies O 0 6.279709486989304e-05
. O 0 3.6746969271916896e-05

The O 0 1.4754295989405364e-05
first O 0 4.331533091317397e-06
recognized O 0 3.3774415442167083e-06
human O 0 9.761031833477318e-06
kindred O 0 0.0011125124292448163
with O 0 1.227196571562672e-05
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9566196203231812
the I-Disease 0 0.0025253009516745806
fifth I-Disease 0 0.06388206034898758
component I-Disease 0 5.81685662837117e-06
of I-Disease 0 3.3507046737213386e-06
complement I-Disease 0 8.193617759388871e-06
( O 0 6.479546300397487e-06
C5 O 1 0.9997231364250183
) O 0 1.3398711189438473e-06
is O 0 2.0956122170900926e-06
described O 0 1.8560524040367454e-05
. O 0 1.47719101732946e-05

The O 0 0.00011198128049727529
proband O 0 0.0005644508637487888
, O 0 6.216617293830495e-06
a O 0 9.295082236349117e-06
20 O 0 1.4444717635342386e-05
- O 0 5.156431143404916e-05
year O 0 1.022242668113904e-05
- O 0 5.0444687076378614e-05
old O 0 7.4237154876755085e-06
black O 0 1.6791099142210442e-06
female O 0 7.0923597377259284e-06
with O 0 0.00021220541384536773
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.8477417230606079
age O 0 0.00010149338049814105
11 O 0 1.1932086636079475e-05
, O 0 7.704508675487887e-07
lacked O 0 1.591520594956819e-05
serum O 0 0.014094789512455463
hemolytic O 1 0.9989166259765625
complement O 0 2.7549310743779643e-06
activity O 0 2.002961809921544e-05
, O 0 8.313742227983312e-07
even O 0 3.712921170517802e-07
during O 0 1.4118618310021702e-05
remission O 0 0.0006805306184105575
. O 0 2.7214846340939403e-05

C5 O 1 0.9997825026512146
was O 0 0.0015971047105267644
undetectable O 0 0.0011411606101319194
in O 0 2.7136763947055442e-06
her O 0 3.1366148505185265e-06
serum O 0 6.209892308106646e-05
by O 0 7.133440931283985e-07
both O 0 9.765609547685017e-07
immunodiffusion O 0 0.002986225765198469
and O 0 2.0842295270995237e-05
hemolytic O 1 0.9999997615814209
assays O 0 0.08076700568199158
. O 0 6.688335270155221e-05

Other O 0 3.510188435029704e-06
complement O 0 6.979739737289492e-06
components O 0 3.9341780393442605e-06
were O 0 1.2127362651881413e-06
normal O 0 1.6898439980650437e-06
during O 0 7.822090992704034e-06
remission O 0 0.00010064170783152804
of O 0 1.4472887414740399e-05
lupus O 1 0.9982792139053345
, O 0 3.0370224521902855e-06
but O 0 1.5103527175597264e-06
C1 O 0 0.012384862639009953
, O 0 1.3861310890206369e-06
C4 O 1 0.7443883419036865
, O 0 2.652103603395517e-06
C2 O 0 7.939542410895228e-05
, O 0 2.9051622618680994e-07
and O 0 6.29051100986544e-07
C3 O 1 0.9989232420921326
levels O 0 2.3513253836426884e-05
fell O 0 0.10870686173439026
during O 0 9.649423736846074e-05
exacerbations O 1 0.9910768270492554
. O 0 2.4772418328211643e-05

A O 0 0.0008534514345228672
younger O 0 4.1429317207075655e-05
half O 0 1.1913791240658611e-05
- O 0 1.6980613509076647e-05
sister O 0 8.717433047422674e-06
, O 0 7.235528869387053e-07
who O 0 3.7726897517131874e-07
had O 0 4.011351393273799e-06
no O 0 9.776449587661773e-06
underlying O 1 0.999701201915741
disease O 1 0.9997226595878601
, O 0 1.2984816066818894e-06
was O 0 8.059349784161896e-05
also O 0 3.02071157420869e-07
found O 0 1.2157674689206033e-07
to O 0 3.3940597177206655e-07
lack O 0 5.474269710248336e-05
immunochemically O 1 0.7910116910934448
detectable O 1 0.9961418509483337
C5 O 1 0.999984622001648
. O 0 5.7107372413156554e-05

By O 0 0.00016664784925524145
hemolytic O 1 0.9999680519104004
assay O 0 0.004861752036958933
, O 0 4.927506779495161e-06
she O 0 1.157361111836508e-06
exhibited O 0 1.4051227481104434e-05
1 O 0 3.2087075396702858e-06
- O 0 1.4843640201434027e-06
2 O 0 2.892448378588597e-07
% O 0 6.75451516940484e-08
of O 0 3.2039696407082374e-07
the O 0 6.452078764596081e-07
normal O 0 4.008838914160151e-06
serum O 0 4.223770520184189e-05
C5 O 0 0.0012313941260799766
level O 0 1.1462492466307594e-06
and O 0 1.2488622758155543e-07
normal O 0 3.70994087006693e-07
concentrations O 0 7.668384682801843e-07
of O 0 6.646980068580888e-07
other O 0 1.613620668194926e-07
complement O 0 3.924824795831228e-06
components O 0 1.3262163520266768e-05
. O 0 6.359034159686416e-06

C5 O 1 0.9462741017341614
levels O 0 1.5102551515155938e-05
of O 0 1.6254296042461647e-06
other O 0 9.752359630965657e-08
family O 0 1.6497691035510798e-07
members O 0 4.330614444825187e-08
were O 0 1.7182965450501797e-07
either O 0 1.0913024794945159e-07
normal O 0 8.385198384530668e-07
or O 0 2.1225997670626384e-07
approximately O 0 6.402980261555058e-07
half O 0 1.2253593695277232e-06
- O 0 5.1384408834564965e-06
normal O 0 5.482486358232563e-07
, O 0 5.974360561822323e-08
consistent O 0 2.7695486437551153e-07
with O 0 5.2120540772193635e-08
autosomal O 0 6.021142780809896e-06
codominant O 0 2.5510593332001008e-05
inheritance O 0 1.1436560498623294e-06
of O 0 8.881909820956935e-07
the O 0 2.087052052957006e-06
gene O 0 2.0566894818330184e-05
determining O 0 0.000473665539175272
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 9.691836021374911e-05

Normal O 0 0.002373051829636097
hemolytic O 1 0.9994957447052002
titers O 0 0.003009408712387085
were O 0 5.9164981394133065e-06
restored O 0 8.631993296148721e-06
to O 0 3.470404692507145e-07
both O 0 1.58795842253312e-06
homozygous O 0 0.0010626171715557575
C5 B-Disease 1 1.0
- I-Disease 1 0.9999978542327881
deficient I-Disease 1 0.9999997615814209
( O 0 1.649377190915402e-05
C5D B-Disease 1 0.9999995231628418
) O 0 8.573060199523752e-07
sera O 0 3.957154149247799e-06
by O 0 4.600007486033064e-08
addition O 0 7.27347000406553e-08
of O 0 5.622710546049348e-07
highly O 0 3.4579570638015866e-06
purified O 0 2.188484177167993e-05
human O 0 4.093152892892249e-05
C5 O 1 0.9807430505752563
. O 0 3.213798117940314e-05

In O 0 4.691004505730234e-05
specific O 0 1.610071922186762e-05
C5 O 1 0.8212011456489563
titrations O 0 0.0002470017352607101
, O 0 7.368575438704283e-07
however O 0 1.745813591469414e-07
, O 0 7.182029548857827e-08
it O 0 5.224146804039265e-08
was O 0 2.266519231852726e-06
noted O 0 2.1388721904713748e-07
that O 0 2.6681668430228456e-08
when O 0 6.329216262201953e-08
limited O 0 5.7650158424848996e-08
amounts O 0 9.556766400464767e-08
of O 0 1.4538060213453718e-06
C5 O 0 0.0011332397116348147
were O 0 6.925199045326735e-07
assayed O 0 8.885739589459263e-06
in O 0 1.447664317311137e-07
the O 0 1.5287261589946866e-07
presence O 0 2.483298828792613e-07
of O 0 5.82634470447374e-07
low O 0 1.0519244824536145e-05
dilutions O 0 3.2010582799557596e-05
of O 0 3.897446731571108e-06
either O 0 8.113002877507824e-06
C5D B-Disease 1 0.9999997615814209
serum O 0 0.00017259360174648464
, O 0 1.4011708344696672e-06
curving O 0 1.0252262654830702e-05
rather O 0 1.2433956442237104e-07
than O 0 4.140900955462712e-08
linear O 0 4.824243546863727e-07
dose O 0 2.102259713865351e-06
- O 0 8.051801501096634e-07
response O 0 1.524105783801133e-07
plots O 0 3.230656773212104e-07
were O 0 1.8376684352006123e-07
consistently O 0 3.2059926979854936e-07
obtained O 0 4.655811380871455e-07
, O 0 1.3297189127570164e-07
suggesting O 0 7.951015845719667e-07
some O 0 1.7242733463262994e-07
inhibitory O 0 3.8468060665763915e-05
effect O 0 1.2834498193114996e-05
. O 0 8.839389010972809e-06

Further O 0 2.3589842385263182e-05
studies O 0 1.4830219697614666e-05
suggested O 0 5.2366594900377095e-06
that O 0 1.3191222478781128e-06
low O 0 4.277201514923945e-05
dilutions O 0 0.0005995423998683691
of O 0 3.349356120452285e-05
C5D B-Disease 1 0.9999995231628418
serum O 0 0.00010852808190975338
contain O 0 1.574982093188737e-06
a O 0 4.180742962489603e-06
factor O 0 3.857234787574271e-06
( O 0 2.6449455958754697e-07
or O 0 1.3879629534585547e-07
factors O 0 3.5561842537390476e-07
) O 0 1.0273291195517231e-07
interfering O 0 3.4756641298372415e-07
at O 0 5.167046879250847e-07
some O 0 3.106364587779353e-08
step O 0 3.2675794159331417e-07
in O 0 3.916013042726263e-07
the O 0 2.073660652968101e-06
hemolytic O 1 0.915647566318512
assay O 0 9.312691690865904e-05
of O 0 5.282160418573767e-05
C5 O 1 0.9905694723129272
, O 0 2.078993759369041e-07
rather O 0 5.8427819027428995e-08
than O 0 3.9280561026089345e-08
a O 0 7.66809193919471e-07
true O 0 4.454040663404157e-06
C5 O 0 0.22553981840610504
inhibitor O 0 0.00019011164840776473
or O 0 4.110458576178644e-06
inactivator O 0 0.0003285181592218578
. O 0 1.1582661500142422e-05

Of O 0 6.384246808011085e-05
clinical O 0 0.0003415811515878886
interest O 0 8.70824351295596e-06
are O 0 6.516104917864141e-07
( O 0 3.796485543716699e-07
a O 0 5.772056965724914e-07
) O 0 9.020266844572689e-08
the O 0 1.5262526176229585e-07
documentation O 0 1.1746051313821226e-06
of O 0 2.2797888959757984e-05
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 1 0.9950462579727173
vasculitis B-Disease 1 1.0
, O 1 0.782009482383728
and O 1 0.9894799590110779
arthritis B-Disease 1 1.0
in O 0 0.0005532156210392714
an O 0 1.5432691725436598e-05
individual O 0 6.783654384889815e-07
lacking O 0 0.009596173651516438
C5 O 1 0.9999896287918091
( O 0 8.641230806460953e-07
and O 0 1.8457302530805464e-07
its O 0 4.898144538856286e-07
biologic O 0 0.000247319636400789
functions O 0 3.514116713176918e-07
) O 0 1.4187814656452247e-07
, O 0 1.0597399580092315e-07
and O 0 1.5274933673481428e-07
( O 0 4.901971806248184e-07
b O 0 1.1640004231594503e-06
) O 0 5.843171990704832e-08
a O 0 2.867777482151723e-07
remarkable O 0 1.7202374920088914e-06
propensity O 0 2.4789931558188982e-05
to O 0 4.091771643288666e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 3.7635907119693e-06
the O 0 1.9378144315851387e-06
proband O 0 3.5911507438868284e-05
, O 0 7.071761842780688e-08
even O 0 3.124279501776073e-08
during O 0 1.8295303050308576e-07
periods O 0 3.3200777238562296e-07
of O 0 1.7534483731651562e-06
low O 0 6.255944754229859e-05
- O 0 1.4558451766788494e-05
dose O 0 5.500876795849763e-06
or O 0 9.926399116011453e-07
alternate O 0 2.3130569388740696e-06
- O 0 4.8656824219506234e-05
day O 0 2.007404327741824e-05
corticosteroid O 0 0.06358682364225388
therapy O 0 8.580626308685169e-05
. O 0 1.0548427781031933e-05

Other O 0 5.791814146505203e-06
observations O 0 1.2943920410179999e-05
indicate O 0 9.518756087345537e-06
that O 0 7.622065254508925e-07
the O 0 2.4816752102196915e-06
C5D B-Disease 1 0.9995962977409363
state O 0 2.8437759169719357e-07
is O 0 1.9244646409788402e-07
compatible O 0 3.470444482900348e-07
with O 0 7.788945310949202e-08
normal O 0 1.4330395288197906e-06
coagulation O 0 1.1782912224589381e-05
function O 0 3.3376463193235395e-07
and O 0 1.2248518999058433e-07
the O 0 1.9681489504819183e-07
capacity O 0 6.13047461683891e-07
to O 0 1.775876796727971e-07
mount O 0 2.3513926862506196e-05
a O 0 7.752469173283316e-06
neutrophilic O 0 0.2984827756881714
leukocytosis O 0 0.39932021498680115
during O 0 0.0024894243106245995
pyogenic B-Disease 1 0.9929482936859131
infection I-Disease 0 0.3686175048351288
. O 0 3.5223608847445576e-06
. O 0 9.357378075947054e-06

Susceptibility O 1 0.9998462200164795
to O 0 0.020064178854227066
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.07093971222639084
twins O 0 0.15110912919044495
: O 0 9.983037898564362e-07
the O 0 3.428714308029157e-07
role O 0 3.4205820043098356e-07
of O 0 6.826200547038752e-07
genes O 0 8.73762246555998e-07
, O 0 3.1565341487294063e-06
HLA O 0 0.35648882389068604
, O 0 8.037685006456741e-07
and O 0 7.557176786576747e-07
the O 0 5.190395313547924e-06
environment O 0 3.2637337426422164e-05
. O 0 1.702161353023257e-05

OBJECTIVE O 0 9.046730701811612e-05
To O 0 1.2669768238993129e-06
determine O 0 3.3463251725152077e-07
the O 0 4.1481189327896573e-07
relative O 0 3.0248393159126863e-06
effects O 0 3.2738478239480173e-06
of O 0 6.565256853718893e-07
genetic O 0 2.1818700588482898e-06
and O 0 6.852035312476801e-07
environmental O 0 2.8053018468199298e-06
factors O 0 1.231743681273656e-06
in O 0 1.4002117723066476e-06
susceptibility O 1 0.7820470929145813
to O 0 0.0026335695292800665
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.5003376007080078
AS B-Disease 1 0.999998927116394
) O 0 4.46230615125387e-06
. O 0 4.792291747435229e-06

METHODS O 0 0.0004442835343070328
Twins O 0 0.00042991439113393426
with O 0 5.309185780788539e-06
AS B-Disease 0 0.04601757228374481
were O 0 1.5582487549181678e-06
identified O 0 8.557857995583618e-07
from O 0 4.4122481313024764e-07
the O 0 4.1365444758412195e-07
Royal O 0 0.0007094881730154157
National O 0 0.00035941251553595066
Hospital O 1 0.9999113082885742
for O 0 0.0010151893366128206
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.007498165126889944
. O 0 4.6925750211812556e-05

Clinical O 0 0.015767421573400497
and O 0 4.6512941480614245e-06
radiographic O 0 0.00019926841196138412
examinations O 0 1.555371272843331e-05
were O 0 6.218433554749936e-07
performed O 0 7.172453706516535e-07
to O 0 8.855776911786961e-08
establish O 0 1.9993135538243223e-06
diagnoses O 1 0.9217239618301392
, O 0 5.281401627144078e-06
and O 0 1.3778733773506247e-05
disease O 1 0.9999926090240479
severity O 0 0.35822972655296326
was O 0 0.00023941825202200562
assessed O 0 1.0261888974127942e-06
using O 0 7.517449063243475e-08
a O 0 2.8615377800633723e-07
combination O 0 1.7970310750570206e-07
of O 0 8.593450502303313e-07
validated O 0 7.6352935138857e-06
scoring O 0 4.113619070267305e-06
systems O 0 1.4408037714019883e-05
. O 0 1.1723909665306564e-05

HLA O 1 0.9969492554664612
typing O 0 0.0029684703331440687
for O 0 9.43235500017181e-05
HLA O 1 0.9970791339874268
- O 0 0.030542703345417976
B27 O 1 0.6595824360847473
, O 0 1.8377737433183938e-05
HLA O 0 0.3050540089607239
- O 0 9.884544851956889e-05
B60 O 0 0.00014069219469092786
, O 0 1.0430688917040243e-06
and O 0 2.28464000429085e-06
HLA O 1 0.7552339434623718
- O 0 0.00032384804217144847
DR1 O 1 0.7621486783027649
was O 0 1.319386501563713e-05
performed O 0 1.383967401125119e-06
by O 0 5.694765263797308e-07
polymerase O 0 1.182777759822784e-05
chain O 0 1.967421894732979e-06
reaction O 0 2.4536606701985875e-07
with O 0 6.431289989450306e-08
sequence O 0 7.152801231313788e-07
- O 0 1.4241429653338855e-06
specific O 0 1.5331616509683954e-07
primers O 0 3.104782535956474e-06
, O 0 3.6620289733946265e-07
and O 0 4.274833713679982e-07
zygosity O 0 3.334730354254134e-05
was O 0 9.180547749565449e-06
assessed O 0 2.6936036192637403e-06
using O 0 9.63938191489433e-07
microsatellite O 0 8.693279232829809e-05
markers O 0 5.0345301133347675e-05
. O 0 1.8242046280647628e-05

Genetic O 0 7.958438800415024e-05
and O 0 3.765363999264082e-06
environmental O 0 6.628637038375018e-06
variance O 0 4.1298294490843546e-06
components O 0 2.39850078287418e-06
were O 0 4.776745754497824e-07
assessed O 0 4.949935146214557e-07
with O 0 4.5748606680717785e-08
the O 0 4.910234565613791e-07
program O 0 6.054950745237875e-07
Mx O 0 9.839979611570016e-06
, O 0 9.998207417538651e-08
using O 0 5.272516290233398e-08
data O 0 1.584949274047176e-07
from O 0 8.107628701736758e-08
this O 0 3.825458705364326e-08
and O 0 5.612307774072178e-08
previous O 0 3.829065349236771e-07
studies O 0 9.208986853082024e-07
of O 0 2.5882798126986017e-06
twins O 0 6.727188883814961e-05
with O 0 5.752445304096909e-06
AS B-Disease 1 0.9999860525131226
. O 0 4.401893966132775e-05

RESULTS O 0 0.00018249062122777104
Six O 0 1.028815040626796e-05
of O 0 1.2293412510189228e-05
8 O 0 4.916757461614907e-05
monozygotic O 0 0.00041856872849166393
( O 0 1.6774512914707884e-05
MZ O 1 0.9490916132926941
) O 0 2.6749728476715973e-06
twin O 0 2.1104247934999876e-05
pairs O 0 1.049297679855954e-06
were O 0 2.9341551908146357e-06
disease O 0 0.023343876004219055
concordant O 0 7.411644764943048e-05
, O 0 5.096981681163015e-07
compared O 0 5.632446118397638e-07
with O 0 8.899684189600521e-08
4 O 0 2.3034065179672325e-06
of O 0 3.404875542400987e-06
15 O 0 9.69257416727487e-06
B27 O 0 0.00012935460836160928
- O 0 9.153176506515592e-06
positive O 0 1.6996027625282295e-06
dizygotic O 0 2.6937786969938315e-05
( O 0 1.8663419041331508e-06
DZ O 0 0.06305163353681564
) O 0 9.922121080307988e-07
twin O 0 6.441482128138887e-06
pairs O 0 2.696988872230577e-07
( O 0 1.8820155389676074e-07
27 O 0 7.473635719179583e-07
% O 0 1.9268300377461856e-07
) O 0 7.55996794055136e-08
and O 0 7.323235706735431e-08
4 O 0 8.280784413727815e-07
of O 0 2.465563056830433e-06
32 O 0 2.0552839487208985e-05
DZ O 1 0.9855256676673889
twin O 0 6.377097452059388e-05
pairs O 0 1.0621961337164976e-06
overall O 0 6.311642209766433e-06
( O 0 2.509204364287143e-07
12 O 0 3.0785483318140905e-07
. O 0 1.1698691793071703e-07
5 O 0 5.291537945595337e-07
% O 0 6.52976552828477e-07
) O 0 1.1941110642510466e-06
. O 0 4.874234946328215e-06

Nonsignificant O 0 0.0015831122873350978
increases O 0 1.0579870831861626e-05
in O 0 5.902100497223728e-07
similarity O 0 5.317255613590532e-07
with O 0 5.0354575620303876e-08
regard O 0 5.588528324551589e-07
to O 0 1.0355130086736608e-07
age O 0 8.099813385342713e-06
at O 0 0.409168541431427
disease O 1 0.9998629093170166
onset O 1 0.9984490871429443
and O 0 2.2053598058846546e-07
all O 0 3.133751036443755e-08
of O 0 6.443353868235135e-07
the O 0 4.617659669747809e-06
disease O 0 0.14286550879478455
severity O 0 1.9898347090929747e-05
scores O 0 7.339036187659076e-07
assessed O 0 9.911548204399878e-07
were O 0 6.481001832980837e-07
noted O 0 2.366811941101332e-06
in O 0 4.3973368519800715e-06
disease O 1 0.9934832453727722
- O 0 0.49161845445632935
concordant O 0 0.44778603315353394
MZ O 1 0.9998847246170044
twins O 0 2.2691408958053216e-05
compared O 0 3.7714878544647945e-06
with O 0 1.67593111655151e-06
concordant O 0 0.011685119941830635
DZ O 1 0.9999943971633911
twins O 0 0.0019475168082863092
. O 0 6.269441655604169e-05

HLA O 1 0.9999709129333496
- O 0 0.26836156845092773
B27 O 0 0.01273867953568697
and O 0 5.702836460841354e-06
B60 O 0 0.0002982310252264142
were O 0 1.901746031762741e-06
associated O 0 6.821606461926422e-07
with O 0 1.8013085423262964e-07
the O 0 6.8928543441870715e-06
disease O 0 0.4334484338760376
in O 0 2.8133126761531457e-06
probands O 0 0.02038818784058094
, O 0 3.28343560340727e-07
and O 0 1.1819841461147007e-07
the O 0 5.483040581566456e-07
rate O 0 4.672242994274711e-06
of O 0 1.1991974133707117e-06
disease O 0 0.000249940698267892
concordance O 0 2.4174867576221004e-05
was O 0 2.097449396387674e-05
significantly O 0 1.2933650168633903e-06
increased O 0 1.353737388853915e-06
among O 0 1.0585415566310985e-06
DZ O 1 0.8256121277809143
twin O 0 1.565135426062625e-05
pairs O 0 2.6853064127863036e-07
in O 0 2.3854792630118027e-07
which O 0 3.1843762826611055e-07
the O 0 1.7848547031462658e-06
co O 0 1.6811554814921692e-05
- O 0 1.3976854461361654e-05
twin O 0 1.6042014976846986e-05
was O 0 8.973067451734096e-06
positive O 0 2.514738355330337e-07
for O 0 2.0448578652576543e-07
both O 0 7.5439561442181e-07
B27 O 0 0.00016714786761440337
and O 0 7.751108569209464e-06
DR1 O 1 0.9246481657028198
. O 0 4.142248508287594e-05

Additive O 0 0.0001509575522504747
genetic O 0 2.7756785129895434e-05
effects O 0 1.363906903861789e-05
were O 0 6.895207889101584e-07
estimated O 0 2.1272364847391145e-07
to O 0 4.513591278509921e-08
contribute O 0 1.2679218741595832e-07
97 O 0 1.1745851224986836e-06
% O 0 1.1153169765520943e-07
of O 0 4.272282581041509e-07
the O 0 5.217295893089613e-07
population O 0 5.88941531987075e-07
variance O 0 7.323428235395113e-06
. O 0 1.3639798453368712e-05

CONCLUSION O 0 0.0004989381413906813
Susceptibility O 0 0.0014057832304388285
to O 0 4.816634827875532e-06
AS B-Disease 0 0.00032694434048607945
is O 0 3.0991213861852884e-07
largely O 0 2.8438543608899636e-07
genetically O 0 1.0614392209618018e-07
determined O 0 1.505068496499007e-07
, O 0 5.389906831965163e-08
and O 0 4.3346883416006676e-08
the O 0 3.1217157925311767e-07
environmental O 0 3.40901192430465e-06
trigger O 0 4.18478384744958e-06
for O 0 3.6427459804144746e-07
the O 0 9.683712960395496e-06
disease O 1 0.6088748574256897
is O 0 5.134183993504848e-06
probably O 0 1.568162042531185e-05
ubiquitous O 0 6.869026401545852e-05
. O 0 1.2581974260683637e-05

HLA O 1 0.9999409914016724
- O 0 0.001931499456986785
B27 O 0 0.00023312540724873543
accounts O 0 7.514781827921979e-07
for O 0 1.3037485757649847e-07
a O 0 2.8809407126573205e-07
minority O 0 5.401536284921349e-08
of O 0 1.7653889017310576e-07
the O 0 2.0833284963828191e-07
overall O 0 4.4484245336207096e-06
genetic O 0 7.134827228583163e-06
susceptibility O 0 0.06974871456623077
to O 0 1.0465730156283826e-05
AS B-Disease 1 0.9999984502792358
. O 0 6.0806960391346365e-05

Cell O 1 0.7405863404273987
cycle O 0 0.0014419647632166743
- O 0 0.00016124354442581534
dependent O 0 1.5177487512119114e-05
colocalization O 0 8.760610944591463e-05
of O 0 7.454107162629953e-06
BARD1 O 0 0.0006161115015856922
and O 0 9.634584330342477e-07
BRCA1 O 0 6.436102921725251e-06
proteins O 0 3.754034310077259e-07
in O 0 4.963094966115023e-07
discrete O 0 3.0590970254706917e-06
nuclear O 0 2.65802755166078e-05
domains O 0 4.641398481908254e-05
. O 0 1.4875261513225269e-05

Germ O 1 0.9999899864196777
- O 0 0.004885871894657612
line O 0 1.8195256416220218e-05
mutations O 0 1.2522782526502851e-06
of O 0 1.2482399824875756e-06
the O 0 1.1353176887496375e-06
BRCA1 O 0 5.6779386795824394e-05
gene O 0 4.307648850954138e-06
predispose O 0 3.1608080462319776e-05
women O 0 7.365919145740918e-07
to O 0 3.6438024153540027e-07
early O 0 0.0003012254019267857
- O 1 0.9999864101409912
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 0.999954104423523
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 9.13296389626339e-06
compromising O 0 1.0925455171673093e-05
the O 0 1.2100180128982174e-06
genes O 0 1.3439303074846976e-06
presumptive O 0 4.452916982700117e-05
function O 0 8.665145969644072e-07
as O 0 1.112972427108616e-06
a O 0 1.65541405294789e-05
tumor B-Disease 1 0.9999927282333374
suppressor O 1 0.9999825954437256
. O 0 3.257372372900136e-05

Although O 0 1.3894760741095524e-05
the O 0 6.415622920030728e-06
biochemical O 0 4.1562161641195416e-05
properties O 0 5.1810293371090665e-06
of O 0 4.051427822560072e-06
BRCA1 O 0 0.00013413155102171004
polypeptides O 0 5.474860699905548e-06
are O 0 1.2204957045014453e-07
not O 0 5.415793324914375e-08
understood O 0 2.2120264020486502e-07
, O 0 7.266675083883456e-08
their O 0 3.120795355471273e-08
expression O 0 5.142633767718507e-07
pattern O 0 3.1883739666227484e-06
and O 0 2.451471630138258e-07
subcellular O 0 0.0001158601080533117
localization O 0 4.934494063491002e-05
suggest O 0 2.85297090840686e-07
a O 0 4.809617166756652e-07
role O 0 1.0417170415166765e-06
in O 0 1.1720204611265217e-06
cell O 0 0.001653557876124978
- O 0 0.0001049792263074778
cycle O 0 5.965924356132746e-05
regulation O 0 1.8641485439729877e-05
. O 0 1.065735978045268e-05

When O 0 0.00010465608647791669
resting O 0 0.00020581105491146445
cells O 0 1.2925578630529344e-05
are O 0 2.952817794721341e-07
induced O 0 1.8704560716287233e-05
to O 0 2.994498800035217e-07
proliferate O 0 2.7888356726180064e-06
, O 0 2.2713481939717894e-07
the O 0 3.2941593985924555e-07
steady O 0 8.646014066471253e-06
- O 0 2.937235876743216e-07
state O 0 2.1464117594405252e-08
levels O 0 5.593723173547005e-08
of O 0 1.0550890294780402e-07
BRCA1 O 0 1.0592675607767887e-06
increase O 0 5.553813480219105e-07
in O 0 6.75857336318586e-07
late O 0 4.492113021115074e-06
G1 O 0 1.5092588000698015e-05
and O 0 6.959150056218277e-08
reach O 0 1.0857818466547542e-07
a O 0 3.331102220727189e-07
maximum O 0 9.131746310231392e-07
during O 0 4.64921413367847e-06
S O 0 5.330246494850144e-05
phase O 0 1.845320002757944e-05
. O 0 6.557212145708036e-06

Moreover O 0 0.00015758691006340086
, O 0 8.14192844700301e-06
in O 0 7.525628006987972e-06
S O 0 0.0002613387769088149
phase O 0 4.880274718743749e-05
cells O 0 1.0659371582733002e-05
, O 0 1.1610923138505314e-06
BRCA1 O 0 2.799796493491158e-05
polypeptides O 0 5.2893656175001524e-06
are O 0 1.5061310421060625e-07
hyperphosphorylated O 0 7.208707302197581e-06
and O 0 3.384466253919527e-07
accumulate O 0 5.660728561451833e-07
into O 0 3.5348182336747414e-07
discrete O 0 3.704845994434436e-06
subnuclear O 0 4.548635843093507e-05
foci O 0 3.84004415536765e-05
termed O 0 1.6322646843036637e-05
" O 0 7.973493666213471e-06
BRCA1 O 0 4.382003680802882e-05
nuclear O 0 7.270026253536344e-05
dots O 0 0.00019695278024300933
. O 0 2.906569352489896e-05

" O 0 0.0004186138685327023
BRCA1 O 0 0.04766543582081795
associates O 0 0.0004072008887305856
in O 0 2.7164778657606803e-06
vivo O 0 4.231228740536608e-05
with O 0 6.28573729954951e-07
a O 0 1.3523937923309859e-05
structurally O 0 6.634695455431938e-05
related O 0 9.780776963452809e-06
protein O 0 8.265008364105597e-05
termed O 0 0.0029059043154120445
BARD1 O 1 0.9644044637680054
. O 0 2.619393853819929e-05

Here O 0 1.755148514348548e-05
we O 0 8.133253004416474e-07
show O 0 1.0738103810581379e-06
that O 0 3.479528061234305e-07
the O 0 1.5795154695297242e-06
steady O 0 3.171729258610867e-05
- O 0 1.5550986063317396e-06
state O 0 1.3469504267504817e-07
levels O 0 4.90729462399031e-07
of O 0 8.495092060911702e-07
BARD1 O 0 0.0010729311034083366
, O 0 1.3835409617968253e-07
unlike O 0 7.680615965455218e-08
those O 0 1.5222312299556506e-08
of O 0 3.3596336379559943e-07
BRCA1 O 0 7.112394541763933e-06
, O 0 3.4196750675619114e-07
remain O 0 3.6937646541446156e-07
relatively O 0 1.0834317976105012e-07
constant O 0 5.044879003435199e-07
during O 0 2.5691692826512735e-06
cell O 0 6.174868758535013e-05
cycle O 0 5.233904084889218e-05
progression O 0 9.482985478825867e-05
. O 0 9.499874067842029e-06

However O 0 6.0492959164548665e-05
, O 0 7.89278419688344e-06
immunostaining O 0 0.00021274205937515944
revealed O 0 9.777830200619064e-06
that O 0 8.806127880234271e-07
BARD1 O 0 0.0004002560453955084
resides O 0 3.887305410898989e-06
within O 0 5.808535661344649e-07
BRCA1 O 0 8.783105840848293e-06
nuclear O 0 2.739352385106031e-05
dots O 0 2.308760849700775e-05
during O 0 1.4342222129926085e-05
S O 0 2.2131827790872194e-05
phase O 0 9.022801918945333e-07
of O 0 4.563348170449899e-07
the O 0 5.172243504603102e-07
cell O 0 4.9436985136708245e-06
cycle O 0 1.9723402147064917e-06
, O 0 6.55562217843908e-08
but O 0 2.0748139206716587e-08
not O 0 3.8466474450160604e-08
during O 0 1.4141764950181823e-06
the O 0 3.0745393360120943e-06
G1 O 0 0.00019753015658352524
phase O 0 2.7357444196240976e-05
. O 0 1.1979473129031248e-05

Nevertheless O 0 0.00041203401633538306
, O 0 2.887503978854511e-05
BARD1 O 0 0.0006779325776733458
polypeptides O 0 1.4945549082767684e-05
are O 0 1.4694465733100515e-07
found O 0 1.2442022523373453e-07
exclusively O 0 1.1069667493757152e-07
in O 0 1.0375136838547405e-07
the O 0 2.58169535527486e-07
nuclear O 0 2.317981397936819e-06
fractions O 0 1.3243039802546264e-06
of O 0 1.047833620759775e-06
both O 0 1.1138217814732343e-06
G1 O 0 0.0019881678745150566
- O 0 1.408267235092353e-05
and O 0 2.3033494471746963e-06
S O 0 0.00022400080342777073
- O 0 2.652188777574338e-05
phase O 0 2.927653258666396e-05
cells O 0 2.356506411160808e-05
. O 0 7.345558515226003e-06

Therefore O 0 2.253835009469185e-05
, O 0 6.161825240269536e-06
progression O 0 3.3414344215998426e-05
to O 0 7.694471264585445e-07
S O 0 2.7541887902771123e-05
phase O 0 3.975188974436605e-06
is O 0 2.1935734650924132e-07
accompanied O 0 7.656466323169298e-07
by O 0 8.887148084113505e-08
the O 0 3.801971217853861e-07
aggregation O 0 2.099420953527442e-06
of O 0 2.577995019237278e-06
nuclear O 0 3.019106952706352e-05
BARD1 O 0 0.00018421720596961677
polypeptides O 0 3.6054786960448837e-06
into O 0 1.5686786127844243e-06
BRCA1 O 0 4.993200127501041e-05
nuclear O 0 0.00015476939734071493
dots O 0 0.0002862522378563881
. O 0 2.9338862077565864e-05

This O 0 6.620500789722428e-05
cell O 0 0.0010623813141137362
cycle O 0 0.000184001459274441
- O 0 2.1247709810268134e-05
dependent O 0 2.951695933006704e-06
colocalization O 0 1.701492874417454e-05
of O 0 2.4505650344508467e-06
BARD1 O 0 0.0003082801413256675
and O 0 5.335196533451381e-07
BRCA1 O 0 1.5810339391464368e-05
indicates O 0 4.005029040854424e-06
a O 0 9.71575332187058e-07
role O 0 8.912251701076457e-07
for O 0 5.904560111957835e-07
BARD1 O 0 0.00025432900292798877
in O 0 2.086206222884357e-06
BRCA1 O 0 0.001152522163465619
- O 0 0.03907127305865288
mediated O 1 0.5382335782051086
tumor B-Disease 1 0.9999997615814209
suppression O 1 0.9976911544799805
. O 0 3.528636079863645e-05

Ethnic O 0 2.3558681277791038e-05
differences O 0 1.4973553334129974e-05
in O 0 9.889350621961057e-06
the O 0 1.4953448044252582e-05
HFE O 0 0.0023939437232911587
codon O 0 0.00013195197971072048
282 O 0 5.370107828639448e-05
( O 0 1.1769872799050063e-05
Cys O 1 0.9345299601554871
/ O 0 0.00025383042520843446
Tyr O 0 0.00025065665249712765
) O 0 4.645305580197601e-06
polymorphism O 0 0.00011728224490070716
. O 0 1.6250442058662884e-05

Recent O 0 2.03886393137509e-05
studies O 0 1.396631523675751e-05
have O 0 6.790631914554979e-07
shown O 0 3.652385657915147e-06
that O 0 1.2085893104085699e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.7762407660484314
HH B-Disease 1 1.0
) O 0 1.2144388392698602e-06
is O 0 2.356262456260083e-07
likely O 0 1.6221545706684992e-07
to O 0 3.300558049090796e-08
be O 0 1.50044229485502e-07
caused O 0 2.4303171812789515e-06
by O 0 5.148135073795856e-07
homozygosity O 0 1.2186956155346707e-05
for O 0 1.8845749139018153e-07
a O 0 2.2578381049243035e-06
Cys282Tyr O 0 4.240919224685058e-05
mutation O 0 9.287481930186914e-07
in O 0 6.768939329049317e-07
the O 0 2.9401883239188464e-06
HFE O 0 0.00025486762751825154
gene O 0 3.2993702916428447e-06
located O 0 1.958716893568635e-05
4 O 0 3.441521039349027e-05
. O 0 1.8017646652879193e-05

5 O 0 0.0005161985172890127
Mb O 0 0.00590944942086935
telomeric O 0 0.0036608483642339706
to O 0 0.00016759999562054873
HLA O 1 0.999961256980896
- O 0 0.03012196347117424
A O 0 0.000602761865593493
. O 0 2.6532154151936993e-05

Population O 0 4.140643341088435e-06
studies O 0 3.5848968309437623e-06
of O 0 8.144577350321924e-07
this O 0 2.3099038060081512e-07
polymorphism O 0 1.636098431845312e-06
are O 0 3.136011272886208e-08
facilitated O 0 1.0127529321835027e-06
by O 0 1.1604109317886468e-07
the O 0 1.4520750823976414e-07
fact O 0 1.2652596126372373e-07
that O 0 1.0425920748957651e-07
the O 0 1.3452254279400222e-06
Cys282Tyr O 0 6.861876317998394e-05
mutation O 0 2.785552851491957e-06
creates O 0 2.73756427304761e-06
a O 0 6.058733106328873e-06
Rsal O 0 8.710288966540247e-05
restriction O 0 1.99187397811329e-05
site O 0 1.0324869435862638e-05
. O 0 8.403038918913808e-06

We O 0 6.011429377394961e-06
have O 0 8.080471616267459e-07
studied O 0 4.503282070800196e-06
the O 0 2.6223910936096217e-06
codon O 0 2.9469645596691407e-05
282 O 0 3.058039874304086e-05
( O 0 6.982722879911307e-06
Cys O 1 0.8176513910293579
/ O 0 6.089840826462023e-05
Tyr O 0 1.832079578889534e-05
) O 0 1.8241729549117736e-07
polymorphism O 0 9.418294553142914e-07
in O 0 8.698913234184147e-08
different O 0 2.5244066392815512e-08
ethnic O 0 1.6940961700129264e-07
groups O 0 6.065156981094333e-07
. O 0 4.858371994487243e-06

In O 0 2.1707435735152103e-05
agreement O 0 3.6546152841765434e-06
with O 0 8.100818149614497e-07
previous O 0 2.161969177905121e-06
observations O 0 4.3590744098764844e-06
the O 0 1.7197322677020566e-06
Tyr O 0 2.1465715690283105e-05
allele O 0 1.1946053746214602e-06
appeared O 0 1.5496401601922116e-06
to O 0 7.077159125401522e-08
be O 0 2.3482313338263339e-07
rare O 0 4.353630060904834e-07
or O 0 6.16267982422869e-07
absent O 0 2.9114326025592163e-06
in O 0 4.4050503333892266e-07
Asiatic O 0 4.253604856785387e-05
( O 0 1.0785226578491347e-07
Indian O 0 5.27354757196008e-07
, O 0 2.0119306043397955e-07
Chinese O 0 6.287985456765455e-07
) O 0 5.066909238848893e-07
populations O 0 1.3139105021764408e-06
. O 0 4.723000074591255e-06

The O 0 4.422139681992121e-05
highest O 0 3.4498640161473304e-05
allele O 0 9.492991921433713e-06
frequency O 0 9.987941666622646e-06
( O 0 6.955778530937096e-07
7 O 0 1.1209999684069771e-06
. O 0 3.737440579243412e-08
5 O 0 1.701299368050968e-07
% O 0 1.022424598318139e-07
) O 0 1.0963199770230858e-07
was O 0 2.47843490797095e-06
found O 0 3.718977552580327e-07
in O 0 1.885253936961817e-06
Swedes O 0 2.9433751478791237e-05
. O 0 1.515271287644282e-05

Saamis O 0 0.001184268156066537
( O 0 1.5256344340741634e-05
2 O 0 5.9378426158218645e-06
% O 0 1.0911854815276456e-06
) O 0 3.3192355886058067e-07
and O 0 3.032768631783256e-07
Mordvinians O 0 2.2598484065383673e-05
( O 0 2.978089526095573e-07
1 O 0 3.2461730370414443e-07
. O 0 4.9099536880703454e-08
8 O 0 1.9711318088866392e-07
% O 0 6.857389678316395e-08
) O 0 5.655591905906476e-08
had O 0 4.234275650105701e-07
significantly O 0 7.810887154846569e-07
lower O 0 8.900539114620187e-07
frequencies O 0 4.0688880176276143e-07
of O 0 1.8459923012414947e-06
the O 0 9.746799150889274e-06
Tyr O 0 0.00011782556975958869
allele O 0 2.8179525543237105e-05
. O 0 1.1039943274226971e-05

Comparisons O 0 9.295763447880745e-05
with O 0 4.083834483026294e-06
allele O 0 1.4055395695322659e-05
frequencies O 0 3.185863079124829e-06
based O 0 9.929617590387352e-07
on O 0 1.764948933669075e-06
prevalence O 0 4.792631443706341e-05
estimates O 0 1.2908167263958603e-06
of O 0 1.6619108009763295e-06
HH B-Disease 1 0.9707533717155457
showed O 0 3.26248391502304e-06
some O 0 1.0549663187475744e-07
disagreements O 0 1.1799697858805303e-06
with O 0 1.8473556906428712e-07
the O 0 2.1688749711756827e-06
RFLP O 0 4.181496478850022e-05
data O 0 7.549361384917574e-07
, O 0 2.7351219955562556e-07
particularly O 0 6.545164978888351e-07
in O 0 2.51906635639898e-06
Finns O 0 1.85545959539013e-05
. O 0 9.831969691731501e-06

The O 0 2.9847626137780026e-05
newly O 0 4.669959162129089e-05
described O 0 2.7650103220366873e-05
HFE O 0 0.01042908988893032
marker O 0 2.624997796374373e-05
provides O 0 4.536298661150795e-07
a O 0 5.587196483247681e-07
new O 0 2.2262693732955086e-07
approach O 0 3.488489142000617e-07
to O 0 3.449849472758615e-08
the O 0 1.418489148363733e-07
screening O 0 5.045417879045999e-07
of O 0 2.398953711235663e-06
HH B-Disease 1 0.994952917098999
as O 0 3.2929028748185374e-07
well O 0 4.961504984635212e-08
as O 0 5.575178718686402e-08
studies O 0 1.2139693694734888e-07
of O 0 2.2254754128425702e-07
the O 0 4.2670055222515657e-07
relationship O 0 2.33399163107606e-07
between O 0 5.23032838373183e-07
the O 0 6.7120581661583856e-06
HFE O 1 0.9646463394165039
Tyr O 0 5.194225741433911e-05
allele O 0 2.842600906660664e-06
and O 0 5.093813228995714e-07
different O 0 6.347627845570969e-07
disorders O 1 0.9999881982803345
including O 0 0.028780419379472733
cancer B-Disease 1 1.0

Autosomal B-Disease 1 0.9999877214431763
dominant I-Disease 1 0.9999866485595703
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999997615814209
associated O 0 2.6102496121893637e-05
with O 0 4.7143780079750286e-07
a O 0 4.314646048442228e-06
missense O 0 2.0181707441224717e-05
mutation O 0 3.101119318671408e-06
encoding O 0 3.2682826258678688e-06
Gly23 O 0 0.0016007089288905263
- O 0 0.0002887506561819464
- O 0 0.00023857194173615426
> O 0 2.1789921447634697e-05
Val O 0 3.831101275864057e-05
in O 0 6.1748373809678014e-06
neurophysin O 0 0.0012079455191269517
II O 1 0.920030415058136
. O 0 2.9625722163473256e-05

Autosomal B-Disease 1 0.999941349029541
dominant I-Disease 1 0.9995291233062744
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.00013307822518981993
ADNDI B-Disease 1 0.9999957084655762
) O 0 1.726588379824534e-06
is O 0 4.940960138810624e-07
an O 0 6.64391482132487e-05
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9999992847442627
by O 0 0.01435350812971592
progressive O 1 0.999998927116394
degeneration O 1 1.0
of O 0 0.003144554328173399
the O 0 4.8067337047541514e-05
magnocellular O 0 0.0013895404990762472
neurons O 0 7.62264880904695e-06
of O 0 5.229911948845256e-06
the O 0 4.401238584250677e-06
hypothalamus O 0 4.8324258386855945e-05
leading O 0 1.1139749403810129e-05
to O 0 2.513376387014432e-07
decreased O 0 0.000469409889774397
ability O 0 6.944537176423182e-07
to O 0 5.809909566778515e-07
produce O 0 1.6424297655248665e-06
the O 0 4.4209846237208694e-05
hormone O 0 0.00035599456168711185
arginine O 0 6.274285988183692e-05
vasopressin O 0 8.923608402255923e-05
( O 0 9.316915566159878e-06
AVP O 0 0.004709930159151554
) O 0 5.39651773578953e-06
. O 0 1.1402014933992177e-05

Affected O 0 5.8157838793704286e-05
individuals O 0 1.953594164660899e-06
are O 0 4.109507756311359e-07
not O 0 5.697845040231186e-07
symptomatic O 0 0.002677807817235589
at O 0 1.8879758499679156e-05
birth O 0 1.0563184332568198e-05
, O 0 4.814012868337159e-07
but O 0 2.0014701362924825e-07
usually O 0 4.592556024363148e-07
develop O 0 3.838325937977061e-06
diabetes B-Disease 1 0.9999983310699463
insipidus I-Disease 1 0.9651475548744202
at O 0 0.00011568137415451929
1 O 0 1.1529914445418399e-05
- O 0 8.130490459734574e-05
6 O 0 4.4031956349499524e-05
yr O 0 0.0005861628451384604
of O 0 8.43002362671541e-06
age O 0 1.920257454912644e-05
. O 0 1.5907058696029708e-05

The O 0 1.6601698007434607e-05
genetic O 0 2.8606247724383138e-05
locus O 0 0.00023938172671478242
of O 0 1.7318723621428944e-05
the O 0 3.848068445222452e-05
disease O 1 0.8775048851966858
is O 0 3.554651812009979e-06
the O 0 1.325893845205428e-05
AVP O 1 0.8585859537124634
- O 0 8.917373634176329e-05
neurophysin O 0 0.00044164303108118474
II O 1 0.6781294345855713
( O 0 2.1638916223309934e-06
NPII O 0 0.002303458983078599
) O 0 2.5673858772279345e-07
gene O 0 2.370122729189461e-07
, O 0 1.36480352352919e-07
and O 0 8.049447330904513e-08
mutations O 0 3.9046165056788595e-07
that O 0 2.566328305420029e-07
cause O 0 2.4294724425999448e-05
ADNDI B-Disease 0 0.007482546381652355
have O 0 1.1486289253070936e-07
been O 0 2.477418377111462e-07
found O 0 8.717565691540585e-08
in O 0 7.626646691960559e-08
both O 0 4.8059394686106316e-08
the O 0 7.684468528168509e-07
signal O 0 9.677205525804311e-06
peptide O 0 2.7515936835698085e-06
of O 0 2.067771902147797e-06
the O 0 8.40755910758162e-06
prepro O 0 0.009047881700098515
- O 0 0.1184074804186821
AVP O 1 0.9990352392196655
- O 0 0.00011129750782856718
NPII O 0 0.0003246372798457742
precursor O 0 7.011938123469008e-06
and O 0 2.969776460304274e-07
within O 0 1.4015075748829986e-06
NPII O 0 0.0008790243300609291
itself O 0 7.463496785931056e-06
. O 0 1.1724100659193937e-05

An O 0 5.51622397324536e-05
affected O 0 2.2330716092255898e-05
girl O 0 2.29662600759184e-05
who O 0 8.419438017881475e-07
presented O 0 1.5151770185184432e-06
at O 0 3.6775859371118713e-06
9 O 0 3.028230594281922e-06
months O 0 6.238094556465512e-07
of O 0 6.756620791747991e-07
age O 0 1.261274519492872e-06
and O 0 3.335476321808528e-07
her O 0 2.977576968987705e-06
similarly O 0 8.635845915705431e-06
affected O 0 3.260166749896598e-06
younger O 0 5.26932717548334e-06
brother O 0 1.14448612293927e-05
and O 0 2.5763384314814175e-07
father O 0 2.8514523364719935e-06
were O 0 3.15856482302479e-07
all O 0 2.2814727884679087e-08
found O 0 8.561763564784997e-08
to O 0 4.6600224123949374e-08
have O 0 5.804250235996733e-08
a O 0 6.112033474892087e-07
novel O 0 2.3608899937244132e-06
missense O 0 9.836132448981516e-06
mutation O 0 4.797134351974819e-06
( O 0 3.795877091761213e-06
G1758 O 0 0.00032663499587215483
- O 0 5.437740037450567e-05
- O 0 7.651558553334326e-05
> O 0 1.701781729934737e-05
T O 0 1.049529601004906e-05
) O 0 1.7011127795285574e-07
encoding O 0 3.861246966607723e-07
the O 0 1.0113091093444382e-06
amino O 0 1.7883918417282985e-06
acid O 0 1.5337218428612687e-06
substitution O 0 7.002675829426153e-06
Gly23 O 0 0.00014731400005985051
- O 0 5.478577804751694e-05
- O 0 4.4056312617613e-05
> O 0 1.8211938368040137e-05
Val O 0 3.767422094824724e-05
within O 0 3.731831839104416e-06
NPII O 0 0.000985980499535799
. O 0 1.4098475730861537e-05

The O 0 2.888222661567852e-05
mutation O 0 2.0008945284644142e-05
was O 0 2.6196885301033035e-05
confirmed O 0 3.7567772324109683e-06
by O 0 1.027356120175682e-06
restriction O 0 2.0326200683484785e-05
endonuclease O 0 0.0006393634830601513
analysis O 0 1.756834717525635e-05
. O 0 1.496811364631867e-05

A O 0 0.0022895485162734985
T1 O 1 0.9728677868843079
- O 0 0.00010167025175178424
weighted O 0 2.3236043489305303e-05
magnetic O 0 1.7621368897380307e-05
resonance O 0 1.6976873666862957e-05
imaging O 0 6.613666482735425e-05
of O 0 7.530086804763414e-06
the O 0 1.4607946468458977e-05
fathers O 0 0.00010560484952293336
pituitary O 1 0.9998511075973511
gland O 1 0.9409938454627991
demonstrates O 0 2.2527714463649318e-05
an O 0 1.5517563952016644e-05
attenuated O 1 0.9908307790756226
posterior O 1 0.9999926090240479
pituitary O 1 0.9999998807907104
bright O 1 0.9287468791007996
spot O 0 0.005380368325859308
. O 0 3.09808092424646e-05

This O 0 9.751233847055119e-06
mutation O 0 1.4896542779752053e-05
may O 0 3.5134537483827444e-06
be O 0 1.596291241412473e-07
valuable O 0 3.4444715879544674e-07
for O 0 1.1095879415279342e-07
developing O 0 4.0712907889428607e-07
models O 0 3.966752331052703e-07
of O 0 2.779884425763157e-06
dominantly B-Disease 0 0.2609099745750427
inherited I-Disease 1 0.9992119073867798
neurodegeneration I-Disease 1 1.0
, O 0 1.3630894954985706e-06
as O 0 1.6967834426395711e-07
the O 0 1.2792366987923742e-07
early O 0 4.236339634644537e-07
age O 0 5.9797531548611e-07
of O 0 3.2745408589107683e-06
onset O 1 0.9991422891616821
of O 0 9.906729246722534e-05
symptoms O 1 0.5350211262702942
suggests O 0 1.1370210586392204e-06
that O 0 5.656659851638324e-08
this O 0 8.351425861974349e-08
mutation O 0 4.2929320898110745e-07
may O 0 3.9603830259693495e-07
be O 0 1.2758155776282365e-07
particularly O 0 2.8925339279339823e-07
deleterious O 0 1.7634650930631324e-06
to O 0 4.862279752160248e-07
the O 0 9.928397957992274e-06
magnocellular O 0 0.001973249949514866
neuron O 0 0.0008743472280912101
. O 0 4.739477844850626e-06
. O 0 1.885737401607912e-05

Frequent O 0 0.00043734986684285104
inactivation O 1 0.9349895119667053
of O 0 0.0006495059933513403
PTEN O 1 0.9999994039535522
/ O 1 0.5472445487976074
MMAC1 O 1 0.997480571269989
in O 0 3.9801234379410744e-05
primary O 1 0.9999942779541016
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0014972840435802937

Sporadic B-Disease 1 0.9999960660934448
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 0.00012253838940523565
the O 0 1.7044089872797485e-06
most O 0 1.756401104557881e-07
common O 0 4.0963527681014966e-07
male B-Disease 0 1.1498456842673477e-05
cancer I-Disease 0 0.005966009572148323
in O 0 4.240762052631908e-07
the O 0 5.176951276553154e-07
Western O 0 1.5735632814539713e-06
world O 0 2.8230530801920395e-07
, O 0 3.283679106402815e-08
yet O 0 1.7694132381507188e-08
many O 0 3.6432024064225743e-09
of O 0 5.0903942394597834e-08
the O 0 1.1212935646653932e-07
major O 0 4.690591595135629e-07
genetic O 0 1.7634671678479208e-07
events O 0 1.52038353462558e-07
involved O 0 1.7659142770298786e-07
in O 0 1.413492753954415e-07
the O 0 2.970022876525036e-07
progression O 0 1.1016732969437726e-05
of O 0 2.7305350158712827e-07
this O 0 1.525738895225004e-07
often O 0 5.997778771416051e-07
fatal O 1 0.9593886137008667
cancer B-Disease 1 0.9298840761184692
remain O 0 1.7746065168466885e-06
to O 0 2.7200400154470117e-07
be O 0 2.7667213089443976e-06
elucidated O 0 0.0007044724188745022
. O 0 1.0589296834950801e-05

Numerous O 0 4.9373651563655585e-05
cytogenetic O 0 0.028454715386033058
and O 0 6.80254697726923e-06
allelotype O 0 0.00024481682339683175
studies O 0 5.325057372829178e-06
have O 0 2.907845555455424e-07
reported O 0 1.3490036963048624e-06
frequent O 0 1.7838575558926095e-06
loss O 0 3.38209792971611e-05
of O 0 8.762959623709321e-06
heterozygosity O 1 0.7235044836997986
on O 0 7.80926420702599e-05
chromosomal O 1 0.999954342842102
arm O 1 0.9984775185585022
10q O 1 0.7762029767036438
in O 0 2.5924133296939544e-05
sporadic B-Disease 1 0.9999984502792358
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00029656043625436723

Deletion O 0 0.00032212925725616515
mapping O 0 5.139759014127776e-05
studies O 0 6.912365734024206e-06
have O 0 9.7704355539463e-07
unambiguously O 0 8.990053174784407e-06
identified O 0 1.2737978067889344e-06
a O 0 8.235421660174325e-07
region O 0 4.862019977736054e-07
of O 0 1.1157291055496898e-06
chromosome O 0 0.00016380766464862972
10q23 O 0 0.000135495065478608
to O 0 1.7726364376358106e-07
be O 0 1.4965725370075234e-07
the O 0 2.2781208031119604e-07
minimal O 0 2.3253010112966876e-06
area O 0 3.146081780869281e-06
of O 0 7.620024916832335e-06
loss O 0 0.001350828679278493
. O 0 1.8563638150226325e-05

A O 0 0.00021930274670012295
new O 0 1.688925112830475e-05
tumor B-Disease 1 0.9891124367713928
suppressor O 1 0.9990492463111877
gene O 0 1.183400490845088e-05
, O 0 4.351108600531006e-06
PTEN O 1 0.9872335195541382
/ O 0 9.240950021194294e-05
MMAC1 O 0 0.048161398619413376
, O 0 6.246320936043048e-07
was O 0 6.217536338226637e-06
isolated O 0 9.740329005580861e-07
recently O 0 1.128016833717993e-06
at O 0 6.197913648975373e-07
this O 0 3.661113368025326e-08
region O 0 1.3918095476128656e-07
of O 0 8.656275554130843e-07
chromosome O 0 0.00017747028323356062
10q23 O 0 0.00017662350728642195
and O 0 1.7710414113025763e-07
found O 0 8.459771549951256e-08
to O 0 2.566915213719767e-08
be O 0 1.1875657435211906e-07
inactivated O 0 2.611925765449996e-06
by O 0 5.281615145236174e-08
mutation O 0 2.2152352130433428e-07
in O 0 6.820233693360933e-07
three O 0 3.289155210950412e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9997764229774475
lines O 0 0.0003655105538200587
. O 0 2.59870539593976e-05

We O 0 2.6054869522340596e-05
screened O 0 0.00019802816677838564
80 O 0 0.00029945155256427824
prostate B-Disease 1 0.9999998807907104
tumors I-Disease 1 1.0
by O 0 3.7933366456854856e-06
microsatellite O 0 0.000657705997582525
analysis O 0 1.0118541240444756e-06
and O 0 1.0914919812421431e-07
found O 0 3.3649050124040514e-07
chromosome O 0 3.960862522944808e-05
10q23 O 0 7.246120367199183e-05
to O 0 3.458108039922081e-07
be O 0 4.081153122115211e-07
deleted O 0 5.565875653701369e-07
in O 0 8.675895060150651e-07
23 O 0 1.63750046340283e-05
cases O 0 3.5133903111272957e-06
. O 0 1.318044542131247e-05

We O 0 7.99258668848779e-06
then O 0 1.562934016874351e-06
proceeded O 0 2.5937681584764505e-06
with O 0 8.11284195378903e-08
sequence O 0 3.254089335769095e-07
analysis O 0 1.8431269666052685e-07
of O 0 3.663950280952122e-07
the O 0 6.503154850179271e-07
entire O 0 8.754273039812688e-06
PTEN O 1 0.931626558303833
/ O 0 4.3467098294058815e-05
MMAC1 O 0 0.0002448486047796905
coding O 0 3.6949277273379266e-06
region O 0 5.786563406218193e-07
and O 0 2.2449931691426173e-07
tested O 0 5.154206519364379e-07
for O 0 1.7482810221736145e-07
homozygous O 0 1.765304205036955e-06
deletion O 0 1.5790064935572445e-06
with O 0 1.0385591053818644e-07
new O 0 5.29058922893455e-07
intragenic O 0 7.032685061858501e-06
markers O 0 5.767082598140405e-07
in O 0 7.933513757052424e-08
these O 0 2.5575271678235367e-08
23 O 0 1.182529217658157e-06
cases O 0 1.4183268604028854e-07
with O 0 3.5045383128817775e-07
10q23 O 0 0.001956685446202755
loss O 0 0.00012661975051742047
of O 0 0.00017934096103999764
heterozygosity O 1 0.6603220701217651
. O 0 3.108839155174792e-05

The O 0 1.9294300727779046e-05
identification O 0 5.435337698145304e-06
of O 0 3.990640379925026e-06
the O 0 2.7781879907706752e-06
second O 0 5.5704867918393575e-06
mutational O 0 5.91005155001767e-05
event O 0 1.4920178728061728e-06
in O 0 4.1451136212344863e-07
10 O 0 3.2596335586276837e-07
( O 0 1.7544994079798926e-07
43 O 0 2.5252841169276508e-06
% O 0 1.6386280776714557e-06
) O 0 4.077763151144609e-06
tumors B-Disease 1 1.0
establishes O 0 0.007360370829701424
PTEN O 1 0.9999961853027344
/ O 0 0.00038605736335739493
MMAC1 O 0 0.0009689549333415926
as O 0 3.392535461443913e-07
a O 0 3.3145192901429255e-07
main O 0 1.6129972664202796e-06
inactivation O 0 4.782805990544148e-05
target O 0 6.51082473268616e-07
of O 0 1.007594960356073e-06
10q O 0 4.287517367629334e-05
loss O 0 1.0599087545415387e-05
in O 0 5.176786544325296e-06
sporadic B-Disease 1 0.9999819993972778
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.53296057053376e-05
. O 0 1.747604073898401e-05

Risk O 0 0.0003027155762538314
reversals O 0 0.0002608817012514919
in O 0 2.4623109311505686e-06
predictive O 0 3.275763810961507e-05
testing O 0 1.2647262337850407e-05
for O 0 4.741946031572297e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.79790433018934e-05

The O 0 1.6492907889187336e-05
first O 0 4.997309133614181e-06
predictive O 0 3.765949441003613e-05
testing O 0 1.0595904313959181e-05
for O 0 1.7839556676335633e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999990463256836
( O 0 2.35656648328586e-06
HD B-Disease 0 3.4407199564157054e-05
) O 0 2.497472735285555e-07
was O 0 1.507825459157175e-06
based O 0 8.814910046339719e-08
on O 0 3.2984314657369396e-07
analysis O 0 1.9694296327088523e-07
of O 0 6.299563892753213e-07
linked O 0 7.844293577363715e-06
polymorphic O 0 2.7440623853181023e-06
DNA O 0 8.208299959733267e-07
markers O 0 1.569188839312119e-06
to O 0 1.3413678345841618e-07
estimate O 0 8.439069461019244e-07
the O 0 3.106270298758318e-07
likelihood O 0 5.6631802181073e-07
of O 0 6.359982762660366e-07
inheriting O 0 4.168810846749693e-06
the O 0 7.775406061227841e-07
mutation O 0 1.1657745062620961e-06
for O 0 1.31295848859736e-06
HD B-Disease 0 0.00010792991088237613
. O 0 8.589127901359461e-06

Limits O 0 1.5443274605786428e-05
to O 0 4.6986994561848405e-07
accuracy O 0 2.317649887118023e-06
included O 0 3.4757539424390416e-07
recombination O 0 4.304168612634385e-07
between O 0 2.30525586175645e-07
the O 0 3.691630752200581e-07
DNA O 0 8.337013355230738e-07
markers O 0 1.6668282114551403e-06
and O 0 2.0479062357026123e-07
the O 0 1.0714443305914756e-06
mutation O 0 2.1905475477979053e-06
, O 0 6.838124591013184e-07
pedigree O 0 6.445230610552244e-06
structure O 0 1.4820442402196932e-06
, O 0 1.6084460696674796e-07
and O 0 3.790464830899509e-08
whether O 0 2.8587875178232025e-08
DNA O 0 3.3766320939321304e-07
samples O 0 2.3191125819721492e-07
were O 0 4.1686575968924444e-07
available O 0 1.404913092528659e-07
from O 0 6.300297172856517e-07
family O 0 9.873056114884093e-07
members O 0 1.3169388921596692e-06
. O 0 7.551639555458678e-06

With O 0 6.056526217435021e-06
direct O 0 8.778049050306436e-06
tests O 0 1.9019456658497802e-06
for O 0 3.7482922721210343e-07
the O 0 5.11396422098187e-07
HD B-Disease 0 3.945081061829114e-06
mutation O 0 2.400509231392789e-07
, O 0 7.415822977918651e-08
we O 0 1.6321129336915874e-08
have O 0 1.8050309691375332e-08
assessed O 0 2.4963156874946435e-07
the O 0 6.331352864208384e-08
accuracy O 0 4.2216308315801143e-07
of O 0 3.807860480264935e-07
results O 0 5.161191438673995e-07
obtained O 0 6.996694992267294e-07
by O 0 2.4568547019043763e-07
linkage O 0 4.9831746764539275e-06
approaches O 0 4.1900085534507525e-07
when O 0 9.193001915264176e-08
requested O 0 1.10059403368723e-07
to O 0 5.980038508823782e-08
do O 0 5.06684578738259e-08
so O 0 4.087205240921321e-08
by O 0 8.443377907951799e-08
the O 0 6.654103117398336e-07
test O 0 1.370436962133681e-06
individuals O 0 7.453990065187099e-07
. O 0 9.955085261026397e-06

For O 0 5.827150289405836e-06
six O 0 9.102774924940604e-07
such O 0 7.372104704472804e-08
individuals O 0 2.5880398268895988e-08
, O 0 5.9146771036466816e-08
there O 0 6.888669190630026e-08
was O 0 1.5234736565616913e-06
significant O 0 2.174637785401501e-07
disparity O 0 1.3567358791988227e-06
between O 0 5.642080509460357e-07
the O 0 1.9616556983237388e-06
tests O 0 4.523270945355762e-06
. O 0 1.2318480912654195e-05

Three O 0 1.548741784063168e-05
went O 0 7.768848263367545e-06
from O 0 6.353551498250454e-07
a O 0 1.156389089373988e-06
decreased O 0 2.2256577722146176e-05
risk O 0 5.604813395621022e-07
to O 0 3.3092064199991e-08
an O 0 2.623489194775175e-07
increased O 0 4.323444500187179e-06
risk O 0 1.4005629509483697e-06
, O 0 6.494143178770173e-08
while O 0 4.4843556423757036e-08
in O 0 5.112881851232487e-08
another O 0 8.2572782389434e-08
three O 0 4.680706666704282e-08
the O 0 5.222433401286253e-07
risk O 0 2.9931534299976192e-06
was O 0 0.00020785076776519418
decreased O 0 0.0028167283162474632
. O 0 1.0863523129955865e-05

Knowledge O 0 3.945533899241127e-05
of O 0 4.820449248654768e-06
the O 0 1.9602175598265603e-06
potential O 0 1.1934655503864633e-06
reasons O 0 1.9595189826304704e-07
for O 0 4.272608222777308e-08
these O 0 1.1301349189807297e-08
changes O 0 2.2789850007143286e-08
in O 0 8.060570166890102e-08
results O 0 1.3179246138861345e-07
and O 0 4.549902854478205e-08
impact O 0 4.161960305282264e-07
of O 0 2.1073633149626403e-07
these O 0 9.108422460712973e-08
risk O 0 2.1652085706591606e-06
reversals O 0 2.7054049496655352e-05
on O 0 1.2419183121892274e-06
both O 0 2.2714564806847193e-07
patients O 0 1.9623726643658301e-07
and O 0 1.300471552667659e-07
the O 0 8.384814691453357e-07
counseling O 0 6.019955094416218e-07
team O 0 8.970236820005084e-08
can O 0 1.484718570310406e-08
assist O 0 1.0036095687837587e-07
in O 0 8.491781500197249e-08
the O 0 1.717393729450123e-07
development O 0 2.278753186146787e-07
of O 0 2.925552848864754e-07
strategies O 0 1.495799040185375e-07
for O 0 6.073712199849979e-08
the O 0 4.0829203840075934e-07
prevention O 0 1.7538615111334366e-06
and O 0 8.562171416315323e-08
, O 0 7.590294615056337e-08
where O 0 1.1004765099187352e-07
necessary O 0 1.5821976262486714e-07
, O 0 2.4648878138577857e-07
management O 0 8.823243433653261e-07
of O 0 3.565145618722454e-07
a O 0 2.0678271539509296e-06
risk O 0 2.1331939024094027e-06
reversal O 0 3.1269557894120226e-06
in O 0 6.033277344386079e-08
any O 0 4.745004389405949e-08
predictive O 0 1.3707062862522434e-06
testing O 0 4.4324454506750044e-07
program O 0 9.164672860606515e-07
. O 0 4.995661697648757e-07
. O 0 4.651857125281822e-06

A O 0 7.407892553601414e-05
novel O 0 9.778408639249392e-06
common O 0 2.4947548808995634e-06
missense O 0 2.037767626461573e-05
mutation O 0 9.137896086031105e-06
G301C O 0 8.488029561704025e-05
in O 0 1.945881422216189e-06
the O 0 4.220079517835984e-06
N O 0 3.114961873507127e-05
- O 0 2.5529043341521174e-05
acetylgalactosamine O 0 0.00015999733295757324
- O 0 3.1093550205696374e-05
6 O 0 4.22517659899313e-05
- O 0 4.639690450858325e-05
sulfate O 0 3.351167470100336e-05
sulfatase O 0 0.0001231533824466169
gene O 0 2.5869203454931267e-06
in O 0 4.761218860949157e-06
mucopolysaccharidosis B-Disease 0 0.0016079297056421638
IVA I-Disease 1 0.8319696187973022
. O 0 2.9676026315428317e-05

Mucopolysaccharidosis B-Disease 1 0.9509522914886475
IVA I-Disease 1 0.9999474287033081
( O 0 0.0008387562702409923
MPS B-Disease 1 0.9999935626983643
IVA I-Disease 1 1.0
) O 0 2.6678774247557158e-06
is O 0 3.3208030458808935e-07
an O 0 1.000171437226527e-06
autosomal B-Disease 1 0.8943993449211121
recessive I-Disease 1 0.9999996423721313
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.999995231628418
by O 0 4.0465634810971096e-05
a O 1 0.6319862008094788
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999996423721313
in O 0 0.0004068505368195474
N O 0 0.029178211465477943
- O 0 0.031063862144947052
acetylgalactosamine O 1 0.8096907138824463
- O 0 0.0005271650152280927
6 O 0 0.00023029166914056987
- O 0 0.0009961805772036314
sulfate O 0 0.00018083849863614887
sulfatase O 0 0.0020023381803184748
( O 0 6.4400692281196825e-06
GALNS O 0 0.008962372317910194
) O 0 6.631318228755845e-06
. O 0 7.221973191917641e-06

In O 0 1.4033791558176745e-05
previous O 0 4.701690158981364e-06
studies O 0 4.793960670212982e-06
, O 0 4.157315061092959e-07
we O 0 9.303441572683369e-08
have O 0 6.78603626624863e-08
found O 0 6.099705274209555e-08
two O 0 2.877096072495533e-08
common O 0 8.892472180832556e-08
mutations O 0 6.920445230207406e-07
in O 0 1.0034312936113565e-06
Caucasians O 0 5.0560274758026935e-06
and O 0 1.040980123434565e-06
Japanese O 0 3.6125460610492155e-05
, O 0 2.1743007891927846e-06
respectively O 0 1.896605135698337e-05
. O 0 1.4219595868780743e-05

To O 0 2.483756725268904e-05
characterize O 0 5.794553362648003e-05
the O 0 9.966190191335045e-06
mutational O 0 0.00037491353577934206
spectrum O 0 4.326092494011391e-06
in O 0 2.557484037879476e-07
various O 0 4.2607346983913885e-08
ethnic O 0 4.728146407728673e-08
groups O 0 2.0083453122765604e-08
, O 0 6.30350598385121e-08
mutations O 0 1.7918799244398542e-07
in O 0 4.573438445731881e-07
the O 0 1.428397695235617e-06
GALNS O 0 0.00024414691142737865
gene O 0 7.656378784304252e-07
in O 0 2.1136602299520746e-06
Colombian O 0 0.00017417791241314262
MPS B-Disease 1 0.9990313053131104
IVA I-Disease 1 0.9999998807907104
patients O 0 2.84412499240716e-06
were O 0 6.055158792150905e-07
investigated O 0 1.8934197214548476e-06
, O 0 1.072372910471131e-07
and O 0 6.533452534540629e-08
genetic O 0 2.831141330261744e-07
backgrounds O 0 8.588045830038027e-08
were O 0 9.047077043078389e-08
extensively O 0 1.4388854197022738e-07
analyzed O 0 8.030201570363715e-08
to O 0 3.0997714617342353e-08
identify O 0 5.060452323846221e-08
racial O 0 3.732667721578764e-07
origin O 0 4.731321894269058e-07
, O 0 2.854971228316572e-07
based O 0 3.9967011389308027e-07
on O 0 1.5906442740742932e-06
mitochondrial O 0 2.672500158951152e-05
DNA O 0 4.950798029312864e-06
( O 0 1.0405919965705834e-06
mtDNA O 0 6.007939191476908e-06
) O 0 1.6570805883020512e-06
lineages O 0 1.0077918886963744e-05
. O 0 1.266978961211862e-05

Three O 0 1.4051334801479243e-05
novel O 0 7.385879143839702e-06
missense O 0 2.427647268632427e-05
mutations O 0 4.887812792730983e-06
never O 0 2.5940723844541935e-06
identified O 0 1.7248240737899323e-06
previously O 0 8.615919000476424e-07
in O 0 1.3987313707275462e-07
other O 0 2.718768676857053e-08
populations O 0 4.435731071339433e-08
and O 0 7.342480756733494e-08
found O 0 2.59058168694537e-07
in O 0 6.840850801381748e-07
16 O 0 1.1930308119190158e-06
out O 0 3.0536210715581547e-07
of O 0 2.5049059786397265e-06
19 O 0 2.6564159270492382e-05
Colombian O 0 5.662787225446664e-05
MPS B-Disease 0 0.0068327500484883785
IVA I-Disease 1 0.9803664088249207
unrelated O 0 3.1079109703568975e-06
alleles O 0 1.1411763125579455e-06
account O 0 6.715001745760674e-07
for O 0 1.392227773067134e-06
84 O 0 6.02136533416342e-05
. O 0 1.557661744300276e-05

2 O 0 3.316690708743408e-05
% O 0 2.8865038075309712e-06
of O 0 1.8946624322779826e-06
the O 0 6.793222837586654e-07
alleles O 0 6.729329697918729e-07
in O 0 2.897276942803728e-07
this O 0 4.309487735554285e-07
study O 0 2.3873460577306105e-06
. O 0 4.58399790659314e-06

The O 0 0.00018122307665180415
G301C O 0 0.0009781953413039446
and O 0 6.804616077715764e-06
S162F O 0 0.00014422547246795148
mutations O 0 7.629957508470397e-06
account O 0 2.2216127035790123e-06
for O 0 3.1200836474454263e-06
68 O 0 0.000153928020154126
. O 0 3.7507204979192466e-05

4 O 0 0.00012214231537654996
% O 0 1.968525793927256e-05
and O 0 1.3445274817058817e-05
10 O 0 3.886526610585861e-05
. O 0 3.280274904682301e-05

5 O 0 2.225740536232479e-05
% O 0 1.961838961506146e-06
of O 0 1.017641920952883e-06
mutations O 0 1.6347992186638294e-06
, O 0 8.644173021821189e-07
respectively O 0 1.928287247210392e-06
, O 0 1.7072041202936816e-07
whereas O 0 1.377563592086517e-07
the O 0 2.7970423843726167e-07
remaining O 0 5.103075864099083e-07
F69V O 0 5.6966444390127435e-05
is O 0 1.700149425687414e-07
limited O 0 8.897765724213968e-08
to O 0 7.745803287662056e-08
a O 0 1.298313122788386e-06
single O 0 3.2596724395261845e-06
allele O 0 1.2423432963259984e-05
. O 0 8.394733413297217e-06

The O 0 6.132834096206352e-05
skewed O 0 0.00010615428618621081
prevalence O 0 0.00011457708751549944
of O 0 9.006166692415718e-06
G301C O 0 0.00011249264207435772
in O 0 9.040674626703549e-07
only O 0 3.873746834415215e-07
Colombian O 0 1.6103744201245718e-05
patients O 0 7.863054065637698e-07
and O 0 4.6785245899627625e-07
haplotype O 0 2.9801462005707435e-05
analysis O 0 5.291931302053854e-07
by O 0 1.8337610185881204e-07
restriction O 0 1.0139732466996065e-06
fragment O 0 9.107168352784356e-07
length O 0 4.584945543228969e-07
polymorphisms O 0 8.642673492431641e-07
in O 0 4.1356767610523093e-07
the O 0 7.756815989523602e-07
GALNS O 0 7.731917867204174e-05
gene O 0 5.265371214591141e-07
suggest O 0 2.933221594503266e-07
that O 0 2.7284420411888277e-07
G301C O 0 1.5510491721215658e-05
originated O 0 1.4275806279329117e-06
from O 0 4.832020294998074e-07
a O 0 2.316724021511618e-06
common O 0 2.474257144058356e-06
ancestor O 0 6.64539766148664e-05
. O 0 1.819126555346884e-05

Investigation O 0 8.270968100987375e-05
of O 0 5.015203441871563e-06
the O 0 2.2212736894289264e-06
genetic O 0 3.3639598768786527e-06
background O 0 8.890248750503815e-07
by O 0 1.5810874742783199e-07
means O 0 1.409036514132822e-07
of O 0 4.129437627398147e-07
mtDNA O 0 8.099574984044011e-07
lineages O 0 1.3272584453716263e-07
indicate O 0 1.0777884540402738e-07
that O 0 1.603392796312164e-08
all O 0 3.57881511092728e-08
our O 0 1.933486117877692e-07
patients O 0 2.353567367663345e-07
are O 0 6.127609708528325e-08
probably O 0 6.218101589183789e-07
of O 0 1.4910917798260925e-06
native O 0 6.085614131734474e-06
American O 0 8.161172445397824e-05
descent O 0 0.0013193765189498663

Low O 0 0.00011871391325257719
frequency O 0 1.229932331625605e-05
of O 0 3.977934738941258e-06
BRCA1 O 0 6.699870573356748e-05
germline O 0 4.202171476208605e-05
mutations O 0 1.0737550155681674e-06
in O 0 8.16755459709384e-07
45 O 0 6.231248789845267e-06
German O 1 0.9997829794883728
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.6637320085428655e-05
. O 0 3.9937582187121734e-05

In O 0 2.7250716811977327e-06
this O 0 2.2874341709666624e-07
study O 0 3.5734342418436427e-07
we O 0 7.333090223937688e-08
investigated O 0 1.2743724937536172e-06
45 O 0 5.342346867109882e-06
German O 1 0.9999330043792725
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.326544456034753e-07
for O 0 4.253719509961229e-07
germline O 0 4.529913712758571e-05
mutations O 0 5.587185682998097e-07
in O 0 5.52654000784969e-07
the O 0 2.4189082523662364e-06
BRCA1 O 0 8.249409438576549e-05
gene O 0 3.277551513747312e-05
. O 0 2.0103581846342422e-05

We O 0 1.243215683643939e-05
identified O 0 9.65249455475714e-06
four O 0 2.02354863176879e-06
germline O 0 0.0001200962724396959
mutations O 0 3.893345365213463e-06
in O 0 2.3398401935992297e-06
three O 0 6.752055014658254e-06
breast B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999562501907349
families O 0 2.806940244681755e-07
and O 0 4.3259296944597736e-07
in O 0 3.5001335163542535e-06
one O 0 0.13155712187290192
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.455989932874218e-06
. O 0 7.452377559502565e-08
among O 0 1.7311764466398927e-08
these O 0 5.465205177301868e-09
were O 0 8.03646855729312e-08
one O 0 1.3805517085074825e-07
frameshift O 0 7.510492650908418e-06
mutation O 0 6.213306278368691e-07
, O 0 1.8293033576810558e-07
one O 0 1.9581476351504534e-07
nonsense O 0 7.856954653107096e-06
mutation O 0 6.839415505055513e-07
, O 0 1.5374898509890045e-07
one O 0 9.102517850578806e-08
novel O 0 4.627366365639318e-07
splice O 0 2.152764182028477e-06
site O 0 6.00210398715717e-07
mutation O 0 5.208754600971588e-07
, O 0 1.0450489185132028e-07
and O 0 1.5987090762337175e-07
one O 0 9.070018904822064e-07
missense O 0 8.832920138956979e-05
mutation O 0 5.5988191888900474e-05
. O 0 2.0071094695595093e-05

The O 0 2.590258554846514e-05
missense O 0 8.950146730057895e-05
mutation O 0 2.982574369525537e-05
was O 0 5.618855357170105e-05
also O 0 2.3971379050635733e-06
found O 0 1.3468016959450324e-06
in O 0 2.3614056772203185e-06
2 O 0 1.9556075130822137e-05
. O 0 2.1435214875964448e-05

8 O 0 3.711811586981639e-05
% O 0 2.0620825580408564e-06
of O 0 1.1139960633954615e-06
the O 0 7.463236784133187e-07
general O 0 8.604504841969174e-07
population O 0 8.960916630940119e-08
, O 0 9.504141473826166e-08
suggesting O 0 3.8213752873161866e-07
that O 0 4.0186083793969374e-08
it O 0 7.029252913071105e-08
is O 0 6.095496019042912e-07
not O 0 1.5721727777417982e-06
disease O 1 0.9570791125297546
associated O 0 5.5972443078644574e-05
. O 0 2.7044710805057548e-05

The O 0 2.0376472093630582e-05
average O 0 1.2458741366572212e-05
age O 0 6.047822353139054e-06
of O 0 4.3380761781008914e-05
disease O 1 0.9999967813491821
onset O 1 0.999988317489624
in O 0 3.1967620088835247e-06
those O 0 1.698645348824357e-07
families O 0 1.7881549752019055e-07
harbouring O 0 9.568424866301939e-05
causative O 0 2.9605191230075434e-05
mutations O 0 3.2854195524123497e-06
was O 0 0.00011664339399430901
between O 0 6.892788405821193e-06
32 O 0 3.9228994864970446e-05
. O 0 2.027200025622733e-05

3 O 0 0.000171623716596514
and O 0 2.84625402855454e-05
37 O 0 0.0002673300914466381
. O 0 4.685152816819027e-05

4 O 0 7.580710371257737e-05
years O 0 7.617953997396398e-06
, O 0 1.1498185585878673e-06
whereas O 0 5.143967882759171e-07
the O 0 5.384244445849617e-07
family O 0 6.162715067148383e-07
harbouring O 0 4.433181311469525e-05
the O 0 5.976378361083334e-07
missense O 0 6.708103683195077e-06
mutation O 0 1.7908787413034588e-06
had O 0 4.78409992865636e-06
an O 0 1.3075416518404381e-06
average O 0 1.7696074792183936e-06
age O 0 8.468568921671249e-07
of O 0 4.474053184821969e-06
onset O 1 0.7322890162467957
of O 0 9.0984241978731e-05
51 O 0 0.00022466493828687817
. O 0 3.326167643535882e-05

2 O 0 0.0003672618477139622
years O 0 0.00010796704737003893
. O 0 6.793641659896821e-05

These O 0 4.825430551136378e-06
findings O 0 5.925725417910144e-06
show O 0 1.1475005976535613e-06
that O 0 5.61882984584372e-07
BRCA1 O 0 2.353777745156549e-05
is O 0 8.152013606377295e-07
implicated O 0 2.4176515580620617e-06
in O 0 7.72175923202667e-08
a O 0 9.75356897470192e-08
small O 0 5.5982056323955476e-08
fraction O 0 3.741524210454372e-07
of O 0 1.1032723705284297e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.669923658999323e-07
suggesting O 0 2.9041339075774886e-06
the O 0 4.136993823067314e-07
involvement O 0 9.24579580896534e-07
of O 0 1.8148233493775479e-06
another O 0 3.2300083603331586e-06
susceptibility O 0 0.0002543811278883368
gene O 0 3.1983578082872555e-05
( O 0 2.5523515432723798e-05
s O 0 0.0004309454816393554
) O 0 5.0023270887322724e-05

Paternal O 1 0.9165252447128296
transmission O 1 0.9997643828392029
of O 1 0.999984622001648
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.4765082001686096

We O 0 1.3679397852683906e-05
report O 0 7.711508260399569e-06
a O 0 1.4947338513593422e-06
rare O 0 2.1954917883704184e-06
case O 0 2.4087655674520647e-06
of O 0 3.216370168956928e-05
paternally O 1 0.9999890327453613
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9992961883544922
DM B-Disease 1 1.0
) O 0 3.800457852776162e-05
. O 0 1.727344533719588e-05

The O 0 0.00011101271229563281
proband O 0 0.00044593369239009917
is O 0 4.36707978224149e-06
a O 0 3.7072352370159933e-06
23 O 0 2.1772098989458755e-05
year O 0 6.981151273066644e-06
old O 0 0.00012993441487196833
, O 0 5.1681276090675965e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.18477237224578857
who O 0 0.10293899476528168
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.6726042628288269

He O 0 5.3931722504785284e-05
presented O 0 2.916276025644038e-05
with O 0 9.394976586918347e-06
respiratory O 1 1.0
and O 0 3.479696897557005e-05
feeding O 0 0.013398402370512486
difficulties O 0 0.014116179198026657
at O 0 0.02958671748638153
birth O 0 0.0017758723115548491
. O 0 5.047543527325615e-05

His O 0 0.0002376001502852887
two O 0 7.745836046524346e-05
sibs O 1 0.9998687505722046
suffer O 0 0.1540503054857254
from O 0 0.00012229185085743666
childhood O 1 0.9998929500579834
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.0013006185181438923

Their O 0 1.9552158846636303e-05
late O 0 4.048721166327596e-05
father O 0 1.3737941117142327e-05
had O 0 2.8140075301053002e-06
the O 0 9.58792952587828e-07
adult O 0 1.3980927633383544e-06
type O 0 1.4925736650184263e-05
of O 0 0.11187075078487396
DM B-Disease 1 1.0
, O 0 2.2407159576687263e-06
with O 0 5.702476641999965e-07
onset O 1 0.7943593859672546
around O 0 2.466793148414581e-06
30 O 0 4.5069341467751656e-06
years O 0 3.81484596800874e-06
. O 0 6.553417733812239e-06

Only O 0 4.961749709764263e-06
six O 0 1.0909669754255447e-06
other O 0 9.183941074297763e-08
cases O 0 1.4113038560026325e-07
of O 0 1.3565754670707975e-06
paternal O 1 0.6706634759902954
transmission O 1 0.9926515221595764
of O 1 0.9980760812759399
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 2.2559554054168984e-05
been O 0 1.7724007193464786e-05
reported O 0 1.251556932402309e-05
recently O 0 1.8846352759283036e-05
. O 0 8.100354534690268e-06

We O 0 1.0630743418005295e-05
review O 0 4.955049007548951e-06
the O 0 9.061745345206873e-07
sex O 0 7.162016117945313e-07
related O 0 1.3807139112032019e-06
effects O 0 8.857279681251384e-06
on O 0 1.4797386938880663e-05
transmission O 0 0.08414576202630997
of O 1 0.668012797832489
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0005882069817744195

Decreased O 0 0.005557653959840536
fertility O 0 0.00015283696120604873
of O 0 1.8606940557219787e-06
males O 0 5.503077886714891e-07
with O 0 2.889365759983775e-07
adult O 0 6.748127634637058e-05
onset O 1 1.0
DM B-Disease 1 1.0
and O 0 9.966884135792498e-06
contraction O 0 0.010544070042669773
of O 0 8.472599688502669e-07
the O 0 3.9171783328129095e-07
repeat O 0 2.444602955620212e-07
upon O 0 1.5415730558743235e-07
male O 0 3.493026667911181e-07
transmission O 0 8.708108225619071e-07
contribute O 0 5.2451436971523435e-08
to O 0 5.567878247347835e-08
the O 0 2.3539513449577498e-07
almost O 0 6.440435527110822e-07
absent O 0 1.8834838328984915e-06
occurrence O 0 8.721580684323271e-07
of O 0 1.5365620811280678e-06
paternal O 0 0.00040272390469908714
transmission O 0 0.015430730767548084
of O 1 0.9102302193641663
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0029105390422046185

Also O 0 3.389990160940215e-05
the O 0 6.345488600345561e-06
fathers O 0 4.109196652279934e-06
of O 0 1.948391854966758e-06
the O 0 2.854379772543325e-06
reported O 0 2.3439908545697108e-05
congenitally O 0 0.0005017354269511998
affected O 0 7.94200559539604e-07
children O 0 3.1394918664773286e-07
showed O 0 5.6289363783434965e-06
, O 0 2.222048323119452e-07
on O 0 1.4824188383499859e-06
average O 0 1.9065619198954664e-06
, O 0 6.591895385099633e-07
shorter O 0 6.7680689426197205e-06
CTG O 0 7.189947791630402e-05
repeat O 0 1.634223963264958e-06
lengths O 0 2.5810454644670244e-06
and O 0 2.55960202366623e-07
hence O 0 9.415583122063254e-07
less O 0 1.196666971736704e-06
severe O 1 0.9995129108428955
clinical O 1 0.9999902248382568
symptoms O 1 0.6577408313751221
than O 0 1.9270395057446876e-07
the O 0 4.6947442911005055e-07
mothers O 0 3.8181042327778414e-07
of O 0 9.895094308376429e-07
children O 0 3.4925444651889848e-06
with O 0 0.00018267097766511142
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.16129504144191742

We O 0 1.1869460649904795e-05
conclude O 0 2.4024469894357026e-05
that O 0 1.5274787301677861e-06
paternal O 0 0.0001559766969876364
transmission O 0 0.02637343667447567
of O 1 0.9639076590538025
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 5.169360156287439e-05
rare O 0 1.562229158480477e-06
and O 0 1.1615038175705195e-07
preferentially O 0 3.0268941486610856e-07
occurs O 0 1.6625165244477103e-07
with O 0 1.1221344209388917e-07
onset O 0 0.2658146619796753
of O 0 0.0009564597276039422
DM B-Disease 1 1.0
past O 0 2.051183400908485e-06
30 O 0 1.0048793228634167e-06
years O 0 1.936460876095225e-07
in O 0 1.8527599365825154e-07
the O 0 6.254535378502624e-07
father O 0 7.332694167416776e-06
. O 0 1.6821968529256992e-06
. O 0 9.996870176109951e-06

The O 0 9.578566096024588e-05
RB1 O 0 0.0029747707303613424
gene O 0 5.195634912524838e-06
mutation O 0 3.466756652414915e-06
in O 0 1.1345633765813545e-06
a O 0 4.502822775975801e-06
child O 0 1.7463746189605445e-05
with O 0 1.068106485035969e-05
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.0012082746252417564

The O 0 0.00025316866231150925
RB1 O 0 0.004709896631538868
gene O 0 1.3621949619846418e-05
mutation O 0 1.1089178769907448e-05
was O 0 1.7180051145260222e-05
investigated O 0 3.1433226013177773e-06
in O 0 7.172515097408905e-07
a O 0 2.9373243251029635e-06
child O 0 8.700888429302722e-06
with O 0 5.574068381974939e-06
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9998874664306641
using O 0 7.968490649545856e-07
DNA O 0 1.4707100035593612e-06
obtained O 0 9.056207659341453e-07
from O 0 3.5915073226533423e-07
both O 0 1.5989942880878516e-07
the O 0 3.7126344523130683e-06
pineal B-Disease 1 0.9630177617073059
and I-Disease 0 1.1924248610739596e-05
retinal I-Disease 1 1.0
tumours I-Disease 1 1.0
of O 1 0.5444706082344055
the O 0 0.002648072550073266
patient O 0 0.023283742368221283
. O 0 5.0853490392910317e-05

A O 0 0.00044406531378626823
nonsense O 0 0.0003058908914681524
mutation O 0 1.2857492947659921e-05
in O 0 3.6143123907095287e-06
exon O 0 7.488292339985492e-06
17 O 0 6.371940344251925e-06
( O 0 7.85650286161399e-07
codon O 0 5.6793310250213835e-06
556 O 0 4.371680461190408e-06
) O 0 2.3673442228755448e-07
of O 0 7.207705152723065e-07
the O 0 1.446338274035952e-06
RB1 O 0 9.408774349140003e-05
gene O 0 5.701345457964635e-07
was O 0 4.046369667776162e-06
found O 0 2.834188705946872e-07
to O 0 5.782922585240158e-08
be O 0 1.363694934752857e-07
present O 0 3.2589156262474717e-07
homozygously O 0 1.0699926860979758e-05
in O 0 2.6689258447731845e-07
both O 0 1.8064780249460455e-07
the O 0 3.6293756693339674e-06
retinal B-Disease 0 0.37706178426742554
and I-Disease 0 1.0957114682241809e-05
the I-Disease 0 0.00046381360152736306
pineal I-Disease 1 0.9999945163726807
tumours I-Disease 1 1.0
. O 0 0.0003864693862851709

The O 0 1.3169490557629615e-05
same O 0 1.7065412976080552e-06
mutation O 0 3.774510560106137e-06
was O 0 1.2663786037592217e-05
present O 0 5.129232931722072e-07
heterozygously O 0 1.7802458387450315e-05
in O 0 3.812046145412751e-07
the O 0 3.642801686964958e-07
DNA O 0 5.691833280252467e-07
from O 0 2.573637232217152e-07
the O 0 4.58835302197258e-07
constitutional O 0 1.1511943966979743e-06
cells O 0 6.143666837488126e-07
of O 0 6.998349704190332e-07
the O 0 1.347456873190822e-06
patient O 0 3.215231799913454e-06
, O 0 2.0057579774857004e-07
proving O 0 9.502815601081238e-07
it O 0 2.3620350120268085e-08
to O 0 3.2119292114884956e-08
be O 0 2.1971243313601008e-07
of O 0 2.8521403692138847e-06
germline O 0 0.00018345226999372244
origin O 0 1.1127952348033432e-05
. O 0 2.7190853870706633e-05

The O 0 1.1475878636701964e-05
initial O 0 6.357021447911393e-06
mutation O 0 2.8565939373947913e-06
was O 0 4.143408204981824e-06
shown O 0 1.6166626437552623e-07
to O 0 7.889722297704793e-08
have O 0 1.0841986863852071e-07
occurred O 0 2.8021893285767874e-06
in O 0 8.735189567232737e-07
the O 0 5.118158696859609e-06
paternally O 0 0.00011988447658950463
derived O 0 4.605443245964125e-05
RB1 O 0 0.00185374915599823
allele O 0 4.793906555278227e-05
. O 0 1.5105591955943964e-05

The O 0 4.335085759521462e-05
mutation O 0 1.3939355085312854e-05
is O 0 1.7939674989975174e-06
in O 0 4.795501240550948e-07
an O 0 5.261791784505476e-07
area O 0 5.239634219833533e-07
of O 0 7.438076750077016e-07
the O 0 5.849058766216331e-07
gene O 0 1.6402495361944602e-07
that O 0 1.0748835421736658e-07
encodes O 0 1.2803172921849182e-06
the O 0 1.9319816146889934e-06
protein O 0 3.207740746802301e-06
- O 0 3.057093408642686e-06
binding O 0 3.0213197987905005e-07
region O 0 2.2967591917222308e-07
known O 0 5.245858574198792e-07
as O 0 2.3567523044221161e-07
the O 0 3.402443553568446e-07
pocket O 0 3.760598247026792e-06
region O 0 2.564899546086963e-07
and O 0 1.052010532021086e-07
has O 0 1.6153373394445225e-07
been O 0 3.270269814947824e-07
detected O 0 7.823254577488115e-07
in O 0 1.847466677418197e-07
other O 0 7.836749915668406e-08
cases O 0 3.149895633214328e-07
of O 0 1.0828696758835576e-05
retinoblastoma B-Disease 1 0.7169842720031738
. O 0 6.242984454729594e-06
. O 0 7.709868441452272e-06

Low O 0 0.00040157311013899744
levels O 0 8.246658580901567e-06
of O 0 3.911230578523828e-06
beta O 0 1.6327365301549435e-05
hexosaminidase O 0 5.7068005844485015e-05
A O 0 6.132811904535629e-06
in O 0 5.219620220486831e-07
healthy O 0 6.179640763548377e-07
individuals O 0 5.7221818394737056e-08
with O 0 4.45194132225879e-07
apparent O 1 0.9989362359046936
deficiency O 1 0.9999996423721313
of O 0 0.00025101611390709877
this O 0 1.3194732673582621e-05
enzyme O 0 3.7743913708254695e-05
. O 0 2.240772664663382e-05

Appreciable O 0 0.0028031491674482822
beta O 0 0.00033360716770403087
hexosaminidase O 0 0.000937220873311162
A O 0 0.00011485339200589806
( O 0 2.958070353997755e-06
hex O 0 2.185639641538728e-05
A O 0 3.6357810131448787e-06
) O 0 1.387298596000619e-07
activity O 0 2.595455441678496e-07
has O 0 6.51406608653815e-08
been O 0 2.4436891976620245e-07
detected O 0 3.106518079221132e-06
in O 0 4.7121307034103666e-06
cultured O 1 0.999995231628418
skin O 1 1.0
fibroblasts O 1 1.0
and O 1 0.9919834733009338
melanoma B-Disease 1 1.0
tissue O 1 0.9999998807907104
from O 0 3.48554240190424e-05
healthy O 0 1.8322173218621174e-06
individuals O 0 3.685551419607691e-08
previously O 0 6.109760306571843e-07
reported O 0 1.4818803037996986e-06
as O 0 9.551615676173242e-07
having O 0 6.236105491552735e-06
deficiency B-Disease 1 0.590481162071228
of I-Disease 0 2.818546363414498e-06
hex I-Disease 0 2.5768380510271527e-05
A I-Disease 0 3.108847522526048e-06
activity O 0 1.4749097090316354e-06
indistinguishable O 0 3.1550186463391583e-07
from O 0 7.638060139925074e-08
that O 0 3.053810004871593e-08
of O 0 7.666542387596564e-07
patients O 0 3.5975137961941073e-06
with O 0 0.00025960191851481795
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 7.449205440934747e-05
TSD B-Disease 1 0.9497252702713013
) O 0 6.4930677581287455e-06
. O 0 1.7701677279546857e-05

Identification O 0 8.733176946407184e-05
and O 0 7.767366696498357e-06
quantitation O 0 0.00033841305412352085
of O 0 2.7889798730029725e-05
hex O 0 0.0002211515820818022
A O 0 2.2534008166985586e-05
, O 0 8.110642966130399e-07
amounting O 0 8.690464710525703e-06
to O 0 1.989954853343079e-06
3 O 0 3.446040136623196e-05
. O 0 3.312846820335835e-05

5 O 0 0.00028572461451403797
% O 0 6.398942787200212e-05
- O 0 0.0005594370304606855
6 O 0 0.0002669065725058317
. O 0 4.812470797332935e-05

9 O 0 4.543113027466461e-05
% O 0 1.1180724186488078e-06
of O 0 1.010086862152093e-06
total O 0 2.3498807877331274e-06
beta O 0 4.871516011917265e-06
hexosaminidase O 0 1.9711520508280955e-05
activity O 0 2.6383931981399655e-06
, O 0 1.7132518337348301e-07
has O 0 1.2042764296893438e-07
been O 0 3.816931553046743e-07
obtained O 0 1.2645396054722369e-06
by O 0 3.278146550655947e-06
cellulose O 0 0.00042422875412739813
acetate O 0 0.00010606271825963631
gel O 0 7.478701445506886e-05
electrophoresis O 0 9.733113256515935e-05
, O 0 1.116814928536769e-05
DEAE O 0 0.007936781272292137
- O 0 6.862432201160118e-05
cellulose O 0 3.78110671590548e-05
ion O 0 1.4981551430537365e-05
- O 0 1.0993348951160442e-05
exchange O 0 9.099250746658072e-06
chromatography O 0 2.389525980106555e-05
, O 0 1.5130630117710098e-06
radial O 0 0.00010251019557472318
immunodiffusion O 0 0.00012977120059076697
, O 0 2.853685600712197e-06
and O 0 7.740375622233842e-06
radioimmunoassay O 0 0.0021977098658680916
. O 0 3.168974944856018e-05

Previous O 0 4.356803037808277e-05
family O 0 5.7353818192495964e-06
studies O 0 4.356223143986426e-06
suggested O 0 8.052346629483509e-07
that O 0 1.1911659214547399e-07
these O 0 3.266463366458083e-08
individuals O 0 6.143185515838923e-08
may O 0 8.980317147688766e-07
be O 0 4.203384094125795e-07
compound O 0 8.345377864316106e-06
heterozygotes O 0 1.1479011163828545e-06
for O 0 5.992346530092618e-08
the O 0 1.5943970765874838e-07
common O 0 3.4944460480801354e-07
mutant O 0 1.54057088366244e-05
TSD B-Disease 0 0.00021439635020215064
gene O 0 6.981791216276179e-07
and O 0 3.648750634965836e-07
a O 0 1.9527560652932152e-06
rare O 0 1.4960144198994385e-06
( O 0 5.012249744140718e-07
allelic O 0 6.0303655118332244e-06
) O 0 7.852203225411358e-07
mutant O 0 1.8467759218765423e-05
gene O 0 1.5264333342202008e-05
. O 0 1.245263592863921e-05

Thus O 0 3.0634517315775156e-05
, O 0 2.5707133772812085e-06
the O 0 1.2929148169860127e-06
postulated O 0 1.0404310160083696e-05
rate O 0 2.1484204353328096e-06
mutant O 0 2.203502390329959e-06
gene O 0 4.677962408550229e-07
appears O 0 3.6919053059136786e-07
to O 0 4.351662141743873e-08
code O 0 5.541084746596425e-08
for O 0 5.032058680853879e-08
the O 0 1.735283063908355e-07
expression O 0 3.374105119746673e-07
of O 0 6.754630703653675e-07
low O 0 2.242546088382369e-06
amounts O 0 7.407820703519974e-07
of O 0 7.79538822825998e-06
hex O 0 0.0002478068054188043
A O 0 8.243659976869822e-05
. O 0 2.095939635182731e-05

Heterozygotes O 0 0.0007570147281512618
for O 0 4.6196200855774805e-06
the O 0 1.4890996453686967e-06
rare O 0 3.566866553228465e-06
mutant O 0 2.7859572583111003e-05
may O 0 2.216605707872077e-06
be O 0 2.671462198122754e-07
indistinguishable O 0 8.182968258552137e-07
from O 0 2.41674001699721e-07
heterozygotes O 0 1.4888794339640299e-06
for O 0 9.761385655338017e-08
the O 0 1.0750317187557812e-06
common O 0 6.460591066570487e-06
TSD B-Disease 0 0.0011438619112595916
mutant O 0 6.15121316513978e-05
. O 0 1.6307478290400468e-05

However O 0 1.1384163371985778e-05
, O 0 1.6572955701121828e-06
direct O 0 4.2752026274683885e-06
visualization O 0 4.493159212870523e-05
and O 0 1.0968738024530467e-06
quantitation O 0 0.0001642983843339607
of O 0 8.322489520651288e-06
hex O 0 5.772856093244627e-05
A O 0 2.9471982543327613e-06
by O 0 7.022914871868124e-08
the O 0 2.5131944880740775e-07
methods O 0 3.7779284411953995e-07
described O 0 1.3060512173979077e-06
may O 0 6.573977771040518e-07
prevent O 0 1.2595244243129855e-06
false O 0 3.532241680659354e-05
- O 0 0.00424723606556654
positive O 0 5.7240977184847e-06
prenatal O 1 0.9520530700683594
diagnosis O 1 0.7285025119781494
of O 0 2.650540045578964e-05
TSD B-Disease 0 0.41363751888275146
in O 0 1.2224659258208703e-06
fetuses O 0 4.29572310167714e-06
having O 0 7.872185392443498e-07
the O 0 1.0218763009106624e-06
incomplete O 0 1.5287805581465364e-05
hex B-Disease 0 0.00039925455348566175
A I-Disease 0 0.012307833880186081
deficiency I-Disease 1 0.8815082311630249
of O 0 3.976137122663204e-06
the O 0 2.283028152305633e-06
type O 0 5.511736162588932e-06
described O 0 4.89146850668476e-06
in O 0 9.445981845601636e-07
the O 0 2.8282045150263002e-06
four O 0 4.012346380477538e-06
healthy O 0 1.4316504348244052e-05
individuals O 0 1.085778512788238e-05

The O 0 0.0002669226087164134
tumor B-Disease 1 0.9999055862426758
suppressor O 1 0.999937891960144
gene O 0 0.00011538909166119993
Smad4 O 1 0.5675513744354248
/ O 0 0.0001729195937514305
Dpc4 O 0 7.835476571926847e-05
is O 0 1.325143728081457e-07
required O 0 3.404835169362741e-08
for O 0 1.2632389712052827e-07
gastrulation O 0 8.538483598385938e-06
and O 0 1.881757043520338e-07
later O 0 7.167270155150618e-07
for O 0 3.989929950876103e-07
anterior O 0 0.0005755734164267778
development O 0 1.497591824772826e-06
of O 0 3.617070888140006e-06
the O 0 1.1105509656772483e-05
mouse O 0 0.00010578355431789532
embryo O 0 0.00015988083032425493
. O 0 3.4704939025687054e-05

Mutations O 0 0.00011825904221041128
in O 0 1.3278348887979519e-05
the O 0 2.444082565489225e-05
SMAD4 O 1 0.9904493689537048
/ O 0 0.007675384171307087
DPC4 O 1 0.9952613711357117
tumor B-Disease 1 0.9999788999557495
suppressor O 1 0.9993839263916016
gene O 0 1.7966659697776777e-06
, O 0 2.9068749540783756e-07
a O 0 1.226735662385181e-06
key O 0 3.0450323720287997e-06
signal O 0 5.329965006239945e-06
transducer O 0 4.16920420320821e-06
in O 0 3.7836323940609873e-07
most O 0 4.726600195681385e-07
TGFbeta O 0 0.0002720290212891996
- O 0 1.8759601516649127e-05
related O 0 1.4943645965104224e-06
pathways O 0 5.8867703955911566e-06
, O 0 6.374684602405978e-08
are O 0 8.789186267676996e-09
involved O 0 4.422915012014528e-08
in O 0 1.1418007517249862e-07
50 O 0 6.097635605328833e-07
% O 0 7.373643029495724e-07
of O 0 3.321695112390444e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
. O 0 0.0002941085258498788

Homozygous O 0 0.0022348419297486544
Smad4 O 0 0.007593767251819372
mutant O 0 0.0007591524627059698
mice O 0 0.00022643111879006028
die O 0 4.9548878450877964e-05
before O 0 2.8328015559964115e-06
day O 0 4.598569375957595e-06
7 O 0 2.547932672314346e-05
. O 0 9.137616871157661e-06

5 O 0 0.00017030410526786
of O 0 6.401768769137561e-05
embryogenesis O 0 0.0018303371034562588
. O 0 0.00011897251533810049

Mutant O 0 8.596367842983454e-05
embryos O 0 1.2957456419826485e-05
have O 0 6.696379841741873e-07
reduced O 0 1.342252517133602e-06
size O 0 4.4950428446099977e-07
, O 0 4.2844533254537964e-07
fail O 0 3.4187945630037575e-07
to O 0 1.176807913338962e-07
gastrulate O 0 2.4496128389728256e-05
or O 0 3.8562274085052195e-07
express O 0 4.910262987323222e-07
a O 0 1.5895766409812495e-06
mesodermal O 0 9.265903645427898e-05
marker O 0 3.0211635021260008e-05
, O 0 2.042320375039708e-07
and O 0 1.7782272720978654e-07
show O 0 3.1611398298991844e-06
abnormal O 1 0.7749993205070496
visceral O 1 0.9889305233955383
endoderm O 1 0.9970346689224243
development O 0 0.00031749819754622877
. O 0 3.0940151191316545e-05

Growth B-Disease 1 0.9999996423721313
retardation I-Disease 1 0.9999994039535522
of O 0 0.00010848213423741981
the O 0 0.00010886597738135606
Smad4 O 1 0.9983199238777161
- O 0 0.4043034315109253
deficient O 0 0.00021826245938427746
embryos O 0 2.7227076770941494e-06
results O 0 8.609118253843917e-07
from O 0 2.4261757403110096e-07
reduced O 0 1.3968825669508078e-06
cell O 0 8.396566954615992e-06
proliferation O 0 9.258526915800758e-06
rather O 0 1.2559736717321357e-07
than O 0 1.1823087930906695e-07
increased O 0 5.472819339047419e-06
apoptosis O 0 0.00013738239067606628
. O 0 7.5693687904276885e-06

Aggregation O 0 0.0005502118146978319
of O 0 6.147823296487331e-05
mutant O 0 0.0005898360977880657
Smad4 O 1 0.5968388319015503
ES O 1 0.931072473526001
cells O 0 7.087951416906435e-06
with O 0 4.465893255201081e-07
wild O 0 5.076997695141472e-06
- O 0 1.7174743334180675e-05
type O 0 1.2512823559518438e-05
tetraploid O 0 0.000135337162646465
morulae O 0 0.00024529953952878714
rescues O 0 2.6655410692910664e-05
the O 0 6.848084012744948e-06
gastrulation B-Disease 0 0.0013773494865745306
defect I-Disease 0 0.0003215726464986801
. O 0 2.487162419129163e-05

These O 0 4.89187914354261e-06
results O 0 5.2595019042200875e-06
indicate O 0 2.327102265553549e-06
that O 0 3.9768085002833686e-07
Smad4 O 0 2.5212575565092266e-05
is O 0 2.2460702098214824e-07
initially O 0 3.4224026990159473e-07
required O 0 3.3916776942533033e-08
for O 0 5.621842902314711e-08
the O 0 3.176181166963943e-07
differentiation O 0 1.7471039654992637e-06
of O 0 1.4338393157231621e-06
the O 0 2.5932238258974394e-06
visceral O 0 0.00015484691539313644
endoderm O 0 0.00013091963774058968
and O 0 3.784830653330573e-07
that O 0 2.3306685648094572e-07
the O 0 2.100670599247678e-06
gastrulation B-Disease 0 0.00013247823517303914
defect I-Disease 0 5.771738415205618e-06
in O 0 2.9110114496688766e-07
the O 0 1.3152945257388637e-06
epiblast O 0 6.365881563397124e-05
is O 0 5.256802069197875e-07
secondary O 0 4.812801307707559e-06
and O 0 4.3588730136434606e-07
non O 0 9.560507896821946e-05
- O 0 0.0005799040663987398
cell O 0 0.00031194117036648095
autonomous O 0 2.056397352134809e-05
. O 0 1.4127398571872618e-05

Rescued O 0 0.000405074970331043
embryos O 0 7.23849589121528e-05
show O 0 8.591450023232028e-05
severe O 1 0.9996100068092346
anterior O 1 0.9999923706054688
truncations O 1 0.9982044696807861
, O 0 4.591540346154943e-06
indicating O 0 1.2432512448867783e-05
a O 0 2.0115999177505728e-06
second O 0 1.2466387033782667e-06
important O 0 2.7558482429412834e-07
role O 0 1.0139781352336286e-06
for O 0 1.0431485861772671e-06
Smad4 O 0 0.009118116460740566
in O 0 8.569785677536856e-06
anterior O 1 0.9947125911712646
patterning O 1 0.9993181228637695
during O 0 0.05628017708659172
embryogenesis O 0 0.015847720205783844
. O 0 3.3408290619263425e-05

Prevalence O 0 0.0060096257366240025
of O 0 5.052281994721852e-05
p16 O 0 0.0006809081532992423
and O 0 6.742595815012464e-06
CDK4 O 0 0.09414119273424149
germline O 0 0.0001631604100111872
mutations O 0 3.687964181153802e-06
in O 0 4.184827503195265e-06
48 O 0 0.0007313875830732286
melanoma B-Disease 1 1.0
- O 1 0.9770771861076355
prone O 0 0.00010938772902591154
families O 0 1.7473526270350703e-07
in O 0 1.507369688624749e-06
France O 0 2.2430174794862978e-05
. O 0 1.1827248272311408e-05

The O 0 6.982102058827877e-05
French O 0 0.0012574788415804505
Familial B-Disease 1 0.9999892711639404
Melanoma I-Disease 1 1.0
Study O 0 0.020296504721045494
Group O 0 6.268700235523283e-05
. O 0 2.0373576262500137e-05

Germline O 0 0.002980458550155163
mutations O 0 5.4416093917097896e-05
in O 0 6.347171165543841e-06
the O 0 5.109945504955249e-06
p16 O 0 5.0871243729488924e-05
and O 0 1.4499870530926273e-06
CDK4 O 0 0.00013241924170870334
genes O 0 4.802980129170464e-07
have O 0 1.1048194892282481e-07
been O 0 6.235976570678758e-07
reported O 0 5.108817049404024e-07
in O 0 1.344369593425654e-07
a O 0 7.784146305311879e-07
subset O 0 3.0020755730220117e-06
of O 0 9.342352313979063e-06
melanoma B-Disease 1 0.9999997615814209
pedigrees O 0 2.3027230781735852e-05
, O 0 1.6856530749009835e-07
but O 0 2.200352966497121e-08
their O 0 4.213417525988916e-08
prevalence O 0 1.139649157266831e-05
is O 0 3.014176570559357e-07
not O 0 1.6465594399051042e-07
well O 0 7.113536071301496e-07
known O 0 1.2446771506802179e-05
. O 0 9.29345242184354e-06

We O 0 9.82138044491876e-06
searched O 0 6.390208909579087e-06
for O 0 3.434745678987383e-07
such O 0 2.5822370730566035e-07
germline O 0 2.5559444111422636e-05
mutations O 0 2.357027142352308e-06
in O 0 2.8056283554178663e-06
48 O 0 4.590351090882905e-05
French O 1 0.9928112626075745
melanoma B-Disease 1 1.0
- O 1 0.8132866621017456
prone O 0 1.9258324755355716e-05
families O 0 5.386628032510998e-08
selected O 0 1.1856239012786318e-07
according O 0 5.8803916402894174e-08
to O 0 4.3346801703592064e-08
two O 0 8.054899325316e-08
major O 0 1.3269234386825701e-06
criteria O 0 3.0299528930299857e-07
families O 0 3.5207779802703953e-08
with O 0 4.9611546870664824e-08
at O 0 2.198504489570041e-06
least O 0 8.494664882618963e-08
three O 0 1.0799717387044439e-07
affected O 0 1.5410894604883651e-07
members O 0 1.090349570631588e-07
( O 0 2.7629482701740926e-07
n O 0 1.2679486189881572e-06
= O 0 1.593887759554491e-06
20 O 0 1.1538135140654049e-06
) O 0 1.285370672121644e-07
or O 0 5.718101547813603e-08
families O 0 1.1803615862504557e-08
with O 0 1.9988105393053957e-08
two O 0 6.535658769735164e-08
affected O 0 1.5647401596652344e-07
members O 0 3.766078648936855e-08
, O 0 5.928422552869961e-08
one O 0 3.079557941987332e-08
of O 0 8.84539517187477e-08
them O 0 2.1516008530397812e-08
affected O 0 1.494165076110221e-07
before O 0 1.09882165588715e-07
the O 0 1.3883281724247354e-07
age O 0 1.3619872163417313e-07
of O 0 4.915481781608833e-07
50 O 0 4.484227531520446e-07
( O 0 2.5076687393266184e-07
n O 0 1.447547106181446e-06
= O 0 2.4779053546808427e-06
28 O 0 2.408439513601479e-06
) O 0 1.1929780896480224e-07
, O 0 8.415948116180516e-08
and O 0 5.789257429000827e-08
one O 0 1.7813945873967896e-07
additional O 0 8.706613243703032e-07
minor O 0 2.964103623526171e-05
criterion O 0 0.000303636712487787
. O 0 2.039122409769334e-05

Sixteen O 0 8.4317522123456e-05
different O 0 2.882946546378662e-06
p16 O 0 0.00015890826762188226
germline O 0 8.056651859078556e-05
mutations O 0 2.721601958910469e-06
were O 0 1.2705208973784465e-06
found O 0 3.895990516866732e-07
in O 0 3.456545130120503e-07
21 O 0 1.6397503941334435e-06
families O 0 4.605362136089752e-08
, O 0 1.6851387840688403e-07
while O 0 1.5022550314824912e-07
one O 0 2.643016614456428e-07
germline O 0 1.6694288206053898e-05
mutation O 0 1.5459322639799211e-06
, O 0 9.046021887115785e-07
Arg24His O 0 2.953708462882787e-05
, O 0 2.3632657075722818e-07
was O 0 3.7929348764009774e-06
detected O 0 1.5344035091402475e-06
in O 0 9.64536866376875e-07
the O 0 7.764922884234693e-06
CDK4 O 0 0.17255358397960663
gene O 0 4.400017860461958e-05
. O 0 2.497513560228981e-05

The O 0 2.4526210836484097e-05
frequency O 0 1.0148139153898228e-05
of O 0 3.4590520954225212e-06
p16 O 0 1.8308619473828003e-05
gene O 0 4.637217898562085e-07
mutation O 0 3.2466715538248536e-07
in O 0 1.6437901706467528e-07
our O 0 7.316799610634916e-08
sample O 0 9.160847724842824e-08
( O 0 1.1037158742510655e-07
44 O 0 7.926236662569863e-07
% O 0 1.2987845821044175e-07
) O 0 9.078000573481404e-08
is O 0 4.5611120214061884e-08
among O 0 1.5776857154037316e-08
the O 0 8.944405038846526e-08
highest O 0 1.3302075103638344e-06
rates O 0 2.475132419021975e-07
yet O 0 8.2972839265949e-08
reported O 0 2.8429866461010533e-07
and O 0 8.525716310714415e-08
the O 0 7.026893626971287e-07
CDK4 O 0 0.00011164370516780764
mutation O 0 4.4297451040620217e-07
is O 0 1.1906094243840926e-07
the O 0 1.0660490090685926e-07
second O 0 4.768739358951279e-07
mutation O 0 2.220510424422173e-07
detected O 0 7.266411330419942e-07
in O 0 1.6850181339123083e-07
this O 0 2.0660871768996003e-07
gene O 0 2.240179810542031e-06
worldwide O 0 9.496152415522374e-06
. O 0 9.952106665878091e-06

In O 0 6.206114630913362e-05
summary O 0 9.576832235325128e-05
, O 0 1.035914579006203e-06
our O 0 2.802245830935135e-07
results O 0 3.0279596785476315e-07
show O 0 1.757071430574797e-07
frequent O 0 4.199281420369516e-07
involvement O 0 1.6214213474086137e-06
of O 0 1.0790766964419163e-06
the O 0 2.1473163087648572e-06
p16 O 0 4.265360985300504e-05
gene O 0 7.377631732197187e-07
in O 0 1.1414690561650787e-06
familial B-Disease 1 0.9792729616165161
melanoma I-Disease 1 1.0
and O 0 2.0589836822182406e-06
confirm O 0 9.315103852713946e-07
the O 0 5.798617053187627e-07
role O 0 9.923653578880476e-07
of O 0 2.3498741938965395e-06
the O 0 3.5218233733758098e-06
CDK4 O 0 0.03227018937468529
gene O 0 2.313251115992898e-06
as O 0 3.048333155675209e-06
a O 0 0.0004221680574119091
melanoma B-Disease 1 1.0
- O 1 0.7992962002754211
predisposing O 0 0.023342786356806755
gene O 0 1.2241305739735253e-05
. O 0 4.271302714187186e-06
. O 0 1.3480993402481545e-05

Progression O 0 0.005193325690925121
of O 0 5.746097303926945e-05
somatic O 0 0.0008971947827376425
CTG O 0 0.0018118515145033598
repeat O 0 5.120819423609646e-06
length O 0 2.831980509654386e-06
heterogeneity O 0 6.00110206505633e-06
in O 0 7.810440365574323e-07
the O 0 1.3397790326052927e-06
blood O 0 4.943136445945129e-05
cells O 0 0.08374902606010437
of O 1 0.9994902610778809
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.33477169275283813
. O 0 4.138730218983255e-05

The O 0 1.6331414371961728e-05
genetic O 0 1.3454638065013569e-05
basis O 0 2.8277270757826045e-05
of O 0 0.00423852913081646
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.04795832186937332
DM B-Disease 1 1.0
) O 0 1.0648474244590034e-06
is O 0 2.592143459878571e-07
the O 0 1.7203312552283023e-07
expansion O 0 9.84793018687924e-07
of O 0 9.337874189441209e-07
an O 0 2.652402145031374e-06
unstable O 0 6.463688623625785e-05
CTG O 0 0.00010705076419981197
repeat O 0 1.166505171568133e-06
in O 0 3.049436259061622e-07
the O 0 1.1929546417377423e-06
34 O 0 4.7062030716915615e-06
UTR O 0 0.00013955566100776196
of O 0 7.77482182456879e-06
the O 0 3.793209180003032e-05
DM B-Disease 1 0.9999998807907104
protein O 0 1.0432935596327297e-05
kinase O 0 2.244692950625904e-05
gene O 0 1.470053803132032e-06
on O 0 4.898153292742791e-06
chromosome O 0 0.0011349573032930493
19 O 0 0.00017674750415608287
. O 0 3.174673474859446e-05

One O 0 2.0698353182524443e-05
of O 0 8.026409886952024e-06
the O 0 4.266486484993948e-06
principal O 0 1.1974116205237806e-05
features O 0 5.523905315385491e-07
of O 0 3.7752881780761527e-06
the O 0 2.908932037826162e-05
DM B-Disease 1 1.0
mutation O 0 3.7690572298743064e-06
is O 0 3.6728363284055376e-07
an O 0 5.770240818492312e-07
extraordinarily O 0 9.951612810255028e-06
high O 0 8.607980817032512e-06
level O 0 6.895063506817678e-07
of O 0 8.43568159325514e-07
somatic O 0 0.00013640888209920377
mosaicism O 0 0.03221733868122101
, O 0 1.359573360559807e-07
due O 0 3.402751929115766e-07
to O 0 3.3590758619084227e-08
an O 0 1.5160615873810457e-07
extremely O 0 2.5421255145374744e-07
high O 0 1.4408740298677003e-06
degree O 0 2.005338501476217e-06
of O 0 1.2592217899509706e-06
somatic O 0 0.0001359598245471716
instability O 0 1.5480756701435894e-05
both O 0 7.437510163299521e-08
within O 0 9.325809458005097e-08
and O 0 1.4328301745081262e-07
between O 0 6.039195454832225e-07
different O 0 5.937701530456252e-07
tissues O 0 7.138775254134089e-05
. O 0 2.425157799734734e-05

This O 0 2.1240517526166514e-05
instability O 0 7.872714922996238e-05
appears O 0 2.079651267195004e-06
to O 0 1.7805045615659765e-07
be O 0 2.060145192217533e-07
biased O 0 8.039210683818965e-07
towards O 0 2.1360936841574585e-07
further O 0 5.56520269867633e-08
expansion O 0 3.08574414020768e-07
and O 0 1.926991188838656e-08
continuous O 0 2.5720495955283695e-07
throughout O 0 3.0589749400178334e-08
the O 0 1.4840340156752063e-07
life O 0 9.413843571337566e-08
of O 0 1.3425733413896523e-07
an O 0 1.2603051402493293e-07
individual O 0 1.5162330058160478e-08
, O 0 3.558829675398556e-08
features O 0 2.5024979422028082e-08
that O 0 1.7526923912214443e-08
could O 0 4.209096005070023e-08
be O 0 5.8070739328286436e-08
associated O 0 1.3187997183194966e-07
with O 0 3.5540747234108494e-08
the O 0 7.967221904436883e-07
progressive O 0 1.482647166994866e-05
nature O 0 1.6522676560271066e-06
of O 0 1.5271338270395063e-05
the O 0 0.0002013766934396699
disease O 1 0.9968288540840149
. O 0 3.0933457310311496e-05

Although O 0 1.2270935258129612e-05
increasing O 0 5.5470077313657384e-06
measured O 0 6.1957130128575955e-06
allele O 0 1.5711175365140662e-06
size O 0 4.707198968390003e-07
between O 0 5.960491762380116e-07
patients O 0 6.918928079358011e-07
clearly O 0 4.535727384791244e-07
correlates O 0 1.2846885510953143e-06
with O 0 3.3926870202094506e-08
an O 0 4.075342303622165e-07
increased O 0 9.068030522030313e-06
severity O 0 7.39315728424117e-05
of O 0 2.1369616661104374e-05
symptoms O 0 0.09425520151853561
and O 0 4.6016839405638166e-07
an O 0 1.2128415391998715e-06
earlier O 0 1.082842459254607e-06
age O 0 4.2422220758453477e-07
of O 0 1.2897991155114141e-06
onset O 0 0.15446995198726654
, O 0 1.5286678944903542e-07
this O 0 5.063899521928761e-08
correlation O 0 4.821116021958005e-07
is O 0 9.274775436551863e-08
not O 0 3.262702463757705e-08
precise O 0 2.2292118728728383e-07
and O 0 6.654769180158837e-08
measured O 0 9.73962301031861e-07
allele O 0 2.9849755378563714e-07
length O 0 2.852655143215088e-07
cannot O 0 5.749598130933009e-08
be O 0 3.9484426395119954e-08
used O 0 5.935414648661208e-08
as O 0 5.9023147258585595e-08
an O 0 1.6449365602966282e-07
accurate O 0 1.2236509974172805e-06
predictor O 0 2.208342448284384e-05
of O 0 1.16813498607371e-06
age O 0 3.996855866716942e-06
of O 0 2.708890133362729e-05
onset O 1 0.9972559809684753
. O 0 4.371397881186567e-05

In O 0 9.141914233623538e-06
order O 0 1.2269462104086415e-06
to O 0 2.963679435197264e-07
further O 0 8.832360549604346e-07
characterize O 0 3.2087627914734185e-06
the O 0 2.8794845547963632e-06
dynamics O 0 7.922270015114918e-06
of O 0 3.1847441277932376e-05
DM B-Disease 1 1.0
CTG O 0 0.0021161313634365797
repeat O 0 2.993472890011617e-06
somatic O 0 9.947646503860597e-06
instability O 0 4.835975687456084e-06
, O 0 8.554009411909647e-08
we O 0 1.5059006486239923e-08
have O 0 1.1677229849738069e-08
studied O 0 3.1100822184271237e-07
repeat O 0 1.5925157015317382e-07
length O 0 1.338311363952016e-07
changes O 0 2.3587213959785913e-08
over O 0 7.071410834669223e-08
time O 0 1.299342216043442e-07
in O 0 6.791253781557316e-07
111 O 1 0.6963996291160583
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.9446272290224442e-06
with O 0 8.154481179190043e-08
varying O 0 7.788304401401547e-07
clinical O 0 0.012910333462059498
severity O 0 0.00021614364231936634
and O 0 2.188338385167299e-06
CTG O 0 8.348895062226802e-05
repeat O 0 5.820135697831574e-07
size O 0 1.0723218224484299e-07
over O 0 1.0414532169988888e-07
time O 0 7.900338516719785e-08
intervals O 0 1.9277159424291312e-07
of O 0 5.643845497615985e-07
1 O 0 1.5520464557994273e-06
- O 0 5.656790108332643e-06
7 O 0 6.849253168184077e-06
years O 0 5.030877673561918e-06
. O 0 5.679189598595258e-06

We O 0 5.198915914661484e-06
have O 0 8.200780143852171e-07
found O 0 4.0896546238400333e-07
a O 0 8.252553129750595e-07
direct O 0 1.0746033467512461e-06
progression O 0 2.5651012037997134e-05
of O 0 6.42691873053991e-07
the O 0 1.6102003996820713e-07
size O 0 5.3425583956823175e-08
heterogeneity O 0 6.211593586158415e-07
over O 0 2.0265311206912884e-07
time O 0 1.1988311143795727e-07
related O 0 1.3464688208841835e-07
to O 0 6.937084862101983e-08
initial O 0 2.9114851258782437e-06
CTG O 0 3.912542524631135e-05
repeat O 0 4.707764560407668e-07
size O 0 1.5364052785571403e-07
and O 0 9.216000762535259e-08
the O 0 1.9294043340778444e-07
time O 0 6.342847314044775e-08
interval O 0 2.86754811895662e-07
and O 0 7.034363136426691e-08
always O 0 6.310399669473554e-08
biased O 0 9.21787886909442e-07
towards O 0 6.029447376931785e-07
further O 0 5.417662123363698e-07
expansion O 0 1.4062809896131512e-05
. O 0 4.484626060730079e-06

Attempts O 0 3.894473775289953e-05
to O 0 1.7191879351230455e-06
mathematically O 0 1.0463255421200301e-05
model O 0 1.7775165588318487e-06
the O 0 3.722344672496547e-07
dynamics O 0 8.021397661650553e-07
have O 0 4.643209550181382e-08
proved O 0 4.4521493691718206e-07
only O 0 6.498727600501297e-08
partially O 0 1.3381676353674266e-06
successful O 0 3.179854388690728e-07
suggesting O 0 2.721793919135962e-07
that O 0 1.0654935600484805e-08
individual O 0 9.334187645038128e-09
specific O 0 2.1063824462430603e-08
genetic O 0 8.75468856520456e-07
and O 0 2.0460840914893197e-06
/ O 0 0.0002931978087872267
or O 0 6.231993552319182e-07
environmental O 0 2.8331662633718224e-06
factors O 0 2.8398730478329526e-07
also O 0 9.800450584407372e-08
play O 0 1.257445347846442e-07
a O 0 4.804221589438384e-07
role O 0 9.811875543164206e-07
in O 0 1.3846961337549146e-06
somatic O 0 0.0002362261147936806
mosaicism O 0 0.08631222695112228
. O 0 3.4641093407117296e-06
. O 0 1.080062247638125e-05

Aspartylglucosaminuria B-Disease 1 0.9981895089149475
among O 0 6.221212970558554e-05
Palestinian O 0 0.000281136337434873
Arabs O 0 0.00018814779468812048
. O 0 3.5877168556908146e-05

Aspartylglucosaminuria B-Disease 1 0.9999998807907104
( O 0 0.0831933543086052
AGU B-Disease 1 1.0
) O 0 7.258423011080595e-06
is O 0 9.118884349845757e-07
a O 0 1.5774591020090156e-06
rare O 0 2.1895615645917132e-05
disorder B-Disease 1 0.9999377727508545
of I-Disease 1 0.9821855425834656
glycoprotein I-Disease 1 1.0
metabolism I-Disease 1 0.9999971389770508
caused O 0 0.42854997515678406
by O 0 1.2083228284609504e-06
the O 0 6.476176349679008e-05
deficiency B-Disease 1 0.9999285936355591
of I-Disease 0 0.0007124225376173854
the I-Disease 0 0.0008300216868519783
lysosomal I-Disease 1 0.9999872446060181
enzyme I-Disease 0 0.0013708540936931968
aspartylglucosaminidase I-Disease 1 0.9950460195541382
( O 0 6.112700793892145e-05
AGA O 1 0.9999434947967529
) O 0 1.1662555152724963e-05
. O 0 1.4446191016759258e-05

AGU B-Disease 1 1.0
is O 0 0.00018840344273485243
inherited O 0 0.042592354118824005
as O 0 5.254568804957671e-06
an O 0 4.844232989853481e-06
autosomal O 1 0.9046555757522583
recessive O 1 0.9991102814674377
trait O 0 0.01566670648753643
and O 0 1.2858799891546369e-06
occurs O 0 5.664103355229599e-07
with O 0 1.4063019193599757e-07
a O 0 1.3678882169188e-06
high O 0 5.995781521050958e-06
frequency O 0 7.125934189389227e-07
in O 0 1.6751324949382251e-07
Finland O 0 1.9503312387314509e-07
because O 0 9.339123607787769e-08
of O 0 8.959077604231425e-07
a O 0 1.0971481970045716e-05
founder O 0 0.00016371801029890776
effect O 0 2.617630707391072e-05
. O 0 2.1546213247347623e-05

While O 0 3.359999755048193e-05
very O 0 5.252579740044894e-06
few O 0 3.013730292877881e-06
patients O 0 3.1491285881202202e-06
with O 0 2.185083076255978e-06
AGU B-Disease 1 0.9999997615814209
have O 0 4.758608724841906e-07
been O 0 9.1382975142551e-07
reported O 0 1.0512919743632665e-06
from O 0 5.908847811042506e-07
non O 0 3.1292199764720863e-06
- O 0 4.440676548256306e-06
Finnish O 0 6.568878688995028e-06
origin O 0 2.69214012860175e-07
, O 0 5.051069820183329e-07
we O 0 4.544187675037392e-07
diagnosed O 1 0.5724871754646301
the O 0 4.410861038195435e-06
disorder O 0 0.04267130792140961
in O 0 1.2243419860169524e-06
8 O 0 8.15181829239009e-06
patients O 0 1.6397882518504048e-07
originating O 0 3.497866885027179e-07
from O 0 3.29558275780073e-07
3 O 0 6.28289058113296e-07
unrelated O 0 2.535365695166547e-07
families O 0 2.0002026701604336e-08
, O 0 5.228093868936412e-08
all O 0 2.9978071580671894e-08
Palestinian O 0 1.1333187330819783e-06
Arabs O 0 4.8140407216124e-07
from O 0 1.9429684527949576e-07
the O 0 2.7851282879964856e-07
region O 0 3.8382492562050174e-07
of O 0 3.0945075195631944e-06
Jerusalem O 0 0.00023376890749204904
. O 0 2.1411391571746208e-05

The O 0 9.39272649702616e-05
clinical O 1 0.9927805066108704
diagnosis O 1 0.9999356269836426
of O 1 0.9916229844093323
AGU B-Disease 1 1.0
is O 0 4.143281785218278e-06
often O 0 2.933216194378474e-07
difficult O 0 1.527426292113887e-07
, O 0 4.8032088528771055e-08
in O 0 5.3558835588773945e-08
particular O 0 3.9596798728780414e-08
early O 0 1.0503504199732561e-07
in O 0 6.333297619676159e-08
the O 0 1.7196620660797635e-07
course O 0 5.556843802878575e-07
of O 0 6.863841122140002e-07
the O 0 6.777034286642447e-06
disease O 1 0.6292120814323425
, O 0 3.5505249229572655e-07
and O 0 1.2655034709041502e-07
most O 0 8.48533758812664e-08
of O 0 6.35029834938905e-07
the O 0 2.180168621634948e-06
patients O 0 1.6356037804143853e-06
are O 0 2.2839421376374958e-07
diagnosed O 0 0.4238402247428894
after O 0 2.106118927258649e-06
the O 0 5.046081810178293e-07
age O 0 9.024772680277238e-07
of O 0 2.509908426873153e-06
5 O 0 7.356537025771104e-06
years O 0 9.7482488854439e-06
. O 0 1.1234938028792385e-05

However O 0 2.9573247957159765e-05
, O 0 2.7935177513427334e-06
since O 0 1.35783227506181e-06
these O 0 1.778505520633189e-07
patients O 0 4.553979522370355e-07
excrete O 0 6.417675990633143e-07
early O 0 2.519342388040968e-07
large O 0 1.526290418496501e-07
amounts O 0 2.96497148610797e-07
of O 0 3.4028921618300956e-06
aspartylglucosamine O 0 7.97741231508553e-05
in O 0 1.2285573802728322e-06
urine O 0 1.7160821244033286e-06
, O 0 2.4476076987411943e-07
biochemical O 0 8.64941921463469e-06
screening O 0 1.0777118859550683e-06
is O 0 2.3162525053521676e-07
easy O 0 2.1960622120786866e-07
by O 0 3.5697894418262877e-07
urine O 0 3.7655904634448234e-06
chromatography O 0 8.290353434858844e-05
. O 0 5.016337127017323e-06
. O 0 1.2162179700681008e-05

Detection O 0 0.00027963772299699485
of O 0 2.5650670067989267e-05
heterozygous O 0 2.343391861359123e-05
carriers O 0 4.23232768298476e-06
of O 0 1.1069579159084242e-05
the O 0 3.778882455662824e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999973773956299
telangiectasia I-Disease 1 1.0
( O 0 7.197919330792502e-05
ATM O 1 0.5710920691490173
) O 0 5.620619845103647e-07
gene O 0 5.976235684101994e-07
by O 0 6.396144272002857e-07
G2 O 0 0.0573592409491539
phase O 0 1.20779423014028e-05
chromosomal O 0 0.00020392023725435138
radiosensitivity O 0 0.0002256182488054037
of O 0 2.8459853638196364e-05
peripheral O 1 0.9988125562667847
blood O 1 0.7396888136863708
lymphocytes O 1 0.9811400175094604
. O 0 4.1415969462832436e-05

In O 0 0.0009774231584742665
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 1 0.9942629933357239
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 9.721370588522404e-07
patients O 0 1.5097377570327808e-07
, O 0 3.225699884978894e-08
mutations O 0 3.948804305764497e-08
in O 0 9.946244006187044e-08
a O 0 2.609224338812055e-07
single O 0 4.1162937236549624e-07
gene O 0 3.940257897738775e-07
, O 0 5.926274297962664e-07
ATM O 0 0.00048677853192202747
, O 0 1.0937864658444596e-07
result O 0 2.738000546287367e-07
in O 0 5.122242896504758e-07
an O 0 0.0025186040438711643
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 3.2807158277137205e-05
embraces O 0 4.639293365471531e-06
a O 0 1.5355453797383234e-06
variety O 0 1.8648388788733428e-07
of O 0 1.908332023958792e-06
clinical O 0 0.0009653143933974206
features O 0 6.755647632417094e-07
and O 0 4.681157577124395e-07
manifests O 0 3.2316786473529646e-06
extreme O 0 2.8214588382979855e-05
radiosensitivity O 0 0.007792973425239325
and O 0 5.967618790236884e-07
a O 0 5.651651463267626e-06
strong O 0 7.466657280019717e-06
pre O 0 0.0598473958671093
- O 0 0.0005212026881054044
disposition O 0 0.0002842709654942155
to O 0 7.212116997834528e-06
malignancy B-Disease 1 0.999834418296814
. O 0 4.284444003133103e-05

Heterozygotes O 0 0.000481881172163412
for O 0 3.540996431183885e-06
the O 0 1.8312389329366852e-06
ATM O 0 3.840252975351177e-05
gene O 0 5.314862505656492e-07
have O 0 1.0105997461096194e-07
no O 0 3.353180488829821e-07
clinical O 0 4.4932705350220203e-05
expression O 0 5.87688191444613e-06
of O 0 0.0002550618664827198
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
but O 0 2.2079208861214283e-07
may O 0 1.05042806808342e-06
be O 0 8.642978173156735e-07
cancer B-Disease 0 0.0027016950771212578
prone O 0 2.8992385523451958e-06
with O 0 6.401416641210744e-08
a O 0 6.900207267790393e-07
moderate O 0 1.4926155245120754e-06
increase O 0 3.0225069735934085e-07
in O 0 3.8687221604050137e-07
in O 0 1.6494809642608743e-06
vitro O 0 0.00015478460409212857
radiosensitivity O 0 0.0011454276973381639
. O 0 2.2140231521916576e-05

We O 0 2.0258199583622627e-05
performed O 0 2.4896495233406313e-05
a O 0 2.712141940719448e-05
blind O 0 0.00018940870359074324
chromosomal O 0 0.009029951877892017
analysis O 0 1.817136217141524e-05
on O 0 4.988245927961543e-05
G2 O 1 0.9963412880897522
- O 0 1.1601963706198148e-05
phase O 0 4.318766968935961e-06
lymphocytes O 0 2.52294194069691e-06
from O 0 5.75134151858947e-07
7 O 0 2.4676214707142208e-06
unrelated O 0 5.354910626920173e-06
A B-Disease 1 0.9999963045120239
- I-Disease 1 0.9999971389770508
T I-Disease 1 0.9999994039535522
patients O 0 1.7853723193184123e-06
, O 0 4.201500587441842e-07
13 O 0 1.933332669068477e-06
obligate O 0 7.028889740468003e-06
A B-Disease 1 0.9999849796295166
- I-Disease 1 0.999862790107727
T I-Disease 1 0.9997738003730774
heterozygotes O 0 7.012994501565117e-06
( O 0 1.3417312061392295e-07
parents O 0 3.618833233076657e-08
of O 0 2.9015708946644736e-07
the O 0 8.005982863323879e-07
patients O 0 4.820913659386861e-07
) O 0 1.30979145751553e-07
, O 0 1.0739900346834474e-07
and O 0 1.2132910853779322e-07
14 O 0 1.089005422727496e-06
normal O 0 9.692366802482866e-07
controls O 0 1.1045282235500054e-06
following O 0 1.5152969581322395e-06
X O 0 1.5616300515830517e-05
- O 0 2.0240890989953186e-06
irradiation O 0 1.7007735095830867e-06
with O 0 1.830270122127331e-07
1 O 0 2.4436246803816175e-06
Gy O 0 1.828051608754322e-05
in O 0 7.695543757790801e-08
order O 0 2.5561032401810735e-08
to O 0 1.5747003700994355e-08
evaluate O 0 1.0983459475255586e-07
this O 0 6.416660625063741e-08
cytogenetic O 0 9.446762305742595e-06
method O 0 1.728501217712619e-07
as O 0 1.9143858764891775e-07
a O 0 4.331167815507797e-07
tool O 0 1.3960010392111144e-06
for O 0 1.1851241765725717e-07
detection O 0 3.199711272827699e-06
of O 0 1.1408942555135582e-05
ATM O 0 0.0013376206625252962
carriers O 0 2.355715332669206e-05
. O 0 1.572940163896419e-05

Both O 0 0.00017291531548835337
A B-Disease 1 0.999976396560669
- I-Disease 1 0.9999939203262329
T I-Disease 1 0.9999991655349731
homozygotes O 0 6.77436328260228e-05
and O 0 4.5286216732165485e-07
heterozygotes O 0 5.650249931932194e-06
showed O 0 1.6587868003625772e-06
significantly O 0 7.742272600808064e-07
increased O 0 7.89691625868727e-07
levels O 0 3.680571296627022e-07
of O 0 1.0541804158492596e-06
radiation O 0 0.4875221252441406
- O 0 0.00050919852219522
induced O 0 0.3689868152141571
chromatid O 0 0.0005989461787976325
damage O 0 1.9226965378038585e-05
relative O 0 1.0006199318013387e-06
to O 0 5.6593794539594455e-08
that O 0 1.1126185484044981e-07
of O 0 1.5524077525697066e-06
normal O 0 1.8359956811764278e-05
controls O 0 2.3242604584083892e-05
. O 0 8.916604201658629e-06

These O 0 3.5760356240643887e-06
results O 0 4.905253717879532e-06
show O 0 2.5822935185715323e-06
that O 0 8.247423579632596e-07
the O 0 1.0731791007856373e-05
G2 O 1 0.9873279929161072
- O 0 3.057320282096043e-05
phase O 0 1.500743383076042e-05
chromosomal O 0 6.702778773615137e-05
radiosensitivity O 0 4.72475730930455e-05
assay O 0 4.044702563987812e-06
can O 0 3.53395108732002e-08
be O 0 2.657105824255268e-08
used O 0 4.856130075836518e-08
for O 0 7.948629843212984e-08
the O 0 4.62765768816098e-07
detection O 0 5.547060936805792e-06
of O 0 5.1016846555285156e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.999998927116394
T I-Disease 1 0.9999986886978149
heterozygotes O 0 0.00027354457415640354
. O 0 1.6220821635215543e-05

In O 0 2.945306732726749e-05
combination O 0 1.2551044164865743e-05
with O 0 7.050024350974127e-07
molecular O 0 9.006403706735e-05
genetic O 0 6.359816779877292e-06
analyses O 0 2.6360919491708046e-06
, O 0 3.4906921086985676e-07
this O 0 8.53915906873226e-08
test O 0 1.668060605197752e-07
may O 0 1.2318923836573958e-07
be O 0 1.9405311135756165e-08
of O 0 5.902674615754222e-08
value O 0 6.234133564930744e-08
in O 0 3.9128764228735236e-08
studies O 0 1.2866414067502774e-07
of O 0 1.5079304205301014e-07
familial B-Disease 0 1.7505528830952244e-06
and I-Disease 0 3.8904917687432317e-07
sporadic I-Disease 0 0.0001149151794379577
cancers I-Disease 1 0.9473801851272583
aimed O 0 6.35671221971279e-06
at O 0 2.1214796106505673e-06
determination O 0 2.7962983040197287e-07
of O 0 2.9128969458724896e-07
the O 0 1.166123198004243e-07
potential O 0 1.1493696661091235e-07
involvement O 0 4.191439302303479e-07
of O 0 4.2503293684603705e-07
ATM O 0 4.875557351624593e-05
mutations O 0 1.9835165403492283e-06
in O 0 4.945046839566203e-06
tumor B-Disease 1 0.9999997615814209
risk O 0 5.3841482440475374e-05
or O 0 1.3718085938307922e-06
development O 0 7.538342288171407e-06
. O 0 1.8701529143072548e-06
. O 0 8.94822551344987e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
telangiectasia I-Disease 1 1.0
: O 0 1.718680141493678e-05
identification O 0 2.3484603843826335e-06
and O 0 6.543080530718726e-07
detection O 0 2.0316283553256653e-05
of O 0 3.619919152697548e-05
founder O 0 0.04697280377149582
- O 0 5.647335456160363e-06
effect O 0 3.3690088230287074e-07
mutations O 0 7.539620128227398e-08
in O 0 6.018898801585237e-08
the O 0 2.0041365189626958e-07
ATM O 0 6.535361535497941e-06
gene O 0 1.4558868599579e-07
in O 0 1.3734498338635603e-07
ethnic O 0 3.0610590329160914e-07
populations O 0 2.3119323486753274e-06
. O 0 7.193351848400198e-06

To O 0 6.407410637621069e-06
facilitate O 0 8.747997526370455e-06
the O 0 1.053418600349687e-06
evaluation O 0 3.3328258268738864e-06
of O 0 3.3465146316302707e-06
ATM O 0 0.0020956702064722776
heterozygotes O 0 1.363857609248953e-05
for O 0 4.889687374998175e-07
susceptibility O 0 9.826680616242811e-05
to O 0 3.9622869962840923e-07
other O 0 7.013871368144464e-07
diseases O 1 0.9989732503890991
, O 0 4.105641266960447e-07
such O 0 1.0579505271834933e-07
as O 0 6.594790193048539e-06
breast B-Disease 1 0.9998816251754761
cancer I-Disease 1 0.8697366118431091
, O 0 2.2620656636718195e-07
we O 0 1.689751627509395e-08
have O 0 2.257268150174241e-08
attempted O 0 3.512334103561443e-07
to O 0 6.317468859151631e-08
define O 0 1.5752839033211785e-07
the O 0 1.881936526615391e-07
most O 0 4.4032606894006676e-08
common O 0 5.299455807517006e-08
mutations O 0 6.766519788925507e-08
and O 0 4.328772718054097e-08
their O 0 4.479261050960304e-08
frequencies O 0 1.0180718845731462e-06
in O 0 3.7209076708677458e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999945163726807
telangiectasia I-Disease 1 1.0
( O 0 0.1307997852563858
A B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
T I-Disease 1 0.9999963045120239
) O 0 5.093220352136996e-07
homozygotes O 0 1.7492644701633253e-06
from O 0 1.300046221786033e-07
10 O 0 1.377495379983884e-07
ethnic O 0 1.0904473413120286e-07
populations O 0 7.094241141203383e-07
. O 0 4.160942353337305e-06

Both O 0 5.529863301489968e-06
genomic O 0 2.855478487617802e-05
mutations O 0 3.5395173654251266e-06
and O 0 3.098453476013674e-07
their O 0 1.2835064922001038e-07
effects O 0 4.888638159172842e-06
on O 0 2.6389845970697934e-06
cDNA O 0 1.3054822375124786e-05
were O 0 3.2558507427893346e-06
characterized O 0 2.7729109206120484e-05
. O 0 1.568673542351462e-05

Protein O 0 0.000998341478407383
- O 0 0.00018064976029563695
truncation O 0 0.000246311305090785
testing O 0 4.224996700941119e-06
of O 0 2.0217914880049648e-06
the O 0 6.525190201500664e-07
entire O 0 1.6176140889001545e-06
ATM O 0 7.744791219010949e-06
cDNA O 0 4.593038283928763e-06
detected O 0 2.2788060505263275e-06
92 O 0 3.6563340017892187e-06
( O 0 3.100909964359744e-07
66 O 0 2.1518631001526956e-06
% O 0 2.7346393949301273e-07
) O 0 1.0948593143211838e-07
truncating O 0 1.5173981182670104e-06
mutations O 0 2.3235158153056545e-07
in O 0 6.150537501525832e-07
140 O 0 2.1548532913584495e-06
mutant O 0 8.067019734880887e-06
alleles O 0 5.402212991612032e-06
screened O 0 3.7607602280331776e-05
. O 0 1.234515366377309e-05

The O 0 8.014797640498728e-05
haplotyping O 0 0.002828680444508791
of O 0 1.316027464781655e-05
patients O 0 1.969280447156052e-06
with O 0 1.2232339940965176e-07
identical O 0 7.189381676653284e-07
mutations O 0 1.4861600448057288e-06
indicates O 0 5.404593593993923e-06
that O 0 5.3014275636087405e-08
almost O 0 7.070021723620812e-08
all O 0 9.934598921290672e-09
of O 0 8.60673949887314e-08
these O 0 2.1766519253674232e-08
represent O 0 4.861922420218434e-08
common O 0 9.062517136726456e-08
ancestry O 0 2.167244588235917e-07
and O 0 4.902476291590574e-08
that O 0 5.574551309450726e-08
very O 0 8.264416351266846e-08
few O 0 8.547616658916013e-08
spontaneously O 0 5.121549406794657e-07
recurring O 0 1.0552733328950126e-05
ATM O 0 5.5681717640254647e-05
mutations O 0 2.867700459319167e-06
exist O 0 2.183118795073824e-06
. O 0 8.211452950490639e-06

Assays O 0 0.00011567752517294139
requiring O 0 7.446021754731191e-06
minimal O 0 8.807254744169768e-06
amounts O 0 6.7877317633247e-07
of O 0 8.340441013388045e-07
genomic O 0 3.5265354654256953e-06
DNA O 0 4.77935714116029e-07
were O 0 1.389886108427163e-07
designed O 0 1.5428599908773322e-07
to O 0 1.9316683363967968e-08
allow O 0 5.3401031152588985e-08
rapid O 0 1.8727390624917462e-06
screening O 0 2.836297596786608e-07
for O 0 7.467260587645796e-08
common O 0 2.5523524982418166e-07
ethnic O 0 4.454701922895765e-07
mutations O 0 1.0952987395285163e-05
. O 0 1.5154345419432502e-05

These O 0 2.7725664040190168e-06
rapid O 0 2.401776146143675e-05
assays O 0 6.832265171397012e-06
detected O 0 3.868636667903047e-06
mutations O 0 6.74878435802384e-07
in O 0 5.366414939089736e-07
76 O 0 2.3951772618602263e-06
% O 0 2.3828393125313596e-07
of O 0 1.0976209523505531e-06
Costa O 0 2.823563818310504e-06
Rican O 0 1.8621125491335988e-05
patients O 0 6.003294856782304e-07
( O 0 2.2050883785595943e-07
3 O 0 5.406441800914763e-07
) O 0 9.937900813383749e-08
, O 0 5.054462093312395e-08
50 O 0 1.230112758321411e-07
% O 0 7.772071342060372e-08
of O 0 4.627640066701133e-07
Norwegian O 0 2.9476925192284398e-05
patients O 0 6.001417318657332e-07
( O 0 2.5610620468796697e-07
1 O 0 4.910426696369541e-07
) O 0 8.280383667624847e-08
, O 0 4.6182488944168654e-08
25 O 0 2.267184271431688e-07
% O 0 6.227086402077475e-08
of O 0 7.57363352477114e-07
Polish O 0 5.5164920922834426e-05
patients O 0 9.212553209181351e-07
( O 0 2.3645010571726743e-07
4 O 0 1.0229400686512236e-06
) O 0 1.091725110313746e-07
, O 0 8.026159292739976e-08
and O 0 5.721395979207955e-08
14 O 0 3.4369577406323515e-07
% O 0 1.0040690767709748e-07
of O 0 9.937045888364082e-07
Italian O 0 1.7353606381220743e-05
patients O 0 6.817600137765112e-07
( O 0 1.996698415496212e-07
1 O 0 9.732298167364206e-07
) O 0 9.736933037629569e-08
, O 0 6.240534133894471e-08
as O 0 9.239214904255277e-08
well O 0 8.592617461999907e-08
as O 0 1.3540714860482694e-07
in O 0 2.066611415330044e-07
patients O 0 2.447126803417632e-07
of O 0 2.0560580651363125e-06
Amish O 0 6.475034024333581e-05
/ O 0 3.1593132007401437e-05
Mennonite O 0 8.191831147996709e-05
and O 0 6.063121418264927e-07
Irish O 0 1.0695693163143005e-05
English O 0 8.133431038004346e-06
backgrounds O 0 4.379178790259175e-06
. O 0 8.161269761330914e-06

Additional O 0 1.4630044461227953e-05
mutations O 0 1.0026096788351424e-05
were O 0 1.6939425222517457e-06
observed O 0 1.3131764262652723e-06
in O 0 5.509415927917871e-07
Japanese O 0 2.9624434318975545e-06
, O 0 2.2232225660445692e-07
Utah O 0 1.7777080074665719e-06
Mormon O 0 1.4788181488256669e-06
, O 0 1.9688324925937195e-07
and O 0 4.980601033821586e-07
African O 0 6.524687705677934e-06
American O 0 5.700845213141292e-05
patients O 0 2.2146377887111157e-05
. O 0 2.7342162866261788e-05

These O 0 2.9311961498024175e-06
assays O 0 9.243474778486416e-06
should O 0 3.3554260880919173e-07
facilitate O 0 8.764629910729127e-07
screening O 0 3.7814425013493747e-06
for O 0 2.8025101528328378e-06
A B-Disease 1 0.9999935626983643
- I-Disease 1 0.9999384880065918
T I-Disease 1 0.9999092817306519
heterozygotes O 0 2.0876848338957643e-06
in O 0 1.0848647491457086e-07
the O 0 9.60185957410431e-08
populations O 0 8.719744215568426e-08
studied O 0 2.541321237004013e-06
. O 0 8.16652573121246e-07
. O 0 4.412106591189513e-06

The O 0 0.00048019399400800467
von B-Disease 1 0.9915562868118286
Hippel I-Disease 1 0.9999988079071045
- I-Disease 1 0.9999886751174927
Lindau I-Disease 1 0.9999963045120239
tumor I-Disease 1 0.9999998807907104
suppressor O 1 0.9999768733978271
gene O 0 2.046052941295784e-06
is O 0 2.0535659928100358e-07
required O 0 5.426050009305072e-08
for O 0 1.8646431954039144e-07
cell O 0 2.001386928895954e-05
cycle O 0 8.2450851550675e-06
exit O 0 5.902539214730496e-06
upon O 0 2.449251951475162e-06
serum O 0 7.458587788278237e-05
withdrawal O 0 9.819420665735379e-05
. O 0 2.536975807743147e-05

The O 0 8.239220187533647e-05
inactivation O 0 0.0018518144497647882
of O 0 5.927707752562128e-05
the O 0 7.21772012184374e-05
von B-Disease 1 0.9989736080169678
Hippel I-Disease 1 0.9999996423721313
- I-Disease 1 0.9999946355819702
Lindau I-Disease 1 0.9999985694885254
( I-Disease 0 0.00036276396713219583
VHL I-Disease 1 0.9999679327011108
) I-Disease 0 7.453324997186428e-06
tumor I-Disease 1 0.9999995231628418
suppressor O 1 0.9999995231628418
gene O 0 7.252784143929603e-06
predisposes O 0 2.3960314138093963e-05
affected O 0 7.848273071431322e-07
individuals O 0 4.365362116232063e-08
to O 0 9.037866988137466e-08
the O 0 6.860196208435809e-06
human O 1 0.9989622831344604
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 3.2041920349001884e-05
is O 0 1.6254730326181743e-06
associated O 0 6.291818408499239e-07
with O 0 3.5104591233903193e-07
sporadic B-Disease 1 0.9999963045120239
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.7278832197189331
RCC B-Disease 1 1.0
) O 0 7.15780788596021e-06
and O 0 5.344431701814756e-05
brain B-Disease 1 0.9999997615814209
hemangioblastomas I-Disease 1 0.9999978542327881
. O 0 0.00014166277833282948

VHL O 1 0.9988877177238464
- O 0 0.004715781658887863
negative O 0 0.00024034843954723328
786 O 0 0.20191138982772827
- O 0 0.0007113523315638304
0 O 0 5.039602183387615e-05
RCC B-Disease 1 0.9114848375320435
cells O 0 4.78385345559218e-06
are O 0 1.8879730134813144e-07
tumorigenic O 0 1.4401788575924002e-05
in O 0 4.867973188993346e-07
nude O 0 1.4198444659996312e-05
mice O 0 1.4954010794099304e-06
which O 0 1.503378541656275e-07
is O 0 2.3383850589198119e-07
suppressed O 0 1.1901887546628132e-06
by O 0 8.976483911737887e-08
the O 0 4.178508277163928e-07
reintroduction O 0 8.61679291119799e-06
of O 0 7.597022886329796e-06
VHL B-Disease 0 0.0015032155206426978
. O 0 1.1748566066671629e-05

Remarkably O 0 0.0011125950841233134
, O 0 4.548997821984813e-06
this O 0 6.136423280622694e-07
occurs O 0 5.385949179981253e-07
without O 0 1.448959920935522e-07
affecting O 0 3.7039453104625863e-07
the O 0 4.772142574438476e-07
growth O 0 3.2181767437577946e-06
rate O 0 1.1319966688461136e-06
and O 0 1.3405441734448686e-07
cell O 0 9.88752071862109e-06
cycle O 0 2.3701368263573386e-06
profile O 0 3.004877271450823e-07
of O 0 1.520238583907485e-07
these O 0 5.541179959323017e-08
cells O 0 1.1186718893441139e-06
in O 0 1.6535634586034575e-06
culture O 0 4.212596650177147e-06
. O 0 4.468297447601799e-06

The O 0 9.656944894231856e-05
786 O 0 0.0008003203547559679
- O 0 9.463861351832747e-05
0 O 0 1.2559174138004892e-05
cell O 0 9.000566933536902e-05
line O 0 6.75340743327979e-06
, O 0 1.0335556055451889e-07
like O 0 3.420607086468408e-08
many O 0 2.899738937856e-08
cancer B-Disease 0 0.00011414740583859384
cells O 0 2.1824193936481606e-06
, O 0 2.0838889724927867e-07
fails O 0 1.7270085095333343e-07
to O 0 7.177510497058393e-08
exit O 0 2.2539077235705918e-06
the O 0 1.3359054946704418e-06
cell O 0 2.2105823518359102e-05
cycle O 0 4.460106538317632e-06
upon O 0 2.470710796842468e-06
serum O 0 7.731121149845421e-05
withdrawal O 0 7.043586083455011e-05
. O 0 2.765872523013968e-05

Here O 0 3.8863858208060265e-05
, O 0 2.2846443243906833e-06
it O 0 1.7183620570904168e-07
is O 0 9.70496785157593e-08
shown O 0 1.2576349206483428e-07
that O 0 7.632031184812149e-08
reintroduction O 0 2.7534993023436982e-06
of O 0 8.547254992663511e-07
the O 0 1.051125536832842e-06
wild O 0 3.142998821203946e-06
- O 0 4.369188900454901e-05
type O 0 3.8733025576220825e-05
VHL B-Disease 0 0.08538225293159485
gene O 0 1.8231082776765106e-06
restores O 0 8.251968210970517e-06
the O 0 1.069843278855842e-06
ability O 0 2.8783483685401734e-07
of O 0 1.5109883861441631e-05
VHL O 1 0.9999949932098389
- O 1 0.9810340404510498
negative O 0 0.20103232562541962
RCC B-Disease 1 0.9999997615814209
cancer I-Disease 0 0.008151463232934475
cells O 0 1.2248020766492118e-06
to O 0 1.0459602606260887e-07
exit O 0 1.165374328593316e-06
the O 0 4.197887619739049e-07
cell O 0 7.987870048964396e-06
cycle O 0 1.3310831263879663e-06
and O 0 1.353467240505779e-07
enter O 0 2.0508000488916878e-06
G0 O 0 0.0006332722841762006
/ O 0 1.4043336705071852e-05
quiescence O 0 3.4992506698472425e-05
in O 0 3.5383327485760674e-06
low O 0 9.599178156349808e-05
serum O 0 0.0005095910746604204
. O 0 2.4017324903979897e-05

Both O 0 0.00014927881420589983
VHL O 1 0.9992973804473877
- O 0 0.0027007455937564373
positive O 0 1.686800351308193e-05
and O 0 5.466413767862832e-06
VHL O 1 0.9999645948410034
- O 0 0.04959243908524513
negative O 0 8.55871694511734e-05
RCC B-Disease 1 0.9949079155921936
cells O 0 1.915179836942116e-06
exit O 0 2.5971394279622473e-06
the O 0 6.182788752084889e-07
cell O 0 9.955000678019132e-06
cycle O 0 4.558277851174353e-06
by O 0 4.6190598368411884e-07
contact O 0 4.373927822598489e-06
inhibition O 0 0.00040736704249866307
. O 0 1.8655075109563768e-05

The O 0 0.00013209109602030367
cyclin O 0 0.00045543460873886943
- O 0 0.00011908988381037489
dependent O 0 1.5660969438613392e-05
kinase O 0 6.933930126251653e-05
inhibitor O 0 8.002104732440785e-05
, O 0 7.637686962880252e-07
p27 O 0 3.2279916922561824e-05
, O 0 2.964544307815231e-07
accumulates O 0 1.3383003079070477e-06
upon O 0 3.0632315883849515e-07
serum O 0 3.045479843422072e-06
withdrawal O 0 3.3877452096930938e-06
, O 0 1.0202835909467467e-07
only O 0 2.3329405962613237e-08
in O 0 8.361515568822142e-08
the O 0 2.0955451418558368e-07
presence O 0 6.853035756648751e-07
of O 0 6.043855591997271e-06
VHL B-Disease 0 0.022986963391304016
, O 0 2.918168888754735e-07
as O 0 1.4322864672067226e-07
a O 0 2.1991158405398892e-07
result O 0 1.6123516388688586e-07
of O 0 4.4460693970904686e-07
the O 0 6.716058464917296e-07
stabilization O 0 5.397660515882308e-06
of O 0 1.6492922441102564e-06
the O 0 6.706287422275636e-06
protein O 0 3.0822415283182636e-05
. O 0 1.2544798664748669e-05

We O 0 9.20643924473552e-06
propose O 0 4.0741756492934655e-06
that O 0 7.052593105072447e-07
the O 0 1.4936479146854253e-06
loss O 0 4.627856924344087e-06
of O 0 4.879578682448482e-06
wild O 0 3.273609036114067e-05
- O 0 0.305843323469162
type O 0 0.011640962213277817
VHL B-Disease 1 0.9914541244506836
gene O 0 1.460064027014596e-06
results O 0 3.704044218011404e-07
in O 0 1.3829316003466374e-07
a O 0 5.597158860837226e-07
specific O 0 4.7034967565195984e-07
cellular O 0 0.17014704644680023
defect O 0 5.7070021284744143e-05
in O 0 2.171002506656805e-06
serum O 0 0.0050150551833212376
- O 0 4.405446088640019e-05
dependent O 0 1.5049722605908755e-06
growth O 0 2.838781256286893e-06
control O 0 3.3645426356088137e-07
, O 0 6.38242170225567e-08
which O 0 1.0379967108065102e-07
may O 0 5.820213573315414e-07
initiate O 0 5.3514440878643654e-06
tumor B-Disease 1 0.9983231425285339
formation O 0 0.00010076828039018437
. O 0 2.8599371944437735e-05

This O 0 2.080490048683714e-05
is O 0 8.238231202994939e-06
corrected O 0 1.8733588149189018e-05
by O 0 4.19005658613969e-07
the O 0 5.507462219611625e-07
reintroduction O 0 3.282034413132351e-06
of O 0 1.5350622106780065e-06
wild O 0 8.175992661563214e-06
- O 0 0.000894769502338022
type O 0 0.008222107775509357
VHL B-Disease 1 0.9998505115509033
, O 0 8.99899077921873e-06
implicating O 1 0.8959033489227295
VHL B-Disease 1 0.8135255575180054
as O 0 1.3156156910554273e-06
the O 0 5.490680337061349e-07
first O 0 4.259566594555508e-06
tumor B-Disease 1 0.9973934888839722
suppressor O 1 0.9926328063011169
involved O 0 1.0145053011001437e-06
in O 0 5.025939344704966e-07
the O 0 4.780765721079661e-07
regulation O 0 5.54876805836102e-07
of O 0 1.1316933523630723e-06
cell O 0 2.1607658709399402e-05
cycle O 0 3.620073357524234e-06
exit O 0 1.1139704838569742e-06
, O 0 6.049224765547478e-08
which O 0 2.5116602131447507e-08
is O 0 5.839729055878706e-08
consistent O 0 1.8312688609967154e-07
with O 0 2.096574114318628e-08
its O 0 2.2828227486115793e-07
gatekeeper O 0 7.993356848601252e-05
function O 0 3.428792751947185e-07
in O 0 4.154909163389675e-07
the O 0 4.438592895894544e-06
kidney O 1 0.962052583694458
. O 0 4.783625172422035e-06
. O 0 1.6489131667185575e-05

Piebaldism B-Disease 1 0.9999990463256836
with O 0 0.00016458891332149506
deafness B-Disease 1 1.0
: O 0 1.671823520155158e-05
molecular O 0 6.270141602726653e-05
evidence O 0 1.4590367527489434e-06
for O 0 3.997951409928646e-07
an O 0 1.0723912964749616e-05
expanded O 0 0.022660359740257263
syndrome O 1 1.0
. O 0 0.000126294165966101

In O 0 4.2101015424123034e-05
a O 0 2.1903551896684803e-05
South O 0 1.120843990065623e-05
African O 0 3.359503580213641e-06
girl O 0 4.23213805333944e-06
of O 0 4.756385351356585e-06
Xhosa O 0 0.09668109565973282
stock O 0 3.501072933431715e-05
with O 0 6.016127258590132e-07
severe O 1 0.9999570846557617
piebaldism B-Disease 1 0.9999908208847046
and O 0 0.0011752324644476175
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 4.37297421740368e-05
identified O 0 7.295711839105934e-06
a O 0 1.7829884200182278e-06
novel O 0 1.9900514871551422e-06
missense O 0 8.555020940548275e-06
substitution O 0 3.3744279335223837e-06
at O 0 1.3725689314014744e-06
a O 0 6.443900701924576e-07
highly O 0 5.69675307815487e-07
conserved O 0 7.100224479472672e-07
residue O 0 2.973893515445525e-06
in O 0 3.2212184919444553e-07
the O 0 1.1490708402561722e-06
intracellular O 0 1.0712240509747062e-05
kinase O 0 8.43180896481499e-06
domain O 0 1.9982749108748976e-06
of O 0 4.8464930841873866e-06
the O 0 1.8392323909210972e-05
KIT O 0 0.00023132728529162705
proto O 0 0.15326930582523346
- O 0 0.07850022614002228
oncogene O 1 0.87437903881073
, O 0 8.965052984422073e-06
R796G O 0 0.00047377528971992433
. O 0 1.745056033541914e-05

Though O 0 4.7798741434235126e-05
auditory B-Disease 0 0.004349979571998119
anomalies I-Disease 0 0.005383880343288183
have O 0 1.618299165784265e-06
been O 0 1.4216353747542598e-06
observed O 0 1.5255468497343827e-06
in O 0 1.0474431064722012e-06
mice O 0 2.58195382230042e-06
with O 0 2.448174996061425e-07
dominant O 0 1.0442332495586015e-05
white O 0 5.977318323857617e-06
spotting O 0 0.0004080697544850409
( O 0 8.365410394617356e-06
W O 1 0.6882731318473816
) O 0 4.3966687712782004e-07
due O 0 2.0182428670523223e-06
to O 0 3.9664001860728604e-07
KIT O 0 9.473151294514537e-05
mutations O 0 1.1079095202148892e-05
, O 0 2.3839629648136906e-05
deafness B-Disease 1 1.0
is O 0 4.168850864516571e-06
not O 0 1.1777870412288394e-07
typical O 0 1.4838743709333357e-06
in O 0 1.738686705721193e-06
human O 0 1.4999550330685452e-05
piebaldism B-Disease 0 0.002128165913745761
. O 0 3.123531860182993e-05

Thus O 0 1.7948650565813296e-05
, O 0 1.7974697357203695e-06
the O 0 4.6651717866552644e-07
occurrence O 0 9.237951417162549e-06
of O 0 0.00022671371698379517
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 0.0011723008938133717
this O 0 1.510025754214439e-06
patient O 0 1.1185374205524568e-05
extends O 0 2.69328279500769e-06
considerably O 0 1.1172134009029833e-06
the O 0 2.315201186320337e-07
phenotypic O 0 5.54060875401774e-07
range O 0 6.30723434369429e-07
of O 0 1.4253848803491564e-06
piebaldism B-Disease 0 4.5797827624483034e-05
due O 0 2.0499592210398987e-06
to O 0 3.3377577324245067e-07
KIT O 0 1.058243287843652e-05
gene O 0 8.448241146652435e-07
mutation O 0 6.948929467398557e-07
in O 0 6.835261956439354e-07
humans O 0 2.6659495233616326e-07
and O 0 3.226211049423e-07
tightens O 0 6.3221727941709105e-06
the O 0 1.457449769759478e-07
clinical O 0 2.6459952096047346e-06
similarity O 0 4.871902206105005e-07
between O 0 6.598033905902412e-07
piebaldism B-Disease 0 3.314253262942657e-05
and O 0 1.1220551954238545e-07
the O 0 1.1830317703243054e-07
various O 0 1.0257470961505533e-07
forms O 0 1.4549848401657073e-06
of O 1 0.7883718013763428
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 4.3499985622474924e-05
. O 0 2.8187589123263024e-05

Cycloheximide O 0 0.0033062042202800512
facilitates O 0 8.591778168920428e-05
the O 0 5.231004251982085e-06
identification O 0 2.434141833873582e-06
of O 0 3.603361165005481e-06
aberrant O 0 0.00016615408821962774
transcripts O 0 2.4887616746127605e-05
resulting O 0 7.978459507285152e-06
from O 0 1.6576085499764304e-06
a O 0 2.781947614494129e-06
novel O 0 5.594364210992353e-06
splice O 0 3.1463001505471766e-05
- O 0 5.9620829233608674e-06
site O 0 4.280585699234507e-07
mutation O 0 2.049918634838832e-07
in O 0 3.924222653495235e-07
COL17A1 O 0 0.00013075146125629544
in O 0 4.085312070856162e-07
a O 0 3.4819486245396547e-06
patient O 0 9.497718565398827e-06
with O 0 4.758418072015047e-06
generalized O 1 0.9999349117279053
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999993085861206
. O 0 7.830949471099302e-05

Patients O 0 0.0006177070317789912
with O 0 2.345672510273289e-05
generalized O 1 0.9997561573982239
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999929666519165
often O 0 1.0429724852656364e-06
show O 0 8.634064556645171e-07
decreased O 0 1.8091959645971656e-05
expression O 0 2.410381057416089e-06
of O 0 5.21528363606194e-06
type O 0 0.004619149956852198
XVII O 1 0.9999974966049194
collagen O 0 0.013254440389573574
, O 0 1.575093165229191e-06
a O 0 3.3673172765702475e-06
transmembrane O 0 3.8110225432319567e-05
hemidesmosomal O 0 7.420194015139714e-05
protein O 0 3.5505963751347736e-06
encoded O 0 3.1914432838675566e-06
by O 0 9.70123892329866e-06
COL17A1 O 0 0.13387137651443481
. O 0 3.8282487366814166e-05

This O 0 1.831265581131447e-05
report O 0 1.5075011106091551e-05
documents O 0 3.332565029268153e-06
a O 0 5.275712737784488e-06
novel O 0 1.0084610039484687e-05
splice O 0 7.965325494296849e-05
- O 0 1.033114403981017e-05
site O 0 1.014792701425904e-06
mutation O 0 4.746778756725689e-07
in O 0 6.148889042378869e-07
COL17A1 O 0 0.0004477115289773792
in O 0 6.747535508111469e-07
a O 0 3.881155862472951e-06
patient O 0 8.354216333827935e-06
with O 0 2.8900872166559566e-06
generalized O 1 0.9998674392700195
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9998680353164673
, O 0 4.620601714577788e-07
and O 0 9.751168761340523e-08
applies O 0 1.7361453785724734e-07
a O 0 1.985845443641665e-07
new O 0 1.3946767296602047e-07
methodology O 0 5.318848366187012e-07
to O 0 6.697568011304611e-08
define O 0 3.422872794089926e-07
and O 0 4.039519012621895e-07
characterize O 0 3.011136186614749e-06
the O 0 1.4543994666382787e-06
resulting O 0 7.829793503333349e-06
mRNA O 0 2.0204795873723924e-05
splice O 0 3.602136712288484e-05
variants O 0 1.330687155132182e-05
. O 0 1.6328267520293593e-05

Mutational O 0 0.19269880652427673
analysis O 0 0.0001644580770516768
of O 0 7.676098903175443e-05
COL17A1 O 0 0.0756843164563179
identified O 0 2.9964900022605434e-05
a O 0 3.465311965555884e-05
maternally O 0 0.00018237042240798473
inherited O 0 0.03104844130575657
G O 0 0.055479783564805984
- O 0 9.673229942563921e-05
to O 0 3.6006199479743373e-06
- O 0 0.0005844526458531618
T O 0 0.00013985288387630135
transversion O 0 1.1562112376850564e-05
at O 0 1.8977403897224576e-06
the O 0 5.225685981713468e-07
- O 0 5.97098960497533e-07
1 O 0 4.555773500669602e-07
position O 0 7.684146225983568e-07
of O 0 1.3016058346693171e-06
exon O 0 1.0454358744027559e-05
32 O 0 1.7039381418726407e-05
. O 0 1.3272904652694706e-05

This O 0 2.3915341444080696e-05
acceptor O 0 2.6055367925437167e-05
splice O 0 0.00015375403745565563
- O 0 2.0857785784755833e-05
site O 0 1.9046466377403704e-06
mutation O 0 6.201235578373598e-07
led O 0 8.066620580393646e-07
to O 0 6.43750013296085e-08
the O 0 3.0048485655242985e-07
formation O 0 1.184401639875432e-06
of O 0 1.032938257594651e-06
aberrant O 0 3.241187732783146e-05
transcripts O 0 7.827359695511404e-06
present O 0 9.778992762221606e-07
at O 0 3.6843779525952414e-05
extremely O 0 2.0804205632884987e-05
low O 0 8.085421723080799e-05
levels O 0 1.6207724911510013e-05
. O 0 7.261199243657757e-06

Based O 0 2.8525284506031312e-05
on O 0 6.923865839780774e-06
our O 0 1.5152781998040155e-06
recent O 0 1.5937555417622207e-06
finding O 0 6.905256668687798e-07
that O 0 7.72626606249105e-07
cycloheximide O 0 0.00025018819724209607
stabilized O 0 0.00025855997228063643
mutant O 0 2.7152318580192514e-05
COL17A1 O 0 0.0006899671861901879
transcripts O 0 7.992716746230144e-06
in O 0 7.078062935761409e-07
keratinocytes O 0 3.4117017548851436e-06
homozygous O 0 5.481482503455481e-07
for O 0 6.709355915290871e-08
a O 0 6.545976134475495e-07
frameshift O 0 6.944524557184195e-06
mutation O 0 8.608625421402394e-07
, O 0 2.2049370329568774e-07
the O 0 3.1777568665347644e-07
effects O 0 1.8372915064901463e-06
of O 0 2.401148776698392e-06
the O 0 2.5953465865313774e-06
splice O 0 1.8884637029259466e-05
- O 0 5.863160822627833e-06
site O 0 8.615097044639697e-07
mutation O 0 3.385821969459357e-07
on O 0 4.7447693418689596e-07
splicing O 0 8.151586712301651e-07
of O 0 1.3403503089648439e-06
COL17A1 O 0 2.6437794076628052e-05
transcripts O 0 1.4751600474482984e-06
were O 0 1.9371073278762196e-07
determined O 0 2.817480151406926e-07
using O 0 2.8139518803982355e-07
reverse O 0 3.7522049751714803e-06
transcriptase O 0 2.9413462470984086e-05
polymerase O 0 1.2633158803510014e-05
chain O 0 1.5258974599419162e-06
reaction O 0 2.5815575099841226e-07
of O 0 2.1181065790187859e-07
total O 0 7.748949428787455e-07
RNA O 0 3.45282637681521e-06
from O 0 6.221725925570354e-07
keratinocytes O 0 3.687802518470562e-06
incubated O 0 4.00998214900028e-06
for O 0 5.20509047419182e-07
2 O 0 8.10540859674802e-06
. O 0 9.775191756489221e-06

5 O 0 0.00015548814553767443
h O 0 6.624947127420455e-05
in O 0 2.0615279936464503e-06
the O 0 8.257056265392748e-07
presence O 0 1.3461622074828483e-06
or O 0 5.04000240653113e-07
absence O 0 3.2223965718003456e-06
of O 0 1.989594238693826e-06
10 O 0 5.060200237494428e-06
microg O 0 0.00017426280828658491
cycloheximide O 0 0.00013756750558968633
per O 0 1.9495628293952905e-05
ml O 0 6.696389027638361e-05
. O 0 1.2679411156568676e-05

Using O 0 1.2719812730210833e-05
this O 0 2.3524123662355123e-06
approach O 0 7.863467544666491e-06
, O 0 7.342262620113615e-07
an O 0 8.863328275765525e-07
abnormally O 0 0.00015419904957525432
spliced O 0 1.1345729944878258e-05
transcript O 0 3.483216278254986e-05
was O 0 2.151385706383735e-05
identified O 0 3.7274173791956855e-07
that O 0 9.062880224064429e-08
contains O 0 1.2251369696514303e-07
an O 0 4.1824432628345676e-07
extra O 0 4.3790140580313164e-07
264 O 0 4.229592377669178e-06
bases O 0 1.4138569213173469e-06
upstream O 0 4.2433325688762125e-06
from O 0 4.879872221863479e-07
exon O 0 1.3554516726799193e-06
32 O 0 1.1712918421835639e-06
, O 0 1.287741326905234e-07
resulting O 0 7.343264769588131e-07
in O 0 5.187952751839475e-07
a O 0 5.042832981416723e-06
premature O 0 3.995563747594133e-05
termination O 0 2.344487074878998e-05
codon O 0 1.5954123227857053e-05
27 O 0 1.4612181985285133e-05
bp O 0 1.1645938684523571e-05
downstream O 0 8.848971447150689e-06
from O 0 1.1786358982135425e-06
the O 0 2.6142806746065617e-06
cryptic O 0 2.9122213163645938e-05
splice O 0 6.58786520943977e-05
site O 0 3.430537253734656e-05
. O 0 1.4963417015678715e-05

Three O 0 2.455050162097905e-05
other O 0 1.6475991060360684e-06
splice O 0 2.8286523956921883e-05
variants O 0 4.471630290936446e-06
, O 0 6.13661654824682e-07
including O 0 3.069489764584432e-07
one O 0 2.285663356360601e-07
derived O 0 4.6235948047979036e-07
from O 0 3.9950398900145956e-07
the O 0 5.492634045367595e-07
skipping O 0 7.568572186755773e-07
of O 0 5.029458520766639e-07
exon O 0 2.137099500032491e-06
32 O 0 1.4941394965717336e-06
, O 0 2.3707420382379496e-07
were O 0 8.502038326696493e-07
also O 0 1.68330404903827e-06
identified O 0 1.296754453505855e-05
. O 0 1.888150472950656e-05

These O 0 4.978562174073886e-06
results O 0 6.319580734270858e-06
indicate O 0 4.001012712251395e-06
the O 0 8.412960710302286e-07
usefulness O 0 4.931991497869603e-06
of O 0 3.4717493235802976e-06
cycloheximide O 0 0.00020024742116220295
treatment O 0 3.2729487884353148e-06
in O 0 3.8147774716890126e-07
evaluating O 0 5.083137466499466e-07
the O 0 1.1419285783631494e-06
abnormal O 0 1.853554931585677e-05
processing O 0 4.771742624143371e-06
of O 0 2.2298995645542163e-06
mRNA O 0 3.338844635436544e-06
due O 0 1.7693290601528133e-06
to O 0 2.5971641548494517e-07
splice O 0 8.684854947205167e-06
- O 0 6.58983026369242e-06
site O 0 1.3653467476615333e-06
mutations O 0 4.1518669036122446e-07
, O 0 2.2395060739199835e-07
because O 0 1.8672768931082828e-07
( O 0 2.898020170505333e-07
i O 0 6.304720727712265e-07
) O 0 2.0442924153485365e-07
aberrant O 0 3.520822701830184e-06
splicing O 0 7.736264819868666e-07
often O 0 1.3625172812226083e-07
generates O 0 8.300083891299437e-07
a O 0 3.3719572911650175e-06
premature O 0 2.98534614557866e-05
termination O 0 9.071854037756566e-06
codon O 0 6.6845582296082284e-06
, O 0 3.7117314377610455e-07
( O 0 3.0904678283150133e-07
ii O 0 9.138828318100423e-06
) O 0 2.539576655635756e-07
transcripts O 0 1.369214260193985e-06
with O 0 1.8561625836355233e-07
premature O 0 2.442071672703605e-05
termination O 0 5.824105755891651e-06
codons O 0 9.264763889405003e-07
can O 0 4.292735411581816e-08
occur O 0 1.5359583471763472e-07
at O 0 3.994774942839285e-06
low O 0 8.40915527078323e-06
or O 0 1.4380502761923708e-06
undetectable O 0 2.0790839698747732e-05
levels O 0 7.71291183809808e-07
due O 0 1.0233605962639558e-06
to O 0 3.2016205864238145e-07
nonsense O 0 1.892123145808e-05
- O 0 4.303419700590894e-06
mediated O 0 4.781399638886796e-06
mRNA O 0 2.852608304237947e-06
decay O 0 1.7230483990715584e-06
, O 0 2.2171332147991052e-07
and O 0 1.0596409794061401e-07
( O 0 2.003009313966686e-07
iii O 0 5.600289568974404e-06
) O 0 8.20036802906543e-08
the O 0 1.6498194099767716e-07
levels O 0 1.208208288971946e-07
of O 0 1.0961066720938106e-07
these O 0 1.458864762327039e-08
transcripts O 0 6.746004146407358e-07
can O 0 2.2849741654340505e-08
be O 0 1.5948822351674607e-07
increased O 0 3.2466389257024275e-06
by O 0 4.214256023260532e-06
cycloheximide O 0 0.0002493665961083025
. O 0 9.955417226592544e-06

A O 0 0.00019726043683476746
deletion O 0 9.349512401968241e-05
mutation O 0 1.493623130954802e-05
in O 0 4.505898232309846e-06
COL17A1 O 0 0.0005591801600530744
in O 0 5.658623649651418e-07
five O 0 3.645265849172574e-07
Austrian O 0 2.8042562917107716e-05
families O 0 2.3069405585829372e-07
with O 0 1.301387442254054e-06
generalized O 1 0.999924898147583
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999996542930603
represents O 0 4.745140358863864e-06
propagation O 0 1.3039893019595183e-05
of O 0 1.951657623067149e-06
an O 0 2.107404498019605e-06
ancestral O 0 3.309256862848997e-05
allele O 0 4.963414903613739e-05
. O 0 2.5727667889441364e-05

Patients O 0 0.0003118501917924732
with O 0 3.4994507586816326e-05
generalized O 1 0.9997727274894714
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999980926513672
, O 0 2.794781039483496e-06
a O 0 8.329201364176697e-07
usually O 0 1.739388721944124e-07
nonlethal O 0 6.146553459984716e-06
form O 0 2.937852059403667e-07
of O 0 8.190781954908744e-06
junctional B-Disease 1 0.9999179840087891
epidermolysis I-Disease 1 0.9999933242797852
bullosa I-Disease 1 0.9987518787384033
, O 0 1.6029118796723196e-06
have O 0 6.111613402026705e-07
generalized O 0 0.0001520228834124282
blistering B-Disease 1 0.999584972858429
, O 0 0.0004217437235638499
nail B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
, O 0 5.1917097152909264e-05
patchy B-Disease 1 0.9999911785125732
alopecia I-Disease 1 1.0
, O 0 0.000491479120682925
and O 0 0.03328178450465202
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.5739983916282654

Skin B-Disease 1 0.9999862909317017
fragility I-Disease 1 0.9978111386299133
in O 0 9.135804248217028e-06
most O 0 6.296158403529262e-07
cases O 0 2.438697777051857e-07
is O 0 1.7673463048595295e-07
due O 0 4.4608026428250014e-07
to O 0 5.168880079509108e-08
mutations O 0 2.776816643290658e-07
in O 0 1.5293619526346447e-07
the O 0 4.012550220977573e-07
gene O 0 6.415424422812066e-07
encoding O 0 1.783110860742454e-06
type O 0 0.0012084972113370895
XVII O 1 0.9999994039535522
collagen O 1 0.9919672608375549
( O 0 4.9155758460983634e-05
COL17A1 O 1 0.9585112929344177
) O 0 7.082896900101332e-06
. O 0 7.051550255710026e-06

Recently O 0 0.00014163578453008085
, O 0 2.825274123097188e-06
we O 0 5.159237730367749e-07
reported O 0 1.6922227814575308e-06
five O 0 3.636453129729489e-07
Austrian O 0 2.1571955585386604e-05
families O 0 3.8596786566813535e-07
with O 0 2.642311073941528e-06
generalized O 1 0.9999817609786987
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999767541885376
who O 0 1.4924006563887815e-06
share O 0 3.660974243757664e-07
the O 0 5.1225850938863e-07
same O 0 2.7777114155469462e-06
COL17A1 O 0 0.012103691697120667
mutation O 0 5.074449654784985e-05
. O 0 2.5974637537728995e-05

Affected O 0 4.307500785216689e-05
individuals O 0 1.2709547263511922e-06
in O 0 8.823992061479657e-07
three O 0 2.2590732839944394e-07
families O 0 4.129369912675429e-08
are O 0 1.5441750988998137e-08
homozygous O 0 5.90811509937339e-07
for O 0 2.1903542801737785e-07
4003delTC O 0 9.206298273056746e-06
, O 0 2.1053142518212553e-07
whereas O 0 1.3645718865973322e-07
those O 0 2.7024260162988867e-08
in O 0 1.361485999495926e-07
two O 0 1.3798000964015955e-07
others O 0 3.780963311328378e-07
are O 0 4.3022970430683927e-07
compound O 0 5.8680230722529814e-05
heterozygotes O 0 5.782162043033168e-05
. O 0 9.472266356169712e-06

To O 0 7.836315489839762e-06
determine O 0 1.7638418512433418e-06
if O 0 3.18657555453683e-07
the O 0 4.2075231476701447e-07
occurrence O 0 1.271890823772992e-06
of O 0 6.21161177605245e-07
4003delTC O 0 5.103263902128674e-06
in O 0 2.2051935388844868e-07
these O 0 3.880457200011733e-08
unrelated O 0 9.189808451992576e-07
families O 0 1.2022429984881455e-07
signifies O 0 4.5065298763802275e-06
propagation O 0 1.1961173186136875e-05
of O 0 9.422149105375865e-07
an O 0 7.762262725918845e-07
ancestral O 0 3.204004542567418e-06
allele O 0 1.3571267345469096e-06
or O 0 3.5910346696255147e-07
a O 0 4.63499918623711e-06
mutational O 0 0.0007859351462684572
hot O 0 4.2524981836322695e-05
spot O 0 5.960474027233431e-06
, O 0 1.689140276539547e-07
haplotypes O 0 6.454836238845019e-07
were O 0 1.5609661829785182e-07
determined O 0 1.2359627987734711e-07
for O 0 7.897385501109966e-08
polymorphisms O 0 1.1851609542645747e-06
both O 0 1.8640102439348993e-07
within O 0 9.103452498493425e-07
and O 0 3.639180249592755e-06
flanking O 0 0.11672835052013397
COL17A1 O 1 0.9540891051292419
. O 0 1.851173692557495e-05

Five O 0 5.3806481446372345e-05
intragenic O 0 0.0002621840685606003
polymorphisms O 0 3.2111820473801345e-05
were O 0 3.5430671232461464e-06
chosen O 0 1.5503512713621603e-06
based O 0 9.455571898797643e-07
on O 0 4.943980911775725e-06
their O 0 3.696080057125073e-06
informativeness O 0 0.005145339295268059
. O 0 5.438289372250438e-05

One O 0 1.2573592357512098e-05
of O 0 3.55631686943525e-06
these O 0 2.046270139999251e-07
, O 0 3.5589391700341366e-07
not O 0 1.7494534176876186e-07
previously O 0 1.3990317029310972e-06
reported O 0 1.4808630339757656e-06
, O 0 5.405508431977069e-07
was O 0 2.9209018975961953e-05
2988 O 0 3.2103002013172954e-05
A O 0 1.2021507245663088e-05
or O 0 1.249223601007543e-06
C O 0 8.639898624096531e-06
that O 0 8.095653214468257e-08
introduces O 0 6.314577376542729e-07
a O 0 5.238125595496967e-07
new O 0 2.8520730666059535e-07
restriction O 0 1.369410256302217e-06
site O 0 1.214875510413549e-06
for O 0 1.395542994941934e-06
Eco0109 O 0 0.00020139013940934092
I O 0 5.813499228679575e-05
. O 0 2.3149077605921775e-05

All O 0 4.48676064479514e-06
the O 0 5.442916517495178e-06
4003delTC O 0 5.57743405806832e-05
alleles O 0 3.8896710066183005e-06
showed O 0 3.079716179854586e-06
the O 0 4.065350651671906e-07
same O 0 3.3227988183170964e-07
haplotype O 0 6.119059889897471e-06
for O 0 2.024537764100387e-07
these O 0 1.0235543612679976e-07
five O 0 1.790849637473002e-06
polymorphic O 0 4.2031177144963294e-05
markers O 0 9.163657523458824e-05
. O 0 2.935915472335182e-05

Fourteen O 0 0.00012368400348350406
microsatellite O 0 0.0004981620004400611
polymorphisms O 0 8.762908692006022e-05
were O 0 3.951467078877613e-06
selected O 0 1.2159755442553433e-06
based O 0 6.29483167813305e-07
on O 0 1.0613537142489804e-06
their O 0 3.3648024100330076e-07
high O 0 4.0926919609773904e-05
heterozygosity O 0 4.018702020402998e-05
and O 0 2.5802924596973753e-07
their O 0 1.5477850467959797e-07
location O 0 3.4758838864945574e-06
within O 0 2.454883087921189e-06
10q23 O 0 0.0013171401806175709
- O 0 0.00044580106623470783
q25 O 0 0.0009715021005831659
near O 0 0.0004778356815222651
COL17A1 O 0 0.03543738275766373
. O 0 2.0351963030407205e-05

Three O 0 1.185663313663099e-05
families O 0 1.425787331754691e-06
shared O 0 2.9315988285816275e-06
microsatellite O 0 0.00012132892879890278
polymorphisms O 0 3.300328171462752e-05
covering O 0 4.2273164581274614e-05
at O 0 2.2677671950077638e-05
most O 0 3.592610084979242e-07
19 O 0 4.073534000781365e-06
cM O 0 1.5268542483681813e-05
, O 0 1.9977859722075664e-07
whereas O 0 1.3832585921136342e-07
the O 0 1.6377362044295296e-07
others O 0 4.15834513489699e-08
shared O 0 7.399574997180025e-08
smaller O 0 8.570602716417852e-08
regions O 0 1.1121687037984884e-07
consistent O 0 6.94744585416629e-07
with O 0 9.477675178004574e-08
cross O 0 2.2464569155999925e-06
- O 0 1.1318541055516107e-06
over O 0 5.442883477257965e-08
events O 0 4.065629255478598e-08
during O 0 8.410348328879991e-08
passage O 0 8.926068062464765e-08
of O 0 3.983215179914623e-08
this O 0 2.2245963293698878e-08
mutation O 0 7.171804128347503e-08
through O 0 1.0799202954103748e-07
several O 0 2.7698234816853073e-07
generations O 0 2.018188979491242e-06
. O 0 7.012145488261012e-06

These O 0 1.222580158355413e-05
results O 0 7.558267952845199e-06
indicate O 0 1.8654416180652333e-06
that O 0 2.2058121373902395e-07
4003delTC O 0 7.593039754283382e-06
occurs O 0 3.670693331514485e-07
on O 0 7.349822226387914e-07
a O 0 9.292336926591815e-07
single O 0 1.0174983344768407e-06
ancestral O 0 7.082038791850209e-06
allele O 0 7.141246896935627e-06
. O 0 1.7316538105660584e-06
. O 0 6.457541985582793e-06

The O 0 0.00023204543686006218
haptoglobin O 0 0.003482063766568899
- O 0 0.00011878433724632487
gene O 0 1.1314395123918075e-05
deletion O 0 2.1025882233516313e-05
responsible O 0 9.810858500713948e-06
for O 0 6.450063665397465e-06
anhaptoglobinemia B-Disease 0 0.026083005592226982
. O 0 2.704102371353656e-05

We O 0 1.3708520782529376e-05
have O 0 1.153229504780029e-06
found O 0 7.140015441109426e-07
an O 0 5.27419672380347e-07
allelic O 0 5.229278485785471e-06
deletion O 0 6.547894827235723e-06
of O 0 6.380154900398338e-06
the O 0 8.976499884738587e-06
haptoglobin O 0 0.00020441664673853666
( O 0 2.613134256534977e-06
Hp O 0 1.825248727982398e-05
) O 0 1.6732323615542555e-07
gene O 0 2.442272659664013e-07
from O 0 3.998748638878169e-07
an O 0 4.70467227842164e-07
individual O 0 1.7896444148846058e-07
with O 0 1.4199064253261895e-06
anhaptoglobinemia B-Disease 1 0.7693352103233337
. O 0 4.7161232942016795e-05

The O 0 0.00017155110253952444
Hp O 0 0.0002809910802170634
gene O 0 4.400739271659404e-06
cluster O 0 5.7903785091184545e-06
consists O 0 5.094688049211982e-07
of O 0 1.1193953923793742e-06
coding O 0 1.625872982913279e-06
regions O 0 1.5144850351589412e-07
of O 0 1.1786886489062454e-06
the O 0 2.1694129372917814e-06
alpha O 0 3.768094074985129e-06
chain O 0 1.6213471099035814e-06
and O 0 1.2600119703165547e-07
beta O 0 9.017357456286845e-07
chain O 0 6.387957114384335e-07
of O 0 4.2923551291096373e-07
the O 0 8.924788517106208e-07
haptoglobin O 0 1.0136097444046754e-05
gene O 0 9.290972116104967e-07
( O 0 7.797609100634872e-07
Hp O 0 4.473080480238423e-06
) O 0 5.851848783322566e-08
and O 0 3.7969918764702015e-08
of O 0 3.252029330269579e-07
the O 0 5.168890311324503e-07
alpha O 0 2.820834879457834e-06
chain O 0 7.870413583077607e-07
and O 0 1.3702511125757155e-07
beta O 0 1.218713009620842e-06
chain O 0 8.051916893236921e-07
of O 0 7.195679359028873e-07
the O 0 1.1458940889497171e-06
haptoglobin O 0 1.8829625332728028e-05
- O 0 3.505999757180689e-06
related O 0 7.837734301574528e-07
gene O 0 6.910474326105032e-07
( O 0 6.863880344099016e-07
Hpr O 0 7.872082278481685e-06
) O 0 1.5831061261906143e-07
, O 0 1.5984194590146217e-07
in O 0 2.857785261767276e-07
tandem O 0 8.697951670910697e-06
from O 0 5.151685513737903e-07
the O 0 8.405182256865373e-07
5 O 0 7.002675829426153e-06
side O 0 1.4700449355586898e-05
. O 0 1.324071672570426e-05

Southern O 0 8.786655962467194e-05
blot O 0 0.0003833489608950913
and O 0 1.1601300684560556e-05
PCR O 0 5.6741333537502214e-05
analyses O 0 2.7524176857696148e-06
have O 0 3.1458728244615486e-07
indicated O 0 1.4622127082475345e-06
that O 0 1.299426344303356e-07
the O 0 3.207619840850384e-07
individual O 0 6.505139538148796e-08
with O 0 1.876169903880509e-07
anhaptoglobinemia B-Disease 0 6.518947338918224e-05
was O 0 1.9992501620436087e-05
homozygous O 0 1.345129135188472e-06
for O 0 1.3668446285919345e-07
the O 0 2.838819739281462e-07
gene O 0 3.09779750296002e-07
deletion O 0 1.1277876410531462e-06
and O 0 1.4393822311831173e-07
that O 0 7.761197906575035e-08
the O 0 1.493123846785238e-07
gene O 0 2.0663865996084496e-07
deletion O 0 9.770417364052264e-07
was O 0 1.0376347745477688e-05
included O 0 4.1473714418316376e-07
at O 0 1.6529406821064185e-06
least O 0 9.4113843829291e-08
from O 0 2.6524909912950534e-07
the O 0 7.792791620886419e-07
promoter O 0 9.146536285697948e-06
region O 0 7.336439580285514e-07
of O 0 5.627444352285238e-06
Hp O 0 8.703020284883678e-06
to O 0 2.727828132265131e-07
Hpr O 0 8.438653821940534e-06
alpha O 0 1.300134499615524e-06
but O 0 6.427990939528172e-08
not O 0 4.3085833567602094e-08
to O 0 3.432407709169638e-07
Hpr O 0 2.010830030485522e-05
beta O 0 1.0223665412922855e-05
( O 0 4.5149013203626964e-06
Hpdel O 0 0.0001795878924895078
) O 0 4.977874141331995e-06
. O 0 1.0393887350801378e-05

In O 0 2.6444855393492617e-05
addition O 0 2.3072889234754257e-06
, O 0 6.198806090651487e-07
we O 0 1.1763098228811941e-07
found O 0 2.0573337167206773e-07
seven O 0 1.366423560966723e-07
individuals O 0 4.350716054091208e-08
with O 0 1.3302337720233481e-07
hypohaptoglobinemia B-Disease 0 0.00014599379210267216
in O 0 8.526242822881613e-07
three O 0 2.1335306144010246e-07
families O 0 5.5734030723897376e-08
, O 0 1.5978066869593022e-07
and O 0 8.373581295018084e-08
the O 0 6.243647021619836e-07
genotypes O 0 7.021936312412436e-07
of O 0 1.2394524446790456e-06
six O 0 3.20135484344064e-07
of O 0 4.117113974189124e-07
the O 0 2.3098024826140318e-07
seven O 0 1.517040715270923e-07
individuals O 0 1.9826391195465476e-08
were O 0 1.6449162387743854e-07
found O 0 2.2748903916181007e-07
to O 0 3.443502691879985e-07
be O 0 5.76012007513782e-06
Hp2 O 0 0.1958155483007431
/ O 0 0.0012860058341175318
Hpdel O 0 0.0022632621694356203
. O 0 2.055940785794519e-05

The O 0 4.612792326952331e-05
phenotypes O 0 6.481890886789188e-05
and O 0 1.5410262221848825e-06
genotypes O 0 7.1571935222891625e-06
in O 0 3.9079247926565586e-07
one O 0 9.567654757347555e-08
of O 0 3.355708031449467e-07
these O 0 3.128889503045684e-08
three O 0 9.199456485475821e-08
families O 0 5.9163358656633136e-08
showed O 0 1.5606402712364797e-06
the O 0 1.15628870389628e-06
father O 0 2.7886121642950457e-06
to O 0 4.6448127477560774e-07
be O 0 1.977463170987903e-06
hypohaptoglobinemic B-Disease 0 0.00011493622878333554
( O 0 1.4205036222847411e-06
Hp2 O 0 3.6448844184633344e-05
) O 0 2.4327744085894665e-07
and O 0 4.296823021832097e-07
Hp2 O 0 0.0008682200568728149
/ O 0 3.790590926655568e-05
Hpdel O 0 0.00012770401372108608
, O 0 6.091096906857274e-07
the O 0 4.4322257508611074e-07
mother O 0 9.516119234831422e-07
to O 0 1.834306715409184e-07
be O 0 9.10003222998057e-07
Hp2 O 0 4.2001567635452375e-05
- O 0 5.722383775719209e-06
1 O 0 1.5484096138607129e-06
and O 0 9.25042684229993e-07
Hp1 O 0 0.0001197535457322374
/ O 0 9.06375043996377e-06
Hp2 O 0 1.6827885701786727e-05
, O 0 1.1961655843606422e-07
one O 0 3.970328066316142e-08
of O 0 1.2816204275623022e-07
the O 0 1.551281485490108e-07
two O 0 4.552698129600685e-08
children O 0 9.604551820530105e-08
to O 0 2.1553844931077037e-07
be O 0 2.1708533495257143e-06
hypohaptoglobinemic B-Disease 0 8.604715549154207e-05
( O 0 1.3595349628303666e-06
Hp2 O 0 3.400752757443115e-05
) O 0 2.033886659091877e-07
and O 0 5.083738869871013e-07
Hp2 O 0 0.0009381705895066261
/ O 0 3.778158497880213e-05
Hpdel O 0 8.005631389096379e-05
, O 0 3.428982324749086e-07
and O 0 8.695894138099902e-08
the O 0 1.4999072561749927e-07
other O 0 2.655859177025377e-08
child O 0 4.745465957967099e-07
to O 0 1.4155945393667935e-07
be O 0 9.60742568167916e-07
Hp1 O 0 8.510333282174543e-05
and O 0 2.0186046185699524e-06
Hp1 O 1 0.6299352049827576
/ O 0 0.00014386452676262707
Hpdel O 0 0.0001376149884890765
, O 0 3.1212246653922193e-07
showing O 0 7.85320708018844e-07
an O 0 6.063815476409218e-07
anomalous O 0 4.276736581232399e-05
inheritance O 0 4.207846814097138e-06
of O 0 3.872770685120486e-05
Hp O 0 9.293724724557251e-05
phenotypes O 0 1.8669685459826724e-06
in O 0 5.666140054927382e-07
the O 0 9.42400959047518e-07
child O 0 4.809938218386378e-06
with O 0 3.677960876302677e-06
Hp1 O 1 0.6593714356422424
. O 0 3.9496713725384325e-05

The O 0 0.00011520549014676362
Hp2 O 0 0.03349849954247475
/ O 0 0.0003067462530452758
Hpdel O 0 0.00021594240388367325
individuals O 0 5.711626158699801e-07
had O 0 4.943330623063957e-06
an O 0 2.910263901867438e-06
extremely O 0 5.4528863984160125e-06
low O 0 1.4768697838007938e-05
level O 0 4.028864623251138e-06
of O 0 5.108103778184159e-06
Hp O 0 9.40812151384307e-06
( O 0 2.458101562297088e-07
mean O 0 6.196158324200951e-07
+ O 0 7.920939424366225e-07
/ O 0 1.122966750699561e-06
- O 0 1.1682921012834413e-06
SD O 0 4.567511950881453e-06
= O 0 8.292275310850528e-07
0 O 0 2.366143263543563e-07
. O 0 1.4102288048434275e-07
049 O 0 5.533830972126452e-06
+ O 0 1.0767236062747543e-06
/ O 0 1.147533339462825e-06
- O 0 9.184778946291772e-07
0 O 0 4.2533056898719224e-07
. O 0 1.8212803354344942e-07
043 O 0 8.077797247096896e-06
mg O 0 6.597256287932396e-06
/ O 0 1.652118044148665e-06
ml O 0 9.290413913731754e-07
; O 0 7.425645520697799e-08
n O 0 2.573261497218482e-07
= O 0 4.1455959376435203e-07
6 O 0 4.239710449382983e-07
) O 0 6.72311486482613e-08
, O 0 5.325568608327558e-08
compared O 0 1.3314445368450833e-07
with O 0 1.7817438191514157e-08
the O 0 2.7248043465988303e-07
level O 0 9.209065865434241e-07
( O 0 9.236677556145878e-08
1 O 0 1.5624733862296125e-07
. O 0 5.6463978381771085e-08
64 O 0 5.134058369549166e-07
+ O 0 9.461525110054936e-07
/ O 0 1.6404450207119226e-06
- O 0 1.1894001090695383e-06
1 O 0 7.305754365916073e-07
. O 0 2.2720803372067166e-07
07 O 0 1.578040792082902e-05
mg O 0 1.0750813999038655e-05
/ O 0 2.263723899886827e-06
ml O 0 8.309081636070914e-07
) O 0 4.038201240064154e-08
obtained O 0 1.2755418765664217e-07
from O 0 1.9074681745223643e-07
52 O 0 2.3079403490555706e-06
healthy O 0 7.131617394406931e-07
volunteers O 0 6.713567586302815e-07
having O 0 1.0413891686766874e-06
phenotype O 0 4.443457874003798e-05
Hp2 O 0 7.629685569554567e-05
, O 0 3.2934713090071455e-07
whereas O 0 4.952541985403514e-07
the O 0 5.958377755632682e-07
serum O 0 2.294809019076638e-05
Hp O 0 1.332762258243747e-05
level O 0 6.228808615560411e-07
of O 0 4.0963294622997637e-07
an O 0 3.2603608701720077e-07
individual O 0 1.0024157148791346e-07
with O 0 5.271471081869095e-07
Hp1 O 0 0.11103013902902603
/ O 0 0.00018456779071129858
Hpdel O 0 0.00031268972088582814
was O 0 7.754586840746924e-05
0 O 0 6.379138994816458e-06
. O 0 4.506426648731576e-06

50 O 0 0.00022195557539816946
mg O 0 0.00035175285302102566
/ O 0 5.5343862186418846e-05
ml O 0 2.03336458071135e-05
, O 0 3.65231215937456e-07
which O 0 9.284544688625829e-08
was O 0 1.142552719102241e-06
approximately O 0 1.5772079109410697e-07
half O 0 1.7739066038302553e-07
the O 0 3.5620527683022374e-07
level O 0 1.213690779877652e-06
of O 0 1.605867964826757e-06
Hp O 0 7.953533895488363e-06
in O 0 3.4430001960572554e-07
control O 0 2.9546506539190887e-06
sera O 0 3.1377367122331634e-05
from O 0 8.433445373157156e-07
the O 0 1.3032120023126481e-06
Hp1 O 0 2.0049934391863644e-05
phenotype O 0 4.719443495559972e-06
( O 0 2.9650419719473575e-07
1 O 0 3.708618123710039e-07
. O 0 8.674805940245278e-08
26 O 0 1.9194128526578424e-06
+ O 0 8.465483460895484e-07
/ O 0 1.4362616411744966e-06
- O 0 9.610156439521234e-07
0 O 0 2.698018022329052e-07
. O 0 6.993386847398142e-08
33 O 0 1.616756662770058e-06
mg O 0 5.125036295794416e-06
/ O 0 2.9203813483036356e-06
ml O 0 1.0217056569672422e-06
; O 0 4.2823824486504236e-08
n O 0 5.261139790491143e-07
= O 0 7.303385700652143e-07
9 O 0 7.994896691343456e-07
) O 0 7.149977676590424e-08
, O 0 6.264791352350585e-08
showing O 0 3.9601752632734133e-07
a O 0 1.5104665180842858e-06
gene O 0 5.04409854329424e-06
- O 0 4.531966624199413e-05
dosage O 0 4.4329532101983204e-05
effect O 0 1.2930868251714855e-05
. O 0 8.62860179040581e-06

The O 0 4.934635217068717e-05
other O 0 2.6827005967788864e-06
allele O 0 1.4203128557710443e-05
( O 0 3.1476420190301724e-06
Hp2 O 0 6.003333328408189e-05
) O 0 4.840109681936156e-07
of O 0 3.2661648674547905e-07
individuals O 0 5.812393055748544e-08
with O 0 3.999930981990474e-07
Hp2 O 1 0.7093877792358398
/ O 0 0.0007706485339440405
Hpdel O 0 0.0013865845976397395
was O 0 3.938410372938961e-05
found O 0 2.4009511889744317e-07
to O 0 5.6719795082926794e-08
have O 0 1.0068517752870321e-07
, O 0 5.0314444166588146e-08
in O 0 4.7120405355371986e-08
all O 0 2.1225385893330895e-08
exons O 0 6.762493285350502e-07
, O 0 7.802832868719634e-08
no O 0 1.3153017164313496e-07
mutation O 0 5.281202106743876e-07
, O 0 1.7007704400384682e-07
by O 0 2.3799438508831372e-07
DNA O 0 4.1909465835487936e-06
sequencing O 0 4.957738201483153e-05
. O 0 3.053057662327774e-05

On O 0 1.6205700376303867e-05
the O 0 1.087169721358805e-06
basis O 0 5.075716558167187e-07
of O 0 2.1376752101787133e-07
the O 0 1.2493852352690737e-07
present O 0 7.374579524821456e-08
study O 0 1.6079721376627276e-07
, O 0 8.001824625125664e-08
the O 0 1.946288250564976e-07
mechanism O 0 7.193572173491702e-07
of O 0 1.5007643696662853e-06
anhaptoglobinemia B-Disease 0 3.116349034826271e-05
and O 0 2.5570207640157605e-07
the O 0 8.035516430027201e-07
mechanism O 0 9.705835282147746e-07
of O 0 8.328025842274656e-07
anomalous O 0 4.2753134039230645e-05
inheritance O 0 4.9921745812753215e-06
of O 0 2.9904151233495213e-05
Hp O 0 4.6188008127501234e-05
phenotypes O 0 2.9307825570867863e-06
were O 0 1.5350196918006986e-06
well O 0 2.8410941013135016e-06
explained O 0 1.4251212633098476e-05
. O 0 9.783089808479417e-06

However O 0 3.0666702514281496e-05
, O 0 5.693565526598832e-06
the O 0 3.6957735574105754e-06
mechanism O 0 1.0250464583805297e-05
of O 0 1.0304882380296476e-05
hypohaptoglobinemia B-Disease 0 0.005034489091485739
remains O 0 0.000268141069682315
unknown O 0 0.00026549011818133295

ATM O 0 0.004446534439921379
mutations O 0 8.050470933085307e-05
and O 0 1.1192662896064576e-05
phenotypes O 0 0.00035596778616309166
in O 0 0.0002068214089376852
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.4045047009858536e-06
in O 0 3.4084330309269717e-06
the O 0 2.565467184467707e-06
British O 0 1.5195359083008952e-05
Isles O 0 4.7645485210523475e-06
: O 0 3.088787892124856e-08
expression O 0 5.127149194095182e-08
of O 0 8.809935536646663e-08
mutant O 0 1.745804752317781e-06
ATM O 0 2.2271337002166547e-05
and O 0 1.0241636516639119e-07
the O 0 7.04869989931467e-07
risk O 0 3.062266841880046e-06
of O 0 3.085205389652401e-05
leukemia B-Disease 1 1.0
, O 1 0.9990020394325256
lymphoma B-Disease 1 1.0
, O 0 0.10441655665636063
and O 0 0.4616420567035675
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0006416410324163735

We O 0 2.1187188394833356e-05
report O 0 6.918611688888632e-06
the O 0 6.077316356822848e-07
spectrum O 0 1.319906232311041e-06
of O 0 7.639399655090529e-07
59 O 0 1.0642337656463496e-05
ATM O 0 2.562470399425365e-05
mutations O 0 1.6200332311200327e-06
observed O 0 6.750291049684165e-06
in O 0 8.529352271580137e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999982118606567
telangiectasia I-Disease 1 1.0
( O 0 0.3800904452800751
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.96420488061267e-07
patients O 0 2.5131319603133306e-07
in O 0 3.1170660008683626e-07
the O 0 2.8600802579603624e-06
British O 0 5.039544339524582e-05
Isles O 0 4.301203807699494e-05
. O 0 1.0555984772508964e-05

Of O 0 7.256222306750715e-05
51 O 0 8.952502685133368e-05
ATM O 0 0.00021307253336999565
mutations O 0 6.161090368550504e-06
identified O 0 2.60017259279266e-06
in O 0 1.0431643886477104e-06
families O 0 1.4201729925389373e-07
native O 0 2.8333022328297375e-07
to O 0 1.6478537645525648e-07
the O 0 1.4769422023164225e-06
British O 0 1.2827460523112677e-05
Isles O 0 3.6773963074665517e-06
, O 0 1.8730003148448304e-07
11 O 0 5.688902433576004e-07
were O 0 3.5648702123580733e-07
founder O 0 2.6835502922040178e-06
mutations O 0 1.1499233920631013e-07
, O 0 8.54039754472069e-08
and O 0 8.277431362557763e-08
2 O 0 2.358317061634807e-07
of O 0 2.2839988389478094e-07
these O 0 5.647474665693153e-08
11 O 0 8.358500167560123e-07
conferred O 0 5.99932218392496e-06
a O 0 5.5061250350263435e-06
milder O 0 3.678767097881064e-05
clinical O 0 0.00034021487226709723
phenotype O 0 5.235116532276152e-06
with O 0 3.623557276455358e-08
respect O 0 1.6390862356274738e-07
to O 0 2.6657588136913546e-07
both O 0 3.6071155591343995e-06
cerebellar B-Disease 1 0.9999923706054688
degeneration I-Disease 1 1.0
and O 0 4.441169949132018e-05
cellular O 1 0.8180511593818665
features O 0 2.135614886356052e-05
. O 0 2.4426914023933932e-05

We O 0 7.004127837717533e-05
report O 0 2.4913953893701546e-05
, O 0 2.7272296847513644e-06
in O 0 1.4999174027252593e-06
two O 0 1.5587409052386647e-06
A B-Disease 1 0.9999814033508301
- I-Disease 1 0.9999856948852539
T I-Disease 1 0.9999971389770508
families O 0 3.102607877281116e-07
, O 0 1.916387901701455e-07
an O 0 5.885518703507842e-07
ATM O 0 3.481243766145781e-05
mutation O 0 2.127683956132387e-06
( O 0 1.4393619949260028e-06
7271T O 0 0.00016993896861094981
- O 0 3.3638018066994846e-05
- O 0 3.899185685440898e-05
> O 0 1.1958629329456016e-05
G O 0 6.204126748343697e-06
) O 0 8.36022380212853e-08
that O 0 4.325512392711062e-08
may O 0 1.7695421661301225e-07
be O 0 4.935125019756015e-08
associated O 0 7.625730802374164e-08
with O 0 1.4789640623291689e-08
an O 0 2.219968280314788e-07
increased O 0 4.426072791829938e-06
risk O 0 2.431953816994792e-06
of O 0 6.914409823366441e-06
breast B-Disease 1 0.9999855756759644
cancer I-Disease 1 0.9983208775520325
in O 0 1.3441533610603074e-06
both O 0 4.6636145611955726e-07
homozygotes O 0 8.823858479445335e-06
and O 0 5.131655029799731e-07
heterozygotes O 0 4.81045208289288e-06
( O 0 2.167265051866707e-07
relative O 0 1.4678320212624385e-06
risk O 0 7.061315159262449e-07
12 O 0 4.35235136819756e-07
. O 0 4.9366597920652566e-08
7 O 0 1.0815854238899192e-06
; O 0 2.5671070602584223e-07
P O 0 2.5031909899553284e-05
= O 0 1.4660301985713886e-06
. O 0 1.8620416142312024e-07
0025 O 0 1.5622661521774717e-05
) O 0 5.033584926650292e-08
, O 0 2.6387420248852322e-08
although O 0 2.6575314393539884e-08
there O 0 4.1874439915545736e-08
is O 0 6.82377958582947e-08
a O 0 5.142933332535904e-07
less O 0 1.3053800103079993e-06
severe O 1 0.9999523162841797
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.1721383998519741e-05
in O 0 1.1975421898569039e-07
terms O 0 8.856300581783216e-08
of O 0 1.7285903197716834e-07
the O 0 4.942247073813633e-07
degree O 0 3.99204836867284e-05
of O 0 0.0001645092124817893
cerebellar B-Disease 1 0.9999921321868896
degeneration I-Disease 1 1.0
. O 0 9.167609096039087e-05

This O 0 3.5997567465528846e-05
mutation O 0 5.8419591368874535e-05
( O 0 1.3360965567699168e-05
7271T O 0 0.0003445636830292642
- O 0 9.55027571762912e-05
- O 0 9.007177141029388e-05
> O 0 3.24688371620141e-05
G O 0 1.5246758266584948e-05
) O 0 9.419716917591359e-08
also O 0 1.2552624184536398e-07
allows O 0 2.8565965592974862e-08
expression O 0 3.0996534405858256e-07
of O 0 9.817715636017965e-07
full O 0 1.4207611229721806e-06
- O 0 1.872283746706671e-06
length O 0 1.124316895584343e-06
ATM O 0 1.2291584425838664e-05
protein O 0 6.974976258788956e-07
at O 0 9.395149618285359e-07
a O 0 2.6553991006039723e-07
level O 0 2.887839798404457e-07
comparable O 0 1.6853910267400352e-07
with O 0 1.825740447713997e-08
that O 0 8.603489476399773e-08
in O 0 7.764928113829228e-07
unaffected O 0 1.7638518329476938e-05
individuals O 0 9.061684522748692e-07
. O 0 7.173881385824643e-06

In O 0 1.615343899175059e-05
addition O 0 1.986397819564445e-06
, O 0 3.6124649227531336e-07
we O 0 4.195534586415306e-08
have O 0 5.1377416099285256e-08
studied O 0 3.848178039334016e-06
18 O 0 3.213430318282917e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.8603249145598966e-06
, O 0 1.638779707491267e-07
in O 0 1.7920883976785262e-07
15 O 0 3.316599759273231e-07
families O 0 4.0125804900981166e-08
, O 0 1.3906365836646728e-07
who O 0 2.888550341140217e-07
developed O 0 3.549262692104094e-05
leukemia B-Disease 1 1.0
, O 1 0.9879536628723145
lymphoma B-Disease 1 1.0
, O 1 0.74252849817276
preleukemic O 1 0.9999998807907104
T O 1 0.9999866485595703
- O 0 0.20900966227054596
cell O 0 0.2880430817604065
proliferation O 1 0.5637151002883911
, O 0 3.008908834090107e-06
or O 0 0.00448950519785285
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.2874761270941235e-05
mostly O 0 1.7168614476759103e-06
in O 0 3.8090115594968665e-06
childhood O 0 0.0002518169640097767
. O 0 3.96031464333646e-05

A O 0 0.00017275990103371441
wide O 0 1.9925806554965675e-05
variety O 0 1.421681417923537e-06
of O 0 2.6678619633457856e-06
ATM O 0 7.189584721345454e-05
mutation O 0 1.0013358178184717e-06
types O 0 1.8898933262789797e-07
, O 0 8.854966182525459e-08
including O 0 9.835711978212203e-08
missense O 0 4.439075837581186e-06
mutations O 0 9.928945701176417e-07
and O 0 9.975148032026482e-07
in O 0 3.5659993500303244e-06
- O 0 2.8726861273753457e-05
frame O 0 8.371084732061718e-06
deletions O 0 2.2890453692525625e-06
, O 0 1.5340040704359126e-07
were O 0 2.906204201735818e-07
seen O 0 6.465321575888083e-07
in O 0 2.7773197075475764e-07
these O 0 3.0824145369479083e-07
patients O 0 8.114937372738495e-06
. O 0 1.794267700461205e-05

We O 0 8.378080565307755e-06
also O 0 1.5405308886329294e-06
show O 0 4.057008311519894e-07
that O 0 2.488025643287983e-07
25 O 0 1.358118538519193e-06
% O 0 2.1590710730379215e-07
of O 0 7.049029022709874e-07
all O 0 5.511491849574668e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 8.332077072736865e-07
carried O 0 2.4854862203937955e-06
in O 0 1.417308908457926e-06
- O 0 7.505351277359296e-06
frame O 0 2.33730884247052e-06
deletions O 0 6.408270110114245e-07
or O 0 1.1052874526740197e-07
missense O 0 1.5220808791127638e-06
mutations O 0 1.8932901468815544e-07
, O 0 8.424861874800627e-08
many O 0 1.1782202768984007e-08
of O 0 1.0245543080600328e-07
which O 0 3.746419352523844e-08
were O 0 2.933512348590739e-07
also O 0 1.273450038752344e-07
associated O 0 1.2745947230996535e-07
with O 0 4.1658232419194974e-08
expression O 0 1.6779654288257007e-06
of O 0 5.745701400883263e-06
mutant O 0 7.517970516346395e-05
ATM O 0 0.0016516863834112883
protein O 0 9.303088882006705e-05
. O 0 4.405345316627063e-05

The O 0 0.00016206185682676733
DMPK O 0 0.0887797474861145
gene O 0 6.234403554117307e-05
of O 0 9.197538020089269e-05
severely O 1 0.999998927116394
affected O 1 0.9999864101409912
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.27649012207984924
is O 0 1.0482061952643562e-05
hypermethylated O 0 0.0025650348979979753
proximal O 0 5.422065805760212e-05
to O 0 1.293922338163611e-07
the O 0 7.295755608538457e-07
largely O 0 2.3619079456693726e-06
expanded O 0 3.863216988975182e-06
CTG O 0 0.0002344038657611236
repeat O 0 2.3531963961431757e-05
. O 0 1.6659838365740143e-05

Using O 0 0.00013269986084196717
methylation O 0 0.0004599866224452853
- O 0 0.00019747101760003716
sensitive O 0 3.425130853429437e-05
restriction O 0 1.144555881182896e-05
enzymes O 0 1.1698830348905176e-06
, O 0 2.3305975105358812e-07
we O 0 9.210183549157591e-08
characterized O 0 7.082310276018688e-07
the O 0 2.743958020801074e-07
methylation O 0 1.3698229395231465e-06
pattern O 0 2.284956053699716e-06
on O 0 8.043658681344823e-07
the O 0 5.716993882742827e-07
5 O 0 9.663109494795208e-07
side O 0 5.775074214398046e-07
of O 0 7.484613320229982e-07
the O 0 7.701702315898729e-07
CTG O 0 3.4471082472009584e-05
repeat O 0 3.9181122701847926e-07
in O 0 1.536466811558057e-07
the O 0 2.9851037197659025e-07
DMPK O 0 2.3563399736303836e-05
gene O 0 1.1069012373354781e-07
of O 0 3.727659247942938e-07
normal O 0 8.451689836874721e-07
individuals O 0 4.1873878586784485e-08
and O 0 1.5374958195479849e-07
of O 0 7.2296215876122005e-06
patients O 0 3.815895979641937e-05
affected O 0 2.75733218586538e-05
with O 0 0.003602565499022603
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.1524048204591963e-06
showing O 0 1.825690333134844e-06
expansions O 0 2.081669435938238e-06
of O 0 6.692255283269333e-07
the O 0 1.680832156125689e-06
repetitive O 0 1.5883864762145095e-05
sequence O 0 9.246719855582342e-06
. O 0 1.4473384908342268e-05

The O 0 3.0982908356236294e-05
gene O 0 1.5533405530732125e-05
segment O 0 1.3848884009348694e-05
analyzed O 0 3.0876033179083606e-06
corresponds O 0 2.4706660042284057e-06
to O 0 6.294519607763505e-07
the O 0 2.4328005565621424e-06
genomic O 0 4.781711322721094e-05
SacI O 0 0.0024640685878694057
- O 0 3.11849253193941e-05
HindIII O 0 3.4940956538775936e-05
fragment O 0 3.407604253879981e-06
carrying O 0 1.987278665183112e-06
exons O 0 8.322084795509e-06
11 O 0 1.5296029232558794e-05
- O 0 2.6285822968930006e-05
15 O 0 1.5127920960367192e-05
. O 0 1.1455299500084948e-05

There O 0 4.903786975773983e-05
is O 0 9.951205356628634e-06
constitutive O 0 5.4691867262590677e-05
methylation O 0 1.2985784451302607e-05
in O 0 1.9745609733945457e-06
intron O 0 3.266343264840543e-05
12 O 0 4.9280092753178906e-06
at O 0 2.268404841743177e-06
restriction O 0 1.2183318176539615e-06
sites O 0 2.3509113589170738e-07
of O 0 8.731358889235707e-07
SacII O 0 3.5106415452901274e-05
and O 0 9.453498250877601e-07
HhaI O 0 2.050219518423546e-05
, O 0 2.9910995635873405e-07
localized O 0 3.0869025522406446e-06
1 O 0 1.4915639212631504e-06
, O 0 4.6601959979852836e-07
159 O 0 2.0785309970960952e-06
- O 0 2.8398915219440823e-06
1 O 0 1.7055390344467014e-06
, O 0 2.1244731840397435e-07
232 O 0 1.1739221008610912e-06
bp O 0 2.2242945760808652e-06
upstream O 0 2.5659026050561806e-06
of O 0 9.776811111805728e-07
the O 0 1.4502470548904967e-06
CTG O 0 3.739231760846451e-05
repeat O 0 6.641835170739796e-07
, O 0 1.7460449441841774e-07
whereas O 0 1.427361269179528e-07
most O 0 5.043079553956886e-08
, O 0 5.022086924100222e-08
if O 0 1.4038063156363023e-08
not O 0 1.4195549624673731e-08
all O 0 2.4279112054159668e-08
, O 0 4.455385749224661e-08
of O 0 2.1437897146370233e-07
the O 0 1.1667728472275485e-07
other O 0 1.6781504186269558e-08
sites O 0 1.260800388536154e-07
of O 0 9.475612046117021e-07
SacII O 0 5.6898585171438754e-05
, O 0 1.0828590575329144e-06
HhaI O 0 3.5215831303503364e-05
, O 0 2.8893492753923056e-07
and O 0 2.9069693141536845e-07
HpaII O 0 1.7589265553397126e-05
in O 0 1.9131520900828036e-07
this O 0 6.935602669955188e-08
region O 0 1.0952937401498275e-07
are O 0 2.0015267665485226e-08
unmethylated O 0 5.99230702391651e-07
, O 0 3.686114169454413e-08
in O 0 5.1685749014040994e-08
normal O 0 2.0534915279313282e-07
individuals O 0 2.205954530154486e-08
and O 0 8.26288726329949e-08
most O 0 8.45153067530191e-08
of O 0 1.3095744861857384e-06
the O 0 5.87390650252928e-06
patients O 0 1.0591235877654981e-05
. O 0 1.153198263637023e-05

In O 0 2.3335571313509718e-05
a O 0 6.97657878845348e-06
number O 0 1.8206845879831235e-06
of O 0 3.7695606351917377e-06
young O 0 4.870842531090602e-06
and O 0 1.96064570445742e-06
severely O 1 0.8512367010116577
affected O 0 7.5156372076889966e-06
patients O 0 2.4264727471745573e-06
, O 0 4.254563350514218e-07
however O 0 2.4731903636165953e-07
, O 0 8.143290841644557e-08
complete O 0 2.05690994903307e-07
methylation O 0 4.3638431179715553e-07
of O 0 1.7294114229571278e-07
these O 0 3.6437114658838254e-08
restriction O 0 5.412714472186053e-07
sites O 0 1.0328166410999984e-07
was O 0 1.6850340216478799e-06
found O 0 1.653965711057026e-07
in O 0 3.013090292824927e-07
the O 0 2.6443678962095873e-06
mutated O 0 2.630069138831459e-05
allele O 0 4.354854900157079e-05
. O 0 2.8715383450617082e-05

In O 0 1.0137451681657694e-05
most O 0 3.986879448802938e-07
of O 0 4.533669084594294e-07
these O 0 1.0678662931695726e-07
patients O 0 5.428694294096204e-07
, O 0 1.7729814771882957e-07
the O 0 1.0516420161366113e-06
onset O 1 0.8546605706214905
of O 0 6.438336276914924e-05
the O 0 0.021101918071508408
disease O 1 0.9999998807907104
was O 1 0.9999997615814209
congenital O 1 1.0
. O 0 0.001400406239554286

Preliminary O 0 0.0001086258125724271
in O 0 2.322625005035661e-05
vivo O 0 0.001030425075441599
footprinting O 0 0.0012442528968676925
data O 0 7.502088010369334e-06
gave O 0 1.9760793747991556e-06
evidence O 0 2.058341578958789e-06
for O 0 1.0563874184299493e-06
protein O 0 1.3899638361181132e-05
- O 0 5.1919672841904685e-05
DNA O 0 2.4016687802941306e-06
contact O 0 8.664749202580424e-07
in O 0 1.2787089644916705e-06
normal O 0 3.4596127989061642e-06
genes O 0 1.1719421308953315e-06
at O 0 5.20762978339917e-06
an O 0 9.998997256843722e-07
Sp1 O 0 4.227217232255498e-06
consensus O 0 2.869533943794522e-07
binding O 0 1.2238338342740462e-07
site O 0 3.1599807925886125e-07
upstream O 0 5.821790409754612e-07
of O 0 5.195716425987484e-07
the O 0 1.206810793519253e-06
CTG O 0 3.3792868634918705e-05
repeat O 0 3.4831137440960447e-07
and O 0 5.4381931846592124e-08
for O 0 3.732973752335056e-08
a O 0 1.0519303117462186e-07
significant O 0 1.785496976935974e-07
reduction O 0 9.804280125536025e-07
of O 0 2.8304316401772667e-07
this O 0 5.513379974786403e-08
interaction O 0 1.600313765948158e-07
in O 0 1.8890861497311562e-07
cells O 0 5.231964337326644e-07
with O 0 1.1934696431126213e-07
a O 0 1.1392547094146721e-05
hypermethylated O 0 0.034161731600761414
DMPK O 0 0.07323531061410904
gene O 0 6.983761522860732e-06
. O 0 3.3382302717654966e-06
. O 0 1.0349861440772656e-05

The O 0 0.0005147296469658613
hemochromatosis B-Disease 1 1.0
gene O 0 5.5815791711211205e-05
product O 0 8.370366231247317e-06
complexes O 0 9.570212569087744e-06
with O 0 7.003256996540586e-07
the O 0 4.908590653940337e-06
transferrin O 0 8.15284947748296e-05
receptor O 0 1.1873865332745481e-05
and O 0 1.268134951715183e-06
lowers O 0 1.5330288078985177e-05
its O 0 4.0472932028023934e-07
affinity O 0 3.1966978895070497e-06
for O 0 7.7645353258049e-07
ligand O 0 4.006067320005968e-05
binding O 0 1.793476076272782e-05
. O 0 1.409174183208961e-05

We O 0 1.1609933608269785e-05
recently O 0 9.639578820497263e-06
reported O 0 2.378070348640904e-06
the O 0 3.7341490610742767e-07
positional O 0 6.034513717168011e-06
cloning O 0 1.6263583120235126e-06
of O 0 5.697622214029252e-07
a O 0 1.4255263067752821e-06
candidate O 0 2.483834578015376e-06
gene O 0 1.5084126971487422e-05
for O 0 6.57511773169972e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999990463256836
HFE O 1 0.9999998807907104
. O 0 0.00021737626229878515

The O 0 5.888314626645297e-05
gene O 0 2.0526102161966264e-05
product O 0 6.3802217482589185e-06
, O 0 9.424836093785416e-07
a O 0 1.300831627304433e-06
member O 0 5.035765298089245e-07
of O 0 6.807704835409822e-07
the O 0 9.794831612452981e-07
major O 0 1.369259462080663e-05
histocompatibility O 0 0.057713013142347336
complex O 0 3.0538787541445345e-05
class O 0 6.906679573148722e-06
I O 0 1.7836238839663565e-05
- O 0 9.282734026783146e-06
like O 0 1.4219158117612096e-07
family O 0 1.6811530656468676e-07
, O 0 1.2404677818267373e-07
was O 0 1.7480955420978717e-06
found O 0 1.0850013865137953e-07
to O 0 5.776980671612364e-08
have O 0 1.3869333770344383e-07
a O 0 1.5487552218473866e-06
mutation O 0 5.712285656045424e-06
, O 0 5.013080226490274e-06
Cys O 0 0.06010876223444939
- O 0 6.956726429052651e-05
282 O 0 9.056786802830175e-05
- O 0 6.14769451203756e-05
- O 0 4.733086097985506e-05
> O 0 5.162893103261013e-06
Tyr O 0 8.982786312117241e-06
( O 0 3.833420407772792e-07
C282Y O 0 4.656273631553631e-06
) O 0 7.210662289480751e-08
, O 0 2.9431230785803564e-08
in O 0 6.570343202838558e-08
85 O 0 5.185920031181013e-07
% O 0 3.482738293314469e-07
of O 0 3.0918672564439476e-06
patient O 0 6.585729715880007e-05
chromosomes O 0 9.062938624992967e-05
. O 0 6.547981320181862e-05

This O 0 7.640210242243484e-06
mutation O 0 1.1879108569701202e-05
eliminates O 0 1.0482041943760123e-05
the O 0 1.3825480209561647e-06
ability O 0 7.720271355537989e-07
of O 0 3.750487849174533e-06
HFE O 0 0.007182755507528782
to O 0 1.3833076764058205e-06
associate O 0 1.8084232578985393e-05
with O 0 1.5659030623282888e-06
beta2 O 1 0.7746144533157349
- O 0 0.08658382296562195
microglobulin O 0 0.06337393075227737
( O 0 2.4363412194361445e-06
beta2m O 0 0.00016672890342306346
) O 0 4.4920773234480293e-07
and O 0 5.915241558795969e-07
prevents O 0 8.223687473218888e-06
cell O 0 0.1354236602783203
- O 0 0.00018349179299548268
surface O 0 0.00013544199464377016
expression O 0 0.00011864477710332721
. O 0 2.5628542061895132e-05

A O 0 0.00014817943156231195
second O 0 7.956888111948501e-06
mutation O 0 2.694413069548318e-06
that O 0 4.213104318750993e-07
has O 0 4.3081479361717356e-07
no O 0 4.145864807014732e-07
effect O 0 1.2493142094172072e-06
on O 0 4.100584192201495e-06
beta2m O 0 9.436519758310169e-05
association O 0 1.6742744719522307e-06
, O 0 3.256122624861746e-07
H63D O 0 7.70759506849572e-05
, O 0 3.2483438872077386e-07
was O 0 3.3096910101448884e-06
found O 0 1.0054066734710432e-07
in O 0 1.7885609793211188e-07
eight O 0 1.4837424089364504e-07
out O 0 6.787279005493474e-08
of O 0 5.255317887531419e-07
nine O 0 1.8313892269361531e-06
patients O 0 4.753383677780221e-07
heterozygous O 0 8.537055578017316e-07
for O 0 5.421853757070494e-07
the O 0 6.793444299546536e-06
C282Y O 0 0.0003716634528245777
mutant O 0 7.412223931169137e-05
. O 0 2.387484892096836e-05

In O 0 3.0837290978524834e-05
this O 0 1.7086274510802468e-06
report O 0 9.62705257734342e-07
, O 0 1.5428246058490913e-07
we O 0 5.187220608604548e-08
demonstrate O 0 4.009956739992049e-07
in O 0 5.484614575834712e-07
cultured O 0 6.751056935172528e-05
293 O 0 7.601188553962857e-05
cells O 0 5.997754124109633e-05
overexpressing O 0 0.0001762318570399657
wild O 0 6.903781468281522e-06
- O 0 1.4280341019912157e-05
type O 0 1.6933448705458432e-06
or O 0 3.8589496398344636e-07
mutant O 0 1.2701993000518996e-05
HFE O 0 0.0001285080361412838
proteins O 0 1.6784328238372836e-07
that O 0 5.449718898375977e-08
both O 0 5.897127053344775e-08
the O 0 5.274865770843462e-07
wild O 0 2.2887791146786185e-06
- O 0 4.617479135049507e-05
type O 0 9.935501111613121e-06
and O 0 7.114917934814002e-06
H63D O 1 0.9996352195739746
HFE O 0 0.4053671956062317
proteins O 0 7.813069942130824e-07
form O 0 5.251550305729324e-07
stable O 0 3.9873848436400294e-06
complexes O 0 7.305544613700476e-07
with O 0 1.5732722147276945e-07
the O 0 2.6138618522963952e-06
transferrin O 0 6.348870374495164e-05
receptor O 0 3.1992945878300816e-05
( O 0 4.6391737669182476e-06
TfR O 0 0.11889317631721497
) O 0 6.444985046982765e-06
. O 0 1.306745434703771e-05

The O 0 4.870547491009347e-05
C282Y O 0 0.0002776667242869735
mutation O 0 1.1586616892600432e-05
nearly O 0 6.758117251592921e-06
completely O 0 4.5306619540497195e-06
prevents O 0 1.3432744481178815e-06
the O 0 9.438958272767195e-07
association O 0 5.311164272825408e-07
of O 0 4.98256781611417e-07
the O 0 1.0360163287259638e-06
mutant O 0 3.7964371585985646e-05
HFE O 0 0.015697114169597626
protein O 0 7.491799806302879e-06
with O 0 1.4071700888962368e-06
the O 0 4.740742951980792e-05
TfR O 1 0.9998600482940674
. O 0 5.9343470638850704e-05

Studies O 0 0.00025179944350384176
on O 0 7.835438736947253e-05
cell O 0 0.0013148359721526504
- O 0 5.75668309465982e-05
associated O 0 4.702627393271541e-06
transferrin O 0 3.1362018489744514e-05
at O 0 3.873598416248569e-06
37 O 0 2.1096727778058266e-06
degrees O 0 1.1256869584030937e-05
C O 0 1.8567250663181767e-05
suggest O 0 6.292142984420934e-07
that O 0 1.7714062039431155e-07
the O 0 7.68035135934042e-07
overexpressed O 0 2.5011031539179385e-05
wild O 0 2.8396150355547434e-06
- O 0 1.0913031474046875e-05
type O 0 6.8761842157982755e-06
HFE O 0 0.011671493761241436
protein O 0 8.330233640663209e-07
decreases O 0 1.1750802286769613e-06
the O 0 2.675049302069965e-07
affinity O 0 7.038254352664808e-07
of O 0 2.1992491383571178e-06
the O 0 4.402783361001639e-06
TfR O 0 0.014849579893052578
for O 0 3.283390242359019e-06
transferrin O 0 0.0004086408589500934
. O 0 2.179445255023893e-05

The O 0 0.00020459407824091613
overexpressed O 0 0.011675950139760971
H63D O 0 0.2725268602371216
protein O 0 1.4345313502417412e-05
does O 0 2.259741336274601e-07
not O 0 5.550891302164018e-08
have O 0 2.345299066064399e-08
this O 0 3.222895372800849e-08
effect O 0 1.0671148942265063e-07
, O 0 2.586224034928364e-08
providing O 0 2.7499037713596408e-08
the O 0 3.530629655301709e-08
first O 0 7.609355634485837e-08
direct O 0 1.3720072900014202e-07
evidence O 0 2.775479401861958e-07
for O 0 7.866206885864813e-08
a O 0 1.0219717978543486e-06
functional O 0 2.2162905679579126e-06
consequence O 0 5.404521743912483e-06
of O 0 4.473020908335457e-06
the O 0 1.9266002709628083e-05
H63D O 0 0.0031127333641052246
mutation O 0 4.723950769403018e-05
. O 0 2.1844622096978128e-05

Addition O 0 4.751505912281573e-05
of O 0 3.688782817334868e-05
soluble O 0 0.00017485984426457435
wild O 0 5.044054705649614e-05
- O 0 0.008302474394440651
type O 0 0.017796287313103676
HFE O 1 0.9999783039093018
/ O 0 0.0005064821452833712
beta2m O 0 0.00020746744121424854
heterodimers O 0 1.0380900675954763e-05
to O 0 6.847652684882632e-07
cultured O 0 5.9050882555311546e-05
cells O 0 3.85615703635267e-06
also O 0 7.984990588738583e-07
decreased O 0 8.15053590486059e-06
the O 0 3.0263834105426213e-07
apparent O 0 1.1651532076939475e-06
affinity O 0 6.801689096391783e-07
of O 0 1.4221208175513311e-06
the O 0 2.501415792721673e-06
TfR O 0 0.0004430851258803159
for O 0 1.8410715085792617e-07
its O 0 2.2555666134849162e-07
ligand O 0 3.503092102619121e-06
under O 0 1.3977194157632766e-06
steady O 0 4.643151623895392e-05
- O 0 9.71347390077426e-07
state O 0 1.6904327537758945e-07
conditions O 0 4.110354439035291e-07
, O 0 5.523663304529691e-08
both O 0 3.975041096282439e-08
in O 0 2.69732851165827e-07
293 O 0 5.0674148042162415e-06
cells O 0 1.6451953115392826e-06
and O 0 5.103577223053435e-07
in O 0 8.28428255772451e-06
HeLa O 0 0.04372638836503029
cells O 0 6.149042746983469e-05
. O 0 1.1742438800865784e-05

Furthermore O 0 8.238929876824841e-05
, O 0 8.699427780811675e-06
at O 0 8.738541509956121e-06
4 O 0 5.4784486565040424e-06
degrees O 0 3.114454011665657e-05
C O 0 7.053823355818167e-05
, O 0 5.858934741809207e-07
the O 0 7.622123234796163e-07
added O 0 1.9352826257090783e-06
soluble O 0 4.123194685234921e-06
complex O 0 2.358592155360384e-06
of O 0 1.5428555343532935e-05
HFE O 1 0.9833347797393799
/ O 0 5.197485734242946e-05
beta2m O 0 4.7937191993696615e-05
inhibited O 0 4.536360393103678e-06
binding O 0 5.684455572918523e-07
of O 0 1.652778337302152e-06
transferrin O 0 1.703530506347306e-05
to O 0 5.68043446946831e-07
HeLa O 0 0.000460730807390064
cell O 0 0.00010742902668425813
TfR O 0 0.010595983825623989
in O 0 5.914993153055548e-07
a O 0 2.6980255825037602e-06
concentration O 0 6.676737393718213e-05
- O 0 5.9106827393407e-05
dependent O 0 7.906360224296805e-06
manner O 0 2.2098320187069476e-05
. O 0 1.4375222235685214e-05

Scatchard O 0 0.0007322562742047012
plots O 0 5.1325831009307876e-05
of O 0 3.842563728539972e-06
these O 0 2.5846514972727164e-07
data O 0 9.943234999809647e-07
indicate O 0 7.793148597556865e-07
that O 0 1.1166004298956977e-07
the O 0 9.90398802969139e-07
added O 0 2.0333429802121827e-06
heterodimer O 0 1.00561455838033e-05
substantially O 0 1.5254042864398798e-06
reduced O 0 4.463074958493962e-07
the O 0 4.7320034468611993e-07
affinity O 0 2.105160774590331e-06
of O 0 8.964983862824738e-06
TfR O 0 0.19800403714179993
for O 0 5.17308990310994e-06
transferrin O 0 0.00039117864798754454
. O 0 2.434918496874161e-05

These O 0 2.1730527350882767e-06
results O 0 2.211116225225851e-06
establish O 0 5.63723972391017e-07
a O 0 1.2025036539853318e-06
molecular O 0 8.584149327361956e-06
link O 0 5.643787517328747e-06
between O 0 2.46133686232497e-06
HFE O 0 0.01648402214050293
and O 0 8.831989930513373e-07
a O 0 2.5335580176033545e-06
key O 0 3.2160539831238566e-06
protein O 0 8.457736839773133e-07
involved O 0 3.571434206151025e-07
in O 0 1.3847713944414863e-06
iron O 0 0.0002595204859972
transport O 0 8.460798198939301e-06
, O 0 5.031516820963589e-07
the O 0 1.2303936500757118e-06
TfR O 0 0.004148226696997881
, O 0 1.5834716293738893e-07
and O 0 5.701960859028077e-08
raise O 0 8.735142387195083e-08
the O 0 1.406488223665292e-07
possibility O 0 2.145593498426024e-07
that O 0 4.8793136642188983e-08
alterations O 0 6.231874749573763e-07
in O 0 1.2818917127788154e-07
this O 0 9.751039442562615e-08
regulatory O 0 6.842351467639674e-07
mechanism O 0 8.782518534644623e-07
may O 0 2.0120303645398963e-07
play O 0 6.773195337927973e-08
a O 0 2.463654027451412e-07
role O 0 4.831904902857787e-07
in O 0 5.108495315653272e-07
the O 0 4.166744020039914e-06
pathogenesis O 1 0.9804085493087769
of O 0 0.11064086109399796
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0005082603893242776
. O 0 3.6778656067326665e-05

Genomic O 0 0.0006001907167956233
organization O 0 3.747939263121225e-05
of O 0 1.1963671568082646e-05
the O 0 2.4239023332484066e-05
UBE3A O 1 0.835770308971405
/ O 0 0.00031922670314088464
E6 O 1 0.5423030853271484
- O 0 0.0040750885382294655
AP O 0 6.867892807349563e-05
gene O 0 1.7278632640227443e-06
and O 0 1.154128312919056e-06
related O 0 2.176312955270987e-05
pseudogenes O 0 0.0003009472566191107
. O 0 3.315387948532589e-05

The O 0 0.00015895736578386277
UBE3A O 0 0.003036852926015854
gene O 0 6.160164775792509e-05
encodes O 0 6.0065915022278205e-05
the O 0 4.086892295163125e-05
E6 O 0 0.38477250933647156
- O 0 0.46620073914527893
AP O 0 0.009167669340968132
ubiquitin O 0 0.0003341581323184073
- O 0 4.133161201025359e-05
protein O 0 4.456670922081685e-06
ligase O 0 1.3246727803561953e-06
and O 0 1.1425305501688854e-07
has O 0 1.511737508508304e-07
recently O 0 1.803801126243343e-07
been O 0 7.755456721270093e-08
shown O 0 4.18865795381862e-08
to O 0 3.4561651318654185e-08
be O 0 2.3825781170216942e-07
mutated O 0 7.462556823156774e-06
in O 0 0.18866130709648132
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9956325888633728
who O 0 0.00011517407983774319
lack O 0 0.4860456585884094
15q11 O 1 0.9999749660491943
- O 1 0.6698233485221863
q13 O 0 0.012140510603785515
deletions O 0 1.8863525838241912e-05
or O 0 2.69949509856815e-06
chromosome O 0 0.019969122484326363
15 O 0 0.00020248648070264608
paternal O 1 0.9990999698638916
uniparental B-Disease 1 0.9999990463256836
disomy I-Disease 1 0.9997263550758362
. O 0 0.00014634306717198342

Previous O 0 0.00025870720855891705
UBE3A O 0 0.0034564833622425795
cDNA O 0 0.00015043480379972607
analysis O 0 7.279164037754526e-06
has O 0 1.3109803376210039e-06
shown O 0 6.843865776318125e-07
a O 0 1.46427521485748e-06
coding O 0 1.5753005300211953e-06
region O 0 5.724593847844517e-07
of O 0 1.478138528909767e-06
approximately O 0 3.4899971979029942e-06
2 O 0 1.3677597962669097e-05
. O 0 1.1623769751167856e-05

6 O 0 0.0005819055950269103
kb O 0 0.0006330370088107884
and O 0 8.307390089612454e-06
a O 0 1.6237367162830196e-05
3 O 0 1.6454525393783115e-05
- O 0 2.5409999580006115e-05
untranslated O 0 8.51434379001148e-05
region O 0 2.4585449409642024e-06
( O 0 8.631330956632155e-07
UTR O 0 6.945498171262443e-05
) O 0 2.0736909789320634e-07
of O 0 2.5688163987069856e-06
< O 0 1.7551097698742524e-05
50 O 0 2.3779887214914197e-06
bp O 0 3.2862094485608395e-06
, O 0 1.384203471843648e-07
whereas O 0 1.3295108658439858e-07
Northern O 0 1.940779554843175e-07
analysis O 0 1.2532552773336647e-07
has O 0 1.2027682316784194e-07
indicated O 0 5.61184663183667e-07
mRNA O 0 7.396462819997396e-07
sizes O 0 1.693802147428869e-07
of O 0 1.2343730304564815e-06
5 O 0 8.129437446768861e-06
- O 0 3.2010248105507344e-05
8 O 0 3.369838304934092e-05
kb O 0 0.00025565593387000263
. O 0 1.7039528756868094e-05

We O 0 4.1245866668759845e-06
have O 0 6.78483218052861e-07
analyzed O 0 1.1700939239744912e-06
additional O 0 8.122981398628326e-07
cDNA O 0 1.0767744242912158e-05
clones O 0 2.2379952042683726e-06
and O 0 1.6907358713069698e-07
provide O 0 1.299418954658904e-07
evidence O 0 6.349819727802242e-07
for O 0 3.255436524796096e-07
an O 0 9.621179515306721e-07
additional O 0 1.1218299960091827e-06
0 O 0 6.7890405262005515e-06
. O 0 6.46155194772291e-06

5 O 0 0.0002429855230730027
kb O 0 0.00041294886614196
of O 0 5.0696806283667684e-05
5 O 0 5.339062408893369e-05
- O 0 5.421150490292348e-05
UTR O 0 0.00032454318716190755
and O 0 1.626701191526081e-06
> O 0 5.056717327533988e-06
2 O 0 2.6750210508907912e-06
kb O 0 1.922221781569533e-05
of O 0 1.03606053016847e-05
3 O 0 4.921223080600612e-05
- O 0 0.0004984883707948029
UTR O 0 0.008148637600243092
. O 0 1.8932892999146134e-05

We O 0 5.93972299611778e-06
have O 0 3.3758948347895057e-07
established O 0 6.836201009718934e-07
the O 0 2.9712921900681977e-07
genomic O 0 3.938991085306043e-06
organization O 0 7.777155701660377e-07
of O 0 2.013089215324726e-06
UBE3A O 0 0.0005967785837128758
and O 0 3.594446980059729e-07
the O 0 6.138712365100218e-07
sequence O 0 7.971021318553539e-07
of O 0 1.1899995115527418e-05
intron O 0 0.0006086728535592556
- O 0 0.00012101166066713631
exon O 0 3.5022552765440196e-05
borders O 0 1.0035069863079116e-05
. O 0 1.7036118151736446e-05

We O 0 1.8800377802108414e-05
have O 0 2.1766347799712094e-06
also O 0 1.1413754918976338e-06
mapped O 0 2.8160236524854554e-06
two O 0 4.5635223955287074e-07
highly O 0 1.547323222439445e-06
homologous O 0 1.864502451098815e-06
processed O 0 3.2940222354227444e-06
pseudogenes O 0 1.5961686585796997e-05
, O 0 2.163194267268409e-06
UBE3AP1 O 0 0.0001920327777042985
and O 0 1.2922467931275605e-06
UBE3AP2 O 0 0.00019514127052389085
, O 0 3.736069231763395e-07
to O 0 5.6950700155766754e-08
chromosomes O 0 6.629849167438806e-07
2 O 0 9.973330179491313e-07
and O 0 2.133166390194674e-07
21 O 0 2.3179395611805376e-06
, O 0 1.8097441056852404e-07
respectively O 0 3.629651814662793e-07
, O 0 5.5886573591124034e-08
and O 0 5.885688025841773e-08
determined O 0 1.7120497375344712e-07
their O 0 1.8745244290130358e-07
genomic O 0 1.1649971384031232e-05
organization O 0 1.2531980246421881e-05
. O 0 1.2053777936671395e-05

These O 0 3.2371538054576376e-06
results O 0 1.7189747723023174e-06
will O 0 9.315995441738778e-08
form O 0 1.8359163078685015e-08
the O 0 4.18045296157743e-08
basis O 0 3.733707387709728e-08
for O 0 1.9806510209718908e-08
studies O 0 1.9299048403809138e-07
of O 0 4.359388299235434e-07
mutation O 0 9.026718430504843e-07
and O 0 8.132484481393476e-07
imprinting O 0 0.00022081276983954012
of O 0 0.00040662407991476357
UBE3A O 1 0.9987056255340576
. O 0 6.094785203458741e-05

Mutation O 0 0.0005729991826228797
spectrum O 0 0.00018698461644817144
and O 0 1.240669189428445e-05
genotype O 0 0.001692296122200787
- O 0 0.10248702764511108
phenotype O 0 0.0038502721581608057
analyses O 0 4.936866844218457e-06
in O 0 6.695717274851631e-06
Cowden B-Disease 1 0.9999977350234985
disease I-Disease 1 0.9994791150093079
and O 0 0.00012968610099051148
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 6.051151103747543e-06
two O 0 3.702574986164109e-06
hamartoma B-Disease 1 0.9999967813491821
syndromes I-Disease 1 0.9999303817749023
with O 0 3.0036966563784517e-05
germline O 1 0.9999926090240479
PTEN O 1 0.9999995231628418
mutation O 0 0.0012670523719862103
. O 0 6.237169145606458e-05

The O 0 0.0012522329343482852
tumour B-Disease 1 1.0
suppressor O 1 0.9999983310699463
gene O 0 0.0004277180996723473
PTEN O 1 0.8196678161621094
, O 0 1.6676342511345865e-06
which O 0 7.119576252989646e-07
maps O 0 4.165151040069759e-06
to O 0 4.127183728996897e-06
10q23 O 0 0.0025620816741138697
. O 0 7.992306200321764e-05

3 O 0 5.6944714742712677e-05
and O 0 2.44327975451597e-06
encodes O 0 1.2630364835786168e-05
a O 0 5.905184934817953e-06
403 O 0 1.604790668352507e-05
amino O 0 5.8037403505295515e-06
acid O 0 2.3782949938322417e-06
dual O 0 1.019777209876338e-05
specificity O 0 3.2631520298309624e-05
phosphatase O 1 0.5656810998916626
( O 0 7.2132038440031465e-06
protein O 0 1.4054188795853406e-05
tyrosine O 0 6.641044456046075e-05
phosphatase O 0 0.0011316669406369328
; O 0 3.641947046162386e-07
PTPase O 0 3.624154123826884e-05
) O 0 1.0270234440667991e-07
, O 0 4.205147874358772e-08
was O 0 4.7246757617358526e-07
shown O 0 5.670638358878932e-08
recently O 0 6.841843713800699e-08
to O 0 1.3518259400768784e-08
play O 0 1.2006984206891502e-07
a O 0 4.84850431803352e-07
broad O 0 2.215751692347112e-06
role O 0 1.9016898704649066e-06
in O 0 1.7036338704201626e-06
human O 0 2.3488220904255286e-05
malignancy B-Disease 1 0.9995576739311218
. O 0 2.8308948458288796e-05

Somatic O 1 0.7461073994636536
PTEN O 1 0.9952636957168579
deletions O 0 0.0001301531447097659
and O 0 1.0040095048680087e-06
mutations O 0 1.363982846669387e-06
were O 0 3.4240349577885354e-07
observed O 0 2.096098796755541e-07
in O 0 1.592933500660365e-07
sporadic B-Disease 0 0.0001342641335213557
breast I-Disease 1 0.9999774694442749
, I-Disease 0 0.0013823496410623193
brain I-Disease 1 1.0
, I-Disease 0 0.19994595646858215
prostate I-Disease 1 1.0
and I-Disease 1 0.9654093384742737
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9998956918716431
lines O 0 3.7466663798113586e-06
and O 0 9.996053051963827e-08
in O 0 1.1829200730062439e-07
several O 0 1.5431012911903963e-07
primary O 0 0.001107343821786344
tumours B-Disease 1 1.0
such O 0 1.1220162150493707e-06
as O 0 0.0024065785109996796
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999996423721313
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.33582940697669983

In O 0 3.568618558347225e-05
addition O 0 7.348221060965443e-06
, O 0 9.058678188011982e-06
PTEN O 1 0.8382388949394226
was O 0 2.5295714294770733e-05
identified O 0 9.955674613593146e-07
as O 0 1.6370022137834894e-07
the O 0 3.082934938447579e-07
susceptibility O 0 6.216124893398955e-05
gene O 0 1.4107968127063941e-06
for O 0 7.608897476529819e-07
two O 0 1.2180496014480013e-05
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 1.245116345671704e-05
CD B-Disease 0 0.00011354035814292729
; O 0 1.3866745121049462e-06
MIM O 0 0.023612625896930695
158350 O 0 4.228663237881847e-05
) O 0 9.473316708863422e-07
and O 0 1.4678208799523418e-06
Bannayan B-Disease 0 0.0006898310966789722
- I-Disease 0 0.0004952252493239939
Zonana I-Disease 0 0.011959047056734562
( I-Disease 0 1.5009476328486926e-06
BZS I-Disease 0 0.0001590061729075387
) I-Disease 0 6.653106652265706e-07
or I-Disease 0 1.4687871043861378e-06
Ruvalcaba I-Disease 0 0.011292810551822186
- I-Disease 0 0.0568193718791008
Riley I-Disease 0 0.011031441390514374
- I-Disease 1 0.7689883708953857
Smith I-Disease 0 0.20274536311626434
syndrome I-Disease 1 0.9999996423721313
( O 0 4.616915975930169e-05
MIM O 1 0.9999856948852539
153480 O 0 0.0034851660020649433
) O 0 8.104039807221852e-06
. O 0 8.617705134383868e-06

Constitutive O 0 0.0009642333607189357
DNA O 0 6.626651884289458e-05
from O 0 1.3081867109576706e-05
37 O 0 1.4619849025621079e-05
CD B-Disease 0 8.405859261984006e-06
families O 0 2.367899583077815e-07
and O 0 4.2509537934165564e-07
seven O 0 3.621167707024142e-06
BZS B-Disease 0 0.00025266542797908187
families O 0 2.0710821502234467e-07
was O 0 2.97424253403733e-06
screened O 0 3.4904001040558796e-06
for O 0 1.4999287714090315e-06
germline O 0 0.010412381961941719
PTEN O 1 0.9806098341941833
mutations O 0 5.051033804193139e-05
. O 0 3.4662007237784564e-05

PTEN O 0 0.027591293677687645
mutations O 0 3.1547664548270404e-05
were O 0 6.3467537074757274e-06
identified O 0 1.0451680054757162e-06
in O 0 5.338641813068534e-07
30 O 0 6.860274197606486e-07
of O 0 7.160431323427474e-07
37 O 0 2.417686118860729e-06
( O 0 2.520419002394192e-07
81 O 0 2.4763037345110206e-06
% O 0 2.939959813375026e-07
) O 0 1.824895008439853e-07
CD B-Disease 0 8.243617344305676e-07
families O 0 1.2184669273551663e-08
, O 0 3.1345521733783244e-08
including O 0 4.8471356706158986e-08
missense O 0 2.034322506005992e-06
and O 0 3.096388638823555e-07
nonsense O 0 4.465990059543401e-05
point O 0 2.738483544817427e-06
mutations O 0 2.2718420211731427e-07
, O 0 1.7997322743212862e-07
deletions O 0 6.415773441403871e-07
, O 0 1.7824991971338022e-07
insertions O 0 1.6930654282987234e-06
, O 0 4.400179420827044e-07
a O 0 2.374530367887928e-06
deletion O 0 4.7818983148317784e-05
/ O 0 4.0197330235969275e-05
insertion O 0 9.60213401413057e-06
and O 0 9.96564949673484e-07
splice O 0 3.574722359189764e-05
site O 0 9.420977221452631e-06
mutations O 0 1.8092183381668292e-05
. O 0 2.2004987840773538e-05

These O 0 2.5509514216537355e-06
mutations O 0 3.4200768368464196e-06
were O 0 1.0557961331869592e-06
scattered O 0 4.341043222666485e-07
over O 0 2.7227599730395013e-07
the O 0 3.0100056847004453e-07
entire O 0 5.182187692298612e-07
length O 0 8.993318942884798e-07
of O 0 3.8115842926345067e-06
PTEN O 0 0.008767252787947655
, O 0 2.0313376580816112e-07
with O 0 3.801383030577199e-08
the O 0 2.130549887624511e-07
exception O 0 2.2381823328032624e-07
of O 0 4.773599471263879e-07
the O 0 6.693379077660211e-07
first O 0 1.7127941873695818e-06
, O 0 5.953413619863568e-07
fourth O 0 1.4354372979141772e-05
and O 0 9.078984817278979e-07
last O 0 2.3050650270306505e-05
exons O 0 5.460822649183683e-05
. O 0 2.2736483515473083e-05

A O 0 0.0009152998100034893
hot O 0 0.00021126220235601068
spot O 0 4.607854498317465e-05
for O 0 3.594567488107714e-06
PTEN O 0 0.0021724600810557604
mutation O 0 3.102571554336464e-06
in O 0 1.638640583223605e-06
CD B-Disease 0 4.901120519207325e-06
was O 0 6.135778221505461e-06
identified O 0 3.9173502841549634e-07
in O 0 2.7848943773278734e-07
exon O 0 9.121510515797127e-07
5 O 0 3.5855799751516315e-07
that O 0 8.240601090392374e-08
contains O 0 1.7903049354117684e-07
the O 0 9.426705673831748e-07
PTPase O 0 7.620254473295063e-05
core O 0 1.549480475659948e-05
motif O 0 3.3330386486341013e-06
, O 0 1.3318661729044834e-07
with O 0 5.240243794446542e-08
13 O 0 7.230313485706574e-07
of O 0 1.331827320427692e-06
30 O 0 2.065448143184767e-06
( O 0 2.126778042566002e-07
43 O 0 1.1144571772092604e-06
% O 0 2.0400972289280617e-07
) O 0 1.5262570229879202e-07
CD B-Disease 0 9.08406036614906e-07
mutations O 0 2.1353503143473063e-07
identified O 0 2.7033880201088323e-07
in O 0 3.8288351333903847e-07
this O 0 1.0142024393644533e-06
exon O 0 2.068676803901326e-05
. O 0 5.265750587568618e-06

Seven O 0 5.877414878341369e-05
of O 0 1.744907785905525e-05
30 O 0 9.489724106970243e-06
( O 0 8.153701287483273e-07
23 O 0 2.4491023395967204e-06
% O 0 2.2597112092626048e-07
) O 0 9.129816191943974e-08
were O 0 1.7293487530878338e-07
within O 0 1.278719565789288e-07
the O 0 7.210234684862371e-07
core O 0 4.1440880522714e-06
motif O 0 1.979802846108214e-06
, O 0 1.6863749863205157e-07
the O 0 2.2025999157904153e-07
majority O 0 7.87694105497394e-08
( O 0 1.0039732956101943e-07
five O 0 8.758081548876362e-08
of O 0 3.401921162549115e-07
seven O 0 3.413741467284126e-07
) O 0 5.5794338038595015e-08
of O 0 1.0856037846451727e-07
which O 0 4.817374588128587e-08
were O 0 1.3032686752012523e-07
missense O 0 1.0146445674763527e-06
mutations O 0 1.7648652317348024e-07
, O 0 1.3354248551422643e-07
possibly O 0 3.2727001553212176e-07
pointing O 0 5.754677090408222e-07
to O 0 2.3687753980539128e-08
the O 0 1.3810678467507387e-07
functional O 0 3.8557308812414703e-07
significance O 0 4.1900963765328925e-07
of O 0 7.663786050216004e-07
this O 0 9.680192079031258e-07
region O 0 7.316753908526152e-06
. O 0 9.1558476924547e-06

Germline O 0 0.18520043790340424
PTEN O 0 0.17668269574642181
mutations O 0 3.7193018215475604e-05
were O 0 9.748323464009445e-06
identified O 0 3.296445356681943e-06
in O 0 5.334285901881231e-07
four O 0 2.58623458648799e-07
of O 0 5.90608124184655e-07
seven O 0 6.370831329149951e-07
( O 0 4.745964190533414e-07
57 O 0 4.29853434980032e-06
% O 0 1.969246568478411e-06
) O 0 2.4043270059337374e-06
BZS B-Disease 0 0.0006878118147142231
families O 0 1.1863652389365598e-06
studied O 0 6.721013050992042e-05
. O 0 2.1634172298945487e-05

Interestingly O 0 0.00027079242863692343
, O 0 3.988448952441104e-06
none O 0 5.404786520557536e-07
of O 0 4.421346204708243e-07
these O 0 3.349798305407603e-08
mutations O 0 5.388836825659382e-07
was O 0 7.763470421195962e-06
observed O 0 7.934404493425973e-07
in O 0 5.451750553220336e-07
the O 0 2.582522711236379e-06
PTPase O 0 0.00026422302471473813
core O 0 7.246106542879716e-05
motif O 0 0.00012440791761036962
. O 0 1.5792829799465835e-05

It O 0 9.708976904221345e-06
is O 0 1.71291003425722e-06
also O 0 4.006837457382062e-07
worthy O 0 1.0186176950810477e-06
of O 0 5.804747615911765e-07
note O 0 4.938250981467718e-07
that O 0 6.860346957182628e-08
a O 0 5.402349074756785e-07
single O 0 6.723826118104625e-07
nonsense O 0 2.1441144781420007e-05
point O 0 2.279979980812641e-06
mutation O 0 6.828329901509278e-07
, O 0 2.9878006557737535e-07
R233X O 0 9.533401680528186e-06
, O 0 1.6297900629069773e-07
was O 0 1.3070790600977489e-06
observed O 0 3.1265869893104536e-07
in O 0 1.0764469493551587e-07
the O 0 3.1706971981293464e-07
germline O 0 9.319856872025412e-06
DNA O 0 9.57512725108245e-07
from O 0 4.534589947979839e-07
two O 0 2.1586757270597445e-07
unrelated O 0 3.4037686873489292e-06
CD B-Disease 0 6.619085525016999e-06
families O 0 1.8750931474187382e-07
and O 0 1.422096374881221e-06
one O 0 9.26280154089909e-06
BZS B-Disease 0 0.1554834544658661
family O 0 8.990336027636658e-06
. O 0 1.5823930880287662e-05

Genotype O 0 0.0050110118463635445
- O 0 0.0008108812617138028
phenotype O 0 0.00010190999455517158
studies O 0 3.243757646487211e-06
were O 0 4.752386644213402e-07
not O 0 7.503582111212381e-08
performed O 0 2.7838456162498915e-07
on O 0 3.06843901398679e-07
this O 0 6.066857594078101e-08
small O 0 2.3704707530214364e-07
group O 0 3.49205720340251e-07
of O 0 3.0493449685309315e-06
BZS B-Disease 0 0.0011307073291391134
families O 0 1.940666379596223e-06
. O 0 8.770324711804278e-06

However O 0 8.966548193711787e-05
, O 0 2.4623468561912887e-05
genotype O 0 0.0002478689420968294
- O 0 0.0021976076532155275
phenotype O 0 0.0007720955181866884
analysis O 0 5.219393642619252e-06
inthe O 0 3.8350117392838e-05
group O 0 6.236606964193925e-07
of O 0 6.9386982204378e-07
CD B-Disease 0 3.1615891202818602e-06
families O 0 9.217353635904146e-08
revealed O 0 1.3817888202538597e-06
two O 0 7.046422467738012e-08
possible O 0 8.425086406305127e-08
associations O 0 1.1940593935833022e-07
worthy O 0 8.548151981813135e-07
of O 0 9.568180985297658e-07
follow O 0 6.25117195340863e-07
- O 0 2.077678800560534e-06
up O 0 3.9960073650036065e-07
in O 0 3.333418874262861e-07
independent O 0 1.1679489944071975e-06
analyses O 0 7.567781267425744e-06
. O 0 1.2782988051185384e-05

The O 0 2.5841563910944387e-05
first O 0 1.1930494110856671e-05
was O 0 3.244682739023119e-05
an O 0 1.5332304883486358e-06
association O 0 1.4411131132874289e-06
noted O 0 4.786673457601864e-07
in O 0 1.3560253364630626e-07
the O 0 2.654143429481337e-07
group O 0 1.671211862230848e-07
of O 0 8.68208644533297e-07
CD B-Disease 0 8.331160643137991e-06
families O 0 2.1418156848085346e-07
with O 0 1.0079745152324904e-05
breast B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.009230444207787514

A O 0 7.293858652701601e-05
correlation O 0 3.905806443071924e-05
was O 0 1.0270367056364194e-05
observed O 0 6.68328823394404e-07
between O 0 2.7823301707030623e-07
the O 0 4.189169544588367e-07
presence O 0 2.219122507085558e-06
/ O 0 8.056309525272809e-06
absence O 0 1.060854856405058e-06
of O 0 6.538770094266511e-07
a O 0 7.346175152633805e-06
PTEN O 0 0.3743743598461151
mutation O 0 3.4808689974852314e-07
and O 0 7.69830421631923e-08
the O 0 2.625388901833503e-07
type O 0 1.7337177951048943e-06
of O 0 2.206599310738966e-05
breast O 1 0.999932050704956
involvement O 1 0.650924801826477
( O 0 2.0452884200494736e-05
unaffected O 0 0.08274132758378983
versus O 0 0.053145501762628555
benign O 1 0.9998323917388916
versus O 0 0.0022455458529293537
malignant O 1 0.9999724626541138
) O 0 5.022095592721598e-06
. O 0 5.537393917620648e-06

Specifically O 0 2.5868268494377844e-05
and O 0 2.266357114422135e-06
more O 0 3.1212246653922193e-07
directly O 0 7.132495056794141e-07
, O 0 5.420727120508673e-07
an O 0 7.722744612692622e-07
association O 0 7.930576657599886e-07
was O 0 2.5901490516844206e-06
also O 0 5.467167696338038e-08
observed O 0 5.5466784942836966e-08
between O 0 2.533784204672429e-08
the O 0 5.65521425244242e-08
presence O 0 6.51421530051266e-08
of O 0 2.0350080376374535e-07
a O 0 6.737909643561579e-06
PTEN O 1 0.9984235763549805
mutation O 0 2.1106683561811224e-05
and O 0 0.0019541301298886538
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00028826380730606616

Secondly O 0 0.0005702322814613581
, O 0 9.128662895818707e-06
there O 0 1.1460831501608482e-06
appeared O 0 3.907908649125602e-06
to O 0 2.3238902713274e-07
be O 0 4.536800588539336e-07
an O 0 6.705018904540339e-07
interdependent O 0 6.599137577723013e-06
association O 0 3.7864191426706384e-07
between O 0 2.1105290670675458e-07
mutations O 0 4.160849016443535e-07
upstream O 0 3.2836530863278313e-06
and O 0 1.6558675497435615e-07
within O 0 2.243520498268481e-07
the O 0 8.859778404257668e-07
PTPase O 0 6.43206512904726e-05
core O 0 1.2949254596605897e-05
motif O 0 3.860105152853066e-06
, O 0 2.06001359970287e-07
the O 0 5.16043826337409e-07
core O 0 2.07366269933118e-06
motif O 0 8.269199724963983e-07
containing O 0 1.408640031286268e-07
the O 0 1.195157608435693e-07
majority O 0 3.13271115714997e-08
of O 0 2.2193502502432239e-07
missense O 0 3.0061210054554977e-06
mutations O 0 5.675425427398295e-07
, O 0 1.8349645358739508e-07
and O 0 5.642672462613518e-08
the O 0 2.2148381617626e-07
involvement O 0 7.672093715882511e-07
of O 0 5.297339384924271e-07
all O 0 9.15228994813333e-08
major O 0 1.2989239621674642e-05
organ O 1 0.9792338609695435
systems O 0 5.106381649966352e-05
( O 0 1.2427120736901998e-06
central O 0 2.409753142273985e-05
nervous O 0 0.0005616114940494299
system O 0 5.97121015744051e-06
, O 0 6.202269105415326e-06
thyroid O 1 1.0
, O 0 0.0035262841265648603
breast O 1 1.0
, O 1 0.9953393936157227
skin O 1 1.0
and O 1 0.9999974966049194
gastrointestinal O 1 1.0
tract O 1 1.0
) O 1 0.9569164514541626
. O 0 0.00032568039023317397

However O 0 2.2598915165872313e-05
, O 0 1.2836525229431572e-06
these O 0 1.1303229285886118e-07
observations O 0 1.2455692512958194e-06
would O 0 1.905853395101076e-07
need O 0 7.751773978270649e-08
to O 0 4.572880030195847e-08
be O 0 5.652960410884589e-08
confirmed O 0 8.252303018707607e-08
by O 0 3.9484273628431765e-08
studying O 0 5.951648418545119e-08
a O 0 1.0003053318996535e-07
larger O 0 3.9929290096551995e-08
number O 0 9.246549126373793e-08
of O 0 1.0651053798937937e-06
CD B-Disease 0 8.728620741749182e-06
families O 0 4.805069124813599e-07
. O 0 5.453042376757367e-06

Molecular O 1 0.9997041821479797
defects O 1 0.9993906021118164
leading O 0 9.562851482769474e-05
to O 0 1.2235038866492687e-06
human O 0 5.230645001574885e-06
complement B-Disease 0 0.00027248827973380685
component I-Disease 1 0.9999874830245972
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 9.047143976204097e-06
an O 0 7.545304015366128e-06
African O 0 1.6127180060721003e-05
- O 0 0.00017142224533017725
American O 0 2.132673944288399e-05
family O 0 7.763063877064269e-06
. O 0 1.1364604688424151e-05

Complement B-Disease 0 0.002636445453390479
component I-Disease 1 0.9995023012161255
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.988638491136953e-05
C6D B-Disease 1 0.9761292934417725
) O 0 1.611378252164286e-06
was O 0 0.00013524941459763795
diagnosed O 0 0.0020424469839781523
in O 0 7.899085403550998e-07
a O 0 3.6105193430557847e-06
16 O 0 1.0443686733196955e-05
- O 0 5.252113624010235e-05
year O 0 5.015586339141009e-06
- O 0 9.337409210274927e-06
old O 0 1.924481512105558e-05
African O 0 5.840536687173881e-06
- O 0 1.8804466890287586e-05
American O 0 9.907607818604447e-06
male O 0 6.686540928058093e-06
with O 0 1.7859845684142783e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 6.32564551779069e-05

The O 0 0.00011638586147455499
patients O 0 2.776236942736432e-05
father O 0 2.5681218176032417e-05
and O 0 2.0105969724681927e-06
two O 0 2.0179984403512208e-06
brothers O 0 5.0761726015480235e-05
also O 0 1.7134018435172038e-06
had O 0 2.1882171495235525e-05
C6D B-Disease 1 0.8000212907791138
, O 0 2.344297769241166e-07
but O 0 4.795464292328688e-08
gave O 0 1.2822756900732202e-07
no O 0 8.37687181842739e-08
history O 0 1.2197210708109196e-06
of O 0 0.00011328039545333013
meningitis B-Disease 1 1.0
or O 0 1.93710711755557e-05
other O 0 6.578627562703332e-06
neisserial B-Disease 1 0.9997482895851135
infection I-Disease 1 0.9998846054077148
. O 0 3.613514491007663e-05

By O 0 1.9037066522287205e-05
using O 0 5.970504389551934e-06
exon O 0 3.555116563802585e-05
- O 0 1.187566522276029e-05
specific O 0 1.006146021609311e-06
polymerase O 0 0.0001328717771684751
chain O 0 4.925847679260187e-05
reaction O 0 8.543769581592642e-06
( O 0 1.246270244337211e-06
PCR O 0 1.2917766071041115e-05
) O 0 4.423396262609458e-07
/ O 0 2.378560338911484e-06
single O 0 1.406794353897567e-06
- O 0 6.504247721750289e-06
strand O 0 5.3061839935253374e-06
conformation O 0 5.476832143358479e-07
polymorphism O 0 6.95409426043625e-07
as O 0 1.0722175147748203e-07
a O 0 1.2356446177363978e-07
screening O 0 1.8999953965703753e-07
step O 0 1.5579085754779953e-07
and O 0 5.562019111948757e-08
nucleotide O 0 5.897616119909799e-07
sequencing O 0 3.4877737675742537e-07
of O 0 4.40783196609118e-07
target O 0 9.37288405111758e-07
exons O 0 7.146487064346729e-07
, O 0 1.1042970271546437e-07
we O 0 2.8095479720491312e-08
determined O 0 1.0790205351440818e-07
that O 0 1.0051689258716578e-07
the O 0 8.992186621981091e-07
proband O 0 2.2111622456577606e-05
was O 0 2.7119327569380403e-05
a O 0 3.931260380340973e-06
compound O 0 1.4366245522978716e-05
heterozygote O 0 5.2160598897899035e-06
for O 0 2.1455853982388362e-07
two O 0 1.8298946997674648e-06
C6 O 0 0.2522056996822357
gene O 0 1.7498485249234363e-05
mutations O 0 2.8509348339866847e-05
. O 0 2.392439819232095e-05

The O 0 5.632722968584858e-05
first O 0 1.083508050214732e-05
, O 0 1.4155676808513817e-06
1195delC O 0 3.816618573182495e-06
located O 0 1.152745539911848e-06
in O 0 3.6268974668018927e-07
exon O 0 2.165365685868892e-06
7 O 0 2.902325832110364e-06
, O 0 2.281255859770681e-07
is O 0 2.268590151288663e-07
a O 0 6.555046638823114e-07
novel O 0 7.859785569053201e-07
mutation O 0 5.597468089035829e-07
, O 0 3.600248419388663e-07
while O 0 2.1361935864661064e-07
the O 0 3.3591467740734515e-07
second O 0 1.0200845963481697e-06
, O 0 2.567246326634631e-07
1936delG O 0 1.684813810243213e-06
in O 0 4.3333659505151445e-07
exon O 0 9.104537070925289e-07
12 O 0 1.2214613889227621e-06
, O 0 2.429275980375678e-07
has O 0 2.302496397987852e-07
been O 0 3.2137990046976483e-07
described O 0 4.41514004023702e-07
before O 0 1.66366319831468e-07
to O 0 1.7330073376342625e-07
cause O 0 1.2538494047475979e-05
C6D B-Disease 0 0.10009797662496567
in O 0 1.103636463994917e-06
an O 0 1.5297222262233845e-06
unrelated O 0 8.426213753409684e-06
African O 0 9.476476407144219e-06
- O 0 2.7238809707341716e-05
American O 0 5.623758625006303e-06
individual O 0 9.718839919514721e-07
. O 0 9.446113836020231e-06

Both O 0 8.768326551944483e-06
mutations O 0 9.99332496576244e-06
result O 0 4.096101292816456e-06
in O 0 2.3967425022419775e-06
premature O 0 6.506824138341472e-05
termination O 0 2.1355273929657415e-05
codons O 0 1.0837664376595058e-05
and O 0 1.7974028878597892e-06
C6 O 0 0.007441438268870115
null O 0 0.00020316662266850471
alleles O 0 3.296220529591665e-05
. O 0 2.149822648789268e-05

Allele O 0 0.001037423498928547
- O 0 0.00021151977125555277
specific O 0 4.86151020595571e-06
PCR O 0 0.00012191367568448186
indicated O 0 6.923918590473477e-06
that O 0 5.905804982830887e-07
the O 0 2.8989704787818482e-06
probands O 0 0.00011155208630952984
two O 0 1.9695244191098027e-06
brothers O 0 4.331499440013431e-05
also O 0 1.0596263564366382e-06
inherited O 0 2.0180994397378527e-05
the O 0 3.23562881021644e-06
1195delC O 0 1.7649423170951195e-05
mutation O 0 9.341490567749133e-07
from O 0 3.2207944400397537e-07
their O 0 8.386000871496435e-08
heterozygous O 0 1.105757178265776e-06
mother O 0 1.8855596408684505e-06
and O 0 3.8172993299667723e-07
the O 0 9.082813221539254e-07
1936delG O 0 1.3436698282021098e-05
mutation O 0 6.721101613038627e-07
from O 0 4.797440738002479e-07
their O 0 2.505693998955394e-07
homozygous O 0 1.6929985577007756e-05
father O 0 3.433168603805825e-05
. O 0 4.901522061118158e-06
. O 0 1.0889694749494083e-05

PAX6 O 0 0.39971062541007996
mutations O 0 0.0010646289447322488
reviewed O 0 0.0005987611948512495
. O 0 0.00010124795517185703

Mutations O 0 0.00022930459817871451
in O 0 2.421109275019262e-05
PAX6 O 0 0.002549243625253439
are O 0 6.490935788860952e-07
responsible O 0 1.3188655429985374e-06
for O 0 4.531659101303376e-07
human O 0 6.65741163174971e-06
aniridia B-Disease 1 0.9999867677688599
and O 0 4.066157259785541e-07
have O 0 1.5602458347530046e-07
also O 0 2.4326166681021277e-07
been O 0 4.296651354707137e-07
found O 0 2.1240740011307935e-07
in O 0 4.967650397702528e-07
patients O 0 1.3219444099377142e-06
with O 0 4.941586666973308e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 0.0003470652736723423
with O 0 0.45200592279434204
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.005374627653509378
with O 0 6.066034984542057e-06
autosomal B-Disease 1 0.9999983310699463
dominant I-Disease 1 0.9999828338623047
keratitis I-Disease 1 1.0
, O 0 8.65877063915832e-06
and O 0 1.4095796814217465e-06
with O 0 7.17743978384533e-06
isolated B-Disease 1 0.9999850988388062
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 1 0.6441673040390015

No O 0 6.185364327393472e-05
locus O 0 0.00014454047777689993
other O 0 7.637359544787614e-07
than O 0 5.724025982090097e-07
chromosome O 0 5.580876677413471e-05
11p13 O 0 0.00030824195710010827
has O 0 1.0496710274310317e-06
been O 0 1.730655071696674e-06
implicated O 0 8.728929060453083e-06
in O 0 1.6078786302387016e-06
aniridia B-Disease 1 0.9999463558197021
, O 0 6.325196864054305e-07
and O 0 5.621349146167631e-07
PAX6 O 0 0.06239009276032448
is O 0 3.673677042570489e-07
clearly O 0 5.022422442380048e-07
the O 0 3.4132921200580313e-07
major O 0 1.2353293641353957e-06
, O 0 1.1636858232577652e-07
if O 0 2.739882987157216e-08
not O 0 2.9658727029868714e-08
only O 0 9.453194849129432e-08
, O 0 4.6800192876617075e-07
gene O 0 3.575858272597543e-06
responsible O 0 1.3358161595533602e-05
. O 0 1.9205357602913864e-05

Twenty O 0 0.00014271668624132872
- O 0 3.588562321965583e-05
eight O 0 2.564136593719013e-06
percent O 0 1.4664552736576297e-06
of O 0 9.858717930910643e-07
identified O 0 2.52255472332763e-06
PAX6 O 0 0.0003636992769315839
mutations O 0 3.459355639279238e-06
are O 0 1.562022134748986e-06
C O 0 0.0004361146129667759
- O 0 0.00027838427922688425
T O 0 4.834503852180205e-05
changes O 0 3.097295291354385e-07
at O 0 2.085030928355991e-06
CpG O 0 4.1237253753934056e-06
dinucleotides O 0 2.7020398647437105e-06
, O 0 8.357800851399588e-08
20 O 0 1.0748179590791551e-07
% O 0 5.8478434539210866e-08
are O 0 2.9524001021741242e-08
splicing O 0 9.04003684354393e-07
errors O 0 4.892229299002793e-06
, O 0 2.2596378812522744e-07
and O 0 9.041781368068769e-08
more O 0 2.2731503790396346e-08
than O 0 3.3112396380374776e-08
30 O 0 2.0622091767563688e-07
% O 0 7.463259521500731e-08
are O 0 2.5301428507873425e-08
deletion O 0 9.308577091360348e-07
or O 0 5.924138122281875e-07
insertion O 0 9.224912901117932e-06
events O 0 3.6181750147079583e-06
. O 0 7.41253825253807e-06

There O 0 2.2913736756891012e-05
is O 0 3.2301195460604504e-06
a O 0 8.69413634063676e-06
noticeably O 0 9.511503594694659e-05
elevated O 0 0.000219796784222126
level O 0 2.0991205929021817e-06
of O 0 1.0732481996456045e-06
mutation O 0 8.841681733429141e-07
in O 0 3.4169107721027103e-07
the O 0 3.520536893120152e-07
paired O 0 8.82174504113209e-07
domain O 0 8.547744414499903e-07
compared O 0 7.337398528761696e-07
with O 0 5.0252488392743544e-08
the O 0 3.2753510481597914e-07
rest O 0 2.502011966498685e-07
of O 0 1.4911358903191285e-06
the O 0 4.676558091887273e-06
gene O 0 1.0418509191367775e-05
. O 0 1.2438950761861634e-05

Increased O 0 3.437867053435184e-05
mutation O 0 7.648915016034152e-06
in O 0 1.9515944131853757e-06
the O 0 1.3313725730768056e-06
homeodomain O 0 1.0517860573600046e-05
is O 0 3.120010205748258e-07
accounted O 0 1.1599003073570202e-06
for O 0 1.2830609819047822e-07
by O 0 2.8291441367400694e-07
the O 0 3.5201107948523713e-06
hypermutable O 0 0.00016180785314645618
CpG O 0 9.22657927731052e-05
dinucleotide O 0 2.8326308893156238e-05
in O 0 3.349455255374778e-06
codon O 0 3.8303227483993396e-05
240 O 0 1.1074857866333332e-05
. O 0 8.887239346222486e-06

Very O 0 8.93720607564319e-06
nearly O 0 1.7789375306165311e-06
all O 0 9.372743647872994e-08
mutations O 0 5.374097327148775e-07
appear O 0 4.5122226310922997e-07
to O 0 1.1765970242549884e-07
cause O 0 3.112989361397922e-06
loss O 0 9.106525794777554e-06
of O 0 1.3973796058053267e-06
function O 0 4.4110069552516507e-07
of O 0 3.3491920703454525e-07
the O 0 1.6535999236566568e-07
mutant O 0 1.096300707104092e-06
allele O 0 5.304973456077278e-07
, O 0 1.0560856367192173e-07
and O 0 5.1317474714096534e-08
more O 0 2.552804723165991e-08
than O 0 4.837114886413474e-08
80 O 0 1.8274411672791757e-07
% O 0 1.0312300702253197e-07
of O 0 9.929636917149764e-07
exonic O 0 8.826399607642088e-06
substitutions O 0 8.457608373646508e-07
result O 0 6.45796376375074e-07
in O 0 1.4590339105780004e-06
nonsense O 0 8.329746196977794e-05
codons O 0 3.8812595448689535e-05
. O 0 1.2857799447374418e-05

In O 0 1.107156367652351e-05
a O 0 6.623038188990904e-06
gene O 0 1.415439328411594e-06
with O 0 1.5573084510833723e-07
such O 0 2.981160491799528e-07
extraordinarily O 0 1.141688790085027e-05
high O 0 1.81900270490587e-06
sequence O 0 4.278838972027188e-08
conservation O 0 4.902476291590574e-08
throughout O 0 2.1801129790333107e-08
evolution O 0 7.278327274207186e-08
, O 0 2.0715988924280282e-08
there O 0 2.911077068290524e-08
are O 0 1.8710696991774967e-08
presumed O 0 2.334540113224648e-06
undiscovered O 0 1.7527881936985068e-05
missense O 0 6.650513569184113e-06
mutations O 0 6.710853313052212e-07
, O 0 1.0787098148057339e-07
these O 0 1.3419148459092867e-08
are O 0 1.6515786072091032e-08
hypothesized O 0 2.2958745660162094e-07
to O 0 1.834383134280415e-08
exist O 0 7.109155575335535e-08
in O 0 6.330845394586504e-07
as O 0 1.9915551092708483e-06
- O 0 1.1630689186858945e-05
yet O 0 7.494698479604267e-07
unidentified O 0 9.149467587121762e-06
phenotypes O 0 6.0289166867733e-06
. O 0 1.5222914271362242e-06
. O 0 5.766264166595647e-06

Genetic O 0 0.00017469767772126943
heterogeneity O 0 0.00016341483569703996
and O 0 6.030026270309463e-06
penetrance O 0 0.0010742520680651069
analysis O 0 2.075650854749256e-06
of O 0 9.554557891533477e-07
the O 0 8.853350550452888e-07
BRCA1 O 0 1.98165016627172e-05
and O 0 1.2396192232699832e-06
BRCA2 O 0 0.0002000687672989443
genes O 0 1.4257031580200419e-05
in O 0 0.00023511855397373438
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.4588749763788655e-05
. O 0 5.650062666973099e-05

The O 0 0.003348730970174074
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9999034404754639
Consortium O 0 0.003431586315855384
. O 0 8.592392259743065e-05

The O 0 5.552263701247284e-06
contribution O 0 3.2295558867190266e-06
of O 0 2.9546506539190887e-06
BRCA1 O 0 5.846283966093324e-05
and O 0 1.8628388716024347e-06
BRCA2 O 0 0.03762088343501091
to O 0 1.6042382412706502e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9999477863311768
assessed O 0 1.0283794836141169e-05
by O 0 1.8897455333899416e-07
linkage O 0 2.5060433017642936e-06
and O 0 8.170391652129183e-08
mutation O 0 3.520328561990027e-07
analysis O 0 1.6300448635320208e-07
in O 0 1.228104764550153e-07
237 O 0 8.51766799314646e-07
families O 0 2.999088266619765e-08
, O 0 5.186468499118746e-08
each O 0 1.3872556436922423e-08
with O 0 3.6951313120425766e-08
at O 0 1.606155933586706e-06
least O 0 3.377707002982788e-08
four O 0 2.995326653376651e-08
cases O 0 6.465075585992963e-08
of O 0 9.71458121057367e-06
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9998699426651001
, O 0 2.2597455995310156e-07
collected O 0 2.848316569270537e-07
by O 0 5.090676040708786e-07
the O 0 0.00022008593077771366
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9982988238334656
Consortium O 0 0.00023687926295679063
. O 0 2.0127446987316944e-05

Families O 0 6.443392976507312e-06
were O 0 1.3686216107089422e-06
included O 0 4.8147842335311e-07
without O 0 1.386584358442633e-07
regard O 0 1.925760955145961e-07
to O 0 4.571318967805382e-08
the O 0 3.6939937331226247e-07
occurrence O 0 1.6033816791605204e-05
of O 0 0.00014366685354616493
ovarian B-Disease 1 1.0
or I-Disease 0 0.00035457374178804457
other I-Disease 0 1.2231854270794429e-05
cancers I-Disease 1 0.9999982118606567
. O 0 0.0002853519399650395

Overall O 0 0.005610994063317776
, O 0 7.415680738631636e-05
disease O 0 0.35180675983428955
was O 0 0.0009452591766603291
linked O 0 1.8346778233535588e-05
to O 0 2.635769931202958e-07
BRCA1 O 0 7.161017492762767e-06
in O 0 7.163252462305536e-07
an O 0 3.740107956673455e-07
estimated O 0 2.756789285740524e-07
52 O 0 6.108333536758437e-07
% O 0 8.238903603796643e-08
of O 0 3.4088810707544326e-07
families O 0 4.2224439056326446e-08
, O 0 6.792381412878967e-08
to O 0 5.337231812063692e-08
BRCA2 O 0 1.2671762306126766e-06
in O 0 4.5849154162169725e-07
32 O 0 8.669378530612448e-07
% O 0 1.3330276260603569e-07
of O 0 6.168865525069123e-07
families O 0 5.6513972168659166e-08
, O 0 8.530921746796594e-08
and O 0 4.189281099797881e-08
to O 0 6.706567035053013e-08
neither O 0 1.997724865532291e-07
gene O 0 1.4599704911688605e-07
in O 0 2.965650196529168e-07
16 O 0 3.687021319365158e-07
% O 0 1.0610971656888069e-07
( O 0 8.205515200643276e-08
95 O 0 2.811322872275923e-07
% O 0 1.3235738549610687e-07
confidence O 0 1.369417987007182e-06
interval O 0 3.5818209198623663e-06
[ O 0 1.879097226265003e-06
CI O 0 0.0002611176169011742
] O 0 7.457225592588657e-07
6 O 0 6.649402166658547e-07
% O 0 2.610717899642623e-07
- O 0 1.48528727095254e-06
28 O 0 1.3894306221118313e-06
% O 0 2.441327353608358e-07
) O 0 1.3654180008870753e-07
, O 0 1.7403660024228884e-07
suggesting O 0 1.5261988437487162e-06
other O 0 3.0998572242424416e-07
predisposition O 0 0.00025913160061463714
genes O 0 1.9109736967948265e-05
. O 0 4.131450623390265e-05

The O 0 2.3381662686006166e-05
majority O 0 2.222646799054928e-06
( O 0 1.2547517371785943e-06
81 O 0 3.95518463847111e-06
% O 0 3.3648731800894893e-07
) O 0 9.546873513954779e-08
of O 0 1.0292998240402085e-06
the O 0 0.0007357526337727904
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.061166916675575e-07
were O 0 7.378152417913952e-07
due O 0 1.844521193561377e-06
to O 0 1.8937399204332905e-07
BRCA1 O 0 1.1247951988480054e-05
, O 0 3.87349558650385e-07
with O 0 7.685599001661103e-08
most O 0 8.712795818155428e-08
others O 0 1.0112263737482863e-07
( O 0 8.901364623170593e-08
14 O 0 5.084039003122598e-07
% O 0 2.0008212686661864e-07
) O 0 1.6068010211256478e-07
due O 0 2.082034598061e-06
to O 0 1.9944156974815996e-06
BRCA2 O 0 0.0002927034511230886
. O 0 3.898795694112778e-05

Conversely O 0 0.0002463279233779758
, O 0 4.0294485188496765e-06
the O 0 1.184972120427119e-06
majority O 0 2.254284794389605e-07
of O 0 5.958610813650012e-07
families O 0 1.4789901570111397e-07
with O 0 2.4890081817829923e-07
male B-Disease 0 9.825575398281217e-05
and I-Disease 0 1.1066179467889015e-05
female I-Disease 1 0.9887739419937134
breast I-Disease 1 1.0
cancer I-Disease 1 0.9999967813491821
were O 0 1.2096339560230263e-05
due O 0 1.0187305633735377e-05
to O 0 6.249849207051739e-07
BRCA2 O 0 2.2380239897756837e-05
( O 0 2.6600321234582225e-06
76 O 0 4.440814154804684e-05
% O 0 3.956520231440663e-06
) O 0 5.368603979150066e-06
. O 0 1.4478077901003417e-05

The O 0 4.426882878760807e-05
largest O 0 2.5159373763017356e-05
proportion O 0 7.152001671784092e-06
( O 0 1.2372770470392425e-06
67 O 0 7.5674784056900535e-06
% O 0 5.873430382052902e-07
) O 0 2.108961609792459e-07
of O 0 6.169989319460001e-07
families O 0 6.08536581125918e-08
due O 0 9.057822580871289e-07
to O 0 7.801344992230952e-08
other O 0 6.32516119480897e-08
genes O 0 3.246200890316686e-07
was O 0 1.60013423737837e-05
found O 0 2.5767317879399343e-07
in O 0 1.4077591004024725e-07
families O 0 2.1350933465669186e-08
with O 0 2.573410640138718e-08
four O 0 1.690364967998903e-07
or O 0 2.4639453499730735e-07
five O 0 2.187769894135272e-07
cases O 0 1.6211524211939832e-07
of O 0 9.094461347558536e-06
female O 1 0.6796521544456482
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999808073043823
only O 0 2.1543788534472696e-05
. O 0 2.8786371331079863e-05

These O 0 3.340666580697871e-06
estimates O 0 6.506468707812019e-06
were O 0 7.307858140848111e-07
not O 0 2.858990342247125e-07
substantially O 0 2.0638237856474007e-06
affected O 0 1.797222921595676e-07
either O 0 8.694203046388793e-08
by O 0 8.046238519909821e-08
changing O 0 1.5329979419220763e-07
the O 0 1.1754014650477984e-07
assumed O 0 7.660322580704815e-07
penetrance O 0 2.8312272206676425e-06
model O 0 1.4816694715591439e-07
for O 0 6.080017556087114e-08
BRCA1 O 0 1.8020231209447957e-06
or O 0 1.0186522558797151e-07
by O 0 1.3065292137071083e-07
including O 0 1.464633783143654e-07
or O 0 6.507397642963042e-07
excluding O 0 8.0852887549554e-06
BRCA1 O 0 5.294475704431534e-05
mutation O 0 2.1930765797151253e-05
data O 0 1.745778354234062e-05
. O 0 1.3409946404863149e-05

Among O 0 1.6159001461346634e-05
those O 0 1.1799551202784642e-06
families O 0 3.80558390133956e-07
with O 0 4.830154125556874e-07
disease O 1 0.785555362701416
due O 0 2.1461417418322526e-05
to O 0 1.3772641693776677e-07
BRCA1 O 0 5.8722430367197376e-06
that O 0 1.6859600293628318e-07
were O 0 3.500179559523531e-07
tested O 0 1.2509171654073725e-07
by O 0 5.440039529958085e-08
one O 0 2.5802719960665854e-08
of O 0 1.413874173294971e-07
the O 0 1.1378765663039303e-07
standard O 0 1.313144650794129e-07
screening O 0 9.789744837007675e-08
methods O 0 1.2237100577294768e-07
, O 0 5.189922092085908e-08
mutations O 0 9.077966467430088e-08
were O 0 2.718981875204918e-07
detected O 0 6.453851142396161e-07
in O 0 1.9604722467647662e-07
the O 0 3.21063737374061e-07
coding O 0 4.083796909526427e-07
sequence O 0 1.9082486346633232e-07
or O 0 1.3132097365087247e-07
splice O 0 1.0364788067818154e-06
sites O 0 1.2590726328198798e-07
in O 0 2.1233853431112948e-07
an O 0 2.651744637205411e-07
estimated O 0 4.147055108205677e-07
63 O 0 1.2283722981010214e-06
% O 0 2.2029067281437165e-07
( O 0 8.96279672701894e-08
95 O 0 7.145287668208766e-07
% O 0 5.860957799086464e-07
CI O 0 0.004338392056524754
51 O 0 3.2087627914734185e-06
% O 0 1.098884126804478e-06
- O 0 8.130778951453976e-06
77 O 0 5.20091953148949e-06
% O 0 1.2098309980501654e-06
) O 0 2.0044990378664806e-06
. O 0 6.492201464425307e-06

The O 0 1.1557988727872726e-05
estimated O 0 5.000288638257189e-06
sensitivity O 0 4.286176590539981e-06
was O 0 5.258132659946568e-06
identical O 0 2.431331722618779e-07
for O 0 7.148464220563255e-08
direct O 0 4.958326371706789e-07
sequencing O 0 2.6768996121973032e-06
and O 0 4.444030139438837e-07
other O 0 4.027502029657626e-07
techniques O 0 3.902537719113752e-05
. O 0 2.2372683815774508e-05

The O 0 3.4998647606698796e-05
penetrance O 0 0.00018697571067605168
of O 0 1.4988224393164273e-05
BRCA2 O 0 9.35966381803155e-05
was O 0 3.0443992727668956e-05
estimated O 0 1.372431484014669e-06
by O 0 4.469284817787411e-07
maximizing O 0 2.361502311032382e-06
the O 0 8.135122584462806e-07
LOD O 0 0.0001502467057434842
score O 0 1.0845177484952728e-06
in O 0 9.515384249425551e-07
BRCA2 O 0 1.836584124248475e-05
- O 0 1.0480472155904863e-05
mutation O 0 5.917667635912949e-07
families O 0 6.377907624255386e-08
, O 0 8.066522383387564e-08
over O 0 1.589200735452323e-07
all O 0 7.540698732100282e-08
possible O 0 1.20452261853643e-06
penetrance O 0 6.812182982685044e-05
functions O 0 9.842260624282062e-06
. O 0 1.7028547517838888e-05

The O 0 8.012185389816295e-06
estimated O 0 5.129989403940272e-06
cumulative O 0 1.4465203094005119e-05
risk O 0 4.098855697520776e-06
of O 0 6.331331860565115e-06
breast B-Disease 1 0.9993059635162354
cancer I-Disease 1 0.9961162805557251
reached O 0 6.414442032109946e-05
28 O 0 6.228675829333952e-06
% O 0 3.523633722579689e-07
( O 0 1.2250340830632922e-07
95 O 0 6.874262794553943e-07
% O 0 5.57304645099066e-07
CI O 0 0.0017956893425434828
9 O 0 4.198494480078807e-06
% O 0 3.795826728492102e-07
- O 0 1.4000888768350706e-06
44 O 0 8.719459856365575e-07
% O 0 1.0398970573533006e-07
) O 0 4.994880242747968e-08
by O 0 4.1827501462421424e-08
age O 0 1.0441084441481507e-07
50 O 0 1.486257730221041e-07
years O 0 9.440366000035283e-08
and O 0 7.574067950599783e-08
84 O 0 1.2694429187831702e-06
% O 0 1.8349015817875625e-07
( O 0 1.1037874259045566e-07
95 O 0 3.5737443226935284e-07
% O 0 3.45344460583874e-07
CI O 0 0.00021010893397033215
43 O 0 1.641812900743389e-06
% O 0 3.3415352618249017e-07
- O 0 1.0616350891723414e-06
95 O 0 5.307730930326215e-07
% O 0 1.0843331210708129e-07
) O 0 4.643395712378151e-08
by O 0 1.1423757939610368e-07
age O 0 8.708290692993614e-07
70 O 0 2.997035153384786e-06
years O 0 3.1121878691919846e-06
. O 0 5.9051908465335146e-06

The O 0 0.00014909131277818233
corresponding O 1 0.7368603348731995
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.013659636490046978
were O 0 1.7616293916944414e-05
0 O 0 1.5684148820582777e-05
. O 0 8.31037868920248e-06

4 O 0 0.00012059925211360678
% O 0 8.476692528347485e-06
( O 0 2.6736463496490614e-06
95 O 0 4.34834555562702e-06
% O 0 1.2571255183502217e-06
CI O 0 0.00047834895667620003
0 O 0 1.3347988669920596e-06
% O 0 2.8967932053092227e-07
- O 0 6.15544308857352e-07
1 O 0 3.0158932418089535e-07
% O 0 1.0597804589451698e-07
) O 0 3.905487488964354e-08
by O 0 4.1212498302911627e-08
age O 0 1.493085477477507e-07
50 O 0 1.848122082037662e-07
years O 0 1.2655081604862062e-07
and O 0 8.149086028197416e-08
27 O 0 1.0351610626457841e-06
% O 0 1.1960071333305677e-07
( O 0 6.941691310657916e-08
95 O 0 3.52359023736426e-07
% O 0 1.7217575987160672e-07
CI O 0 8.272166451206431e-05
0 O 0 5.271676855045371e-07
% O 0 2.458701544583164e-07
- O 0 1.443887981622538e-06
47 O 0 1.169424649560824e-06
% O 0 2.1365114832860854e-07
) O 0 7.142290314732236e-08
by O 0 1.3990728575663525e-07
age O 0 1.3040785233897623e-06
70 O 0 3.6241633551981067e-06
years O 0 3.714993454195792e-06
. O 0 1.0229078725387808e-05

The O 0 1.0818435839610174e-05
lifetime O 0 4.3551372073125094e-05
risk O 0 4.0550621633883566e-05
of O 0 5.2050552767468616e-05
breast B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999792575836182
appears O 0 2.860181211872259e-06
similar O 0 1.0567244146386656e-07
to O 0 6.739573876757277e-08
the O 0 5.222692038842069e-07
risk O 0 8.219000164899626e-07
in O 0 1.7762477000360377e-07
BRCA1 O 0 4.170365627942374e-06
carriers O 0 1.8812690427694179e-07
, O 0 9.571378001282937e-08
but O 0 3.0317732324647295e-08
there O 0 7.11455427904184e-08
was O 0 1.080284391719033e-06
some O 0 2.5709576689791902e-08
suggestion O 0 5.983449682389619e-07
of O 0 6.126826974650612e-07
a O 0 3.509441967253224e-06
lower O 0 7.664476470381487e-06
risk O 0 4.698690361237823e-07
in O 0 3.5422490896053205e-07
BRCA2 O 0 4.434370566741563e-06
carriers O 0 7.397069907710829e-07
< O 0 8.08266759122489e-06
50 O 0 4.950473453391169e-07
years O 0 6.254881554923486e-07
of O 0 1.7829815988079645e-06
age O 0 6.791993655497208e-06
. O 0 7.317312793020392e-06

Eye B-Disease 1 0.9999971389770508
movement I-Disease 1 0.9350310564041138
abnormalities I-Disease 1 0.9999858140945435
correlate O 0 6.488057260867208e-05
with O 0 1.839284891502757e-06
genotype O 0 0.00028304397710599005
in O 0 1.1447327779023908e-05
autosomal O 1 0.9892874956130981
dominant O 1 0.9823132157325745
cerebellar B-Disease 1 0.9999998807907104
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999969005584717
. O 0 0.0003725044662132859

We O 0 6.462029705289751e-05
compared O 0 0.00010969681898131967
horizontal O 0 0.0015844559529796243
eye O 0 0.2066987007856369
movements O 0 0.00010594435298116878
( O 0 4.073704985785298e-06
visually O 0 1.6960211723926477e-06
guided O 0 5.307889296091162e-06
saccades O 0 8.303241338580847e-05
, O 0 8.004677169992647e-07
antisaccades O 0 2.2169644580571912e-05
, O 0 2.3605987564678799e-07
and O 0 1.0974664377272347e-07
smooth O 0 3.1112915621633874e-06
pursuit O 0 1.2053386853949632e-05
) O 0 1.1799973265169683e-07
in O 0 1.1147916012532733e-07
control O 0 4.6506900730491907e-07
subjects O 0 4.522588028521568e-07
( O 0 1.780002065743247e-07
n O 0 8.924550343181181e-07
= O 0 1.8809582797985058e-06
14 O 0 1.5559709254375775e-06
) O 0 1.635338833239075e-07
and O 0 1.3085093542031245e-07
patients O 0 1.1642363517694321e-07
with O 0 2.676633314990795e-08
three O 0 1.0204120570733721e-07
forms O 0 3.878555787650839e-07
of O 0 1.1775576240324881e-05
autosomal O 0 0.00250332267023623
dominant O 0 8.235198765760288e-05
cerebellar B-Disease 1 0.7032801508903503
ataxias I-Disease 0 0.06684741377830505
type I-Disease 0 2.746506652329117e-05
I I-Disease 0 8.1531674368307e-05
spinocerebellar B-Disease 0 0.4072018265724182
ataxias I-Disease 0 0.0002570812066551298
1 I-Disease 0 3.7465913464984624e-06
and I-Disease 0 7.425078933920304e-07
2 I-Disease 0 1.6588342077739071e-06
( O 0 7.75285968757089e-07
SCA1 B-Disease 0 3.774931246880442e-05
, O 0 4.931930561724585e-07
n O 0 1.976661906155641e-06
= O 0 1.422492459823843e-06
11 O 0 1.700351958788815e-06
; O 0 1.8602844420456677e-07
SCA2 B-Disease 0 2.4823431886034086e-05
, O 0 2.7489971898830845e-07
n O 0 1.0745449117166572e-06
= O 0 1.5294713193725329e-06
10 O 0 3.8166115245985566e-07
) O 0 1.9850691046485736e-07
and O 0 1.6883460602912237e-06
SCA3 B-Disease 1 0.9999998807907104
/ O 0 0.0001289662905037403
Machado B-Disease 0 7.596753857797012e-05
- I-Disease 0 0.0003020824515260756
Joseph I-Disease 0 0.014806163497269154
disease I-Disease 0 0.017424043267965317
( O 0 2.997409637828241e-06
MJD B-Disease 1 0.9998656511306763
) O 0 5.767313950855169e-07
( O 0 3.3878217209348804e-07
n O 0 1.2043744845868787e-06
= O 0 5.5718041949148756e-06
16 O 0 5.917666385357734e-06
) O 0 1.7768893485481385e-06
. O 0 7.051671218505362e-06

In O 0 0.00011149116471642628
SCA1 B-Disease 0 0.001478256075643003
, O 0 3.9566034502058756e-06
saccade O 0 7.822455518180504e-05
amplitude O 0 1.3000976650801022e-05
was O 0 6.276276963035343e-06
significantly O 0 5.938347271694511e-07
increased O 0 7.94639959167398e-07
, O 0 4.850187451665988e-07
resulting O 0 2.030901214311598e-06
in O 0 2.6885375064011896e-06
hypermetria B-Disease 0 0.000361591053660959
. O 0 1.607834747119341e-05

The O 0 2.5697505407151766e-05
smooth O 0 8.382009400520474e-05
pursuit O 0 0.00010657937673386186
gain O 0 5.331420834409073e-05
was O 0 0.0004143495170865208
decreased O 0 0.005345440469682217
. O 0 3.1201165256788954e-05

In O 0 0.00016587640857324004
SCA2 B-Disease 0 0.003856685943901539
, O 0 1.8103799447999336e-05
saccade O 0 0.000391003442928195
velocity O 0 0.00010954733443213627
was O 0 0.00016361720918212086
markedly O 0 0.0002497553650755435
decreased O 0 0.0002752722648438066
. O 0 2.8552552976179868e-05

The O 0 1.2937625797349028e-05
percentage O 0 4.771023213834269e-06
of O 0 1.0510202628211118e-06
errors O 0 9.045383194461465e-06
in O 0 8.787797014520038e-07
antisaccades O 0 2.9780383556499146e-05
was O 0 3.884562829625793e-06
greatly O 0 4.2145751422140165e-07
increased O 0 4.127032298129052e-07
and O 0 5.20510994306278e-08
was O 0 4.48303126177052e-06
significantly O 0 3.065440807858977e-07
correlated O 0 7.131522465897433e-07
with O 0 6.765332472014052e-08
age O 0 1.5089781300048344e-05
at O 1 0.5708047151565552
disease O 1 0.9999425411224365
onset O 1 0.9999139308929443
. O 0 3.421291330596432e-05

In O 0 1.32378127091215e-05
addition O 0 1.1397384014344425e-06
, O 0 3.975731885930145e-07
a O 0 3.193402449142013e-07
correlation O 0 9.555960787110962e-07
between O 0 2.858799348359753e-07
smooth O 0 2.966664624182158e-06
pursuit O 0 4.527124929154525e-06
gain O 0 7.338819045799028e-07
and O 0 4.3248526537809084e-08
the O 0 5.1211969775977195e-08
number O 0 6.885542092049945e-08
of O 0 1.6048545603553066e-06
trinucleotide O 0 9.617253817850724e-05
repeats O 0 6.948108421056531e-06
was O 0 6.083752305130474e-05
found O 0 4.736256869364297e-06
. O 0 1.0298742381564807e-05

In O 0 0.0009928405052050948
SCA3 B-Disease 1 0.9999995231628418
, O 0 0.0001465995010221377
gaze B-Disease 0 0.3303702473640442
- I-Disease 0 0.0023977102246135473
evoked I-Disease 0 0.0003361634735483676
nystagmus I-Disease 0 0.023040005937218666
was O 0 1.7772566934581846e-05
often O 0 9.287342805919252e-08
present O 0 1.1756279860719587e-07
as O 0 2.0764733221767528e-07
was O 0 1.1061812074331101e-05
saccade O 0 3.4733384381979704e-05
hypometria O 0 1.0690522685763426e-05
and O 0 2.845921756033931e-07
smooth O 0 9.451097866985947e-06
pursuit O 0 3.189226845279336e-05
gain O 0 2.8839842343586497e-05
was O 0 0.0001218179240822792
markedly O 0 0.00011610584624577314
decreased O 0 0.00014520063996315002
. O 0 1.4081719200476073e-05

Three O 0 3.9335722249234095e-05
major O 0 3.4761415008688346e-05
criteria O 0 6.278371984080877e-06
, O 0 2.399475533820805e-06
saccade O 0 5.692392005585134e-05
amplitude O 0 1.7289317838731222e-05
, O 0 1.8886785255745053e-06
saccade O 0 3.6843601264990866e-05
velocity O 0 1.2296251043153461e-05
, O 0 3.890963284902682e-07
and O 0 1.8875805096740805e-07
presence O 0 1.6151445834111655e-06
of O 0 6.715957624692237e-06
gaze B-Disease 1 0.6142621040344238
- I-Disease 0 0.00043894071131944656
evoked I-Disease 0 5.645968849421479e-05
nystagmus I-Disease 0 1.578555747983046e-05
, O 0 8.096301939986006e-08
permitted O 0 7.269989055203041e-08
the O 0 1.9401727513468359e-07
correct O 0 2.9409972057692357e-07
assignment O 0 6.625601258747338e-07
of O 0 4.893741447631328e-07
90 O 0 3.8690612313985184e-07
% O 0 1.4113778945556987e-07
of O 0 5.664908258040668e-07
the O 0 1.3767482869297964e-06
SCA1 B-Disease 0 4.874014121014625e-05
, O 0 2.608423130823212e-07
90 O 0 3.043546996650548e-07
% O 0 1.2882841815553547e-07
of O 0 6.278985438257223e-07
the O 0 1.9803694613074185e-06
SCA2 B-Disease 0 0.00015084388724062592
, O 0 2.0767190278547787e-07
and O 0 1.0721724663653731e-07
93 O 0 2.761588575594942e-06
% O 0 2.0267245304239623e-07
of O 0 7.787413096593809e-07
the O 0 1.8247363868795219e-06
patients O 0 8.84686869540019e-07
with O 0 7.637665930815274e-07
SCA3 B-Disease 1 1.0
to O 0 1.1652371512127502e-07
their O 0 5.844442441116371e-08
genetically O 0 1.1507805766086676e-06
confirmed O 0 3.1870270049694227e-06
patient O 0 3.839372766378801e-06
group O 0 4.803684987564338e-07
and O 0 1.615374287666782e-07
, O 0 1.607736095365908e-07
therefore O 0 2.3732394538455992e-07
, O 0 2.134063805669939e-07
may O 0 5.863222440893878e-07
help O 0 1.7836283916494722e-07
orient O 0 6.0597696574404836e-05
diagnoses O 0 9.675241017248482e-05
of O 0 2.5467203158768825e-05
SCA1 B-Disease 1 0.9868962168693542
, O 0 3.6047497360414127e-06
SCA2 B-Disease 0 0.016734914854168892
, O 0 6.582472451555077e-07
and O 0 8.86036957581382e-07
SCA3 B-Disease 1 0.9999992847442627
at O 0 5.364351181924576e-06
early O 0 6.845380084996577e-07
clinical O 0 6.427589141821954e-06
stages O 0 1.5488733424717793e-06
of O 0 2.9898924367444124e-06
the O 0 3.284209378762171e-05
diseases O 1 0.9989608526229858
. O 0 5.4565434766118415e-06
. O 0 2.0418507119757123e-05

Genetic O 0 3.213099262211472e-05
basis O 0 5.10711970491684e-06
and O 0 1.7579658333488624e-06
molecular O 0 8.351888391189277e-05
mechanism O 0 6.017955456627533e-05
for O 0 9.794984362088144e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.001398472348228097

Ventricular B-Disease 1 0.9999998807907104
fibrillation I-Disease 1 0.9999700784683228
causes O 0 3.6081630241824314e-05
more O 0 2.5639849354774924e-07
than O 0 8.502235004925751e-08
300 O 0 2.400829828275164e-07
, O 0 7.32010718706988e-08
000 O 0 1.5633603425158071e-06
sudden O 0 2.346060909985681e-06
deaths O 0 3.384146793905529e-07
each O 0 3.800180081725557e-08
year O 0 3.608859628911887e-07
in O 0 2.2537797406130267e-07
the O 0 8.285587682621554e-07
USA O 0 1.2601176422322169e-05
alone O 0 3.957652552344371e-06
. O 0 1.0332424608350266e-05

In O 0 1.863569013949018e-05
approximately O 0 4.033554887428181e-06
5 O 0 4.97058726978139e-06
- O 0 2.588855068097473e-06
12 O 0 2.539886452268547e-07
% O 0 5.538337788379977e-08
of O 0 6.275351438489452e-08
these O 0 9.887378027428895e-09
cases O 0 2.5457007168938617e-08
, O 0 2.2386299036725177e-08
there O 0 2.6594888069553235e-08
are O 0 1.621031131548989e-08
no O 0 6.602830353585887e-07
demonstrable O 1 0.999695897102356
cardiac O 1 1.0
or O 0 2.5139108402072452e-05
non O 1 0.9690830707550049
- O 1 0.9998279809951782
cardiac O 1 0.9999998807907104
causes O 0 6.450405294344819e-07
to O 0 3.914892232614875e-08
account O 0 4.2839673142225365e-08
for O 0 3.361806122370581e-08
the O 0 1.5159994859459403e-07
episode O 0 5.963704552414129e-07
, O 0 5.634477773241997e-08
which O 0 5.378066347816457e-08
is O 0 1.132040310380944e-07
therefore O 0 1.8091505182837864e-07
classified O 0 2.8813908556912793e-06
as O 0 0.00012231938308104873
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.1050865650177002
IVF B-Disease 1 1.0
) O 0 2.224072886747308e-05
. O 0 1.1386725418560673e-05

A O 0 0.0001300403819186613
distinct O 0 6.21518847765401e-06
group O 0 2.901121888498892e-06
of O 0 1.196165248984471e-05
IVF B-Disease 1 1.0
patients O 0 4.449931111594196e-06
has O 0 3.128609193936427e-07
been O 0 1.2007511429601436e-07
found O 0 3.102965706602845e-08
to O 0 1.1458931581387333e-08
present O 0 8.276057172906803e-08
with O 0 9.143931833932584e-08
a O 0 6.2835533753968775e-06
characteristic O 0 0.00021692801965400577
electrocardiographic O 1 0.9627259969711304
pattern O 0 0.006552697625011206
. O 0 2.5979345082305372e-05

Because O 0 1.3678562936547678e-05
of O 0 3.2531011129321996e-06
the O 0 9.00797090253036e-07
small O 0 1.7250923178835365e-07
size O 0 9.405928835803934e-08
of O 0 4.4820126277045347e-07
most O 0 9.322074134843206e-08
pedigrees O 0 5.116471584187821e-07
and O 0 6.291758580800888e-08
the O 0 6.73817908136698e-07
high O 0 0.0005092968349345028
incidence O 0 0.20749251544475555
of O 0 2.88573373836698e-05
sudden B-Disease 1 0.9181905388832092
death I-Disease 0 0.0037346482276916504
, O 0 2.3462391141038097e-07
however O 0 1.0076087164634373e-07
, O 0 8.443071664032686e-08
molecular O 0 1.228378209816583e-06
genetic O 0 4.5500593159886193e-07
studies O 0 1.3381853705141111e-06
of O 0 3.091687403866672e-06
IVF B-Disease 1 0.9999419450759888
have O 0 3.4919875702144054e-07
not O 0 1.439917696188786e-07
yet O 0 4.729648139800702e-07
been O 0 1.796251353880507e-06
done O 0 3.0197202249837574e-06
. O 0 6.086229859647574e-06

Because O 0 0.0003960189351346344
IVF B-Disease 1 0.9999998807907104
causes O 1 0.89494389295578
cardiac O 1 1.0
rhythm O 1 0.532164990901947
disturbance O 0 0.0013430778635665774
, O 0 3.072459549002815e-07
we O 0 4.357027449941597e-08
investigated O 0 3.6507103118310624e-07
whether O 0 1.3186564729039674e-07
malfunction O 0 3.3141961466753855e-05
of O 0 5.124910558151896e-07
ion O 0 1.2414257071213797e-06
channels O 0 4.7503021960437763e-07
could O 0 5.346809643924644e-07
cause O 0 4.903434728475986e-06
the O 0 1.1776381825256976e-06
disorder O 0 0.00017263409972656518
by O 0 1.1352231155115078e-07
studying O 0 1.6612722220088472e-07
mutations O 0 1.833738139112029e-07
in O 0 2.7091203946838505e-07
the O 0 3.667687678898801e-06
cardiac O 1 0.996330201625824
sodium O 0 1.461604279029416e-05
channel O 0 2.4864391889423132e-05
gene O 0 6.235211913008243e-05
SCN5A O 0 0.12106554210186005
. O 0 3.506252323859371e-05

We O 0 9.433195373276249e-06
have O 0 1.1360499456714024e-06
now O 0 6.094443847359798e-07
identified O 0 9.981484936361085e-07
a O 0 1.2862957419201848e-06
missense O 0 7.712214028288145e-06
mutation O 0 2.7017565571441082e-06
, O 0 7.94844595475297e-07
a O 0 1.953590526682092e-06
splice O 0 2.8021897378494032e-05
- O 0 1.4689658200950362e-05
donor O 0 1.0053699952550232e-06
mutation O 0 9.780681011761772e-07
, O 0 1.6582204409587575e-07
and O 0 1.081963461047053e-07
a O 0 8.425180908488983e-07
frameshift O 0 9.021984624268953e-06
mutation O 0 4.549859795588418e-07
in O 0 2.111265899884529e-07
the O 0 4.165005691447732e-07
coding O 0 8.634887649350276e-07
region O 0 4.971043949808518e-07
of O 0 4.590940534399124e-06
SCN5A O 0 0.00040347405592910945
in O 0 2.198596803282271e-06
three O 0 3.820391157205449e-06
IVF B-Disease 1 0.9999735355377197
families O 0 3.4947968288179254e-06
. O 0 1.5601459381286986e-05

We O 0 6.337330432870658e-06
show O 0 1.361198087579396e-06
that O 0 1.8780998800593807e-07
sodium O 0 5.624308414553525e-07
channels O 0 1.8120651645858743e-07
with O 0 5.8317258577744724e-08
the O 0 2.4097482764773304e-07
missense O 0 4.604269634000957e-06
mutation O 0 8.291120821013465e-07
recover O 0 1.3143603609933052e-06
from O 0 6.242801759981376e-07
inactivation O 0 0.0005554293747991323
more O 0 2.6076218517800953e-08
rapidly O 0 1.4778875367937871e-07
than O 0 1.869528709619317e-08
normal O 0 9.042177850915323e-08
and O 0 1.7585524147989418e-08
that O 0 2.5395706870767754e-08
the O 0 3.041336071873957e-07
frameshift O 0 5.32012336407206e-06
mutation O 0 4.4364671225594066e-07
causes O 0 3.211556247606495e-07
the O 0 2.748939493812941e-07
sodium O 0 4.649670302114828e-07
channel O 0 6.024803269610857e-07
to O 0 1.280318144836201e-07
be O 0 1.0130427199328551e-06
non O 0 2.8194790502311662e-05
- O 0 5.341771975508891e-05
functional O 0 1.642945244384464e-05
. O 0 6.461971224780427e-06

Our O 0 1.8734372133621946e-05
results O 0 6.368380581989186e-06
indicate O 0 3.3146470741485246e-06
that O 0 2.5203036102539045e-07
mutations O 0 9.034762342707836e-07
in O 0 2.4813959953462472e-06
cardiac O 1 0.9998553991317749
ion O 0 1.408038951922208e-05
- O 0 2.8729205041599926e-06
channel O 0 2.873748599085957e-07
genes O 0 4.432567735079829e-08
contribute O 0 3.281807181565455e-08
to O 0 3.037961349150464e-08
the O 0 3.9441528087991173e-07
risk O 0 7.064710416671005e-07
of O 0 2.0840529941779096e-06
developing O 0 1.3953560483059846e-05
IVF B-Disease 1 0.9999691247940063
. O 0 1.9427811821515206e-06
. O 0 4.647445621230872e-06

Molecular O 0 0.000740218092687428
heterogeneity O 0 0.00021889850904699415
in O 0 1.9380549929337576e-05
mucopolysaccharidosis B-Disease 0 0.0007784839253872633
IVA I-Disease 0 0.027329105883836746
in O 0 2.4819260033837054e-06
Australia O 0 5.189585863263346e-07
and O 0 1.0746170886477557e-07
Northern O 0 4.415535670432291e-07
Ireland O 0 1.964634748219396e-07
: O 0 5.198531738415113e-08
nine O 0 1.041874497786921e-07
novel O 0 2.3342498423062352e-07
mutations O 0 1.701982625945675e-07
including O 0 3.923698841390433e-07
T312S O 0 5.686386066372506e-05
, O 0 1.696501925607663e-07
a O 0 3.485954778170708e-07
common O 0 1.9389555916404788e-07
allele O 0 7.652159297322214e-07
that O 0 1.924784100992838e-07
confers O 0 1.5163425814535003e-05
a O 0 5.266839434625581e-05
mild O 1 0.9114263653755188
phenotype O 1 0.6067802309989929
. O 0 4.628249371307902e-05

Mucopolysaccharidosis B-Disease 1 0.9895277619361877
IVA I-Disease 1 0.9999562501907349
( O 0 0.0013831621035933495
MPS B-Disease 1 0.9999868869781494
IVA I-Disease 1 1.0
) O 0 5.7364591157238465e-06
is O 0 1.0055790653495933e-06
an O 0 3.0864493965054862e-06
autosomal B-Disease 1 0.985722541809082
recessive I-Disease 1 0.9999997615814209
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999852180480957
by O 0 2.127295192622114e-05
a O 0 0.14352548122406006
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999998807907104
in O 0 0.0004417703894432634
N O 0 0.031645070761442184
- O 0 0.0706292986869812
acetylgalactosamine O 1 0.8788735270500183
- O 0 0.000509080826304853
6 O 0 0.00029906415147706866
- O 0 0.0022801668383181095
sulfate O 0 0.0007291571237146854
sulfatase O 0 0.2460756003856659
( O 0 1.59994960995391e-05
GALNS O 0 0.12462704628705978
) O 0 7.156394985941006e-06
. O 0 1.1375611393305007e-05

Previous O 0 4.429724140209146e-05
studies O 0 1.652874198043719e-05
of O 0 7.404384632536676e-06
patients O 0 4.779903974849731e-06
from O 0 2.325119112356333e-06
a O 0 8.386498848267365e-06
British O 0 0.00029641290893778205
- O 0 1.6449866961920634e-05
Irish O 0 1.019042315419938e-06
population O 0 4.7099735667188725e-08
showed O 0 3.5815128285321407e-07
that O 0 5.008522308003194e-08
the O 0 3.010970317518513e-07
I113F O 0 1.3300907085067593e-05
mutation O 0 4.927619556838181e-07
is O 0 1.0020984575476177e-07
the O 0 6.472021141235018e-08
most O 0 1.6982493633577178e-08
common O 0 5.535528657674149e-08
single O 0 1.9745637303003605e-07
mutation O 0 7.221823921099713e-07
among O 0 2.249080580440932e-06
MPS B-Disease 1 0.999997615814209
IVA I-Disease 1 1.0
patients O 0 6.8224012466089334e-06
and O 0 4.636377468614228e-07
produces O 0 1.3982221389596816e-06
a O 0 4.1215149394702166e-05
severe O 1 0.9999767541885376
clinical O 1 0.9999428987503052
phenotype O 1 0.8956699371337891
. O 0 2.472085543558933e-05

We O 0 5.552772108785575e-06
studied O 0 1.7396425391780213e-05
mutations O 0 4.45663272330421e-06
in O 0 2.7067828796134563e-06
the O 0 3.566533223420265e-06
GALNS O 0 0.00010178500815527514
gene O 0 9.091479000744584e-07
from O 0 9.752041023602942e-07
23 O 0 3.89741671824595e-06
additional O 0 2.669363766472088e-06
MPS B-Disease 1 0.890148937702179
IVA I-Disease 1 0.9999994039535522
patients O 0 6.9718112172267865e-06
( O 0 4.860133344664064e-07
15 O 0 1.0741104006228852e-06
from O 0 3.262093457578885e-07
Australia O 0 1.743716921964733e-07
, O 0 5.722509044403523e-08
8 O 0 2.0166523029274686e-07
from O 0 1.0277877748876563e-07
Northern O 0 1.1561262169834663e-07
Ireland O 0 4.7754387111353935e-08
) O 0 2.161843681847131e-08
, O 0 8.720538957618373e-09
with O 0 4.903811134937541e-09
various O 0 8.209695323557753e-08
clinical O 0 0.03598085418343544
phenotypes O 0 0.0002043529093498364
( O 0 5.885109203518368e-06
severe O 1 0.9694682359695435
, O 0 7.878186352172634e-07
16 O 0 6.783880621696881e-07
cases O 0 1.1065191785064599e-07
; O 0 7.115151134939879e-08
intermediate O 0 1.326682991020789e-06
, O 0 8.735009515703496e-08
4 O 0 7.710646059422288e-07
cases O 0 3.4209472232760163e-07
; O 0 5.09182200403302e-07
mild O 0 6.1034050304442644e-05
, O 0 9.21794025998679e-07
3 O 0 2.342367452001781e-06
cases O 0 1.3755199006482144e-06
) O 0 3.835625648207497e-06
. O 0 1.0966941772494465e-05

We O 0 8.768527550273575e-06
found O 0 1.6009732917154906e-06
two O 0 2.0422170621259284e-07
common O 0 1.5298928701668046e-07
mutations O 0 2.6724816848400224e-07
that O 0 8.476100532561759e-08
together O 0 4.820370946845287e-08
accounted O 0 7.694985129091947e-07
for O 0 1.1791942000627387e-07
32 O 0 8.119272365547658e-07
% O 0 1.1538394772969696e-07
of O 0 3.2146263606591674e-07
the O 0 6.349577574837895e-07
44 O 0 2.4850050976965576e-06
unrelated O 0 8.977766015050292e-07
alleles O 0 8.148011829689494e-07
in O 0 6.271241090871627e-07
these O 0 4.893424261354085e-07
patients O 0 8.118172445392702e-06
. O 0 9.724098163133021e-06

One O 0 3.169512638123706e-05
is O 0 3.4014710763585754e-06
the O 0 2.8635572562052403e-06
T312S O 0 8.352048462256789e-05
mutation O 0 1.7716168940751231e-06
, O 0 2.265118155264645e-07
a O 0 6.751023988726956e-07
novel O 0 1.159706812359218e-06
mutation O 0 7.411425144709938e-07
found O 0 3.3289870771113783e-07
exclusively O 0 4.813370537704031e-07
in O 0 1.500595431025431e-06
milder O 0 9.250365837942809e-05
patients O 0 2.609756847959943e-05
. O 0 2.09844765777234e-05

The O 0 9.663740456744563e-06
other O 0 6.166700927678903e-07
is O 0 2.9085913411108777e-07
the O 0 2.721321834542323e-07
previously O 0 1.7774486877897289e-06
described O 0 3.7713082292611944e-06
I113F O 0 3.931625542463735e-05
that O 0 3.539284421094635e-07
produces O 0 2.0355430478957715e-06
a O 0 4.8753667215351015e-05
severe O 1 0.9999524354934692
phenotype O 1 0.9961473941802979
. O 0 5.6211920309579e-05

The O 0 0.00010268297046422958
I113F O 0 0.0002730236737988889
and O 0 4.446053935680538e-06
T312S O 0 5.7566940085962415e-05
mutations O 0 3.1603410661773523e-06
accounted O 0 4.482782969716936e-06
for O 0 6.050235583643371e-07
8 O 0 2.955848231067648e-06
( O 0 2.391624889241939e-07
18 O 0 4.6381467200262705e-07
% O 0 1.2169508067927381e-07
) O 0 6.845028366342376e-08
and O 0 9.196649131126833e-08
6 O 0 1.4545701105816988e-06
( O 0 2.0043792403612315e-07
14 O 0 5.953550044068834e-07
% O 0 1.3326489067821967e-07
) O 0 4.0280546897975e-08
of O 0 4.513307487741258e-07
44 O 0 2.2483236534753814e-06
unrelated O 0 1.963538579730084e-06
alleles O 0 2.3873506052041193e-06
, O 0 2.3120821879274445e-06
respectively O 0 1.890874955279287e-05
. O 0 9.465727998758666e-06

The O 0 7.217597885755822e-05
relatively O 0 3.2859257771633565e-05
high O 0 6.307370495051146e-05
residual O 0 0.00017285713693127036
GALNS O 0 0.012231281027197838
activity O 0 1.363440060231369e-05
seen O 0 3.0086105198279256e-06
when O 0 3.263126302499586e-07
the O 0 4.6196498715289636e-07
T312S O 0 1.171560688817408e-05
mutant O 0 3.324283397887484e-06
cDNA O 0 1.0037068932433613e-05
is O 0 4.49272846481108e-07
overexpressed O 0 5.991243142489111e-06
in O 0 1.765213681892419e-07
mutant O 0 1.7808625898396713e-06
cells O 0 9.271994372284098e-07
provides O 0 1.0648113857314456e-07
an O 0 1.3692230993456178e-07
explanation O 0 2.661298310613347e-07
for O 0 9.672738343624587e-08
the O 0 1.1653733054117765e-06
mild O 0 0.2492559403181076
phenotype O 0 0.016386354342103004
in O 0 8.007822884792404e-07
patients O 0 3.694599683967681e-07
with O 0 9.457378524757587e-08
this O 0 9.580700179867563e-07
mutation O 0 2.2250169422477484e-05
. O 0 1.3770116311206948e-05

The O 0 8.391059054702055e-06
distribution O 0 1.8384482700639637e-06
and O 0 3.7443624023580924e-07
relative O 0 9.120519166572194e-07
frequencies O 0 1.2141446177338366e-06
of O 0 1.4347160686156712e-06
the O 0 2.0233867417118745e-06
I113F O 0 3.106702206423506e-05
and O 0 4.982520067642326e-07
T312S O 0 3.2040607038652524e-05
mutations O 0 4.254445684637176e-07
in O 0 3.2137805305865186e-07
Australia O 0 1.582587003667868e-07
corresponded O 0 2.0848470683176856e-07
to O 0 2.594306813819003e-08
those O 0 2.2857848946955528e-08
observed O 0 1.6361656207664055e-07
in O 0 7.640610277803717e-08
Northern O 0 8.943398199789954e-08
Ireland O 0 4.5190095221414595e-08
and O 0 2.031964640991646e-08
are O 0 4.615015480879947e-09
unique O 0 9.014811119811839e-09
to O 0 7.991921791017376e-09
these O 0 4.853220048062212e-09
two O 0 1.962888696027676e-08
populations O 0 7.158943304830245e-08
, O 0 7.053037620607938e-08
suggesting O 0 1.9426869357630494e-07
that O 0 1.669275739857312e-08
both O 0 2.2024776669127277e-08
mutations O 0 1.124604906976856e-07
were O 0 3.0354249247466214e-07
probably O 0 4.067669863161427e-07
introduced O 0 1.1411933087401849e-07
to O 0 3.619633659468491e-08
Australia O 0 1.6093713384179864e-07
by O 0 1.0913024794945159e-07
Irish O 0 4.6428377231677587e-07
migrants O 0 2.779327985535929e-07
during O 0 5.017204216528626e-07
the O 0 8.421839083894156e-07
19th O 0 1.3327710803423543e-05
century O 0 1.898284608614631e-05
. O 0 8.926856935431715e-06

Haplotype O 0 0.0012201395584270358
analysis O 0 2.054613651125692e-05
using O 0 5.441162102215458e-06
6 O 0 1.5888032066868618e-05
RFLPs O 0 4.539206565823406e-05
provides O 0 5.29727856246609e-07
additional O 0 3.507811641156877e-07
data O 0 7.637789281034202e-07
that O 0 1.6408706926540617e-07
the O 0 1.0771817642307724e-06
I113F O 0 3.7846861232537776e-05
mutation O 0 7.497358183172764e-07
originated O 0 1.6238213902397547e-06
from O 0 1.1268007256148849e-06
a O 0 2.6160016659559915e-06
common O 0 2.6243048978358274e-06
ancestor O 0 6.408162880688906e-05
. O 0 1.489519218011992e-05

The O 0 2.722834688029252e-05
other O 0 9.580143114362727e-07
9 O 0 5.625866378977662e-06
novel O 0 1.4777410797250923e-06
mutations O 0 5.779812681794283e-07
identified O 0 3.042525520413619e-07
in O 0 1.0637232605859026e-07
these O 0 5.86193671381352e-08
23 O 0 1.7124053783845739e-06
patients O 0 9.341813722585357e-08
were O 0 1.0209338086042408e-07
each O 0 1.0116619542088756e-08
limited O 0 1.0430993313548242e-07
to O 0 7.705487092835028e-08
a O 0 1.885717892946559e-06
single O 0 4.648531103157438e-06
family O 0 6.912378921697382e-06
. O 0 1.3679828953172546e-05

These O 0 5.583150141319493e-06
data O 0 3.0882335977366893e-06
provide O 0 7.851237455724913e-07
further O 0 4.790848038283002e-07
evidence O 0 5.441434609565476e-07
for O 0 1.6066017849425407e-07
extensive O 0 1.8534132095737732e-06
allelic O 0 1.2773091839335393e-05
heterogeneity O 0 2.36727501032874e-05
in O 0 9.978867637983058e-06
MPS B-Disease 1 0.9579581618309021
IVA I-Disease 1 0.9999974966049194
in O 0 5.475074431160465e-06
British O 0 0.00025096797617152333
- O 0 4.2085401219082996e-05
Irish O 0 1.8780616528601968e-06
patients O 0 1.345266156249636e-07
and O 0 3.4711554519617493e-08
provide O 0 3.119641078797031e-08
evidence O 0 1.9122911965041567e-07
for O 0 6.474293456903979e-08
their O 0 6.280763642507736e-08
transmission O 0 9.501093813923944e-07
to O 0 9.308907777949571e-08
Australia O 0 4.1037938558474707e-07
by O 0 4.391572758777329e-07
British O 0 8.306994459417183e-06
- O 0 3.864860900648637e-06
Irish O 0 1.4058073247724678e-06
migrants O 0 5.945748284830188e-07
. O 0 2.796015508010896e-07
. O 0 3.1129802664509043e-06

Identification O 0 3.712020406965166e-05
of O 0 9.733496881381143e-06
constitutional O 0 7.358046423178166e-05
WT1 O 1 0.5013378262519836
mutations O 0 8.406300366914365e-06
, O 0 6.584544394172553e-07
in O 0 6.157263214845443e-07
patients O 0 7.011523734945513e-07
with O 0 3.314440277790709e-07
isolated O 1 0.8082278370857239
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.276425448144437e-06
and O 0 2.88051211327911e-07
analysis O 0 4.451886184142495e-07
of O 0 1.6174412849068176e-06
genotype O 0 5.721459092455916e-05
/ O 0 3.486233617877588e-05
phenotype O 0 6.298437710938742e-06
correlations O 0 2.636737917782739e-06
by O 0 1.267706579710648e-07
use O 0 3.996860797883528e-08
of O 0 2.9037414606136736e-07
a O 0 2.045081373580615e-06
computerized O 0 1.903657721413765e-05
mutation O 0 1.1370037100277841e-05
database O 0 7.314702997973654e-06
. O 0 8.123376574076246e-06

Constitutional O 0 0.00012445918400771916
mutations O 0 2.6207104383502156e-05
of O 0 1.5470810467377305e-05
the O 0 6.69320797896944e-06
WT1 O 0 0.0002012828190345317
gene O 0 1.5080785260579432e-06
, O 0 4.1061935007746797e-07
encoding O 0 8.529568731319159e-07
a O 0 2.3639702703803778e-05
zinc O 1 0.9971803426742554
- O 0 0.027133183553814888
finger O 0 0.005399765912443399
transcription O 0 3.518585435813293e-05
factor O 0 1.9238568711443804e-06
involved O 0 4.2021616764031933e-07
in O 0 4.817365606868407e-06
renal O 1 0.9999997615814209
and O 0 4.891631760983728e-06
gonadal O 1 0.9999969005584717
development O 0 6.341774223983521e-06
, O 0 2.3298595408505207e-07
are O 0 2.628314099695217e-08
found O 0 7.004587132541928e-08
in O 0 1.64744832886754e-07
most O 0 1.8510679922201234e-07
patients O 0 3.559125616448e-07
with O 0 5.982890911582217e-07
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.018808957189321518
DDS B-Disease 1 1.0
) O 0 2.6523844098846894e-06
, O 0 1.3067326563032111e-06
or O 0 6.599118933081627e-06
diffuse B-Disease 1 0.9999691247940063
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 1 0.9189335703849792
DMS B-Disease 1 1.0
) O 0 2.3008333300822414e-06
associated O 0 2.5351969270559493e-06
with O 0 1.6123806290124776e-06
pseudohermaphroditism B-Disease 1 0.9999998807907104
and O 0 3.087822551606223e-05
/ O 0 0.3467685580253601
or O 0 0.0033384740818291903
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 0 0.0002391437883488834
WT B-Disease 1 0.9999998807907104
) O 0 8.244079253927339e-06
. O 0 1.1569986781978514e-05

Most O 0 1.4999435734353028e-05
mutations O 0 4.597211227519438e-05
in O 0 4.543516115518287e-05
DDS B-Disease 1 1.0
patients O 0 3.511036993586458e-05
lie O 0 1.2734668416669592e-05
in O 0 1.9667602373374393e-06
exon O 0 6.056318397895666e-06
8 O 0 2.7577830223890487e-06
or O 0 6.582026799151208e-07
exon O 0 4.964802883478114e-06
9 O 0 3.667379814942251e-06
, O 0 4.6041816403885605e-07
encoding O 0 1.2535114137790515e-06
zinc O 0 0.0001319478324148804
finger O 0 0.00011566517787287012
2 O 0 7.758038918836974e-06
or O 0 4.2716978896351065e-06
zinc O 0 0.3708781599998474
finger O 0 0.0019339609425514936
3 O 0 5.130816589371534e-06
, O 0 3.203239202775876e-07
respectively O 0 5.098031579109374e-07
, O 0 4.5541398208115424e-08
with O 0 2.8290029874256106e-08
a O 0 2.056369794445345e-06
hot O 0 3.5033372114412487e-05
spot O 0 2.130765096808318e-05
( O 0 1.3320051266418886e-06
R394W O 0 1.824437640607357e-05
) O 0 2.5350854571115633e-07
in O 0 7.245672009048576e-07
exon O 0 8.741533747524954e-06
9 O 0 1.6331196093233302e-05
. O 0 1.4117500541033223e-05

We O 0 7.936349902593065e-06
analyzed O 0 8.223428267228883e-06
a O 0 2.7379169296182226e-06
series O 0 1.4562231172021711e-06
of O 0 2.75094294011069e-06
24 O 0 1.3151304301572964e-05
patients O 0 9.006940331346414e-07
, O 0 1.5670876507556386e-07
10 O 0 2.561895087183075e-07
with O 0 3.131313803805824e-07
isolated B-Disease 0 7.235873636091128e-05
DMS I-Disease 1 0.9998852014541626
( O 0 3.4926442822325043e-06
IDMS B-Disease 0 0.0014697863953188062
) O 0 3.4185990216428763e-07
, O 0 1.7974285526634048e-07
10 O 0 2.571233039816434e-07
with O 0 4.501056878325471e-07
DDS B-Disease 1 1.0
, O 0 8.99840642887284e-07
and O 0 3.352554074353975e-07
4 O 0 3.103642711721477e-06
with O 0 9.058012437890284e-07
urogenital B-Disease 1 0.9999998807907104
abnormalities I-Disease 1 0.9999998807907104
and O 0 0.2221965193748474
/ O 1 0.9999939203262329
or O 1 0.6350565552711487
WT B-Disease 1 1.0
. O 0 0.00011247343354625627

We O 0 8.965376764535904e-05
report O 0 5.478227467392571e-05
WT1 O 0 0.0004403169732540846
heterozygous O 0 4.828763394471025e-06
mutations O 0 1.5540846334261005e-06
in O 0 9.760162811289774e-07
16 O 0 4.799335329153109e-06
patients O 0 5.376414264901541e-07
, O 0 2.898183311117464e-07
4 O 0 1.3428824559014174e-06
of O 0 1.304329771301127e-06
whom O 0 8.332180527759192e-07
presented O 0 4.088565219717566e-06
with O 0 6.823396233812673e-06
IDMS B-Disease 1 0.9962937235832214
. O 0 3.9034832298057154e-05

One O 0 5.761384090874344e-05
male O 0 3.0303017410915345e-05
and O 0 3.1391136872116476e-06
two O 0 2.736256647040136e-06
female O 0 0.001254142727702856
IDMS B-Disease 1 0.9999982118606567
patients O 0 1.5640311175957322e-05
with O 0 8.249293387052603e-06
WT1 O 1 0.999995231628418
mutations O 0 0.17830492556095123
underwent O 1 0.9999984502792358
normal O 1 0.616516649723053
puberty O 1 0.9431673884391785
. O 0 2.9484490369213745e-05

Two O 0 1.9584256733651273e-05
mutations O 0 7.840849866624922e-05
associated O 0 1.7719394236337394e-05
with O 0 1.6301612504321383e-06
IDMS B-Disease 1 0.8080859780311584
are O 0 9.36275625917915e-08
different O 0 1.700002627558206e-08
from O 0 2.589329142210772e-07
those O 0 8.77958967748782e-08
described O 0 3.3851097214210313e-06
in O 0 3.7388108466984704e-05
DDS B-Disease 1 1.0
patients O 0 0.00011731088306987658
. O 0 2.739140654739458e-05

No O 0 0.00010085623944178224
WT1 O 0 0.0010405583307147026
mutations O 0 8.239253475039732e-06
were O 0 1.427114966645604e-06
detected O 0 3.455283604125725e-06
in O 0 2.8659567874456116e-07
the O 0 3.269025796726055e-07
six O 0 5.525391202354513e-07
other O 0 5.138937240189989e-07
IDMS B-Disease 1 0.9999125003814697
patients O 0 2.161756810892257e-06
, O 0 2.0585740401202202e-07
suggesting O 0 1.6115380958581227e-06
genetic O 0 1.2929949662066065e-06
heterogeneity O 0 2.323941225768067e-05
of O 0 3.45217740687076e-05
this O 0 2.3419310309691355e-05
disease O 1 0.9999076128005981
. O 0 4.411134432302788e-05

We O 0 2.058836616924964e-05
analyzed O 0 4.303944660932757e-05
genotype O 0 0.00021657625620719045
/ O 0 7.929138519102708e-05
phenotype O 0 2.831909660017118e-05
correlations O 0 1.2682409760600422e-05
, O 0 3.480215013951238e-07
on O 0 2.0408366196988936e-07
the O 0 6.920565454038297e-08
basis O 0 1.0981805331766736e-07
of O 0 2.9896048658883956e-07
the O 0 2.1423099383355293e-07
constitution O 0 1.3057518799541867e-07
of O 0 6.05411969445413e-07
a O 0 1.8229102352051996e-06
WT1 O 0 3.7702007830375805e-05
mutation O 0 5.275131798043731e-07
database O 0 3.0048914823055384e-07
of O 0 6.580174840564723e-07
84 O 0 0.00011597373668337241
germ O 1 0.9999020099639893
- O 0 0.0023352690041065216
line O 0 8.231949323089793e-06
mutations O 0 2.5793156055442523e-07
, O 0 7.092036469202867e-08
to O 0 1.9631883674264827e-08
compare O 0 2.8361290205225487e-08
the O 0 9.718619509158088e-08
distribution O 0 1.0229727109845044e-07
and O 0 5.130084090865239e-08
type O 0 3.974503499648563e-07
of O 0 7.407298312500643e-07
mutations O 0 7.271041795320343e-07
, O 0 1.4940624737391772e-07
according O 0 6.46946674009996e-08
to O 0 4.22016555035043e-08
the O 0 1.5338256389441085e-06
different O 0 9.307396453550609e-07
symptoms O 0 0.007114553824067116
. O 0 4.1580988181522116e-05

This O 0 2.0550054614432156e-05
demonstrated O 0 2.536354077165015e-05
( O 0 2.00917452275462e-06
1 O 0 2.4961352664831793e-06
) O 0 3.8562347981496714e-07
the O 0 3.9011251828924287e-07
association O 0 2.2105946584360936e-07
between O 0 7.48876942679999e-08
mutations O 0 3.14900034936727e-07
in O 0 3.8842526350890694e-07
exons O 0 2.4059922907326836e-06
8 O 0 1.8962315380122163e-06
and O 0 6.701120014440676e-07
9 O 0 1.2202261132188141e-05
and O 0 4.106763753952691e-06
DMS B-Disease 1 0.996928870677948
; O 0 1.9720947364021413e-07
( O 0 1.6805759628368833e-07
2 O 0 4.031791149827768e-07
) O 0 5.6769582812421504e-08
among O 0 9.408817902567534e-08
patients O 0 2.756300432338321e-07
with O 0 3.579286556032457e-07
DMS B-Disease 1 0.9999849796295166
, O 0 2.818788971126196e-07
a O 0 5.231665340943437e-07
higher O 0 3.8466885143861873e-07
frequency O 0 1.4726846586654574e-07
of O 0 2.4058951453298505e-07
exon O 0 6.60066461932729e-07
8 O 0 3.513687829581613e-07
mutations O 0 1.2745313426876237e-07
among O 0 1.7082528813716635e-07
46 O 0 3.1309184578276472e-06
, O 0 2.1161008589842822e-06
XY O 1 0.9976595640182495
patients O 0 1.7896818462759256e-06
with O 0 2.4240247853413166e-07
female O 0 4.458628609427251e-05
phenotype O 0 0.0001072004233719781
than O 0 1.9131194051169587e-07
among O 0 1.395686552996267e-07
46 O 0 1.9384208371775458e-06
, O 0 6.281087507886696e-07
XY O 1 0.9673316478729248
patients O 0 4.849785000260454e-07
with O 0 9.070316053794159e-08
sexual O 0 3.2406039736088132e-06
ambiguity O 0 3.0289495043689385e-05
or O 0 8.39622225612402e-06
male O 0 1.4933210877643432e-05
phenotype O 0 3.7154550227569416e-05
; O 0 1.4064117692669242e-07
and O 0 1.8151023084556073e-07
( O 0 1.7385958983595629e-07
3 O 0 2.3624454570381204e-07
) O 0 2.355026218481271e-08
statistically O 0 5.294495508678665e-08
significant O 0 2.3952262395710022e-08
evidence O 0 5.0848438348793934e-08
that O 0 2.0889780572019845e-08
mutations O 0 7.952223768370459e-08
in O 0 2.6032344635495974e-07
exons O 0 1.0638170806487324e-06
8 O 0 1.0920912245637737e-06
and O 0 2.708004558371613e-07
9 O 0 3.027138973266119e-06
preferentially O 0 8.798883186500461e-07
affect O 0 1.2386276466713753e-06
amino O 0 1.4736175444340915e-06
acids O 0 2.0114202925469726e-07
with O 0 1.8902714060686776e-08
different O 0 2.671527710162991e-08
functions O 0 5.36020195340825e-07
. O 0 1.2076926623194595e-06
. O 0 4.861250090471003e-06

The O 0 7.209864998003468e-05
185delAG O 0 0.0003602186043281108
BRCA1 O 0 9.468049393035471e-05
mutation O 0 6.137650871096412e-06
originated O 0 4.0775762499833945e-06
before O 0 4.802682269655634e-07
the O 0 3.0773333037359407e-07
dispersion O 0 3.129736342089018e-06
of O 0 3.8985029959803796e-07
Jews O 0 4.1259576732954883e-07
in O 0 1.3367933604513382e-07
the O 0 1.5128840402667265e-07
diaspora O 0 6.116762847341306e-07
and O 0 1.297182876669467e-07
is O 0 1.609831912219306e-07
not O 0 8.461143607974009e-08
limited O 0 6.328853032755433e-07
to O 0 1.4788280395805486e-06
Ashkenazim O 0 0.000143476267112419
. O 0 1.8728067516349256e-05

The O 0 2.7422065613791347e-05
185delAG O 0 0.00010158119403058663
mutation O 0 6.248977115319576e-06
in O 0 1.440864366486494e-06
BRCA1 O 0 1.9325276298332028e-05
is O 0 3.944070101624675e-07
detected O 0 1.1850784176203888e-06
in O 0 2.855352647657128e-07
Ashkenazi O 0 2.221506974819931e-06
Jews O 0 2.2235745689158648e-07
both O 0 4.219336346977798e-08
in O 0 5.066286234978179e-07
familial B-Disease 1 0.9994837045669556
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.00028031866531819105
in O 0 1.1310706213407684e-05
the O 0 8.877235813997686e-06
general O 0 8.467998668493237e-06
population O 0 3.931908850063337e-06
. O 0 1.0578074579825625e-05

All O 0 1.4374674719874747e-05
tested O 0 1.678393891779706e-05
Ashkenazi O 0 4.243112198309973e-05
mutation O 0 5.227144356467761e-06
carriers O 0 6.828805680925143e-07
share O 0 1.26080408335838e-07
the O 0 1.5162481759034563e-07
same O 0 1.4115124713498517e-07
allelic O 0 2.0082741229998646e-06
pattern O 0 2.438168166918331e-06
at O 0 4.378631729196059e-06
the O 0 2.7259657144895755e-06
BRCA1 O 0 0.00019081933714915067
locus O 0 0.000934322364628315
. O 0 3.1339088309323415e-05

Our O 0 2.1775920686195605e-05
previous O 0 6.638822924287524e-06
study O 0 2.9565276236098725e-06
showed O 0 5.37499772690353e-06
that O 0 1.4706495221616933e-07
this O 0 2.1680033057691617e-07
Ashkenazi O 0 1.547386455058586e-05
mutation O 0 9.779701031220611e-07
also O 0 2.492264741249528e-07
occurs O 0 1.1864179327858437e-07
in O 0 1.2057772380558163e-07
Iraqi O 0 1.267606535293453e-06
Jews O 0 1.6737239150188543e-07
with O 0 3.795905811898592e-08
a O 0 3.663335519377142e-07
similar O 0 3.418348057948606e-07
allelic O 0 2.716019116633106e-05
pattern O 0 0.00017669207591097802
. O 0 1.9736648027901538e-05

We O 0 9.307803338742815e-06
extended O 0 6.526181095978245e-06
our O 0 2.1320590803952655e-06
analysis O 0 1.3205495861257077e-06
to O 0 4.300069917917426e-07
other O 0 4.596587075411662e-07
non O 0 1.49424276969512e-05
- O 0 2.4778088118182495e-05
Ashkenazi O 0 1.184930806630291e-05
subsets O 0 2.4973828658403363e-06
354 O 0 5.9566955314949155e-06
of O 0 8.658785191073548e-07
Moroccan O 0 3.918225775123574e-05
origin O 0 3.2614713063594536e-07
, O 0 1.8853641847726976e-07
200 O 0 5.277114496493596e-07
Yemenites O 0 3.040413048438495e-06
and O 0 4.2937182342939195e-07
150 O 0 2.424233798592468e-06
Iranian O 0 1.286103724851273e-05
Jews O 0 1.5651950889150612e-05
. O 0 1.8850343622034416e-05

Heteroduplex O 0 0.003044926794245839
analysis O 0 3.1739014957565814e-05
complemented O 0 1.9287677787360735e-05
by O 0 5.597895551545662e-07
direct O 0 8.525144608029223e-07
DNA O 0 4.0002419154916424e-06
sequencing O 0 4.2379374463052955e-06
of O 0 3.993282462033676e-06
abnormally O 0 9.710909944260493e-05
migrating O 0 1.5079461945788353e-06
bands O 0 9.524409279038082e-07
were O 0 1.1276016493866337e-06
employed O 0 1.2525289093900938e-05
. O 0 9.073757610167377e-06

Four O 0 3.145262235193513e-05
of O 0 1.5898003766778857e-05
Moroccan O 0 0.0001909097918542102
origin O 0 1.3517467323254095e-06
( O 0 6.3181914811139e-07
1 O 0 5.256936788100575e-07
. O 0 5.1000736078776754e-08
1 O 0 2.0465530781166308e-07
% O 0 1.2912363445138908e-07
) O 0 5.189308538433579e-08
and O 0 6.275949715472962e-08
none O 0 1.921632986068289e-07
of O 0 7.045601932986756e-07
the O 0 1.3057472187938401e-06
Yemenites O 0 4.337577138358029e-06
or O 0 1.9374066084765218e-07
Iranians O 0 1.8190339687862433e-06
was O 0 3.0471765057882294e-06
a O 0 6.725448429278913e-07
carrier O 0 7.275994562405685e-07
of O 0 8.320976121467538e-07
the O 0 3.941936938645085e-06
185delAG O 0 0.00010233555804006755
mutation O 0 4.773296677740291e-05
. O 0 2.07279827009188e-05

BRCA1 O 0 0.00042045951704494655
allelic O 0 0.00017067980661522597
patterns O 0 2.2835572963231243e-05
were O 0 1.9966707895946456e-06
determined O 0 3.5440129408925714e-07
for O 0 7.057963102852227e-08
four O 0 5.5496315098935156e-08
of O 0 9.057056615802139e-08
these O 0 1.6878448860779827e-08
individuals O 0 1.1141386480062465e-08
and O 0 5.3364988872317554e-08
for O 0 9.222348040793804e-08
12 O 0 7.755232900308329e-07
additional O 0 4.407289679875248e-07
non O 0 3.550193287082948e-05
- O 0 7.529636786784977e-05
Ashkenazi O 0 1.2698432328761555e-05
185delAG O 0 3.3260687359870644e-06
mutation O 0 5.617137048830045e-07
carriers O 0 4.4860496473120293e-07
who O 0 7.643801041012921e-07
had O 0 0.00012309160956647247
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0037214544136077166

Six O 0 0.00024876411771401763
non O 0 0.001394269522279501
- O 0 0.0015037015546113253
Ashkenazi O 0 9.732714534038678e-05
individuals O 0 2.0632163000300352e-07
shared O 0 6.506361955871398e-07
the O 0 1.2236439488333417e-06
common O 0 1.6010022818591096e-06
Ashkenazi O 0 0.00032704195473343134
haplotype O 0 2.5098959667957388e-05
, O 0 2.89580185608429e-07
four O 0 8.162525944044319e-08
had O 0 4.7131189262472617e-07
a O 0 4.961088961863425e-07
closely O 0 1.9657180416743358e-07
related O 0 6.906428779984708e-07
pattern O 0 1.543600228615105e-05
, O 0 3.295963040272909e-07
and O 0 1.1037558067528153e-07
the O 0 4.630907142200158e-07
rest O 0 3.4198478715552483e-07
( O 0 1.8753077313249378e-07
n O 0 1.468121809011791e-06
= O 0 9.856385077000596e-07
6 O 0 9.513914847048e-07
) O 0 1.029372995731137e-07
displayed O 0 3.7627546589646954e-07
a O 0 5.142820214132371e-07
distinct O 0 2.2446677405696391e-07
BRCA1 O 0 3.0095749025349505e-05
allelic O 0 6.253069295780733e-05
pattern O 0 0.00015455322863999754
. O 0 1.9084929590462707e-05

We O 0 8.339856321981642e-06
conclude O 0 1.711561890260782e-05
that O 0 1.2115582421756699e-06
the O 0 2.3291761408472667e-06
185delAG O 0 4.1918730858014897e-05
BRCA1 O 0 4.7673278459114954e-05
mutation O 0 3.923911208403297e-06
occurs O 0 8.62323474848381e-07
in O 0 4.7294093974414864e-07
some O 0 1.8371217436197185e-07
non O 0 1.0168164408241864e-05
- O 0 1.1069789252360351e-05
Ashkenazi O 0 2.438856654407573e-06
populations O 0 4.977836809416658e-08
at O 0 3.8451958062069025e-07
rates O 0 1.7698256726816908e-07
comparable O 0 1.4817754845353193e-07
with O 0 4.413097798305898e-08
that O 0 1.762747530165143e-07
of O 0 5.939280981692718e-06
Ashkenazim O 0 0.00014297246525529772
. O 0 8.375308425456751e-06

The O 0 1.1792018085543532e-05
majority O 0 5.868189418833936e-07
of O 0 1.293329205509508e-06
Jewish O 0 7.677094799873885e-06
185delAG O 0 2.0249739463906735e-05
mutation O 0 1.917219151437166e-06
carriers O 0 5.15350393470726e-07
have O 0 6.120286144550846e-08
a O 0 3.028612525213248e-07
common O 0 2.445591746891296e-07
allelic O 0 5.1585075198090635e-06
pattern O 0 4.72731699119322e-06
, O 0 2.038098045886727e-07
supporting O 0 4.822918526770081e-07
the O 0 5.107019092065457e-07
founder O 0 3.819739049504278e-06
effect O 0 3.5794982977677137e-07
notion O 0 4.821272341359872e-07
, O 0 6.246070682891514e-08
but O 0 2.9046100635810035e-08
dating O 0 1.0078335321850318e-07
the O 0 7.210304175941928e-08
mutations O 0 9.543050083493654e-08
origin O 0 1.5427040978011064e-07
to O 0 6.94471040674216e-08
an O 0 2.979930115998286e-07
earlier O 0 6.38451638224069e-07
date O 0 6.20691537278617e-07
than O 0 1.0944479811314523e-07
currently O 0 6.126313678578299e-07
estimated O 0 2.0787331322935643e-06
. O 0 5.7346765061083715e-06

However O 0 1.8238619304611348e-05
, O 0 1.3522534345611348e-06
the O 0 4.0356493968829454e-07
different O 0 6.447637446171939e-08
allelic O 0 7.396522960334551e-06
pattern O 0 1.2457126103981864e-05
at O 0 2.7739472443499835e-06
the O 0 4.2324344917687995e-07
BRCA1 O 0 5.148118361830711e-06
locus O 0 5.983786195429275e-06
even O 0 4.904206818423518e-08
in O 0 3.331918208004936e-08
some O 0 1.4728075647951755e-08
Jewish O 0 3.1099989428184927e-07
mutation O 0 3.251049349728419e-07
carriers O 0 2.5275099346799834e-07
, O 0 9.043298376809616e-08
might O 0 5.305190597937326e-08
suggest O 0 5.1459107197615594e-08
that O 0 1.0382655624141535e-08
the O 0 7.194135775989707e-08
mutation O 0 2.36733498581998e-07
arose O 0 5.129858777763729e-07
independently O 0 3.3381718367309077e-07
. O 0 1.2497897614593967e-06
. O 0 8.464938218821771e-06

Crystal O 0 0.0016252222703769803
structure O 0 6.680253864033148e-05
of O 0 3.016493792529218e-05
the O 0 8.147821063175797e-05
hemochromatosis B-Disease 1 1.0
protein O 0 0.008914661593735218
HFE O 1 0.9991292357444763
and O 0 1.3078796428089845e-06
characterization O 0 9.029232387547381e-06
of O 0 1.5944076494633919e-06
its O 0 5.331168608790904e-07
interaction O 0 1.811880110835773e-06
with O 0 1.8071482372761238e-06
transferrin O 0 0.0004303715832065791
receptor O 0 0.00020391556608956307
. O 0 2.509749901946634e-05

HFE O 1 0.9975900650024414
is O 0 5.660951501340605e-05
an O 0 4.4321626774035394e-05
MHC O 0 0.05160197243094444
- O 0 0.00013364832557272166
related O 0 3.933731932193041e-06
protein O 0 8.864832352628582e-07
that O 0 6.962030596469049e-08
is O 0 1.6421309112502058e-07
mutated O 0 3.5581652468863467e-07
in O 0 8.432672871094837e-07
the O 0 4.665824235416949e-05
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9839215278625488

HFE O 0 0.008413936011493206
binds O 0 8.956286183092743e-05
to O 0 7.447982625308214e-06
transferrin O 0 0.00019945089297834784
receptor O 0 5.809271169709973e-05
( O 0 4.1987473196059e-06
TfR O 0 0.3777730464935303
) O 0 2.9098455911480414e-07
and O 0 9.45678308994502e-08
reduces O 0 8.204746677620278e-07
its O 0 3.3192989690178365e-07
affinity O 0 1.6975778862615698e-06
for O 0 2.3897903247416252e-06
iron O 1 0.5949007272720337
- O 0 0.0005596714909188449
loaded O 0 3.0032328140805475e-05
transferrin O 0 7.726861804258078e-05
, O 0 3.1318054425355513e-06
implicating O 0 0.014458808116614819
HFE O 1 0.9994263648986816
in O 0 0.00013351062079891562
iron O 1 0.9999809265136719
metabolism O 1 0.9509210586547852
. O 0 3.3305292163277045e-05

The O 0 0.00031185257830657065
2 O 0 0.00028383274911902845
. O 0 0.0001049773272825405

6 O 0 0.00039923214353621006
A O 0 0.00023739431344438344
crystal O 0 0.00011167075717821717
structure O 0 8.790229003352579e-06
of O 0 9.301485079049598e-06
HFE O 1 0.6071288585662842
reveals O 0 2.399109234829666e-06
the O 0 6.055603307686397e-07
locations O 0 8.150265102813137e-07
of O 0 8.525717021257151e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 9.653240340412594e-06
and O 0 2.34013009503542e-06
a O 0 4.239932604832575e-05
patch O 0 0.011909370310604572
of O 0 2.0197592675685883e-05
histidines O 0 0.00017294993449468166
that O 0 1.285008011109312e-07
could O 0 1.68792610111268e-07
be O 0 1.273552072689199e-07
involved O 0 4.3107289116051106e-07
in O 0 1.829571942835173e-06
pH O 0 0.00037736870581284165
- O 0 4.794994674739428e-05
dependent O 0 2.6887400963460095e-06
interactions O 0 3.3458318284829147e-06
. O 0 7.411944807245163e-06

We O 0 1.4716146324644797e-05
also O 0 3.385794343557791e-06
demonstrate O 0 5.972229701001197e-06
that O 0 2.610409410408465e-06
soluble O 0 0.0001541196834295988
TfR O 1 0.9932157397270203
and O 0 4.832766535400879e-06
HFE O 0 0.006171968765556812
bind O 0 1.5437577758348198e-06
tightly O 0 3.5299674436828354e-06
at O 0 4.047133643325651e-06
the O 0 8.260254276137857e-07
basic O 0 9.784188250705483e-07
pH O 0 3.387170181667898e-06
of O 0 1.0248880926155834e-06
the O 0 1.7610650502319913e-06
cell O 0 1.71767569554504e-05
surface O 0 8.318243999383412e-06
, O 0 3.304722326902265e-07
but O 0 8.124518302565775e-08
not O 0 9.746594997750435e-08
at O 0 2.3574341412313515e-06
the O 0 2.896806563512655e-06
acidic O 0 3.532477421686053e-05
pH O 0 6.292465695878491e-05
of O 0 3.306743019493297e-05
intracellular O 0 0.0010012205457314849
vesicles O 0 0.0005276463343761861
. O 0 4.029793126392178e-05

TfR O 1 0.9964646100997925
HFE O 0 0.36193394660949707
stoichiometry O 0 0.0006837144028395414
( O 0 2.5217217626050115e-05
2 O 0 6.415089956135489e-06
1 O 0 4.092458311788505e-06
) O 0 5.076306592854962e-07
differs O 0 3.915766342288407e-07
from O 0 7.518409006479487e-07
TfR O 0 0.00026075911591760814
transferrin O 0 1.835715738707222e-05
stoichiometry O 0 4.779494247486582e-06
( O 0 2.6593423285703466e-07
2 O 0 6.806867531850003e-07
2 O 0 5.578794457505865e-07
) O 0 9.885401652809378e-08
, O 0 5.9756715131698e-08
implying O 0 4.5625560574080737e-07
a O 0 9.188374150426171e-08
different O 0 7.211924391015145e-09
mode O 0 1.385550518762102e-07
of O 0 1.2571193508392753e-07
binding O 0 2.673544372555625e-07
for O 0 4.34297703577613e-07
HFE O 0 8.366676047444344e-05
and O 0 3.3234007901228324e-07
transferrin O 0 1.0058907719212584e-05
to O 0 3.1131921218729985e-07
TfR O 1 0.5109620094299316
, O 0 2.3889350586614455e-07
consistent O 0 2.720379654874705e-07
with O 0 3.30939577963818e-08
our O 0 1.3314954117049638e-07
demonstration O 0 3.415970013520564e-06
that O 0 3.078102110976033e-07
HFE O 0 0.00012380305270198733
, O 0 7.130311701075698e-07
transferrin O 0 1.8039378119283356e-05
, O 0 3.7012932807556354e-07
and O 0 5.424910796136828e-07
TfR O 0 0.15604275465011597
form O 0 1.214598569276859e-06
a O 0 1.0000007023336366e-05
ternary O 0 6.269034929573536e-05
complex O 0 3.788281901506707e-05
. O 0 1.0825009667314589e-05

Identification O 0 2.9559685572166927e-05
of O 0 5.556129963224521e-06
three O 0 7.530895231866452e-07
novel O 0 2.0984521142963786e-06
mutations O 0 7.66694427056791e-07
and O 0 2.1827806051533116e-07
a O 0 1.0989291467922158e-06
high O 0 6.4391360865556635e-06
frequency O 0 1.1065357057304936e-06
of O 0 4.0116015043167863e-07
the O 0 7.000365940257325e-07
Arg778Leu O 0 3.575393930077553e-05
mutation O 0 7.616295647494553e-07
in O 0 8.651035159346065e-07
Korean O 0 7.189042662503198e-05
patients O 0 2.556060508140945e-06
with O 0 4.33352533946163e-06
Wilson B-Disease 1 0.9905990958213806
disease I-Disease 1 0.9999394416809082
. O 0 5.075586523162201e-05

Four O 0 7.633469795109704e-05
mutations O 0 0.0001029443446896039
- O 0 0.0006587812677025795
- O 0 0.00032976927468553185
R778L O 0 0.0002313453733222559
, O 0 1.9626436369435396e-06
A874V O 0 3.1103754736250266e-05
, O 0 1.067959487954795e-06
L1083F O 0 2.2294605514616705e-05
, O 0 6.902832865307573e-07
and O 0 6.480631213889865e-07
2304delC O 0 2.1325804482330568e-05
- O 0 2.385693551332224e-05
- O 0 1.441288895875914e-05
in O 0 2.498335334166768e-06
the O 0 3.5185771594115067e-06
copper O 0 0.0004249965713825077
- O 0 8.179010364983696e-06
transporting O 0 1.0961566658806987e-05
enzyme O 0 4.331723175710067e-06
, O 0 2.4515607037756126e-06
P O 0 0.00019728412735275924
- O 0 1.1448244549683295e-05
type O 0 1.059725764207542e-05
ATPase O 0 0.0005645297351293266
( O 0 7.108083082130179e-07
ATP7B O 0 4.2033701902255416e-05
) O 0 4.2938985700402554e-08
, O 0 2.5820639848461724e-08
were O 0 6.70872921659793e-08
identified O 0 2.2758472084660752e-07
in O 0 5.507608875632286e-07
Korean O 0 0.0006425094325095415
Patients O 0 4.029418050777167e-06
with O 0 4.059855655214051e-06
Wilson B-Disease 1 0.9954800605773926
disease I-Disease 1 0.9998533725738525
. O 0 4.188341335975565e-05

Arg778Leu O 0 0.011370791122317314
, O 0 8.70684834808344e-06
the O 0 1.8075274965667631e-06
most O 0 2.1049369536285667e-07
frequently O 0 1.5859592394917854e-07
reported O 0 7.392915790660481e-07
mutation O 0 3.2417645456916944e-07
of O 0 1.2442679917512578e-06
this O 0 3.252690135013836e-07
enzyme O 0 5.502253657141409e-07
, O 0 8.829010766930878e-08
was O 0 1.949324996530777e-06
found O 0 6.800431862075129e-08
in O 0 1.107486298224103e-07
six O 0 9.320456939576616e-08
of O 0 4.7141935510808253e-07
eight O 0 1.0357100563851418e-06
unrelated O 0 3.1567328733217437e-06
patients O 0 6.492588795481424e-07
studied O 0 3.7162656099098967e-06
, O 0 2.1277983819345536e-07
an O 0 4.576959611313214e-07
allele O 0 5.010118115933437e-07
frequency O 0 2.034106955761672e-06
of O 0 5.635924480884569e-06
37 O 0 5.3673236834583804e-05
. O 0 1.8493916286388412e-05

5 O 0 2.9167627872084267e-05
% O 0 2.1270629986247513e-06
, O 0 1.9810295270872302e-07
which O 0 1.0177821252455033e-07
is O 0 1.5774367057019845e-07
considerably O 0 4.9690339665176e-07
higher O 0 2.170106796484106e-07
than O 0 1.472619448605883e-08
those O 0 2.5503373635160642e-08
in O 0 2.327851831296357e-07
other O 0 3.247380675475142e-07
Asian O 0 3.418837650315254e-06
populations O 0 2.1549949451582506e-06
. O 0 5.07461118104402e-06

The O 0 4.063993401359767e-05
novel O 0 1.294456251343945e-05
single O 0 2.2468705083156237e-06
nucleotide O 0 1.2090008567611221e-05
deletion O 0 1.0140796803170815e-05
, O 0 1.0854375886992784e-06
2304delC O 0 7.622445082233753e-06
, O 0 3.946598781112698e-07
was O 0 4.2619849409675226e-06
found O 0 3.105091366251145e-07
in O 0 6.432541681533621e-07
one O 0 3.414865659578936e-06
patient O 0 0.00013022948405705392
. O 0 2.4944882170530036e-05

Since O 0 6.375881639542058e-05
a O 0 1.592634907865431e-05
mutation O 0 6.162154022604227e-06
at O 0 1.998516199819278e-05
cDNA O 0 2.3174436137196608e-05
nucleotide O 0 3.967792144976556e-05
2302 O 0 0.00018776034994516522
( O 0 1.6376219491576194e-06
2302insC O 0 7.533828920713859e-06
) O 0 2.461784731622174e-07
had O 0 6.118652322584239e-07
been O 0 7.099601475601958e-07
previously O 0 1.095255697691755e-06
described O 0 8.190814924091683e-07
, O 0 9.868898587228614e-08
this O 0 8.520351713059426e-08
region O 0 4.1189559851773083e-07
of O 0 1.0741124469859642e-06
the O 0 3.4566580779937794e-06
ATP7B O 0 0.11924636363983154
gene O 0 3.4774022878991673e-06
may O 0 2.0306492842792068e-06
be O 0 3.369734997704654e-07
susceptible O 0 2.650126589287538e-06
to O 0 2.4692428723938065e-07
gene O 0 1.6907059034565464e-05
rearrangements O 1 0.7212604284286499
causing O 1 0.9999794960021973
Wilson B-Disease 1 0.9999769926071167
disease I-Disease 1 0.999983549118042
. O 0 5.880004391656257e-05

Disruption O 0 0.0012255371548235416
of O 0 1.3356901945371646e-05
splicing O 0 1.880469972093124e-05
regulated O 0 4.076993263879558e-06
by O 0 4.824574943995685e-07
a O 0 8.16954707261175e-06
CUG O 0 0.19499069452285767
- O 0 2.3174192392616533e-05
binding O 0 5.23146309205913e-06
protein O 0 2.491300256224349e-05
in O 0 0.00011620144505286589
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00015697965864092112

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6093837022781372
DM B-Disease 1 1.0
) O 0 1.218530633195769e-05
is O 0 1.1739724641302018e-06
caused O 0 5.02651846545632e-06
by O 0 3.908640451300016e-07
a O 0 1.3550238691095728e-06
CTG O 0 2.3512109692092054e-05
expansion O 0 8.752735425332503e-07
in O 0 1.3317493596787244e-07
the O 0 1.6390829671308893e-07
3 O 0 6.222159072422073e-07
untranslated O 0 9.281034181185532e-06
region O 0 8.311228612001287e-07
of O 0 5.351035724743269e-06
the O 0 0.00016901174967642874
DM B-Disease 1 1.0
gene O 0 0.00012126752699259669
. O 0 5.103479998069815e-05

One O 0 2.8516062229755335e-05
model O 0 3.001311415573582e-05
of O 0 0.00010282346920575947
DM B-Disease 1 1.0
pathogenesis O 1 0.9970188140869141
suggests O 0 2.5744473077793373e-06
that O 0 4.0191147832047136e-07
RNAs O 0 5.549934485316044e-06
from O 0 1.1447053083202263e-07
the O 0 6.15888353650007e-08
expanded O 0 1.403172547043141e-07
allele O 0 1.3436672929856286e-07
create O 0 8.048110800018549e-08
a O 0 1.2395624935379601e-06
gain O 0 6.476234830188332e-06
- O 0 7.780949090374634e-06
of O 0 3.1099655188882025e-06
- O 0 3.0893029361322988e-06
function O 0 2.1031230801327183e-07
mutation O 0 1.2597428167282487e-07
by O 0 7.2336803214057e-08
the O 0 2.0860184690718597e-07
inappropriate O 0 5.299305030348478e-07
binding O 0 1.1970033142461034e-07
of O 0 5.997732728246774e-07
proteins O 0 3.038002489574865e-07
to O 0 4.95037909331586e-07
the O 0 8.32769728731364e-06
CUG O 0 0.04172678664326668
repeats O 0 6.697729986626655e-05
. O 0 2.2193884433363564e-05

Data O 0 5.7161309086950496e-05
presented O 0 1.0933304110949393e-05
here O 0 2.060413635263103e-06
indicate O 0 1.4132947399048135e-06
that O 0 3.4278704674761684e-07
the O 0 9.122232995650847e-07
conserved O 0 6.38489063931047e-06
heterogeneous O 0 1.787951259757392e-05
nuclear O 0 8.953296492109075e-05
ribonucleoprotein O 0 0.0005792886367999017
, O 0 3.107990778516978e-06
CUG O 0 0.00023298074665945023
- O 0 7.49792525311932e-06
binding O 0 2.463391410856275e-06
protein O 0 4.960136720910668e-06
( O 0 1.8762715399134322e-06
CUG O 0 0.0012803685385733843
- O 0 4.5702498027822e-05
BP O 0 5.402349779615179e-05
) O 0 3.927202669729013e-07
, O 0 2.0950976420408551e-07
may O 0 4.429863338373252e-07
mediate O 0 1.3520007087208796e-06
the O 0 3.1002468858787324e-06
trans O 0 1.028523638524348e-05
- O 0 5.670190148521215e-06
dominant O 0 7.00066607350891e-07
effect O 0 6.236356853150937e-07
of O 0 1.003863985715725e-06
the O 0 3.889934760081815e-06
RNA O 0 3.003519304911606e-05
. O 0 1.00980059869471e-05

CUG O 1 0.9991710186004639
- O 0 0.06155995652079582
BP O 0 0.0006049549556337297
was O 0 1.0518603630771395e-05
found O 0 2.735294231115404e-07
to O 0 9.47480174318116e-08
bind O 0 2.703019674754614e-07
to O 0 1.3253787756184465e-07
the O 0 3.8077512272138847e-06
human O 0 0.007341654505580664
cardiac O 1 1.0
troponin O 1 0.9999995231628418
T O 0 0.17203819751739502
( O 0 2.2877577521285275e-06
cTNT O 0 1.689750024524983e-05
) O 0 3.003499102760543e-07
pre O 0 6.415635198209202e-06
- O 0 3.1407187179866014e-06
messenger O 0 1.7406644019501982e-06
RNA O 0 4.853467885368445e-07
and O 0 4.633195160863579e-08
regulate O 0 2.1467991473400616e-07
its O 0 3.5460482195048826e-07
alternative O 0 1.7610316263017012e-06
splicing O 0 1.027518737828359e-05
. O 0 5.681026323145488e-06

Splicing O 0 0.00019994880130980164
of O 0 2.305113412148785e-05
cTNT O 0 0.00025409364025108516
was O 0 9.610956476535648e-05
disrupted O 0 0.00044692668598145247
in O 0 6.397788820322603e-05
DM B-Disease 1 1.0
striated O 1 0.9964873790740967
muscle O 0 0.0027332324534654617
and O 0 5.550742230298056e-07
in O 0 5.450570483844785e-07
normal O 0 1.8075274965667631e-06
cells O 0 9.255465442947752e-07
expressing O 0 4.746869421978772e-07
transcripts O 0 2.4607688828837126e-06
that O 0 4.0097731357491284e-07
contain O 0 2.6612526653480018e-06
CUG O 0 0.0034634710755199194
repeats O 0 7.4273586506024e-05
. O 0 3.357757304911502e-05

Altered O 0 0.00011003425606759265
expression O 0 1.665286617935635e-05
of O 0 4.3051104512414895e-06
genes O 0 3.3185976917593507e-06
regulated O 0 6.3248444348573685e-06
posttranscriptionally O 0 3.7384754250524566e-05
by O 0 2.2965584776102332e-06
CUG O 0 0.037413548678159714
- O 0 9.736381616676226e-05
BP O 0 3.20536237268243e-05
therefore O 0 3.208066345905536e-07
may O 0 4.5672231863136403e-07
contribute O 0 8.916051683627302e-07
to O 0 6.010483957652468e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9988430738449097
. O 0 5.138386768521741e-06
. O 0 8.392691597691737e-06

Identification O 0 3.281444878666662e-05
of O 0 7.432789971062448e-06
a O 0 8.749432709009852e-06
novel O 0 7.903570804046467e-06
nonsense O 0 3.7628979043802246e-05
mutation O 0 1.521256649539282e-06
and O 0 2.7463610763334145e-07
a O 0 7.536390853601915e-07
missense O 0 4.424363851285307e-06
substitution O 0 2.144614882126916e-06
in O 0 4.7390307145178667e-07
the O 0 2.26677002501674e-06
vasopressin O 0 3.0215840524761006e-05
- O 0 3.720295353559777e-05
neurophysin O 0 0.00014164793537929654
II O 0 0.0046691568568348885
gene O 0 9.23230686566967e-07
in O 0 3.5951225640928897e-07
two O 0 2.2816911382506078e-07
Spanish O 0 6.590062639588723e-06
kindreds O 0 2.7566931748879142e-05
with O 0 2.244600182166323e-06
familial B-Disease 1 0.9998818635940552
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 0.000357834214810282

Familial B-Disease 1 0.9999994039535522
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.5785772800445557
FNDI B-Disease 1 1.0
) O 0 2.4462312921968987e-06
is O 0 4.5463593778549694e-07
an O 0 1.0017446356869186e-06
autosomal B-Disease 1 0.998072624206543
dominant I-Disease 1 0.9999856948852539
disease I-Disease 1 1.0
caused O 1 0.9999997615814209
by O 0 0.4867704510688782
deficiency O 1 1.0
in O 0 0.0003136583254672587
the O 0 0.004137137904763222
antidiuretic O 1 0.9917930960655212
hormone O 0 0.0009228938724845648
arginine O 0 7.006739906501025e-05
vasopressin O 0 3.8701717130606994e-05
( O 0 3.3681715194688877e-06
AVP O 0 0.000263055699178949
) O 0 2.1863765198304463e-07
encoded O 0 4.351347229203384e-07
by O 0 7.781206932122586e-07
the O 0 1.5450608771061525e-05
AVP O 1 0.9883270859718323
- O 0 0.00896669365465641
neurophysin O 1 0.6446071267127991
II O 1 0.9999762773513794
( O 0 4.22844932472799e-05
AVP O 1 0.9995450377464294
- O 0 0.00020289466192480177
NPII O 0 0.007972804829478264
) O 0 4.136757354444853e-07
gene O 0 1.349014041807095e-06
on O 0 1.4600595022784546e-05
chromosome O 1 0.6569207906723022
20p13 O 1 0.6848130822181702
. O 0 3.110867692157626e-05

In O 0 1.606311161594931e-05
this O 0 1.0865499007195467e-06
study O 0 1.0114035831065848e-06
, O 0 1.673529226309256e-07
we O 0 5.6667783354669155e-08
analyzed O 0 3.0275120366241026e-07
two O 0 4.845194467861802e-08
families O 0 8.881742985522578e-08
with O 0 2.780581951355998e-07
FNDI B-Disease 1 0.9996786117553711
using O 0 2.7717948114514e-07
direct O 0 6.666456897619355e-07
automated O 0 6.95924973115325e-06
fluorescent O 0 2.586047003205749e-06
, O 0 1.6261415680673963e-07
solid O 0 4.810213454220502e-07
phase O 0 1.2798606121577905e-06
, O 0 1.6396458590861585e-07
single O 0 6.465247679443564e-07
- O 0 2.3100544694898417e-06
stranded O 0 9.62308718044369e-07
DNA O 0 5.424315645541355e-07
sequencing O 0 3.6910603284923127e-06
of O 0 6.618075985898031e-06
PCR O 0 0.00010446545638842508
- O 0 0.00012468488421291113
amplified O 0 0.0002783237723633647
AVP O 0 0.07254942506551743
- O 0 0.00019401345343794674
NPII O 0 0.0008066345471888781
DNA O 0 3.147020470350981e-05
. O 0 1.0803011718962807e-05

In O 0 1.7572336219018325e-05
one O 0 1.7455832903578994e-06
of O 0 1.681095113781339e-06
the O 0 7.07143044564873e-07
families O 0 1.457298282048214e-07
, O 0 2.14114578511726e-07
affected O 0 2.422809188828978e-07
individuals O 0 7.538699975384588e-08
presented O 0 1.8618335388964624e-06
a O 0 2.0176694306428544e-06
novel O 0 2.86206682176271e-06
nonsense O 0 4.306662958697416e-06
mutation O 0 3.2872895872060326e-07
in O 0 3.7461768442881294e-07
exon O 0 7.547129712293099e-07
3 O 0 4.016505386061908e-07
of O 0 4.861551587964641e-07
the O 0 4.281541237105557e-07
gene O 0 2.2967066115597845e-07
, O 0 1.5091532645783445e-07
consisting O 0 1.6445773098894279e-07
in O 0 3.3442387348259217e-07
a O 0 6.606700935662957e-06
G O 0 5.510262053576298e-05
to O 0 1.2488044376368634e-06
T O 0 0.0001385527430102229
transition O 0 4.1141329347738065e-06
at O 0 4.008391442766879e-06
nucleotide O 0 4.895743131783092e-06
2101 O 0 1.3210395991336554e-05
, O 0 9.504014286676465e-08
which O 0 4.4541454968793914e-08
produces O 0 7.607803098608201e-08
a O 0 3.245306174903817e-07
stop O 0 4.1603453837524285e-07
signal O 0 2.5505937628622632e-06
in O 0 4.581602013331576e-07
codon O 0 3.693979806485004e-06
82 O 0 4.559878107102122e-06
( O 0 8.107487587949436e-07
Glu O 0 6.846405449323356e-05
) O 0 8.8607248471817e-07
of O 0 1.1366664693923667e-05
NPII O 0 0.07941767573356628
. O 0 1.5640087440260686e-05

The O 0 0.0001825896615628153
premature O 0 0.0007711958605796099
termination O 0 6.700676021864638e-05
eliminates O 0 1.1427726349211298e-05
part O 0 2.295174908795161e-06
of O 0 5.19943205290474e-06
the O 0 1.070260077540297e-05
C O 0 0.00012815707304980606
- O 0 1.9769802747759968e-05
terminal O 0 3.6443627323023975e-05
domain O 0 1.207908098876942e-06
of O 0 2.716783455980476e-06
NPII O 0 0.0002392628521192819
, O 0 3.8978859606686456e-07
including O 0 2.06145017500603e-07
a O 0 1.4099358622843283e-06
cysteine O 0 2.5251924284930283e-07
residue O 0 1.6823413488964434e-06
in O 0 4.0195439510171127e-07
position O 0 9.357593739878212e-07
85 O 0 6.83606401707948e-07
, O 0 6.278452246988309e-08
which O 0 3.027913209052713e-08
could O 0 4.734807035333688e-08
be O 0 4.59124187557336e-08
involved O 0 1.382757375267829e-07
in O 0 2.5633494260546286e-07
the O 0 1.0688927432056516e-06
correct O 0 2.2161216293170583e-06
folding O 0 8.270869329862762e-06
of O 0 3.2421062314824667e-06
the O 0 2.2589134459849447e-05
prohormone O 0 0.029389718547463417
. O 0 2.7476437026052736e-05

In O 0 2.6711497412179597e-05
the O 0 6.782167929486604e-06
second O 0 1.1421788258303422e-05
family O 0 1.3726762517762836e-06
, O 0 7.792145311213972e-07
a O 0 2.98672603094019e-06
G279A O 0 5.595264519797638e-05
substitution O 0 1.1053543857997283e-05
at O 0 5.823200353916036e-06
position O 0 2.2273491140367696e-06
- O 0 6.758399422324146e-07
1 O 0 1.9113066684894875e-07
of O 0 1.590918969895938e-07
the O 0 2.1469199396051408e-07
signal O 0 1.9761546354857273e-06
peptide O 0 8.210233772842912e-07
was O 0 1.2395115618346608e-06
observed O 0 2.548013640080171e-07
in O 0 1.0590509447183649e-07
all O 0 1.0857444721068532e-07
affected O 0 8.366355359612498e-07
individuals O 0 8.248509288932837e-07
. O 0 1.2522613360488322e-05

This O 0 1.0574564839771483e-05
missense O 0 0.0001287801278522238
mutation O 0 3.393343649804592e-05
, O 0 4.7448143050132785e-06
which O 0 3.821910922852112e-06
replaces O 0 0.00017296594160143286
Ala O 0 0.00807071290910244
with O 0 9.081271059585561e-07
Thr O 1 0.595040500164032
, O 0 4.717733190773288e-07
is O 0 1.4058673514227849e-07
frequent O 0 6.283453899413871e-07
among O 0 1.7539719010528643e-06
FNDI B-Disease 1 1.0
patients O 0 1.5311160268538515e-06
and O 0 1.4561464922735468e-07
is O 0 2.028302219514444e-07
thought O 0 5.872982455912279e-08
to O 0 2.2219165174419686e-08
reduce O 0 7.485942177254401e-08
the O 0 2.2176702429987927e-07
efficiency O 0 4.4023411760463205e-07
of O 0 6.477245051428326e-07
cleavage O 0 1.0149215086130425e-05
by O 0 6.532455927299452e-07
signal O 0 2.0622832380468026e-05
peptidases O 0 4.28543244197499e-05
. O 0 1.555160906718811e-06
. O 0 7.5093612394994125e-06

Genetic O 0 0.00025127612752839923
heterogeneity O 0 0.0005075845983810723
of O 0 0.000286179652903229
Saethre B-Disease 1 0.999998927116394
- I-Disease 1 0.9999998807907104
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.8218678380653728e-06
due O 0 1.4279822607932147e-05
to O 0 8.620916105428478e-07
TWIST O 0 0.0001314748515142128
and O 0 1.160499596153386e-05
FGFR O 1 0.9276047348976135
mutations O 0 6.168694380903617e-05
. O 0 5.782023799838498e-05

Thirty O 0 0.00038855880848132074
- O 0 0.00017879510414786637
two O 0 1.5781965885253157e-06
unrelated O 0 1.0924747584795114e-05
patients O 0 8.228552133004996e-07
with O 0 1.262706490479104e-07
features O 0 7.801789365657896e-07
of O 0 0.00030067309853620827
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.120968573166465e-07
a O 0 2.443214498271118e-06
common O 0 1.1146358701807912e-05
autosomal B-Disease 1 0.8331131339073181
dominant I-Disease 0 0.3290729522705078
condition I-Disease 0 0.04768574237823486
of O 0 0.11741910874843597
craniosynostosis B-Disease 1 1.0
and O 0 0.010428761132061481
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999113082885742
, O 0 1.2054200624334044e-06
were O 0 7.175593168540217e-07
screened O 0 6.415583584384876e-07
for O 0 8.19778733784915e-08
mutations O 0 4.6994884428386285e-07
in O 0 2.6164207156398334e-06
TWIST O 0 0.0004390653921291232
, O 0 4.248523964633932e-06
FGFR2 O 0 0.14756670594215393
, O 0 2.664859039214207e-06
and O 0 1.1376533620932605e-05
FGFR3 O 1 0.9873101711273193
. O 0 3.2303843909176067e-05

Nine O 0 5.021641118219122e-05
novel O 0 1.1247287147853058e-05
and O 0 1.9841049834212754e-06
three O 0 1.5385048754978925e-06
recurrent O 0 0.040786199271678925
TWIST O 0 0.00010232035128865391
mutations O 0 1.8458304111845791e-06
were O 0 7.364332077486324e-07
found O 0 2.493053727903316e-07
in O 0 5.913780114497058e-07
12 O 0 7.09313007973833e-06
families O 0 1.468959339945286e-06
. O 0 1.8244498278363608e-05

Seven O 0 2.1421461497084238e-05
families O 0 4.4603390847441915e-07
were O 0 7.319541168726573e-07
found O 0 2.100280909189678e-07
to O 0 1.471513826345472e-07
have O 0 3.323974624436232e-07
the O 0 4.013050329376711e-06
FGFR3 O 0 0.24160948395729065
P250R O 0 0.0001283527526538819
mutation O 0 2.127986135747051e-06
, O 0 3.087009758928616e-07
and O 0 1.0087047286333473e-07
one O 0 1.1542974931444405e-07
individual O 0 6.182021650147362e-08
was O 0 8.584214810980484e-06
found O 0 2.177645086476332e-07
to O 0 9.080650897885789e-08
have O 0 4.638544623958296e-07
an O 0 8.463994163321331e-06
FGFR2 O 1 0.9112904667854309
VV269 O 0 0.00474126311019063
- O 0 0.00010374592966400087
270 O 0 4.535234620561823e-05
deletion O 0 7.563020335510373e-05
. O 0 2.4271776055684313e-05

To O 0 4.986374278814765e-06
date O 0 5.008048901800066e-06
, O 0 2.901001039390394e-07
our O 0 3.523674365624174e-07
detection O 0 4.035752226627665e-06
rate O 0 3.5022537758777617e-06
for O 0 4.4500143303594086e-07
TWIST O 0 1.0267067409586161e-05
or O 0 6.206767579897132e-07
FGFR O 0 0.0001503966486779973
mutations O 0 4.605665822055016e-07
is O 0 2.8482648417593737e-07
68 O 0 1.608961497368e-06
% O 0 1.2858882314503717e-07
in O 0 2.4002207510420703e-07
our O 0 3.298775482107885e-06
Saethre B-Disease 1 0.9995622038841248
- I-Disease 1 0.9999969005584717
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 9.267316272598691e-06
, O 0 3.639360386387125e-07
including O 0 1.4828499672603357e-07
our O 0 2.153695533024802e-07
five O 0 2.9309595106497e-07
patients O 0 6.975807309572701e-07
elsewhere O 0 7.301171081053326e-07
reported O 0 1.8535494064053637e-06
with O 0 6.418808879971039e-07
TWIST O 0 0.00014742204803042114
mutations O 0 1.5197011634882074e-05
. O 0 2.7466008759802207e-05

More O 0 4.097468718100572e-06
than O 0 1.311594473918376e-06
35 O 0 1.4056062127565383e-06
different O 0 4.6293081368276034e-08
TWIST O 0 2.5883909984258935e-06
mutations O 0 3.0405385587073397e-07
are O 0 3.11736876312807e-08
now O 0 9.185289684410236e-08
known O 0 2.1120513338246383e-07
in O 0 2.0211540174841502e-07
the O 0 1.0997396202583332e-06
literature O 0 1.1635947885224596e-05
. O 0 1.1549945156730246e-05

The O 0 2.439455420244485e-05
most O 0 1.1968107855864218e-06
common O 0 7.581930390188063e-07
phenotypic O 0 3.0416890695050824e-06
features O 0 1.1678208693410852e-06
, O 0 2.8160457077319734e-07
present O 0 1.019787490008639e-07
in O 0 1.1335311000948423e-07
more O 0 1.112573499995051e-08
than O 0 2.3469009846621702e-08
a O 0 2.1368090585838218e-07
third O 0 6.110698791417235e-07
of O 0 6.163537591419299e-07
our O 0 4.262978734459466e-07
patients O 0 2.5658584945631446e-07
with O 0 1.1278291367489146e-07
TWIST O 0 9.549416063237004e-06
mutations O 0 5.201899284656974e-07
, O 0 5.53781944745424e-07
are O 0 2.1814278738929715e-07
coronal B-Disease 0 0.004820709116756916
synostosis I-Disease 0 0.0002903163549490273
, O 0 1.6336598491761833e-06
brachycephaly B-Disease 0 0.000232660211622715
, O 0 5.183984740142478e-06
low B-Disease 1 0.9465503096580505
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 0.13889943063259125
facial B-Disease 1 1.0
asymmetry I-Disease 1 0.9999998807907104
, O 0 0.0003793333889916539
ptosis B-Disease 1 0.9999997615814209
, O 0 3.1069332180777565e-05
hypertelorism B-Disease 1 0.9785791039466858
, O 0 5.531071110453922e-06
broad B-Disease 0 0.00044398551108315587
great I-Disease 0 0.07499134540557861
toes I-Disease 1 0.9998700618743896
, O 0 7.366744739556452e-06
and O 0 1.325640914728865e-05
clinodactyly B-Disease 1 0.9574490189552307
. O 0 9.537734149489552e-05

Significant O 0 0.0002086854074150324
intra O 0 0.12008045613765717
- O 0 0.0003227289707865566
and O 0 2.431209622955066e-06
interfamilial O 0 4.5820106606697664e-05
phenotypic O 0 3.707787072926294e-06
variability O 0 4.594588972395286e-06
is O 0 1.6032865346460312e-07
present O 0 1.0211928014314253e-07
for O 0 8.672539308918203e-08
either O 0 2.996515320319304e-07
TWIST O 0 8.545221135136671e-06
mutations O 0 3.019812311322312e-06
or O 0 9.552585652272683e-06
FGFR O 1 0.7037912607192993
mutations O 0 2.75681413768325e-05
. O 0 2.3737247829558328e-05

The O 0 7.283448212547228e-06
overlap O 0 4.384991370898206e-06
in O 0 1.0494849220776814e-06
clinical O 0 2.614233198983129e-05
features O 0 1.15733905658999e-06
and O 0 2.8543860253194e-07
the O 0 3.8211348396544054e-07
presence O 0 3.942393220768281e-07
, O 0 1.3823803612922347e-07
in O 0 9.469345485513259e-08
the O 0 1.3023418432567269e-07
same O 0 9.0245350747864e-08
genes O 0 1.1675809474809284e-07
, O 0 9.482105411962038e-08
of O 0 3.1362898766928993e-07
mutations O 0 3.199346565452288e-07
for O 0 1.7769797011624178e-07
more O 0 7.162030613017123e-08
than O 0 1.1475252392756374e-07
one O 0 5.926229391661764e-07
craniosynostotic B-Disease 0 0.00028481840854510665
condition I-Disease 0 2.4701037546037696e-05
- O 0 3.96715267925174e-06
such O 0 1.9600946643549833e-07
as O 0 2.0375105123093817e-06
Saethre B-Disease 0 0.00018356145301368088
- I-Disease 0 3.502936669974588e-05
Chotzen I-Disease 0 9.17943543754518e-05
, I-Disease 0 1.6193305327760754e-06
Crouzon I-Disease 0 0.00014233504771254957
, I-Disease 0 1.475224735258962e-06
and I-Disease 0 8.097812496998813e-06
Pfeiffer I-Disease 1 0.9999762773513794
syndromes I-Disease 1 0.999976634979248
- O 0 0.00016412990225944668
support O 0 1.1494149703139556e-06
the O 0 7.956667218422808e-07
hypothesis O 0 1.00429485883069e-06
that O 0 1.3291241884871852e-07
TWIST O 0 2.8578256205946673e-06
and O 0 2.96466311056065e-07
FGFRs O 0 7.64230117056286e-06
are O 0 4.930364383426422e-08
components O 0 2.3440205154656724e-07
of O 0 2.7512109568306187e-07
the O 0 2.266609300249911e-07
same O 0 1.408234453492696e-07
molecular O 0 3.5324997043062467e-06
pathway O 0 2.835929080902133e-06
involved O 0 1.1600558735835875e-07
in O 0 1.5589489521516953e-07
the O 0 5.260362172521127e-07
modulation O 0 1.4154179552861024e-05
of O 0 2.9661765438504517e-05
craniofacial O 1 0.9999998807907104
and O 0 0.00044904203969053924
limb O 1 0.9999998807907104
development O 0 0.00010206561273662373
in O 0 4.099602847418282e-06
humans O 0 1.1882425496878568e-06
. O 0 9.702355328045087e-07
. O 0 6.873011443531141e-06

Mutation O 0 0.00016473290452267975
analysis O 0 2.348676571273245e-05
of O 0 5.1267867092974484e-05
UBE3A O 1 0.9999964237213135
in O 1 0.9955649971961975
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9999376535415649
. O 0 0.0008249347447417676

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.8780401945114136
AS B-Disease 1 0.9999997615814209
) O 0 3.0996318400866585e-06
is O 0 1.0640383152349386e-06
caused O 0 1.1559267477423418e-05
by O 0 1.5711430023657158e-06
chromosome O 1 0.9049915075302124
15q11 O 1 0.99983811378479
- O 1 0.9251731634140015
q13 O 0 0.3264801502227783
deletions O 0 1.979036460397765e-05
of O 0 1.1188682037754916e-05
maternal O 0 0.12414595484733582
origin O 0 5.939479251537705e-06
, O 0 1.5876465795372496e-06
by O 0 1.6701568483767915e-06
paternal O 0 0.3841816484928131
uniparental B-Disease 1 0.9999949932098389
disomy I-Disease 1 0.9999274015426636
( O 0 4.367493966128677e-05
UPD B-Disease 1 0.9999997615814209
) O 0 7.188031645455339e-07
15 O 0 1.11335145902558e-06
, O 0 1.21538491271167e-07
by O 0 2.3106484547952277e-07
imprinting O 1 0.9921879768371582
defects O 1 0.999711811542511
, O 0 2.7599512009146565e-07
and O 0 6.896924986676822e-08
by O 0 1.4232399792035721e-07
mutations O 0 3.3162459089908225e-07
in O 0 1.0056480732600903e-06
the O 0 1.2221895303810015e-05
UBE3A O 1 0.9529755115509033
gene O 0 3.612721775425598e-05
. O 0 2.2483864086098038e-05

UBE3A O 0 0.3303910791873932
encodes O 0 0.0010665841400623322
a O 0 0.0004522863309830427
ubiquitin O 0 0.003509004833176732
- O 0 0.00043368685874156654
protein O 0 1.9384395272936672e-05
ligase O 0 1.1583721970964689e-05
and O 0 8.5488522927335e-07
shows O 0 7.273009032360278e-06
brain O 1 0.9917299151420593
- O 0 0.0013826248468831182
specific O 0 3.6873029785056133e-06
imprinting O 0 0.04991798475384712
. O 0 2.78363331744913e-05

Here O 0 4.364138294477016e-05
we O 0 4.908698429062497e-06
describe O 0 8.969849659479223e-06
UBE3A O 0 0.0015612817369401455
coding O 0 5.356861584004946e-05
- O 0 6.801728886784986e-06
region O 0 5.224834467298933e-07
mutations O 0 7.778870099173218e-07
detected O 0 2.946883569165948e-06
by O 0 8.569325018470408e-07
SSCP O 0 0.00045532479998655617
analysis O 0 4.788445266967756e-07
in O 0 4.499915462474746e-07
13 O 0 6.506375484605087e-06
AS B-Disease 0 0.027186984196305275
individuals O 0 3.239857448988914e-07
or O 0 1.9819867702608462e-06
families O 0 2.225955995527329e-06
. O 0 1.2586799130076542e-05

Two O 0 1.999570486077573e-05
identical O 0 1.7719545212457888e-05
de O 0 0.00011628800712060183
novo O 0 6.821569695603102e-05
5 O 0 1.109635104512563e-05
- O 0 1.2725927263090853e-05
bp O 0 7.311292392842006e-06
duplications O 0 5.933546162850689e-06
in O 0 6.779101227039064e-07
exon O 0 5.507438345375704e-06
16 O 0 4.80845665151719e-06
were O 0 2.886936044887989e-06
found O 0 8.619143955002073e-06
. O 0 1.8502541934140027e-05

Among O 0 1.0153532457479741e-05
the O 0 3.268690534241614e-06
other O 0 2.2687783030050923e-07
11 O 0 1.066510094460682e-06
unique O 0 1.967822385040563e-07
mutations O 0 6.39541212876793e-07
, O 0 4.624525047347561e-07
8 O 0 1.1771563777074334e-06
were O 0 2.482247509760782e-07
small O 0 1.7632049775784253e-07
deletions O 0 1.3195235624152701e-06
or O 0 4.2561745772218273e-07
insertions O 0 6.79374898027163e-06
predicted O 0 1.377748412778601e-05
to O 0 1.6560758808736864e-07
cause O 0 4.974319381290115e-06
frameshifts O 0 6.725559796905145e-05
, O 0 4.242671138854348e-07
1 O 0 9.36073490720446e-07
was O 0 2.9599555091408547e-06
a O 0 2.9470393769770453e-07
mutation O 0 7.487940933970094e-08
to O 0 7.739438245835117e-08
a O 0 6.387573421307025e-07
stop O 0 4.476216020066204e-07
codon O 0 1.1052701438529766e-06
, O 0 4.7723972329549724e-08
1 O 0 1.5198587277609477e-07
was O 0 5.485613883138285e-07
a O 0 1.7224161297235696e-07
missense O 0 1.2493975418692571e-06
mutation O 0 2.9603407369904744e-07
, O 0 1.1277420242095104e-07
and O 0 1.0544351880525937e-07
1 O 0 9.667451195127796e-07
was O 0 1.6060432244557887e-05
predicted O 0 2.7347721243131673e-06
to O 0 1.0199003241950777e-07
cause O 0 3.010544787684921e-06
insertion O 0 7.4697768468467984e-06
of O 0 1.1624889339145739e-05
an O 0 1.8762068066280335e-05
isoleucine O 0 0.00019815508858300745
in O 0 8.741089914110489e-07
the O 0 1.4126021596894134e-06
hect O 0 1.243536826223135e-05
domain O 0 9.462743264521123e-07
of O 0 1.1827931984953466e-06
the O 0 3.3984881611104356e-06
UBE3A O 0 0.0001881849457276985
protein O 0 6.542363166772702e-07
, O 0 1.0890609303260135e-07
which O 0 7.243096433739993e-08
functions O 0 1.5651430373964104e-07
in O 0 5.574603960667446e-07
E2 O 0 3.420077700866386e-05
binding O 0 8.439914722657704e-07
and O 0 1.8012362943409244e-06
ubiquitin O 0 3.180418934789486e-05
transfer O 0 1.1136796274513472e-05
. O 0 1.5228463780658785e-05

Eight O 0 1.1129724953207187e-05
of O 0 1.266581875825068e-06
the O 0 4.5230410705698887e-07
cases O 0 2.1047965503839805e-07
were O 0 4.9638146037978e-07
familial O 0 9.49130753724603e-06
, O 0 1.2750497262459248e-06
and O 0 5.508733238457353e-07
five O 0 9.461389822718047e-07
were O 0 3.850513166980818e-06
sporadic O 0 0.00012740259990096092
. O 0 2.1662724975612946e-05

In O 0 1.4209346772986464e-05
two O 0 1.0825389153978904e-06
familial O 0 2.9096314392518252e-05
cases O 0 1.107723505811009e-06
and O 0 3.8946572544773517e-07
one O 0 3.1694455060460314e-07
sporadic O 0 6.0403344832593575e-06
case O 0 2.098077857226599e-06
, O 0 3.6782589063477644e-07
mosaicism O 0 2.3632466763956472e-05
for O 0 2.9567939918706543e-07
UBE3A O 0 0.00012929245713166893
mutations O 0 6.245845156627183e-07
was O 0 1.2015651009278372e-05
detected O 0 1.7531490357214352e-06
in O 0 4.309758878662251e-07
the O 0 5.872914812243835e-07
mother O 0 1.1009883564838674e-06
of O 0 3.0208523185137892e-06
three O 0 3.147744337184122e-06
AS B-Disease 1 0.9999257326126099
sons O 0 8.168989734258503e-05
, O 0 3.556153842509957e-07
in O 0 6.780057901778491e-07
the O 0 1.9143508325214498e-06
maternal O 0 0.00027086364571005106
grandfather O 0 0.0002042424603132531
of O 0 2.6530815375735983e-05
two O 0 1.4416258409255533e-06
AS B-Disease 1 0.903965175151825
first O 0 5.371784482122166e-06
cousins O 0 5.212350060901372e-06
, O 0 2.1930212312781805e-07
and O 0 1.384895256251184e-07
in O 0 5.483364589053963e-07
the O 0 2.1475068479048787e-06
mother O 0 7.4997847150370944e-06
of O 0 4.7890171117614955e-05
an O 0 0.009701674804091454
AS B-Disease 1 0.9999996423721313
daughter O 1 0.9982317090034485
. O 0 0.00013818185834679753

The O 0 1.329514998360537e-05
frequencies O 0 3.0637449981441023e-06
with O 0 1.1033285574058027e-07
which O 0 1.6601286745299149e-07
we O 0 6.390717288695669e-08
detected O 0 5.409845584836148e-07
mutations O 0 2.118734983014292e-07
were O 0 7.998732485248183e-07
5 O 0 6.34236357655027e-07
( O 0 1.096859563176622e-07
14 O 0 5.640014251184766e-07
% O 0 1.0200948707961288e-07
) O 0 3.9229348658409435e-08
of O 0 1.2983883834749577e-07
35 O 0 3.2749670708653866e-07
in O 0 7.611127017526087e-08
sporadic O 0 7.724431725364411e-07
cases O 0 1.2653150349706266e-07
and O 0 1.3030251011514338e-07
8 O 0 8.694034363543324e-07
( O 0 6.989625944697764e-08
80 O 0 1.0109139481073726e-07
% O 0 4.583288770731997e-08
) O 0 2.557888123533303e-08
of O 0 1.0335732980593093e-07
10 O 0 1.3113800889641425e-07
in O 0 1.6222165299950575e-07
familial O 0 1.0609453056531493e-05
cases O 0 6.048629984434228e-06
. O 0 3.844113962259144e-06
. O 0 8.532988431397825e-06

The O 0 0.0011437981156632304
hemochromatosis B-Disease 1 0.9999998807907104
845 O 1 0.9997027516365051
G O 1 0.8517869114875793
- O 0 0.0010780899319797754
- O 0 0.00011632915993686765
> O 0 7.33272190700518e-06
A O 0 5.4576726142840926e-06
and O 0 4.580453207836399e-07
187 O 0 9.356841474073008e-06
C O 0 3.864879545290023e-05
- O 0 2.0225654225214384e-05
- O 0 5.425727795227431e-05
> O 0 1.6156427591340616e-05
G O 0 1.185918790724827e-05
mutations O 0 7.256840603986348e-07
: O 0 2.170309869597986e-07
prevalence O 0 7.82891220296733e-06
in O 0 9.423155233889702e-07
non O 0 1.400726250722073e-05
- O 0 3.522423139656894e-05
Caucasian O 0 2.2363725292962044e-05
populations O 0 3.009448391821934e-06
. O 0 6.3138095356407575e-06

Hemochromatosis B-Disease 1 0.9999971389770508
, O 0 0.00013871322153136134
the O 0 0.0014638311695307493
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9999998807907104
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9999969005584717
, O 0 3.148999212498893e-06
leads O 0 7.65233016863931e-06
, O 0 1.2261110668987385e-06
if O 0 7.782512625453819e-07
untreated O 0 0.18875154852867126
, O 0 1.6574535948166158e-06
to O 0 1.93855385077768e-06
progressive O 1 0.9999910593032837
iron B-Disease 1 1.0
overload I-Disease 1 0.9999991655349731
and O 0 0.0031361905857920647
premature B-Disease 1 0.9999778270721436
death I-Disease 1 0.8910187482833862
. O 0 4.4965112465433776e-05

The O 0 0.0004044730158057064
hemochromatosis B-Disease 1 0.9999998807907104
gene O 0 0.00010581169044598937
, O 0 7.950227882247418e-06
HFE O 1 0.574613094329834
, O 0 1.024419020723144e-06
recently O 0 1.370651375509624e-06
has O 0 3.3843630831142946e-07
been O 0 5.453820222101058e-07
identified O 0 5.317605769050715e-07
, O 0 1.0898609303922058e-07
and O 0 1.0496774649482177e-07
characterization O 0 3.8792168197687715e-06
of O 0 1.5495841125812149e-06
this O 0 1.8991185868344473e-07
gene O 0 1.3970104362215352e-07
has O 0 1.2345785194156633e-07
shown O 0 6.881603553665627e-08
that O 0 3.60156313661264e-08
it O 0 1.562419171818874e-08
contains O 0 2.999396997438453e-08
two O 0 2.844412172464672e-08
mutations O 0 1.9751458069094951e-07
that O 0 2.030036228006793e-07
result O 0 1.530059307697229e-06
in O 0 1.986081315408228e-06
amino O 0 1.6563458302698564e-06
acid O 0 1.7822404743128573e-06
substitutions O 0 2.634523525557597e-06
- O 0 8.541586794308387e-06
cDNA O 0 1.2113874618080445e-05
nucleotides O 0 5.749045158154331e-06
845 O 0 8.073933713603765e-05
G O 0 5.6133230827981606e-05
- O 0 1.8118065781891346e-05
- O 0 2.0433137251529843e-05
> O 0 5.241750841378234e-06
A O 0 6.708839919156162e-06
( O 0 4.5379772473097546e-07
C282Y O 0 6.9378784246509895e-06
) O 0 1.519751435807848e-07
and O 0 1.403464153781897e-07
187 O 0 4.357336820248747e-06
C O 0 1.4106963135418482e-05
- O 0 1.2956023056176491e-05
- O 0 2.9035163606749848e-05
> O 0 1.8670556528377347e-05
G O 0 3.121465124422684e-05
( O 0 1.1332149369991384e-06
H63D O 0 0.00015055734547786415
) O 0 1.908887043100549e-06
. O 0 5.611731012322707e-06

Although O 0 0.0007007528329268098
hemochromatosis B-Disease 1 1.0
is O 0 1.0007220225816127e-05
common O 0 1.6516249843334663e-06
in O 0 2.087824213958811e-06
Caucasians O 0 4.810553036804777e-06
, O 0 3.163623318869213e-07
affecting O 0 1.1558432788660866e-06
> O 0 1.96135624719318e-06
= O 0 1.8393409391137538e-06
1 O 0 1.2181587862869492e-06
/ O 0 1.4333238596009323e-06
300 O 0 8.583509725212934e-08
individuals O 0 7.574194604842432e-09
of O 0 1.0983166731648453e-07
northern O 0 9.703024517193626e-08
European O 0 8.749849911282581e-08
origin O 0 4.291163691050315e-08
, O 0 2.1135699412866416e-08
it O 0 4.3255514725615285e-09
has O 0 2.62359609592977e-08
not O 0 1.3245949226359244e-08
been O 0 8.247378247006054e-08
recognized O 0 7.190514139665538e-08
in O 0 1.7350464531773468e-07
other O 0 1.7396077112152852e-07
populations O 0 1.636507249713759e-06
. O 0 6.008208401908632e-06

The O 0 1.4947872841730714e-05
present O 0 2.499910806363914e-06
study O 0 1.9273313682788284e-06
used O 0 2.055432560155168e-06
PCR O 0 2.6467814677744173e-05
and O 0 9.268467238143785e-07
restriction O 0 1.3222622328612488e-05
- O 0 4.1743605834199116e-06
enzyme O 0 4.823746166948695e-07
digestion O 0 7.968445174810768e-07
to O 0 1.2913348257370671e-07
analyze O 0 1.849038966383887e-07
the O 0 3.4716259733613697e-07
frequency O 0 2.2037693270249292e-06
of O 0 2.3637983304070076e-06
the O 0 5.50825734535465e-06
845 O 0 0.00021063890017103404
G O 0 9.964845230570063e-05
- O 0 1.8549624655861408e-05
- O 0 7.88560737419175e-06
> O 0 2.6820562197826803e-06
A O 0 2.880127112803166e-06
and O 0 5.312896291798097e-07
187 O 0 5.748112926085014e-06
C O 0 2.0960635083611123e-05
- O 0 9.971571671485435e-06
- O 0 1.4606664990424179e-05
> O 0 5.817194960400229e-06
G O 0 9.116361979977228e-06
mutations O 0 6.720370606672077e-07
in O 0 4.662174887926085e-06
HLA O 0 0.000785784621257335
- O 0 1.3811609278491233e-05
typed O 0 2.448119175824104e-06
samples O 0 2.9828640890627867e-07
from O 0 7.688397545280168e-07
non O 0 6.368004505930003e-06
- O 0 3.688491915454506e-06
Caucasian O 0 1.24482824048755e-06
populations O 0 1.0646996173591106e-07
, O 0 6.506268590555919e-08
comprising O 0 1.1188154047658827e-07
Australian O 0 1.399795110046398e-06
Aboriginal O 0 5.612092763840337e-07
, O 0 1.9172433951553103e-07
Chinese O 0 5.805888463328301e-07
, O 0 4.363423045106174e-07
and O 0 7.231707286337041e-07
Pacific O 0 2.495237822586205e-05
Islanders O 0 2.3693623006693088e-05
. O 0 1.3014945579925552e-05

Results O 0 0.00011786726099671796
showed O 0 4.3282077967887744e-05
that O 0 2.8056283554178663e-06
the O 0 7.091277439030819e-06
845 O 0 0.005737907253205776
G O 0 0.02829352207481861
- O 0 0.0003033907851204276
- O 0 7.670757622690871e-05
> O 0 3.4632639653864317e-06
A O 0 1.217888097926334e-06
mutation O 0 2.081779513218862e-07
was O 0 6.361311761793331e-07
present O 0 3.555464545001996e-08
in O 0 3.5278091559121094e-08
these O 0 9.54148138276878e-09
populations O 0 5.6721095376133235e-08
( O 0 5.221018994916449e-08
allele O 0 6.801079877050142e-08
frequency O 0 1.9915843552098522e-07
0 O 0 8.361101322407194e-08
. O 0 1.7915445127414387e-08
32 O 0 1.2221588008287654e-07
% O 0 7.767655318957623e-08
) O 0 7.216674902110753e-08
, O 0 4.679948162333858e-08
and O 0 4.4968178514182e-08
, O 0 1.036617689464947e-07
furthermore O 0 3.2651684023221605e-07
, O 0 8.862568989798092e-08
it O 0 3.946349380612446e-08
was O 0 3.3190469821420265e-06
always O 0 1.0815549700282645e-07
seen O 0 1.877193511745645e-07
in O 0 1.0074703737927848e-07
conjunction O 0 6.519374551317014e-07
with O 0 3.4602490472934733e-07
HLA O 0 0.0031626324634999037
haplotypes O 0 7.081991498125717e-06
common O 0 5.095120059195324e-07
in O 0 1.1261927284067497e-06
Caucasians O 0 2.485865479684435e-06
, O 0 5.219316108195926e-07
suggesting O 0 1.986926235986175e-06
that O 0 6.816085260652471e-07
845 O 0 0.0002714528236538172
G O 0 0.000850846990942955
- O 0 0.00013027121894992888
- O 0 4.9463615141576156e-05
> O 0 3.057055437238887e-06
A O 0 1.218986199091887e-06
may O 0 9.40766895496381e-08
have O 0 9.813053480911549e-09
been O 0 4.557606914090684e-08
introduced O 0 2.0347298956835402e-08
into O 0 2.7922494538756837e-08
these O 0 9.099493603059727e-09
populations O 0 6.810413566427087e-08
by O 0 3.4942161164508434e-07
Caucasian O 0 1.58150760398712e-05
admixture O 0 0.00011194668331881985
. O 0 1.6701724234735593e-05

187 O 0 0.0018299443181604147
C O 0 0.0018251235596835613
- O 0 0.00022876806906424463
- O 0 0.00012982121552340686
> O 0 3.715554703376256e-05
G O 0 2.780473732855171e-05
was O 0 3.521615326462779e-06
present O 0 2.491782424840494e-07
at O 0 7.866706823733693e-07
an O 0 1.46501520248421e-07
allele O 0 4.7662891233812843e-07
frequency O 0 1.731837301122141e-06
of O 0 4.696303221862763e-06
2 O 0 2.4799224775051698e-05
. O 0 1.653810977586545e-05

68 O 0 0.0002528030308894813
% O 0 6.979300906095887e-06
in O 0 9.577402124705259e-07
the O 0 6.997042305556533e-07
two O 0 1.266848528302944e-07
populations O 0 2.0972105119199114e-07
analyzed O 0 1.01382238426595e-06
( O 0 7.106578436832933e-07
Australian O 0 7.426915999531047e-06
Aboriginal O 0 1.9584292658691993e-06
and O 0 1.182581058856158e-06
Chinese O 0 8.177092240657657e-06
) O 0 2.01960619961028e-06
. O 0 6.603620477108052e-06

In O 0 5.5541280744364485e-05
the O 0 8.047593837545719e-06
Australian O 0 1.4722125342814252e-05
Aboriginal O 0 4.423034624778666e-06
samples O 0 1.3150988706911448e-06
, O 0 1.1407638567106915e-06
187 O 0 1.3053057045908645e-05
C O 0 9.715477062854916e-05
- O 0 4.4477525079855695e-05
- O 0 0.00016163715918082744
> O 0 2.0980734916520305e-05
G O 0 1.8170583643950522e-05
was O 0 3.1971308089850936e-06
found O 0 1.4520030333642353e-07
to O 0 8.829802311538515e-08
be O 0 4.812952738575405e-07
associated O 0 1.3279994846016052e-06
with O 0 9.47527780681412e-07
HLA O 1 0.9617655873298645
haplotypes O 0 7.209119758044835e-06
common O 0 3.5847179447046074e-07
in O 0 7.36539959689253e-07
Caucasians O 0 1.546075282021775e-06
, O 0 7.986653116631715e-08
suggesting O 0 2.2285486522832798e-07
that O 0 1.9376868110043688e-08
it O 0 2.4200005555030657e-08
was O 0 7.665657335564902e-07
introduced O 0 2.6513805551076075e-07
by O 0 1.770440150039576e-07
recent O 0 1.4199741826814716e-06
admixture O 0 3.752581324079074e-05
. O 0 9.71671033767052e-06

In O 0 3.938316513085738e-05
the O 0 6.356900485116057e-06
Chinese O 0 2.4686078177182935e-06
samples O 0 8.06630453098478e-07
analyzed O 0 1.5255192238328164e-06
, O 0 6.905032137183298e-07
187 O 0 6.293340447882656e-06
C O 0 5.659995804307982e-05
- O 0 6.435409159166738e-05
- O 0 0.00019926803361158818
> O 0 3.2078271033242345e-05
G O 0 1.927728771988768e-05
was O 0 2.1445146103360457e-06
present O 0 1.0964203767116487e-07
in O 0 1.9926179106732889e-07
association O 0 1.0277054229845817e-07
with O 0 1.4576243323460858e-08
a O 0 4.741173427191825e-07
wide O 0 1.16981505016156e-06
variety O 0 1.9305382181755704e-07
of O 0 2.0051043975399807e-05
HLA O 1 0.7606166005134583
haplotypes O 0 7.75210719439201e-06
, O 0 1.191506768805084e-07
showing O 0 2.32096226682188e-07
this O 0 1.398706928057436e-08
mutation O 0 4.3268986615885296e-08
to O 0 1.298709850772184e-08
be O 0 4.3452921261177835e-08
widespread O 0 8.635101949039381e-07
and O 0 1.7935143148406496e-07
likely O 0 3.841182376618235e-07
to O 0 1.0939470485027414e-07
predate O 0 2.755919012997765e-06
the O 0 3.6982731899115606e-07
more O 0 4.235430495214132e-08
genetically O 0 4.5217171873446205e-07
restricted O 0 2.4933467557275435e-06
845 O 0 0.00018840236589312553
G O 0 0.0001979688968276605
- O 0 2.328813206986524e-05
- O 0 2.968734952446539e-05
> O 0 5.001371391699649e-06
A O 0 5.635182787955273e-06
mutation O 0 6.6174006860819645e-06
. O 0 5.092918399896007e-06

Genotype O 0 0.1544266939163208
- O 0 0.006725020706653595
phenotype O 0 0.0006282753893174231
correlations O 0 0.00012110412353649735
in O 0 3.503264451865107e-05
attenuated B-Disease 1 0.9998307228088379
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.006885038688778877

Germ O 1 0.9999921321868896
- O 0 0.002786139724776149
line O 0 1.7262889741687104e-05
mutations O 0 1.9073856947215972e-06
of O 0 1.956196683750022e-06
the O 0 7.015951268840581e-06
tumor B-Disease 1 0.9999957084655762
suppressor O 1 0.9999948740005493
APC O 0 8.373580931220204e-05
are O 0 1.5100027894732193e-07
implicated O 0 1.0529241990298033e-05
in O 0 7.069494586176006e-06
attenuated B-Disease 1 0.9995342493057251
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9997106194496155
AAPC B-Disease 1 1.0
) O 0 6.452700631598418e-07
, O 0 1.8749285857211362e-07
a O 0 5.316475153449574e-07
variant O 0 4.197770067548845e-06
of O 0 1.784934283932671e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999487400054932
FAP B-Disease 1 0.999998927116394
) O 0 6.187216786202043e-05
. O 0 3.1651750759920105e-05

AAPC B-Disease 1 0.9999703168869019
is O 0 7.933232154755387e-06
recognized O 0 2.075741804219433e-06
by O 0 5.872209385415772e-07
the O 0 5.747706381953321e-07
occurrence O 0 3.5655402825796045e-06
of O 0 2.929519496319699e-06
< O 0 4.819613241124898e-05
100 O 0 5.725714345317101e-06
colonic B-Disease 1 0.9239146113395691
adenomas I-Disease 0 0.04480798915028572
and O 0 2.690715348308004e-07
a O 0 1.5876435099926312e-06
later O 0 6.597319497814169e-06
onset O 1 0.999819815158844
of O 1 0.9970049262046814
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.3582210815220606e-06
age O 0 6.401889550033957e-06
> O 0 3.4492750273784623e-06
40 O 0 1.774928136910603e-06
years O 0 3.108805913143442e-06
) O 0 5.03980481880717e-06
. O 0 1.085841631720541e-05

The O 0 1.0768431820906699e-05
aim O 0 4.777862613991601e-06
of O 0 8.349099402948923e-07
this O 0 2.8299510290707985e-07
study O 0 6.208289278220036e-07
was O 0 5.053694621892646e-06
to O 0 4.170140925907617e-07
assess O 0 5.036743914388353e-06
genotype O 0 7.890346751082689e-05
- O 0 0.010581664741039276
phenotype O 0 0.0019020530162379146
correlations O 0 0.0002284432848682627
in O 0 0.00010703840962378308
AAPC B-Disease 1 0.9999991655349731
families O 0 3.486820105536026e-06
. O 0 1.2368804163997993e-05

By O 0 0.0001043426018441096
protein O 0 9.932401007972658e-05
- O 0 8.318783511640504e-05
truncation O 0 0.0003756845253519714
test O 0 7.3972560130641796e-06
( O 0 9.07933156213403e-07
PTT O 0 2.900267645600252e-05
) O 0 2.5890528831951087e-07
assay O 0 2.1411835859908024e-06
, O 0 1.0764222935222278e-07
the O 0 1.3223890960034623e-07
entire O 0 3.638156442775653e-07
coding O 0 8.035094651859254e-07
region O 0 1.8605985019348736e-07
of O 0 5.955247388556018e-07
the O 0 1.0863706165764597e-06
APC B-Disease 0 4.720136530522723e-06
gene O 0 1.9408574303270143e-07
was O 0 1.3372592775340308e-06
screened O 0 5.284734356791887e-07
in O 0 1.1527595233928878e-07
affected O 0 1.6113278888951754e-07
individuals O 0 8.709256604788607e-08
from O 0 2.2194781195139512e-06
11 O 0 0.0005730024422518909
AAPC B-Disease 1 0.9999995231628418
kindreds O 0 4.562272079056129e-05
, O 0 3.573140929802321e-07
and O 0 5.1608910922595896e-08
their O 0 3.260973002738865e-08
phenotypic O 0 1.1599578328969073e-06
differences O 0 6.912965204719512e-07
were O 0 7.513960099458927e-06
examined O 0 6.079790910007432e-05
. O 0 2.411081914033275e-05

Five O 0 0.0001586971920914948
novel O 0 0.0003911081876140088
germ O 1 0.9995922446250916
- O 0 0.002013668417930603
line O 0 5.8880785218207166e-05
APC B-Disease 0 1.8956141502712853e-05
mutations O 0 7.622065254508925e-07
were O 0 5.508339313564647e-07
identified O 0 9.939944902725983e-07
in O 0 9.115614716392884e-07
seven O 0 5.505573881237069e-06
kindreds O 0 0.0001537030329927802
. O 0 2.502730603737291e-05

Mutations O 0 3.66293425031472e-05
were O 0 4.769185125041986e-06
located O 0 2.388220536886365e-06
in O 0 2.768241529338411e-07
three O 0 8.952853391974713e-08
different O 0 1.8981257454697698e-08
regions O 0 1.4115825308635976e-07
of O 0 1.8777518562274054e-06
the O 0 2.1744915557064814e-06
APC B-Disease 0 4.050203187944135e-06
gene O 0 3.485466208985599e-07
( O 0 1.9131120154725068e-07
1 O 0 5.052467031418928e-07
) O 0 9.802132439062916e-08
at O 0 5.59908073682891e-07
the O 0 1.4212893972853635e-07
5 O 0 4.3296444118823274e-07
end O 0 2.754760544121382e-07
spanning O 0 4.042347825361503e-07
exons O 0 6.672461267953622e-07
4 O 0 5.741871405007259e-07
and O 0 2.6087815285791294e-07
5 O 0 1.4517373756461893e-06
, O 0 2.3071166310728586e-07
( O 0 1.3092245865209406e-07
2 O 0 2.256029176805896e-07
) O 0 3.083778210566379e-08
within O 0 4.641624329337901e-08
exon O 0 4.3969370722152235e-07
9 O 0 8.903111279323639e-07
, O 0 1.1568077695756074e-07
and O 0 1.237485491856205e-07
( O 0 1.4840679796179757e-07
3 O 0 4.191019513655192e-07
) O 0 1.0053300059098547e-07
at O 0 8.94219283509301e-07
the O 0 4.786148792845779e-07
3 O 0 8.31549471058679e-07
distal O 0 5.635559318761807e-06
end O 0 6.162385375318991e-07
of O 0 6.385392907759524e-07
the O 0 1.7061930748241139e-06
gene O 0 5.090101694804616e-06
. O 0 9.687334568297956e-06

Variability O 0 0.0002834069018717855
in O 0 6.3508950916002505e-06
the O 0 1.1141511322421138e-06
number O 0 1.8802013528329553e-06
of O 0 0.01479610800743103
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.8868054747581482
most O 0 1.909055100668411e-07
apparent O 0 2.5020121938723605e-06
in O 0 7.676310076476511e-08
individuals O 0 8.249750216293705e-09
with O 0 1.6855446816066433e-08
mutations O 0 1.1135059452271889e-07
in O 0 2.953499347313482e-07
region O 0 1.094535264201113e-06
1 O 0 4.1658818190626334e-06
, O 0 1.7985979638979188e-06
and O 0 9.446303920412902e-06
upper O 1 0.9999830722808838
- O 1 0.9999988079071045
gastrointestinal O 1 0.9999998807907104
manifestations O 1 0.9995291233062744
were O 0 1.564392186992336e-05
more O 0 2.8754234904226905e-07
severe O 0 0.1828790158033371
in O 0 4.055718818563037e-06
them O 0 8.438159397883283e-07
. O 0 8.51455388328759e-06

In O 0 1.2727565263048746e-05
individuals O 0 3.8524228784808656e-07
with O 0 1.8776663068820199e-07
mutations O 0 8.899563113118347e-07
in O 0 7.223256375255005e-07
either O 0 1.43195876489699e-07
region O 0 2.597500952106202e-07
2 O 0 4.339478323345247e-07
or O 0 1.0522633431264694e-07
region O 0 2.903636016071687e-07
3 O 0 4.687926207225246e-07
, O 0 7.199750484687684e-08
the O 0 5.630792543342977e-08
average O 0 1.0832106767111327e-07
number O 0 7.408061719615944e-08
of O 0 1.3134770142642083e-06
adenomas B-Disease 0 0.0003723209665622562
tended O 0 5.005332468499546e-07
to O 0 1.1233893815187912e-07
be O 0 2.7930732926506607e-07
lower O 0 1.5261697399182594e-06
than O 0 2.3591892883700893e-08
those O 0 7.082517239354047e-09
in O 0 2.2974901980887807e-08
individuals O 0 5.62410296112148e-09
with O 0 8.031117104678742e-09
mutations O 0 8.159163655818702e-08
in O 0 8.556261832382006e-08
region O 0 2.599890081000922e-07
1 O 0 4.0568264125795395e-07
, O 0 6.197440427513357e-08
although O 0 5.0640927895528876e-08
age O 0 3.3108167940554267e-07
at O 0 6.724897957610665e-06
diagnosis O 0 0.00015919671568553895
was O 0 4.7507721319561824e-05
similar O 0 2.5515912511764327e-06
. O 0 8.663330845593009e-06

In O 0 5.548628541873768e-05
all O 0 2.3607397451996803e-05
AAPC B-Disease 1 0.9999949932098389
kindreds O 0 0.00014525491860695183
, O 0 1.385036966894404e-06
a O 0 3.224757620046148e-06
predominance O 0 0.00020387882250361145
of O 0 7.675820961594582e-05
right O 1 0.9409961700439453
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9892731308937073
rectal B-Disease 1 1.0
polyp I-Disease 1 1.0
sparing O 0 0.00025724153965711594
was O 0 0.0003048614307772368
observed O 0 2.4357896108995192e-05
. O 0 7.827031367924064e-06

No O 0 0.0005396027700044215
desmoid B-Disease 1 0.9997430443763733
tumors I-Disease 1 0.9999998807907104
were O 0 1.5144492863328196e-05
found O 0 2.6635580070433207e-06
in O 0 1.4596073469874682e-06
these O 0 1.1835107898150454e-06
kindreds O 0 0.000233340440900065
. O 0 2.0321902411524206e-05

Our O 0 1.971986966964323e-05
data O 0 7.96640870248666e-06
suggest O 0 2.7402234081819188e-06
that O 0 6.156682275104686e-07
, O 0 9.740682571646175e-07
in O 0 4.824579264095519e-06
AAPC B-Disease 1 0.999994158744812
families O 0 2.894200576974981e-07
, O 0 1.6729100593693147e-07
the O 0 2.0500321795680065e-07
location O 0 7.417420988531376e-07
of O 0 1.046096372192551e-06
the O 0 2.674822326298454e-06
APC B-Disease 0 2.8748156182700768e-05
mutation O 0 1.7242714420717675e-06
may O 0 1.1112840638816124e-06
partially O 0 4.33520290243905e-06
predict O 0 5.170892336536781e-07
specific O 0 2.1534798122502252e-07
phenotypic O 0 6.711130481562577e-06
expression O 0 2.043984022748191e-05
. O 0 1.5654846720281057e-05

This O 0 6.014761311234906e-06
should O 0 5.559170404012548e-07
help O 0 1.8521733124998718e-07
in O 0 2.424910405807168e-07
the O 0 4.069772785442183e-07
design O 0 2.6466866529517574e-06
of O 0 2.0972736365365563e-06
tailored O 0 1.0350177035434172e-05
clinical O 1 0.8257641196250916
- O 0 0.013761734589934349
management O 0 6.054470759409014e-06
protocols O 0 6.792834028601646e-07
in O 0 1.078530829090596e-07
this O 0 1.1162043023205115e-07
subset O 0 1.0754408776847413e-06
of O 0 2.423161276965402e-06
FAP B-Disease 0 0.0004124586412217468
patients O 0 3.5784305509878322e-06
. O 0 1.9640517621155595e-06
. O 0 7.03407977198367e-06

Wilms B-Disease 1 0.99994957447052
' I-Disease 0 0.0022176080383360386
tumor I-Disease 1 0.9676623940467834
1 O 0 4.038259794469923e-05
and O 0 5.720927219954319e-06
Dax O 1 0.9999428987503052
- O 0 2.192875945183914e-05
1 O 0 1.8287363445779192e-06
modulate O 0 3.0992830488685286e-06
the O 0 9.286675890507468e-07
orphan O 0 1.724110552459024e-05
nuclear O 0 1.5909166904748417e-05
receptor O 0 2.642897015903145e-05
SF O 1 0.9775379300117493
- O 0 4.550893663690658e-06
1 O 0 7.408485203086457e-07
in O 0 1.0981511877616867e-07
sex O 0 2.601333619622892e-07
- O 0 1.318011754847248e-06
specific O 0 1.1052978976522354e-07
gene O 0 2.133954922101111e-06
expression O 0 1.900570532598067e-05
. O 0 1.0703499356168322e-05

Products O 0 0.00012928283831570297
of O 0 3.153800935251638e-05
steroidogenic O 0 0.000874579360242933
factor O 0 1.592486114532221e-05
1 O 0 7.228352842503227e-06
( O 0 2.930002665380016e-06
SF O 0 0.07495269924402237
- O 0 9.2212540039327e-06
1 O 0 1.6800389630589052e-06
) O 0 2.787328128306399e-07
and O 0 7.639370096512721e-07
Wilms B-Disease 1 0.982075035572052
tumor I-Disease 1 0.9824879765510559
1 O 0 5.493086973729078e-06
( O 0 6.283663651629467e-07
WT1 O 0 1.946837619470898e-05
) O 0 4.3632645940760995e-08
genes O 0 3.205142107276515e-08
are O 0 1.890332690379637e-08
essential O 0 1.481550953030819e-07
for O 0 1.5898238814315846e-07
mammalian O 0 9.154922736342996e-06
gonadogenesis O 0 1.5138053640839644e-05
prior O 0 9.431444709662173e-07
to O 0 3.058476636397245e-07
sexual O 0 5.0608177843969315e-06
differentiation O 0 0.0002555908286012709
. O 0 2.6161811547353864e-05

In O 0 5.1026090659433976e-05
males O 0 1.0147588909603655e-05
, O 0 9.035262337420136e-06
SF O 1 0.9173749089241028
- O 0 8.16604915598873e-06
1 O 0 6.10511847298767e-07
participates O 0 9.661952304895749e-08
in O 0 5.439645178739738e-08
sexual O 0 8.22436447833752e-08
development O 0 3.362447955623793e-07
by O 0 1.1245963804640269e-07
regulating O 0 5.002536340725783e-07
expression O 0 6.792789122300746e-07
of O 0 2.3017505554889794e-06
the O 0 1.023654385789996e-05
polypeptide O 0 0.00021957287390250713
hormone O 0 6.705763371428475e-05
Mullerian O 0 0.0005544968298636377
inhibiting O 0 0.00011758437176467851
substance O 0 4.0668506699148566e-05
( O 0 1.8133501725969836e-05
MIS O 1 0.9965841770172119
) O 0 9.709866390039679e-06
. O 0 1.0996285709552467e-05

Here O 0 6.258390931179747e-05
, O 0 3.428152467677137e-06
we O 0 7.205161978163233e-07
show O 0 2.4023054265853716e-06
that O 0 3.0108492410363397e-06
WT1 O 0 0.0019076940370723605
- O 0 0.00017612436204217374
KTS O 0 0.06663496792316437
isoforms O 0 3.03087131214852e-06
associate O 0 4.2644442146411166e-06
and O 0 4.947306706526433e-07
synergize O 0 8.730211447982583e-06
with O 0 1.5130109431993333e-06
SF O 1 0.9999922513961792
- O 0 2.3580800188938156e-05
1 O 0 1.280053538721404e-06
to O 0 4.463411187316524e-07
promote O 0 6.482883691205643e-06
MIS O 1 0.9926286935806274
expression O 0 5.0479909987188876e-05
. O 0 1.9764374883379787e-05

In O 0 2.7718269848264754e-05
contrast O 0 1.9506043827277608e-05
, O 0 4.85428699903423e-06
WT1 O 0 0.0007740934961475432
missense O 0 8.868070290191099e-05
mutations O 0 2.851429599104449e-05
, O 0 3.046537131012883e-06
associated O 0 4.88793421027367e-06
with O 0 8.211415547521028e-07
male B-Disease 0 0.00965422298759222
pseudohermaphroditism I-Disease 1 1.0
in O 0 0.00022797392739448696
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 4.257832642906578e-06
fail O 0 1.0539522463659523e-06
to O 0 5.323111054167384e-07
synergize O 0 5.8387457102071494e-05
with O 0 1.4791038665862288e-05
SF O 1 0.9999998807907104
- O 0 0.0552358515560627
1 O 0 4.2449741158634424e-05
. O 0 9.38426728680497e-06

Additionally O 0 0.00011590275971684605
, O 0 1.185724340757588e-05
the O 0 8.897424777387641e-06
X O 0 0.000447682075900957
- O 0 0.00045054874499328434
linked O 0 0.0001177777157863602
, O 0 1.822169679144281e-06
candidate O 0 9.316507203038782e-06
dosage O 0 9.97140450635925e-05
- O 0 2.1725951228290796e-05
sensitive O 0 7.88759280112572e-06
sex O 0 9.833777312451275e-07
- O 0 9.108749509323388e-06
reversal O 0 1.4201503290678374e-05
gene O 0 7.230369192257058e-07
, O 0 8.047517781051283e-07
Dax O 1 0.9471262097358704
- O 0 5.791902367491275e-06
1 O 0 1.3064322956779506e-06
, O 0 2.658561299995199e-07
antagonizes O 0 1.852234731813951e-06
synergy O 0 8.063743166530912e-07
between O 0 1.460749217585544e-06
SF O 1 0.7352784276008606
- O 0 6.604760528716724e-06
1 O 0 9.711945949675282e-07
and O 0 4.2692443003033986e-07
WT1 O 0 2.982324076583609e-05
, O 0 1.1969940771905385e-07
most O 0 3.08422549721854e-08
likely O 0 6.946591923906453e-08
through O 0 4.466071956699125e-08
a O 0 1.353358811684302e-07
direct O 0 2.759006747510284e-07
interaction O 0 5.887270617677132e-07
with O 0 1.98422799257969e-06
SF O 1 0.9999891519546509
- O 0 7.975861080922186e-05
1 O 0 1.6280253475997597e-05
. O 0 4.3271238610032015e-06

We O 0 1.3178396329749376e-05
propose O 0 1.3210496945248451e-05
that O 0 4.0742920646152925e-06
WT1 O 0 0.0005323145305737853
and O 0 1.219195473822765e-05
Dax O 1 0.9997915625572205
- O 0 1.5049815374368336e-05
1 O 0 1.0508038030820899e-06
functionally O 0 7.079156603140291e-07
oppose O 0 8.031457809920539e-08
each O 0 1.5101949912832424e-08
other O 0 2.264832410503459e-08
in O 0 3.327549222831294e-07
testis O 0 2.3071805117069744e-05
development O 0 1.8530333818489453e-06
by O 0 1.7825361737777712e-06
modulating O 0 0.00018883329175878316
SF O 1 0.9978569149971008
- O 0 2.957364085887093e-05
1 O 0 6.337614649964962e-06
- O 0 9.905604201776441e-06
mediated O 0 1.1662843462545425e-05
transactivation O 0 4.8747951950645074e-05
. O 0 1.3505857623385964e-06
. O 0 5.964301180938492e-06

A O 0 0.00042082162690348923
mouse O 0 7.630209438502789e-05
model O 0 2.491039049346e-05
for O 0 3.861357254208997e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999988079071045
centre O 1 0.9995346069335938
mutations O 0 0.00014269530947785825
. O 0 2.0021197997266427e-05

Imprinting O 0 0.0033230879344046116
in O 0 9.446468175156042e-05
the O 0 3.4959321055794135e-05
15q11 O 0 0.0024519090075045824
- O 0 0.00017335294978693128
q13 O 0 0.0001469987037125975
region O 0 1.820502234295418e-06
involves O 0 1.5434220586030278e-06
an O 0 2.4583362119301455e-06
imprinting O 0 5.124020390212536e-05
centre O 0 0.00013748882338404655
( O 0 6.289839120654506e-07
IC O 0 3.8248075725277886e-05
) O 0 8.377335092291105e-08
, O 0 3.5151145993950195e-08
mapping O 0 2.518400776807539e-07
in O 0 6.828623355659147e-08
part O 0 1.3262209108688694e-07
to O 0 1.2925644909955736e-07
the O 0 1.3436113022180507e-06
promoter O 0 2.9247708880575374e-05
and O 0 6.303392297013488e-07
first O 0 7.069427738315426e-06
exon O 0 2.0350486011011526e-05
of O 0 5.895990034332499e-05
SNRPN O 1 0.6551960110664368
. O 0 3.8079131627455354e-05

Deletion O 0 0.0003462093591224402
of O 0 2.876971302612219e-05
this O 0 6.888648385938723e-06
IC O 0 0.0016109355492517352
abolishes O 0 3.37898381985724e-05
local O 0 9.560892522131326e-07
paternally O 0 6.525023309222888e-06
derived O 0 5.046004503128643e-07
gene O 0 4.6786630036876886e-07
expression O 0 1.2695047644228907e-06
and O 0 2.565242027685599e-07
results O 0 2.302552047694917e-06
in O 0 3.883277531713247e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999990463256836
PWS B-Disease 1 1.0
) O 0 0.0012964173220098019
. O 0 5.592011075350456e-05

We O 0 8.620278094895184e-06
have O 0 5.683436370418349e-07
created O 0 4.3297265506225813e-07
two O 0 1.6485799392285116e-07
deletion O 0 2.598605988168856e-06
mutations O 0 5.86576163641439e-07
in O 0 6.069045070944412e-07
mice O 0 2.5814738364715595e-06
to O 0 4.089225456027634e-07
understand O 0 2.560051598266e-06
PWS B-Disease 1 1.0
and O 0 7.133331791919773e-07
the O 0 8.760493415138626e-07
mechanism O 0 1.984968093893258e-06
of O 0 2.2608458039030666e-06
this O 0 2.6818261176231317e-06
IC O 0 0.0006890156655572355
. O 0 1.0194077731284779e-05

Mice O 0 0.006752645131200552
harbouring O 0 0.10357809066772461
an O 0 4.132893081987277e-05
intragenic O 0 0.0021449991036206484
deletion O 0 6.936085992492735e-05
in O 0 3.2975992780848173e-06
Snrpn O 0 0.0002317381149623543
are O 0 2.6904794481197314e-07
phenotypically O 0 1.1701380572048947e-05
normal O 0 1.3301543049237807e-06
, O 0 1.31767833977392e-07
suggesting O 0 2.5408263581994106e-07
that O 0 2.7799529789263033e-08
mutations O 0 2.662214626525383e-07
of O 0 1.5151596244322718e-06
SNRPN O 0 9.015426621772349e-05
are O 0 6.08050427786111e-08
not O 0 1.0148221463168738e-07
sufficient O 0 8.234408710450225e-07
to O 0 1.599122356310545e-06
induce O 0 0.003515382995828986
PWS B-Disease 1 1.0
. O 0 0.00016716601385269314

Mice O 0 0.00015249152784235775
with O 0 1.2261718893569196e-06
a O 0 2.5096403533098055e-06
larger O 0 6.399445169336104e-07
deletion O 0 2.795692580548348e-06
involving O 0 1.2240034266142175e-06
both O 0 7.962648851389531e-07
Snrpn O 0 0.00011979249393334612
and O 0 6.779437171644531e-07
the O 0 6.856958407297498e-06
putative O 1 0.8877585530281067
PWS O 1 1.0
- O 1 0.9951573014259338
IC O 1 0.8704231977462769
lack O 0 3.4447191410436062e-06
expression O 0 1.5383185427708668e-06
of O 0 1.897932179417694e-06
the O 0 2.46208333010145e-06
imprinted O 0 1.4317213754111435e-05
genes O 0 3.039998546228162e-06
Zfp127 O 0 0.00030505910399369895
( O 0 2.8213485165906604e-06
mouse O 0 1.2133054951846134e-05
homologue O 0 3.581956843845546e-05
of O 0 5.551760750677204e-06
ZNF127 O 0 0.0014923270791769028
) O 0 1.0264081993227592e-06
, O 0 9.606545745555195e-07
Ndn O 0 5.715417501050979e-05
and O 0 1.0126979077540454e-06
Ipw O 0 6.90933593432419e-05
, O 0 2.785569108709751e-07
and O 0 1.512646008450247e-07
manifest O 0 1.2114959417885984e-06
several O 0 2.1441086062168324e-07
phenotypes O 0 1.0835928151209373e-05
common O 0 6.524836862809025e-06
to O 0 2.667834996827878e-05
PWS B-Disease 1 1.0
infants O 1 0.9934619665145874
. O 0 4.8437803343404084e-05

These O 0 3.6886713132844307e-06
data O 0 4.62598609374254e-06
demonstrate O 0 2.104568693539477e-06
that O 0 2.351570600467312e-07
both O 0 2.2015541389919235e-07
the O 0 7.718209644735907e-07
position O 0 1.5302140354833682e-06
of O 0 1.4316148053694633e-06
the O 0 2.49909567173745e-06
IC O 0 0.00013272972137201577
and O 0 1.6949348946582177e-07
its O 0 2.0045493442921725e-07
role O 0 6.498027573798026e-07
in O 0 3.8989975337244687e-07
the O 0 3.9233472648447787e-07
coordinate O 0 2.0375189535570826e-07
expression O 0 6.314625125014572e-07
of O 0 6.877666010041139e-07
genes O 0 2.695883267733734e-07
is O 0 1.8972937709804683e-07
conserved O 0 2.562962890806375e-07
between O 0 3.045132359602576e-07
mouse O 0 1.271182668460824e-06
and O 0 6.768662785816559e-08
human O 0 2.4000377152333385e-07
, O 0 1.0371160641398092e-07
and O 0 7.279840730234355e-08
indicate O 0 3.880143140122527e-07
that O 0 7.383136590988215e-08
the O 0 5.711941639674478e-07
mouse O 0 1.201791747007519e-06
is O 0 9.466690897852459e-08
a O 0 1.3760720207756094e-07
suitable O 0 1.1864722182508558e-07
model O 0 1.3144828869826597e-07
system O 0 4.3704943664124585e-08
in O 0 2.926285880278101e-08
which O 0 1.5539075803872038e-08
to O 0 2.630932272040809e-08
investigate O 0 1.20856086027743e-07
the O 0 2.849957922990143e-07
molecular O 0 5.317769591783872e-06
mechanisms O 0 5.774627993559989e-07
of O 0 8.056525189203967e-07
imprinting O 0 7.71967552282149e-06
in O 0 1.8333413720483804e-07
this O 0 5.6699029471474205e-08
region O 0 1.0238746028790047e-07
of O 0 4.149943322317995e-07
the O 0 1.2573258345582872e-06
genome O 0 2.903549329857924e-06
. O 0 1.211661128763808e-06
. O 0 7.190937139966991e-06

Mutations O 0 9.654375753598288e-05
of O 0 1.832738234952558e-05
the O 0 4.3356790229154285e-06
ATM O 0 8.77096681506373e-05
gene O 0 3.3791104669944616e-06
detected O 0 1.4674689737148583e-05
in O 0 5.987405074847629e-06
Japanese O 1 0.9812098145484924
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.5673835277557373
: O 0 4.56187763120397e-07
possible O 0 3.8225053344831394e-07
preponderance O 0 1.8044969692709856e-05
of O 0 6.436738999582303e-07
the O 0 5.110103415972844e-07
two O 0 2.7712025030268705e-07
founder O 0 2.7325400878908113e-05
mutations O 0 4.510657618084224e-06
4612del165 O 0 0.0004758928553201258
and O 0 2.928136382251978e-05
7883del5 O 1 0.5430924892425537
. O 0 4.623899076250382e-05

The O 0 0.00015981847536750138
ATM O 0 0.003577938536182046
( O 0 9.772593330126256e-05
A O 1 0.9999929666519165
- O 1 0.9999922513961792
T O 1 0.9999934434890747
, O 0 8.024840667530952e-07
mutated O 0 1.6595129181951052e-06
) O 0 2.528643392452068e-07
gene O 0 3.758096340789052e-07
on O 0 2.309719548065914e-06
human O 0 9.482496352575254e-06
chromosome O 0 0.33015570044517517
11q22 O 1 0.9469040632247925
. O 0 4.409498069435358e-05

3 O 0 3.0976942070992664e-05
has O 0 2.0690501969511388e-06
recently O 0 1.5715040717623197e-06
been O 0 5.159513420949224e-07
identified O 0 3.407850499570486e-07
as O 0 1.0025056695894818e-07
the O 0 1.4574803230971156e-07
gene O 0 3.539490194270911e-07
responsible O 0 4.291843254122796e-07
for O 0 1.4047255092464184e-07
the O 0 2.3494551442126976e-06
human O 0 0.005485524423420429
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999967813491821
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.1195030058152042e-05
. O 0 1.2650833014049567e-05

In O 0 1.0009004654421005e-05
order O 0 1.4090609283812228e-06
to O 0 3.2138908068191085e-07
define O 0 5.839762025061646e-07
the O 0 8.909651114663575e-07
types O 0 7.789849405526184e-07
of O 0 2.524223964428529e-05
disease O 1 0.9999681711196899
- O 0 0.009991991333663464
causing O 0 2.5496196030871943e-05
ATM O 0 7.468224794138223e-05
mutations O 0 7.841719025236671e-07
in O 0 1.6963869029495982e-06
Japanese O 0 0.0021980800665915012
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999979734420776
T I-Disease 1 0.9999970197677612
patients O 0 2.103492136029672e-07
as O 0 7.599971496574653e-08
well O 0 3.808277426742279e-08
as O 0 4.4143266819673954e-08
to O 0 1.873926969153672e-08
look O 0 7.439552973664831e-08
for O 0 6.382494888157453e-08
possible O 0 5.520729473573738e-07
mutational O 0 5.9251528000459075e-05
hotspots O 0 1.5983348930603825e-05
, O 0 6.749775138814584e-07
reverse O 0 6.5673380049702246e-06
- O 0 6.5102426560770255e-06
transcribed O 0 8.096044439298566e-06
RNA O 0 4.234826519677881e-06
derived O 0 4.3339696276234463e-07
from O 0 1.6670524871642556e-07
ten O 0 2.2956774614613096e-07
patients O 0 8.306373189270744e-08
belonging O 0 3.1826729696149414e-07
to O 0 8.428317244124628e-08
eight O 0 8.943063676269958e-07
unrelated O 0 5.417753072833875e-06
Japanese O 0 0.004436114337295294
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999574422836304
T I-Disease 1 0.9963424801826477
families O 0 6.383456252478936e-08
was O 0 1.0522709317228873e-06
analyzed O 0 1.5313409562622837e-07
for O 0 4.8713815203882405e-08
mutations O 0 1.3862906200756697e-07
by O 0 1.2865199039424624e-07
the O 0 5.973164434180944e-07
restriction O 0 3.274640675954288e-06
endonuclease O 0 5.1678911404451355e-05
fingerprinting O 0 1.317658734478755e-05
method O 0 1.2516906281234697e-05
. O 0 1.4953989193600137e-05

As O 0 1.8797760276356712e-05
has O 0 2.1793348423670977e-06
been O 0 8.439069461019244e-07
reported O 0 1.0628892823660863e-06
by O 0 2.2103859009803273e-07
others O 0 6.129339880089901e-08
, O 0 4.467741732128161e-08
mutations O 0 1.1193895943506504e-07
that O 0 8.943449358866928e-08
lead O 0 5.953328354735277e-07
to O 0 1.9633573344890465e-07
exon O 0 1.2385010450088885e-05
skipping O 0 7.512519459851319e-06
or O 0 1.3807954246658483e-06
premature O 0 2.3967148081283085e-05
protein O 0 1.951903414010303e-06
truncation O 0 5.2787061576964334e-05
were O 0 1.0477177738721366e-06
also O 0 2.4328903691639425e-07
predominant O 0 1.774471115822962e-06
in O 0 3.800702472744888e-07
our O 0 8.026157161111769e-07
mutants O 0 1.5689503925386816e-05
. O 0 6.5941617322096135e-06

Six O 0 4.4347343646222726e-06
different O 0 1.844285577590199e-07
mutations O 0 8.670105557939678e-07
were O 0 6.715367248943949e-07
identified O 0 5.744254281125905e-07
on O 0 1.9441970380285056e-06
12 O 0 8.877624395609018e-07
of O 0 7.659570542273286e-07
the O 0 8.22710887860012e-07
16 O 0 3.4438189686625265e-06
alleles O 0 4.5680517359869555e-06
examined O 0 2.468610546202399e-05
. O 0 1.6462106941617094e-05

Four O 0 1.7182213923661038e-05
were O 0 3.971157184423646e-06
deletions O 0 1.1516026461322326e-05
involving O 0 4.20511878473917e-06
a O 0 6.611887783947168e-06
loss O 0 1.2869637430412695e-05
of O 0 4.594343408825807e-06
a O 0 4.7179228204186074e-06
single O 0 1.6504266113770427e-06
exon O 0 3.5200368984078523e-06
exon O 0 3.3477149372629356e-06
7 O 0 2.176769612560747e-06
, O 0 2.6052163093481795e-07
exon O 0 9.16390320071514e-07
16 O 0 1.2967676639163983e-06
, O 0 2.917832091497985e-07
exon O 0 3.6652538710768567e-06
33 O 0 4.430904482433107e-06
or O 0 1.6063826251411228e-06
exon O 0 1.8557213479653e-05
35 O 0 2.9036604246357456e-05
. O 0 1.4230245142243803e-05

The O 0 6.47712149657309e-05
others O 0 3.609290388340014e-06
were O 0 1.6090228882603697e-06
minute O 0 2.3370703274849802e-06
deletions O 0 5.094457719678758e-06
, O 0 6.660744134023844e-07
4649delA O 0 3.595747330109589e-06
in O 0 9.513125291960023e-07
exon O 0 3.959974492317997e-06
33 O 0 4.9116720219899435e-06
and O 0 1.179056312139437e-06
7883del5 O 0 0.00017351831775158644
in O 0 5.208335096540395e-06
exon O 0 4.400697798701003e-05
55 O 0 3.4788408811436966e-05
. O 0 1.53915516420966e-05

The O 0 5.257395241642371e-05
mutations O 0 7.321503653656691e-05
4612del165 O 0 0.0006283766124397516
and O 0 2.991500878124498e-06
7883del5 O 0 5.155683174962178e-05
were O 0 1.2174097037132015e-06
found O 0 3.4489650602154143e-07
in O 0 1.5684483400946192e-07
more O 0 2.4214644511744154e-08
than O 0 3.982098206734008e-08
two O 0 5.133265190693237e-08
unrelated O 0 4.4983707425672037e-07
families O 0 6.821645825993983e-08
; O 0 1.1669442301354138e-07
44 O 0 1.2818236427847296e-06
% O 0 3.9664001860728604e-07
( O 0 3.138106023925502e-07
7 O 0 1.3471253623720258e-06
of O 0 6.68202631004533e-07
16 O 0 7.940112141113786e-07
) O 0 4.0566050074630766e-08
of O 0 7.714575644968136e-08
the O 0 1.0992870613790728e-07
mutant O 0 3.8186502138159995e-07
alleles O 0 1.6318149675953464e-07
had O 0 4.6671030418110604e-07
one O 0 1.0674793315956776e-07
of O 0 5.26230905961711e-07
the O 0 4.993223114979628e-07
two O 0 4.4014933564540115e-07
mutations O 0 1.421152956027072e-05
. O 0 1.329654514847789e-05

The O 0 0.00011533904034877196
4612del165 O 0 0.000360930513124913
mutations O 0 8.39715085021453e-06
in O 0 8.339073360730254e-07
three O 0 1.383292982382045e-07
different O 0 7.260382961504774e-09
families O 0 2.090472683846656e-08
were O 0 1.3294855705225928e-07
all O 0 4.912416784463858e-08
ascribed O 0 1.6409550198659417e-06
to O 0 1.98902569081838e-07
the O 0 1.636081265132816e-06
same O 0 5.335488367563812e-06
T O 0 0.0012551413383334875
- O 0 2.93096909445012e-05
- O 0 2.1936748453299515e-05
> O 0 3.4683703233895358e-06
A O 0 3.544195578797371e-06
substitution O 0 1.4346832131195697e-06
at O 0 6.913189736224012e-07
the O 0 2.8719048827952065e-07
splice O 0 1.5517964584432775e-06
donor O 0 7.241313824124518e-07
site O 0 9.763560910869273e-07
in O 0 2.5690123948152177e-06
intron O 0 0.00028779805870726705
33 O 0 9.488567593507469e-05
. O 0 2.556607432779856e-05

Microsatellite O 0 0.0030521294102072716
genotyping O 0 0.0002834341721609235
around O 0 6.419705186999636e-06
the O 0 2.4923103865148732e-06
ATM O 0 3.543621642165817e-05
locus O 0 1.4441357052419335e-05
also O 0 3.440358113948605e-07
indicated O 0 3.881782504322473e-07
that O 0 4.459993974137433e-08
a O 0 2.87980356006301e-07
common O 0 3.17795667115206e-07
haplotype O 0 1.0422166269563604e-05
was O 0 2.6532243282417767e-06
shared O 0 1.4558328587099822e-07
by O 0 1.3338313920030487e-07
the O 0 1.7320490997008164e-07
mutant O 0 1.418975102751574e-06
alleles O 0 4.041696399781358e-07
in O 0 4.6113618168419634e-07
both O 0 6.057007340132259e-07
mutations O 0 1.5822481145733036e-05
. O 0 1.3601829778053798e-05

This O 0 1.4195126823324244e-05
suggests O 0 6.179208412504522e-06
that O 0 2.3897734990896424e-07
these O 0 6.821450426741649e-08
two O 0 2.76898106221779e-07
founder O 0 1.6721854990464635e-05
mutations O 0 1.2422547115420457e-06
may O 0 1.28039903302124e-06
be O 0 1.5592314639434335e-07
predominant O 0 2.750922021732549e-06
among O 0 1.412845733739232e-07
Japanese O 0 4.965958396496717e-06
ATM O 0 5.690910620614886e-05
mutant O 0 2.6373558284831233e-05
alleles O 0 1.3406122889136896e-05
. O 0 1.4659248336101882e-05

W474C O 0 0.08644084632396698
amino O 0 0.00048740251804701984
acid O 0 3.54281764884945e-05
substitution O 0 1.7070986359613016e-05
affects O 0 1.8922355593531393e-06
early O 0 6.784586048524943e-07
processing O 0 1.3837853884979268e-06
of O 0 8.979658332464169e-07
the O 0 5.489664545166306e-07
alpha O 0 2.2812955648987554e-06
- O 0 3.7052100765322393e-07
subunit O 0 1.8490742093035806e-07
of O 0 5.294152174428746e-07
beta O 0 2.573058054622379e-06
- O 0 5.566588697547559e-06
hexosaminidase O 0 2.0815557945752516e-05
A O 0 4.731832177640172e-06
and O 0 2.3858044073676865e-07
is O 0 6.23669052401965e-07
associated O 0 1.2182761111034779e-06
with O 0 1.6280482668662444e-06
subacute O 1 0.9999994039535522
G B-Disease 1 0.9957742094993591
( I-Disease 0 1.658381734159775e-05
M2 I-Disease 1 0.9985359907150269
) I-Disease 0 1.067297034751391e-05
gangliosidosis I-Disease 0 0.00037560504279099405
. O 0 1.692531986918766e-05

Mutations O 0 0.00015533019904978573
in O 0 1.709940261207521e-05
the O 0 1.1920246834051795e-05
HEXA O 0 0.002730517415329814
gene O 0 2.301454287589877e-06
, O 0 4.69082408471877e-07
encoding O 0 3.249676296945836e-07
the O 0 8.36585229535558e-07
alpha O 0 2.5396154796908377e-06
- O 0 1.2061698271281784e-06
subunit O 0 2.873962614557968e-07
of O 0 7.947331255309109e-07
beta O 0 2.460731138853589e-06
- O 0 2.2524077394336928e-06
hexosaminidase O 0 1.3777721505903173e-05
A O 0 7.210371222754475e-06
( O 0 3.2850832099029503e-07
Hex O 0 5.931673513259739e-06
A O 0 1.9409421838645358e-06
) O 0 9.672222489598425e-08
, O 0 3.5572824685914384e-08
that O 0 3.249139624017516e-08
abolish O 0 7.028890536275867e-07
Hex O 0 5.40925520908786e-06
A O 0 1.4239067240851e-06
enzyme O 0 1.026292693495634e-06
activity O 0 1.6536972907488234e-05
cause O 1 0.9793955683708191
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999926090240479
( O 0 4.6522436605300754e-06
TSD B-Disease 0 0.48601749539375305
) O 0 2.345984171370219e-07
, O 0 1.4370587564371817e-07
the O 0 1.0386527264927281e-06
fatal O 0 0.10561612993478775
infantile B-Disease 0 0.4536241888999939
form I-Disease 0 9.9235126072017e-07
of I-Disease 0 0.0008287354721687734
G I-Disease 0 0.005203606560826302
( I-Disease 0 2.2009317035553977e-06
M2 I-Disease 0 0.149383082985878
) I-Disease 0 9.577968285157112e-07
gangliosidosis I-Disease 0 2.9288457881193608e-05
, I-Disease 0 8.454817361780442e-07
Type I-Disease 0 6.825016953371232e-06
1 I-Disease 0 1.8116874343832023e-05
. O 0 1.5602679923176765e-05

Less O 0 0.0003725911374203861
severe O 1 0.9995871186256409
, O 0 0.00012503443576861173
subacute O 1 0.9999994039535522
( O 0 0.0002116426476277411
juvenile O 1 0.9999990463256836
- O 1 0.9988700747489929
onset O 1 0.9999996423721313
) O 0 5.370980034058448e-06
and O 0 1.5324440028052777e-05
chronic O 1 1.0
( O 0 2.2032601918908767e-05
adult O 0 0.00641248282045126
- O 1 0.9770188927650452
onset O 1 0.9997981190681458
) O 0 1.8099304099905567e-07
variants O 0 1.3714839042222593e-07
are O 0 1.4049420293815729e-08
characterized O 0 3.425968486681086e-07
by O 0 4.542393838846692e-08
a O 0 3.0744996593057294e-07
broad O 0 9.71537360783259e-07
spectrum O 0 5.813473649141088e-07
of O 0 4.996356892661424e-07
clinical O 0 3.382013528607786e-05
manifestations O 0 1.3612820112030022e-05
and O 0 2.5250983526348136e-07
are O 0 3.6414188997468955e-08
associated O 0 1.7762646109531488e-07
with O 0 5.338137754051786e-08
residual O 0 2.260667497466784e-05
levels O 0 9.155272664429503e-07
of O 0 1.4340142797664157e-06
Hex O 0 1.8696393453865312e-05
A O 0 6.932686574145919e-06
enzyme O 0 3.160371079502511e-06
activity O 0 9.280847734771669e-06
. O 0 6.544654752360657e-06

We O 0 3.554238719516434e-05
identified O 0 3.7411435187095776e-05
a O 0 3.9521273720311e-05
1422 O 0 0.35074901580810547
G O 0 0.006000446621328592
- O 0 0.0004955973709002137
- O 0 0.0005037353257648647
> O 0 4.0657650970388204e-05
C O 0 2.5609897420508787e-05
( O 0 6.176818487801938e-07
amino O 0 9.133453318099782e-07
acid O 0 4.638305881599081e-07
W474C O 0 4.980171979696024e-06
) O 0 6.733021251648097e-08
substitution O 0 2.9423719638543844e-07
in O 0 1.0097750191562227e-07
the O 0 2.173420767803691e-07
first O 0 2.847031908004283e-07
position O 0 4.850729169447732e-07
of O 0 4.4424029965739464e-07
exon O 0 1.1461301028248272e-06
13 O 0 1.1359849168002256e-06
of O 0 3.4969602893397678e-06
HEXA O 0 0.027242615818977356
of O 0 4.479740255192155e-06
a O 0 8.38589039631188e-06
non O 0 2.7790689273388125e-05
- O 0 2.079119803966023e-05
Jewish O 0 8.162966878444422e-06
proband O 0 5.36984734935686e-05
who O 0 1.0138891184396925e-06
manifested O 0 5.646404133585747e-06
a O 0 1.013966539176181e-05
subacute O 0 0.2242666780948639
variant O 0 2.817791209963616e-05
of O 0 6.765440775780007e-05
G B-Disease 0 0.006192306522279978
( I-Disease 0 4.457750492292689e-06
M2 I-Disease 0 0.39962923526763916
) I-Disease 0 4.007940333394799e-06
gangliosidosis I-Disease 0 0.0002127130574081093
. O 0 1.8058433852274902e-05

On O 0 8.076413359958678e-05
the O 0 7.83729410613887e-06
second O 0 1.7084830687963404e-05
maternally O 0 6.253927858779207e-05
inherited O 0 2.80591757473303e-05
allele O 0 7.91079492046265e-06
, O 0 3.825477392638277e-07
we O 0 9.446489457332063e-08
identified O 0 4.3356561718610465e-07
the O 0 1.1508485613376251e-06
common O 0 4.8744135710876435e-05
infantile O 1 1.0
disease O 1 0.9999998807907104
- O 1 0.8258946537971497
causing O 0 0.06892254203557968
4 O 0 7.980319060152397e-05
- O 0 6.621321517741308e-05
bp O 0 1.4095397091296036e-05
insertion O 0 4.567189535009675e-06
, O 0 1.330321651948907e-06
+ O 0 5.005002094549127e-06
TATC O 0 7.232210191432387e-05
1278 O 0 6.16149918641895e-05
, O 0 5.118707235851616e-07
in O 0 7.81860080678598e-07
exon O 0 1.784255073289387e-05
11 O 0 2.1922736777924e-05
. O 0 2.1374527932493947e-05

Pulse O 0 0.18725302815437317
- O 0 0.0005634462577290833
chase O 0 4.072210140293464e-05
analysis O 0 3.0127794161671773e-06
using O 0 2.189691258536186e-06
proband O 0 0.0002525213931221515
fibroblasts O 0 0.00015742199320811778
revealed O 0 2.0358231267891824e-05
that O 0 8.029012406041147e-07
the O 0 4.1207258618669584e-06
W474C O 0 6.70841836836189e-05
- O 0 4.2293140722904354e-06
containing O 0 1.151257038145559e-06
alpha O 0 2.828819560818374e-06
- O 0 1.3094384030409856e-06
subunit O 0 7.577187943752506e-07
precursor O 0 2.843474021574366e-06
was O 0 5.353960659704171e-06
normally O 0 2.5573328343853063e-07
synthesized O 0 1.1596050626394572e-06
, O 0 1.0214188250756706e-07
but O 0 2.6542995357203836e-08
not O 0 3.531929593236782e-08
phosphorylated O 0 1.1420418104535202e-06
or O 0 2.2272590172178752e-07
secreted O 0 2.0912559648422757e-06
, O 0 1.6578948702772323e-07
and O 0 1.1581080627820484e-07
the O 0 8.530431045983278e-07
mature O 0 2.356370941924979e-06
lysosomal O 0 0.0001908204285427928
alpha O 0 7.748396456008777e-06
- O 0 1.9618428268586285e-06
subunit O 0 1.1351889952493366e-06
was O 0 1.1817934137070552e-05
not O 0 7.128544439183315e-07
detected O 0 1.903913653222844e-05
. O 0 2.319039595022332e-05

When O 0 0.0001415194128639996
the O 0 4.269434430170804e-05
W474C O 0 0.0003469362563919276
- O 0 2.7171694455319084e-05
containing O 0 3.941027443943312e-06
alpha O 0 8.759969205129892e-06
- O 0 1.9798369521595305e-06
subunit O 0 1.1808455155914999e-06
was O 0 1.0720038517320063e-05
transiently O 0 1.6107427654787898e-05
co O 0 7.423814622598002e-06
- O 0 1.5552840295640635e-06
expressed O 0 2.2043778358238342e-07
with O 0 7.666140788842313e-08
the O 0 6.306981958914548e-07
beta O 0 9.234948947778321e-07
- O 0 4.274312175311934e-07
subunit O 0 2.0528727873170283e-07
to O 0 1.5468052083633665e-07
produce O 0 6.277973056967312e-07
Hex O 0 2.2932252250029705e-05
A O 0 1.053862342814682e-05
( O 0 9.725310974317836e-07
alphabeta O 0 1.5336940123233944e-05
) O 0 4.204694903364725e-07
in O 0 2.1270934666972607e-06
COS O 0 0.0004577688523568213
- O 0 9.22322396945674e-06
7 O 0 3.203213509550551e-06
cells O 0 6.050125307410781e-07
, O 0 1.3099202078592498e-07
the O 0 2.0492834096330625e-07
mature O 0 2.9263119927236403e-07
alpha O 0 7.244042308229837e-07
- O 0 2.2531177990003926e-07
subunit O 0 8.034231058218211e-08
was O 0 3.9142767604971596e-07
present O 0 3.939370785133178e-08
, O 0 3.3443591007653595e-08
but O 0 1.088034817797734e-08
its O 0 4.552506993604766e-08
level O 0 4.7490701149399683e-07
was O 0 6.4767659750941675e-06
much O 0 4.4639858742812066e-07
lower O 0 1.7039279782693484e-06
than O 0 4.949057341718799e-08
that O 0 6.394338925019838e-08
from O 0 3.5263835229670804e-07
normal O 0 8.650861218484351e-07
alpha O 0 2.0802624476345954e-06
- O 0 9.009860946207482e-07
subunit O 0 6.01129272581602e-07
transfections O 0 6.4642331381037366e-06
, O 0 1.270376372985993e-07
although O 0 7.121084166783476e-08
higher O 0 4.3460801180117414e-07
than O 0 2.4613333593492825e-08
in O 0 7.2990417265828e-08
those O 0 4.903888850549265e-08
cells O 0 1.1707156772899907e-06
transfected O 0 6.2652011365571525e-06
with O 0 1.429071971870144e-07
an O 0 2.8479846605478087e-06
alpha O 0 8.078444807324558e-06
- O 0 4.244668616593117e-06
subunit O 0 2.0446834696485894e-06
associated O 0 1.762812644301448e-06
with O 0 2.60588990386168e-06
infantile O 1 0.9997321963310242
TSD B-Disease 1 0.985133171081543
. O 0 3.873376772389747e-05

Furthermore O 0 0.00012997355952393264
, O 0 8.114642696455121e-06
the O 0 2.084609377561719e-06
precursor O 0 1.7098082025768235e-05
level O 0 3.082983994318056e-06
of O 0 1.4967679362598574e-06
the O 0 2.157944209102425e-06
W474C O 0 4.957738201483153e-05
alpha O 0 7.614881724293809e-06
- O 0 2.0824795683438424e-06
subunit O 0 9.414163741894299e-07
was O 0 2.5253323201468447e-06
found O 0 1.6856867546266585e-07
to O 0 8.427159770008075e-08
accumulate O 0 3.2603455224489153e-07
in O 0 2.3336421861586132e-07
comparison O 0 2.7551809012038575e-07
to O 0 9.89102204584924e-08
the O 0 7.088032702995406e-07
normal O 0 2.9903314953116933e-06
alpha O 0 4.691486992669525e-06
- O 0 2.557660081947688e-06
subunit O 0 1.788801228030934e-06
precursor O 0 1.9270046323072165e-05
levels O 0 6.02548470851616e-06
. O 0 7.33687738829758e-06

We O 0 1.4732293493580073e-05
conclude O 0 3.49506844941061e-05
that O 0 3.588067556847818e-06
the O 0 1.4164077583700418e-05
1422 O 0 0.25579553842544556
G O 0 0.008715087547898293
- O 0 0.0003404997696634382
- O 0 0.00013807609502691776
> O 0 9.883071470540017e-06
C O 0 4.543227078102063e-06
mutation O 0 1.8794722222992277e-07
is O 0 9.57501242737635e-08
the O 0 1.846054260568053e-07
cause O 0 6.523391675727908e-07
of O 0 4.104801973880967e-06
Hex B-Disease 0 0.00868150033056736
A I-Disease 1 0.8265413641929626
enzyme I-Disease 1 0.9999970197677612
deficiency I-Disease 1 0.9999998807907104
in O 0 4.892891411145683e-06
the O 0 2.598744868009817e-05
proband O 0 0.006243693642318249
. O 0 2.107964792230632e-05

The O 0 3.247206041123718e-05
resulting O 0 4.4724129111273214e-05
W474C O 0 0.0002884930872824043
substitution O 0 2.1599169485853054e-05
clearly O 0 3.80707933800295e-06
interferes O 0 2.1784103410027456e-06
with O 0 3.7228559790492e-07
alpha O 0 4.2090746319445316e-06
- O 0 9.967122878151713e-07
subunit O 0 4.439916949650069e-07
processing O 0 7.313296919164713e-07
, O 0 1.7680947905773792e-07
but O 0 3.3107721009173474e-08
because O 0 2.5476438736404816e-08
the O 0 2.8094871140638134e-07
base O 0 1.4760128124180483e-06
substitution O 0 3.1628408123651752e-06
falls O 0 1.0080706488224678e-05
at O 0 1.7323162637694622e-06
the O 0 1.915784935135889e-07
first O 0 4.2179729575764213e-07
position O 0 5.393124524744053e-07
of O 0 9.4360240154856e-07
exon O 0 1.8039593214780325e-06
13 O 0 1.3699979035664e-06
, O 0 4.1411388451706443e-07
aberrant O 0 5.6214580581581686e-06
splicing O 0 3.0290248105302453e-06
may O 0 6.881313652229437e-07
also O 0 2.213263030625967e-07
contribute O 0 2.3856566144786484e-07
to O 0 3.7594475088553736e-07
Hex B-Disease 0 0.0013945690589025617
A I-Disease 0 0.04099884629249573
deficiency I-Disease 1 0.9209945201873779
in O 0 2.4143037080648355e-06
this O 0 8.055434932430217e-07
proband O 0 8.813912427285686e-05
. O 0 1.4111155905993655e-06
. O 0 4.933793661621166e-06

Two O 0 9.043089448823594e-06
frequent O 0 2.5653678676462732e-05
missense O 0 0.00035858701448887587
mutations O 0 0.00046658713836222887
in O 0 0.08027184754610062
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.002469239290803671

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.007326061371713877
an O 1 0.9419595003128052
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 1.0
by O 0 0.04311570152640343
early O 1 0.9987770915031433
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999998807907104
goiter B-Disease 1 1.0
. O 1 0.9540826678276062

A O 0 9.311334724770859e-05
century O 0 1.0253269465465564e-05
after O 0 1.426014364369621e-06
its O 0 1.3213401928169333e-07
recognition O 0 4.563500510812446e-07
as O 0 2.145877260772977e-06
a O 0 0.00011206545605091378
syndrome O 1 0.9999998807907104
by O 0 7.532549716415815e-06
Vaughan O 0 0.49704834818840027
Pendred O 1 0.8366583585739136
, O 0 2.172808308387175e-06
the O 0 7.954186912684236e-06
disease O 0 0.44651681184768677
gene O 0 8.52280754770618e-06
( O 0 4.41800966655137e-06
PDS O 0 0.0003891611995641142
) O 0 3.663272707399301e-07
was O 0 4.46613330495893e-06
mapped O 0 2.1339956219890155e-06
to O 0 1.0045016551885055e-06
chromosome O 1 0.9557932019233704
7q22 O 1 0.9999721050262451
- O 1 0.9990760087966919
q31 O 1 0.953183650970459
. O 0 3.1994135497370735e-05

1 O 0 8.746729145059362e-05
and O 0 7.140109119063709e-06
, O 0 1.385010477861215e-06
recently O 0 1.2304146821406903e-06
, O 0 1.4472115594799106e-07
found O 0 7.29183398107125e-08
to O 0 4.600182634817429e-08
encode O 0 6.847769782325486e-07
a O 0 7.994630323082674e-06
putative O 0 0.0006816938403062522
sulfate O 0 0.000491961429361254
transporter O 0 0.021645916625857353
. O 0 3.285042475908995e-05

We O 0 4.8665519898349885e-06
performed O 0 5.978606623102678e-06
mutation O 0 3.874241429002723e-06
analysis O 0 8.163395932569983e-07
of O 0 9.17208694772853e-07
the O 0 2.4499877326888964e-06
PDS B-Disease 0 7.418949098791927e-05
gene O 0 8.628096566098975e-07
in O 0 1.0531063026064658e-06
patients O 0 5.318331091075379e-07
from O 0 1.1335544058965752e-06
14 O 0 6.732868314429652e-06
Pendred B-Disease 0 2.205579039582517e-05
families O 0 2.9463359751957796e-08
originating O 0 2.4020343403208244e-07
from O 0 1.2042649188970245e-07
seven O 0 7.173787963665745e-08
countries O 0 1.2346605515745068e-08
and O 0 1.123142894243756e-07
identified O 0 8.503182016283972e-07
all O 0 4.755106601805892e-07
mutations O 0 1.0582150935078971e-05
. O 0 1.6476149539812468e-05

The O 0 2.0704175767605193e-05
mutations O 0 6.277234206208959e-06
include O 0 1.0361229669797467e-06
three O 0 6.901023539285234e-07
single O 0 1.300402345805196e-06
base O 0 7.595140232297126e-06
deletions O 0 5.885041900910437e-06
, O 0 3.776123662646569e-07
one O 0 1.190405072293288e-07
splice O 0 1.938953346325434e-06
site O 0 3.279361067143327e-07
mutation O 0 3.449580106007488e-07
and O 0 2.611056402201939e-07
10 O 0 2.1317846403690055e-06
missense O 0 3.689155710162595e-05
mutations O 0 2.0677225620602258e-05
. O 0 1.6214449715334922e-05

One O 0 2.0666184354922734e-05
missense O 0 0.00015862334112171084
mutation O 0 4.767295831697993e-05
( O 0 9.769300959305838e-06
L236P O 0 0.0003120491746813059
) O 0 8.372349498131371e-07
was O 0 6.100262453401228e-06
found O 0 2.4848196744642337e-07
in O 0 1.4618903776408843e-07
a O 0 3.7444121403495956e-07
homozygous O 0 4.002506557299057e-07
state O 0 1.0391575244739215e-07
in O 0 2.9752592922704935e-07
two O 0 1.2473790889089287e-07
consanguineous O 0 6.6266647991142236e-06
families O 0 6.043446632020277e-08
and O 0 7.296898019149012e-08
in O 0 9.430143421695902e-08
a O 0 1.8243103738768696e-07
heterozygous O 0 7.850274386100864e-08
state O 0 2.9187884109660445e-08
in O 0 8.106283644337964e-08
five O 0 7.782114153087605e-08
additional O 0 4.255009571352275e-07
non O 0 1.5894638636382297e-05
- O 0 5.831906673847698e-05
consanguineous O 0 9.561666229274124e-05
families O 0 1.7493146060587605e-06
. O 0 9.371110536449123e-06

Another O 0 6.816237146267667e-05
missense O 0 0.000198404275579378
mutation O 0 2.541814319556579e-05
( O 0 4.9458012654213235e-06
T416P O 0 0.0001257130061276257
) O 0 7.791491043462884e-07
was O 0 2.547324356783065e-06
found O 0 9.325898275847067e-08
in O 0 5.791919122088984e-08
a O 0 1.6550544046367577e-07
homozygous O 0 2.2341048122598295e-07
state O 0 6.857167988982837e-08
in O 0 1.6275517111807858e-07
one O 0 1.707037995402061e-07
family O 0 1.2299895502110303e-07
and O 0 6.378186867550539e-08
in O 0 1.7627743886805547e-07
a O 0 4.7141799086602987e-07
heterozygous O 0 2.686943503249495e-07
state O 0 1.4404341186491365e-07
in O 0 5.613795224235218e-07
four O 0 7.059800282149808e-07
families O 0 1.0002926273955381e-06
. O 0 7.992610335350037e-06

Pendred B-Disease 1 0.7685731053352356
patients O 0 8.372390584554523e-05
in O 0 5.579599928751122e-06
three O 0 2.154958110622829e-06
non O 0 1.2173156392236706e-05
- O 0 1.1873672519868705e-05
consanguineous O 0 1.1842540516227018e-05
families O 0 5.60908652857961e-08
were O 0 1.39467147164396e-07
shown O 0 1.8689408420868858e-07
to O 0 1.1407406930175057e-07
be O 0 7.555007641713019e-07
compound O 0 1.3934251001046505e-05
heterozygotes O 0 3.713562364282552e-06
for O 0 8.498017791680468e-07
L236P O 0 0.00013780224253423512
and O 0 8.80050447449321e-06
T416P O 0 0.0013646607985720038
. O 0 2.3795315428287722e-05

In O 0 2.0494726413744502e-05
total O 0 1.1216630809940398e-05
, O 0 1.1196366358490195e-06
one O 0 2.981624049880338e-07
or O 0 1.1864677418316205e-07
both O 0 4.558145860755758e-08
of O 0 2.1652323312082444e-07
these O 0 2.4520929287064064e-08
mutations O 0 1.1349720097086902e-07
were O 0 2.2464880089501094e-07
found O 0 1.3116978436755744e-07
in O 0 1.983392508009274e-07
nine O 0 3.123213616618159e-07
of O 0 4.4802689558309794e-07
the O 0 8.100554964585172e-07
14 O 0 2.1547157302848063e-06
families O 0 3.703235336161015e-07
analyzed O 0 9.058281648322009e-06
. O 0 9.902770216285717e-06

The O 0 7.881035344325937e-06
identification O 0 2.0880395368294558e-06
of O 0 1.362622924716561e-06
two O 0 3.78110740939519e-07
frequent O 0 3.908724920620443e-06
PDS B-Disease 0 0.00022557178454007953
mutations O 0 5.103596549815848e-07
will O 0 9.227908748243863e-08
facilitate O 0 7.251603619806701e-07
the O 0 1.4728996120538795e-06
molecular O 0 0.13306036591529846
diagnosis O 1 0.9994805455207825
of O 1 0.9999829530715942
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.016162317246198654

Insertional O 0 0.0008993995725177228
mutation O 0 1.3263238543004263e-05
by O 0 1.3876018556402414e-06
transposable O 0 3.1275943911168724e-05
element O 0 4.6504692363669164e-06
, O 0 5.943015821685549e-07
L1 O 0 3.242189632146619e-05
, O 0 2.2006892663739563e-07
in O 0 3.2693375828785065e-07
the O 0 2.8931538054166595e-06
DMD B-Disease 1 0.9999998807907104
gene O 0 5.037993105361238e-06
results O 0 4.830057605431648e-06
in O 0 8.734650691621937e-06
X B-Disease 1 0.999923586845398
- I-Disease 1 0.9999992847442627
linked I-Disease 1 0.9999996423721313
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
. O 0 0.001653122715651989

X B-Disease 1 0.9995183944702148
- I-Disease 1 0.9999672174453735
linked I-Disease 1 0.9999865293502808
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 0.0020590806379914284
XLDCM B-Disease 1 0.9999916553497314
) O 0 9.165004257738474e-07
is O 0 3.4070674814756785e-07
a O 0 1.2720048516712268e-06
clinical O 0 0.001044920296408236
phenotype O 0 4.353529948275536e-05
of O 0 7.469092906831065e-06
dystrophinopathy B-Disease 0 0.01809556409716606
which O 0 2.3357374345778226e-07
is O 0 1.6243961908912752e-07
characterized O 0 5.449447826322285e-07
by O 0 1.0349719303803795e-07
preferential O 0 1.333288582827663e-05
myocardial B-Disease 1 1.0
involvement I-Disease 0 3.0607825465267524e-05
without O 0 1.3908142193486128e-07
any O 0 1.6094909938146884e-07
overt O 0 3.97826406697277e-05
clinical O 1 0.9898179173469543
signs O 0 0.09859586507081985
of O 1 0.9965631365776062
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.008553869090974331

To O 0 3.848314008791931e-06
date O 0 4.305611582822166e-06
, O 0 3.0679532869726245e-07
several O 0 9.095783326529272e-08
mutations O 0 7.863504265515076e-07
in O 0 2.1702778667531675e-06
the O 0 0.0014154735254123807
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.0033426161389797926
, O 0 2.7740587029256858e-05
DMD O 1 1.0
, O 0 3.3896540685418586e-07
have O 0 5.393372504158833e-08
been O 0 4.181521831014834e-07
identified O 0 5.673780947290652e-07
in O 0 4.934400408274087e-07
patients O 0 5.062065042693575e-07
with O 0 4.801954105460027e-07
XLDCM B-Disease 1 0.9999077320098877
, O 0 9.120710160459566e-07
but O 0 1.483816021163875e-07
a O 0 5.192675303078431e-07
pathogenic O 0 8.964803441813274e-07
correlation O 0 1.0205576472799294e-06
of O 0 5.128044335833692e-07
these O 0 8.640062532094817e-08
cardiospecific O 0 2.5278857719968073e-05
mutations O 0 1.8312599650016637e-06
in O 0 5.646506451739697e-06
DMD O 1 1.0
with O 0 6.670412631137879e-07
the O 0 1.2696325029537547e-05
XLDCM B-Disease 1 0.9686552882194519
phenotype O 0 3.6903587897541e-05
has O 0 8.644181548334018e-07
remained O 0 4.3291424844937865e-06
to O 0 1.419368800270604e-07
be O 0 8.270682201327872e-07
elucidated O 0 0.00010507486877031624
. O 0 1.181786683446262e-05

We O 0 4.174564310233109e-05
report O 0 1.3948185369372368e-05
here O 0 1.3869138228983502e-06
the O 0 3.697782631206792e-07
identification O 0 3.390785536794283e-07
of O 0 6.64827382479416e-07
a O 0 9.482482141720538e-07
unique O 0 3.581827172638441e-07
de O 0 1.2763362065015826e-05
novo O 0 1.6784450053819455e-05
L1 O 0 1.506848548160633e-05
insertion O 0 1.5804647546246997e-06
in O 0 3.7138420339033473e-07
the O 0 1.010452024274855e-06
muscle O 0 1.7431594869776745e-06
exon O 0 1.8283597000845475e-06
1 O 0 2.0497948298725532e-06
in O 0 3.468717750365613e-06
DMD O 1 0.9999996423721313
in O 0 1.2983242640984827e-06
three O 0 1.778637397364946e-06
XLDCM B-Disease 1 0.9394413232803345
patients O 0 1.0632907105900813e-06
from O 0 4.956241355102975e-07
two O 0 4.2603289784892695e-07
unrelated O 0 1.2335856808931567e-05
Japanese O 0 2.80284984910395e-05
families O 0 1.3091125765640754e-06
. O 0 8.436054486082867e-06

The O 0 5.2597923058783635e-05
insertion O 0 7.117669883882627e-05
was O 0 7.936287147458643e-05
a O 0 1.5777492080815136e-05
5 O 0 1.1815703146567103e-05
- O 0 7.007004569459241e-06
truncated O 0 4.17960245613358e-06
form O 0 1.7800293505843e-07
of O 0 6.432394457078772e-07
human O 0 2.108699391101254e-06
L1 O 0 2.3396451069856994e-05
inversely O 0 8.164267455867957e-06
integrated O 0 2.746481413851143e-06
in O 0 5.799248015136982e-07
the O 0 7.780212740726711e-07
5 O 0 1.982818730539293e-06
- O 0 3.589169409679016e-06
untranslated O 0 1.911907020257786e-05
region O 0 8.007478982108296e-07
in O 0 5.132462206347554e-07
the O 0 8.581354222769733e-07
muscle O 0 1.0303310773451813e-06
exon O 0 1.072517761713243e-06
1 O 0 6.604329314541246e-07
, O 0 5.313534856554725e-08
which O 0 2.3332253462626795e-08
affected O 0 4.6187160762656276e-08
the O 0 1.378460012801952e-07
transcription O 0 1.4925743698768201e-06
or O 0 9.938089817751461e-08
the O 0 2.8963955855942913e-07
stability O 0 1.013987798614835e-06
of O 0 9.032306707013049e-07
the O 0 2.2104079562268453e-06
muscle O 0 2.1113958155183354e-06
form O 0 1.3955842348423175e-07
of O 0 1.6406482927777688e-06
dystrophin O 0 6.028864845575299e-06
transcripts O 0 1.7197322677020566e-06
but O 0 4.824731192343279e-08
not O 0 2.3962680728573105e-08
that O 0 6.048486511645024e-08
of O 0 1.4259069303079741e-06
the O 0 8.940923180489335e-06
brain O 1 0.922147274017334
or O 0 4.427009480423294e-05
Purkinje O 1 0.9999271631240845
cell O 0 0.001746994093991816
form O 0 4.659880232793512e-07
, O 0 2.907837028942595e-07
probably O 0 3.9978982613320113e-07
due O 0 4.1887940938067914e-07
to O 0 2.754796391002401e-08
its O 0 5.1372321507869856e-08
unique O 0 9.658856470196042e-08
site O 0 7.223394504762837e-07
of O 0 2.3119409888749942e-06
integration O 0 1.607794729352463e-05
. O 0 1.0654634934326168e-05

We O 0 1.6852327462402172e-05
speculate O 0 1.0752525668067392e-05
that O 0 3.410282545246446e-07
this O 0 3.4165847750955436e-07
insertion O 0 2.511780849090428e-06
of O 0 6.037836897121451e-07
an O 0 5.550747346205753e-07
L1 O 0 8.267124030680861e-06
sequence O 0 4.977462140232092e-07
in O 0 2.2016811271896586e-06
DMD O 1 1.0
is O 0 2.8934911711075983e-07
responsible O 0 2.9654887612196035e-07
for O 0 5.229889410429678e-08
some O 0 1.549867079120304e-08
of O 0 1.4626755273638992e-07
the O 0 1.299582521596676e-07
population O 0 5.114978662845715e-08
of O 0 7.514108233408479e-07
Japanese O 0 2.8413889594958164e-05
patients O 0 1.5156625750023522e-06
with O 0 1.0880701211135602e-06
XLDCM B-Disease 1 0.9676271080970764
. O 0 2.638695150380954e-06
. O 0 9.898569260258228e-06

Severe O 1 0.9999476671218872
early O 1 0.9186175465583801
- O 1 0.9999997615814209
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9921900629997253
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9723551273345947
red O 1 0.9999994039535522
hair O 1 1.0
pigmentation O 1 1.0
caused O 1 0.9999899864196777
by O 0 0.00017215542902704328
POMC O 1 0.9993973970413208
mutations O 0 5.124014478496974e-06
in O 0 4.518485184235033e-06
humans O 0 6.635626050410792e-06
. O 0 1.3242914064903744e-05

Sequential O 0 0.0015287246787920594
cleavage O 0 0.0015532751567661762
of O 0 4.6824727178318426e-05
the O 0 9.58373857429251e-06
precursor O 0 3.286082574049942e-05
protein O 0 6.758555173291825e-06
pre O 0 0.00021208968246355653
- O 0 0.0001373484992654994
pro O 0 0.00016375284758396447
- O 0 3.1066578230820596e-05
opiomelanocortin O 0 6.841849972261116e-05
( O 0 1.1717902452801354e-06
POMC O 0 6.486874917754903e-05
) O 0 2.791041424643481e-07
generates O 0 6.122061222413322e-07
the O 0 1.1523454759299057e-06
melanocortin O 0 9.094797860598192e-05
peptides O 0 1.124850950873224e-05
adrenocorticotrophin O 0 6.878137355670333e-05
( O 0 3.65587038686499e-06
ACTH O 0 0.00012836375390179455
) O 0 9.429807619198982e-07
, O 0 1.410390495948377e-06
melanocyte O 0 0.000531810917891562
- O 0 0.00011479197564767674
stimulating O 0 2.5935209123417735e-05
hormones O 0 6.67089807393495e-06
( O 0 3.507718133732851e-07
MSH O 0 1.184311622637324e-05
) O 0 8.572907717052658e-08
alpha O 0 3.7258891438796127e-07
, O 0 7.983987870829878e-08
beta O 0 3.836968289760989e-07
and O 0 1.0592307120305122e-07
gamma O 0 1.549363901176548e-06
as O 0 2.216063705873239e-07
well O 0 1.8103050081208494e-07
as O 0 3.853900238937058e-07
the O 0 6.995521175667818e-07
opioid O 0 1.6066453099483624e-05
- O 0 8.7705921032466e-06
receptor O 0 1.3336904885363765e-05
ligand O 0 7.25384961697273e-05
beta O 0 6.844296876806766e-05
- O 0 0.0004645250737667084
endorphin O 0 0.0011910644825547934
. O 0 2.2842827092972584e-05

While O 0 1.6688367395545356e-05
a O 0 5.722624337067828e-06
few O 0 6.8286681198515e-07
cases O 0 4.937012931804929e-07
of O 0 1.2110593161196448e-05
isolated O 0 0.33287185430526733
ACTH B-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9964227080345154
have O 0 5.238774747340358e-07
been O 0 1.8175963987232535e-06
reported O 0 5.3245998969941866e-06
( O 0 1.5635154113624594e-06
OMIM O 0 0.00476800324395299
201400 O 0 3.238678982597776e-05
) O 0 4.614493889221194e-07
, O 0 1.8277654589837766e-07
an O 0 2.244585175503744e-06
inherited O 1 0.9590749144554138
POMC O 1 0.9999990463256836
defect O 0 0.0020489105954766273
has O 0 6.22251548065833e-07
not O 0 1.241466662804669e-07
been O 0 7.461408131348435e-07
described O 0 1.514791165391216e-06
so O 0 2.4086133976197743e-07
far O 0 2.6339810119679896e-06
. O 0 5.536010576179251e-06

Recent O 0 4.3691223254427314e-05
studies O 0 1.4389212992682587e-05
in O 0 1.458552560507087e-06
animal O 0 1.5389523468911648e-06
models O 0 9.723827361085569e-07
elucidated O 0 1.047575642587617e-05
a O 0 1.7724551071296446e-06
central O 0 1.6901423123272252e-06
role O 0 8.221289249377151e-07
of O 0 2.571110599092208e-06
alpha O 0 2.1198022295720875e-05
- O 0 1.872556640591938e-05
MSH O 0 6.789535109419376e-05
in O 0 3.9441755461666617e-07
the O 0 4.950850893692404e-07
regulation O 0 8.086492471193196e-07
of O 0 9.444918873668939e-07
food O 0 1.3455320413413574e-06
intake O 0 3.838205429929076e-06
by O 0 2.3256593806308956e-07
activation O 0 3.338099759275792e-06
of O 0 2.715457412705291e-06
the O 0 6.343371296679834e-06
brain O 0 0.003467513946816325
melanocortin O 0 0.0030321909580379725
- O 0 1.5953011825331487e-05
4 O 0 5.70701513424865e-06
- O 0 5.236020570009714e-06
receptor O 0 5.082432835479267e-06
( O 0 9.744213684825809e-07
MC4 O 0 0.00019067512766923755
- O 0 9.5089390015346e-06
R O 0 3.864964128297288e-06
; O 0 1.2410380634264584e-07
refs O 0 1.970798393813311e-06
3 O 0 5.237326377027784e-07
- O 0 8.868308327691921e-07
5 O 0 2.870199296012288e-07
) O 0 4.757447058523212e-08
and O 0 3.738438891787155e-08
the O 0 3.202313791916822e-07
linkage O 0 7.83712948759785e-06
of O 0 2.6366801648691762e-06
human O 0 1.2642546607821714e-05
obesity B-Disease 1 0.9993323683738708
to O 0 4.1163013975165086e-07
chromosome O 0 1.0011601261794567e-05
2 O 0 1.4599052065022988e-06
in O 0 5.482454525918001e-07
close O 0 5.466192192216113e-07
proximity O 0 5.672065981343621e-07
to O 0 1.0384858484258075e-07
the O 0 1.568927018524846e-06
POMC O 0 7.188227027654648e-05
locus O 0 7.520985946030123e-06
, O 0 2.834832173448376e-07
led O 0 6.35507205970498e-07
to O 0 4.1451997390140605e-08
the O 0 2.45365356477123e-07
proposal O 0 1.908457960553278e-07
of O 0 6.415619964172947e-07
an O 0 1.2330000345173175e-06
association O 0 2.09339486900717e-06
of O 0 9.74701288214419e-06
POMC O 1 0.6266306638717651
with O 0 4.489346338232281e-06
human O 1 0.5533926486968994
obesity B-Disease 1 1.0
. O 0 0.00011348992120474577

The O 0 3.4564800444059074e-05
dual O 0 4.150873064645566e-05
role O 0 1.076845273928484e-05
of O 0 1.8655427993508056e-05
alpha O 0 0.00013789885269943625
- O 0 0.00030340178636834025
MSH O 0 0.007382607087492943
in O 0 1.2091758208043757e-06
regulating O 0 5.505442914000014e-06
food O 0 2.2008289306540973e-06
intake O 0 1.0988360372721218e-05
and O 0 1.3671475471710437e-06
influencing O 0 0.0001249458728125319
hair O 1 0.9308708906173706
pigmentation O 1 0.9997352957725525
predicts O 0 6.396916433004662e-05
that O 0 1.5636661032658594e-07
the O 0 6.106917567194614e-07
phenotype O 0 2.237671651528217e-05
associated O 0 3.9044417121658626e-07
with O 0 8.66723084413934e-08
a O 0 9.2417221821961e-06
defect O 0 6.675261101918295e-05
in O 0 2.8699055292236153e-06
POMC O 0 0.1790454238653183
function O 0 7.623882538609905e-07
would O 0 2.015475786265597e-07
include O 0 2.644965888976003e-06
obesity B-Disease 1 0.9999998807907104
, O 0 9.439570476388326e-07
alteration O 0 0.003959713503718376
in O 0 0.00010927200492005795
pigmentation O 1 0.9999979734420776
and O 1 0.9991763234138489
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.921754488255829e-05

The O 0 1.3429179489321541e-05
observation O 0 5.919832256040536e-05
of O 0 2.0443208086362574e-06
these O 0 3.8274515645753127e-07
symptoms O 0 4.604301284416579e-05
in O 0 1.3188617913328926e-06
two O 0 3.063126428060059e-07
probands O 0 6.595451850444078e-05
prompted O 0 2.2202486889000284e-06
us O 0 1.877770188229988e-07
to O 0 2.4813711974047692e-08
search O 0 6.794532225740113e-08
for O 0 4.2047471282558035e-08
mutations O 0 2.624713033583248e-07
within O 0 2.1738850364272366e-07
their O 0 5.848802402397268e-07
POMC O 0 0.003191422438248992
genes O 0 1.3267133908811957e-05
. O 0 1.70229614013806e-05

Patient O 0 0.00035478471545502543
1 O 0 4.1716750274645165e-05
was O 0 2.946483982668724e-05
found O 0 1.1496101706143236e-06
to O 0 2.594270256395248e-07
be O 0 6.445639542107529e-07
a O 0 3.2091299999592593e-06
compound O 0 1.3690530067833606e-05
heterozygote O 0 4.056639681948582e-06
for O 0 9.012390478346788e-08
two O 0 7.14075127916658e-08
mutations O 0 2.0548040424728242e-07
in O 0 7.643363346687693e-07
exon O 0 3.4147124097216874e-06
3 O 0 2.4047235456237104e-06
( O 0 4.976161562808556e-07
G7013T O 0 1.856431299529504e-05
, O 0 4.83253643324133e-07
C7133delta O 0 8.195439477276523e-06
) O 0 8.39001543795348e-08
which O 0 3.5412586640859445e-08
interfere O 0 1.0078873913244024e-07
with O 0 6.457693046968416e-08
appropriate O 0 4.585286887959228e-07
synthesis O 0 7.168814136093715e-06
of O 0 3.849110271403333e-06
ACTH O 0 0.00024975824635475874
and O 0 2.240284402432735e-06
alpha O 0 7.768012437736616e-05
- O 0 0.0003390838683117181
MSH O 0 0.0014220216544345021
. O 0 9.756526196724735e-06

Patient O 0 0.0005124987219460309
2 O 0 3.7134323065401986e-05
was O 0 2.2655924112768844e-05
homozygous O 0 3.809225745499134e-06
for O 0 4.13271578736385e-07
a O 0 1.0640698064889875e-06
mutation O 0 7.608919077028986e-07
in O 0 1.184410621135612e-06
exon O 0 4.536313099379186e-06
2 O 0 4.924105724057881e-06
( O 0 1.2665093436226016e-06
C3804A O 0 3.722726250998676e-05
) O 0 6.845216944384447e-07
which O 0 1.0971699566653115e-06
abolishes O 0 0.0001340598100796342
POMC O 0 0.002133276779204607
translation O 0 0.0001093161990866065
. O 0 1.4089496289670933e-05

These O 0 3.3180028822243912e-06
findings O 0 2.694423301363713e-06
represent O 0 2.468691775447951e-07
the O 0 2.509429464225832e-07
first O 0 3.151091334530065e-07
examples O 0 3.502009064959566e-07
of O 0 6.093414981478418e-07
a O 0 4.378394442028366e-05
genetic B-Disease 1 0.9999419450759888
defect I-Disease 1 0.9987290501594543
within O 0 8.723918085706828e-07
the O 0 4.079770405951422e-06
POMC O 0 0.011914994567632675
gene O 0 4.6789571683802933e-07
and O 0 1.9141485552154336e-07
define O 0 4.397746238282707e-07
a O 0 1.9983358470199164e-06
new O 0 5.187752776691923e-06
monogenic B-Disease 1 0.9999998807907104
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9998918771743774
resulting O 0 1.485582470195368e-05
in O 0 3.824302439170424e-06
early O 0 0.02636852115392685
- O 1 0.9999988079071045
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9008048176765442
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.12168493866920471
red O 1 0.9999879598617554
hair O 1 0.9999996423721313
pigmentation O 1 0.9999996423721313
. O 0 4.6235378249548376e-05
. O 0 2.1028108676546253e-05

A O 0 0.00017395518079865724
European O 0 3.949825986637734e-05
multicenter O 0 0.015387664549052715
study O 0 1.540679659228772e-05
of O 0 0.0002744559897109866
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 3.944855507143075e-06
classification O 0 3.419294216655544e-06
of O 0 1.9237927517679054e-06
105 O 0 2.721300916164182e-06
mutations O 0 4.4475240201791166e-07
and O 0 2.6054894419758057e-07
a O 0 4.55241297458997e-06
general O 0 3.2539171570533654e-06
system O 0 7.807446422702924e-07
for O 0 3.4139335980398755e-07
genotype O 0 2.31620178965386e-05
- O 0 0.00021610471594613045
based O 0 3.415618039070978e-06
prediction O 0 8.973811054602265e-05
of O 0 2.2122543668956496e-05
metabolic O 1 0.9999257326126099
phenotype O 0 0.06541990488767624
. O 0 3.735831705853343e-05

Phenylketonuria B-Disease 1 0.9987359642982483
( O 0 0.0003881286538671702
PKU B-Disease 1 0.9970571994781494
) O 0 2.163895987905562e-05
and O 0 1.4138342521619052e-05
mild B-Disease 1 0.9999997615814209
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9593292474746704
MHP B-Disease 1 1.0
) O 0 1.6730183460822445e-06
are O 0 3.4849344388021564e-07
allelic B-Disease 1 0.7070674896240234
disorders I-Disease 1 0.9999943971633911
caused O 0 0.14310985803604126
by O 0 1.176282239612192e-06
mutations O 0 9.299349130742485e-07
in O 0 7.136325734791171e-07
the O 0 3.1534923436993267e-06
gene O 0 4.798932423000224e-06
encoding O 0 1.2436211363819893e-05
phenylalanine O 0 0.0004014762816950679
hydroxylase O 0 0.16937373578548431
( O 0 0.00021294683392625302
PAH O 1 0.9999998807907104
) O 0 5.269094981485978e-05
. O 0 5.655799031956121e-05

Previous O 0 1.8627039025886916e-05
studies O 0 4.631128376786364e-06
have O 0 5.695264917449094e-07
suggested O 0 1.0541492656557239e-06
that O 0 1.610833066933992e-07
the O 0 7.612294439240941e-07
highly O 0 6.831880909885513e-06
variable O 0 8.077037637121975e-05
metabolic O 1 0.9999784231185913
phenotypes O 1 0.6088063716888428
of O 1 0.9998353719711304
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.1799435317516327
with O 0 0.0032282881438732147
PAH O 1 1.0
genotypes O 1 0.9996019005775452
. O 0 0.00015806773444637656

We O 0 1.6648307791911066e-05
identified O 0 6.369656148308422e-06
both O 0 8.321388804688468e-07
causative O 0 5.0620088586583734e-05
mutations O 0 8.147574590111617e-06
in O 0 5.589186002907809e-06
686 O 0 0.018306465819478035
patients O 0 1.7824800124799367e-06
from O 0 8.320864708366571e-07
seven O 0 8.15832947864692e-07
European O 0 2.1427688352559926e-06
centers O 0 1.0174751878366806e-05
. O 0 5.468207291414728e-06

On O 0 2.9445935069816187e-05
the O 0 1.8264599930262193e-06
basis O 0 6.962800398468971e-07
of O 0 5.483694280883356e-07
the O 0 3.2762540058683953e-07
phenotypic O 0 1.018478769765352e-06
characteristics O 0 4.848744197261112e-07
of O 0 4.688588433054974e-06
297 O 0 0.00011287140659987926
functionally O 0 9.945841156877577e-05
hemizygous O 0 0.00055085209896788
patients O 0 7.731551363576727e-07
, O 0 1.2795064208148688e-07
105 O 0 5.797057838208275e-07
of O 0 1.8598730378016626e-07
the O 0 7.587616579485257e-08
mutations O 0 5.4522761416819776e-08
were O 0 1.0817488771408534e-07
assigned O 0 2.091877178145296e-07
to O 0 6.36189412261956e-08
one O 0 1.8106210575297155e-07
of O 0 8.242918170253688e-07
four O 0 1.1310783065709984e-06
arbitrary O 0 1.1915234608750325e-05
phenotype O 0 0.0001737481215968728
categories O 0 1.371677171846386e-05
. O 0 1.0738281162048224e-05

We O 0 5.777124442829518e-06
proposed O 0 2.9222644570836565e-06
and O 0 4.1963107832998503e-07
tested O 0 1.2808277460862882e-06
a O 0 5.300285579323827e-07
simple O 0 2.047437561714105e-07
model O 0 1.723921485563551e-07
for O 0 3.916669655268379e-08
correlation O 0 8.232241839323251e-07
between O 0 4.090481695584458e-07
genotype O 0 1.731924726300349e-06
and O 0 1.757111647293641e-07
phenotypic O 0 5.19867808179697e-06
outcome O 0 1.6420570318587124e-05
. O 0 8.619193067715969e-06

The O 0 3.75993549823761e-05
observed O 0 3.724700945895165e-05
phenotype O 0 0.00010291548824170604
matched O 0 1.4461326827586163e-05
the O 0 4.0505083234165795e-06
predicted O 0 1.0163792467210442e-05
phenotype O 0 3.773315484068007e-06
in O 0 3.89662631050669e-07
79 O 0 2.067353761958657e-06
% O 0 1.1696940305228054e-07
of O 0 4.7632036626055196e-07
the O 0 5.485153451445512e-07
cases O 0 1.1812494449259248e-07
, O 0 9.982849746847933e-08
and O 0 3.795399194927995e-08
in O 0 7.991635442294864e-08
only O 0 6.638592964236523e-08
5 O 0 3.4198217235825723e-07
of O 0 7.461692916876927e-07
184 O 0 4.8261304073093925e-06
patients O 0 2.9340944251998735e-07
was O 0 6.107673470978625e-06
the O 0 4.83962992348097e-07
observed O 0 5.838369929733744e-07
phenotype O 0 1.2019568202958908e-06
more O 0 2.0005879619588995e-08
than O 0 2.0161134983709417e-08
one O 0 7.190801909473521e-08
category O 0 3.019430039330473e-07
away O 0 8.834030751359023e-08
from O 0 1.351112359770923e-07
that O 0 2.4251949071185663e-07
expected O 0 5.1049282774329185e-06
. O 0 4.882851499132812e-06

Among O 0 6.283115908445325e-06
the O 0 1.2051442581650917e-06
seven O 0 5.08775428897934e-07
contributing O 0 1.0666871048670146e-06
centers O 0 4.886270517090452e-07
, O 0 7.516014477459976e-08
the O 0 9.537264133996359e-08
proportion O 0 3.264788404067076e-07
of O 0 1.2789723768946715e-06
patients O 0 6.61092713016842e-07
for O 0 1.1893111917515853e-07
whom O 0 2.701591768072831e-07
the O 0 3.1996975735637534e-07
observed O 0 1.1757663287426112e-06
phenotype O 0 3.383863941053278e-06
did O 0 1.3472651971824234e-07
not O 0 6.61991776951254e-08
match O 0 4.1898965719155967e-07
the O 0 7.147836527110485e-07
predicted O 0 4.044139586767415e-06
phenotype O 0 2.78410266218998e-06
was O 0 6.267143362492789e-06
4 O 0 1.5135175317482208e-06
% O 0 3.7893019566581643e-07
- O 0 1.35873642648221e-06
23 O 0 2.0569189018715406e-06
% O 0 3.703267168475577e-07
( O 0 6.1944393792146e-07
P O 0 5.684949428541586e-05
< O 0 5.326885911927093e-06
. O 0 1.8532723800035455e-07
0001 O 0 7.814053788024466e-06
) O 0 4.724000035594145e-08
, O 0 1.1444384995229484e-08
suggesting O 0 5.03797430440045e-08
that O 0 4.731418812298216e-09
differences O 0 5.51999512765633e-09
in O 0 2.4146938670810414e-08
methods O 0 5.043175477226214e-08
used O 0 4.003620546200182e-08
for O 0 6.238284555593054e-08
mutation O 0 2.1496582576219225e-06
detection O 0 2.9244165489217266e-05
or O 0 4.278449523553718e-06
phenotype O 0 0.06612659990787506
classification O 0 5.012459041608963e-06
may O 0 4.216376225940621e-07
account O 0 2.4981583024441534e-08
for O 0 3.976072449063395e-08
a O 0 2.002791461563902e-07
considerable O 0 5.05396087646659e-07
proportion O 0 2.1033347366028465e-06
of O 0 1.154285291704582e-05
genotype O 0 0.0005232160910964012
- O 0 0.24897977709770203
phenotype O 0 0.029670260846614838
inconsistencies O 0 0.00024805005523376167
. O 0 3.3992062526522204e-05

Our O 0 3.7330930354073644e-05
data O 0 1.6132871678564698e-05
indicate O 0 1.1393123713787645e-05
that O 0 3.197545538569102e-06
the O 0 0.00019892025738954544
PAH O 1 1.0
- O 0 0.017148034647107124
mutation O 0 1.3595604286820162e-05
genotype O 0 7.289007498911815e-06
is O 0 3.645411652541952e-07
the O 0 5.509621132659959e-07
main O 0 4.0991371861309744e-06
determinant O 0 2.1654876036336645e-05
of O 0 7.252050636452623e-06
metabolic O 1 0.9995214939117432
phenotype O 0 0.0001428553950972855
in O 0 2.161857992177829e-06
most O 0 2.1196271973167313e-06
patients O 0 3.7210331356618553e-05
with O 0 0.004290309268981218
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.006696744821965694

In O 0 1.8528411601437256e-05
the O 0 2.694721388252219e-06
present O 0 1.2206264727865346e-06
study O 0 1.0823046068253461e-06
, O 0 4.41024553765601e-07
the O 0 4.3737802002397075e-07
classification O 0 2.1220423604972893e-06
of O 0 7.503647793782875e-06
105 O 0 0.0005597842973656952
PAH O 1 0.9999970197677612
mutations O 0 6.542420578625752e-06
may O 0 4.485733825276839e-06
allow O 0 2.617945824567869e-07
the O 0 1.5383391200884944e-06
prediction O 0 4.245913805789314e-05
of O 0 1.2287472372918273e-06
the O 0 1.523472178632801e-06
biochemical O 0 7.683011790504679e-05
phenotype O 0 1.2441169019439258e-05
in O 0 1.47925959481654e-06
> O 0 1.5342719734690036e-06
10 O 0 2.422938791823981e-07
, O 0 1.3365281859023526e-07
000 O 0 7.605755740769382e-07
genotypes O 0 8.286433512694202e-07
, O 0 9.56977217470012e-08
which O 0 4.063264924525356e-08
may O 0 9.289735203310556e-08
be O 0 2.314591363017371e-08
useful O 0 3.6015084248219864e-08
for O 0 4.16135996772482e-08
the O 0 8.350914413313149e-07
management O 0 3.799821115535451e-06
of O 0 9.439882887818385e-06
hyperphenylalaninemia B-Disease 1 0.9999940395355225
in O 0 1.4470294445345644e-05
newborns O 0 0.00021189948893152177
. O 0 3.667460259748623e-05

Somatic O 0 0.006188651081174612
instability O 0 0.0008594965911470354
of O 0 3.182615910191089e-05
the O 0 1.951672493305523e-05
CTG O 0 0.001013527624309063
repeat O 0 4.1639909795776475e-06
in O 0 1.131288740907621e-06
mice O 0 3.6344395084597636e-06
transgenic O 0 6.7913720158685464e-06
for O 0 7.2180023380497e-07
the O 0 0.0014161147410050035
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 3.784285581787117e-06
is O 0 3.9053688283274823e-07
age O 0 3.111966009328171e-07
dependent O 0 1.633524391309038e-07
but O 0 2.952107358566991e-08
not O 0 2.4621595429152876e-08
correlated O 0 4.459484159724525e-07
to O 0 5.38300284347315e-08
the O 0 4.7077193698896735e-07
relative O 0 3.5491204926074715e-06
intertissue O 0 7.5177988037467e-05
transcription O 0 3.312366607133299e-05
levels O 0 3.1841500458540395e-06
and O 0 2.562572490205639e-06
proliferative O 1 0.9998843669891357
capacities O 0 0.0003452854580245912
. O 0 4.2466141167096794e-05

A O 0 0.0017107551684603095
( O 0 0.00012703043466899544
CTG O 0 0.0019368421053513885
) O 0 9.332032277598046e-06
nexpansion O 0 4.560192974167876e-05
in O 0 1.7583932958586956e-06
the O 0 1.4159686543280259e-06
3 O 0 4.052459644299233e-06
- O 0 1.1174925020895898e-05
untranslated O 0 5.158856220077723e-05
region O 0 2.8849983664258616e-06
( O 0 1.2120738119847374e-06
UTR O 0 0.0001525534753454849
) O 0 2.7838402161250997e-07
of O 0 2.3698248696746305e-06
the O 0 2.2179223378770985e-05
DM O 1 0.9999992847442627
protein O 0 1.2210817658342421e-05
kinase O 0 2.205051168857608e-05
gene O 0 2.5148010536213405e-06
( O 0 1.4387621831701836e-06
DMPK O 0 0.00024861618294380605
) O 0 1.657743098348874e-07
is O 0 1.0968910402198162e-07
responsible O 0 7.81407607064466e-07
for O 0 2.302224856975954e-06
causing O 1 0.9990649819374084
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9065290093421936
DM B-Disease 1 1.0
) O 0 3.0333925678860396e-05
. O 0 1.2427200999809429e-05

Major O 0 0.0006003097514621913
instability O 0 0.0005782765801995993
, O 0 1.3134006167092593e-06
with O 0 1.0766645175408485e-07
very O 0 1.3996681502703723e-07
large O 0 1.3058640035978897e-07
expansions O 0 3.7596734614453453e-07
between O 0 8.47681249638299e-08
generations O 0 8.44070484617987e-08
and O 0 9.560157110399814e-08
high O 0 2.0799745925614843e-06
levels O 0 2.677851966836897e-07
of O 0 6.158531391520228e-07
somatic O 0 7.728431955911219e-05
mosaicism O 0 0.00831444188952446
, O 0 3.139985835787229e-07
is O 0 2.0011914614315174e-07
observed O 0 7.938347721392347e-07
in O 0 2.070769369311165e-06
patients O 0 4.537191216513747e-06
. O 0 1.131725457526045e-05

There O 0 2.095489799103234e-05
is O 0 2.670509729796322e-06
a O 0 1.4071673604121315e-06
good O 0 6.324485184450168e-07
correlation O 0 2.1037501483078813e-06
between O 0 3.392435417026718e-07
repeat O 0 1.0401683994132327e-06
size O 0 3.766682539207977e-07
( O 0 1.6840768068959733e-07
at O 0 4.4334814219837426e-07
least O 0 2.101558749245669e-08
in O 0 1.6520928625141096e-07
leucocytes O 0 1.8006756363320164e-05
) O 0 1.9614932966760534e-07
, O 0 2.2047498760002782e-07
clinical O 0 0.00010329933138564229
severity O 0 3.0000039259903133e-05
and O 0 5.565939318330493e-07
age O 0 4.659987553168321e-06
of O 0 7.393100531771779e-05
onset O 1 0.9999504089355469
. O 0 2.5179226213367656e-05

The O 0 4.997058567823842e-05
trinucleotide O 0 0.0014009878505021334
repeat O 0 4.241675924276933e-05
instability O 0 0.0001279475400224328
mechanisms O 0 1.4829724932496902e-05
involved O 0 5.262823378870962e-06
in O 0 1.7174284948850982e-05
DM B-Disease 1 1.0
and O 0 8.296032660837227e-07
other O 0 3.8825973547318426e-07
human O 0 0.00032465337426401675
genetic B-Disease 1 0.9999998807907104
diseases I-Disease 1 1.0
are O 0 2.6205811991530936e-06
unknown O 0 7.915117021184415e-05
. O 0 9.726593816594686e-06

We O 0 1.2819157745980192e-05
studied O 0 3.2072643080027774e-05
somatic O 0 0.00014518637908622622
instability O 0 8.506844460498542e-05
by O 0 1.325705284216383e-06
measuring O 0 5.764307206845842e-05
the O 0 7.467839623132022e-06
CTG O 0 0.00018682406516745687
repeat O 0 1.2990415143576683e-06
length O 0 8.541550755580829e-07
at O 0 1.2098125807824545e-06
several O 0 3.662147207705857e-08
ages O 0 8.398789930197381e-08
in O 0 6.349589654064403e-08
various O 0 7.170955740321006e-08
tissues O 0 1.1861603752549854e-06
of O 0 2.073810946967569e-06
transgenic O 0 2.011362994380761e-05
mice O 0 4.4483567762654275e-06
carrying O 0 2.9332122721825726e-06
a O 0 5.0272615226276685e-06
( O 0 1.2834897233915399e-06
CTG O 0 2.6318155505578034e-05
) O 0 2.7891150011782884e-07
55expansion O 0 3.828915396297816e-06
surrounded O 0 1.1989618542429525e-06
by O 0 1.2465157794849802e-07
45 O 0 5.805949285786483e-07
kb O 0 2.031009444181109e-06
of O 0 8.101706612251292e-07
the O 0 2.323479066035361e-06
human O 0 1.4905139323673211e-05
DM B-Disease 1 0.9999994039535522
region O 0 2.4622358978376724e-06
, O 0 4.671253179822088e-07
using O 0 5.061085062152415e-07
small O 0 2.941910679510329e-06
- O 0 3.817636024905369e-05
pool O 0 2.1563604605034925e-05
PCR O 0 6.008768832543865e-05
. O 0 9.305460480391048e-06

These O 0 5.728871201426955e-06
mice O 0 7.666456440347247e-06
have O 0 3.518808284752595e-07
been O 0 3.3483331662864657e-07
shown O 0 2.4263562181658926e-07
to O 0 5.8075720232864114e-08
reproduce O 0 2.1153550733288284e-07
the O 0 2.1995352028625348e-07
intergenerational O 0 7.992205610207748e-06
and O 0 4.687300076966494e-07
somatic O 0 3.891266533173621e-05
instability O 0 3.801900675171055e-05
of O 0 3.0109065392025514e-06
the O 0 2.3857573978602886e-06
55 O 0 4.339124643593095e-06
CTG O 0 3.6765195545740426e-05
repeat O 0 5.357105123948713e-07
suggesting O 0 6.1664366057812e-07
that O 0 3.979532081643811e-08
surrounding O 0 2.493153772320511e-07
sequences O 0 1.528635777958698e-07
and O 0 6.126382601223668e-08
the O 0 1.646242253627861e-07
chromatin O 0 6.97310042596655e-07
environment O 0 1.0977532838296611e-07
are O 0 1.9767448122820497e-08
involved O 0 2.2141391298191593e-07
in O 0 8.682136467541568e-07
instability O 0 0.00010319811553927138
mechanisms O 0 4.0559829358244315e-05
. O 0 2.3481166863348335e-05

As O 0 1.4711150470247958e-05
observed O 0 4.507303856371436e-06
in O 0 9.097602742258459e-07
some O 0 1.267776781332941e-07
of O 0 1.07568394014379e-06
the O 0 3.4028469144686824e-06
tissues O 0 7.648049358977005e-05
of O 1 0.6130204796791077
DM B-Disease 1 1.0
patients O 0 1.1860375707328785e-05
, O 0 1.7443389310756174e-07
there O 0 8.920910232745882e-08
is O 0 9.061601247140061e-08
a O 0 2.079368641716428e-07
tendency O 0 2.0607188844223856e-07
for O 0 4.797019315105899e-08
repeat O 0 2.1681272244222782e-07
length O 0 2.491133557214198e-07
and O 0 1.2327043918958225e-07
somatic O 0 7.231966264953371e-06
mosaicism O 0 3.669198849820532e-05
to O 0 7.811067348484357e-08
increase O 0 2.5094149691540224e-07
with O 0 4.427244704174882e-08
the O 0 5.595904326582968e-07
age O 0 1.0420707212688285e-06
of O 0 3.458702167336014e-06
the O 0 1.5102753422979731e-05
mouse O 0 7.177431689342484e-05
. O 0 1.4917497537680902e-05

Furthermore O 0 2.4553966795792803e-05
, O 0 1.1853338719447493e-06
we O 0 9.687971669336548e-08
observed O 0 3.2038380481935747e-07
no O 0 1.1594983817531102e-07
correlation O 0 7.418708491968573e-07
between O 0 1.911510878471745e-07
the O 0 4.839574216930487e-07
somatic O 0 7.23370476407581e-06
mutation O 0 2.425218781354488e-06
rate O 0 4.55246936326148e-06
and O 0 1.5037672937978641e-06
tissue O 1 0.9416446089744568
proliferation O 1 0.975453794002533
capacity O 0 8.690128743182868e-05
. O 0 1.2769231034326367e-05

The O 0 5.4008403822081164e-05
somatic O 0 0.0003176619648002088
mutation O 0 2.3529786631115712e-05
rates O 0 4.613416422216687e-06
in O 0 3.2091099910758203e-07
different O 0 3.129056480588588e-08
tissues O 0 9.238754046236863e-07
were O 0 5.523483537217544e-07
also O 0 1.6329762786426727e-07
not O 0 2.7391617862804196e-08
correlated O 0 3.459226149971073e-07
to O 0 6.161997134768171e-08
the O 0 7.704347240178322e-07
relative O 0 4.866849394602468e-06
inter O 0 3.686405761982314e-05
- O 0 0.00010311746154911816
tissue O 0 5.333506123861298e-05
difference O 0 3.4291196016056347e-07
in O 0 2.631399809160939e-07
transcriptional O 0 2.5447043299209327e-06
levels O 0 2.1262425775603333e-07
of O 0 2.400367407062731e-07
the O 0 2.8844846156061976e-07
three O 0 1.3845625801423012e-07
genes O 0 5.738050390391436e-07
( O 0 9.945824785972945e-07
DMAHP O 0 0.00022282366990111768
, O 0 5.088171519673779e-07
DMPK O 0 2.443339144519996e-05
and O 0 2.6979409994964954e-07
59 O 0 2.4201312953664456e-06
) O 0 1.551817092604324e-07
surrounding O 0 6.159823442430934e-07
the O 0 1.6305592680510017e-06
repeat O 0 3.2368541269534035e-06
. O 0 1.8997901634065784e-06
. O 0 7.52227697375929e-06

A O 0 7.399440801236778e-05
novel O 0 2.0796154785784893e-05
missense O 0 0.0001009822080959566
mutation O 0 1.6784259059932083e-05
in O 0 1.7985602198677952e-06
patients O 0 2.027293930950691e-06
from O 0 8.178528787539108e-07
a O 0 6.262811439228244e-06
retinoblastoma B-Disease 1 0.5286330580711365
pedigree O 0 3.639528586063534e-05
showing O 0 4.015044396510348e-06
only O 0 3.846703009457997e-07
mild O 0 0.00017096487863454968
expression O 0 5.588184194493806e-06
of O 0 9.587741260475013e-06
the O 0 5.534913725568913e-05
tumor B-Disease 1 0.9999970197677612
phenotype O 0 0.0345652811229229
. O 0 4.9325553845847026e-05

We O 0 7.619923508173088e-06
have O 0 1.3990825209475588e-06
used O 0 9.899870292429114e-07
single O 0 1.3411456620815443e-06
strand O 0 8.83868142409483e-06
conformation O 0 1.9791648355749203e-06
polymorphism O 0 1.7753885686033755e-06
analysis O 0 2.5803169023674855e-07
to O 0 4.874987880043591e-08
study O 0 1.785469834203468e-07
the O 0 3.566111388408899e-07
27 O 0 2.0907752968923887e-06
exons O 0 2.271476660098415e-06
of O 0 1.1182856951563735e-06
the O 0 2.172066842831555e-06
RB1 O 0 0.00034310383489355445
gene O 0 2.3165175377926062e-07
in O 0 1.0265436856116139e-07
individuals O 0 4.197247349679856e-08
from O 0 2.878573468478862e-07
a O 0 1.116422026825603e-06
family O 0 1.1252629974478623e-06
showing O 0 4.15908289141953e-05
mild O 0 0.005282060243189335
expression O 0 5.951403181825299e-06
of O 0 9.06142668100074e-06
the O 0 1.8276559785590507e-05
retinoblastoma B-Disease 0 0.392478883266449
phenotype O 0 0.004890034906566143
. O 0 3.356576053192839e-05

In O 0 1.2332422556937672e-05
this O 0 1.0108751666848548e-06
family O 0 5.208441962167853e-07
affected O 0 3.026178490017628e-07
individuals O 0 8.089201486427555e-08
developed O 0 2.1752507564087864e-06
unilateral B-Disease 0 0.3522014617919922
tumors I-Disease 1 1.0
and O 0 2.228749281130149e-06
, O 0 2.6725629709289933e-07
as O 0 1.2082473688224127e-07
a O 0 1.543115928370753e-07
result O 0 8.557599784353442e-08
of O 0 3.6425515759219707e-07
linkage O 0 2.0657198547269218e-05
analysis O 0 4.701335285517416e-07
, O 0 1.7512763861304848e-07
unaffected O 0 1.3227690942585468e-06
mutation O 0 1.750601796857154e-07
carriers O 0 2.058770292023837e-07
were O 0 1.5208736670047074e-07
also O 0 2.426527601073758e-07
identified O 0 2.9130970347068796e-07
within O 0 5.065812729299068e-07
the O 0 6.165457762108417e-06
pedigree O 0 0.00010970821313094348
. O 0 1.9940045604016632e-05

A O 0 0.00013084313832223415
single O 0 8.664842425787356e-06
band O 0 5.924583547312068e-06
shift O 0 4.507488483795896e-06
using O 0 1.1300982123430003e-06
SSCP O 0 0.00011633503891061991
was O 0 1.10393430077238e-05
identified O 0 6.921997055542306e-07
in O 0 1.8825073766493006e-07
exon O 0 1.154066694653011e-06
21 O 0 9.644641068007331e-07
which O 0 8.412482088715478e-08
resulted O 0 7.525137561970041e-07
in O 0 2.1037409680957353e-07
a O 0 8.615220394858625e-07
missense O 0 5.784284894616576e-06
mutation O 0 1.3763333299721126e-06
converting O 0 5.062521722720703e-06
a O 0 1.1864300176966935e-05
cys O 0 0.0009406148456037045
- O 0 5.879101809114218e-05
- O 0 2.931516974058468e-05
> O 0 7.446476502082078e-06
arg O 0 5.991425950924167e-06
at O 0 2.0609795683412813e-06
nucleotide O 0 9.255191457668843e-07
position O 0 1.5248951967805624e-06
28 O 0 2.0051356841577217e-06
in O 0 4.84203951600648e-07
the O 0 2.3702543785475427e-06
exon O 0 3.2577143429080024e-05
. O 0 1.1508889656397514e-05

The O 0 4.659563637687825e-05
mutation O 0 2.3729373424430378e-05
destroyed O 0 0.00012053902173647657
an O 0 1.2196420357213356e-05
NdeI O 0 0.0005554569070227444
restriction O 0 2.70304772129748e-05
enzyme O 0 1.0648235729604494e-05
site O 0 1.2079992302460596e-05
. O 0 9.443115231988486e-06

Analysis O 0 4.1478338971501216e-05
of O 0 5.16625686941552e-06
all O 0 6.817248845436552e-07
family O 0 6.463386057475873e-07
members O 0 9.376928034043885e-08
demonstrated O 0 4.4961231537854474e-07
that O 0 6.307908506641979e-08
the O 0 4.895599090559699e-07
missense O 0 2.2656617147731595e-05
mutation O 0 1.1966866622969974e-05
co O 0 0.001255122129805386
- O 0 0.0004643714928533882
segregated O 0 3.4391682675050106e-06
with O 0 1.4366587208769488e-07
patients O 0 1.8159815908802557e-06
with O 0 3.463805796855013e-06
tumors B-Disease 1 1.0
or O 0 0.0005264128558337688
who O 0 3.458023002167465e-06
, O 0 2.1325256227555656e-07
as O 0 2.158333956003844e-07
a O 0 3.80374814312745e-07
result O 0 1.6169155969691928e-07
of O 0 4.4971693569095805e-07
linkage O 0 9.694681466498878e-06
analysis O 0 4.232821879668336e-07
had O 0 5.327214012140757e-07
been O 0 4.464726544028963e-07
predicted O 0 1.4345519048220012e-06
to O 0 8.811027640831526e-08
carry O 0 4.4148535494059615e-07
the O 0 3.7284808058757335e-06
predisposing O 0 0.00014538559480570257
mutation O 0 4.3657197238644585e-05
. O 0 1.8695465769269504e-05

These O 0 4.4187090679770336e-06
observations O 0 1.4057204680284485e-05
point O 0 8.250434802903328e-06
to O 0 2.68877101916587e-07
another O 0 4.764848426930257e-07
region O 0 4.0117851085597067e-07
of O 0 1.0869064226426417e-06
the O 0 2.110027025992167e-06
RB1 O 0 5.4879590607015416e-05
gene O 0 1.3991503067245503e-07
where O 0 6.380084727197755e-08
mutations O 0 1.0391773486162492e-07
only O 0 3.753221022861908e-08
modify O 0 6.035072885879345e-08
the O 0 1.1261546717378224e-07
function O 0 9.83032961698882e-08
of O 0 1.4272863779751788e-07
the O 0 2.424672231882141e-07
gene O 0 1.457669469573375e-07
and O 0 4.8870905544617926e-08
raise O 0 1.087811156708085e-07
important O 0 5.7087294891289275e-08
questions O 0 7.822532666068582e-08
for O 0 8.781331928275904e-08
genetic O 0 2.0825211777264485e-06
counseling O 0 1.786653115232184e-06
in O 0 3.3694846024445724e-07
families O 0 3.639467749394498e-08
with O 0 5.261375335408047e-08
these O 0 1.534413911485899e-07
distinctive O 0 5.603233148576692e-06
phenotypes O 0 4.309226278564893e-05
. O 0 2.0733402834594017e-06
. O 0 1.1791241377068218e-05

Maternal B-Disease 1 0.9340897798538208
disomy I-Disease 1 0.9997057318687439
and O 1 0.7944728136062622
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 1 0.9995662569999695
with O 0 4.26404585596174e-06
gamete O 1 0.9921160340309143
complementation O 1 0.9956511855125427
in O 0 1.6807600786705734e-06
a O 0 2.2779997834732058e-06
case O 0 6.134258683232474e-07
of O 0 6.8378892592591e-07
familial O 0 3.7840109143871814e-05
translocation O 0 0.048725128173828125
( O 0 3.1032018341647927e-06
3 O 0 7.048282895993907e-06
; O 0 3.6500486544355226e-07
15 O 0 2.2242650175030576e-06
) O 0 5.119912884765654e-07
( O 0 9.83809172794281e-07
p25 O 0 3.745609865291044e-05
; O 0 2.2396170606953092e-07
q11 O 0 1.867579157988075e-05
. O 0 5.886916483177629e-07
2 O 0 3.464268047537189e-06
) O 0 2.846301185854827e-06
. O 0 9.130673788604327e-06

Maternal B-Disease 1 0.9877722263336182
uniparental I-Disease 1 0.999971866607666
disomy I-Disease 1 0.9995560050010681
( I-Disease 0 0.00034664166742004454
UPD I-Disease 1 0.9999918937683105
) I-Disease 0 2.7373921511752997e-06
for I-Disease 0 4.1247031390412303e-07
chromosome I-Disease 0 1.855531991168391e-05
15 I-Disease 0 2.6939196686726063e-06
is O 0 3.169741660258296e-07
responsible O 0 4.3116131109854905e-07
for O 0 1.1686682199751885e-07
an O 0 2.5819119287007197e-07
estimated O 0 3.04045471466452e-07
30 O 0 2.26597165919884e-07
% O 0 7.652029410110117e-08
of O 0 2.6350662096774613e-07
cases O 0 4.3740473643083533e-07
of O 0 0.002861388260498643
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999938011169434
PWS B-Disease 1 1.0
) O 0 8.837056520860642e-05
. O 0 3.0096092814346775e-05

We O 0 2.3065384084475227e-05
report O 0 8.843504474498332e-06
on O 0 1.9405163129704306e-06
an O 0 1.175897523353342e-06
unusual O 0 1.7301830439464538e-06
case O 0 1.3557735201175092e-06
of O 0 4.602175977197476e-06
maternal B-Disease 0 0.028276018798351288
disomy I-Disease 0 0.06279975920915604
15 I-Disease 0 1.1287225788692012e-05
in O 0 1.5381661796709523e-05
PWS B-Disease 1 1.0
that O 0 7.643931780876301e-07
is O 0 4.704533012045431e-07
most O 0 7.520933564819643e-08
consistent O 0 3.3923413411685033e-07
with O 0 5.984625062183113e-08
adjacent O 0 2.215033418906387e-06
- O 0 2.3647273792448686e-06
1 O 0 5.863440151188115e-07
segregation O 0 4.095247447821748e-07
of O 0 4.011375835943909e-07
a O 0 2.148346766261966e-06
paternal O 0 1.9311330106575042e-05
t O 0 6.345725068968022e-06
( O 0 3.5746336379816057e-07
3 O 0 6.476256544374337e-07
; O 0 9.763172670318454e-08
15 O 0 9.203130844070984e-07
) O 0 1.2048782593865326e-07
( O 0 2.2282915779214818e-07
p25 O 0 1.1491220902826171e-05
; O 0 6.199201862955306e-08
q11 O 0 2.4299324650201015e-06
. O 0 2.3344806976410837e-08
2 O 0 9.511304455145364e-08
) O 0 1.6694668758532316e-08
with O 0 1.065652188714239e-08
simultaneous O 0 1.4944145050321822e-06
maternal O 0 0.0003511265094857663
meiotic O 0 0.02144227921962738
nondisjunction O 0 0.00017582334112375975
for O 0 1.542233235340973e-06
chromosome O 0 0.00027306145057082176
15 O 0 6.0929374740226194e-05
. O 0 2.2877053197589703e-05

The O 0 0.000210463025723584
patient O 0 0.00022606873244512826
( O 0 2.201075949415099e-05
J O 0 0.005403351970016956
. O 0 1.5188023780865478e-06
B O 0 8.122269719024189e-06
. O 0 1.1751571094009705e-07
) O 0 8.112192517728545e-08
, O 0 6.78284024502318e-08
a O 0 9.478540050622541e-07
17 O 0 5.043506462243386e-06
- O 0 2.3532660634373315e-05
year O 0 8.260968570539262e-06
- O 0 1.6278267139568925e-05
old O 0 1.130868804466445e-05
white O 0 2.1333200947992736e-06
male O 0 1.829022266974789e-06
with O 0 1.722345359667088e-06
PWS B-Disease 1 1.0
, O 0 1.6820429209474241e-06
was O 0 9.542915904603433e-06
found O 0 1.4163940420530707e-07
to O 0 6.685213094215214e-08
have O 0 1.2776517621659877e-07
47 O 0 2.3653342395846266e-06
chromosomes O 0 1.2592926168508711e-06
with O 0 4.828261239708809e-07
a O 0 2.0142693756497465e-05
supernumerary O 1 0.9998027682304382
, O 0 3.820562142209383e-06
paternal O 0 0.00021714880131185055
der O 0 0.014581577852368355
( O 0 4.062536902438296e-07
15 O 0 6.814726702941698e-07
) O 0 7.406747926097523e-08
consisting O 0 1.3708066148865328e-07
of O 0 8.589771596234641e-07
the O 0 2.9281115985213546e-06
short O 0 1.0709738489822485e-05
arm O 0 5.948579928372055e-05
and O 0 9.988769988922286e-07
the O 0 9.878906894300599e-06
proximal O 1 0.8112848997116089
long O 0 5.570827124756761e-05
arm O 0 3.4596785553731024e-05
of O 0 1.8506756305214367e-06
chromosome O 0 4.107401400688104e-05
15 O 0 5.255590622255113e-06
, O 0 1.2708117083093384e-06
and O 0 2.819223936967319e-06
distal O 1 0.9996482133865356
chromosome O 1 0.9999977350234985
arm O 1 0.999996542930603
3p O 1 0.9999631643295288
. O 0 0.00011143524898216128

The O 0 0.0003476186248008162
t O 0 0.00011597240518312901
( O 0 3.2150601327884942e-06
3 O 0 1.836650426412234e-06
; O 0 1.0491150703728636e-07
15 O 0 5.807682441627549e-07
) O 0 1.1459001569846805e-07
was O 0 6.783175194868818e-07
present O 0 4.398509645398008e-08
in O 0 5.220909216063774e-08
the O 0 7.184975459040288e-08
balanced O 0 8.115473804082285e-08
state O 0 2.191310599641838e-08
in O 0 1.3951689936675393e-07
the O 0 8.280697443296958e-07
patients O 0 1.006319621410512e-06
father O 0 4.739641099149594e-06
and O 0 1.6481145621582982e-06
a O 0 8.931927004596218e-05
sister O 0 0.002097092103213072
. O 0 5.9128589782631025e-05

Fluorescent O 0 0.00026907658320851624
in O 0 5.594913545792224e-06
situ O 0 3.2325973734259605e-05
hybridization O 0 5.938612957834266e-06
analysis O 0 9.586137821315788e-07
demonstrated O 0 1.3024180134380003e-06
that O 0 1.8982801464062504e-07
the O 0 2.798285322569427e-06
PWS B-Disease 1 0.9999983310699463
critical O 0 3.462279664745438e-06
region O 0 5.562718570217839e-07
resided O 0 2.859703954527504e-06
on O 0 1.376070940750651e-06
the O 0 5.543241172745184e-07
derivative O 0 3.3455510219937423e-06
chromosome O 0 3.60975514013262e-06
3 O 0 8.991869435703848e-07
and O 0 1.254238100045768e-07
that O 0 7.941280699697018e-08
there O 0 1.7973292187889456e-07
was O 0 3.112526201221044e-06
no O 0 1.8694436221267097e-07
deletion O 0 1.0453434242663207e-06
of O 0 2.0151423996139783e-06
the O 0 9.164051334664691e-06
PWS B-Disease 1 0.9999990463256836
region O 0 2.162400051020086e-06
on O 0 2.8068941446690587e-06
the O 0 6.867107913421933e-07
normal O 0 1.1631459528871346e-06
pair O 0 1.2108282589906594e-06
of O 0 4.216688466840424e-06
15s O 0 5.456736107589677e-05
present O 0 1.0922714182015625e-06
in O 0 9.35830485104816e-06
J O 0 0.033997416496276855
. O 0 1.9943545339629054e-05

B O 0 0.02293362095952034
. O 0 0.00036087509943172336

Methylation O 0 0.0004116938216611743
analysis O 0 3.347213350934908e-05
at O 0 1.8512195310904644e-05
exon O 0 1.029049508360913e-05
alpha O 0 3.995118277089205e-06
of O 0 5.280452342049102e-07
the O 0 7.412238005599647e-07
small O 0 9.835034688876476e-07
nuclear O 0 7.459228072548285e-05
ribonucleoprotein O 0 0.01959984190762043
- O 0 5.233459887676872e-05
associated O 0 8.313460966746788e-06
polypeptide O 0 7.756287232041359e-05
N O 0 1.1379061106708832e-05
( O 0 5.52548613086401e-07
SNRPN O 0 4.631388219422661e-05
) O 0 8.114173510875844e-08
gene O 0 1.4486475663488818e-07
showed O 0 8.147599714902753e-07
a O 0 6.911436116752157e-07
pattern O 0 2.507185854483396e-06
characteristic O 0 4.912656095257262e-07
of O 0 5.355199732548499e-07
only O 0 6.288555454148081e-08
the O 0 4.491212166612968e-07
maternal O 0 2.5925319278030656e-05
chromosome O 0 8.857861394062638e-05
15 O 0 1.6219135432038456e-05
in O 0 2.525213494664058e-05
J O 1 0.8185015320777893
. O 0 3.196598481736146e-05

B O 0 0.021315647289156914
. O 0 0.0005226346547715366

Maternal B-Disease 0 0.005016523413360119
disomy I-Disease 0 0.005376409739255905
was O 0 0.00014627596829086542
confirmed O 0 8.219045412261039e-06
by O 0 2.0905340534227435e-06
polymerase O 0 8.28891497803852e-05
chain O 0 2.4584145648987032e-05
reaction O 0 2.021571617660811e-06
analysis O 0 3.20232288686384e-07
of O 0 9.046107720678265e-07
microsatellite O 0 2.421007775410544e-05
repeats O 0 4.87213401356712e-06
at O 0 5.76267984797596e-06
the O 0 2.1460386960825417e-06
gamma O 0 1.5821591659914702e-05
- O 0 4.091950540896505e-05
aminobutyric O 0 7.903095684014261e-05
acid O 0 2.6089408038387774e-06
receptor O 0 3.7521015201491537e-06
beta3 O 0 2.1425896193250082e-05
subunit O 0 4.637616711988812e-06
( O 0 2.165861360481358e-06
GABRB3 O 0 0.0003247970307711512
) O 0 3.0072505978750996e-06
locus O 0 8.032908954191953e-05
. O 0 9.464735740039032e-06

A O 0 0.001550793880596757
niece O 0 0.0027395228389650583
( O 0 3.2807784009492025e-05
B O 0 6.982141348998994e-05
. O 0 1.1499928405100945e-06
B O 0 7.2673237809794955e-06
. O 0 6.765177573697656e-08
) O 0 5.2121137628091674e-08
with O 0 4.163344868857166e-08
45 O 0 3.3952898093048134e-07
chromosomes O 0 3.512411410611094e-07
and O 0 1.9942338269629545e-07
the O 0 7.814731475264125e-07
derivative O 0 3.872482920996845e-06
3 O 0 7.165075999182591e-07
but O 0 6.794039819624231e-08
without O 0 1.5094413186034217e-07
the O 0 6.780575745324313e-07
der O 0 2.5306910174549557e-05
( O 0 1.1157424495422674e-07
15 O 0 3.8761376686125004e-07
) O 0 4.5214409993832305e-08
demonstrated O 0 2.9615773655677913e-07
a O 0 4.674252238601184e-07
phenotype O 0 3.240121714043198e-06
consistent O 0 5.435983325696725e-07
with O 0 5.2069566436330206e-08
that O 0 1.82706472173777e-07
reported O 0 2.2958665795158595e-06
for O 0 4.596731741912663e-07
haploinsufficiency O 0 5.010419408790767e-05
of O 0 1.0377050784882158e-05
distal O 0 0.002579325810074806
3 O 0 6.979904719628394e-05
p O 0 0.00022479734616354108
. O 0 1.4800929420744069e-05

Uniparental B-Disease 1 0.9999998807907104
disomy I-Disease 1 0.9999966621398926
associated O 0 0.0001463631633669138
with O 0 5.857108590134885e-06
unbalanced O 0 0.004015395417809486
segregation O 0 1.9630217138910666e-05
of O 0 7.60939292376861e-06
non O 0 3.233654933865182e-05
- O 0 2.870448588510044e-05
Robertsonian O 0 3.7798952689627185e-05
translocations O 0 5.140484972798731e-06
has O 0 5.081174094812013e-07
been O 0 5.502253657141409e-07
reported O 0 4.685074372900999e-07
previously O 0 3.8916348898965225e-07
but O 0 2.8798908147109614e-08
has O 0 6.537977981224685e-08
not O 0 2.5719581131511404e-08
, O 0 2.6298787147993608e-08
to O 0 1.3896523931578031e-08
our O 0 6.521040774032372e-08
knowledge O 0 2.1999254329330142e-07
, O 0 9.205388806776682e-08
been O 0 1.4283826033079094e-07
observed O 0 1.4203003217971855e-07
in O 0 2.0609979856089922e-07
a O 0 1.8294933852303075e-06
case O 0 5.527949724637438e-06
of O 0 4.973506656824611e-05
PWS B-Disease 1 1.0
. O 0 4.914020246360451e-05

Furthermore O 0 0.00017371634021401405
, O 0 4.892215201834915e-06
our O 0 1.8075827483698959e-06
findings O 0 1.5449344346052385e-06
are O 0 8.938658169199698e-08
best O 0 2.2773171792778157e-07
interpreted O 0 8.889163609637762e-07
as O 0 3.195425222202175e-07
true O 0 1.427223992322979e-06
gamete O 0 4.537401764537208e-05
complementation O 0 0.0013823265908285975
resulting O 0 8.986264219856821e-06
in O 0 4.641103259928059e-06
maternal B-Disease 1 0.9925544857978821
UPD I-Disease 1 1.0
15 I-Disease 0 0.0003632378939073533
and O 0 0.0005966260796412826
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9994230270385742
- I-Disease 1 0.999919056892395
Jampel I-Disease 1 0.999998927116394
syndrome I-Disease 1 1.0
type I-Disease 0 0.01982194371521473
2 I-Disease 0 7.3072878876701e-05
and O 0 1.316933958150912e-05
Stuve B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999997615814209
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 8.790630090516061e-07
a O 0 1.4828952998868772e-06
case O 0 8.673248430568492e-07
for O 0 3.31243683149296e-07
" O 0 4.486418674787274e-06
lumping O 0 1.2557462468976155e-05
" O 0 1.8357874068897218e-05
. O 0 8.748731488594785e-06

Recent O 0 2.3154310838435777e-05
studies O 0 8.509472536388785e-06
demonstrated O 0 2.9744380753982114e-06
the O 0 3.6214157717040507e-07
existence O 0 5.184293172533216e-07
of O 0 4.7192361307679676e-07
a O 0 6.767093054804718e-07
genetically O 0 2.921084103491012e-07
distinct O 0 1.177584820766242e-07
, O 0 1.1087586671010285e-07
usually O 0 1.325405492025311e-07
lethal O 0 1.0173877171837375e-06
form O 0 1.2583187469772383e-07
of O 0 2.0479933482420165e-06
the O 0 2.0354271327960305e-05
Schwartz B-Disease 1 0.9775126576423645
- I-Disease 1 0.9998829364776611
Jampel I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 0.00014587912301067263
SJS B-Disease 1 0.9999991655349731
) O 0 1.6949508108154987e-06
of O 0 3.6287226976128295e-05
myotonia B-Disease 1 0.9992274045944214
and O 0 2.9643044399563223e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 0.9999994039535522
, O 0 1.3492018524630112e-06
which O 0 3.627270928063808e-07
we O 0 5.675074135069735e-07
called O 0 1.1741073649318423e-05
SJS B-Disease 1 0.9775877594947815
type I-Disease 0 2.7878548280568793e-05
2 I-Disease 0 4.183694545645267e-05
. O 0 2.160990516131278e-05

This O 0 5.6898585171438754e-05
disorder O 1 0.9777596592903137
is O 0 4.131185050937347e-06
reminiscent O 0 1.6818579751998186e-05
of O 0 1.4476493106485577e-06
another O 0 2.431007942504948e-06
rare O 0 7.009150067460723e-06
condition O 0 0.0006872312515042722
, O 0 2.1744294826930854e-06
the O 0 2.865495662263129e-05
Stuve B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.018532749265432358
SWS B-Disease 1 0.9999998807907104
) O 0 1.7406511005901848e-06
, O 0 3.345163577250787e-07
which O 0 2.130326350879841e-07
comprises O 0 1.2990934692425071e-06
campomelia B-Disease 0 0.0027339032385498285
at O 0 9.08299334696494e-05
birth O 0 0.015497179701924324
with O 0 8.1031204899773e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 1 0.7847039699554443
contractures B-Disease 1 0.9999998807907104
, O 0 7.307786290766671e-06
and O 0 2.994303940795362e-06
early B-Disease 0 0.00024491024669259787
death I-Disease 1 0.6493358612060547
. O 0 4.328856084612198e-05

To O 0 7.89523073763121e-06
test O 0 3.509023827064084e-06
for O 0 2.9260971246003464e-07
possible O 0 1.6705886309864582e-06
nosologic O 0 3.9659229514654726e-05
identity O 0 4.222001450671087e-07
between O 0 6.260395366552984e-07
these O 0 2.710797843974433e-07
disorders O 0 0.49488896131515503
, O 0 2.0593829219706095e-07
we O 0 4.2774601638484455e-08
reviewed O 0 1.3986580427172157e-07
the O 0 9.228946851180808e-08
literature O 0 2.39758065845308e-07
and O 0 4.1257013805307e-08
obtained O 0 4.5731201225862605e-07
a O 0 1.2153378747825627e-06
follow O 0 2.2845563307782868e-07
- O 0 1.6654362298140768e-06
up O 0 3.2319698561877885e-07
of O 0 2.795367777252977e-07
the O 0 1.5668872777041543e-07
only O 0 7.992702677483976e-08
two O 0 1.076208775430132e-07
surviving O 0 3.9075025597412605e-06
patients O 0 1.4847561260467046e-06
, O 0 3.739751548437198e-07
one O 0 4.6240313622547546e-07
with O 0 6.886815526740975e-07
SJS B-Disease 1 0.9722062945365906
type I-Disease 0 4.184125373285497e-06
2 I-Disease 0 2.118909833370708e-06
at O 0 2.025419462370337e-06
age O 0 2.600567086119554e-07
10 O 0 2.0427995650607045e-07
years O 0 8.46456558178943e-08
and O 0 4.6713775958551196e-08
another O 0 2.1762706126082776e-07
with O 0 3.124744694105175e-07
SWS B-Disease 0 0.10090206563472748
at O 0 7.085680408636108e-06
age O 0 3.0582452836824814e-06
7 O 0 1.5949057342368178e-05
years O 0 1.051268645824166e-05
. O 0 1.9029643226531334e-05

Patients O 0 0.00027813701308332384
reported O 0 2.210234379163012e-05
as O 0 2.1585451577266213e-06
having O 0 2.7708349534805166e-06
either O 0 8.74019224283984e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 1.3409473467618227e-05
SWS B-Disease 1 0.9999411106109619
presented O 0 1.1062613793910714e-06
a O 0 8.358165359823033e-07
combination O 0 8.560388664591301e-07
of O 0 2.0654422314692056e-06
a O 0 5.635640991386026e-05
severe O 1 0.9997852444648743
, O 0 4.057437399751507e-05
prenatal O 1 1.0
- O 1 1.0
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.00016568356659263372
with O 0 0.00010648439638316631
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.999874472618103
respiratory O 1 1.0
and O 0 0.0002421189856249839
feeding O 1 0.8666867017745972
difficulties O 0 0.16487646102905273
, O 0 2.5507422378723277e-06
tendency O 0 1.0127517271030229e-05
to O 0 9.711463917483343e-07
hyperthermia B-Disease 1 0.9999195337295532
, O 0 5.659248927258886e-07
and O 0 1.8388763578514045e-07
frequent O 0 2.7315400075167418e-06
death O 0 0.2896782159805298
in O 0 8.971039278549142e-06
infancy O 0 0.00018657180771697313
) O 0 1.2832396123485523e-07
with O 0 9.539628820220969e-08
a O 0 6.18354715697933e-06
distinct O 0 1.3922164725954644e-05
campomelic B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999998807907104
metaphyseal I-Disease 1 1.0
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.003428604919463396

The O 0 1.572161818330642e-05
similarity O 0 1.2488956599554513e-05
of O 0 5.545860403799452e-06
the O 0 5.477111244545085e-06
clinical O 0 0.006641735788434744
and O 0 1.0226834774584859e-06
radiographic O 0 0.13223262131214142
findings O 0 4.7591533984814305e-06
is O 0 1.9612370749655383e-07
so O 0 4.0010327495565434e-08
extensive O 0 5.862931402589311e-07
that O 0 1.777021907400922e-07
these O 0 2.935247493951465e-07
disorders O 1 0.9304958581924438
appear O 0 7.310995329135039e-07
to O 0 1.576462125285616e-07
be O 0 2.6405274411445134e-07
a O 0 1.155340783043357e-06
single O 0 2.1557330001087394e-06
entity O 0 1.01787500170758e-05
. O 0 1.6353076716768555e-05

The O 0 5.502673957380466e-05
follow O 0 6.029290489095729e-06
- O 0 1.0918571206275374e-05
up O 0 8.284702630589891e-07
observation O 0 6.726405899826204e-06
of O 0 3.811122724073357e-07
an O 0 2.1314237130809488e-07
identical O 0 1.7613494662782614e-07
and O 0 6.743264435726815e-08
unique O 0 1.1963618362642592e-07
pattern O 0 5.9632788179442286e-05
of O 0 0.0004179404058959335
progressive O 1 0.999998927116394
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 6.174589998408919e-06
the O 0 2.7588273496803595e-06
two O 0 2.895390309731738e-07
patients O 0 8.961128514783923e-07
( O 0 3.925761120626703e-07
one O 0 3.987841523667157e-07
with O 0 1.1166285958097433e-06
SJS B-Disease 1 0.9998086094856262
type I-Disease 0 2.9227718187030405e-05
2 I-Disease 0 8.022920155781321e-06
, O 0 3.4056802178383805e-07
one O 0 2.723396335113648e-07
with O 0 4.259950685536751e-07
SWS B-Disease 1 0.8797094821929932
) O 0 4.2911801756417844e-07
surviving O 0 3.6452902349992655e-06
beyond O 0 1.8183523025072645e-06
infancy O 0 4.915856607112801e-06
adds O 0 1.3387199260250782e-07
to O 0 2.6126947716420545e-08
the O 0 1.1108352282462874e-07
evidence O 0 1.9270376583335747e-07
in O 0 1.1779375341802734e-07
favor O 0 2.304372372918806e-07
of O 0 1.3729760439673555e-06
identity O 0 6.920287432876648e-06
. O 0 1.3281921383168083e-05

The O 0 1.7644979379838333e-05
hypothesis O 0 1.7840577129391022e-05
that O 0 3.2686191389075248e-06
SWS B-Disease 1 0.92453932762146
and O 0 1.2229567801114172e-05
SJS B-Disease 1 0.999975323677063
type I-Disease 0 8.025200258998666e-06
2 I-Disease 0 1.5478825616810354e-06
are O 0 3.9660744022285144e-08
the O 0 1.39462358106357e-07
same O 0 2.557488869570079e-07
disorder O 0 1.1580982572922949e-05
should O 0 3.9561545150945676e-08
be O 0 5.6306316054133276e-08
testable O 0 7.061429982968548e-07
by O 0 1.3927866859830829e-07
molecular O 0 3.883762474288233e-06
methods O 0 1.9558722215151647e-06
. O 0 1.8286996237293351e-06
. O 0 7.050534804875497e-06

A O 0 0.000403799582272768
mouse O 0 0.00011061666009481996
model O 0 9.012018381326925e-06
of O 0 1.1674328561639413e-05
severe O 1 0.9999996423721313
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.7267162203788757
defects O 1 0.9999964237213135
in O 0 0.0003429061616770923
hemostasis O 1 0.9999659061431885
and O 0 0.0011820800136774778
thrombosis B-Disease 1 1.0
. O 0 0.0010388991795480251

von B-Disease 1 0.9961115717887878
Willebrand I-Disease 1 0.9999961853027344
factor I-Disease 0 0.005353950895369053
( I-Disease 0 7.926960824988782e-05
vWf I-Disease 1 0.7649604082107544
) I-Disease 0 0.00031932105775922537
deficiency I-Disease 1 1.0
causes O 1 0.9999696016311646
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.8875113129615784
humans O 0 4.4203901779837906e-05
. O 0 1.5026653272798285e-05

We O 0 4.79140999232186e-06
generated O 0 3.090024847551831e-06
a O 0 3.103687276961864e-06
mouse O 0 3.49919559994305e-06
model O 0 4.4038489477316034e-07
for O 0 7.554547210020246e-08
this O 0 9.65684918696752e-08
disease O 0 1.7011839190672617e-06
by O 0 6.059536872271565e-08
using O 0 1.9219262981096108e-07
gene O 0 2.5377414658578346e-06
targeting O 0 3.528006709530018e-05
. O 0 1.473343036195729e-05

vWf B-Disease 1 0.9893223643302917
- I-Disease 1 0.9982454776763916
deficient I-Disease 1 0.9166494011878967
mice O 0 0.000114134352770634
appeared O 0 1.0463165381224826e-05
normal O 0 2.238037950519356e-06
at O 0 1.1119243481516605e-06
birth O 0 5.35745755314565e-07
; O 0 2.2336866578598347e-08
they O 0 1.49696290918655e-08
were O 0 2.3367444157429418e-07
viable O 0 1.2940607803102466e-06
and O 0 1.2868246130892658e-06
fertile O 0 0.00015964516205713153
. O 0 3.388577533769421e-05

Neither O 0 0.0004919075290672481
vWf O 0 0.004016617313027382
nor O 0 0.00021405114966910332
vWf O 0 0.0015013207448646426
propolypeptide O 0 0.002890336560085416
( O 0 4.571465979097411e-05
von B-Disease 1 0.6182725429534912
Willebrand I-Disease 1 0.999616265296936
antigen O 0 0.011139879934489727
II O 1 0.6314164996147156
) O 0 3.0737959377802326e-07
were O 0 3.3150345757348987e-07
detectable O 0 2.2292383619060274e-06
in O 0 3.6327062957752787e-07
plasma O 0 2.283871071995236e-05
, O 0 4.928061230202729e-07
platelets O 0 9.666929145168979e-06
, O 0 1.188723103950906e-06
or O 0 2.4164089609257644e-06
endothelial O 0 0.2917102575302124
cells O 0 1.6890868437258177e-06
of O 0 1.3082850500722998e-06
the O 0 2.3100544694898417e-06
homozygous O 0 1.8422620996716432e-05
mutant O 0 5.770500501967035e-05
mice O 0 9.454615792492405e-05
. O 0 1.6237552699749358e-05

The O 0 7.185868889791891e-05
mutant O 0 0.0005173883400857449
mice O 0 0.0003802864230237901
exhibited O 0 0.05985928326845169
defects O 1 0.9805221557617188
in O 0 3.6572582757798955e-06
hemostasis O 0 0.01372662466019392
with O 0 6.644546033385268e-07
a O 0 1.8696660845307633e-05
highly O 0 0.0008025236311368644
prolonged O 1 0.9999877214431763
bleeding O 1 0.9999895095825195
time O 0 9.971438430511625e-07
and O 0 3.870456453114457e-07
spontaneous O 0 1.6906638848013245e-05
bleeding O 0 0.10222092270851135
events O 0 1.995074683236453e-07
in O 0 6.133971197641586e-08
approximately O 0 2.0478904616538784e-07
10 O 0 2.3501313251017564e-07
% O 0 4.571981833123573e-07
of O 0 4.789103059010813e-06
neonates O 0 0.0002692498383112252
. O 0 2.2834701667306945e-05

As O 0 1.6100197171908803e-05
in O 0 2.1226292119536083e-06
the O 0 3.5562150060286513e-06
human O 0 9.892208254314028e-06
disease O 0 0.0655745267868042
, O 0 3.238544650230324e-07
the O 0 9.001693683785561e-07
factor O 0 2.410332854196895e-06
VIII O 0 0.0008169396314769983
level O 0 1.54734243551502e-06
in O 0 1.1739921745856918e-07
these O 0 4.0208469442859496e-08
mice O 0 1.0125675089511788e-06
was O 0 4.2559772737149615e-06
reduced O 0 5.161905392014887e-07
strongly O 0 1.147065802342695e-07
as O 0 7.511945199212278e-08
a O 0 1.1568629076919024e-07
result O 0 8.404495588365535e-08
of O 0 1.493749124392707e-07
the O 0 1.791623560620792e-07
lack O 0 5.474967679219844e-07
of O 0 8.801568469607446e-07
protection O 0 1.6725253999538836e-06
provided O 0 2.0311140360718127e-06
by O 0 3.491152256174246e-06
vWf O 0 0.00015002297004684806
. O 0 1.2971724572707899e-05

Defective O 1 0.9994978904724121
thrombosis B-Disease 1 0.9999995231628418
in O 0 2.301058884768281e-05
mutant O 0 0.00026032590540125966
mice O 0 5.0922302762046456e-05
was O 0 5.289312684908509e-05
also O 0 4.606522168160154e-07
evident O 0 8.981739370028663e-07
in O 0 1.859379921143045e-07
an O 0 1.515416840902617e-07
in O 0 3.223101998628408e-07
vivo O 0 4.060428909724578e-05
model O 0 5.3878070502833e-06
of O 0 0.0012516856659203768
vascular B-Disease 1 1.0
injury I-Disease 1 0.9999970197677612
. O 0 0.00010773514077300206

In O 0 1.4356372048496269e-05
this O 0 1.4550930700352183e-06
model O 0 3.250325562476064e-06
, O 0 7.308903491320962e-07
the O 0 1.5782221680638031e-06
exteriorized O 0 0.0001156437792815268
mesentery O 0 0.00021376479708123952
was O 0 7.889796688687056e-05
superfused O 0 6.332054908853024e-05
with O 0 1.1195246543138637e-06
ferric O 0 0.00011589336645556614
chloride O 0 4.615511443262221e-06
and O 0 5.319162710293313e-07
the O 0 3.6392289075593e-06
accumulation O 0 0.00010649191244738176
of O 0 1.7116417438955978e-05
fluorescently O 0 0.0006021055742166936
labeled O 0 1.041842915583402e-05
platelets O 0 9.81559423962608e-06
was O 0 1.2831731510232203e-05
observed O 0 1.4154259133647429e-06
by O 0 6.309412583505036e-07
intravital O 0 4.512542000156827e-05
microscopy O 0 4.1574610804673284e-05
. O 0 1.2147922461736016e-05

We O 0 7.954475222504698e-06
conclude O 0 1.0067353287013248e-05
that O 0 2.33589773301901e-07
these O 0 1.9963651709531405e-07
mice O 0 6.3003599279909395e-06
very O 0 3.423548378123087e-07
closely O 0 1.5154428183450364e-06
mimic O 0 0.0004428151296451688
severe O 1 0.9999516010284424
human O 1 0.9730958938598633
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 4.477399670577142e-06
will O 0 2.102513292356889e-07
be O 0 5.9584181144600734e-08
very O 0 2.539130150580604e-08
useful O 0 2.7158193915965967e-08
for O 0 1.70758429618445e-08
investigating O 0 8.098139403500682e-08
the O 0 1.444682311557699e-07
role O 0 3.8832340010230837e-07
of O 0 9.954478628060315e-07
vWf O 0 6.579813543794444e-06
in O 0 5.247925400908571e-07
normal O 0 3.2135001220012782e-06
physiology O 0 0.00011601820006035268
and O 0 5.659356929754722e-07
in O 0 4.7444618758163415e-06
disease O 1 0.8826446533203125
models O 0 6.105343800300034e-06
. O 0 2.1861774257558864e-06
. O 0 8.749982953304425e-06

Oral O 0 0.004363540094345808
contraceptives O 0 0.02688036486506462
and O 0 2.5792517135414528e-06
the O 0 5.9623107517836615e-06
risk O 0 0.000229519180720672
of O 1 0.5208293199539185
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.4064379632472992

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9999996423721313
Study O 0 0.0012433156371116638
Group O 0 7.901957724243402e-05
. O 0 2.6422370865475386e-05

BACKGROUND O 0 0.00040647079003974795
Women O 0 5.690124453394674e-06
with O 0 2.679009014627809e-07
mutations O 0 9.812398502617725e-07
in O 0 3.2320315312972525e-07
either O 0 1.4511337553813064e-07
the O 0 4.257546777353127e-07
BRCA1 O 0 3.7483175674424274e-06
or O 0 1.2954669159626064e-07
the O 0 5.11674556946673e-07
BRCA2 O 0 5.103721377963666e-06
gene O 0 3.380775694949989e-07
have O 0 8.179716104450563e-08
a O 0 7.009090268184082e-07
high O 0 1.4840731637377758e-05
lifetime O 0 1.489451005909359e-05
risk O 0 6.148544343886897e-05
of O 1 0.9555056691169739
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0006223912350833416

Oral O 0 0.002652340102940798
contraceptives O 0 0.21987777948379517
protect O 0 6.407772161765024e-05
against O 1 0.9958027005195618
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.958941619610414e-05
general O 0 1.0786799066409003e-05
, O 0 2.779436556465953e-07
but O 0 3.968450457136896e-08
it O 0 2.254901332321424e-08
is O 0 4.1308588549782144e-08
not O 0 1.5247708873289412e-08
known O 0 1.3316173408384202e-07
whether O 0 3.4199093335018915e-08
they O 0 3.3501112994827054e-08
also O 0 2.602013182695373e-07
protect O 0 3.473785454843892e-07
against O 0 3.6757587622560095e-06
hereditary B-Disease 1 0.9833666086196899
forms I-Disease 0 0.00010996460332535207
of I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0017065305728465319

METHODS O 0 5.816261182189919e-05
We O 0 4.25128791903262e-06
enrolled O 0 2.320796193089336e-05
207 O 0 4.2826712160604075e-05
women O 0 2.5466392798989546e-06
with O 0 3.83659153158078e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.0003645559772849083
161 O 0 6.0771533753722906e-05
of O 0 5.309884272719501e-06
their O 0 2.890468522309675e-07
sisters O 0 8.364500899915583e-06
as O 0 4.944108695781324e-07
controls O 0 6.970534514039173e-07
in O 0 1.658054458175684e-07
a O 0 2.1121693407621933e-06
case O 0 3.872999968734803e-06
- O 0 1.7995322195929475e-05
control O 0 6.001136171107646e-06
study O 0 4.584609996527433e-06
. O 0 5.417598458734574e-06

All O 0 6.498803941212827e-06
the O 0 3.9622673284611665e-06
patients O 0 1.1377412647561869e-06
carried O 0 1.698807068351016e-06
a O 0 1.3948937294117059e-06
pathogenic O 0 1.4203642422216944e-06
mutation O 0 5.576720241151634e-07
in O 0 2.0635351916098443e-07
either O 0 1.7091556969717203e-07
BRCA1 O 0 6.911410309839994e-06
( O 0 6.834688974777237e-07
179 O 0 4.3419227040431e-06
women O 0 5.31084481281141e-07
) O 0 3.3718629310897086e-07
or O 0 6.12067765359825e-07
BRCA2 O 0 1.3289903108670842e-05
( O 0 2.3126510768634034e-06
28 O 0 3.7232872273307294e-05
women O 0 3.775392542593181e-06
) O 0 3.879268660966773e-06
. O 0 8.615593287686352e-06

The O 0 2.7672209398588166e-05
control O 0 7.794406883476768e-06
women O 0 6.154444918138324e-07
were O 0 4.5098610712557274e-07
enrolled O 0 8.450351742794737e-07
regardless O 0 1.1058673266006736e-07
of O 0 2.820856934704352e-07
whether O 0 8.959361963434276e-08
or O 0 1.578444965844028e-07
not O 0 4.745593074062526e-08
they O 0 7.542093527490579e-08
had O 0 1.7715831290843198e-06
either O 0 1.6915241758397315e-06
mutation O 0 1.2584902833623346e-05
. O 0 1.2405390407366212e-05

Lifetime O 0 0.00018870909116230905
histories O 0 1.9923338186345063e-05
of O 0 1.0676869351300411e-05
oral O 0 0.00014721670595463365
- O 0 0.0006699992227368057
contraceptive O 0 0.00019774252723436803
use O 0 1.2959316109117935e-07
were O 0 2.657577624631813e-07
obtained O 0 4.3555320416999166e-07
by O 0 1.4801811687448208e-07
interview O 0 1.2154862361057894e-06
or O 0 1.3414368993380776e-07
by O 0 1.2645925551169057e-07
written O 0 7.66764784998486e-08
questionnaire O 0 1.1795248155976878e-07
and O 0 5.525107127368756e-08
were O 0 6.324448804662097e-07
compared O 0 1.0125800145033281e-06
between O 0 3.636747862856282e-07
patients O 0 3.3621626016611117e-07
and O 0 2.197187143337942e-07
control O 0 2.2109011297288816e-06
women O 0 1.981626667202363e-07
, O 0 9.492528363352903e-08
after O 0 4.93500749598752e-07
adjustment O 0 1.1706999885063851e-06
for O 0 4.750673454623211e-08
year O 0 1.6601097740931436e-07
of O 0 4.652522420656169e-07
birth O 0 6.108313755248673e-06
and O 0 2.8043843940395163e-06
parity O 0 0.00010149183071916923
. O 0 1.866795719251968e-05

RESULTS O 0 0.00019322882872074842
The O 0 1.1188297321496066e-05
adjusted O 0 2.689712528081145e-05
odds O 0 2.019069688685704e-05
ratio O 0 2.041969491983764e-05
for O 0 2.5852634280454367e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 7.150167220970616e-06
with O 0 5.4549808226056484e-08
any O 0 1.0186541743451016e-07
past O 0 4.5190699893282726e-07
use O 0 8.211135593683139e-08
of O 0 8.265659516837331e-07
oral O 0 1.5216645806503948e-05
contraceptives O 0 6.979604950174689e-05
was O 0 0.00019916736346203834
0 O 0 1.3355258488445543e-05
. O 0 1.009442530630622e-05

5 O 0 0.00010214388748863712
( O 0 7.2641914812265895e-06
95 O 0 9.221535037795547e-06
percent O 0 3.2079794891615165e-06
confidence O 0 3.963918970839586e-06
interval O 0 2.031966687354725e-06
, O 0 1.9826813968393253e-07
0 O 0 1.2957166006799525e-07
. O 0 2.9592669648081937e-08
3 O 0 1.5006455100774474e-07
to O 0 6.674396502148738e-08
0 O 0 6.142535653452796e-07
. O 0 2.848349254236382e-07
8 O 0 5.281361154629849e-06
) O 0 2.8999659207329387e-06
. O 0 5.552486072701868e-06

The O 0 3.208408452337608e-05
risk O 0 2.359105747018475e-05
decreased O 0 1.5191070815490093e-05
with O 0 1.9735206535642646e-07
increasing O 0 4.4076051608499256e-07
duration O 0 1.6535398117412115e-06
of O 0 1.2334787697909633e-06
use O 0 3.2121687354447204e-07
( O 0 8.326247211698501e-07
P O 0 1.5530888049397618e-05
for O 0 1.744788136193165e-07
trend O 0 1.6622468592686346e-06
, O 0 9.015433732884048e-08
< O 0 6.661569500465703e-07
0 O 0 2.0597954630829918e-07
. O 0 6.195372037609559e-08
001 O 0 3.4554911962914048e-06
) O 0 6.256563267470483e-08
; O 0 2.0067448147642608e-08
use O 0 1.781737068995426e-08
for O 0 7.119454181747642e-08
six O 0 1.9195449851849844e-07
or O 0 1.184581819302366e-07
more O 0 2.79914953438265e-08
years O 0 1.6279848580325051e-07
was O 0 1.8800453744916013e-06
associated O 0 5.840743000362636e-08
with O 0 9.858866611978101e-09
a O 0 2.468564730406797e-07
60 O 0 3.3670110610728443e-07
percent O 0 1.02619958397554e-06
reduction O 0 2.87965485767927e-06
in O 0 2.0264822069293587e-06
risk O 0 1.629693724680692e-05
. O 0 1.1291154805803671e-05

Oral O 0 0.0073781260289251804
- O 0 0.010870340280234814
contraceptive O 0 0.010193733498454094
use O 0 3.0279475140559953e-06
protected O 0 5.9905800299020484e-05
against O 0 0.2530457377433777
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 4.636784467493271e-07
for O 0 2.303432040662301e-07
carriers O 0 1.306000854128797e-07
of O 0 2.607657449971157e-07
the O 0 5.294187417348439e-07
BRCA1 O 0 5.777217666036449e-06
mutation O 0 1.0441547146911034e-06
( O 0 3.573911442344979e-07
odds O 0 1.4529355212289374e-06
ratio O 0 4.5294424921848986e-07
, O 0 5.87894497527941e-08
0 O 0 7.642476163027823e-08
. O 0 1.6687886628119486e-08
5 O 0 1.766820503235067e-07
; O 0 3.46455415467517e-08
95 O 0 3.0770573289373715e-07
percent O 0 3.7826509924343554e-07
confidence O 0 1.0962527312585735e-06
interval O 0 9.61107275543327e-07
, O 0 7.86488669746177e-08
0 O 0 6.72857964900686e-08
. O 0 1.4269769366137552e-08
3 O 0 6.270457930668272e-08
to O 0 2.1166764341273847e-08
0 O 0 1.2377179814393457e-07
. O 0 2.4562213596368565e-08
9 O 0 3.3622492878748744e-07
) O 0 4.7863355945310104e-08
and O 0 4.279002041585045e-08
for O 0 7.326868711743373e-08
carriers O 0 1.4849995011445571e-07
of O 0 4.336168899499171e-07
the O 0 1.5104102430996136e-06
BRCA2 O 0 8.542678187950514e-06
mutation O 0 1.6856623687999672e-06
( O 0 4.405600293466705e-07
odds O 0 1.079097273759544e-06
ratio O 0 4.3130151539116923e-07
, O 0 5.585577866895619e-08
0 O 0 1.2442377794741333e-07
. O 0 1.6188375084880136e-08
4 O 0 2.1180177611768158e-07
; O 0 2.3307167751340785e-08
95 O 0 2.462453778662166e-07
percent O 0 3.349332757807133e-07
confidence O 0 7.421829195664031e-07
interval O 0 6.317625320662046e-07
, O 0 9.806639411635842e-08
0 O 0 1.0201746647453547e-07
. O 0 2.112078867355649e-08
2 O 0 7.094864429291192e-08
to O 0 4.1565051844827394e-08
1 O 0 6.533390433105524e-07
. O 0 2.3870904897194123e-07
1 O 0 3.174166067765327e-06
) O 0 1.7815624460126855e-06
. O 0 4.650295977626229e-06

CONCLUSIONS O 0 0.0009567331289872527
Oral O 0 0.001165891415439546
- O 0 0.002853144658729434
contraceptive O 0 0.04098919779062271
use O 0 1.238669028680306e-06
may O 0 1.8215059753856622e-06
reduce O 0 7.133522217372956e-07
the O 0 1.4369206837727688e-06
risk O 0 4.0070950490189716e-05
of O 1 0.639160692691803
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.47607513301773e-05
women O 0 4.128280295390141e-07
with O 0 5.2937380701223447e-08
pathogenic O 0 8.23517041226296e-07
mutations O 0 5.140089456290298e-07
in O 0 5.308136223902693e-07
the O 0 1.9200883798475843e-06
BRCA1 O 0 8.138347038766369e-05
or O 0 2.085720916511491e-05
BRCA2 O 0 0.009284785017371178
gene O 0 0.0012995926663279533

A O 0 0.001544999424368143
Japanese O 0 0.00027763203252106905
family O 0 9.51811125560198e-06
with O 0 5.233779120317195e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 1.8399988448436488e-06
a O 0 1.2344329661573283e-05
codon O 0 2.8754269806086086e-05
291 O 0 1.0275667591486126e-05
deletion O 0 6.409702564269537e-06
: O 0 2.7496264465298736e-07
a O 0 1.1045050314351101e-06
clinical O 0 3.206799374311231e-05
, O 0 8.082413387455745e-07
biochemical O 0 0.001095708110369742
, O 0 1.992757916013943e-06
pathological O 1 0.9385229349136353
, O 0 1.4684522966490476e-06
and O 0 1.631293457649008e-06
genetic O 0 0.00038424209924414754
report O 0 0.00015416156384162605
. O 0 2.137195951945614e-05

We O 0 3.7247042200760916e-05
report O 0 3.156837192364037e-05
a O 0 9.909959771903232e-06
Japanese O 0 3.553283022483811e-05
family O 0 3.849003860523226e-06
with O 0 1.3430319086182863e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.3855780363082886
ALD B-Disease 1 1.0
) O 0 1.5314387837861432e-06
with O 0 3.0687610319546366e-07
a O 0 2.742105607467238e-06
three O 0 5.599924293164804e-07
base O 0 7.5621110227075405e-06
pair O 0 2.3446918930858374e-06
deletion O 0 4.209524377074558e-06
( O 0 9.47582918797707e-07
delGAG O 0 1.722243905533105e-05
291 O 0 5.7060024118982255e-06
) O 0 2.5289085670010536e-07
in O 0 7.852457883927855e-07
the O 0 1.565798265801277e-05
ALD B-Disease 1 1.0
gene O 0 9.118052548728883e-05
. O 0 6.172130815684795e-05

A O 0 5.213619442656636e-05
variety O 0 1.6830906588438665e-06
of O 0 1.7207725022672093e-06
phenotypes O 0 7.052699857013067e-06
were O 0 4.283971293261857e-07
observed O 0 7.431114568134944e-07
within O 0 3.980762812716421e-07
this O 0 7.472930292351521e-07
family O 0 3.598182502173586e-06
. O 0 1.1087043276347686e-05

While O 0 5.3798987210029736e-05
the O 0 1.892404725367669e-05
proband O 0 0.00031124247470870614
( O 0 3.5761174785875482e-06
patient O 0 7.603219728480326e-06
1 O 0 2.7614621558313956e-06
) O 0 2.800245226808329e-07
was O 0 7.476683094864711e-06
classified O 0 4.4452889369495097e-07
as O 0 1.146016046504883e-07
having O 0 2.0146417512023618e-07
a O 0 6.128838094809907e-07
rare O 0 9.897001973513397e-07
intermediate O 0 5.366244295146316e-06
type O 0 1.3953009556644247e-06
of O 0 7.426519459841074e-06
adult O 0 0.00018225517123937607
cerebral O 1 0.9999699592590332
and O 0 0.00034859063453041017
cerebello O 1 0.9999992847442627
- O 1 0.9999376535415649
brain O 1 0.999974250793457
stem O 0 0.3521759510040283
forms O 0 2.3875420538388425e-06
, O 0 1.3727337773161707e-06
his O 0 1.4775544514122885e-05
younger O 0 1.010964570014039e-05
brother O 0 4.3065396312158555e-05
( O 0 8.08845925348578e-07
patient O 0 8.468814485240728e-06
2 O 0 2.726917500694981e-06
) O 0 5.771445898972161e-07
and O 0 1.2739994872390525e-06
nephew O 0 0.19060197472572327
( O 0 1.1293709576420952e-06
patient O 0 3.340185458000633e-06
3 O 0 1.554831783323607e-06
) O 0 3.581263570140436e-07
had O 0 3.0228982268454274e-06
a O 0 2.262755333504174e-05
childhood O 1 0.9287739992141724
ALD B-Disease 1 1.0
type O 1 0.5662126541137695
. O 0 9.033783135237172e-05

Another O 0 0.00047033457667566836
nephew O 0 0.0023949278984218836
( O 0 7.317898507608334e-06
patient O 0 1.586250618856866e-05
4 O 0 4.354997599875787e-06
) O 0 1.495636468007433e-07
of O 0 5.75514377487707e-07
patient O 0 2.8841620860475814e-06
1 O 0 1.6227144215008593e-06
was O 0 1.7728911188896745e-05
classified O 0 7.107277042450733e-07
as O 0 2.9293192937984713e-07
having O 0 5.425516178547696e-07
an O 0 1.9676997453643708e-06
adolescent O 0 0.00019102341320831329
form O 0 8.068142960837577e-06
. O 0 2.5078577891690657e-05

The O 0 3.5901437513530254e-05
tau O 0 7.379534508800134e-05
level O 0 1.2813145986001473e-05
in O 0 4.399648332764627e-06
the O 0 7.1610788836551365e-06
cerebrospinal O 0 0.00455704377964139
fluid O 0 0.0004312669043429196
( O 0 9.451061487197876e-06
CSF O 1 0.5298978686332703
) O 0 5.847575152984064e-07
in O 0 3.0289243113656994e-07
patient O 0 1.1589218047447503e-06
1 O 0 1.0593998922558967e-06
was O 0 8.05773106549168e-06
as O 0 2.06213826459134e-07
high O 0 1.8980173308591475e-06
as O 0 4.192382618839474e-08
that O 0 1.7489321990638018e-08
of O 0 9.253496955352603e-07
patients O 0 2.368889454373857e-06
with O 0 9.430875252292026e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 2.1744586774730124e-05
AD B-Disease 0 0.025047123432159424
) O 0 4.330790034146048e-06
. O 0 9.177912943414412e-06

His O 0 0.0004801429167855531
brain O 0 0.41323497891426086
magnetic O 0 0.0005197448772378266
resonance O 0 0.0001929200952872634
image O 0 3.730153548531234e-05
( O 0 3.5829177704727044e-06
MRI O 0 0.14750315248966217
) O 0 7.690619554523437e-07
showed O 0 8.099041224340908e-06
abnormalities B-Disease 0 0.057376157492399216
in I-Disease 0 6.309159630291106e-07
the I-Disease 0 1.4068373275222257e-06
bilateral I-Disease 0 0.0005471509066410363
cerebellar I-Disease 1 0.999969482421875
hemispheres I-Disease 0 0.025885771960020065
and O 0 2.917416532000061e-05
brain O 1 0.9999762773513794
stem O 1 0.9325396418571472
, O 0 4.952730705554131e-07
but O 0 4.334862069299561e-08
not O 0 2.7817774750360513e-08
in O 0 2.2286953083039407e-07
the O 0 2.893490545829991e-06
cerebral O 1 0.7820407152175903
white O 0 2.3139659788284916e-06
matter O 0 3.476370409316587e-07
, O 0 1.0189456389753104e-07
where O 0 1.1225176166362871e-07
marked O 0 1.2186386584289721e-06
reductions O 0 8.434748224317445e-07
of O 0 6.158602445793804e-07
the O 0 3.137554358545458e-06
cerebral O 1 0.7893272042274475
blood O 0 1.7594635210116394e-05
flow O 0 2.1975252820993774e-05
and O 0 1.5801573454155005e-06
oxygen O 0 2.1072513845865615e-05
metabolism O 0 1.48907183756819e-05
were O 0 3.8025297044441686e-07
clearly O 0 2.7105366484647675e-07
demonstrated O 0 4.3965303575532744e-07
by O 0 1.6572214178722788e-07
positron O 0 3.4489069093979197e-06
emission O 0 4.1100274756900035e-06
tomography O 0 1.0431840564706363e-05
( O 0 2.179121111112181e-06
PET O 0 1.7058033336070366e-05
) O 0 2.078213810818852e-06
. O 0 3.97325220546918e-06

In O 0 3.1028888770379126e-05
patients O 0 6.768811090296367e-06
2 O 0 2.5827023364399793e-06
and O 0 3.1710601433587726e-07
3 O 0 2.009312538575614e-06
, O 0 2.0769486752669764e-07
the O 0 3.750877795027918e-07
autopsy O 0 1.3866803783457726e-05
findings O 0 2.8317724627413554e-06
showed O 0 2.1129400920472108e-05
massive O 0 0.1683647483587265
demyelination B-Disease 1 1.0
of I-Disease 0 0.00955429021269083
the I-Disease 0 0.019886977970600128
cerebral I-Disease 1 0.9999942779541016
white I-Disease 0 1.3028991816099733e-05
matter I-Disease 0 5.468215249493369e-07
with O 0 1.480220674920929e-07
sparing O 0 1.3682717963092728e-06
of O 0 1.0628958079905715e-05
the O 0 0.00016358756693080068
U O 1 0.999994158744812
- O 1 0.8333215713500977
fibers O 0 0.0019388323416933417
, O 0 3.067561351599579e-07
compatible O 0 1.9779901094807428e-07
with O 0 2.594445192016792e-08
the O 0 4.474671015941567e-07
findings O 0 2.2390820504369913e-06
of O 0 2.3391721697407775e-05
childhood O 1 0.9965155124664307
ALD B-Disease 1 1.0
. O 0 0.0001406259398208931

Oleic O 0 0.038503192365169525
and O 0 0.00022101310605648905
erucic O 1 0.5222739577293396
acids O 0 6.560006295330822e-05
( O 0 6.656980076513719e-06
Lorenzos O 0 0.00030951914959587157
Oil O 0 2.291349483130034e-05
) O 0 1.543472052389916e-07
were O 0 1.0030259289806054e-07
administered O 0 9.184781646354168e-08
to O 0 5.311528639140306e-08
patients O 0 1.6261415680673963e-07
1 O 0 7.966409043547173e-07
and O 0 1.3183922931148118e-07
4 O 0 8.681971053192683e-07
, O 0 5.3444239256350556e-08
but O 0 1.0065595468233823e-08
sufficient O 0 1.0320663079710357e-07
effectiveness O 0 6.11735742950259e-07
was O 0 6.5111116782645695e-06
not O 0 2.803103882342839e-07
obtained O 0 6.85670329403365e-06
. O 0 6.268978722800966e-06

The O 0 2.3810342099750414e-05
findings O 0 1.3057886462775059e-05
in O 0 7.472474408132257e-07
this O 0 1.705937933138557e-07
family O 0 1.5928104346585314e-07
suggest O 0 2.1531492677695496e-07
that O 0 8.837552911700186e-08
delGAG291 O 0 1.6610234752079123e-06
is O 0 7.15759185254683e-08
part O 0 1.3305128732099547e-07
of O 0 6.181202820698672e-07
the O 0 1.0727908374974504e-06
cause O 0 5.496545327332569e-06
of O 0 2.0746987502207048e-05
Japanese O 0 0.4929123818874359
ALD B-Disease 1 1.0
with O 0 9.442766781830869e-07
phenotypic O 0 1.6146525013027713e-05
variations O 0 4.0183495002565905e-05
. O 0 3.8008529372746125e-05

Moreover O 0 7.568929868284613e-05
, O 0 3.3325620734103722e-06
although O 0 2.5558455263308133e-07
the O 0 1.9537044693151984e-07
scale O 0 1.1010208709194558e-06
of O 0 4.80371284083958e-07
the O 0 2.7268265512248036e-07
study O 0 1.254032326869492e-07
is O 0 9.590712579665706e-08
limited O 0 8.728930112056332e-08
, O 0 6.356059856216234e-08
there O 0 6.450959233461617e-08
is O 0 8.44983816250533e-08
a O 0 2.196169077706145e-07
possibility O 0 2.696852732242405e-07
that O 0 1.2816424543871108e-07
PET O 0 1.7832298908615485e-06
can O 0 9.250535981664143e-08
detect O 0 2.9974237349961186e-06
an O 0 1.959598739631474e-05
insidious B-Disease 1 0.9998714923858643
lesion I-Disease 1 0.9999969005584717
which O 0 1.1492418252601055e-06
is O 0 3.5532178799257963e-07
undetectable O 0 3.627621026680572e-06
by O 0 1.2160388962456636e-07
computed O 0 8.92646596639679e-07
tomogram O 0 1.3497460713551845e-05
( O 0 6.471243523265002e-07
CT O 0 9.346828301204368e-05
) O 0 2.1982268094689061e-07
or O 0 1.7587075262781582e-07
MRI O 0 4.7637877287343144e-05
analysis O 0 2.914133290232712e-07
, O 0 3.715081220434513e-08
and O 0 2.6848960388292653e-08
that O 0 2.8761414583300393e-08
the O 0 1.59236691388287e-07
higher O 0 5.309260018293571e-07
level O 0 1.779530123258155e-07
of O 0 4.2223638274663244e-07
tau O 0 1.9152603272232227e-06
reflects O 0 1.5969078503985656e-07
the O 0 1.3545545130000392e-07
process O 0 2.2941893007555336e-07
of O 0 4.57544638265972e-06
neuronal B-Disease 1 0.8947387337684631
degeneration I-Disease 1 0.9999990463256836
in O 0 0.000438361574197188
ALD B-Disease 1 1.0
. O 0 0.00014927767915651202

Lorenzos O 0 0.0038851837161928415
Oil O 0 0.00019315937242936343
should O 0 1.0365064326833817e-06
be O 0 2.3192009734884778e-07
given O 0 1.6069205344138027e-07
in O 0 3.0361428571268334e-07
the O 0 9.642507166063297e-07
early O 0 3.7238824006635696e-06
stage O 0 8.345274181920104e-06
. O 0 1.7609962696951698e-06
. O 0 9.307093932875432e-06

Nonsense O 0 0.0006606602109968662
mutation O 0 2.2900650947121903e-05
in O 0 2.783396666927729e-06
exon O 0 7.894214832049329e-06
4 O 0 2.282527475472307e-06
of O 0 7.373517405540042e-07
human O 0 7.895244493738574e-07
complement O 0 1.832108864618931e-06
C9 O 0 0.0005229428643360734
gene O 0 6.270685162235168e-07
is O 0 2.604073756629077e-07
the O 0 3.4638344459381187e-07
major O 0 3.2918646866164636e-06
cause O 0 2.739810497587314e-06
of O 0 5.991003035887843e-06
Japanese O 0 0.0009841227438300848
complement B-Disease 0 0.000730557250790298
C9 I-Disease 1 0.9999978542327881
deficiency I-Disease 1 0.9999923706054688
. O 0 5.348556078388356e-05

Deficiency B-Disease 1 0.999962329864502
of I-Disease 0 8.68669812916778e-05
the I-Disease 0 2.208321529906243e-05
ninth I-Disease 0 0.0001710799988359213
component I-Disease 0 4.123843609704636e-06
of I-Disease 0 1.5785066125317826e-06
human I-Disease 0 1.491252533014631e-06
complement I-Disease 0 5.380433776736027e-06
( O 0 2.367547949688742e-06
C9 O 0 0.2976827621459961
) O 0 4.134595883442671e-07
is O 0 1.4540623283210152e-07
the O 0 1.2253029524345038e-07
most O 0 9.182382143535506e-08
common O 0 2.031685653491877e-06
complement B-Disease 1 0.9998822212219238
deficiency I-Disease 1 1.0
in O 0 1.4062430864214548e-06
Japan O 0 7.382150215562433e-07
but O 0 5.489759047350162e-08
is O 0 4.368011019550977e-08
rare O 0 8.764013870177223e-08
in O 0 1.2676002825173782e-07
other O 0 7.74843371686984e-08
countries O 0 4.6399694042520423e-07
. O 0 8.47304818307748e-06

We O 0 6.75675710226642e-06
studied O 0 7.694186024309602e-06
the O 0 1.677592422311136e-06
molecular O 0 8.247374353231862e-06
basis O 0 3.134491862510913e-06
of O 0 5.5857959523564205e-05
C9 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999667406082153
in O 0 2.3869044980528997e-06
four O 0 2.0982899968657875e-06
Japanese O 0 0.012973189353942871
C9 B-Disease 1 0.9999992847442627
- I-Disease 1 0.9996684789657593
deficient I-Disease 1 0.990994393825531
patients O 0 4.674493538914248e-06
who O 0 2.2857057047076523e-06
had O 0 0.012779276818037033
suffered O 1 0.9999998807907104
from O 1 0.9974163770675659
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.00019491030252538621

Direct O 0 4.644497676054016e-05
sequencing O 0 6.0568578192032874e-05
of O 0 1.4780364836042281e-05
amplified O 0 0.00015011642244644463
C9 O 0 0.0005281954072415829
cDNA O 0 2.789724567264784e-05
and O 0 1.1820433201137348e-06
DNA O 0 6.177446721267188e-06
revealed O 0 1.0878753528231755e-05
a O 0 8.142937076627277e-06
nonsense O 0 0.00017736606241669506
substitution O 0 2.765197496046312e-05
( O 0 1.424219135515159e-06
CGA O 0 1.6327505363733508e-05
- O 0 1.0289533747709356e-05
- O 0 1.789631824067328e-05
> O 0 6.311335255304584e-06
TGA O 0 1.2106309441151097e-05
) O 0 1.833412994756145e-07
at O 0 7.869363685131248e-07
codon O 0 4.871233159065014e-07
95 O 0 1.9650131832804618e-07
in O 0 1.0333604194556756e-07
exon O 0 4.803731030733616e-07
4 O 0 9.062687240657397e-07
in O 0 3.376055701664882e-07
the O 0 1.0295334504917264e-06
four O 0 3.6462465686781798e-06
C9 B-Disease 1 0.989740252494812
- I-Disease 0 0.48332273960113525
deficient I-Disease 0 0.0027252868749201298
individuals O 0 2.051791852863971e-06
. O 0 9.71877761912765e-06

An O 0 0.00011003803956555203
allele O 0 5.810074435430579e-05
- O 0 3.1053070415509865e-05
specific O 0 1.1684235232678475e-06
polymerase O 0 7.487235416192561e-05
chain O 0 1.0165333151235245e-05
reaction O 0 7.394988870146335e-07
system O 0 2.3114418468139775e-07
designed O 0 2.465459090217337e-07
to O 0 4.111812046403429e-08
detect O 0 2.334276700821647e-07
exclusively O 0 1.5460825864010985e-07
only O 0 6.359734783245585e-08
one O 0 9.681709656206294e-08
of O 0 5.048257776252285e-07
the O 0 2.853890634924028e-07
normal O 0 3.497813736430544e-07
and O 0 3.405575554893403e-08
mutant O 0 6.627080324506096e-07
alleles O 0 3.4151710792684753e-07
indicated O 0 3.587139474348078e-07
that O 0 3.1787926957349555e-08
all O 0 3.4778221191800185e-08
the O 0 1.3624003258883022e-07
four O 0 1.1384257447843993e-07
patients O 0 9.511159504427269e-08
were O 0 1.4767462630516093e-07
homozygous O 0 3.321246424548008e-07
for O 0 6.140655273156881e-08
the O 0 1.3001131549117417e-07
mutation O 0 1.4199753195498488e-07
in O 0 1.631329524798275e-07
exon O 0 6.097960749684717e-07
4 O 0 4.3015219830522256e-07
and O 0 5.083166243480264e-08
that O 0 5.7167383715750475e-08
the O 0 1.5828464938749676e-07
parents O 0 4.329267966340922e-08
of O 0 8.793799679551739e-07
patient O 0 3.436057113503921e-06
2 O 0 2.5819194888754282e-06
were O 0 5.601704742730362e-06
heterozygous O 0 1.7231719539267942e-05
. O 0 1.0077467777591664e-05

The O 0 4.097597047802992e-05
common O 0 5.2141599553579e-06
mutation O 0 4.450346750672907e-06
at O 0 6.3396637415280566e-06
codon O 0 5.351642812456703e-06
95 O 0 4.734107221793238e-07
in O 0 1.2625896772533451e-07
exon O 0 7.82903896379139e-07
4 O 0 6.52828305192088e-07
might O 0 1.307955415086326e-07
be O 0 1.0015423868026119e-07
responsible O 0 3.208418206668284e-07
for O 0 3.127559295990068e-07
most O 0 1.3161628658053814e-06
Japanese O 0 0.019143052399158478
C9 B-Disease 1 0.9999990463256836
deficiency I-Disease 1 0.9999793767929077
. O 0 8.700158105057199e-06
. O 0 1.9052487914450467e-05

BRCA1 O 0 0.0006312578334473073
required O 0 1.2081271052011289e-05
for O 0 5.091499588161241e-06
transcription O 0 0.0005822547827847302
- O 0 0.000516361091285944
coupled O 0 0.000335686287144199
repair O 0 3.233932511648163e-05
of O 0 7.591070243506692e-06
oxidative O 0 0.001782644190825522
DNA O 0 7.030754932202399e-05
damage O 0 0.009202676825225353
. O 0 4.518769492278807e-05

The O 0 0.00021126824140083045
breast B-Disease 1 0.9999938011169434
and I-Disease 1 0.9928287863731384
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9999984502792358
gene O 0 0.00010055862367153168
BRCA1 O 0 0.030730849131941795
encodes O 0 0.00010279877460561693
a O 0 0.0010753741953521967
zinc O 1 0.9998378753662109
finger O 0 0.0065879239700734615
protein O 0 6.1312393881962635e-06
of O 0 5.880900971533265e-06
unknown O 0 2.736647002166137e-05
function O 0 1.6968891941360198e-05
. O 0 1.5312609320972115e-05

Association O 0 0.0001319558941759169
of O 0 1.718432758934796e-05
the O 0 7.4615177254599985e-06
BRCA1 O 0 0.00010226268204860389
protein O 0 6.303629561443813e-06
with O 0 7.108517365850275e-07
the O 0 5.278390290186508e-06
DNA O 0 2.186744677601382e-05
repair O 0 0.00012887740740552545
protein O 0 2.682974809431471e-05
Rad51 O 0 0.0001911079598357901
and O 0 8.289974289255042e-07
changes O 0 2.401700101017923e-07
in O 0 2.4699917844372976e-07
the O 0 2.3110364111289528e-07
phosphorylation O 0 9.346881597593892e-07
and O 0 2.6013435672211926e-07
cellular O 0 2.1191593987168744e-05
localization O 0 2.2358395654009655e-05
of O 0 1.6141791547852335e-06
the O 0 1.2934709729961469e-06
protein O 0 1.5294787090169848e-06
after O 0 1.5893765521468595e-06
exposure O 0 1.7030116623573122e-06
to O 0 1.9423460173584317e-07
DNA O 0 1.9351631635800004e-05
- O 0 0.00015529448864981532
damaging O 0 1.7716860384098254e-05
agents O 0 2.7363248022993503e-07
are O 0 1.3915911978301665e-08
consistent O 0 1.8751467223410145e-07
with O 0 2.465232817883134e-08
a O 0 4.5154081362852594e-07
role O 0 7.301588880181953e-07
for O 0 3.1266466749002575e-07
BRCA1 O 0 1.3389153536991216e-05
in O 0 3.3430856092309114e-06
DNA O 0 7.205095607787371e-05
repair O 0 0.0014252015389502048
. O 0 7.91443744674325e-05

Here O 0 4.200016337563284e-05
, O 0 1.9280630567664048e-06
it O 0 2.8720199907183996e-07
is O 0 2.2553278711257008e-07
shown O 0 3.2555109896748036e-07
that O 0 3.9559361653118685e-07
mouse O 0 1.3699203009309713e-05
embryonic O 0 0.00027876938111148775
stem O 0 0.0030569054652005434
cells O 0 3.4742362913675606e-05
deficient B-Disease 0 2.0410720026120543e-05
in I-Disease 0 6.255168045754544e-07
BRCA1 I-Disease 0 1.1665769307001028e-05
are O 0 1.4637610945555934e-07
defective O 0 3.11739495373331e-06
in O 0 1.6701204685887205e-07
the O 0 2.3784372160662315e-07
ability O 0 8.41826022224268e-08
to O 0 1.146187642575569e-07
carry O 0 4.630407772765466e-07
out O 0 1.1634609791144612e-06
transcription O 0 0.00012311954924371094
- O 0 0.00010826304060174152
coupled O 0 0.00011969669867539778
repair O 0 8.963283107732423e-06
of O 0 2.9192424335633405e-06
oxidative O 0 0.0001263609156012535
DNA O 0 4.283495400159154e-06
damage O 0 6.439951539505273e-05
, O 0 5.684374286829552e-07
and O 0 2.9488921882148134e-07
are O 0 1.2983907993202592e-07
hypersensitive O 0 2.0645935364882462e-05
to O 0 5.09364326717332e-07
ionizing O 0 0.021317556500434875
radiation O 0 0.23475125432014465
and O 0 5.236594461166533e-06
hydrogen O 0 3.587388346204534e-05
peroxide O 0 0.0005173602257855237
. O 0 7.836059376131743e-05

These O 0 6.257648237806279e-06
results O 0 6.7414252953312825e-06
suggest O 0 1.4539723451889586e-06
that O 0 4.0193830841417366e-07
BRCA1 O 0 1.309984418185195e-05
participates O 0 2.3641409825359005e-06
, O 0 6.273220947150548e-07
directly O 0 4.2488460394451977e-07
or O 0 3.2846853059709247e-07
indirectly O 0 6.738217734891805e-07
, O 0 2.5089747168749454e-07
in O 0 8.692824167155777e-07
transcription O 0 0.0003262895334046334
- O 0 0.00041360047180205584
coupled O 0 0.00018982797337230295
repair O 0 1.596296533534769e-05
of O 0 4.903168246528367e-06
oxidative O 0 0.000606069341301918
DNA O 0 1.3052061149210203e-05
damage O 0 0.0004719195712823421
. O 0 3.145799610138056e-06
. O 0 1.0396990546723828e-05

Truncation O 0 0.002504592062905431
mutations O 0 3.2886753615457565e-05
in O 0 4.168703526374884e-06
the O 0 2.84474072032026e-06
transactivation O 0 4.479613562580198e-05
region O 0 1.0156485359402723e-06
of O 0 2.9445939162542345e-06
PAX6 O 0 0.026347829028964043
result O 0 2.6260977392666973e-06
in O 0 3.1872975796432e-06
dominant O 0 4.288146737962961e-05
- O 0 4.793531843461096e-05
negative O 0 1.9485929442453198e-05
mutants O 0 3.371683123987168e-05
. O 0 7.543383617303334e-06

PAX6 O 0 0.475299596786499
is O 0 1.8642747818375938e-05
a O 0 1.544483529869467e-05
transcription O 0 3.308950908831321e-05
factor O 0 3.685095407490735e-06
with O 0 1.4598228403883695e-07
two O 0 2.5155995331260783e-07
DNA O 0 2.769939555946621e-06
- O 0 5.853701622982044e-06
binding O 0 7.468698299817333e-07
domains O 0 1.6628953289909987e-06
( O 0 3.8731519680368365e-07
paired O 0 1.497002131145564e-06
box O 0 3.618737537181005e-06
and O 0 4.3539952798710146e-07
homeobox O 0 2.3964106731000356e-05
) O 0 5.946105261500634e-07
and O 0 6.025032917023054e-07
a O 0 1.9690214685397223e-05
proline O 0 0.00010119032231159508
- O 0 3.8307356589939445e-05
serine O 0 1.9851304386975244e-05
- O 0 2.8514486984931864e-05
threonine O 0 2.0375693566165864e-05
( O 0 1.356161533294653e-06
PST O 0 0.00010678680700948462
) O 0 1.100919121199695e-06
- O 0 7.800556886650156e-06
rich O 0 1.3614902627523406e-06
transactivation O 0 7.140593515941873e-05
domain O 0 1.5407589671667665e-05
. O 0 1.173656255559763e-05

PAX6 O 1 0.9988131523132324
regulates O 0 0.0017419984797015786
eye O 0 0.18273593485355377
development O 0 2.0412178855622187e-05
in O 0 1.5361443956862786e-06
animals O 0 4.4794276732318394e-07
ranging O 0 3.3783885555749293e-06
from O 0 1.6939037550400826e-06
jellyfish O 0 2.1788612230011495e-06
to O 0 2.4594893943685747e-07
Drosophila O 0 7.279823876160663e-06
to O 0 6.125039817561628e-07
humans O 0 6.873030997667229e-06
. O 0 1.4183651728671975e-05

Heterozygous O 0 0.0001308692153543234
mutations O 0 1.2594712643476669e-05
in O 0 1.6087926724139834e-06
the O 0 9.654285122451256e-07
human O 0 2.422107627353398e-06
PAX6 O 0 0.008772256784141064
gene O 0 1.0908764807027183e-06
result O 0 2.3031419971175637e-07
in O 0 1.1742384486979063e-07
various O 0 7.906172072580375e-08
phenotypes O 0 6.763965757272672e-06
, O 0 6.010094466546434e-07
including O 0 3.536457143127336e-06
aniridia B-Disease 1 1.0
, O 0 4.337786594987847e-05
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999998807907104
, O 0 2.2374938453140203e-06
autosomal B-Disease 0 0.24827958643436432
dominant I-Disease 1 0.7182655930519104
keratitis I-Disease 1 0.9999998807907104
, O 0 5.506608431460336e-06
and O 0 1.9667188098537736e-05
familial B-Disease 1 0.9999998807907104
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9880704879760742

It O 0 1.3951656910649035e-05
is O 0 3.2167131394089665e-06
believed O 0 2.8971710435143905e-06
that O 0 2.4784768015706504e-07
the O 0 7.761996130284388e-07
mutated O 0 1.8668011989575461e-06
allele O 0 4.037568942294456e-06
of O 0 7.348606686718995e-06
PAX6 O 0 0.2976285517215729
produces O 0 9.952143500413513e-07
an O 0 8.521722634213802e-07
inactive O 0 6.19413549429737e-06
protein O 0 1.6171020433830563e-06
and O 0 1.2010262935291394e-06
aniridia B-Disease 1 0.9999980926513672
is O 0 1.6350969644918223e-06
caused O 0 1.6334419342456385e-05
due O 0 4.866621566179674e-06
to O 0 8.830768933876243e-07
genetic O 0 0.00013791766832582653
haploinsufficiency O 1 0.9532799124717712
. O 0 9.073955880012363e-05

However O 0 1.0499120435270015e-05
, O 0 1.0236592515866505e-06
several O 0 1.8834592196981248e-07
truncation O 0 1.0146572094527073e-05
mutations O 0 5.211551865613728e-07
have O 0 1.045479578465347e-07
been O 0 1.7097588056458335e-07
found O 0 6.860425827426297e-08
to O 0 3.742305665355161e-08
occur O 0 1.3733320258779713e-07
in O 0 5.36427762654057e-07
the O 0 5.672266979672713e-06
C O 0 0.10611528158187866
- O 0 0.00019151145534124225
terminal O 0 4.0904014895204455e-05
half O 0 2.3002357352197578e-07
of O 0 1.100473923543177e-06
PAX6 O 0 0.0028762954752892256
in O 0 1.1477840189400013e-06
patients O 0 1.204082764161285e-06
with O 0 8.147296739480225e-07
Aniridia B-Disease 1 0.9999970197677612
resulting O 0 3.318192511869711e-06
in O 0 1.1807104556282866e-06
mutant O 0 2.439042873447761e-06
proteins O 0 2.3827416839594662e-07
that O 0 1.693398274937863e-07
retain O 0 3.6511247003545577e-07
the O 0 7.201892344710359e-07
DNA O 0 2.09146332963428e-06
- O 0 2.6672514650272205e-06
binding O 0 3.2940931760094827e-07
domains O 0 4.095438725926215e-07
but O 0 5.600352537271647e-08
have O 0 5.120259416457884e-08
lost O 0 6.435216732825211e-07
most O 0 7.860642625701075e-08
of O 0 5.460028660309035e-07
the O 0 3.556099954948877e-06
transactivation O 0 0.00012203801452415064
domain O 0 1.4015854503668379e-05
. O 0 1.1354228263371624e-05

It O 0 4.534491836238885e-06
is O 0 8.661064612169866e-07
not O 0 1.8181792427185428e-07
clear O 0 3.873942375776096e-07
whether O 0 1.0175104137033486e-07
such O 0 1.6461009977319918e-07
mutants O 0 7.282643309736159e-06
really O 0 2.440001253489754e-06
behave O 0 6.218753583198122e-07
as O 0 7.541819400103122e-07
loss O 0 1.0248626495013013e-05
- O 0 3.6860410546069033e-06
of O 0 2.9551097213698085e-06
- O 0 6.0446282077464275e-06
function O 0 4.958449153491529e-07
mutants O 0 6.832348731222737e-07
as O 0 4.094712551250268e-07
predicted O 0 6.299687356658978e-06
by O 0 2.493284910087823e-06
haploinsufficiency O 0 0.00014563242439180613
. O 0 1.3321243386599235e-05

Contrary O 0 4.506990444497205e-05
to O 0 8.788752552391088e-07
this O 0 2.763586053333711e-07
theory O 0 2.1287148683768464e-06
, O 0 1.6151771831118822e-07
our O 0 1.3525767883493245e-07
data O 0 5.381072014642996e-07
showed O 0 9.783143468666822e-07
that O 0 9.478308271582137e-08
these O 0 4.4463021708907036e-08
mutants O 0 1.4474669569608523e-06
are O 0 1.1980083058915625e-07
dominant O 0 3.6310927953309147e-06
- O 0 4.392675691633485e-06
negative O 0 9.749818445925484e-07
in O 0 3.436675797274802e-07
transient O 0 1.4209050277713686e-05
transfection O 0 1.1148558769491501e-05
assays O 0 7.656415164092323e-07
when O 0 8.49140917580371e-08
they O 0 3.03691294334385e-08
are O 0 3.523344105360593e-08
coexpressed O 0 3.6158292004984105e-06
with O 0 1.5350227045018983e-07
wild O 0 1.5400803022203036e-05
- O 0 0.06468608230352402
type O 0 0.013169829733669758
PAX6 O 1 0.9989606142044067
. O 0 3.298868250567466e-05

We O 0 9.295313248003367e-06
found O 0 1.8379819266556296e-06
that O 0 3.5463557424009196e-07
the O 0 1.5466239347006194e-06
dominant O 0 1.638364301470574e-05
- O 0 1.855638220149558e-05
negative O 0 3.2511563858861336e-06
effects O 0 6.400888196367305e-06
result O 0 7.353425530709501e-07
from O 0 2.882380840674159e-07
the O 0 1.418662236574164e-07
enhanced O 0 3.699447574945225e-07
DNA O 0 3.965523092119838e-07
binding O 0 3.5626541716737847e-07
ability O 0 2.227739201998702e-07
of O 0 1.041449763761193e-06
these O 0 5.494912329595536e-07
mutants O 0 2.6655616238713264e-05
. O 0 7.945149263832718e-06

Kinetic O 0 0.0004646690213121474
studies O 0 3.6011439078720286e-05
of O 0 6.226175628398778e-06
binding O 0 4.4000003072142135e-06
and O 0 1.1063141300837742e-06
dissociation O 0 1.1929094398510642e-05
revealed O 0 2.1250434656394646e-06
that O 0 1.1805173016909976e-07
various O 0 1.5873877146077575e-07
truncation O 0 3.1198072974802926e-05
mutants O 0 2.4119194677041378e-06
have O 0 2.9023073011558154e-07
3 O 0 2.2554127099283505e-06
- O 0 3.7293768855306553e-06
5 O 0 3.746480388144846e-06
- O 0 2.6595248527883086e-06
fold O 0 7.046300538604555e-07
higher O 0 4.535796733762254e-07
affinity O 0 2.3628918199847249e-07
to O 0 5.753141607556245e-08
various O 0 8.095437209476586e-08
DNA O 0 1.5563240367555409e-06
- O 0 1.4417303191294195e-06
binding O 0 1.53631447119551e-07
sites O 0 8.781867677498667e-08
when O 0 1.5654804030873493e-07
compared O 0 4.458246394278831e-07
with O 0 5.57103305709461e-08
the O 0 8.502930199938419e-07
wild O 0 8.092308235063683e-06
- O 0 0.00014621556329075247
type O 0 0.00014867294521536678
PAX6 O 0 0.43254774808883667
. O 0 2.0208513888064772e-05

These O 0 2.55508075497346e-06
results O 0 2.074515123240417e-06
provide O 0 2.6810613462657784e-07
a O 0 1.0539361028349958e-06
new O 0 4.5634308776243415e-07
insight O 0 1.6379967746615876e-06
into O 0 1.0412209405785688e-07
the O 0 2.7512530209605757e-07
role O 0 5.398821372182283e-07
of O 0 1.3420234381555929e-06
mutant O 0 3.484339322312735e-05
PAX6 O 0 0.10267380625009537
in O 0 6.062571173970355e-06
causing O 0 0.001260332646779716
aniridia B-Disease 1 0.9999935626983643
. O 0 7.412057584588183e-06
. O 0 1.469311973778531e-05

Reversal O 0 0.11044726520776749
of O 0 0.0011179886059835553
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.006519526708871126
excellent O 0 0.1314574033021927
neuropsychologic O 1 0.9127906560897827
outcome O 0 1.300717758567771e-05
in O 0 4.7152188926702365e-06
very B-Disease 0 3.6850567539659096e-06
- I-Disease 0 0.0007009238470345736
long I-Disease 0 0.00013714497617911547
- I-Disease 0 0.18993298709392548
chain I-Disease 0 0.0032405992969870567
acyl I-Disease 0 4.8193465772783384e-05
- I-Disease 0 0.000388604385079816
coenzyme I-Disease 0 5.184555993764661e-05
A I-Disease 1 0.7355601787567139
dehydrogenase I-Disease 0 0.05063506215810776
deficiency I-Disease 1 0.9999489784240723
. O 0 4.131151217734441e-05

Very B-Disease 0 0.000505736272316426
- I-Disease 0 0.0027837869711220264
long I-Disease 0 0.0004187559534329921
- I-Disease 0 0.005583660677075386
chain I-Disease 0 0.0002748752594925463
acyl I-Disease 0 5.967089600744657e-05
- I-Disease 0 2.286551534780301e-05
coenzyme I-Disease 0 4.097663804714102e-06
A I-Disease 0 1.7175660104840063e-05
dehydrogenase I-Disease 0 7.1402591856895015e-06
( I-Disease 0 2.152103434127639e-06
VLCAD I-Disease 1 0.9879617094993591
) I-Disease 0 6.160684733913513e-06
deficiency I-Disease 1 0.9913868308067322
is O 0 1.329854853793222e-06
a O 0 3.738354644156061e-05
disorder O 1 0.999002993106842
of O 0 0.45472508668899536
fatty O 0 0.33279114961624146
acid O 0 3.5807997846859507e-06
beta O 0 7.084072990437562e-07
oxidation O 0 3.3082318395827315e-07
that O 0 7.97779193817405e-08
reportedly O 0 1.4195421726981294e-06
has O 0 2.1728445176449895e-07
high O 0 7.564663974335417e-06
rates O 0 1.3785455621473375e-06
of O 0 2.6391658138891216e-06
morbidity O 1 0.9383779168128967
and O 0 6.3769493863219395e-06
mortality O 0 0.12819920480251312
. O 0 2.1803723939228803e-05

We O 0 5.8022624216391705e-06
describe O 0 3.5239736462244764e-06
the O 0 1.3884198324376484e-06
outcome O 0 2.0439135823835386e-06
of O 0 1.2210945214974345e-06
a O 0 4.527215423877351e-06
5 O 0 6.9517204792646226e-06
- O 0 2.4215018129325472e-05
year O 0 3.930382717953762e-06
- O 0 7.838744750188198e-06
old O 0 7.907521649030969e-06
girl O 0 1.46335050885682e-05
with O 0 1.3779467735730577e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.5564557947509456e-06
was O 0 2.201666029577609e-05
first O 0 4.6233742523327237e-07
seen O 0 6.069045070944412e-07
at O 0 7.601318543493107e-07
5 O 0 1.840134160602247e-07
months O 0 1.389845039057036e-07
of O 0 1.8408714197448717e-07
age O 0 1.3349198297873954e-06
with O 0 2.759514018180198e-06
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999984502792358
hepatomegaly B-Disease 1 1.0
, O 1 0.9999994039535522
encephalopathy B-Disease 1 1.0
, O 0 0.004347111564129591
and O 0 0.0009551524999551475
hypotonia B-Disease 1 0.9999868869781494
. O 0 0.0001320928568020463

Biochemical O 1 0.7542949914932251
studies O 0 0.020305722951889038
indicated O 1 0.9995920062065125
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 1 0.914074182510376
by O 0 2.920709903264651e-06
a O 0 6.892275905556744e-06
stable O 0 1.6906993550946936e-05
yet O 0 1.4922867421773844e-06
inactive O 0 3.060420567635447e-05
enzyme O 0 9.509618394076824e-06
. O 0 8.994324161903933e-06

Molecular O 0 0.0017759426264092326
genetic O 0 9.47001826716587e-05
analysis O 0 1.8263473975821398e-05
of O 0 9.307723303209059e-06
her O 0 2.124503589584492e-05
VLCAD O 1 0.9987347722053528
gene O 0 1.8891609215643257e-05
revealed O 0 4.651554627344012e-05
a O 0 2.936884447990451e-05
T1372C O 0 0.0007312572561204433
( O 0 2.58195382230042e-06
F458L O 0 4.807833829545416e-05
) O 0 5.315192197485885e-07
missense O 0 9.620035598345567e-06
mutation O 0 1.8191467461292632e-06
and O 0 3.127382342427154e-06
a O 0 2.9102973712724634e-05
1668 O 1 0.998958945274353
ACAG O 1 0.9970155954360962
1669 O 0 0.41356995701789856
splice O 0 0.00010012165148509666
site O 0 1.3561403648054693e-05
mutation O 0 1.5064562830957584e-05
. O 0 1.0247560567222536e-05

After O 0 9.712410974316299e-05
initial O 0 7.810366514604539e-05
treatment O 0 2.3836788386688568e-05
with O 0 1.454975176784501e-06
intravenous O 0 0.0002518169640097767
glucose O 0 5.954578227829188e-05
and O 0 1.5674808082621894e-06
carnitine O 0 0.004200298804789782
, O 0 5.071971145298448e-07
the O 0 5.598984671451035e-07
patient O 0 2.5761689812497934e-06
has O 0 7.243191930683679e-07
thrived O 0 2.2664933112537256e-06
on O 0 1.1123698868686915e-06
a O 0 6.099349320720648e-06
low O 0 0.0008501487318426371
- O 0 0.00012121317558921874
fat O 0 1.2568136298796162e-05
diet O 0 9.044219382303709e-07
supplemented O 0 4.0687135083317116e-07
with O 0 1.0810805406435975e-07
medium O 0 6.293562364589889e-06
- O 0 2.2046306185075082e-05
chain O 0 8.704772881173994e-06
triglyceride O 0 2.3492522814194672e-05
oil O 0 1.1142926268803421e-05
and O 0 6.53680615414487e-07
carnitine O 0 3.476890560705215e-05
and O 0 9.284116799790354e-07
avoidance O 0 0.0001566212740726769
of O 0 7.633091445313767e-05
fasting O 0 0.0008433547918684781
. O 0 1.8972854377352633e-05

Her O 0 0.003340679919347167
ventricular O 1 0.9999891519546509
hypertrophy O 1 0.9731340408325195
resolved O 0 1.2008730664092582e-05
significantly O 0 2.2893250388733577e-06
over O 0 6.508980732178316e-07
1 O 0 1.1444927849879605e-06
year O 0 4.80992866869201e-07
, O 0 1.5866642399942066e-07
and O 0 3.694155736866378e-07
cognitively O 0 2.6880357836489566e-05
, O 0 1.8091711240231234e-07
she O 0 1.7717205480494158e-07
is O 0 1.589493336950909e-07
in O 0 2.2669506449801702e-07
the O 0 6.616420478167129e-07
superior O 0 5.0252388064109255e-06
range O 0 1.6646677067910787e-06
for O 0 1.0242188182019163e-06
age O 0 3.168841794831678e-05
. O 0 2.346939072594978e-05

Clinical O 0 0.0014248988591134548
recognition O 0 7.546730921603739e-05
of O 1 0.9462621212005615
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.216474513261346e-06
important O 0 2.9640185061907687e-07
because O 0 5.096573119089953e-08
it O 0 1.591516074483934e-08
is O 0 3.235003731560937e-08
one O 0 1.8904083631809954e-08
of O 0 1.2910761881812505e-07
the O 0 4.6723314994778775e-07
few O 0 2.922580222275428e-07
directly O 0 2.444421625114046e-06
treatable O 1 0.9984862804412842
causes O 0 0.004215311724692583
of O 1 0.9954931735992432
cardiomyopathy B-Disease 1 1.0
in O 0 7.418864697683603e-05
children O 0 1.0298859706381336e-05
. O 0 2.704906819417374e-06
. O 0 8.895592145563569e-06

Cloning O 0 0.00013644632417708635
of O 0 9.605733794160187e-06
a O 0 5.632850843539927e-06
novel O 0 4.014156729681417e-06
member O 0 1.3543133263738127e-06
of O 0 1.7263084828300634e-06
the O 0 6.80291623211815e-06
low O 0 0.0013495184248313308
- O 0 0.00010931296128546819
density O 0 3.882866440108046e-05
lipoprotein O 0 0.12339484691619873
receptor O 0 0.00019892292039003223
family O 0 2.5061746782739647e-05
. O 0 2.203869735240005e-05

A O 0 0.00015348217857535928
gene O 0 1.419626369170146e-05
encoding O 0 9.613781003281474e-06
a O 0 7.398088655463653e-06
novel O 0 7.434094641212141e-06
transmembrane O 0 2.0364464944577776e-05
protein O 0 5.787639565824065e-06
was O 0 6.331234999379376e-06
identified O 0 2.983877038786886e-07
by O 0 7.74401627268162e-08
DNA O 0 3.9493244230470737e-07
sequence O 0 2.9904947496106615e-07
analysis O 0 2.2386434750387707e-07
within O 0 3.0673828632643563e-07
the O 0 2.2469262148661073e-06
insulin B-Disease 1 0.9553388953208923
- I-Disease 1 0.9994261264801025
dependent I-Disease 1 0.9791087508201599
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 2.9458491553668864e-05
IDDM B-Disease 1 0.9980412721633911
) O 0 1.1894942417711718e-06
locus O 0 8.355130557902157e-05
IDDM4 O 0 0.0006051011732779443
on O 0 1.7729722458170727e-05
chromosome O 0 0.009669705294072628
11q13 O 0 0.011334959417581558
. O 0 3.378226756467484e-05

Based O 0 2.3028504074318334e-05
on O 0 4.405148047226248e-06
its O 0 8.61889361658541e-07
chromosomal O 0 9.62460326263681e-05
position O 0 4.095972144568805e-06
, O 0 7.987917882701367e-08
this O 0 2.2726908355252817e-08
gene O 0 8.459578282327129e-08
is O 0 6.819057318807609e-08
a O 0 1.627537784543165e-07
candidate O 0 1.723438316503234e-07
for O 0 1.4150842275739706e-07
conferring O 0 1.999814594455529e-05
susceptibility O 1 0.9193417429924011
to O 0 6.835569365648553e-05
diabetes B-Disease 1 1.0
. O 0 0.00021447852486744523

The O 0 9.474570106249303e-05
gene O 0 4.950335278408602e-05
, O 0 8.12920552561991e-06
termed O 0 0.00014755511074326932
low O 0 0.00018839625408872962
- O 0 1.4628370990976691e-05
density O 0 3.79481639356527e-06
lipoprotein O 0 9.318909724242985e-05
receptor O 0 4.8888337005337235e-06
related O 0 1.263135573026375e-06
protein O 0 1.7016463971231133e-06
5 O 0 3.251329872000497e-06
( O 0 1.0450703484821133e-06
LRP5 O 0 0.0001634866785025224
) O 0 2.3254555969742796e-07
, O 0 1.4721678098794655e-07
encodes O 0 7.842444915695523e-07
a O 0 1.2308900068092044e-06
protein O 0 1.8637415450939443e-06
of O 0 1.490465638198657e-05
1615 O 0 0.06273725628852844
amino O 0 3.138275587843964e-06
acids O 0 2.5562306404935953e-07
that O 0 3.2839611918689116e-08
contains O 0 4.045995538604075e-08
conserved O 0 1.7188422418712435e-07
modules O 0 2.1321758936210244e-07
which O 0 2.593989911758854e-08
are O 0 8.020508701633844e-09
characteristic O 0 1.128743747358385e-07
of O 0 6.000650500936899e-07
the O 0 1.0958993925669347e-06
low O 0 5.5820157285779715e-05
- O 0 1.2113180673622992e-05
density O 0 7.463845122401835e-06
lipoprotein O 0 0.14235921204090118
( O 0 8.884426279109903e-06
LDL O 1 0.9885622262954712
) O 0 3.2129025839822134e-06
receptor O 0 4.7945373808033764e-05
family O 0 1.0665085937944241e-05
. O 0 1.4813356756349094e-05

These O 0 5.071065061201807e-06
modules O 0 2.121970283042174e-05
include O 0 1.510067477283883e-06
a O 0 2.787907533274847e-06
putative O 0 2.581996341177728e-05
signal O 0 1.8634164007380605e-05
peptide O 0 3.106142003161949e-06
for O 0 2.33928631132585e-07
protein O 0 1.4061586171010276e-06
export O 0 3.7261595480231335e-06
, O 0 3.732450579718716e-07
four O 0 4.4795856979362725e-07
epidermal O 0 4.380608152132481e-05
growth O 0 1.6156396668520756e-05
factor O 0 1.9142194105370436e-06
( O 0 5.900496375943476e-07
EGF O 0 3.803543222602457e-05
) O 0 2.0852526461112575e-07
repeats O 0 5.77396178869094e-07
with O 0 1.8666858636606776e-07
associated O 0 2.0155250695097493e-06
spacer O 0 2.6177433028351516e-05
domains O 0 2.921417262768955e-06
, O 0 8.263090762739012e-07
three O 0 1.6165638498932822e-06
LDL O 0 0.03784487396478653
- O 0 6.883136666147038e-05
receptor O 0 1.9778100977418944e-05
( O 0 2.0512302398856264e-06
LDLR O 0 0.0022759689018130302
) O 0 3.6916236467732233e-07
repeats O 0 5.832893634760694e-07
, O 0 1.0707031350420948e-07
a O 0 2.7474405328575813e-07
single O 0 4.3070963329228107e-07
transmembrane O 0 2.829785444191657e-06
spanning O 0 2.2768879262002883e-06
domain O 0 2.0363972907944117e-06
, O 0 2.78903257822094e-07
and O 0 5.547154273699562e-07
a O 0 5.455643076857086e-06
cytoplasmic O 0 5.5356373195536435e-05
domain O 0 3.552557609509677e-05
. O 0 1.2641571629501414e-05

The O 0 1.739499748509843e-05
encoded O 0 6.0836759985249955e-06
protein O 0 5.203261480346555e-06
has O 0 6.101626013332861e-07
a O 0 3.5119524000037927e-07
unique O 0 1.8191035167092195e-07
organization O 0 7.119379006326199e-07
of O 0 2.969426986965118e-06
EGF O 0 0.00044157373486086726
and O 0 1.8535847630118951e-06
LDLR O 0 0.3345831632614136
repeats O 0 5.103317107568728e-06
; O 0 2.9676331791961275e-07
therefore O 0 4.6864153091519256e-07
, O 0 3.7210102732387895e-07
LRP5 O 0 0.00010243074939353392
likely O 0 5.204141757531033e-07
represents O 0 2.102028133776912e-07
a O 0 2.662996791968908e-07
new O 0 2.274690729109352e-07
category O 0 7.757297453281353e-07
of O 0 1.966777062989422e-06
the O 0 1.4150847164273728e-05
LDLR O 0 0.1514136642217636
family O 0 1.787296605471056e-05
. O 0 3.200310675310902e-05

Both O 0 3.99075033783447e-05
human O 0 2.5236558940378018e-05
and O 0 6.28512952971505e-06
mouse O 0 0.00011038905358873308
LRP5 O 0 0.1653343141078949
cDNAs O 0 5.9220743423793465e-05
have O 0 3.2169634778256295e-07
been O 0 6.941147603356512e-07
isolated O 0 8.978493610811711e-07
and O 0 1.1552907608347596e-07
the O 0 3.0222591362871754e-07
encoded O 0 2.0966706415492808e-07
mature O 0 2.2269659893936478e-07
proteins O 0 5.842614569928628e-08
are O 0 1.5682651621773402e-08
95 O 0 9.118521404616331e-08
% O 0 2.6779353845540754e-08
identical O 0 5.911812550607465e-08
, O 0 5.7144813325749055e-08
indicating O 0 6.848853786323161e-07
a O 0 2.490038752966939e-07
high O 0 1.2278756003070157e-06
degree O 0 2.704256758079282e-06
of O 0 1.5647714235456078e-06
evolutionary O 0 1.0396453944849782e-05
conservation O 0 2.3220081857289188e-06
. O 0 1.2861117966167512e-06
. O 0 7.333981102419784e-06

The O 0 0.0003140898188576102
APC B-Disease 0 0.0006924872286617756
variants O 0 2.3025713744573295e-05
I1307K O 0 0.0006695434567518532
and O 0 5.829968358739279e-06
E1317Q O 0 0.0030621967744082212
are O 0 6.829221774751204e-07
associated O 0 1.5672621884732507e-05
with O 0 0.04145335033535957
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0009108766680583358
but O 0 2.668691649887478e-07
not O 0 6.177954503527872e-08
always O 0 1.2669235616158403e-07
with O 0 1.0935820426993814e-07
a O 0 3.5738398764806334e-06
family O 0 2.9661891858268064e-06
history O 0 3.2224586902884766e-05
. O 0 3.163250221405178e-05

Classical O 0 0.004857990890741348
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9979168772697449
FAP B-Disease 1 0.9999978542327881
) O 0 3.566526402210002e-06
is O 0 1.0494768503122032e-06
a O 0 7.610169632243924e-06
high O 1 0.98587566614151
- O 1 0.9974760413169861
penetrance O 1 0.9999709129333496
autosomal B-Disease 1 0.9953721165657043
dominant I-Disease 1 0.9850391149520874
disease I-Disease 1 0.9941086769104004
that O 0 3.4472648735572875e-07
predisposes O 0 3.991196081187809e-06
to O 0 1.5591005819715065e-07
hundreds O 0 2.543396249166108e-07
or O 0 2.1217275048002193e-07
thousands O 0 4.840575797970814e-07
of O 0 0.05415420979261398
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9935210347175598
carcinoma I-Disease 1 1.0
and O 0 6.516261692013359e-06
that O 0 3.45582975569414e-07
results O 0 9.038864163812832e-07
from O 0 3.325791624320118e-07
truncating O 0 2.47726279667404e-06
mutations O 0 4.2304571934437263e-07
in O 0 1.1653031606329023e-06
the O 0 6.575961378985085e-06
APC B-Disease 0 0.0001012490174616687
gene O 0 2.0873605535598472e-05
. O 0 2.409458829788491e-05

A O 0 0.0002123454469256103
variant O 0 5.3058731282362714e-05
of O 0 1.8262708181282505e-05
FAP B-Disease 0 0.04896736890077591
is O 0 8.302876267407555e-06
attenuated B-Disease 1 0.6601793169975281
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
, O 0 4.2121864680666476e-05
which O 0 2.967920863738982e-06
results O 0 1.0197451956628356e-05
from O 0 6.500291419797577e-06
germ O 1 0.9998370409011841
- O 0 3.563945574569516e-05
line O 0 2.0218801637383876e-06
mutations O 0 8.881996649279245e-08
in O 0 1.0887348622645732e-07
the O 0 1.5040181722270063e-07
5 O 0 1.3953632560514961e-07
and O 0 3.9318940991961426e-08
3 O 0 2.744423568401544e-07
regions O 0 1.2403222626744537e-07
of O 0 1.3855905081072706e-06
the O 0 8.165878170984797e-06
APC B-Disease 0 0.00017327592649962753
gene O 0 9.351926564704627e-06
. O 0 1.6520501958439127e-05

Attenuated B-Disease 1 0.999968409538269
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.4755423665046692
have O 0 5.085307748231571e-06
" O 0 1.375243937218329e-05
multiple O 0 2.4046383259701543e-05
" O 1 0.9976722598075867
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.555003677822242e-06
typically O 0 1.3258441811103694e-07
fewer O 0 5.523368429294351e-08
than O 0 3.133685311240697e-08
100 O 0 2.984574223319214e-07
) O 0 6.111712735901165e-08
without O 0 1.0758434143554041e-07
the O 0 4.617143929408485e-07
florid O 0 2.9530747269745916e-05
phenotype O 0 7.2014722718449775e-06
of O 0 3.0929732020013034e-06
classical O 0 4.6102719352347776e-05
FAP B-Disease 0 0.0002284310758113861
. O 0 9.969317943614442e-06

Another O 0 9.660556679591537e-05
group O 0 6.051018772268435e-06
of O 0 2.2963656647334574e-06
patients O 0 2.0170230072835693e-06
with O 0 2.5259245717279555e-07
multiple O 0 1.4438258403970394e-05
adenomas B-Disease 1 0.9999845027923584
has O 0 2.3072186650097137e-06
no O 0 2.603800624001451e-07
mutations O 0 3.2834640251167e-07
in O 0 3.166339865856571e-07
the O 0 1.4986105725256493e-06
APC B-Disease 0 1.2588023309945129e-05
gene O 0 4.2287589963052596e-07
, O 0 1.1411824374363277e-07
and O 0 5.464738705995842e-08
their O 0 7.366144672005248e-08
phenotype O 0 5.859008524566889e-05
probably O 0 2.0763477550644893e-06
results O 0 3.2145467798727623e-07
from O 0 1.2710987107311666e-07
variation O 0 3.3674027122287953e-07
at O 0 1.6994472389342263e-06
a O 0 8.396929729315161e-07
locus O 0 7.745219591015484e-06
, O 0 3.230428831102472e-07
or O 0 2.70630067689126e-07
loci O 0 1.5849567489567562e-06
, O 0 1.9335932677222445e-07
elsewhere O 0 1.5503496797464322e-07
in O 0 2.2443808234129392e-07
the O 0 2.7707953904609894e-06
genome O 0 2.452777698636055e-05
. O 0 1.2286895980651025e-05

Recently O 0 0.00014223413018044084
, O 0 2.7104304081149166e-06
however O 0 6.543304493789037e-07
, O 0 3.1394918664773286e-07
a O 0 7.0395969942183e-07
missense O 0 8.918679668568075e-06
variant O 0 1.0484821359568741e-05
of O 0 6.79356453474611e-05
APC B-Disease 0 0.000451903382781893
( O 0 1.2339540944594773e-06
I1307K O 0 6.718860095134005e-05
) O 0 1.6630951904517133e-07
was O 0 3.4091547149728285e-06
described O 0 2.6708150357990235e-07
that O 0 3.386868030474943e-08
confers O 0 7.286528216354782e-07
an O 0 2.1832470054050646e-07
increased O 0 1.1367857041477691e-05
risk O 0 0.00010899187327595428
of O 1 0.9987597465515137
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.8495620426838286e-05
including O 0 3.467666147116688e-06
multiple O 0 6.556265725521371e-05
adenomas B-Disease 1 0.9999855756759644
, O 0 7.2295256359211635e-06
in O 0 2.3535958462161943e-05
Ashkenazim O 0 0.001715721795335412
. O 0 2.1290648874128237e-05

We O 0 5.649290869769175e-06
have O 0 5.594287699750566e-07
studied O 0 2.741946218520752e-06
a O 0 9.385433372699481e-07
set O 0 2.0219367513618636e-07
of O 0 3.5785492968898325e-07
164 O 0 7.642323907930404e-06
patients O 0 5.252011305856286e-07
with O 0 5.397935751716432e-07
multiple O 1 0.9982172846794128
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9862246513366699
/ I-Disease 1 0.9993584752082825
or I-Disease 0 0.0011483392445370555
carcinoma I-Disease 1 1.0
and O 0 4.279486347513739e-06
analyzed O 0 6.294631020864472e-06
codons O 0 1.2985735338588711e-05
1263 O 0 0.00010033458966063336
- O 0 1.9754934328375384e-05
1377 O 0 0.00010434926662128419
( O 0 9.47913690652058e-07
exon O 0 3.6299534258432686e-06
15G O 0 1.4449801710725296e-05
) O 0 2.0588684890299191e-07
of O 0 3.8191419093891454e-07
the O 0 1.3197362704886473e-06
APC B-Disease 0 1.5197243556031026e-05
gene O 0 1.2918338825329556e-06
for O 0 2.130477696482558e-06
germ O 1 0.9999606609344482
- O 0 0.013229336589574814
line O 0 7.958454079926014e-05
variants O 0 9.248184142052196e-06
. O 0 9.827244866755791e-06

Three O 0 4.118399374419823e-05
patients O 0 1.1023575098079164e-05
with O 0 7.059221047711617e-07
the O 0 2.650515853019897e-06
I1307K O 0 6.583695358131081e-05
allele O 0 1.651070533625898e-06
were O 0 7.13654287665122e-07
detected O 0 4.465537131181918e-06
, O 0 1.8395111567315325e-07
each O 0 9.626908337168061e-08
of O 0 9.793713616090827e-06
Ashkenazi O 0 0.004942544735968113
descent O 0 0.006647029425948858
. O 0 3.101421316387132e-05

Four O 0 7.69032776588574e-05
patients O 0 2.3131686248234473e-05
had O 0 2.418160147499293e-05
a O 0 7.27421574993059e-05
germ O 1 0.9999580383300781
- O 0 0.0018117281142622232
line O 0 2.2827909560874104e-05
E1317Q O 0 3.340523471706547e-05
missense O 0 6.379759270203067e-06
variant O 0 1.4806385024712654e-06
of O 0 2.000900622078916e-06
APC O 0 5.092821083962917e-06
that O 0 1.0884856749271421e-07
was O 0 1.3166601320335758e-06
not O 0 3.096084100207008e-08
present O 0 5.758663590427204e-08
in O 0 1.710407957489224e-07
controls O 0 7.426282877531776e-07
; O 0 2.997224157752498e-08
one O 0 6.061767976461852e-08
of O 0 1.1791019005613634e-07
these O 0 2.3899326961895895e-08
individuals O 0 2.853922431711453e-08
had O 0 6.307631679192127e-07
an O 0 3.9211963098750857e-07
unusually O 0 2.1540272427955642e-06
large O 0 1.6797299906556873e-07
number O 0 2.0803385325507406e-07
of O 0 4.285792329028482e-06
metaplastic B-Disease 0 0.0016945654060691595
polyps I-Disease 0 9.42995393415913e-05
of I-Disease 0 8.442686521448195e-06
the I-Disease 0 1.9208106095902622e-05
colorectum I-Disease 0 0.0005590993096120656
. O 0 3.0508919735439122e-05

There O 0 4.960415481036762e-06
is O 0 4.661160346586257e-07
increasing O 0 2.7780322398029966e-07
evidence O 0 1.881308548945526e-07
that O 0 7.398022461302389e-08
there O 0 1.8905458887275017e-07
exist O 0 6.584318157365487e-07
germ O 1 0.9879499673843384
- O 0 2.53949092439143e-05
line O 0 2.148608928109752e-06
variants O 0 1.7236519056496036e-07
of O 0 3.3637115848250687e-07
the O 0 8.809386713437561e-07
APC B-Disease 0 3.534636562108062e-06
gene O 0 1.3914352336996672e-07
that O 0 5.0917151384055614e-08
predispose O 0 1.0397795904282248e-06
to O 0 1.1798555732411842e-07
the O 0 3.2679847095096193e-07
development O 0 9.617601790523622e-07
of O 0 3.3181829621753423e-06
multiple O 1 0.9849417209625244
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999853372573853
carcinoma I-Disease 1 1.0
, O 0 2.2690694095217623e-05
but O 0 2.609682212550979e-07
without O 0 2.1875486311273562e-07
the O 0 9.401621241522662e-07
florid O 0 0.00011877393262693658
phenotype O 0 5.086375040264102e-06
of O 0 1.3416176898317644e-06
classical O 0 2.0236248019500636e-05
FAP B-Disease 0 4.191669722786173e-05
, O 0 8.606362200680451e-08
and O 0 4.760914507073721e-08
possibly O 0 1.0101217640112736e-07
with O 0 2.130033216474203e-08
importance O 0 3.2375087357650045e-06
for O 0 0.05533834174275398
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.005253840237855911
in O 0 5.426970233202155e-07
the O 0 4.179145776106452e-07
general O 0 1.0813296285050455e-06
population O 0 2.0869953232249827e-07
. O 0 1.0396872767159948e-06
. O 0 7.967161764099728e-06

Genomic O 0 0.0009211754659190774
structure O 0 4.14012793044094e-05
of O 0 8.629754120192956e-06
the O 0 1.8888997146859765e-05
human O 1 0.9610375165939331
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9975500702857971
CLD B-Disease 1 0.9999997615814209
) O 0 1.348843943560496e-05
gene O 0 3.241790909669362e-05
. O 0 2.7351108656148426e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9971491694450378
CLD B-Disease 1 0.9999998807907104
) O 0 2.6886632440437097e-06
is O 0 4.051467783483531e-07
caused O 0 1.2126275805712794e-06
by O 0 5.6454823038620816e-08
mutations O 0 1.3272659771246254e-07
in O 0 1.0598875377354489e-07
a O 0 3.225245279736555e-07
gene O 0 3.790472931086697e-07
which O 0 3.8945233882259345e-07
encodes O 0 1.6075893654488027e-05
an O 0 7.808682858012617e-05
intestinal O 1 1.0
anion O 1 0.999561607837677
transporter O 1 0.9970232844352722
. O 0 6.310865865088999e-05

We O 0 1.8768136214930564e-05
report O 0 8.537205758329947e-06
here O 0 5.043123110226588e-07
the O 0 2.812717241340579e-07
complete O 0 5.37273933787219e-07
genomic O 0 3.346399807924172e-06
organization O 0 4.3926829107476806e-07
of O 0 1.2263495818842785e-06
the O 0 2.6197214992862428e-06
human O 0 7.52036885387497e-06
CLD B-Disease 0 0.009895989671349525
gene O 0 5.738488084716664e-07
which O 0 2.497692150882358e-07
spans O 0 2.68412850346067e-06
approximately O 0 1.3499367241820437e-06
39kb O 0 1.8178156096837483e-05
, O 0 3.138848398975824e-07
and O 0 2.7029832949665433e-07
comprises O 0 2.1870991986361332e-06
21 O 0 1.4717380508955102e-05
exons O 0 4.947965862811543e-05
. O 0 2.898829734476749e-05

All O 0 3.5886649129679427e-05
exon O 0 0.0002560908906161785
/ O 0 5.6195312936324626e-05
intron O 0 4.6734839997952804e-05
boundaries O 0 2.5112276489380747e-06
conform O 0 1.8471669136488345e-06
to O 0 9.412099757355463e-07
the O 0 1.617897032701876e-05
GT O 0 0.0006174136651679873
/ O 0 0.00018525082850828767
AG O 0 0.01796361804008484
rule O 0 1.404193062626291e-05
. O 0 1.5762932889629155e-05

An O 0 6.004976239637472e-05
analysis O 0 1.5422450815094635e-05
of O 0 4.964741492585745e-06
the O 0 4.478962637222139e-06
putative O 0 5.0064023525919765e-05
promoter O 0 2.077948192891199e-05
region O 0 4.852014967582363e-07
sequence O 0 5.363438617678185e-07
shows O 0 6.923825708327058e-07
a O 0 1.2707688256341498e-05
putative O 0 0.002094556111842394
TATA O 1 0.7429474592208862
box O 0 1.905779390654061e-05
and O 0 1.230391148965282e-06
predicts O 0 7.475221536878962e-06
multiple O 0 1.3355667078940314e-06
transcription O 0 2.1722036763094366e-05
factor O 0 4.204965989629272e-06
binding O 0 3.6050557810085593e-06
sites O 0 4.599560725182528e-06
. O 0 1.2129214155720547e-05

The O 0 2.3071364921634085e-05
genomic O 0 6.198638584464788e-05
structure O 0 8.772717592364643e-06
was O 0 5.104787305754144e-06
determined O 0 5.261862270344864e-07
using O 0 1.1726851312232611e-07
DNA O 0 6.37681864645856e-07
from O 0 2.4455474090245843e-07
several O 0 4.972958933535665e-08
sources O 0 8.20944450197203e-08
including O 0 5.686310444730225e-08
multiple O 0 3.010970317518513e-07
large O 0 4.112505394004984e-06
- O 0 0.004562858026474714
insert O 0 1.0102283340529539e-05
libaries O 0 2.478806345607154e-05
and O 0 2.093737379027516e-07
genomic O 0 6.790452061977703e-06
DNA O 0 2.9957836886751465e-06
from O 0 4.523607458395418e-06
Finnish O 0 0.010572823695838451
CLD B-Disease 1 0.9968898892402649
patients O 0 7.332092536671553e-06
and O 0 5.2675486585940234e-06
controls O 0 6.758083327440545e-05
. O 0 1.9677954696817324e-05

Exon O 0 0.0006300857639871538
- O 0 7.436359010171145e-05
specific O 0 1.7532661331642885e-06
primers O 0 1.1897565855178982e-05
developed O 0 4.944623128722014e-07
in O 0 4.531542074914796e-08
this O 0 1.6858306750577867e-08
study O 0 2.8082940417561986e-08
will O 0 1.3414721777849081e-08
facilitate O 0 7.165609616777147e-08
mutation O 0 2.121377491448584e-07
screening O 0 3.280174496467225e-07
studies O 0 4.7124586899371934e-07
of O 0 8.741873216422391e-07
patients O 0 6.389785198734899e-07
with O 0 2.2095765928042965e-07
the O 0 9.947082435246557e-05
disease O 1 0.9999754428863525
. O 0 6.196404137881473e-05

Genomic O 0 0.00030352326575666666
sequencing O 0 6.66150008328259e-05
of O 0 3.666648990474641e-05
a O 0 4.083577005076222e-05
BAC O 0 0.04586644098162651
clone O 0 0.0003044036857318133
H O 1 0.9999774694442749
_ O 0 1.917042027343996e-06
RG364P16 O 0 3.7954854633426294e-05
revealed O 0 1.1062528528782423e-06
the O 0 2.0730266214741278e-07
presence O 0 3.446811263074778e-07
of O 0 6.53680615414487e-07
another O 0 1.0823200682352763e-06
, O 0 1.3012692079428234e-07
highly O 0 1.8843790883238398e-07
homologous O 0 1.4801584313772764e-07
gene O 0 2.8649620276155474e-07
3 O 0 6.403779480024241e-07
of O 0 8.661858146297163e-07
the O 0 3.6821552384935785e-06
CLD B-Disease 0 0.03491615504026413
gene O 0 6.530400469273445e-07
, O 0 6.086816739525602e-08
with O 0 1.2847501729140731e-08
a O 0 1.9562942554784968e-07
similar O 0 4.65220750811568e-08
genomic O 0 2.527903461668757e-06
structure O 0 1.3141774388714111e-06
, O 0 2.1601090338663198e-07
recently O 0 8.952184771260363e-07
identified O 0 4.3732006815844215e-07
as O 0 1.0139656296814792e-06
the O 0 4.559710214380175e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.02787664532661438
( O 0 0.00013285165186971426
PDS B-Disease 1 0.9600038528442383
) O 0 3.9123610804381315e-06
. O 0 1.7937313714355696e-06
. O 0 1.1433798135840334e-05

The O 0 5.0679405831033364e-05
APCI1307K O 0 0.023597359657287598
allele O 0 4.206614175927825e-05
and O 0 4.8470983529114164e-06
cancer B-Disease 1 0.9974799752235413
risk O 0 6.9303400778153446e-06
in O 0 6.985454206187569e-07
a O 0 1.8561320302978856e-06
community O 0 6.550079092448868e-07
- O 0 4.4529069782583974e-06
based O 0 2.0110444154397555e-07
study O 0 2.3426775896950858e-07
of O 0 2.1990811092109652e-06
Ashkenazi O 0 5.306617094902322e-05
Jews O 0 2.0921073883073404e-05
. O 0 1.7211848899023607e-05

Mutations O 0 0.0004687852051574737
in O 0 0.0001066315162461251
APC O 0 0.0012448029592633247
are O 0 1.7889070704768528e-06
classically O 0 0.009993840008974075
associated O 0 3.6530475426843623e-06
with O 0 1.385885184390645e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999879598617554
FAP B-Disease 1 1.0
) O 0 2.741964181041112e-06
, O 0 8.106266591312306e-07
a O 0 8.164134669641498e-06
highly O 0 0.19213275611400604
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.999992847442627
by O 0 0.0032347498927265406
multiple O 1 0.9910985827445984
intestinal O 1 1.0
polyps B-Disease 1 1.0
and O 0 9.24691357795382e-06
, O 0 1.2896429097963846e-06
without O 0 9.402499472344061e-07
surgical O 1 0.9999734163284302
intervention O 0 0.008486682549118996
, O 0 4.7355700871776207e-07
the O 0 7.411622959807573e-07
development O 0 2.5728844775585458e-05
of O 1 0.9939553141593933
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.5937879681587219
CRC B-Disease 1 0.9999988079071045
) O 0 2.233229133707937e-05
. O 0 2.3448739739251323e-05

APC B-Disease 0 0.0029293405823409557
is O 0 2.9404629458440468e-05
a O 0 0.00011478573287604377
tumour O 1 1.0
- O 1 0.971274197101593
suppressor O 1 0.9999886751174927
gene O 0 2.097583774229861e-06
, O 0 2.178824871634788e-07
and O 0 2.9004397106291435e-07
somatic O 0 0.004864923655986786
loss O 1 0.631216287612915
occurs O 0 4.5378474169410765e-05
in O 0 0.0008237238507717848
tumours B-Disease 1 1.0
. O 0 0.0001923575036926195

The O 0 0.00030537223210558295
germline O 0 0.2904120683670044
T O 0 0.048171740025281906
- O 0 3.984156865044497e-05
to O 0 1.9231817987019895e-06
- O 0 1.9848806914524175e-05
A O 0 1.5935647752485238e-05
transversion O 0 2.1563892005360685e-05
responsible O 0 1.0681875437512645e-06
for O 0 4.1957144958360004e-07
the O 0 2.812421826092759e-06
APC O 0 2.8653261324507184e-05
I1307K O 0 1.7202250091941096e-05
allele O 0 1.3688761555386009e-06
converts O 0 7.86078260262002e-07
the O 0 3.8912747868380393e-07
wild O 0 1.086429733732075e-06
- O 0 1.7897689303936204e-06
type O 0 4.224449980938516e-07
sequence O 0 1.7122914641731768e-07
to O 0 1.5009833020940277e-07
a O 0 7.0883702392166015e-06
homopolymer O 0 0.08809445798397064
tract O 1 0.9992309808731079
( O 0 1.0532064152357634e-05
A8 O 0 0.337637335062027
) O 0 8.711515420145588e-08
that O 0 4.0784758681411404e-08
is O 0 2.3996580011953483e-07
genetically O 0 1.2376381164358463e-06
unstable O 0 1.8117270883521996e-05
and O 0 4.86847397951351e-07
prone O 0 1.4775009731238242e-05
to O 0 4.9127589818454e-07
somatic O 0 0.00023181390133686364
mutation O 0 6.974243297008798e-05
. O 0 1.848964711825829e-05

The O 0 9.686245175544173e-05
I1307K O 0 0.00045369184226728976
allele O 0 4.543598333839327e-05
was O 0 3.82237158191856e-05
found O 0 2.6505613277549855e-06
in O 0 2.4475357349729165e-06
6 O 0 5.494698416441679e-05
. O 0 1.878639704955276e-05

1 O 0 3.938515510526486e-05
% O 0 5.204159606364556e-06
of O 0 5.336536560207605e-06
unselected O 0 0.0005747127579525113
Ashkenazi O 0 6.420445424737409e-05
Jews O 0 4.151445409661392e-06
and O 0 7.638190027137171e-07
higher O 0 6.669320555374725e-06
proportions O 0 3.823864972218871e-06
of O 0 3.827527962130262e-06
Ashkenazim O 0 2.1245115931378677e-05
with O 0 2.1662548022050032e-07
family O 0 5.868827201993554e-07
or O 0 1.1658122502922197e-06
personal O 0 1.2048341886838898e-05
histories O 0 4.889644969807705e-06
of O 0 0.00464486051350832
CRC B-Disease 1 0.9994589686393738
( O 0 3.4741638046398293e-06
ref O 0 9.500363375991583e-05
. O 0 3.2652835102453537e-07
2 O 0 2.227009190391982e-06
) O 0 1.5885294715189957e-06
. O 0 3.659477215478546e-06

To O 0 1.1205725058971439e-05
evaluate O 0 5.976143711450277e-06
the O 0 1.8771968370856484e-06
role O 0 3.450716349107097e-06
of O 0 6.326418770186137e-06
I1307K O 0 0.0007743989699520171
in O 0 4.359573267720407e-06
cancer B-Disease 0 0.037570130079984665
, O 0 9.834068350755842e-07
we O 0 3.802928461027477e-07
genotyped O 0 1.9769313439610414e-05
5 O 0 2.0545564893836854e-06
, O 0 5.543811880670546e-07
081 O 0 3.35111326421611e-05
Ashkenazi O 0 7.6535561674973e-06
volunteers O 0 4.371278237158549e-07
in O 0 3.0883816748428217e-07
a O 0 1.4359753777171136e-06
community O 0 1.1032533393517951e-06
survey O 0 1.4783184269617777e-05
. O 0 1.2256656191311777e-05

Risk O 0 0.00040102185448631644
of O 0 3.5190889320801944e-05
developing O 0 0.0023664638865739107
colorectal B-Disease 1 1.0
, I-Disease 0 0.0012913228711113334
breast I-Disease 1 0.9998118281364441
and I-Disease 0 5.653376319969539e-06
other I-Disease 0 8.628491627860058e-07
cancers I-Disease 1 0.9982506632804871
were O 0 1.0394263881607912e-05
compared O 0 6.682588718831539e-06
between O 0 1.3864456605006126e-06
genotyped O 0 0.00016159478400368243
I1307K O 0 4.8397672799183056e-05
carriers O 0 7.464454370165186e-07
and O 0 5.445572242024355e-07
non O 0 3.6639958125306293e-06
- O 0 1.7124920077549177e-06
carriers O 0 1.0956907914305702e-07
and O 0 3.257119018940102e-08
their O 0 3.2986697817705135e-08
first O 0 1.405820739819319e-06
- O 0 7.10981748852646e-06
degree O 0 0.00011774302402045578
relatives O 0 1.0402583939139731e-05
. O 0 1.5015651115390938e-05

Sperm O 0 0.00011612379603320733
DNA O 0 3.605026358854957e-05
analysis O 0 6.708379260089714e-06
in O 0 2.5646158974268474e-06
a O 0 2.8231921533006243e-05
Friedreich B-Disease 1 0.9983664155006409
ataxia I-Disease 1 0.9999830722808838
premutation O 1 0.9984586238861084
carrier O 0 4.492195148486644e-05
suggests O 0 2.1047212612756994e-06
both O 0 1.809008978170823e-07
meiotic O 0 1.1391591215215158e-05
and O 0 3.405401116651774e-07
mitotic O 0 1.156629150500521e-05
expansion O 0 3.4536196835688315e-06
in O 0 9.336627613265591e-07
the O 0 3.912335159839131e-06
FRDA B-Disease 0 0.0028418609872460365
gene O 0 2.4747580027906224e-05
. O 0 2.4644657969474792e-05

Friedreich B-Disease 1 0.9999816417694092
ataxia I-Disease 1 0.9999983310699463
is O 0 7.471194840036333e-05
usually O 0 6.624870366067626e-06
caused O 0 4.1758779843803495e-05
by O 0 3.571958586690016e-07
an O 0 2.5795588953769766e-07
expansion O 0 1.14644831228361e-06
of O 0 9.60350575951452e-07
a O 0 2.1341218143788865e-06
GAA O 0 1.0083494998980314e-05
trinucleotide O 0 1.6034551663324237e-05
repeat O 0 1.1486085895739961e-06
in O 0 5.743744395658723e-07
intron O 0 1.9179662558599375e-05
1 O 0 1.161890850198688e-06
of O 0 2.4134681098075816e-06
the O 0 2.0133897123741917e-05
FRDA B-Disease 1 0.7825933694839478
gene O 0 3.370744161657058e-05
. O 0 2.4874329028534703e-05

Occasionally O 0 2.9546383302658796e-05
, O 0 2.4704493171157083e-06
a O 0 1.5051331274662516e-06
fully O 0 5.451147444546223e-07
expanded O 0 3.702024002905091e-07
allele O 0 5.508428557732259e-07
has O 0 1.6796467150470562e-07
been O 0 2.7085829401585215e-07
found O 0 1.138571263936683e-07
to O 0 8.903776205215763e-08
arise O 0 4.4690887079923414e-07
from O 0 3.871486455864215e-07
a O 0 1.3795372524327831e-06
premutation O 0 9.86416398518486e-06
of O 0 1.4891592172716628e-06
100 O 0 2.064241016341839e-06
or O 0 8.139887199831719e-07
less O 0 1.8462741309122066e-06
triplet O 0 0.00039369153091683984
repeats O 0 7.829402602510527e-05
. O 0 2.0794945157831535e-05

We O 0 6.981591013754951e-06
have O 0 8.252167731370719e-07
examined O 0 3.1260046853276435e-06
the O 0 4.713568841907545e-07
sperm O 0 1.350490379081748e-06
DNA O 0 2.077080580420443e-06
of O 0 4.303821697249077e-06
a O 0 2.816614505718462e-05
premutation O 0 0.005862136371433735
carrier O 0 0.0001465592358727008
. O 0 2.9398881451925263e-05

This O 0 3.174976154696196e-05
mans O 0 0.00022361305309459567
leucocyte O 0 0.00031325186137109995
DNA O 0 2.2298048861557618e-05
showed O 0 7.657213245693129e-06
one O 0 4.556516444154113e-07
normal O 0 1.5083360267453827e-06
allele O 0 9.308275252806197e-07
and O 0 1.4194364439390483e-07
one O 0 1.3727085956816154e-07
allele O 0 3.005347366524802e-07
of O 0 4.5056611952531966e-07
approximately O 0 1.1232194765398162e-06
100 O 0 5.899252755625639e-06
repeats O 0 1.3324635801836848e-05
. O 0 1.2647588846448343e-05

His O 0 0.00011933542555198073
sperm O 0 6.268185825319961e-05
showed O 0 2.13603452721145e-05
an O 0 1.6192240082091303e-06
expanded O 0 1.7475554159318563e-06
allele O 0 1.751354261614324e-06
in O 0 6.916948223079089e-07
a O 0 3.7067827634018613e-06
tight O 0 8.297121894429438e-06
range O 0 1.0746308589659748e-06
centering O 0 3.5264447433291934e-06
on O 0 4.946160174768011e-07
a O 0 3.164603867844562e-07
size O 0 1.55563398607228e-07
of O 0 1.4368823713084566e-06
approximately O 0 3.5087025480606826e-06
320 O 0 1.499221343692625e-05
trinucleotide O 0 0.00015593686839565635
repeats O 0 3.5397210012888536e-05
. O 0 1.8968114090966992e-05

His O 0 0.00016245731967501342
affected O 0 3.442453089519404e-05
son O 0 9.700452210381627e-05
has O 0 1.202053113047441e-06
repeat O 0 1.563117393743596e-06
sizes O 0 4.865601113124285e-07
of O 0 3.5735808978643036e-06
1040 O 0 3.182970976922661e-05
and O 0 3.3660876397334505e-06
540 O 0 0.00018658922635950148
. O 0 1.5329789675888605e-05

These O 0 4.7328703658422455e-06
data O 0 4.726518909592414e-06
suggest O 0 1.2598487728610053e-06
that O 0 2.723385819081159e-07
expansion O 0 1.922989213198889e-06
occurs O 0 3.0329422884278756e-07
in O 0 1.7284321529587032e-07
two O 0 6.98217732519879e-08
stages O 0 3.416298000047391e-07
, O 0 8.16923915181178e-08
the O 0 5.6914320367695836e-08
first O 0 9.477965079440764e-08
during O 0 2.736439626005449e-07
meiosis O 0 4.662609853767208e-07
followed O 0 4.6293175159917155e-07
by O 0 1.3718317859456874e-07
a O 0 8.312853765346517e-07
second O 0 4.847944637731416e-06
mitotic O 0 3.312815533718094e-05
expansion O 0 2.283182584505994e-05
. O 0 1.2234911082487088e-05

We O 0 1.0951076546916738e-05
also O 0 1.8813439055520575e-06
show O 0 7.469588467756694e-07
that O 0 1.2559952722313028e-07
in O 0 1.2693205064806534e-07
all O 0 4.851103341252383e-08
informative O 0 1.1799415915447753e-06
carrier O 0 1.5202776921796612e-06
father O 0 9.995096661441494e-07
to O 0 1.0606276390490166e-07
affected O 0 4.45167387397305e-07
child O 0 2.0615066205209587e-06
transmissions O 0 6.2390863604377955e-06
, O 0 1.475721376209549e-07
with O 0 2.7419845949339106e-08
the O 0 2.4722069724703033e-07
notable O 0 2.1376362724367937e-07
exception O 0 2.38909450445135e-07
of O 0 5.034266905568074e-07
the O 0 6.802519010307151e-07
premutation O 0 9.44316889217589e-06
carrier O 0 7.193339115474373e-07
, O 0 8.031213383219438e-08
the O 0 1.36994401600532e-07
expansion O 0 4.385027523312601e-07
size O 0 3.2919419368226954e-07
decreases O 0 7.154818831622833e-06
. O 0 1.1093208058809978e-06
. O 0 6.0983315961493645e-06

The O 0 4.8354217142332345e-05
R496H O 0 0.00028768996708095074
mutation O 0 8.435982636001427e-06
of O 0 7.005053703323938e-06
arylsulfatase O 0 0.0018177467864006758
A O 0 3.273696347605437e-05
does O 0 9.01586076906824e-07
not O 0 2.7608987238636473e-06
cause O 0 0.13336129486560822
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 0.00012570785474963486

Deficiency B-Disease 1 0.9999895095825195
of I-Disease 0 0.0001593811175553128
arylsulfatase I-Disease 1 0.8954678177833557
A I-Disease 0 0.005326255224645138
( O 0 1.7196278349729255e-05
ARSA O 1 0.7162768244743347
) O 0 1.3993067113915458e-06
enzyme O 0 4.933125183015363e-06
activity O 0 3.854922397295013e-05
causes O 0 0.0013302381848916411
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00020210612274240702
MLD B-Disease 1 1.0
) O 0 2.9707256544497795e-05
. O 0 2.814702565956395e-05

A O 0 5.467617302201688e-05
number O 0 4.2742976802401245e-06
of O 0 8.425691703450866e-06
ARSA O 0 0.003214214462786913
gene O 0 2.829979848684161e-06
mutations O 0 2.4277737793454435e-06
responsible O 0 2.8599465622392017e-06
for O 0 1.8282306655237335e-06
MLD B-Disease 1 1.0
have O 0 2.013926405197708e-06
been O 0 6.2334715948964e-06
identified O 0 1.545072882436216e-05
. O 0 1.1592994269449264e-05

Recently O 0 0.00024019611009862274
, O 0 4.424477992870379e-06
the O 0 3.3113926747319056e-06
R496H O 0 3.420632128836587e-05
mutation O 0 2.40544159169076e-06
of O 0 5.109019639348844e-06
ARSA O 0 0.0018795166397467256
was O 0 6.923944965819828e-06
proposed O 0 3.780833424116281e-07
to O 0 7.784949218603288e-08
be O 0 2.2716989178661606e-07
a O 0 1.5605733096890617e-06
cause O 0 8.568805242248345e-06
of O 0 7.192107295850292e-05
MLD B-Disease 1 1.0
( O 0 3.008914518431993e-06
Draghia O 0 5.575738032348454e-05
et O 0 1.5084126971487422e-05
al O 0 1.7732698324834928e-05
. O 0 2.3771853818743693e-07
, O 0 5.645519536301435e-07
1997 O 0 7.065046702336986e-06
) O 0 3.031339701919933e-06
. O 0 1.0264853699482046e-05

We O 0 5.077321930002654e-06
have O 0 5.354924041967024e-07
investigated O 0 3.1189977107715094e-06
the O 0 1.0270798611600185e-06
R496H O 0 2.9295079002622515e-05
mutation O 0 5.466525863084826e-07
and O 0 1.423353950258388e-07
found O 0 1.3889321337501315e-07
this O 0 4.2185316573295495e-08
mutation O 0 2.467086801516416e-07
at O 0 1.0345254395360826e-06
a O 0 3.2926925541687524e-07
relatively O 0 3.2378804348809354e-07
high O 0 1.242183543581632e-06
frequency O 0 5.492555033015378e-07
in O 0 1.6705249095139152e-07
an O 0 2.728369281612686e-07
African O 0 3.745819583400589e-07
American O 0 3.6993031926613185e-07
population O 0 1.1036799918429097e-07
( O 0 1.760891024105149e-07
f O 0 1.2314876585151069e-06
= O 0 5.796256346002338e-07
0 O 0 2.1187571519476478e-07
. O 0 1.001171838765913e-07
09 O 0 6.449909960792866e-06
, O 0 3.3514348274366057e-07
n O 0 1.507372530795692e-06
= O 0 3.5328839658177458e-06
61 O 0 4.446753791853553e-06
subjects O 0 5.458739906316623e-06
) O 0 2.8733068120345706e-06
. O 0 8.823454663797747e-06

The O 0 0.0001938093191711232
ARSA O 0 0.04224184900522232
enzyme O 0 2.1041325453552417e-05
activity O 0 4.31418538937578e-06
in O 0 4.566473990053055e-07
subjects O 0 8.906677635422966e-07
with O 0 1.330403733845742e-07
and O 0 2.410561990018323e-07
without O 0 1.8374650778696378e-07
the O 0 5.554311428568326e-07
R496H O 0 9.106820471060928e-06
mutation O 0 3.1635329378332244e-07
was O 0 2.664724206624669e-06
determined O 0 1.8908542642748216e-07
and O 0 7.328964812813865e-08
found O 0 1.267063538534785e-07
to O 0 2.3410002825130505e-07
be O 0 1.3429695400191122e-06
normal O 0 2.4003815269679762e-05
. O 0 2.0042918549734168e-05

It O 0 6.177594059408875e-06
is O 0 1.7898285022965865e-06
therefore O 0 5.138555252415244e-07
concluded O 0 1.10892949578556e-06
that O 0 1.176908952515987e-07
the O 0 5.340419306776312e-07
R496H O 0 1.6587517166044563e-05
mutation O 0 6.144533699625754e-07
of O 0 3.2443949748994783e-06
ARSA O 0 0.0021904567256569862
does O 0 2.3106750290935452e-07
not O 0 9.914707277403068e-08
negatively O 0 4.261426056473283e-07
influence O 0 2.4237107254521106e-07
the O 0 3.225860325528629e-07
activity O 0 1.8896532765211305e-06
of O 0 1.857394636317622e-06
ARSA O 0 0.0002740825875662267
and O 0 1.7732806156800507e-07
is O 0 1.6459706841942534e-07
not O 0 9.479483509267084e-08
a O 0 2.1016423943365226e-06
cause O 0 8.389900904148817e-05
of O 0 0.22325807809829712
MLD B-Disease 1 1.0

Down O 0 0.0029241847805678844
- O 0 0.00021679175551980734
regulation O 0 1.984203299798537e-05
of O 0 6.717552878399147e-06
transmembrane O 0 0.00023767538368701935
carbonic O 0 0.0030662461649626493
anhydrases O 0 0.31169500946998596
in O 0 0.00026796272140927613
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999165534973145
lines O 0 2.084189691231586e-05
by O 0 1.2655555110541172e-06
wild O 0 7.660354640393052e-06
- O 0 8.835640619508922e-05
type O 0 9.730952297104523e-05
von B-Disease 1 0.9997082352638245
Hippel I-Disease 1 0.9999951124191284
- I-Disease 1 0.9933672547340393
Lindau I-Disease 1 0.9310390949249268
transgenes O 0 0.0009989405516535044
. O 0 2.601606320240535e-05

To O 0 1.7784384908736683e-05
discover O 0 8.267865268862806e-06
genes O 0 3.934440883313073e-06
involved O 0 2.7657979444484226e-06
in O 0 3.679946985357674e-06
von B-Disease 1 0.996357262134552
Hippel I-Disease 1 0.999998927116394
- I-Disease 1 0.9998995065689087
Lindau I-Disease 1 0.9999969005584717
( O 0 5.338705886970274e-05
VHL B-Disease 1 0.9716900587081909
) O 0 1.448220928068622e-06
- O 0 1.105576848203782e-05
mediated O 0 2.973395930894185e-05
carcinogenesis O 0 0.10505735874176025
, O 0 4.0356533759222657e-07
we O 0 2.2287845524715522e-07
used O 0 9.552913979860023e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999216794967651
lines O 0 4.682275903178379e-05
stably O 0 0.00021581251348834485
transfected O 0 1.7076132280635647e-05
with O 0 3.055456261336076e-07
wild O 0 1.1454142622824293e-05
- O 0 0.00010431047121528536
type O 0 0.0003625569224823266
VHL O 1 0.9927362203598022
- O 0 0.00017437964561395347
expressing O 0 2.516196582291741e-05
transgenes O 0 0.0002728321705944836
. O 0 1.84743130375864e-05

Large O 0 7.174407073762268e-05
- O 0 5.076893648947589e-05
scale O 0 2.6378664188086987e-05
RNA O 0 1.6035346561693586e-05
differential O 0 4.652833922591526e-06
display O 0 1.0398470067229937e-06
technology O 0 1.0835108241735725e-06
applied O 0 1.285145287965861e-07
to O 0 2.264426512965656e-08
these O 0 2.903856710645414e-08
cell O 0 3.3610608625167515e-06
lines O 0 4.298487112919247e-07
identified O 0 1.6801465108073899e-07
several O 0 5.050183560229016e-08
differentially O 0 1.4435491948461276e-06
expressed O 0 1.9128238193388825e-07
genes O 0 1.3975819967981806e-07
, O 0 7.566544724113555e-08
including O 0 9.90589867910785e-08
an O 0 1.0735707292042207e-06
alpha O 0 1.1300753612886183e-05
carbonic O 0 2.7124988264404237e-05
anhydrase O 0 7.235376688186079e-05
gene O 0 5.185309873922961e-06
, O 0 4.829785666515818e-06
termed O 0 0.0001777507277438417
CA12 O 0 0.045766398310661316
. O 0 2.904147913795896e-05

The O 0 5.861395038664341e-05
deduced O 0 6.245185068110004e-05
protein O 0 4.709924724011216e-06
sequence O 0 2.311292973899981e-06
was O 0 8.943635293690022e-06
classified O 0 1.5520910210398142e-06
as O 0 5.98140729834995e-07
a O 0 9.464710615247895e-07
one O 0 6.501492748611781e-07
- O 0 1.2004334166704211e-05
pass O 0 1.896660023703589e-06
transmembrane O 0 3.982618363806978e-05
CA O 0 3.566023224266246e-06
possessing O 0 3.2551679396419786e-06
an O 0 1.5942008531055762e-06
apparently O 0 3.779704684347962e-06
intact O 0 1.5779030491103185e-06
catalytic O 0 1.0149175295737223e-06
domain O 0 4.878294816990092e-07
in O 0 3.417539460315311e-07
the O 0 2.0966156171198236e-06
extracellular O 0 6.626665708608925e-05
CA O 0 5.165462425793521e-05
module O 0 0.0003541765618138015
. O 0 2.8823809770983644e-05

Reintroduced O 0 0.0008986912434920669
wild O 0 0.00017495038628112525
- O 0 0.0038573124911636114
type O 0 0.000636342796497047
VHL B-Disease 1 0.9275693297386169
strongly O 0 6.621465672651539e-06
inhibited O 0 9.637024049879983e-06
the O 0 4.276358538390923e-07
overexpression O 0 7.165990609792061e-06
of O 0 5.441875714495836e-07
the O 0 1.4356714927998837e-06
CA12 O 0 0.000323642190778628
gene O 0 5.23796529705578e-07
in O 0 3.712574141445657e-07
the O 0 3.0798482839600183e-06
parental O 0 0.1397985965013504
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.10603015124797821
. O 0 5.1868260925402865e-05

Similar O 0 9.81831817625789e-06
results O 0 4.911264568363549e-06
were O 0 1.7283099396081525e-06
obtained O 0 2.496987690392416e-06
with O 0 1.2111262321923277e-06
CA9 O 0 0.0072877248749136925
, O 0 8.238980058195011e-07
encoding O 0 1.7546008166391402e-06
another O 0 4.184564204479102e-06
transmembrane O 0 5.0596445362316445e-05
CA O 0 3.886055765178753e-06
with O 0 3.2442233077745186e-07
an O 0 4.492541393119609e-06
intact O 0 2.3958622477948666e-05
catalytic O 0 1.559640259074513e-05
domain O 0 1.4017698958923575e-05
. O 0 6.277426109591033e-06

Although O 0 1.4459147678280715e-05
both O 0 1.687039116404776e-06
domains O 0 6.626386948482832e-06
of O 0 5.986925771139795e-06
the O 0 9.671125553722959e-06
VHL B-Disease 0 0.0008933987701311707
protein O 0 1.6290827034026734e-06
contribute O 0 4.5492089384424617e-07
to O 0 4.4864134451927384e-07
regulation O 0 3.3571975563972956e-06
of O 0 6.1119735619286075e-06
CA12 O 0 0.1260182410478592
expression O 0 3.8238795241340995e-06
, O 0 3.1386505838781886e-07
the O 0 6.402308372344123e-07
elongin O 0 5.928901828156086e-06
binding O 0 6.391485385393025e-07
domain O 0 8.785416980572336e-07
alone O 0 3.409801081488695e-07
could O 0 3.0670756245854136e-07
effectively O 0 2.331131781829754e-06
regulate O 0 1.6131732991198078e-05
CA9 O 0 0.001613933825865388
expression O 0 5.0050515710609034e-05
. O 0 1.5652174624847248e-05

We O 0 2.8484020731411874e-05
mapped O 0 0.0002873396733775735
CA12 O 0 0.00394800491631031
and O 0 2.20643723878311e-05
CA9 O 0 0.01835528574883938
loci O 0 2.5230083338101394e-05
to O 0 1.5929151686577825e-06
chromosome O 0 0.00016303911979775876
bands O 0 4.870398697676137e-05
15q22 O 0 0.016050422564148903
and O 0 2.0276736904634163e-05
17q21 O 0 0.3177109360694885
. O 0 3.201861181878485e-05

2 O 0 0.0001248910848516971
respectively O 0 2.2697446183883585e-05
, O 0 1.37109316256101e-06
regions O 0 9.582097391103161e-07
prone O 0 9.54635652306024e-06
to O 0 3.139443833788391e-07
amplification O 0 3.626688339863904e-05
in O 0 1.2921407233079663e-06
some O 0 6.230947633412143e-07
human O 0 3.164155350532383e-05
cancers B-Disease 1 0.9997648596763611
. O 0 8.814299508230761e-05

Additional O 0 8.605723451182712e-06
experiments O 0 1.2820038136851508e-05
are O 0 2.585149445621937e-07
needed O 0 3.770966543470422e-07
to O 0 8.475486623638062e-08
define O 0 2.054616032864942e-07
the O 0 3.6655998769674625e-07
role O 0 1.8654557152331108e-06
of O 0 6.204174042068189e-06
CA O 0 8.66109985508956e-06
IX O 0 0.01067690085619688
and O 0 3.4911124657810433e-06
CA O 0 9.551728908263613e-06
XII O 0 0.019092893227934837
enzymes O 0 8.969446980700013e-07
in O 0 5.140290113558876e-07
the O 0 7.241292792059539e-07
regulation O 0 8.715219337318558e-07
of O 0 1.2542731155917863e-06
pH O 0 7.777736755087972e-06
in O 0 3.3522152875775646e-07
the O 0 8.571278158342466e-07
extracellular O 0 9.256787052436266e-06
microenvironment O 0 2.299994957866147e-05
and O 0 7.288746672884372e-08
its O 0 1.3262538800518087e-07
potential O 0 5.942154075455619e-07
impact O 0 2.4216942620114423e-06
on O 0 1.6674526705173776e-05
cancer B-Disease 1 0.9996563196182251
cell O 1 0.5548076033592224
growth O 0 0.0003406419709790498
. O 0 9.89119871519506e-06

A O 0 0.000135761612909846
gene O 0 2.1396004740381613e-05
encoding O 0 7.549356723757228e-06
a O 0 6.614454832742922e-06
transmembrane O 0 6.077727084630169e-05
protein O 0 5.930225597694516e-06
is O 0 4.099498767118348e-07
mutated O 0 1.4326091104521765e-06
in O 0 9.596180916560115e-07
patients O 0 8.280238034785725e-06
with O 0 0.00027881591813638806
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999998807907104
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999998807907104
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 8.632108074380085e-05
. O 0 2.3857915948610753e-05

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9858186841011047
WFS B-Disease 1 0.9999998807907104
; O 0 7.09890664438717e-05
OMIM O 1 0.9999891519546509
222300 O 0 0.15061278641223907
) O 0 6.957789082662202e-07
is O 0 2.268114229764251e-07
an O 0 1.5818475276319077e-06
autosomal B-Disease 1 0.9999958276748657
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 1 0.8953892588615417
by O 0 0.000920925522223115
young O 0 0.2642645537853241
- O 1 0.9999432563781738
onset O 1 1.0
non O 1 0.9999978542327881
- O 1 0.9999997615814209
immune O 1 0.9999997615814209
insulin B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
dependent I-Disease 1 0.9999990463256836
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.995109498500824
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.007550184614956379

Linkage O 0 0.001157602178864181
to O 0 7.742974048596807e-06
markers O 0 4.542263923212886e-05
on O 0 1.3303774721862283e-05
chromosome O 0 0.08601870387792587
4p O 1 0.9997989535331726
was O 0 0.00045514642260968685
confirmed O 0 3.869511601806153e-06
in O 0 1.1751565125450725e-06
five O 0 1.3587532521341927e-06
families O 0 1.024165044327674e-06
. O 0 8.876490937836934e-06

On O 0 2.2546755644725636e-05
the O 0 1.1769420780183282e-06
basis O 0 2.4238083824457135e-06
of O 0 6.3795891946938355e-06
meiotic O 0 0.3543412387371063
recombinants O 1 0.9955537915229797
and O 0 0.00017960160039365292
disease O 1 0.9999998807907104
- O 1 0.8361780047416687
associated O 0 9.750174285727553e-06
haplotypes O 0 1.6109856005641632e-05
, O 0 5.2759367008548e-07
the O 0 2.8498973279056372e-06
WFS B-Disease 0 0.00022273891954682767
gene O 0 8.463990184282011e-07
was O 0 1.253853042726405e-05
localized O 0 4.0718368836678565e-06
to O 0 7.980133318596927e-07
a O 0 2.8442216716939583e-05
BAC O 0 0.003264395985752344
/ O 0 6.535454303957522e-05
P1 O 0 0.0006698485231027007
contig O 0 2.8233967896085232e-05
of O 0 1.3913490874983836e-06
less O 0 4.05594818175814e-07
than O 0 2.845585242994275e-07
250 O 0 4.038481620227685e-06
kb O 0 8.870371675584465e-05
. O 0 8.606018127466086e-06

Mutations O 0 7.597616786370054e-05
in O 0 5.848568434885237e-06
a O 0 8.94533241080353e-06
novel O 0 1.2564218195620924e-05
gene O 0 4.234786501911003e-06
( O 0 1.805432589208067e-06
WFS1 O 0 0.00012480966688599437
) O 0 2.650243118296203e-07
encoding O 0 3.1006527478893986e-07
a O 0 1.2234619362061494e-06
putative O 0 1.0531542102398816e-05
transmembrane O 0 6.243281859497074e-06
protein O 0 7.818190397301805e-07
were O 0 3.6537196024255536e-07
found O 0 1.1277097655693069e-07
in O 0 1.151658466369554e-07
all O 0 2.3936916448974443e-08
affected O 0 1.6849185158207547e-07
individuals O 0 3.820398220000243e-08
in O 0 5.453866833704524e-07
six O 0 3.4348120152571937e-06
WFS B-Disease 0 0.007265989203006029
families O 0 4.7427786142861805e-08
, O 0 5.837824801346869e-08
and O 0 1.9371841020188185e-08
these O 0 1.2762873424776444e-08
mutations O 0 2.4740822368585214e-07
were O 0 7.328027322728303e-07
associated O 0 9.437905532649893e-07
with O 0 3.132278436623892e-07
the O 0 0.00020974845392629504
disease O 1 0.9999969005584717
phenotype O 1 0.9901424646377563
. O 0 4.142496982240118e-05

WFS1 O 0 0.20459109544754028
appears O 0 3.654109968920238e-05
to O 0 6.929308256076183e-07
function O 0 1.3508575875675888e-06
in O 0 5.066851258561655e-07
survival O 0 2.665133479240467e-06
of O 0 3.5538655538402963e-06
islet O 0 0.10194186121225357
beta O 0 6.450602813856676e-05
- O 0 4.318556602811441e-05
cells O 0 5.240321570454398e-06
and O 0 1.8271516637469176e-06
neurons O 0 2.7762818717746995e-05
. O 0 2.1279515749483835e-06
. O 0 5.7635152188595384e-06

Stable O 0 0.00020392374426592141
interaction O 0 9.635534297558479e-06
between O 0 3.961624770454364e-06
the O 0 1.5905303598628961e-06
products O 0 4.323780729009741e-07
of O 0 3.258890615143173e-07
the O 0 8.603274181950837e-07
BRCA1 O 0 1.9895538571290672e-05
and O 0 4.151821485720575e-06
BRCA2 O 1 0.8291018605232239
tumor B-Disease 1 0.9999998807907104
suppressor O 1 0.9999731779098511
genes O 0 1.637709488022665e-06
in O 0 2.097779770338093e-06
mitotic O 0 3.3494678064016625e-05
and O 0 2.1150635802769102e-06
meiotic O 0 0.027065696194767952
cells O 0 0.0003190703282598406
. O 0 2.6194709789706394e-05

BRCA1 O 0 0.0016025748336687684
and O 0 1.0170570021728054e-05
BRCA2 O 0 7.507690315833315e-05
account O 0 6.053109018466785e-07
for O 0 1.8466951701157086e-07
most O 0 4.1358731550644734e-08
cases O 0 6.949400699340913e-08
of O 0 6.859390850877389e-07
familial O 0 0.006270502228289843
, O 0 4.587356670526788e-06
early O 0 0.0018953876569867134
onset O 1 0.9999997615814209
breast B-Disease 1 0.9999934434890747
and I-Disease 0 0.14717607200145721
/ I-Disease 1 0.9999996423721313
or I-Disease 1 0.9999898672103882
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.3677964691160014e-06
encode O 0 1.1532657708812621e-06
products O 0 6.837811383775261e-07
that O 0 1.0489750223996452e-07
each O 0 4.99027130729246e-08
interact O 0 2.037631645634974e-07
with O 0 7.304039968403231e-07
hRAD51 O 0 0.0001218416218762286
. O 0 1.56789283209946e-05

Results O 0 4.694428207585588e-05
presented O 0 7.516568530263612e-06
here O 0 1.319076886829862e-06
show O 0 4.6884849780326476e-07
that O 0 2.121737594507067e-07
BRCA1 O 0 8.874265404301696e-06
and O 0 6.735166380167357e-07
BRCA2 O 0 7.947286576381885e-06
coexist O 0 4.424261135227425e-07
in O 0 5.35007416146982e-07
a O 0 2.848291615009657e-06
biochemical O 0 0.0003453513199929148
complex O 0 5.336770755093312e-06
and O 0 4.32277033723949e-07
colocalize O 0 3.0117222195258364e-05
in O 0 1.2009289775960497e-06
subnuclear O 0 4.468162660486996e-05
foci O 0 2.147654777218122e-05
in O 0 4.436670337781834e-07
somatic O 0 6.213529559317976e-06
cells O 0 1.5664227248635143e-06
and O 0 1.5859350810387696e-07
on O 0 1.0093607443195651e-06
the O 0 4.115343585908704e-07
axial O 0 1.1121809393443982e-06
elements O 0 3.0372143555723596e-07
of O 0 1.8373019656792167e-06
developing O 0 7.410226771753514e-06
synaptonemal O 0 0.00018439874111209065
complexes O 0 3.8052559830248356e-05
. O 0 1.0499330528546125e-05

Like O 0 7.0522291935049e-05
BRCA1 O 0 0.0006452703382819891
and O 0 2.5843339244602248e-05
RAD51 O 0 0.07488241046667099
, O 0 9.404469892615452e-06
BRCA2 O 0 4.1528724977979437e-05
relocates O 0 1.687519579718355e-05
to O 0 6.481929517576646e-07
PCNA O 0 6.543842027895153e-05
+ O 0 9.524653705739183e-07
replication O 0 4.923758183394966e-07
sites O 0 1.3310713598002621e-07
following O 0 3.2151416462511406e-07
exposure O 0 1.364137688142364e-06
of O 0 3.198896820322261e-06
S O 0 7.364405610132962e-05
phase O 0 4.812369752471568e-06
cells O 0 2.4617474991828203e-06
to O 0 1.3085982573102228e-06
hydroxyurea O 0 8.555853128200397e-05
or O 0 1.2034894098178484e-05
UV O 1 0.9273229837417603
irradiation O 0 0.0005304718506522477
. O 0 1.5040432117530145e-05

Thus O 0 3.936986831831746e-05
, O 0 6.93257425155025e-06
BRCA1 O 0 3.2472678867634386e-05
and O 0 1.1986383015027968e-06
BRCA2 O 0 1.027463804348372e-05
participate O 0 5.374220108933514e-07
, O 0 1.7821253095462453e-07
together O 0 6.995241363938476e-08
, O 0 2.148242970179126e-07
in O 0 4.6399912889683037e-07
a O 0 4.015400918433443e-06
pathway O 0 7.747963536530733e-05
( O 0 1.2832510947191622e-06
s O 0 1.2400185369187966e-05
) O 0 2.733340807026252e-07
associated O 0 3.5562928246690717e-07
with O 0 6.961420240259031e-08
the O 0 8.506612516612222e-07
activation O 0 4.05551008952898e-06
of O 0 5.200265150051564e-06
double O 0 2.1941725208307616e-05
- O 0 1.4208263564796653e-05
strand O 0 1.5525660273851827e-05
break O 0 1.3267917893244885e-06
repair O 0 6.290652436291566e-06
and O 0 9.254061978936079e-07
/ O 0 1.1249518138356507e-05
or O 0 5.54105781702674e-07
homologous O 0 4.39998802903574e-06
recombination O 0 1.0107371053891256e-05
. O 0 7.115223979781149e-06

Dysfunction O 1 0.9940643906593323
of O 0 1.969381992239505e-05
this O 0 2.3856255211285315e-06
pathway O 0 5.699219764210284e-05
may O 0 9.106126981350826e-07
be O 0 9.011324664243148e-08
a O 0 2.4295098910442903e-07
general O 0 3.1210817041937844e-07
phenomenon O 0 2.764339797067805e-07
in O 0 2.321373493430201e-08
the O 0 3.243047430601109e-08
majority O 0 2.0146064372283945e-08
of O 0 1.3332844162050606e-07
cases O 0 1.1523285792236493e-07
of O 0 1.3379313713812735e-05
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9995809197425842
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.8532008551992476e-05
. O 0 2.0014327674289234e-05

A O 0 0.00036975753027945757
novel O 0 0.00013912917347624898
Arg362Ser O 0 0.00033129219082184136
mutation O 0 8.035293831198942e-06
in O 0 2.7658875296765473e-06
the O 0 2.7791156753664836e-06
sterol O 0 4.108655048185028e-05
27 O 0 3.180124986101873e-05
- O 0 2.015345307881944e-05
hydroxylase O 0 2.8581975129782222e-05
gene O 0 3.143520416415413e-06
( O 0 2.1643415948346956e-06
CYP27 O 0 0.0027659577317535877
) O 0 4.4387863340489275e-07
: O 0 9.935227751611819e-08
its O 0 1.080639364658964e-07
effects O 0 1.4641941561421845e-06
on O 0 3.016769824171206e-06
pre O 0 2.485192453605123e-05
- O 0 7.206720511021558e-06
mRNA O 0 4.979383902536938e-06
splicing O 0 1.4456819599217852e-06
and O 0 5.860611622665601e-07
enzyme O 0 4.128734872210771e-06
activity O 0 1.6442369087599218e-05
. O 0 6.868660420877859e-06

A O 0 0.00021793159248773009
novel O 0 6.36009281151928e-05
C O 0 5.5756259826011956e-05
to O 0 6.627080324506096e-07
A O 0 4.4022503971064e-06
mutation O 0 6.525202138618624e-07
in O 0 4.180497228389868e-07
the O 0 9.340012070424564e-07
sterol O 0 1.4739459402335342e-05
27 O 0 1.1342636753397528e-05
- O 0 1.4039614143257495e-05
hydroxylase O 0 1.5914536561467685e-05
gene O 0 9.456221619075222e-07
( O 0 9.027286864693451e-07
CYP27 O 0 0.0004456927126739174
) O 0 2.2817084754933603e-07
was O 0 1.576690806359693e-06
identified O 0 1.1036799918429097e-07
by O 0 1.0272546546730155e-07
sequencing O 0 2.7542873795027845e-06
amplified O 0 3.8380923797376454e-05
CYP27 O 0 0.0014678073348477483
gene O 0 1.4044109093447332e-06
products O 0 6.989332632656442e-07
from O 0 7.681991860408743e-07
a O 0 3.260542825955781e-06
patient O 0 1.1266373803664465e-05
with O 0 6.94533264322672e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999996423721313
( O 0 8.389980939682573e-05
CTX B-Disease 1 0.9965503215789795
) O 0 1.5096992683538701e-05
. O 0 1.5370751498267055e-05

The O 0 5.907036756980233e-05
mutation O 0 4.929188435198739e-05
changed O 0 2.2785063265473582e-05
the O 0 8.458096090180334e-06
adrenodoxin O 0 0.0001667982287472114
cofactor O 0 5.334558227332309e-05
binding O 0 4.618540515366476e-06
residue O 0 1.7163069060188718e-05
362Arg O 0 2.018151462834794e-05
to O 0 1.2549767234304454e-06
362Ser O 0 4.144959166296758e-05
( O 0 3.5409525480645243e-06
CGT O 0 0.0002438916708342731
362Arg O 0 1.3834468518325593e-05
to O 0 8.376119353670219e-07
AGT O 0 0.0003755066136363894
362Ser O 0 1.7864718756754883e-05
) O 0 4.354464806510805e-07
, O 0 1.2067549448602222e-07
and O 0 1.2212804278988187e-07
was O 0 1.2731171409541275e-05
responsible O 0 2.572844550741138e-06
for O 0 2.616196297822171e-06
deficiency O 1 0.9696931838989258
in O 0 1.6560285303057753e-06
the O 0 3.6780768368771533e-06
sterol O 0 7.96644962974824e-05
27 O 0 2.7856491215061396e-05
- O 0 4.4842687202617526e-05
hydroxylase O 0 1.3540558938984759e-05
activity O 0 1.0787874771267525e-06
, O 0 1.0465089417266427e-07
as O 0 8.739975498883723e-08
confirmed O 0 1.7398632223830646e-07
by O 0 6.323496393179084e-08
expression O 0 2.407873864740395e-07
of O 0 7.430816708620114e-07
mutant O 0 4.231823822919978e-06
cDNA O 0 1.0918372026935685e-05
into O 0 4.514345619099913e-06
COS O 0 0.0006360377883538604
- O 0 2.402831887593493e-05
1 O 0 9.643477824283764e-06
cells O 0 2.119614146067761e-05
. O 0 1.0486141036381014e-05

Quantitative O 0 0.0005944872973486781
analysis O 0 2.5635776182753034e-05
showed O 0 9.768323252501432e-06
that O 0 3.7147060538700316e-07
the O 0 6.208016998243693e-07
expression O 0 1.4692213881062344e-06
of O 0 2.4417984150204575e-06
CYP27 O 0 7.803546759532765e-05
gene O 0 6.656978257524315e-07
mRNA O 0 2.1686184936697828e-06
in O 0 3.9281016483982967e-07
the O 0 7.544826985395048e-07
patient O 0 2.2625088149652584e-06
represented O 0 4.404203082231106e-06
52 O 0 7.218698010547087e-05
. O 0 1.3765955372946337e-05

5 O 0 3.1578099878970534e-05
% O 0 5.004816102882614e-06
of O 0 3.6901558360113995e-06
the O 0 4.220341452310095e-06
normal O 0 3.131064659100957e-05
level O 0 5.87384492973797e-05
. O 0 1.4717998055857606e-05

As O 0 2.6334751964895986e-05
the O 0 5.84538429393433e-06
mutation O 0 4.505842753133038e-06
occurred O 0 2.4999251763802022e-05
at O 0 7.751634257147089e-06
the O 0 2.237585476905224e-06
penultimate O 0 1.253360551345395e-05
nucleotide O 0 1.7977148445424973e-06
of O 0 1.9542017071216833e-06
exon O 0 2.9418181384244235e-06
6 O 0 4.818946308660088e-06
( O 0 9.718070259623346e-07
- O 0 3.004355448865681e-06
2 O 0 1.4893154229866923e-06
position O 0 1.5569282822980313e-06
of O 0 8.986589250525867e-07
exon O 0 1.8478239098840277e-06
6 O 0 2.2443732632382307e-06
- O 0 2.561981091275811e-06
intron O 0 6.663547537755221e-06
6 O 0 2.8414572170731844e-06
splice O 0 2.799871026581968e-06
site O 0 6.929585651960224e-07
) O 0 4.764448391370024e-08
of O 0 1.313067059527384e-07
the O 0 1.5989103019364848e-07
gene O 0 2.155293969963168e-07
, O 0 1.0338907685536469e-07
we O 0 3.2417609929780156e-08
hypothesized O 0 4.1302689623989863e-07
that O 0 4.8517236450607015e-08
the O 0 1.456813265576784e-07
mutation O 0 4.776850914822717e-07
may O 0 6.857101766399865e-07
partially O 0 1.3716137345909374e-06
affect O 0 3.5886313298760797e-07
the O 0 3.44054200240862e-07
normal O 0 7.306848033294955e-07
splicing O 0 4.910908728561481e-07
efficiency O 0 4.96761288104608e-07
in O 0 1.5939090758365637e-07
exon O 0 9.5654445431137e-07
6 O 0 6.193021704348212e-07
and O 0 1.1582053360825739e-07
cause O 0 9.978116395359393e-07
alternative O 0 2.762858741789387e-07
splicing O 0 7.853791430534329e-07
elsewhere O 0 1.542690739597674e-07
, O 0 1.8699353176998557e-08
which O 0 1.5142619602670493e-08
resulted O 0 2.879723979276605e-07
in O 0 2.7404482239035133e-07
decreased O 0 2.545159077271819e-05
transcript O 0 6.500322797364788e-06
in O 0 7.615220170009707e-07
the O 0 6.44167857899447e-06
patient O 0 0.0001017585163936019
. O 0 2.422933903289959e-05

Transfection O 0 0.002327683847397566
of O 0 7.585823914268985e-05
constructed O 0 0.00023298741143662483
minigenes O 0 0.0003027519560419023
, O 0 1.5602072380715981e-06
with O 0 3.3200589655280055e-07
or O 0 7.079717079250258e-07
without O 0 4.2865912064371514e-07
the O 0 8.445824164482474e-07
mutation O 0 1.2313208799241693e-06
, O 0 6.053115271242859e-07
into O 0 2.0182485513942083e-06
COS O 0 0.018472298979759216
- O 0 6.120548277976923e-06
1 O 0 1.4723069625688368e-06
cells O 0 4.839255893784866e-07
confirmed O 0 1.463165233417385e-07
that O 0 2.6607267500367016e-08
the O 0 2.1948039830022026e-07
mutant O 0 2.1142691366549116e-06
minigene O 0 1.655573578318581e-05
was O 0 5.346143552742433e-06
responsible O 0 6.499707296825363e-07
for O 0 1.8691119407776569e-07
a O 0 7.105304575816263e-07
mRNA O 0 9.758468877407722e-07
species O 0 5.1473438844595876e-08
alternatively O 0 5.985265261188033e-07
spliced O 0 2.5497449769318337e-06
at O 0 2.647928795340704e-06
an O 0 9.539671737002209e-07
activated O 0 1.0945979738608003e-05
cryptic O 0 8.518029972037766e-06
5 O 0 1.2715634056803538e-06
splice O 0 5.256122221908299e-06
site O 0 3.5523169117368525e-06
88 O 0 6.842450602562167e-06
bp O 0 6.956336619623471e-06
upstream O 0 3.225954287700006e-06
from O 0 5.084155532131263e-07
the O 0 5.051214202467236e-07
3 O 0 1.2032515996907023e-06
end O 0 1.6099573940664413e-06
of O 0 2.444319079586421e-06
exon O 0 1.648215220484417e-05
6 O 0 2.884253626689315e-05
. O 0 1.0942744665953796e-05

Our O 0 2.2200785679160617e-05
data O 0 7.91387356002815e-06
suggest O 0 2.527640390326269e-06
that O 0 5.31851867435762e-07
the O 0 2.681375917745754e-06
C O 0 1.2438488738553133e-05
to O 0 2.144889776900527e-07
A O 0 6.58238695905311e-06
mutation O 0 3.0832131869829027e-06
at O 0 6.902175300638191e-06
the O 0 1.4252273103920743e-06
penultimate O 0 9.387606041855179e-06
nucleotide O 0 8.594319638177694e-07
of O 0 1.2236743032190134e-06
exon O 0 1.0656682434273534e-06
6 O 0 8.722736311028711e-07
of O 0 4.771987960339175e-07
the O 0 7.554863259429112e-07
CYP27 O 0 5.334208253771067e-05
gene O 0 3.1291585855797166e-07
not O 0 9.456512373162695e-08
only O 0 1.713135873160354e-07
causes O 0 6.767101240257034e-06
the O 0 2.7638976462185383e-05
deficiency B-Disease 1 0.9753704071044922
in I-Disease 0 2.585474931038334e-06
the I-Disease 0 3.9449760151910596e-06
sterol I-Disease 0 6.190186104504392e-05
27 I-Disease 0 2.1368108718888834e-05
- I-Disease 0 8.715654075786006e-06
hydroxylase I-Disease 0 5.015394890506286e-06
activity I-Disease 0 1.00878617104172e-06
, O 0 6.12215416140316e-08
but O 0 3.0130664185890055e-08
also O 0 1.9733552392153797e-07
partially O 0 1.5967768831615103e-06
leads O 0 6.557835376952426e-07
to O 0 1.064232648673169e-07
alternative O 0 4.4672566446024575e-07
pre O 0 7.141593869164353e-06
- O 0 2.1754435692855623e-06
mRNA O 0 9.515657097836083e-07
splicing O 0 4.300648299704335e-07
of O 0 9.164620564661163e-07
the O 0 2.686686912056757e-06
gene O 0 1.1852087482111529e-05
. O 0 1.3916749594500288e-05

To O 0 6.721435966028366e-06
our O 0 2.2961119157116627e-06
knowledge O 0 2.7096368739876198e-06
, O 0 4.06738280389618e-07
this O 0 1.6997732643631025e-07
is O 0 9.649722443327846e-08
the O 0 2.0348353757526638e-07
first O 0 8.796827160040266e-07
report O 0 9.010428243527713e-07
regarding O 0 4.652047778108681e-07
effects O 0 3.4483543913665926e-06
on O 0 2.6331319986638846e-06
pre O 0 1.7266675058635883e-05
- O 0 3.0347007395903347e-06
mRNA O 0 1.3168898931326112e-06
splicing O 0 5.532656928153301e-07
of O 0 6.083370180931524e-07
a O 0 1.15454326987674e-06
mutation O 0 1.0534678267504205e-06
at O 0 3.954898147640051e-06
the O 0 1.4461134014709387e-06
- O 0 2.8651636512222467e-06
2 O 0 8.673860634189623e-07
position O 0 9.708168136057793e-07
of O 0 6.712709819112206e-07
a O 0 2.291161763423588e-06
5 O 0 4.099450507055735e-06
splice O 0 3.559835386113264e-05
site O 0 1.4447210560319945e-05
. O 0 1.3157062312529888e-05

ATM O 0 0.009717222303152084
germline O 0 0.0021291004959493876
mutations O 0 4.0100348996929824e-05
in O 0 9.101472642214503e-06
classical O 0 0.082220159471035
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.04995189979672432
in O 0 3.4078741464327322e-06
the O 0 4.6550749175366946e-06
Dutch O 0 4.193624772597104e-05
population O 0 2.257691676277318e-06
. O 0 5.486353984451853e-06

Germline O 0 0.0027688026893883944
mutations O 0 3.5023855161853135e-05
in O 0 3.0820312986179488e-06
the O 0 1.895953118946636e-06
ATM O 0 4.846575393457897e-05
gene O 0 8.189838354155654e-07
are O 0 2.6548363507572503e-08
responsible O 0 2.4452651814499404e-07
for O 0 3.103853885022545e-07
the O 0 0.0004124338738620281
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.573087739525363e-05
. O 0 2.7316722480463795e-05

In O 0 1.4041207577975001e-05
our O 0 1.0109079084941186e-06
study O 0 6.866538342364947e-07
, O 0 2.3903754708953784e-07
we O 0 4.070486525620254e-08
have O 0 4.77726089798125e-08
determined O 0 1.6200365848817455e-07
the O 0 2.869090565127408e-07
ATM O 0 9.14347492653178e-06
mutation O 0 5.86998055496224e-07
spectrum O 0 7.16539091172308e-07
in O 0 4.96932784699311e-07
19 O 0 4.291456662031123e-06
classical O 0 3.556381489033811e-05
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999996423721313
T I-Disease 1 0.9999998807907104
patients O 0 1.0599325150906225e-06
, O 0 5.999219609975626e-08
including O 0 3.7755576443032624e-08
some O 0 1.1366201313478541e-08
immigrant O 0 1.4664550462839543e-07
populations O 0 3.265753178993691e-08
, O 0 3.6475288567316966e-08
as O 0 6.659836060407542e-08
well O 0 6.553933928898914e-08
as O 0 8.035856069454894e-08
12 O 0 2.615288110519032e-07
of O 0 3.2164604135687114e-07
Dutch O 0 2.5211286356352502e-06
ethnic O 0 3.486623256776511e-07
origin O 0 3.1529236821370432e-06
. O 0 9.26939355849754e-06

Both O 0 2.294787009304855e-05
the O 0 1.0128106623596977e-05
protein O 0 1.573618283146061e-05
truncation O 0 0.0001958979555638507
test O 0 9.047419553098734e-06
( O 0 1.3728058547712862e-06
PTT O 0 5.9965590480715036e-05
) O 0 4.6037291667744284e-07
and O 0 1.5066741809732775e-07
the O 0 4.658902525989106e-07
restriction O 0 1.977332885871874e-06
endonuclease O 0 1.4113757970335428e-05
fingerprinting O 0 3.415240144022391e-06
( O 0 4.830766897612193e-07
REF O 0 2.5432766051380895e-05
) O 0 5.240593381472536e-08
method O 0 7.672914392742314e-08
were O 0 5.675160963392045e-08
used O 0 6.165394950130576e-08
and O 0 8.165967813056341e-08
compared O 0 2.86575726704541e-07
for O 0 2.606716620334737e-08
their O 0 3.0383901616914955e-08
detection O 0 1.4898155313858297e-06
efficiency O 0 8.48177535317518e-07
, O 0 5.892213650326994e-08
identifying O 0 1.4213640042726183e-07
76 O 0 1.0385368796050898e-06
% O 0 1.077262368198717e-07
and O 0 1.2424237638697377e-07
60 O 0 3.011728324509022e-07
% O 0 1.5519370322181203e-07
of O 0 6.353091066557681e-07
the O 0 1.3515392538465676e-06
mutations O 0 1.8007571043199277e-06
, O 0 2.660488917172188e-06
respectively O 0 2.6186167815467343e-05
. O 0 1.547807187307626e-05

Most O 0 1.3557330930780154e-05
patients O 0 6.6987890932068694e-06
were O 0 2.8291597118368372e-06
found O 0 1.8460063984093722e-06
to O 0 6.836481247773918e-07
be O 0 5.623415290756384e-06
compound O 0 0.0003679869987536222
heterozygote O 0 0.0003768650349229574
. O 0 2.4561975806136616e-05

Seventeen O 0 5.5187338148243725e-05
mutations O 0 6.333234523481224e-06
were O 0 1.187302359539899e-06
distinct O 0 5.201209773986193e-07
, O 0 2.4045556301643956e-07
of O 0 3.3869719118229114e-07
which O 0 1.5708732803432213e-07
10 O 0 3.0919298410481133e-07
were O 0 2.617373979774129e-07
not O 0 2.6043767320516054e-07
reported O 0 4.725234703073511e-06
previously O 0 1.4785003259021323e-05
. O 0 1.0220272997685242e-05

Mutations O 0 7.744721369817853e-05
are O 0 1.1697379704855848e-06
small O 0 1.0087468353958684e-06
deletions O 0 8.397943929594476e-06
or O 0 1.0456983545736875e-06
point O 0 3.4585802950459765e-06
mutations O 0 1.3711860447074287e-06
frequently O 0 7.167345188463514e-07
affecting O 0 3.0635023904324044e-06
splice O 0 2.257683445350267e-05
sites O 0 4.677690867538331e-06
. O 0 7.2179382186732255e-06

Moreover O 0 0.00028218093211762607
, O 0 2.6629575586412102e-05
a O 0 3.9879578253021464e-05
16 O 0 0.00011931038898183033
. O 0 6.9114648795221e-05

7 O 0 0.0005391077138483524
- O 0 0.0002893718483392149
kb O 0 0.0001741737505653873
genomic O 0 3.888881110469811e-05
deletion O 0 1.499584595876513e-05
of O 0 2.9213001653261017e-06
the O 0 1.235713511960057e-06
3 O 0 1.2548773611342767e-06
end O 0 6.21322897131904e-07
of O 0 2.631959432619624e-07
the O 0 3.2992682008625707e-07
gene O 0 3.0289186270238133e-07
, O 0 1.7815423802858277e-07
most O 0 4.245103468747402e-08
likely O 0 1.5367832872925646e-07
a O 0 2.820528663960431e-07
result O 0 1.597145597997951e-07
of O 0 2.1815277762016194e-07
recombination O 0 1.1497753860112425e-07
between O 0 1.1297851898461886e-07
two O 0 1.2521536518761422e-07
LINE O 0 5.838158813276095e-06
elements O 0 4.0872254203350167e-07
, O 0 3.1891869411992957e-07
was O 0 2.1274190658004954e-05
identified O 0 7.263415682245977e-06
. O 0 6.045746431482257e-06

The O 0 2.91917549475329e-05
most O 0 1.3910027973906836e-06
frequently O 0 6.620750241381756e-07
found O 0 4.775079105456825e-07
mutation O 0 1.3159884701963165e-06
, O 0 3.925790963421605e-07
identified O 0 3.73307358358943e-07
in O 0 2.596178205749311e-07
three O 0 4.1327669464408245e-07
unrelated O 0 3.895008831023006e-06
Turkish O 0 0.00015801678819116205
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999855756759644
T I-Disease 1 0.9999510049819946
individuals O 0 1.310177566438142e-07
, O 0 2.3036120921915426e-07
was O 0 4.023577275802381e-06
previously O 0 3.8581109151891724e-07
described O 0 2.0427995650607045e-07
to O 0 2.5718893681414556e-08
be O 0 9.254612365339199e-08
a O 0 1.742654148984002e-06
Turkish O 0 3.848281266982667e-05
A B-Disease 1 0.9999963045120239
- I-Disease 1 0.9999719858169556
T I-Disease 1 0.9999954700469971
founder O 0 0.0002594974939711392
mutation O 0 1.5803330825292505e-05
. O 0 9.046264494827483e-06

The O 0 2.088710607495159e-05
presence O 0 4.805944627150893e-06
of O 0 2.5608233045204543e-06
a O 0 6.287395535764517e-06
founder O 0 2.12817558349343e-05
mutation O 0 3.96417675574412e-07
among O 0 3.938544423931489e-08
relatively O 0 3.944091986340936e-08
small O 0 9.353827934432957e-09
ethnic O 0 4.727630287248985e-09
population O 0 1.614064792931913e-08
groups O 0 1.1231188423721505e-08
in O 0 6.794039819624231e-08
Western O 0 2.3757849021421862e-07
Europe O 0 1.5696274147103395e-07
could O 0 8.843859689022793e-08
indicate O 0 2.820001441250497e-07
a O 0 3.3004766919475514e-07
high O 0 2.4994508294184925e-06
carrier O 0 3.4207221233373275e-07
frequency O 0 3.5226761951889785e-07
in O 0 7.458137218918637e-08
such O 0 1.2851280928316555e-07
communities O 0 4.972708325112762e-07
. O 0 7.2369475674349815e-06

In O 0 3.697503052535467e-05
patients O 0 5.14281828145613e-06
of O 0 1.296697178077011e-06
Dutch O 0 2.683719230844872e-06
ethnic O 0 1.2398386672884953e-07
origin O 0 1.6506503186519694e-07
, O 0 8.594371081471763e-08
however O 0 4.32003766093203e-08
, O 0 2.708540947082838e-08
no O 0 5.299809657799415e-08
significant O 0 2.05651176088395e-07
founder O 0 5.579152912105201e-06
effect O 0 7.443313165822474e-07
could O 0 4.3605984956229804e-07
be O 0 6.836201009718934e-07
identified O 0 5.669411621056497e-06
. O 0 7.0627561399305705e-06

The O 0 1.2526507816801313e-05
observed O 0 6.1910468502901495e-06
genetic O 0 4.199187515041558e-06
heterogeneity O 0 2.034039789577946e-05
including O 0 6.16219779203675e-07
the O 0 1.0429844223835971e-06
relative O 0 4.752622317027999e-06
high O 0 1.9928773326682858e-05
percentage O 0 2.143193796655396e-06
of O 0 2.0851980480074417e-06
splice O 0 4.062354128109291e-05
- O 0 6.1758623814966995e-06
site O 0 5.800431495117664e-07
mutations O 0 1.7058597734376235e-07
had O 0 9.37501170028554e-07
no O 0 3.5464643133309437e-07
reflection O 0 3.5508132896211464e-06
on O 0 4.265079041942954e-06
the O 0 7.321193606912857e-06
phenotype O 0 0.00022917892783880234
. O 0 2.632435644045472e-05

All O 0 8.192813766072504e-06
patients O 0 4.9830464377009775e-06
manifested O 0 1.4483960512734484e-05
classical O 0 0.0001618813257664442
A B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999443292617798
T I-Disease 1 0.999420166015625
and O 0 3.3220985073967313e-07
increased O 0 6.584295533684781e-06
cellular O 0 7.56422450649552e-05
radioresistant O 0 0.00010810510866576806
DNA O 0 1.6937397958827205e-05
synthesis O 0 0.00017305617802776396
. O 0 2.1398245735326782e-05

Determination O 0 5.469630195875652e-05
of O 0 1.0511123036849312e-05
the O 0 3.532250502757961e-06
genomic O 0 1.809587593015749e-05
structure O 0 3.158304934913758e-06
of O 0 1.7224142538907472e-06
the O 0 2.177118403778877e-06
COL4A4 O 0 0.006265651900321245
gene O 0 8.844160674925661e-07
and O 0 1.7833052368132485e-07
of O 0 1.512021526650642e-06
novel O 0 2.554399543441832e-05
mutations O 0 0.0003589865518733859
causing O 1 0.7277860641479492
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9840499758720398

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.0013859596801921725
a O 0 0.0026326628867536783
progressive O 1 0.9997850060462952
hematuric B-Disease 1 0.9999996423721313
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9995152950286865
by O 0 0.002151347231119871
glomerular B-Disease 1 1.0
basement I-Disease 1 0.9999995231628418
membrane I-Disease 1 0.9999767541885376
abnormalities I-Disease 1 0.9999998807907104
and O 0 4.874211299465969e-06
associated O 0 2.7226401471125428e-06
with O 0 1.1631887275598274e-07
mutations O 0 9.333680850431847e-07
in O 0 1.7471571709393174e-06
either O 0 5.337125230653328e-07
the O 0 4.259583420207491e-06
COL4A3 O 0 0.35203811526298523
or O 0 8.026539717320702e-07
the O 0 3.1313725230575074e-06
COL4A4 O 0 0.0004200377152301371
gene O 0 5.603204726867261e-07
, O 0 1.8223418862817198e-07
which O 0 9.110559062719403e-08
encode O 0 3.0706314646522515e-07
the O 0 2.102105327139725e-06
alpha3 O 0 0.00010413106792839244
and O 0 1.6310150385834277e-06
alpha4 O 0 0.05173330381512642
type O 0 0.3793300688266754
IV O 1 1.0
collagen O 1 0.9999942779541016
chains O 0 0.0003621609939727932
, O 0 4.407930191518972e-06
respectively O 0 1.866925595095381e-05
. O 0 1.3218435924500227e-05

To O 0 7.250142061820952e-06
date O 0 6.745329301338643e-06
, O 0 3.5640067608255777e-07
mutation O 0 3.6813543147218297e-07
screening O 0 3.326349826693331e-07
in O 0 1.0028824704022554e-07
the O 0 8.401946161029628e-08
two O 0 2.151157652008351e-08
genes O 0 8.150826857900029e-08
has O 0 1.677133809607767e-07
been O 0 4.303795151372469e-07
hampered O 0 7.974801519594621e-06
by O 0 6.627762871858067e-08
the O 0 1.3596707049146062e-07
lack O 0 3.797981094066927e-07
of O 0 1.2678652865361073e-06
genomic O 0 3.438109706621617e-05
structure O 0 1.398285439790925e-05
information O 0 4.991365130990744e-06
. O 0 1.9550852812244557e-05

We O 0 3.912535248673521e-05
report O 0 1.0711045433708932e-05
here O 0 1.1136603461636696e-06
the O 0 4.952235030941665e-07
complete O 0 1.2064218708474073e-06
characterization O 0 4.095691110705957e-06
of O 0 1.5262686474670772e-06
the O 0 1.2141354090999812e-06
48 O 0 1.539508843961812e-06
exons O 0 1.2311364798733848e-06
of O 0 1.038497202898725e-06
the O 0 1.976433622985496e-06
COL4A4 O 0 0.0002290572301717475
gene O 0 2.477933378486341e-07
, O 0 5.485624754442142e-08
a O 0 1.4220812261100946e-07
comprehensive O 0 2.934315546099242e-07
gene O 0 2.977799624659383e-07
screen O 0 5.61298179491132e-07
, O 0 6.04624830202738e-08
and O 0 3.68009338558295e-08
the O 0 8.369286064180415e-08
subsequent O 0 2.5445680762459233e-07
detection O 0 5.908909770369064e-07
of O 0 4.07688986570065e-07
10 O 0 3.1183623150354833e-07
novel O 0 3.271420894179755e-07
mutations O 0 3.007862119375204e-07
in O 0 4.5208113874650735e-07
eight O 0 6.394981937773991e-06
patients O 0 0.000581097265239805
diagnosed O 1 0.9998992681503296
with O 0 2.982460500788875e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9965092539787292

Furthermore O 0 6.026747723808512e-05
, O 0 3.741182126759668e-06
we O 0 5.988484872432309e-07
identified O 0 1.0719512602008763e-06
a O 0 2.252869535368518e-06
glycine O 0 4.562583399092546e-06
to O 0 4.2909388753287203e-07
alanine O 0 3.173261120537063e-06
substitution O 0 2.280634589624242e-06
in O 0 5.606935928881285e-07
the O 0 1.1049086197090219e-06
collagenous O 0 4.838470704271458e-05
domain O 0 6.69955397825106e-07
that O 0 8.465776346611165e-08
is O 0 1.657603831972665e-07
apparently O 0 3.9312197941399063e-07
silent O 0 1.3041779993727687e-06
in O 0 1.5021461763353727e-07
the O 0 3.977760627549287e-07
heterozygous O 0 4.830868078897765e-07
carriers O 0 3.9536092799608014e-07
, O 0 3.2886694611988787e-07
in O 0 1.146437284660351e-06
11 O 0 1.7228283468284644e-05
. O 0 1.136419359681895e-05

5 O 0 3.335474684718065e-05
% O 0 2.901041852965136e-06
of O 0 9.80938693828648e-07
all O 0 1.3155765543615416e-07
control O 0 8.786371950009197e-07
individuals O 0 5.3915414355287794e-08
, O 0 1.0548214390837529e-07
and O 0 6.768456017880453e-08
in O 0 1.5717094470346638e-07
one O 0 8.045778798759784e-08
control O 0 2.498197204658936e-07
individual O 0 3.662776038027005e-08
homozygous O 0 6.24378401425929e-07
for O 0 2.7196770702175854e-07
this O 0 7.640652484042221e-07
glycine O 0 1.153868197434349e-05
substitution O 0 2.5780840587685816e-05
. O 0 8.930177500587888e-06

There O 0 1.7676407878752798e-05
has O 0 1.4584135215045535e-06
been O 0 1.047687760546978e-06
no O 0 2.5080512955355516e-07
previous O 0 3.7344909742387244e-07
finding O 0 1.35452353333676e-07
of O 0 2.4652615593367955e-07
a O 0 1.040744905367319e-06
glycine O 0 1.7595206145415432e-06
substitution O 0 1.15351986096357e-06
that O 0 6.405642949403045e-08
is O 0 1.3649180630181945e-07
not O 0 6.689843701224163e-08
associated O 0 2.2032261881577142e-07
with O 0 4.5795399472581266e-08
any O 0 3.732098434738873e-07
obvious O 0 5.456788130686618e-06
phenotype O 0 3.432670928305015e-05
in O 0 1.4473289411398582e-06
homozygous O 0 1.0691317584132776e-05
individuals O 0 1.743003281262645e-06
. O 0 1.0238486538582947e-05

Founder O 0 0.0021573049016296864
BRCA1 O 0 0.00013457391469273716
and O 0 2.670682533789659e-06
BRCA2 O 0 3.6300374631537125e-05
mutations O 0 3.7419883938127896e-06
in O 0 1.7536140148877166e-06
French O 0 0.007542874198406935
Canadian O 1 0.9749161005020142
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9999836683273315
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.90016560535878e-05
. O 0 8.122190774884075e-05

We O 0 1.0597602340567391e-05
have O 0 8.047571782299201e-07
identified O 0 7.816229299351107e-07
four O 0 2.0512192122623674e-07
mutations O 0 2.391697933035175e-07
in O 0 1.3430036460704287e-07
each O 0 3.876595400242877e-08
of O 0 1.5477246506634401e-06
the O 0 3.672727689263411e-05
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 1.0
- O 1 0.9996053576469421
susceptibility O 1 0.8177564144134521
genes O 0 2.1641558305418584e-06
, O 0 5.848032742505893e-07
BRCA1 O 0 1.2235680515004788e-05
and O 0 4.7107647560551413e-07
BRCA2 O 0 1.0560334885667544e-05
, O 0 2.3490467526698922e-07
in O 0 2.778294572181039e-07
French O 0 0.00030629741377197206
Canadian O 1 0.77689129114151
breast B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999998807907104
and O 1 0.9161176681518555
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.998157692170935e-06
from O 0 2.131151268258691e-05
Quebec O 0 0.00018712015298660845
. O 0 2.7994332413072698e-05

To O 0 9.603096259525046e-06
identify O 0 3.910484792868374e-06
founder O 0 0.00013461049820762128
effects O 0 1.801965663617011e-05
, O 0 4.253326153502712e-07
we O 0 5.6107023027607283e-08
examined O 0 4.6686920995853143e-07
independently O 0 9.727261129910403e-08
ascertained O 0 3.007678060384933e-06
French O 0 2.3549337129225023e-05
Canadian O 0 0.0001154311394202523
cancer B-Disease 0 0.0007407399825751781
families O 0 4.0626293440482186e-08
for O 0 2.7592871987280887e-08
the O 0 1.2300716889512842e-07
distribution O 0 1.017215396359461e-07
of O 0 4.4095222051510063e-07
these O 0 1.0465927857694624e-07
eight O 0 1.7659323248153669e-06
mutations O 0 6.027881681802683e-06
. O 0 2.0693674741778523e-05

Mutations O 0 4.061959043610841e-05
were O 0 6.56587872072123e-06
found O 0 1.8253090274811257e-06
in O 0 7.155878165576723e-07
41 O 0 5.48521893506404e-06
of O 0 5.40420751349302e-06
97 O 0 5.4613956308458e-05
families O 0 3.030880179721862e-06
. O 0 2.178040631406475e-05

Six O 0 1.7568063412909396e-05
of O 0 2.8382019081618637e-06
eight O 0 7.303831353056012e-07
mutations O 0 5.57188229777239e-07
were O 0 8.61042394717515e-07
observed O 0 1.6879000668268418e-06
at O 0 2.1701287096220767e-06
least O 0 5.448932824947406e-07
twice O 0 5.403903287515277e-06
. O 0 4.8383421926700976e-06

The O 0 0.00010604036651784554
BRCA1 O 0 0.0014752334682270885
C4446T O 0 0.0015832387143746018
mutation O 0 1.6284197045024484e-05
was O 0 2.4489914721925743e-05
the O 0 3.032525626167626e-07
most O 0 5.2636938363548325e-08
common O 0 7.426623227502205e-08
mutation O 0 4.7103827682803967e-07
found O 0 2.1763825941434334e-07
, O 0 1.1761415663613661e-07
followed O 0 5.624276582238963e-07
by O 0 1.3474887339270936e-07
the O 0 1.1185225048393477e-06
BRCA2 O 0 4.955894473823719e-05
8765delAG O 0 0.00012360679102130234
mutation O 0 6.358262180583552e-05
. O 0 3.2246567570837215e-05

Together O 0 6.687619134027045e-06
, O 0 1.3198445003581583e-06
these O 0 7.82974254320834e-08
mutations O 0 4.1496147673569794e-07
were O 0 3.0258581773523474e-07
found O 0 1.515559944209599e-07
in O 0 2.0366719866160565e-07
28 O 0 1.053591404343024e-06
of O 0 6.234620855138928e-07
41 O 0 2.4231403585872613e-06
families O 0 6.010363762243287e-08
identified O 0 2.810577655054658e-07
to O 0 9.969776471052683e-08
have O 0 4.204025572107639e-07
a O 0 7.810745955794118e-06
mutation O 0 2.7278350898995996e-05
. O 0 1.6768386558396742e-05

The O 0 3.393514998606406e-05
odds O 0 1.688936390564777e-05
of O 0 2.1235362055449514e-06
detection O 0 3.138727606710745e-06
of O 0 9.070192277249589e-07
any O 0 2.8420649300642253e-07
of O 0 1.0958888196910266e-06
the O 0 8.089276661848999e-07
four O 0 6.142161055322504e-07
BRCA1 O 0 1.024293032969581e-05
mutations O 0 6.912088792887516e-06
was O 0 0.007186673581600189
18 O 0 7.136195927159861e-05
. O 0 1.8364458810538054e-05

7x O 0 0.008865872398018837
greater O 0 1.3245957234175876e-05
if O 0 6.262109764065826e-07
one O 0 2.782712158477807e-07
or O 0 1.044072703848542e-07
more O 0 3.224974065574315e-08
cases O 0 1.8089708930801862e-07
of O 0 0.01027267798781395
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 3.000767537741922e-05
also O 0 7.113997071428457e-07
present O 0 2.624417732022266e-07
in O 0 6.320969418993627e-07
the O 0 2.8348151772661367e-06
family O 0 6.596375442313729e-06
. O 0 1.4293488675320987e-05

The O 0 2.7349804440746084e-05
odds O 0 1.399899792886572e-05
of O 0 1.8205943206339725e-06
detection O 0 3.531869879225269e-06
of O 0 1.3724013570026727e-06
any O 0 2.4055464109551394e-07
of O 0 1.3203392654759227e-06
the O 0 7.793653935550537e-07
four O 0 5.267375513540173e-07
BRCA2 O 0 8.30134013085626e-06
mutations O 0 3.855550403386587e-06
was O 0 0.0012395390076562762
5 O 0 3.278429721831344e-05
. O 0 1.3426335499389097e-05

3x O 0 0.000942125276196748
greater O 0 1.1938893294427544e-05
if O 0 4.337757388839236e-07
there O 0 2.5437213935219916e-07
were O 0 2.471777804657904e-07
at O 0 3.022138059805002e-07
least O 0 2.3603416110518083e-08
five O 0 3.2130134997032656e-08
cases O 0 1.2236236557328084e-07
of O 0 1.5298743164748885e-05
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999953508377075
in O 0 1.2159523976151831e-05
the O 0 1.1300753612886183e-05
family O 0 1.0107804882864002e-05
. O 0 1.5814908692846075e-05

Interestingly O 0 0.00011708468809956685
, O 0 2.2556127987627406e-06
the O 0 4.2846087922043807e-07
presence O 0 3.7326071833376773e-07
of O 0 1.9433480247244006e-06
a O 0 9.833936201175675e-05
breast B-Disease 1 0.9999927282333374
cancer I-Disease 1 0.9998340606689453
case O 0 3.290548193035647e-05
< O 0 0.00010505013779038563
36 O 0 1.9809795048786327e-06
years O 0 2.4761334316281136e-07
of O 0 3.5861884839505365e-07
age O 0 4.567332041460759e-07
was O 0 2.7434657567937393e-06
strongly O 0 1.5404634723381605e-07
predictive O 0 7.387093887700757e-07
of O 0 2.578570388322987e-07
the O 0 1.6026352511744335e-07
presence O 0 1.4839632456187246e-07
of O 0 3.3336760907332064e-07
any O 0 1.2978536290120246e-07
of O 0 7.27872873085289e-07
the O 0 7.636558052581677e-07
eight O 0 8.785081604401057e-07
mutations O 0 3.4458064419595757e-06
screened O 0 3.631294021033682e-05
. O 0 1.2168640751042403e-05

Carriers O 0 4.463350705918856e-05
of O 0 5.647427315125242e-06
the O 0 1.7641817748881294e-06
same O 0 4.6384383267650264e-07
mutation O 0 7.184344212873839e-07
, O 0 1.6614559683603147e-07
from O 0 1.0618441592669114e-07
different O 0 5.727900820318155e-09
families O 0 2.043352154146305e-08
, O 0 2.99820754889879e-08
shared O 0 6.460785328954444e-08
similar O 0 1.1666737975701835e-07
haplotypes O 0 2.9300613277882803e-06
, O 0 1.6800376556602714e-07
indicating O 0 9.163606478068687e-07
that O 0 2.950970134918407e-08
the O 0 1.4456774977134046e-07
mutant O 0 5.544408736568585e-07
alleles O 0 1.647651117764326e-07
were O 0 2.0353012075702281e-07
likely O 0 1.0988467380457223e-07
to O 0 2.5041501316991344e-08
be O 0 4.6808942499865225e-08
identical O 0 4.9599435669733793e-08
by O 0 9.343987272814047e-08
descent O 0 1.620608145458391e-06
for O 0 6.094716553661783e-08
a O 0 3.3354635320392845e-07
mutation O 0 3.1524677979177795e-07
in O 0 3.021769146016595e-07
the O 0 1.587679889780702e-06
founder O 0 2.3419310309691355e-05
population O 0 1.3451048062051996e-06
. O 0 7.3027349571930245e-06

The O 0 1.1089401596109383e-05
identification O 0 2.818146185745718e-06
of O 0 2.814904064507573e-06
common O 0 1.5245287841025856e-06
BRCA1 O 0 8.641999738756567e-05
and O 0 1.6012862715797382e-06
BRCA2 O 0 1.3479270819516387e-05
mutations O 0 5.58320664367784e-07
will O 0 5.883061504619036e-08
facilitate O 0 2.652640205269563e-07
carrier O 0 8.255528882727958e-07
detection O 0 8.277681899926392e-07
in O 0 1.3214447847076372e-07
French O 0 2.3909913579700515e-05
Canadian O 0 0.052581362426280975
breast B-Disease 1 0.9999977350234985
cancer I-Disease 1 0.9999991655349731
and O 0 0.4706099033355713
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.76914569339715e-05
. O 0 6.547357043018565e-05

Are O 0 4.017832179670222e-05
Dp71 O 0 0.004527286626398563
and O 0 3.545856452547014e-05
Dp140 O 1 0.9936284422874451
brain O 1 0.9770286679267883
dystrophin O 0 0.0003521368489600718
isoforms O 0 8.046827133512124e-06
related O 0 3.859615389956161e-06
to O 0 1.3157800822227728e-06
cognitive B-Disease 1 0.9994654059410095
impairment I-Disease 1 0.9999997615814209
in O 1 0.9860355854034424
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 0.00743056321516633

Molecular O 0 0.0010328872594982386
study O 0 1.1834919860120863e-05
and O 0 1.230362954629527e-06
neuropsychological O 0 3.4319837141083553e-05
analysis O 0 7.842474474273331e-07
were O 0 4.2508318642831e-07
performed O 0 7.972542448442255e-07
concurrently O 0 1.597893515281612e-06
on O 0 3.569623004295863e-06
49 O 0 2.8584510801010765e-05
patients O 0 7.521014595113229e-06
with O 0 8.411626913584769e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0002495147637091577
DMD B-Disease 1 1.0
) O 0 1.1110280695447727e-07
in O 0 2.0167441050489288e-08
order O 0 1.3792035957749249e-08
to O 0 9.465098926852988e-09
find O 0 2.5114397672609812e-08
a O 0 3.0206683732103556e-07
molecular O 0 3.7550296383415116e-06
explanation O 0 4.214623459120048e-07
for O 0 1.1889891027294652e-07
the O 0 1.578690216774703e-06
cognitive B-Disease 0 0.01577969454228878
impairment I-Disease 0 0.018032969906926155
observed O 0 1.9649567093438236e-06
in O 0 2.405159420959535e-06
most O 0 9.566416338202544e-06
DMD B-Disease 1 1.0
patients O 0 0.00010708711488405243
. O 0 3.6474499211180955e-05

Complete O 0 5.217926445766352e-05
analysis O 0 7.69737107475521e-06
of O 0 4.861969046032755e-06
the O 0 2.335974386369344e-06
dystrophin O 0 2.3675867851125076e-05
gene O 0 1.539121285532019e-06
was O 0 1.1525363333930727e-05
performed O 0 7.918462756606459e-07
to O 0 1.0284309581720663e-07
define O 0 3.2210922995545843e-07
the O 0 9.48970182435005e-07
localization O 0 1.0708296940720174e-05
of O 0 4.600924512487836e-07
deletions O 0 1.2355908438621555e-06
and O 0 1.5491615101836942e-07
duplications O 0 3.227988372600521e-06
in O 0 4.963658852830122e-07
relation O 0 1.2302668892516522e-06
to O 0 1.7163492316285556e-07
the O 0 3.966955773648806e-06
different O 0 1.6457319134133286e-06
DMD B-Disease 1 0.9999998807907104
promoters O 0 0.00046194411697797477
. O 0 4.4495387555798516e-05

Qualitative O 0 0.0006414771778509021
analysis O 0 5.794918251922354e-05
of O 0 9.598526958143339e-06
the O 0 5.323828645487083e-06
Dp71 O 0 0.00015469550271518528
transcript O 0 1.786093707778491e-05
and O 0 5.097443249724165e-07
testing O 0 4.788331011695846e-07
for O 0 7.616064578996884e-08
the O 0 9.789035715357386e-08
specific O 0 4.5277410265498474e-08
first O 0 5.543113843486935e-07
exon O 0 1.2280067949177464e-06
of O 0 1.2326979685894912e-06
Dp140 O 0 3.2127041777130216e-05
were O 0 1.1471088328107726e-06
also O 0 6.466894433287962e-07
carried O 0 3.1157007924775826e-06
out O 0 4.575480943458388e-06
. O 0 1.4648599062638823e-05

Neuropsychological O 0 0.0024923826567828655
analysis O 0 2.9350921977311373e-05
assessed O 0 2.1245217794785276e-05
verbal O 0 4.068208363605663e-05
and O 0 6.1683804233325645e-06
visuospatial O 0 0.10099982470273972
intelligence O 0 3.93568079744e-05
, O 0 1.8467512745701242e-06
verbal O 0 7.999756053322926e-05
memory O 0 0.48355457186698914
, O 0 4.402082595333923e-06
and O 0 3.261721531089279e-06
reading O 0 0.0005698823952116072
skills O 0 9.373356442665681e-05
. O 0 2.1063009626232088e-05

Comparison O 0 5.153688107384369e-05
of O 0 1.1561131032067351e-05
molecular O 0 5.0022455980069935e-05
and O 0 1.7209529232786736e-06
psychometric O 0 0.0002138235286111012
findings O 0 2.593755652924301e-06
demonstrated O 0 1.5466459899471374e-06
that O 0 1.260374915545981e-07
deletions O 0 1.1722664794433513e-06
and O 0 1.7329743684513232e-07
duplications O 0 3.1175022741081193e-06
that O 0 1.3418949151855486e-07
were O 0 6.531029725920234e-07
localized O 0 2.8554525215440663e-06
in O 0 5.9380982975199e-07
the O 0 7.367928560597647e-07
distal O 0 6.780150215490721e-06
part O 0 1.7918935668603808e-07
of O 0 3.466194016255031e-07
the O 0 3.1499374131271907e-07
gene O 0 3.4063364751091285e-07
seemed O 0 3.087206721374969e-07
to O 0 3.301357409668526e-08
be O 0 2.4116243935168313e-07
preferentially O 0 1.6071120398919447e-06
associated O 0 1.6089921928141848e-06
with O 0 2.3131010493671056e-06
cognitive B-Disease 1 0.9997261166572571
impairment I-Disease 1 0.9999904632568359
. O 0 6.764814315829426e-05

Two O 0 4.894517405773513e-05
altered O 0 7.68188401707448e-05
Dp71 O 0 0.00030879612313583493
transcripts O 0 2.9070906748529524e-05
and O 0 6.776082841497555e-07
two O 0 5.461580485643935e-07
deleted O 0 4.054179953527637e-06
Dp140 O 0 1.8140144675271586e-05
DNA O 0 1.133446289713902e-06
sequences O 0 3.819801293047931e-07
were O 0 2.521063322546979e-07
found O 0 1.8078465302551194e-07
in O 0 2.753667729393783e-07
four O 0 9.4147924301069e-07
patients O 0 5.3533985919784755e-06
with O 0 2.1583602574537508e-05
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.0030791936442255974

These O 0 7.3758837970672175e-06
findings O 0 1.02051180874696e-05
suggest O 0 1.5863282669670298e-06
that O 0 1.1240494046660388e-07
some O 0 1.0274310824343047e-07
sequences O 0 3.8036176874811645e-07
located O 0 1.500781650065619e-06
in O 0 5.137506491337263e-07
the O 0 9.92104219221801e-07
distal O 0 4.287885531084612e-06
part O 0 4.893494178759283e-07
of O 0 7.71176416947128e-07
the O 0 5.210046083448105e-07
gene O 0 2.7813777592200495e-07
and O 0 1.6850471240559273e-07
, O 0 1.5025702282400744e-07
in O 0 1.6211153308631765e-07
particular O 0 2.688294387098722e-07
, O 0 2.2203981586699229e-07
some O 0 1.7782272720978654e-07
DMD B-Disease 1 0.9999790191650391
isoforms O 0 5.42691907412518e-07
expressed O 0 2.5768767386580294e-07
in O 0 4.2763915075738623e-07
the O 0 2.309992623850121e-06
brain O 0 0.005703894887119532
may O 0 1.785760446182394e-06
be O 0 1.085404974787707e-07
related O 0 3.709251075179054e-07
to O 0 9.726185368208462e-08
the O 0 6.338956609397428e-06
cognitive B-Disease 1 0.9991740584373474
impairment I-Disease 1 0.9999743700027466
associated O 0 4.6460303565254435e-05
with O 0 3.0897521355655044e-05
DMD B-Disease 1 1.0
. O 0 3.965196810895577e-05
. O 0 3.7791960494359955e-05

I1307K O 0 0.03511983901262283
APC O 0 0.0014343111542984843
and O 0 4.359352715255227e-06
hMLH1 O 0 2.9782257115584798e-05
mutations O 0 2.3386689917970216e-06
in O 0 7.451737360497646e-07
a O 0 4.312947112339316e-06
non O 0 2.306472379132174e-05
- O 0 1.0627154551912099e-05
Jewish O 0 1.1972034599239123e-06
family O 0 1.975390517827691e-07
with O 0 4.070634815889207e-07
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.5663930773735046

We O 0 8.869095836416818e-06
describe O 0 4.612136308423942e-06
a O 0 4.561757123155985e-06
French O 0 5.558361954172142e-05
Canadian O 0 0.0003703682159539312
hereditary B-Disease 1 0.9999996423721313
non I-Disease 1 0.9999998807907104
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9992602467536926
HNPCC B-Disease 1 1.0
) O 0 2.1471096260938793e-06
kindred O 0 1.1481987712613773e-05
which O 0 1.8183351357947686e-07
carries O 0 1.1253564480284695e-06
a O 0 1.1809513580374187e-06
novel O 0 2.2743963654647814e-06
truncating O 0 1.380584217258729e-05
mutation O 0 3.7733373119408498e-06
in O 0 5.657146175508387e-06
hMLH1 O 0 0.00014136215031612664
. O 0 1.6225803847191855e-05

Interestingly O 0 0.0005112417857162654
, O 0 1.3810424206894822e-05
the O 0 1.6105033864732832e-05
I1307K O 0 0.0010477259056642652
APC O 0 0.00012351830082479864
polymorphism O 0 9.361866432300303e-06
, O 0 3.3114989150817564e-07
associated O 0 1.716899333814581e-07
with O 0 2.170669333168007e-08
an O 0 4.311806094392523e-07
increased O 0 0.0002790055295918137
risk O 0 0.006779325660318136
of O 1 0.9995417594909668
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.353519670985406e-06
is O 0 2.8057144163540215e-07
also O 0 1.0582613896303883e-07
present O 0 1.0577629439012526e-07
in O 0 4.5852650032429665e-07
this O 0 9.216691978508607e-07
family O 0 5.035014964960283e-06
. O 0 1.1216888196941e-05

The O 0 0.00010272664076182991
I1307K O 0 0.00034088591928593814
polymorphism O 0 3.449749056017026e-05
has O 0 1.842741880864196e-06
previously O 0 1.0595333606033819e-06
only O 0 6.02479062195016e-08
been O 0 1.722455635899678e-07
identified O 0 1.1715717818105986e-07
in O 0 9.190003424919269e-08
individuals O 0 5.25559826769495e-08
of O 0 5.8892860579362605e-06
self O 0 0.004616959951817989
- O 0 0.05183878913521767
reported O 0 2.9161785278120078e-05
Ashkenazi O 0 3.622816802817397e-05
Jewish O 0 1.3604748346551787e-05
origins O 0 2.6357189199188724e-05
. O 0 1.9356024495209567e-05

In O 0 1.750182309478987e-05
addition O 0 2.6520935989537975e-06
, O 0 5.906154569856881e-07
in O 0 1.8105555454894784e-07
this O 0 7.951981473297565e-08
family O 0 1.088766055090673e-07
, O 0 7.768514365125156e-08
there O 0 7.110457289627448e-08
appears O 0 2.6077916004396684e-07
to O 0 3.368339918097263e-08
be O 0 9.779871845694288e-08
no O 0 1.2598557930232346e-07
relationship O 0 1.3043081992236694e-07
between O 0 3.180097110089264e-07
the O 0 1.0557608902672655e-06
I1307K O 0 1.0010503501689527e-05
polymorphism O 0 1.007126115837309e-06
and O 0 7.914787403251466e-08
the O 0 2.397055141045712e-07
presence O 0 7.114750246728363e-07
or O 0 4.3321927023498574e-07
absence O 0 8.21947651274968e-06
of O 0 2.3382130166282877e-05
cancer B-Disease 1 0.9995059967041016
. O 0 8.88856993697118e-06
. O 0 2.4480830688844435e-05

Identification O 0 1.8645574527909048e-05
of O 0 3.973331786255585e-06
a O 0 2.778309863060713e-06
novel O 0 2.6249783786624903e-06
mutation O 0 1.2409368537191767e-06
of O 0 2.012864570133388e-06
the O 0 3.2360733257519314e-06
CPO O 0 0.005846287123858929
gene O 0 6.919416364326025e-07
in O 0 8.549089329790149e-07
a O 0 1.7195985492435284e-05
Japanese O 0 0.0034520630724728107
hereditary B-Disease 1 0.9999727010726929
coproporphyria I-Disease 1 0.9972962737083435
family O 0 7.626920705661178e-05
. O 0 4.142841135035269e-05

Hereditary B-Disease 1 0.9999978542327881
coproporphyria I-Disease 1 0.9999902248382568
( O 0 0.003817474003881216
HCP B-Disease 1 0.9999980926513672
) O 0 5.620273441309109e-06
is O 0 1.151910396401945e-06
an O 0 4.893927780358354e-06
autosomal B-Disease 1 0.999915599822998
dominant I-Disease 1 0.9999852180480957
disease I-Disease 1 1.0
characterized O 1 0.8587031364440918
by O 0 8.574837920605205e-06
a O 0 0.06222037971019745
deficiency B-Disease 1 0.9999969005584717
of I-Disease 0 0.49320659041404724
coproporphyrinogen I-Disease 1 0.9999659061431885
oxidase I-Disease 0 0.004470802843570709
( O 0 3.879490577674005e-06
CPO O 1 0.7016282677650452
) O 0 4.3866629084732267e-07
caused O 0 2.5434621875319863e-06
by O 0 1.3241482577086572e-07
a O 0 8.5686218653791e-07
mutation O 0 1.3280590565045713e-06
in O 0 1.584445953994873e-06
the O 0 1.347289617115166e-05
CPO O 1 0.8837398290634155
gene O 0 1.7956099327420816e-05
. O 0 1.4092050150793511e-05

Only O 0 5.1556157814047765e-06
11 O 0 9.663132004789077e-06
mutations O 0 1.2159708830949967e-06
of O 0 1.0593555543891853e-06
the O 0 4.912229769615806e-07
gene O 0 2.9170669790801185e-07
have O 0 8.516598626329142e-08
been O 0 6.565801413671579e-07
reported O 0 6.075431429053424e-06
in O 0 1.757783320499584e-05
HCP B-Disease 1 0.9999897480010986
patients O 0 6.205581303220242e-05
. O 0 3.670290971058421e-05

We O 0 1.4353442566061858e-05
report O 0 6.494182798633119e-06
another O 0 1.5325783806474647e-06
mutation O 0 1.6316855635523098e-06
in O 0 1.345956889053923e-06
a O 0 1.0205516446148977e-05
Japanese O 0 9.35797652346082e-05
family O 0 1.2909452379972208e-05
. O 0 2.4926977857830934e-05

Polymerase O 1 0.9815002679824829
chain O 0 0.008657606318593025
reaction O 0 0.00012538472947198898
- O 0 4.168318264419213e-05
single O 0 1.6890578535821987e-06
strand O 0 5.823856099596014e-06
conformational O 0 7.953806857585732e-07
polymorphism O 0 6.546157464981661e-07
and O 0 6.134310126526543e-08
direct O 0 2.502952156646643e-07
sequence O 0 2.3213939925881277e-07
analyses O 0 4.6112825202726526e-07
demonstrated O 0 1.3314690932020312e-06
a O 0 1.8541257986726123e-06
C O 0 7.826941327948589e-06
to O 0 4.6034747924750263e-07
T O 0 5.010327186028007e-06
substitution O 0 8.600960654803202e-07
in O 0 2.3756942368891032e-07
exon O 0 4.926914698444307e-07
1 O 0 3.2473744226990675e-07
of O 0 4.801431714440696e-07
the O 0 1.6124805597428349e-06
CPO O 0 3.4352648071944714e-05
gene O 0 3.4473342225282977e-07
at O 0 1.2536645499494625e-06
nucleotide O 0 1.4409633877221495e-06
position O 0 1.3791623132419772e-06
85 O 0 1.0446537999087013e-06
, O 0 8.291304709473479e-08
which O 0 7.133645851808978e-08
lies O 0 1.1645944368865457e-06
in O 0 3.346682717619842e-07
the O 0 8.868502163750236e-07
putative O 0 1.7716469301376492e-05
presequence O 0 1.823373168008402e-05
for O 0 3.8941558955229993e-07
targeting O 0 6.971618404350011e-06
to O 0 1.774846850821632e-06
mitochondria O 0 0.00013655801012646407
. O 0 3.60771591658704e-05

This O 0 8.684449312568177e-06
mutation O 0 7.975105290825013e-06
changes O 0 1.5057719338074094e-06
the O 0 1.1035438092221739e-06
codon O 0 4.113191153010121e-06
for O 0 1.5161845112743322e-07
glutamine O 0 4.5734557829746336e-07
to O 0 1.0644093606515526e-07
a O 0 2.557462494223728e-06
termination O 0 1.9781929950113408e-05
codon O 0 2.704465987335425e-05
at O 0 1.045467706717318e-05
amino O 0 4.1354892346134875e-06
acid O 0 3.52079246113135e-06
position O 0 1.751217496348545e-05
29 O 0 5.807100023957901e-05
. O 0 1.4616196494898759e-05

MaeI O 0 0.0030836276710033417
restriction O 0 0.0001315361587330699
analysis O 0 1.1431367056502495e-05
showed O 0 5.679043624695623e-06
two O 0 2.7007081371266395e-07
other O 0 1.4393685887625907e-07
carriers O 0 9.25246467886609e-07
in O 0 1.2539334193206741e-06
the O 0 5.724818493035855e-06
family O 0 1.3494423001247924e-05
. O 0 2.5249366444768384e-05

The O 0 0.0005648470250889659
C O 1 0.8565223813056946
- O 0 0.010484568774700165
T O 0 9.266009146813303e-05
mutation O 0 5.695292202290148e-07
is O 0 8.42441210124889e-08
located O 0 1.8335931883939338e-07
within O 0 3.9659230566257975e-08
a O 0 2.6393468033347744e-07
recently O 0 3.9954895214577846e-07
proposed O 0 2.154496598905098e-07
putative O 0 1.3662585161000607e-06
alternative O 0 1.8519473599099e-07
translation O 0 8.868519216775894e-07
initiation O 0 1.3157613238945487e-06
codon O 0 2.3854752271290636e-06
( O 0 4.2688205326157913e-07
TIC O 0 1.0442282473377418e-05
- O 0 1.798304651856597e-06
1 O 0 6.618989232265449e-07
) O 0 7.002623192420288e-08
, O 0 1.030388574463359e-07
supporting O 0 5.535670766221301e-07
that O 0 7.279951432792586e-07
TIC O 0 0.00033038132824003696
- O 0 5.938312824582681e-06
1 O 0 1.2550652854770306e-06
is O 0 2.546031510064495e-07
the O 0 5.775443128186453e-07
real O 0 8.775235983193852e-06
TIC O 0 0.0001548362779431045
rather O 0 5.942698635408306e-07
than O 0 1.5521235354754026e-06
TIC O 0 0.0003015052934642881
- O 0 1.6262287317658775e-05
2 O 0 3.6053615986020304e-06
. O 0 1.5393003423014306e-06
. O 0 8.134253221214749e-06

Human B-Disease 0 0.00013725539611186832
complement I-Disease 0 0.0009171618148684502
factor I-Disease 1 0.9992030262947083
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.01615172065794468
with O 0 0.3347911238670349
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999847412109375

This O 0 7.224129149108194e-06
study O 0 4.3942009142483585e-06
reports O 0 2.7793648769147694e-06
on O 0 1.256879954780743e-06
six O 0 1.0268761343468213e-06
cases O 0 1.0938559853457264e-06
of O 0 8.76167177921161e-05
deficiency B-Disease 1 0.9999933242797852
in I-Disease 0 1.8492871731723426e-06
the I-Disease 0 8.264793223133893e-07
human I-Disease 0 4.719852597645513e-07
complement I-Disease 0 1.312708150180697e-06
regulatory I-Disease 0 3.295232090749778e-06
protein I-Disease 0 7.076158908603247e-06
Factor I-Disease 0 7.872940477682278e-05
H I-Disease 1 0.9999172687530518
( O 0 1.770058133843122e-06
FH O 0 6.539593596244231e-05
) O 0 4.883112225684272e-08
in O 0 5.9321550338609086e-08
the O 0 5.7808055231589606e-08
context O 0 1.029860001722227e-07
of O 0 7.700373316765763e-07
an O 0 0.018183061853051186
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.2524532675743103

Five O 0 8.006487405509688e-06
of O 0 1.3857979865861125e-06
the O 0 2.643074594743666e-07
cases O 0 8.704240883616876e-08
were O 0 1.5906154260392213e-07
observed O 0 2.460535881709802e-07
in O 0 1.3467743542605604e-07
children O 0 2.39771338783612e-07
presenting O 0 2.7042206056648865e-06
with O 0 4.691425056080334e-05
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 1 0.8421077132225037
. O 0 0.0005762732471339405

Two O 0 4.781454208568903e-06
of O 0 2.979463033625507e-06
the O 0 1.585927520864061e-06
children O 0 7.838556257411256e-07
exhibited O 0 8.219005394494161e-05
a O 0 5.147842603037134e-05
homozygous O 1 0.7043244242668152
deficiency O 1 0.9999992847442627
characterized O 0 6.960947212064639e-05
by O 0 8.970046110334806e-07
the O 0 1.0554730351941544e-06
absence O 0 1.7575684978510253e-06
of O 0 7.690935035498114e-07
the O 0 1.234109390679805e-06
150 O 0 1.0337818139305455e-06
- O 0 1.3108078746881802e-06
kD O 0 5.3080261750437785e-06
form O 0 1.1766127272494487e-07
of O 0 1.9572473775042454e-06
Factor O 0 9.618540389055852e-06
H O 0 0.08395938575267792
and O 0 1.240122458057158e-07
the O 0 2.890137693611905e-07
presence O 0 4.852570327784633e-07
, O 0 1.290009095100686e-07
upon O 0 3.70293520290943e-07
immunoblotting O 0 7.524070952058537e-06
, O 0 2.7683128678290814e-07
of O 0 9.242525038644089e-07
the O 0 1.6711957186998916e-06
42 O 0 1.3061896424915176e-05
- O 0 1.966174750123173e-05
kD O 0 0.0001448038237867877
Factor O 0 3.119363827863708e-05
H O 1 0.5547285079956055
- O 0 3.4610518468980445e-06
like O 0 2.956387845642894e-07
protein O 0 6.432044301618589e-07
1 O 0 1.7800033447201713e-06
( O 0 5.314619215823768e-07
FHL O 0 1.79614780790871e-05
- O 0 1.1449994872236857e-06
1 O 0 4.4447634195421415e-07
) O 0 6.172712829766169e-08
and O 0 8.687887032010622e-08
other O 0 1.3981765789594647e-07
FH O 0 0.0017090295441448689
- O 0 1.893804073915817e-05
related O 0 2.8493266199802747e-06
protein O 0 5.6959174798976164e-06
( O 0 3.0563703603547765e-06
FHR O 0 0.0006116571021266282
) O 0 1.6609094473096775e-06
bands O 0 8.591708137828391e-06
. O 0 6.379850674420595e-06

Southern O 0 0.00012729015725199133
blot O 0 0.0004738832067232579
and O 0 1.0007725904870313e-05
PCR O 0 0.00015686685219407082
analysis O 0 1.1411218565626768e-06
of O 0 5.611343567579752e-07
DNA O 0 9.541618055664003e-07
of O 0 2.051330056929146e-06
one O 0 1.1032797146981466e-06
patient O 0 8.682345651322976e-06
with O 0 6.982763238738698e-07
homozygous O 0 0.06268554925918579
deficiency O 1 0.9999418258666992
ruled O 0 2.6094883196492447e-06
out O 0 1.5175123735389207e-07
the O 0 9.253306387790872e-08
presence O 0 1.1091837848198338e-07
of O 0 1.7130818719124363e-07
a O 0 2.0800212041649502e-07
large O 0 1.3880290339329804e-07
deletion O 0 4.6129716224641015e-07
of O 0 4.249960454671964e-07
the O 0 1.0886680001931381e-06
FH O 0 0.00010977016791002825
gene O 0 4.812989118363475e-07
as O 0 4.7602111408195924e-07
the O 0 3.1074810067366343e-06
underlying O 0 0.1192302405834198
defect O 0 6.669540016446263e-05
for O 0 1.6849262465257198e-06
the O 0 0.0007310834480449557
deficiency O 1 0.9999983310699463
. O 0 3.8175887311808765e-05

The O 0 1.2822886674257461e-05
other O 0 4.999550924367213e-07
four O 0 4.2104696262867947e-07
children O 0 2.7348247044756135e-07
presented O 0 1.924961679833359e-06
with O 0 8.016517654141353e-07
heterozygous O 0 0.014917977154254913
deficiency O 1 0.9999349117279053
and O 0 8.116128924484656e-07
exhibited O 0 0.003264641622081399
a O 0 8.187291314243339e-06
normal O 0 7.96893255028408e-06
immunoblotting O 0 5.99659324507229e-05
pattern O 0 2.859714868463925e-06
of O 0 8.130778610393463e-07
proteins O 0 3.0418928531616984e-07
of O 0 2.908654550992651e-06
the O 0 1.6887592209968716e-05
FH O 0 0.028055017814040184
family O 0 1.156229973275913e-05
. O 0 2.1232253857306205e-05

Factor B-Disease 1 0.9999672174453735
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999974966049194
is O 0 2.816394271576428e-06
the O 0 1.4135454193819896e-06
only O 0 2.8463064154493622e-06
complement B-Disease 1 0.9999895095825195
deficiency I-Disease 1 1.0
associated O 0 0.0006722928956151009
with O 0 8.459690434392542e-05
HUS B-Disease 1 1.0
. O 0 0.0006720740348100662

These O 0 3.4497127217036905e-06
observations O 0 1.726530899759382e-05
suggest O 0 4.0553745748184156e-06
a O 0 2.1450628082675394e-06
role O 0 2.323722810615436e-06
for O 0 1.724432536320819e-06
FH O 0 0.08556709438562393
and O 0 4.155775059189182e-06
/ O 0 0.00023199520364869386
or O 0 4.3801101128337905e-06
FH O 0 0.15608397126197815
receptors O 0 2.228152197858435e-06
in O 0 3.904247876107547e-07
the O 0 3.6487369925453095e-06
pathogenesis O 1 0.9336419105529785
of O 0 0.00024105528427753597
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 3.772678610403091e-05
. O 0 4.1179358959198e-05

Further O 0 8.416994205617812e-06
evidence O 0 2.193637556047179e-06
for O 0 2.8547725605676533e-07
a O 0 1.4240791870179237e-06
major O 0 3.426243665671791e-06
ancient O 0 7.489677955163643e-06
mutation O 1 0.8323639631271362
underlying O 1 0.9999998807907104
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.4819601346971467e-05
linkage O 0 0.00045028122258372605
disequilibrium O 0 0.003900561947375536
studies O 0 1.4614333849749528e-06
in O 0 3.5206812754040584e-07
the O 0 5.429776592791313e-07
Japanese O 0 6.666216904704925e-06
population O 0 1.0653054687281838e-06
. O 0 4.619676928996341e-06

The O 0 0.08074148744344711
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.10525062680244446
DM B-Disease 1 1.0
) O 0 5.487856014951831e-06
mutation O 0 4.881673248746665e-06
is O 0 9.42749693422229e-07
an O 0 2.1981650206726044e-06
unstable O 0 3.707347059389576e-05
( O 0 1.7402245475750533e-06
CTG O 0 9.109206439461559e-05
) O 0 4.396983399601595e-07
n O 0 8.894811003301584e-07
repeat O 0 6.357666961775976e-07
, O 0 1.2130399795751146e-07
present O 0 1.5766816829909658e-07
at O 0 7.813375191290106e-07
a O 0 3.9706921484139457e-07
copy O 0 5.843751296197297e-07
number O 0 1.7550013353684335e-07
of O 0 1.8344657064517378e-06
5 O 0 2.754828301476664e-06
- O 0 5.211599727772409e-06
37 O 0 2.3218885871756356e-06
repeats O 0 9.868076631391887e-07
on O 0 1.1208161367903813e-06
normal O 0 6.171136419652612e-07
chromosomes O 0 5.323207119545259e-07
but O 0 1.1366119423428245e-07
amplified O 0 1.1211722039661254e-06
to O 0 8.89788438485084e-08
50 O 0 8.830112392388401e-07
- O 0 1.9877072645613225e-06
3000 O 0 2.0489701455517206e-06
copies O 0 7.255000014083635e-07
on O 0 8.507614438713063e-06
DM B-Disease 1 0.9999747276306152
chromosomes O 0 6.929176743142307e-05
. O 0 1.6177673387574032e-05

Previous O 0 7.705677126068622e-05
findings O 0 1.4857951100566424e-05
in O 0 1.7885728311739513e-06
Caucasian O 0 9.807798960537184e-06
populations O 0 5.059699788034777e-07
of O 0 4.818036359210964e-06
a O 0 0.00656939996406436
DM B-Disease 1 1.0
founder O 0 0.0038821895141154528
chromosome O 0 2.0046571080456488e-05
raise O 0 8.841580552143569e-07
a O 0 8.338786301465007e-07
question O 0 1.4748603405223548e-07
about O 0 3.9812174890130336e-08
the O 0 7.6256142733655e-08
molecular O 0 4.020548374228383e-07
events O 0 1.2685048034200008e-07
involved O 0 1.2019128803331114e-07
in O 0 2.3452257380540686e-07
the O 0 1.0494518392079044e-06
expansion O 0 1.2011652870569378e-05
mutation O 0 8.597831765655428e-06
. O 0 7.003003247518791e-06

To O 0 1.2706997040368151e-05
investigate O 0 5.3984222176950425e-06
whether O 0 1.8945864894703845e-06
a O 0 6.036384547769558e-06
founder O 0 4.902403088635765e-05
chromosome O 0 3.526728323777206e-05
for O 0 6.998830599513894e-07
the O 0 1.4524960533890408e-05
DM B-Disease 1 1.0
mutation O 0 8.073215553849877e-07
exists O 0 8.452401090153217e-08
in O 0 1.1148659950777073e-07
the O 0 1.8862237993744202e-07
Japanese O 0 5.285026531964832e-07
population O 0 3.611000209957638e-08
, O 0 4.2124213450733805e-08
we O 0 4.753936622137189e-08
genotyped O 0 2.3953646177687915e-06
families O 0 7.564279513871952e-08
using O 0 1.5929654750834743e-07
polymorphic O 0 2.704050530155655e-06
markers O 0 3.597818931666552e-06
near O 0 1.4633127648266964e-05
the O 0 1.9001796545126126e-06
( O 0 9.15268913104228e-07
CTG O 0 2.2506839741254225e-05
) O 0 1.5427922051003407e-07
n O 0 4.936994173476705e-07
repeat O 0 4.823507424589479e-07
region O 0 5.080665346213209e-07
and O 0 5.217838179305545e-07
constructed O 0 6.75746487104334e-05
haplotypes O 0 9.435007814317942e-05
. O 0 1.5082357094797771e-05

Six O 0 1.07693558675237e-05
different O 0 5.028729788136843e-07
haplotypes O 0 9.521171705273446e-06
were O 0 1.3424662483885186e-06
found O 0 1.195706431644794e-06
and O 0 2.5603715130273486e-06
DM B-Disease 1 1.0
alleles O 0 5.46570981896366e-06
were O 0 3.878133156831609e-06
always O 0 2.5283131890319055e-06
haplotype O 0 5.7541910791769624e-05
A O 0 7.316262053791434e-05
. O 0 9.05789238458965e-06

To O 0 1.4456845747190528e-05
find O 0 3.00302622235904e-06
an O 0 1.7393783764418913e-06
origin O 0 6.262849865379394e-07
of O 0 2.0955742456862936e-06
the O 0 2.640913180584903e-06
( O 0 9.280362860408786e-07
CTG O 0 3.808348992606625e-05
) O 0 1.558250346533896e-07
n O 0 3.817379479187366e-07
repeat O 0 2.1092694169055903e-07
mutation O 0 1.0868654243267883e-07
and O 0 6.141627295619401e-08
to O 0 5.2852026755090264e-08
investigate O 0 1.4516209034809435e-07
the O 0 3.256666047946055e-07
mechanism O 0 4.821640118279902e-07
of O 0 1.6039609818108147e-07
the O 0 1.019486006725856e-07
expansion O 0 3.991147821125196e-07
mutation O 0 7.480090147282681e-08
in O 0 9.144647350467494e-08
the O 0 1.3243503360627074e-07
Japanese O 0 4.0050571215033415e-07
population O 0 1.6836906979733612e-08
we O 0 1.4749018895088284e-08
have O 0 1.958158435400037e-08
studied O 0 1.228843302669702e-06
90 O 0 1.4528510519085103e-06
Japanese O 0 3.0468272598227486e-05
DM B-Disease 1 0.9998828172683716
families O 0 7.808594659763912e-08
comprising O 0 1.8533253864916333e-07
190 O 0 5.841304755449528e-07
affected O 0 2.741914784110122e-07
and O 0 3.6699617567137466e-07
130 O 0 4.851158792007482e-06
unaffected O 0 1.0048053809441626e-05
members O 0 9.179954076898866e-07
. O 0 4.040746716782451e-06

The O 0 3.528955494402908e-05
results O 0 9.352131201012526e-06
suggest O 0 1.694141246844083e-06
that O 0 2.219583166152006e-07
a O 0 9.757668522070162e-07
few O 0 2.0812554168969655e-07
common O 0 1.5809999354132742e-07
ancestral O 0 1.444451186216611e-06
mutations O 0 3.082608657223318e-07
in O 0 1.923734345155026e-07
both O 0 8.896051895135315e-08
Caucasian O 0 1.8693951915338403e-06
and O 0 1.8953296887502802e-07
Japanese O 0 1.1900808658538153e-06
populations O 0 2.5589812935322698e-08
have O 0 1.3055995395916398e-08
originated O 0 7.471748375564857e-08
by O 0 3.84286344967677e-08
expansion O 0 3.5705997447621485e-07
of O 0 3.2622770618218055e-07
an O 0 3.6495512745204906e-07
ancestral O 0 1.7267512930629891e-06
n O 0 2.38508869188081e-06
= O 0 1.45741523738252e-06
5 O 0 8.518854315298086e-07
repeat O 0 1.1160611848026747e-06
to O 0 3.950371763039584e-07
n O 0 6.371417384798406e-06
= O 0 6.553817911481019e-06
19 O 0 1.1221167369512841e-05
- O 0 1.4241350982047152e-05
37 O 0 1.3754275641986169e-05
copies O 0 9.541004146740306e-06
. O 0 1.1567945875867736e-05

These O 0 3.5373138871364063e-06
data O 0 3.0808205337962136e-06
support O 0 2.5710319278005045e-06
multistep O 0 1.4691886462969705e-05
models O 0 1.1083712934123469e-06
of O 0 7.835021165192302e-07
triplet O 0 1.9448983948677778e-05
repeat O 0 1.2146148264946532e-06
expansion O 0 7.579948828606575e-07
that O 0 2.8308166477586383e-08
have O 0 1.5195219305041974e-08
been O 0 5.2992238153137805e-08
proposed O 0 1.3664967468685063e-07
for O 0 1.4165127026899427e-07
both O 0 1.1663672694339766e-06
DM B-Disease 1 1.0
and O 0 1.2351712030067574e-05
Friedreichs B-Disease 1 0.9963966012001038
ataxia I-Disease 1 0.9999456405639648
. O 0 1.430602242180612e-05
. O 0 1.7773905710782856e-05

The O 0 1.8623823052621447e-05
molecular O 0 2.8501191991381347e-05
basis O 0 1.365760363114532e-05
of O 0 0.0019656342919915915
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.718894615507452e-06
the O 0 2.2760389128961833e-06
western O 0 2.450772853990202e-06
Cape O 0 9.189911907014903e-06
, O 0 8.015294952201657e-07
South O 0 5.320173841028009e-06
Africa O 0 6.278820819716202e-06
. O 0 7.109098987712059e-06

Deficiency B-Disease 1 0.9998286962509155
of I-Disease 0 6.002771988278255e-05
the I-Disease 0 1.525960396975279e-05
sixth I-Disease 0 9.974989370675758e-05
component I-Disease 0 2.8242370717634913e-06
of I-Disease 0 1.8158812054025475e-06
human I-Disease 0 1.2789968195647816e-06
complement I-Disease 0 3.989160632045241e-06
( O 0 2.2848121261631604e-06
C6 O 0 0.21039001643657684
) O 0 2.6887454396273824e-07
has O 0 1.1445437309021145e-07
been O 0 2.3477343802369433e-07
reported O 0 1.6816053971524525e-07
in O 0 4.58009914439117e-08
a O 0 1.4165722461711994e-07
number O 0 9.290656777238837e-08
of O 0 4.396735846512456e-07
families O 0 8.528952832875802e-08
from O 0 2.882606224829942e-07
the O 0 7.044533276712173e-07
western O 0 1.0489665100976708e-06
Cape O 0 7.968810677994043e-06
, O 0 6.634371061409183e-07
South O 0 2.7200526346859988e-06
Africa O 0 3.533052449711249e-06
. O 0 3.212737283320166e-06

Meningococcal B-Disease 1 0.9999990463256836
disease I-Disease 1 0.9979650974273682
is O 0 8.54704649100313e-06
endemic O 0 3.3168291793117533e-06
in O 0 5.930938868914382e-07
the O 0 7.504611971853592e-07
Cape O 0 1.6013121921787388e-06
and O 0 4.64396237020992e-08
almost O 0 6.436628297024072e-08
all O 0 1.8578692362325455e-08
pedigrees O 0 3.220763744593569e-07
of O 0 5.825988864671672e-07
total O 0 0.066524937748909
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 7.465816906915279e-06
C6Q0 O 0 0.03232945501804352
) O 0 6.654464357325196e-08
have O 0 2.3074417043744688e-08
been O 0 2.2264477195221843e-07
ascertained O 0 2.23979964175669e-06
because O 0 3.287433685272845e-07
of O 0 9.668865459389053e-06
recurrent O 1 0.9999992847442627
disease O 1 0.999998927116394
. O 0 7.655668014194816e-05

We O 0 6.3882407630444504e-06
have O 0 1.0321465424567577e-06
sequenced O 0 4.415675903146621e-06
the O 0 9.81788502940617e-07
expressed O 0 5.325984488990798e-07
exons O 0 2.5631243261159398e-06
of O 0 1.2317319715293706e-06
the O 0 2.0920658698742045e-06
C6 O 0 0.014578775502741337
gene O 0 4.770786858898646e-07
from O 0 2.0690291080427414e-07
selected O 0 9.692666225191715e-08
cases O 0 3.980838059192138e-08
and O 0 7.121097667095455e-08
have O 0 6.475750780055023e-08
found O 0 3.709353961767192e-07
three O 0 8.631322430119326e-07
molecular O 1 0.8893740177154541
defects O 1 0.9935896396636963
leading O 0 0.00011180138972122222
to O 0 3.279176610249124e-07
total O 0 0.0009103210177272558
deficiency O 1 0.9999966621398926
879delG O 0 0.0009962469339370728
, O 0 6.512892696264316e-07
which O 0 1.6934420443703857e-07
is O 0 1.5745209225315193e-07
the O 0 3.629748732691951e-07
common O 0 8.747628044147859e-07
defect O 0 5.215412784309592e-06
in O 0 4.176085894869175e-07
the O 0 7.366558065768913e-07
Cape O 0 2.2169608655531192e-06
and O 0 1.7858069156773126e-07
hitherto O 0 8.232672371377703e-06
unreported O 0 4.003516551165376e-06
, O 0 1.4939401182800793e-07
and O 0 1.7580468636424484e-07
1195delC O 0 2.5466270017204806e-06
and O 0 2.414210769074998e-07
1936delG O 0 2.5671608909760835e-06
, O 0 9.485343355208897e-08
which O 0 4.46876420312492e-08
have O 0 4.395624486619454e-08
been O 0 3.476821177628153e-07
previously O 0 7.573691505058378e-07
reported O 0 9.202490218740422e-07
in O 0 6.161280907690525e-07
African O 0 8.535251254215837e-06
- O 0 5.992551086819731e-05
Americans O 0 6.124127139628399e-06
. O 0 9.476693776377942e-06

We O 0 7.483409717679024e-06
also O 0 1.5190167914624908e-06
show O 0 5.610637003883312e-07
that O 0 2.217615389099592e-07
the O 0 9.8002794857166e-07
879delG O 0 2.37977656070143e-05
and O 0 1.841139805947023e-06
1195delC O 0 0.0777045488357544
defects O 1 0.9865538477897644
are O 0 2.984648119763733e-07
associated O 0 1.932624627443147e-06
with O 0 6.644293080171337e-07
characteristic O 1 0.9836474061012268
C6 O 1 1.0
/ O 1 0.9980120658874512
C7 O 1 0.999862790107727
region O 0 2.581345825092285e-06
DNA O 0 2.80092876892013e-06
marker O 0 1.4051469406695105e-05
haplotypes O 0 3.466925363682094e-06
, O 0 7.674480428931929e-08
although O 0 2.8375628957633126e-08
small O 0 4.483859328274775e-08
variations O 0 2.4693653699614515e-07
were O 0 1.123063157137949e-06
observed O 0 5.575562681769952e-06
. O 0 5.779212642664788e-06

The O 0 0.0001407991658197716
1936delG O 0 0.0008903293637558818
defect O 0 0.0002287643583258614
was O 0 1.9532608348526992e-05
observed O 0 1.653910430832184e-06
only O 0 9.850901250274546e-08
once O 0 4.980933567821921e-07
in O 0 2.900879394474032e-07
the O 0 5.367771223063755e-07
Cape O 0 3.75943272956647e-06
, O 0 1.1079004025305039e-07
but O 0 2.6308420331133675e-08
its O 0 1.169939451983737e-07
associated O 0 7.549303973064525e-07
haplotype O 0 7.765041118545923e-06
could O 0 7.234673375933198e-07
be O 0 2.518139353924198e-06
deduced O 0 6.244631367735565e-05
. O 0 1.1376696420484222e-05

The O 0 4.630319745047018e-05
data O 0 1.6003097698558122e-05
from O 0 1.75701040916465e-06
the O 0 6.081943411118118e-07
haplotypes O 0 4.4713874558510724e-06
indicate O 0 6.365170861499791e-07
that O 0 7.001741408885209e-08
these O 0 5.449001605484227e-08
three O 0 6.44597776044975e-07
molecular O 0 0.08352544903755188
defects O 0 0.3255102336406708
account O 0 9.311347071161435e-07
for O 0 5.5500015605503e-07
the O 0 7.498597824451281e-06
defects O 0 0.011691230349242687
in O 0 2.952099862341129e-07
all O 0 4.427363009540386e-08
the O 0 3.621443340762198e-07
38 O 0 1.2846028312196722e-06
unrelated O 0 9.437850962967786e-07
C6Q0 O 0 2.2653550331597216e-05
individuals O 0 2.568810764103091e-08
we O 0 2.295694301324147e-08
have O 0 6.198787616540358e-08
studied O 0 2.2802430521551287e-06
from O 0 2.529478024371201e-06
the O 0 8.954969416663516e-06
Cape O 0 7.318802090594545e-05
. O 0 1.4946575902285986e-05

We O 0 1.2089881238352973e-05
have O 0 1.2642429965126212e-06
also O 0 1.0871397080336465e-06
observed O 0 2.1820053461851785e-06
the O 0 1.3542461374527193e-06
879delG O 0 3.1584153475705534e-05
defect O 0 7.952867235871963e-06
in O 0 1.3134106211509788e-06
two O 0 1.5464822809008183e-06
Dutch O 1 0.9893181920051575
C6 B-Disease 1 1.0
- I-Disease 1 0.999998927116394
deficient I-Disease 1 0.9999992847442627
kindreds O 0 5.793757736682892e-05
, O 0 2.7817966952170536e-07
but O 0 9.095696640315509e-08
the O 0 6.469170443779149e-07
879delG O 0 1.249851266038604e-05
defect O 0 5.546960437641246e-06
in O 0 2.9547953772635083e-07
the O 0 6.847208169347141e-07
Cape O 0 3.7735603655164596e-06
probably O 0 3.663824372779345e-07
did O 0 8.984585520011024e-08
not O 0 7.343839314444267e-08
come O 0 1.8843215343622433e-07
from O 0 4.3303336383360147e-07
The O 0 1.0028917358795297e-06
Netherlands O 0 2.1735252175858477e-06
. O 0 9.381585641676793e-07
. O 0 6.7992905314895324e-06

Complement B-Disease 1 0.9998955726623535
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.0819076123880222e-05
seven O 0 2.885243247874314e-06
further O 0 4.119248842471279e-06
molecular O 1 0.9223983883857727
defects O 1 0.8884354829788208
and O 0 7.263196835083363e-07
their O 0 7.540265869465657e-07
associated O 0 5.529158443096094e-05
marker O 0 0.015474241226911545
haplotypes O 0 0.000497344124596566
. O 0 2.3781769414199516e-05

Seven O 0 1.8824346625478938e-05
further O 0 7.771937816869467e-06
molecular O 0 4.2947609472321346e-05
bases O 0 2.6562893253867514e-05
of O 1 0.5252159237861633
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.95040126729873e-06
described O 0 4.972458918928169e-05
. O 0 1.230492034665076e-05

All O 0 2.9175141662562964e-06
these O 0 8.60570310123876e-07
new O 0 2.7090063667856157e-06
molecular O 0 0.00015667609113734215
defects O 0 0.00039969291538000107
involve O 0 1.955404059117427e-06
single O 0 4.9453205974714365e-06
- O 0 1.0632913472363725e-05
nucleotide O 0 2.228538960480364e-06
events O 0 3.4803775861291797e-07
, O 0 1.1091626106463082e-07
deletions O 0 5.472321049637685e-07
and O 0 1.3822827327203413e-07
substitutions O 0 5.47602724054741e-07
, O 0 1.276470413813513e-07
some O 0 2.321687730955091e-08
of O 0 1.891765037953519e-07
which O 0 8.00949067070178e-08
alter O 0 3.9111162664084986e-07
splice O 0 1.375459646624222e-06
sites O 0 2.1945318451344065e-07
, O 0 3.205259133665095e-07
and O 0 3.606905067954358e-07
others O 0 1.7768520592653658e-06
codons O 0 2.4526654669898562e-05
. O 0 1.1574710697459523e-05

They O 0 4.069433998665772e-06
are O 0 5.242728207122127e-07
distributed O 0 4.689920274358883e-07
along O 0 5.702373186977638e-07
the O 0 9.500840292275825e-07
C7 O 0 0.0006947293877601624
gene O 0 8.209270276893221e-07
, O 0 1.795768440615575e-07
but O 0 2.9759931408079865e-08
predominantly O 0 6.545950981262649e-08
towards O 0 4.3277822214804473e-07
the O 0 5.116950205774629e-07
3 O 0 2.3631041585758794e-06
end O 0 7.5205562097835355e-06
. O 0 5.418931323220022e-06

All O 0 5.967293873254675e-06
were O 0 2.892373231588863e-06
found O 0 1.7143842114819563e-06
in O 0 2.3234813397721155e-06
compound O 0 3.8988921005511656e-05
heterozygous O 0 1.0030811608885415e-05
individuals O 0 2.597790853542392e-06
. O 0 1.804261228244286e-05

The O 0 0.0006365914596244693
C6 O 1 0.9999606609344482
/ O 1 0.5921785235404968
C7 O 1 0.9999521970748901
marker O 0 0.008303231559693813
haplotypes O 0 0.0003019275318365544
associated O 0 8.51297863846412e-06
with O 0 1.6908289808270638e-06
most O 0 4.66080782643985e-05
C7 B-Disease 1 1.0
defects I-Disease 1 0.9995798468589783
are O 0 6.47428691991081e-07
tabulated O 0 1.3269765986478887e-05
. O 0 1.0626552011672175e-06
. O 0 7.023421858320944e-06

A O 0 0.0002264276845380664
genome O 0 7.783078763168305e-05
- O 0 2.5801453375606798e-05
wide O 0 4.44977376901079e-06
search O 0 6.074668021938123e-07
for O 0 3.1325922122960037e-07
chromosomal O 0 0.010175232775509357
loci O 0 0.00017272729019168764
linked O 0 6.793628563173115e-05
to O 0 7.934631298667227e-07
mental O 1 0.9982231259346008
health O 0 0.006216919049620628
wellness O 0 0.00408534100279212
in O 0 1.1623209275057889e-06
relatives O 0 1.0905248473136453e-06
at O 0 1.8786542568705045e-05
high O 0 0.11072951555252075
risk O 0 0.0006082929321564734
for O 0 3.092575934715569e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
among O 0 3.922384621546371e-06
the O 0 5.652718300552806e-06
Old O 0 5.400500594987534e-05
Order O 0 2.945062988146674e-06
Amish O 0 3.968847886426374e-05
. O 0 1.0130299415322952e-05

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999990463256836
BPAD B-Disease 1 1.0
; O 1 0.9999932050704956
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 5.723511640098877e-05
is O 0 1.2515370144683402e-06
characterized O 0 1.4755062238691607e-06
by O 0 6.915973216337079e-08
episodes O 0 6.974377697588352e-07
of O 0 9.88752071862109e-06
mania B-Disease 1 0.9957006573677063
and O 0 2.2537060431204736e-05
/ O 0 0.2546502351760864
or O 0 2.4333565306733362e-05
hypomania B-Disease 1 0.9998942613601685
interspersed O 0 6.0085341829108074e-05
with O 0 6.071384177630534e-07
periods O 0 0.00045198164298199117
of O 0 0.020838845521211624
depression B-Disease 1 0.9999992847442627
. O 0 0.0002487840538378805

Compelling O 0 2.943479012174066e-05
evidence O 0 5.390576916397549e-06
supports O 0 7.347958330683468e-07
a O 0 2.7891684339920175e-07
significant O 0 2.9451064165186835e-07
genetic O 0 1.0314793144061696e-06
component O 0 1.690496901574079e-06
in O 0 2.524737112707953e-07
the O 0 5.750392801928683e-07
susceptibility O 0 2.2393134713638574e-05
to O 0 2.384790604992304e-06
develop O 0 0.00010975529585266486
BPAD B-Disease 1 1.0
. O 0 0.00017004205437842757

To O 0 4.202797299512895e-06
date O 0 6.322969056782313e-06
, O 0 5.368339657252363e-07
however O 0 1.3153280065125728e-07
, O 0 5.4766548629459066e-08
linkage O 0 8.297773206322745e-07
studies O 0 2.1686007301013888e-07
have O 0 2.2876692540307886e-08
attempted O 0 3.802681760589621e-07
only O 0 3.474142573622885e-08
to O 0 7.384108613450735e-08
identify O 0 2.6564273980511643e-07
chromosomal O 0 0.002906703157350421
loci O 0 1.753981996444054e-05
that O 0 3.241597710257338e-07
cause O 0 5.437463187263347e-06
or O 0 4.2021255808322167e-07
increase O 0 9.311906410403026e-07
the O 0 1.3605894082502346e-06
risk O 0 3.2477942113473546e-06
of O 0 6.903623670950765e-06
developing O 0 6.908532668603584e-05
BPAD B-Disease 1 0.9999996423721313
. O 0 3.396536340005696e-05

To O 0 4.818868092115736e-06
determine O 0 7.897955924818234e-07
whether O 0 5.938234153290978e-07
there O 0 6.426827212635544e-07
could O 0 3.1151702728493547e-07
be O 0 3.5449289725875133e-07
protective O 0 1.5938710475893458e-06
alleles O 0 2.2816256262103707e-07
that O 0 3.9511018457005775e-08
prevent O 0 2.3482046174194693e-07
or O 0 1.423693305468987e-07
reduce O 0 2.5124251123997965e-07
the O 0 5.970300094304548e-07
risk O 0 7.401021093755844e-07
of O 0 8.993344522423286e-07
developing O 0 5.17581383974175e-06
BPAD B-Disease 1 0.9999967813491821
, O 0 8.979395005326296e-08
similar O 0 2.291127465525733e-08
to O 0 1.8300497117706982e-08
what O 0 1.8908231425029953e-08
is O 0 3.189165553862949e-08
observed O 0 6.951866993176736e-08
in O 0 7.137360569231532e-08
other O 0 1.4431387285185338e-07
genetic B-Disease 1 0.9999998807907104
disorders I-Disease 1 1.0
, O 0 2.9143993742763996e-06
we O 0 3.0663969141642156e-07
used O 0 4.820830781682162e-06
mental O 1 0.9998605251312256
health O 1 0.615789532661438
wellness O 1 0.9711597561836243
( O 0 1.3403924867816386e-06
absence O 0 5.52742767467862e-06
of O 0 2.7011381007469026e-06
any O 0 4.504716798692243e-06
psychiatric B-Disease 1 1.0
disorder I-Disease 1 0.9999984502792358
) O 0 2.1755411125923274e-06
as O 0 1.6038568446674617e-06
the O 0 1.451694629395206e-06
phenotype O 0 8.698432793607935e-06
in O 0 4.2415666712258826e-07
our O 0 6.415339157683775e-07
genome O 0 5.324173798726406e-06
- O 0 1.2609855730261188e-05
wide O 0 4.661703314923216e-06
linkage O 0 1.7163740267278627e-05
scan O 0 1.2304569736443227e-06
of O 0 6.14859061442985e-07
several O 0 1.6903553046176967e-07
large O 0 1.4892827948642662e-06
multigeneration O 0 6.828962796134874e-05
Old O 0 8.550111488148104e-06
Order O 0 6.775159135941067e-07
Amish O 0 5.192514436203055e-06
pedigrees O 0 4.105859261471778e-06
exhibiting O 0 2.2100557544035837e-06
an O 0 1.5221201010717778e-06
extremely O 0 6.6490865719970316e-06
high O 0 0.0003795547818299383
incidence O 1 0.925368070602417
of O 0 0.005939022172242403
BPAD B-Disease 1 1.0
. O 0 6.273968756431714e-05

We O 0 5.186866928852396e-06
have O 0 5.792968522655428e-07
found O 0 4.334742413902859e-07
strong O 0 7.456833941432706e-07
evidence O 0 7.088641496011405e-07
for O 0 3.703295305967913e-07
a O 0 2.758898517640773e-06
locus O 0 2.941144339274615e-05
on O 0 6.320695774775231e-06
chromosome O 0 0.0009118210291489959
4p O 1 0.9844671487808228
at O 0 7.375799032161012e-05
D4S2949 O 0 8.600810542702675e-05
( O 0 8.627619649814733e-07
maximum O 0 1.4155623830447439e-05
GENEHUNTER O 0 0.0002966831380035728
- O 0 6.211941581568681e-06
PLUS O 0 1.6401382936237496e-06
nonparametric O 0 3.5863224638887914e-06
linkage O 0 3.5456864679872524e-06
score O 0 7.380559168268519e-07
= O 0 1.1386422329451307e-06
4 O 0 1.093760943149391e-06
. O 0 2.1092272106670862e-07
05 O 0 1.2652787518163677e-05
, O 0 6.088732789066853e-07
P O 0 1.2077389328624122e-05
= O 0 1.061521743395133e-06
5 O 0 5.492995001077361e-07
. O 0 7.896029785570136e-08
22 O 0 1.233278794643411e-06
x O 0 1.2175513575130026e-06
10 O 0 7.399235641969426e-07
( O 0 5.499080657500599e-07
- O 0 2.3659636099182535e-06
4 O 0 1.3694545941689285e-06
) O 0 2.2995382664703357e-07
; O 0 1.4650949253791623e-07
SIBPAL O 0 8.378407983400393e-06
Pempirical O 0 3.7194388369243825e-06
value O 0 7.977728841979115e-07
< O 0 2.4504668090230552e-06
3 O 0 5.946275223323028e-07
x O 0 9.148500339506427e-07
10 O 0 3.869404849865532e-07
( O 0 2.0731768302084674e-07
- O 0 7.94168727225042e-07
5 O 0 5.371176712287706e-07
) O 0 8.748314428430604e-08
) O 0 3.8952506997702585e-08
and O 0 7.598724494073394e-08
suggestive O 0 1.1076738246629247e-06
evidence O 0 2.2840313818051072e-07
for O 0 9.544979917563978e-08
a O 0 1.46913578191743e-06
locus O 0 2.8345386454020627e-05
on O 0 1.292978322453564e-05
chromosome O 0 0.14229661226272583
4q O 1 0.9985906481742859
at O 0 5.490089097293094e-05
D4S397 O 0 7.496865146094933e-05
( O 0 1.1406485782572418e-06
maximum O 0 7.2033749347610865e-06
GENEHUNTER O 0 0.00015279295621439815
- O 0 1.0150433809030801e-05
PLUS O 0 1.408833782079455e-06
nonparametric O 0 7.026919320196612e-06
linkage O 0 4.092473773198435e-06
score O 0 9.874430588752148e-07
= O 0 9.560554872223292e-07
3 O 0 4.317785169405397e-07
. O 0 1.0044617226867558e-07
29 O 0 1.9168335256836144e-06
, O 0 3.634882546066365e-07
P O 0 5.630316081806086e-06
= O 0 7.898460125943529e-07
2 O 0 4.6918754037506005e-07
. O 0 1.2492790801843512e-07
57 O 0 1.6470634136567242e-06
x O 0 1.559969177833409e-06
10 O 0 8.520690926161478e-07
( O 0 4.103617357031908e-07
- O 0 2.304432655364508e-06
3 O 0 8.491844596392184e-07
) O 0 1.6244659661879268e-07
; O 0 1.7679532504644158e-07
SIBPAL O 0 1.712686753307935e-05
Pempirical O 0 5.038064955442678e-06
value O 0 5.141888550497242e-07
< O 0 1.3798490954286535e-06
1 O 0 4.0568227177573135e-07
x O 0 6.317938527899969e-07
10 O 0 4.5050936137158715e-07
( O 0 1.7546533115364582e-07
- O 0 6.562177077285014e-07
3 O 0 3.396792465082399e-07
) O 0 3.9344300262200704e-08
) O 0 1.6743841868560594e-08
that O 0 1.6811940284355842e-08
are O 0 3.5315522950440936e-08
linked O 0 2.2403378352464642e-06
to O 0 6.553128173436562e-07
mental O 1 0.9913440942764282
health O 0 0.42088058590888977
wellness O 1 0.9108389616012573
. O 0 5.5074306146707386e-05

These O 0 5.969787252979586e-06
findings O 0 6.312124241958372e-06
are O 0 1.5193340630048624e-07
consistent O 0 5.256912345430464e-07
with O 0 3.779852519869564e-08
the O 0 2.1478393819052144e-07
hypothesis O 0 2.8876030455649015e-07
that O 0 2.478972760400211e-08
certain O 0 4.1455791688349564e-08
alleles O 0 3.0262043537732097e-07
could O 0 1.3116476793584297e-07
prevent O 0 4.353181566330022e-07
or O 0 3.2475819011779095e-07
modify O 0 2.9050821126475057e-07
the O 0 4.080160636021901e-07
clinical O 0 7.971085142344236e-05
manifestations O 0 0.00010304019815521315
of O 0 0.000157586153363809
BPAD B-Disease 1 1.0
and O 0 7.899974434621981e-07
perhaps O 0 6.74148282087117e-07
other O 0 2.9889466190979874e-07
related O 0 0.0027409978210926056
affective B-Disease 1 0.9999998807907104
disorders I-Disease 1 1.0
. O 0 0.0010920100612565875

Segregation O 0 0.012623866088688374
distortion O 1 0.999596893787384
in O 0 0.113261878490448
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0010212560882791877

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9998750686645508
DM B-Disease 1 1.0
) O 0 1.4304520846053492e-05
is O 0 1.3088128980598412e-06
an O 0 2.0758527625730494e-06
autosomal B-Disease 0 0.3125830292701721
dominant I-Disease 1 0.9460958242416382
disease I-Disease 1 0.9978635907173157
which O 0 7.193627880042186e-07
, O 0 1.7686883779788332e-07
in O 0 2.5198997377628984e-07
the O 0 5.914169491916255e-07
typical O 0 1.6550148984606494e-06
pedigree O 0 2.8306060357863316e-06
, O 0 1.828236122491944e-07
shows O 0 1.7606609503673099e-07
a O 0 7.75301487010438e-07
three O 0 4.70671409402712e-07
generation O 0 9.089155355468392e-06
anticipation O 0 3.4638513170648366e-05
cascade O 0 0.000432779110269621
. O 0 2.0408013369888067e-05

This O 0 1.7007709175231867e-05
results O 0 3.089257006649859e-05
in O 0 3.0955437978263944e-05
infertility B-Disease 1 0.9999998807907104
and O 1 0.9997726082801819
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.10185012221336365
CDM B-Disease 1 0.9999527931213379
) O 0 2.909013403495919e-07
with O 0 3.885255850377689e-08
the O 0 5.805367777611536e-07
disappearance O 0 2.412471076240763e-05
of O 0 0.00015478978457394987
DM B-Disease 1 1.0
in O 0 5.7177144299203064e-06
that O 0 2.4385333290410927e-06
pedigree O 0 0.0001864665246102959
. O 0 1.8521785023040138e-05

The O 0 1.3574214790423866e-05
concept O 0 6.8460926740954164e-06
of O 0 4.147369509155396e-06
segregation O 0 1.9196933862986043e-05
distortion O 0 8.115385571727529e-05
, O 0 2.7438531446932757e-07
where O 0 1.4868729181216622e-07
there O 0 5.828990268241796e-08
is O 0 1.0426199281710069e-07
preferential O 0 9.148238859779667e-07
transmission O 0 1.1396851959943888e-06
of O 0 4.508054871621425e-07
the O 0 2.806983161462995e-07
larger O 0 1.6612500530754915e-07
allele O 0 4.25568742912219e-07
at O 0 2.327319862160948e-06
the O 0 3.1834579203859903e-06
DM B-Disease 1 0.9999936819076538
locus O 0 9.41435882850783e-06
, O 0 1.5683195897508995e-07
has O 0 1.2415992500791617e-07
been O 0 2.4807849285934935e-07
put O 0 1.2748255073802284e-07
forward O 0 1.4318275987079687e-07
to O 0 5.413417980548729e-08
explain O 0 4.0775310594654e-07
partially O 0 4.030451691505732e-06
the O 0 1.4228397731130826e-06
maintenance O 0 2.8377897251630202e-05
of O 0 3.081160321016796e-05
DM B-Disease 1 1.0
in O 0 2.2025906218914315e-06
the O 0 3.893545908795204e-06
population O 0 2.7758842406910844e-06
. O 0 6.484819550678367e-06

In O 0 5.054662688053213e-05
a O 0 2.4800832761684433e-05
survey O 0 3.833308073808439e-05
of O 0 3.620719871832989e-05
DM B-Disease 1 0.9999994039535522
in O 0 1.256478526556748e-06
Northern O 0 6.853368859083275e-07
Ireland O 0 1.6758450271936454e-07
, O 0 2.982630746828363e-07
59 O 0 5.815879831061466e-06
pedigrees O 0 4.356115368864266e-06
were O 0 5.167301424080506e-06
ascertained O 0 8.887736476026475e-05
. O 0 1.6254240108537488e-05

Sibships O 0 0.00110530701931566
where O 0 7.4074500844290014e-06
the O 0 1.3451407312459196e-06
status O 0 4.6507170736731496e-07
of O 0 6.457582344410184e-07
all O 0 1.1788950615709837e-07
the O 0 3.3899934237524576e-07
members O 0 7.055876949380036e-08
had O 0 4.038232646053075e-07
been O 0 4.282913437236857e-07
identified O 0 1.744002844361603e-07
were O 0 1.834117853150019e-07
examined O 0 3.2843783515090763e-07
to O 0 6.231447002846835e-08
determine O 0 1.3226488704276562e-07
the O 0 1.4941595054551726e-06
transmission O 0 5.213483291299781e-06
of O 0 3.4054180559905944e-06
the O 0 1.2739223166136071e-05
DM B-Disease 1 0.9999998807907104
expansion O 0 6.181695880513871e-06
from O 0 4.5749521859761444e-07
affected O 0 3.1745881301503687e-07
parents O 0 1.4098388589900424e-07
to O 0 7.320624462181513e-08
their O 0 7.395383363473229e-07
offspring O 0 1.2166866326879244e-05
. O 0 1.2914267244923394e-05

Where O 0 1.643028372200206e-05
the O 0 5.372993655328173e-06
transmitting O 0 0.0001869762345449999
parent O 0 1.3520842912839726e-05
was O 0 0.00010540986841078848
male O 0 1.712136327114422e-05
, O 0 4.352398718765471e-06
58 O 0 9.344324644189328e-05
. O 0 1.746887392073404e-05

3 O 0 3.871445369441062e-05
% O 0 2.4307785224664258e-06
of O 0 1.5530266637142631e-06
the O 0 7.354891522481921e-07
offspring O 0 6.680222668364877e-07
were O 0 5.105495120005799e-07
affected O 0 2.520250745874364e-07
, O 0 9.368471864945604e-08
and O 0 8.600241585554613e-08
in O 0 2.6049133339256514e-07
the O 0 4.432263835951744e-07
case O 0 3.886331114699715e-07
of O 0 7.886018806857464e-07
a O 0 1.7261701259485562e-06
female O 0 5.946218152530491e-06
transmitting O 0 0.0023929181043058634
parent O 0 1.0366239621362183e-05
, O 0 5.823816991323838e-06
68 O 0 0.00011669979721773416
. O 0 2.2798627469455823e-05

7 O 0 0.00012027115735691041
% O 0 9.802945896808524e-06
were O 0 1.5679361240472645e-05
affected O 0 3.410831050132401e-05
. O 0 4.098581848666072e-05

Studies O 0 8.812424493953586e-05
on O 0 2.0588482584571466e-05
meiotic O 0 0.0004062217194586992
drive O 0 1.9512741346261464e-05
in O 0 6.18354715697933e-06
DM B-Disease 1 0.9999829530715942
have O 0 9.504268660975868e-08
shown O 0 2.1945778883036837e-07
increased O 0 6.686016718049359e-07
transmission O 0 8.494436087858048e-07
of O 0 2.843838160515588e-07
the O 0 3.203889775704738e-07
larger O 0 1.9107635296222725e-07
allele O 0 6.892748842801666e-07
at O 0 2.535114617785439e-06
the O 0 2.570595597717329e-06
DM B-Disease 1 0.9999845027923584
locus O 0 2.3448807041859254e-05
in O 0 2.010512389460928e-06
non O 0 0.00010871274571400136
- O 1 0.6729354858398438
DM O 1 1.0
heterozygotes O 0 4.3296160583849996e-05
for O 0 5.755309757660143e-06
CTGn O 0 0.0010399736929684877
. O 0 2.783481977530755e-05

This O 0 5.585381586570293e-06
study O 0 2.392408077867003e-06
provides O 0 4.928160137751547e-07
further O 0 3.747556149846787e-07
evidence O 0 6.263393288463703e-07
that O 0 4.343515342952742e-07
the O 0 4.803493084182264e-06
DM B-Disease 1 0.9999997615814209
expansion O 0 9.068835424841382e-06
tends O 0 6.228416395970271e-07
to O 0 1.078259330711262e-07
be O 0 6.064254876037012e-07
transmitted O 0 1.075816726370249e-05
preferentially O 0 1.1003827239619568e-05
. O 0 8.018598236958496e-06

Diagnosis O 1 0.999980092048645
of O 1 0.6278629302978516
hemochromatosis B-Disease 1 1.0
. O 0 0.0018782473634928465

If O 0 0.00018922076560556889
untreated O 1 0.999187171459198
, O 0 0.00011769711272791028
hemochromatosis B-Disease 1 1.0
can O 0 7.166592240537284e-06
cause O 1 0.9294822812080383
serious O 1 0.9997745156288147
illness O 1 0.9999842643737793
and O 0 1.8080999097946915e-06
early B-Disease 0 8.66005848365603e-06
death I-Disease 0 9.806872549233958e-05
, O 0 2.4447987811981875e-07
but O 0 1.1038105895977424e-07
the O 0 1.0640657137628295e-06
disease O 0 0.002492216881364584
is O 0 4.3339406374798273e-07
still O 0 6.502007181552472e-07
substantially O 0 8.070266630966216e-06
under O 0 5.1699913456104696e-05
- O 1 0.9961733222007751
diagnosed O 1 0.9998927116394043
. O 0 3.2283980544889346e-05

The O 0 3.9826940337661654e-05
cornerstone O 0 0.00013521873916033655
of O 0 2.2492029074783204e-06
screening O 0 1.9260048702562926e-06
and O 0 2.7012492864741944e-07
case O 0 7.897707519077812e-07
detection O 0 2.0888601284241304e-06
is O 0 1.9476547663543897e-07
the O 0 2.465176862642693e-07
measurement O 0 4.101026206626557e-06
of O 0 3.8706298255419824e-06
serum O 0 8.890101162251085e-05
transferrin O 0 6.608094554394484e-05
saturation O 0 4.010681004729122e-05
and O 0 1.3823001836499316e-06
the O 0 7.545750577264698e-06
serum O 0 0.00024953592219389975
ferritin O 0 0.0005991659709252417
level O 0 8.611644443590194e-05
. O 0 3.090459358645603e-05

Once O 0 4.36201153206639e-05
the O 0 4.597245151671814e-06
diagnosis O 0 0.000457065092632547
is O 0 1.1837748843390727e-06
suspected O 0 3.207775080227293e-05
, O 0 4.0279400081999484e-07
physicians O 0 4.772688839693728e-07
must O 0 7.631172138644615e-08
use O 0 3.6349103993416065e-07
serum O 0 0.037503764033317566
ferritin O 0 0.46340492367744446
levels O 0 4.217346941004507e-05
and O 0 1.1876299140567426e-05
hepatic O 1 0.9999998807907104
iron O 1 0.9999659061431885
stores O 0 3.9391488826368e-06
on O 0 1.3630058674607426e-05
liver O 1 0.994841992855072
biopsy O 1 0.7266112565994263
specimens O 0 1.279482262361853e-06
to O 0 2.626841535402491e-07
assess O 0 9.003179002320394e-07
patients O 0 5.16381533088861e-07
for O 0 1.286290540747359e-07
the O 0 1.0293273362549371e-06
presence O 0 4.5189503907749895e-06
of O 0 0.000317472469760105
iron B-Disease 1 0.9999780654907227
overload I-Disease 1 0.9759077429771423
. O 0 3.504042615531944e-05

Liver O 1 0.9999983310699463
biopsy O 1 0.9999479055404663
is O 0 7.974275831656996e-06
also O 0 3.3234897500733496e-07
used O 0 7.323766482159044e-08
to O 0 5.3991467297009876e-08
establish O 0 3.410276008253277e-07
the O 0 7.758732749607589e-07
presence O 0 1.5067904541865573e-06
or O 0 4.868952601100318e-07
absence O 0 5.706252977688564e-06
of O 0 4.754277142637875e-06
cirrhosis B-Disease 1 0.9999986886978149
, O 0 5.282965389596939e-07
which O 0 1.7016709819017706e-07
can O 0 1.7813741237659997e-07
affect O 0 9.215398677042685e-06
prognosis O 1 0.9999493360519409
and O 0 1.5144868484640028e-05
management O 0 0.00020892730390187353
. O 0 1.659773988649249e-05

A O 0 0.0006054876721464097
DNA O 0 9.08831279957667e-05
- O 0 5.6590837630210444e-05
based O 0 1.2600903573911637e-06
test O 0 3.9170137711153075e-07
for O 0 2.230494260402338e-07
the O 0 9.391476964992762e-07
HFE O 0 8.732586138648912e-05
gene O 0 2.6433872335474007e-07
is O 0 6.560112097986348e-08
commercially O 0 1.7256913054097822e-07
available O 0 2.3507718438509073e-08
, O 0 2.5600357389521378e-08
but O 0 8.191578970695446e-09
its O 0 2.7853557682533392e-08
place O 0 1.4403708803456539e-07
in O 0 2.0001382949885738e-07
the O 0 1.1097832839368493e-06
diagnosis O 0 0.011180940084159374
of O 0 0.0026658079586923122
hemochromatosis B-Disease 1 1.0
is O 0 8.452499059785623e-06
still O 0 1.0035270179287181e-06
being O 0 6.193095941853244e-06
evaluated O 0 1.278792569792131e-05
. O 0 9.587311978975777e-06

Currently O 0 4.79921254736837e-05
, O 0 2.4679932266735705e-06
the O 0 4.740526833302283e-07
most O 0 6.312000522257222e-08
useful O 0 1.111093723693557e-07
role O 0 2.3887938027655764e-07
for O 0 6.376131267415985e-08
this O 0 6.85966625724177e-08
test O 0 1.0888678048104339e-07
is O 0 6.367527305428666e-08
in O 0 8.336672863151762e-08
the O 0 4.091468781552976e-07
detection O 0 7.800594175932929e-06
of O 0 6.032325472915545e-05
hemochromatosis B-Disease 1 1.0
in O 0 2.739664296314004e-06
the O 0 8.252285965681949e-07
family O 0 1.2103464541723952e-07
members O 0 3.912279566975485e-08
of O 0 3.796601504291175e-07
patients O 0 2.7981789685327385e-07
with O 0 1.0026529650986049e-07
a O 0 6.8680055846925825e-06
proven O 0 0.00014692106924485415
case O 0 1.9114959286525846e-06
of O 0 6.528316589538008e-06
the O 0 0.00017350705456919968
disease O 1 0.9980652928352356
. O 0 2.6076870199176483e-05

It O 0 5.241700819169637e-06
is O 0 1.5777466160216136e-06
crucial O 0 6.489217867056141e-06
to O 0 4.472338332561776e-06
diagnose O 1 0.999988317489624
hemochromatosis B-Disease 1 1.0
before O 1 0.9999020099639893
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 0.08691223710775375
because O 0 7.170679964474402e-06
phlebotomy O 1 0.9999569654464722
therapy O 0 0.018805207684636116
can O 0 3.5715260082724853e-07
avert O 0 0.11445079743862152
serious O 1 0.9999997615814209
chronic O 1 1.0
disease O 1 0.9999972581863403
and O 0 6.516589223792835e-07
can O 0 4.432812872323666e-08
even O 0 4.51067379003689e-08
lead O 0 1.287404813865578e-07
to O 0 5.029573557635558e-08
normal O 0 2.331113819309394e-06
life O 0 2.302128450537566e-06
expectancy O 0 2.4854743969626725e-05
. O 0 1.4487237649518647e-06
. O 0 4.769826773554087e-06

Prevalence O 0 0.003632721258327365
of O 0 4.5051212509861216e-05
the O 0 2.0528255845420063e-05
I1307K O 0 0.001539331628009677
APC B-Disease 0 6.406819011317566e-05
gene O 0 7.4773572578124e-07
variant O 0 8.294244935314055e-07
in O 0 5.997515017952537e-08
Israeli O 0 3.6234058597983676e-07
Jews O 0 7.443442484600382e-08
of O 0 4.4123741105295267e-08
differing O 0 1.5903447447840335e-08
ethnic O 0 2.0809251211062474e-08
origin O 0 1.223801007199654e-07
and O 0 2.60269843010974e-07
risk O 0 0.00021755998022854328
for O 0 0.0020312131382524967
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.001088102231733501

BACKGROUND O 0 0.0006557184970006347
& O 0 0.00016632750339340419
AIMS O 0 1.769767732184846e-05
Israeli O 0 1.9359604266355745e-05
Jews O 0 2.7099727049062494e-06
of O 0 1.878681473499455e-06
European O 0 8.02830072643701e-07
birth O 0 2.4571220365032787e-06
, O 0 4.6727990365980077e-07
i O 0 4.1942143980122637e-07
. O 0 1.4704784234709223e-07
e O 0 6.127996243776579e-07
. O 0 4.238776440956826e-08
, O 0 1.2853242026267253e-07
Ashkenazim O 0 1.7912304883793695e-06
, O 0 4.495694483352963e-08
have O 0 2.9607010176846416e-08
the O 0 1.1455389312686748e-06
highest O 1 0.9999746084213257
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9999926090240479
of O 0 1.4138894584903028e-05
any O 0 6.220337809281773e-07
Israeli O 0 2.0099440007470548e-05
ethnic O 0 1.4022602954355534e-06
group O 0 5.2863451855955645e-06
. O 0 1.0505900718271732e-05

The O 0 0.000280414882581681
I1307K O 0 0.0030617567244917154
APC B-Disease 0 0.00021360038954298943
gene O 0 9.480407243245281e-06
variant O 0 1.1662898941722233e-05
was O 0 3.613597073126584e-05
found O 0 1.1616671145020518e-06
in O 0 1.951203557837289e-06
6 O 0 4.93410843773745e-05
. O 0 1.6304804375977255e-05

1 O 0 2.403996404609643e-05
% O 0 1.5296171795853297e-06
of O 0 9.76887918113789e-07
American O 0 1.9722046999959275e-06
Jews O 0 4.5506411083806597e-07
, O 0 2.2324286419461714e-07
28 O 0 5.538253162740148e-07
% O 0 9.298722858375186e-08
of O 0 2.6265408337167173e-07
their O 0 1.9540023004083196e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.00022059287584852427
, O 0 9.447342108614976e-07
but O 0 1.1402381971947761e-07
not O 0 1.0775520564720864e-07
in O 0 7.238178909574344e-07
non O 0 1.932472332555335e-05
- O 0 3.331621701363474e-05
Jews O 0 7.292469490494113e-06
. O 0 6.851272246422013e-06

We O 0 1.4639827895734925e-05
assessed O 0 1.5089623047970235e-05
the O 0 2.073747737085796e-06
I1307K O 0 5.6566070270491764e-05
prevalence O 0 9.239087376045063e-06
in O 0 1.7604963886697078e-07
Israeli O 0 4.792776167050761e-07
Jews O 0 1.2266356463896955e-07
of O 0 7.170928739697047e-08
differing O 0 1.9138559181897108e-08
ethnic O 0 1.540821159551342e-08
origin O 0 1.5886143955867738e-07
and O 0 4.102670629890781e-07
risk O 0 7.593133341288194e-05
for O 0 0.0006961136241443455
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.001941676251590252

METHODS O 0 0.00014924563583917916
DNA O 0 2.5773417291929945e-05
samples O 0 5.693891580449417e-06
from O 0 1.9265391983935842e-06
500 O 0 1.3475237210514024e-06
unrelated O 0 7.653093803128286e-07
Jews O 0 4.846858132623311e-07
of O 0 1.1417652103773435e-06
European O 0 1.4275860849011224e-06
or O 0 4.914844566883403e-07
non O 0 4.517029083217494e-06
- O 0 2.6824857286555925e-06
European O 0 2.3179715924470656e-07
origin O 0 5.53817969262127e-08
, O 0 4.023555177923299e-08
with O 0 1.412713235282581e-08
or O 0 9.731770944654272e-08
without O 0 8.514503235801385e-08
a O 0 1.1437629154897877e-06
personal O 0 2.3792090360075235e-06
and O 0 1.8764254718917073e-06
/ O 0 0.00012557461741380394
or O 0 4.4418140987545485e-07
family O 0 1.9017410579635907e-07
history O 0 8.936490871747083e-07
of O 0 6.779006071155891e-06
neoplasia B-Disease 0 0.4418090581893921
, O 0 3.363134339906537e-07
were O 0 4.5476645027520135e-07
examined O 0 9.402535283697944e-07
for O 0 1.9582037680265785e-07
the O 0 8.579709174227901e-07
I1307K O 0 2.6432702725287527e-05
variant O 0 1.5888612097114674e-06
by O 0 3.1109158271647175e-07
the O 0 7.060419875415391e-07
allele O 0 2.0315985693741823e-06
- O 0 4.9232271521759685e-06
specific O 0 6.077918897062773e-07
oligonucleotide O 0 0.00019882526248693466
( O 0 5.079873972135829e-06
ASO O 0 0.0025539910420775414
) O 0 1.6188625977520132e-06
method O 0 4.214609816699522e-06
. O 0 8.918848834582604e-06

RESULTS O 0 5.763148146797903e-05
In O 0 1.2823775250581093e-06
persons O 0 5.55344797703583e-07
at O 0 2.665944521140773e-06
average O 0 4.169589828961762e-06
risk O 0 2.4954280888778158e-05
for O 0 0.00015516586427111179
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.773678614990786e-05
I1307K O 0 0.29259395599365234
was O 0 8.970798080554232e-05
found O 0 6.978561941650696e-07
in O 0 2.0972936454199953e-06
5 O 0 1.201348550239345e-05
. O 0 1.9148263163515367e-05

0 O 0 7.250662019941956e-05
% O 0 5.343534212443046e-06
of O 0 5.302921636030078e-06
120 O 0 5.765895821241429e-06
European O 0 4.8103370318131056e-06
and O 0 2.2292276753432816e-06
1 O 0 2.0452356693567708e-05
. O 0 1.784639789548237e-05

6 O 0 7.649471808690578e-05
% O 0 8.066880582191516e-06
of O 0 7.399612968583824e-06
188 O 0 1.6846992366481572e-05
non O 0 1.1687986443575937e-05
- O 0 7.0354080889956094e-06
European O 0 9.920975116983755e-07
Jews O 0 1.3355361261346843e-06
( O 0 7.172898222052027e-07
P O 0 1.1356339200574439e-05
= O 0 1.4437033541980782e-06
0 O 0 5.174399575480493e-07
. O 0 2.448971088142571e-07
08 O 0 4.798584541276796e-06
) O 0 8.010381975509517e-07
. O 0 4.12550753026153e-06

It O 0 1.368725406791782e-05
occurred O 0 5.7467605074634776e-05
in O 0 9.500636224402115e-06
15 O 0 3.410957651794888e-05
. O 0 2.6459336368134245e-05

4 O 0 8.13748556538485e-05
% O 0 4.456908754946198e-06
of O 0 4.436786184669472e-06
52 O 0 1.7461663446738385e-05
Ashkenazi O 0 3.987068703281693e-05
Israelis O 0 4.965366315445863e-06
with O 0 7.059026074784924e-07
familial O 1 0.8145950436592102
cancer B-Disease 1 0.9999979734420776
( O 0 2.5118593839579262e-05
P O 0 0.010896795429289341
= O 0 2.883260094677098e-06
0 O 0 3.869179749926843e-07
. O 0 8.163927134319238e-08
02 O 0 4.869541953667067e-06
) O 0 3.1629291186163755e-08
and O 0 2.8219432124387822e-08
was O 0 1.0109387176271412e-06
not O 0 2.2520087128441446e-08
detected O 0 3.4145682548114564e-07
in O 0 3.419511926949781e-07
51 O 0 1.9677859199873637e-06
non O 0 3.7645850170520134e-06
- O 0 2.570904371168581e-06
European O 0 1.6145872905326542e-07
Jews O 0 1.7964964627026347e-07
at O 0 1.3643002603203058e-06
increased O 0 1.469503877160605e-05
cancer B-Disease 0 0.07933808863162994
risk O 0 2.7817282898467965e-05
. O 0 1.5229044038278516e-05

Colorectal B-Disease 1 0.9999933242797852
neoplasia I-Disease 1 0.99994957447052
occurred O 0 0.004692914430052042
personally O 0 5.5493634135928005e-05
or O 0 1.7534785001771525e-06
in O 0 8.116631988741574e-07
the O 0 6.285605422817753e-07
families O 0 7.808102964190766e-08
of O 0 9.56960548137431e-07
13 O 0 2.7534968012332683e-06
of O 0 2.8780734737665625e-06
20 O 0 5.426621100923512e-06
Ashkenazi O 0 3.654071770142764e-05
I1307K O 0 3.32942399836611e-05
carriers O 0 4.095259384939709e-07
, O 0 1.6467478758386278e-07
8 O 0 7.762943710076797e-07
of O 0 5.124021527080913e-07
whom O 0 3.636477572399599e-07
also O 0 2.9420354508147284e-07
had O 0 1.1814910294560832e-06
a O 0 1.8736197944235755e-06
personal O 0 3.881659722537734e-06
or O 0 1.2829904108002665e-06
family O 0 1.2436889846867416e-06
history O 0 8.830273145576939e-06
of O 0 0.00019981921650469303
noncolonic O 1 0.9991338849067688
neoplasia B-Disease 1 0.9999411106109619
. O 0 8.067315502557904e-05

CONCLUSIONS O 0 0.0009277339559048414
The O 0 0.0001115313425543718
I1307K O 0 0.006430274806916714
APC O 0 0.0006396527751348913
variant O 0 2.0963974748156033e-05
may O 0 1.6474310768899159e-06
represent O 0 2.3087365264018445e-07
a O 0 1.269208155463275e-06
susceptibility O 0 8.217869617510587e-05
gene O 0 7.5497309808270074e-06
for O 0 1.096302003134042e-05
colorectal B-Disease 1 1.0
, I-Disease 0 9.942628821590915e-06
or I-Disease 0 1.2896834959974512e-06
other I-Disease 0 2.1034661301655433e-07
, I-Disease 0 1.0983948186549242e-06
cancers I-Disease 0 0.49434894323349
in O 0 1.2544788887680625e-06
Ashkenazi O 0 1.0349939657317009e-05
Jews O 0 6.700845460727578e-07
, O 0 9.480495322122806e-08
and O 0 1.5497022332056076e-07
partially O 0 1.7304575521848164e-05
explains O 0 1.6653631291774218e-06
the O 0 8.129166531034571e-07
higher O 0 3.422861118451692e-05
incidence O 1 0.998687207698822
of O 1 0.9988196492195129
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.8740178095176816e-05
European O 0 1.2372307537589222e-05
Israelis O 0 2.13588573387824e-05
. O 0 9.433726518182084e-06

Systematic O 0 0.0006186385289765894
analysis O 0 7.345189806073904e-05
of O 0 3.677578206406906e-05
coproporphyrinogen O 1 0.9815855026245117
oxidase O 0 0.1555744707584381
gene O 0 0.005140198860317469
defects O 1 0.9712966084480286
in O 0 7.854159775888547e-06
hereditary B-Disease 1 0.9999940395355225
coproporphyria I-Disease 1 0.9980127811431885
and O 0 6.557925189554226e-06
mutation O 0 0.00022044379147700965
update O 0 6.172154098749161e-05
. O 0 1.2330987374298275e-05

Hereditary B-Disease 1 0.9999868869781494
coproporphyria I-Disease 1 0.9994044303894043
( O 0 0.00013397328439168632
HC B-Disease 1 0.9999827146530151
) O 0 5.9620829233608674e-06
is O 0 3.028340415767161e-06
an O 0 0.000453530577942729
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.015015925280749798
autosomal O 1 0.9999996423721313
dominant O 1 0.9493180513381958
inheritance O 1 0.6523002982139587
caused O 1 0.9993149042129517
by O 0 8.230662388086785e-06
deficient B-Disease 0 0.13761158287525177
activity I-Disease 0 1.9735405658138916e-05
of I-Disease 0 6.016698171151802e-05
coproporphyrinogen I-Disease 1 0.997240424156189
III I-Disease 1 0.9999958276748657
oxidase I-Disease 0 0.0010638654930517077
( O 0 2.244042480015196e-05
CPO O 1 0.9965224266052246
) O 0 7.825441571185365e-06
. O 0 1.1494235877762549e-05

Clinical O 1 0.906004011631012
manifestations O 0 0.2754985988140106
of O 0 0.0001134105259552598
the O 0 0.000250174110988155
disease O 1 0.9991081357002258
are O 0 2.743303753049986e-07
characterized O 0 2.164149918826297e-05
by O 0 2.9223926958366064e-06
acute O 1 1.0
attacks O 1 0.8111861944198608
of O 1 0.9999477863311768
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.801415030262433e-05
precipitated O 1 0.9836475253105164
by O 0 9.860033287623082e-07
drugs O 0 2.0268996649974724e-06
, O 0 5.117145178701321e-07
fasting O 0 1.2341045476205181e-05
, O 0 1.9003192619493348e-06
cyclical O 1 0.9996516704559326
hormonal O 1 0.9979154467582703
changes O 0 4.689625711762346e-06
, O 0 1.2051847079419531e-05
or O 0 0.007434756960719824
infectious B-Disease 1 1.0
diseases I-Disease 1 1.0
. O 0 0.0008129760972224176

Skin O 1 0.9999955892562866
photosensitivity O 1 0.9999964237213135
may O 0 0.0004979066434316337
also O 0 5.681671154889045e-06
be O 0 1.7637072460274794e-06
present O 0 3.4486370168451685e-06
. O 0 1.2562875781441107e-05

The O 0 2.6953257474815473e-05
seven O 0 4.7270468712667935e-06
exons O 0 1.2469224202504847e-05
, O 0 1.4646410591012682e-06
the O 0 1.9757119389396394e-06
exon O 0 1.57546965056099e-05
/ O 0 9.954022061720025e-06
intron O 0 1.2266641533642542e-05
boundaries O 0 4.287572323846689e-07
and O 0 1.728501217712619e-07
part O 0 4.1881548895617016e-07
of O 0 1.2117732239858015e-06
3 O 0 1.1473856602606247e-06
noncoding O 0 2.6398984118713997e-06
sequence O 0 2.97112791258769e-07
of O 0 7.84862493219407e-07
the O 0 1.0686012501537334e-06
CPO O 0 1.5347768567153253e-05
gene O 0 1.1621574458331452e-07
were O 0 2.0207993145504588e-07
systematically O 0 1.19194032777159e-06
analyzed O 0 8.550948678021086e-07
by O 0 5.182167228667822e-07
an O 0 2.0429486085049575e-06
exon O 0 9.172654245048761e-06
- O 0 9.083523764275014e-06
by O 0 3.399846264073858e-06
- O 0 2.8345415557851084e-05
exon O 0 1.50234291140805e-05
denaturing O 0 0.00010127256973646581
gradient O 0 0.0002083601284539327
gel O 0 2.551292891439516e-05
electrophoresis O 0 1.8241054931422696e-05
( O 0 1.308116679865634e-06
DGGE O 0 6.208636477822438e-05
) O 0 1.4138755943804426e-07
strategy O 0 2.0145917289937643e-07
followed O 0 7.641717303386031e-08
by O 0 2.098078155654548e-08
direct O 0 1.9306412468722556e-07
sequencing O 0 4.808819085155847e-07
in O 0 2.965981025226938e-07
seven O 0 8.129778166221513e-07
unrelated O 0 2.3337365746556316e-06
heterozygous O 0 4.1535008676873986e-06
HC B-Disease 0 0.09195759892463684
patients O 0 1.2002924449916463e-06
from O 0 8.966949849309458e-07
France O 0 1.435675471839204e-06
, O 0 3.080851058712142e-07
Holland O 0 9.055153782355774e-07
, O 0 6.69351933879625e-08
and O 0 1.2351696909718157e-07
Czech O 0 2.768423655652441e-06
Republic O 0 6.87440115143545e-06
. O 0 1.5629902918590233e-05

Seven O 0 3.775464210775681e-05
novel O 0 1.9934816009481438e-05
mutations O 0 7.052881755953422e-06
and O 0 8.424353836744558e-07
two O 0 1.5535852071479894e-07
new O 0 3.025538148904161e-07
polymorphisms O 0 4.421676749188919e-06
were O 0 3.3121159503934905e-06
detected O 0 7.240015111165121e-05
. O 0 1.7593662050785497e-05

Among O 0 4.800415808858816e-06
these O 0 2.718004452617606e-07
mutations O 0 8.817245884529257e-07
two O 0 2.6544850584286905e-07
are O 0 1.363806916288013e-07
missense O 0 1.0517479495320003e-05
( O 0 1.3612058182843612e-06
G197W O 0 6.595999730052426e-05
, O 0 1.0538688002270646e-06
W427R O 0 2.1016763639636338e-05
) O 0 2.941165746506158e-07
, O 0 1.4024233507825556e-07
two O 0 8.877779578142508e-08
are O 0 1.1770144681122474e-07
nonsense O 0 1.6804919141577557e-05
( O 0 1.3536443930206588e-06
Q306X O 0 5.6395660067209974e-05
, O 0 1.4130871477391338e-06
Q385X O 0 2.373075403738767e-05
) O 0 2.3300464135900256e-07
, O 0 1.2672545324221574e-07
two O 0 3.311542684514279e-08
are O 0 2.57888448373933e-08
small O 0 1.7408838459687104e-07
deletions O 0 5.261674232315272e-06
( O 0 2.856226046787924e-06
662de14bp O 0 0.00012869368947576731
; O 0 6.16550153154094e-07
1168del3bp O 0 1.3195575775171164e-05
removing O 0 1.7856651766123832e-06
a O 0 1.6493944485773682e-06
glycine O 0 2.6620928110787645e-06
at O 0 3.389771563888644e-06
position O 0 8.586634976381902e-07
390 O 0 1.4931010809959844e-06
) O 0 9.057661287670271e-08
, O 0 8.522578553993299e-08
and O 0 1.2594712472946412e-07
one O 0 2.0888312235456397e-07
is O 0 3.4276285987289157e-07
a O 0 1.1718617543010623e-06
splicing O 0 2.1638732050632825e-06
mutation O 0 2.525828449506662e-06
( O 0 3.093415671173716e-06
IVS1 O 0 0.006673348601907492
- O 0 5.56491177121643e-05
15c O 0 0.00021908851340413094
- O 0 2.6049328880617395e-05
- O 0 1.752102980390191e-05
> O 0 3.6382016332936473e-06
g O 0 1.8183957308792742e-06
) O 0 7.915089383914165e-08
which O 0 7.869132900850673e-08
creates O 0 5.627946961794805e-07
a O 0 9.86490590548783e-07
new O 0 1.1810956266344874e-06
acceptor O 0 2.502661345715751e-06
splice O 0 2.6886327759712003e-05
site O 0 1.8840817574528046e-05
. O 0 1.2353774764051195e-05

The O 0 3.443572859396227e-05
pathological O 0 0.00011398415517760441
significance O 0 6.669142294413177e-06
of O 0 4.425528459250927e-06
the O 0 2.0780710201506736e-06
point O 0 5.826138931297464e-06
mutations O 0 2.263382839373662e-06
G197W O 0 0.00018080072186421603
, O 0 2.127919060512795e-06
W427R O 0 0.00011658402218017727
, O 0 7.238496664285776e-07
and O 0 2.653879960234917e-07
the O 0 1.3783707117909216e-06
in O 0 3.1758463592268527e-06
- O 0 5.9967420384055004e-05
frame O 0 2.1834124709130265e-05
deletion O 0 4.106548203708371e-06
390delGly O 0 4.855213319387985e-06
were O 0 3.237510100007057e-07
assessed O 0 4.86062504023721e-07
by O 0 5.201229313911426e-08
their O 0 1.8292540815423308e-08
respective O 0 2.202196753842145e-07
expression O 0 6.888760140100203e-07
in O 0 1.978205261821131e-07
a O 0 2.6500333660806064e-07
prokaryotic O 0 2.6251061058246705e-07
system O 0 4.274303648799105e-07
using O 0 2.205572258162647e-07
site O 0 2.386990900049568e-06
- O 0 7.635519068571739e-06
directed O 0 6.551474598381901e-06
mutagenesis O 0 5.822532330057584e-05
. O 0 8.916688784665894e-06

These O 0 1.4328290944831679e-06
mutations O 0 3.0844926186546218e-06
resulted O 0 4.445379545359174e-06
in O 0 4.486314821861015e-07
the O 0 7.493226803489961e-07
absence O 0 2.560408120189095e-06
or O 0 1.0065887323662537e-07
a O 0 6.94888342422928e-07
dramatic O 0 3.6453179745876696e-06
decrease O 0 8.83078701008344e-06
of O 0 2.638120531628374e-05
CPO O 1 0.9237514138221741
activity O 0 7.034148438833654e-05
. O 0 9.441853762837127e-06

The O 0 1.3170420061214827e-05
two O 0 9.93113303593418e-07
polymorphisms O 0 2.7241569569014246e-06
were O 0 5.225601285019366e-07
localized O 0 2.0371276150399353e-06
in O 0 4.1560781482985476e-07
noncoding O 0 1.8401586885374854e-06
part O 0 3.8816713754386e-07
of O 0 6.88337479459733e-07
the O 0 2.837674912825605e-07
gene O 0 1.992568599007427e-07
1 O 0 9.226603197021177e-07
) O 0 2.0084185337054805e-07
a O 0 3.6601613828679547e-06
C O 0 7.111827289918438e-05
/ O 0 2.0142502762610093e-05
G O 0 1.0173732334806118e-05
polymorphism O 0 1.084996711142594e-06
in O 0 4.411347731547721e-07
the O 0 1.1651842442006455e-06
promotor O 0 2.7778552976087667e-05
region O 0 7.778365329613735e-07
, O 0 7.487454354304646e-07
142 O 0 4.805147000297438e-06
bp O 0 7.689895028306637e-06
upstream O 0 3.3950254874071106e-06
from O 0 4.198099929908494e-07
the O 0 4.486811349124764e-07
transcriptional O 0 6.0950233091716655e-06
initiation O 0 3.0348396649060305e-06
site O 0 1.7456882233091164e-06
( O 0 5.837746357428841e-07
- O 0 8.84265227796277e-06
142C O 0 7.16804715921171e-05
/ O 0 1.0555984772508964e-05
G O 0 1.099900146073196e-05
) O 0 1.2929712056575227e-07
, O 0 1.3298088674673636e-07
and O 0 1.477495743529289e-07
2 O 0 8.010526926227612e-07
) O 0 1.4860592045806698e-07
a O 0 1.2365138672976173e-06
6 O 0 2.917013262049295e-06
bp O 0 5.078905360278441e-06
deletion O 0 1.0119670150743332e-06
polymorphism O 0 7.18209776096046e-07
in O 0 1.5874603320753522e-07
the O 0 3.1188204729915014e-07
3 O 0 3.5196438830098487e-07
noncoding O 0 9.072622901840077e-07
part O 0 3.263957353283331e-07
of O 0 1.1497450032038614e-06
the O 0 2.779025635391008e-06
CPO O 0 0.00010442680650157854
gene O 0 9.023335678648436e-07
, O 0 8.222951350944641e-07
574 O 0 1.6620517271803692e-05
bp O 0 4.950217316945782e-06
downstream O 0 2.3172299279394792e-06
of O 0 1.1378692761354614e-06
the O 0 8.241180466939113e-07
last O 0 1.192565605379059e-06
base O 0 1.8032042135018855e-06
of O 0 5.882365599063633e-07
the O 0 1.3375525895753526e-06
normal O 0 4.126699877815554e-06
termination O 0 1.2864471500506625e-05
codon O 0 9.695245353213977e-06
( O 0 6.221173975973215e-07
+ O 0 2.1720918539358536e-06
574 O 0 3.605662641348317e-05
delATTCTT O 0 4.665344022214413e-05
) O 0 4.039182840642752e-06
. O 0 1.1288215318927541e-05

Five O 0 8.449580491287634e-05
intragenic O 0 0.0007352655520662665
dimorphisms O 0 0.00020908295118715614
are O 0 5.727914071940177e-07
now O 0 3.552652287908131e-07
well O 0 1.461608718500429e-07
characterized O 0 6.717692713209544e-07
and O 0 9.487551011488904e-08
the O 0 1.8205372498414363e-07
high O 0 2.412839876342332e-06
degree O 0 2.625554316182388e-06
of O 0 1.0732626378739951e-06
allelic O 0 5.6095746003848035e-06
heterogeneity O 0 6.2273988987726625e-06
in O 0 1.567307435834664e-06
HC B-Disease 0 0.11129447817802429
is O 0 8.46858483782853e-07
demonstrated O 0 8.274446372524835e-07
with O 0 3.209081711474937e-08
seven O 0 8.408535023818331e-08
new O 0 2.6258989649363684e-08
different O 0 3.3937852528254098e-09
mutations O 0 5.4968314344705504e-08
making O 0 6.34609094163352e-08
a O 0 1.3657462716309965e-07
total O 0 6.473601956713537e-07
of O 0 2.3718826014373917e-06
nineteen O 0 4.443601574166678e-05
CPO O 1 0.8970758318901062
gene B-Disease 0 4.491316940402612e-05
defects I-Disease 0 0.10704225301742554
reported O 0 9.821923413255718e-06
so O 0 4.4926085251972836e-07
far O 0 8.322253961523529e-07
. O 0 9.331250794275547e-07
. O 0 4.56002589999116e-06

Coincidence O 0 0.0002596843405626714
of O 0 1.7454121916671284e-05
two O 0 2.997235242219176e-06
novel O 0 1.0822398508025799e-05
arylsulfatase O 0 7.52250271034427e-05
A O 0 4.4224020712135825e-06
alleles O 0 4.673124465170986e-07
and O 0 1.9041928567276045e-07
mutation O 0 3.6983437894377857e-06
459 O 0 0.00013315465184859931
+ O 0 2.543388109188527e-05
1G O 0 0.08769925683736801
> O 0 4.949712547386298e-06
A O 0 1.496642312304175e-06
within O 0 9.080996932198104e-08
a O 0 2.8406179808371235e-07
family O 0 3.971161675053736e-07
with O 0 1.1897835747731733e-06
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 0.9999982118606567
: O 0 3.7629052940246766e-07
molecular O 0 1.4968536561354995e-06
basis O 0 6.642100629505876e-07
of O 0 2.1331695734261302e-06
phenotypic O 0 2.882746593968477e-05
heterogeneity O 0 0.00022645163699053228
. O 0 3.669100988190621e-05

In O 0 3.876565460814163e-05
a O 0 1.0386881513113622e-05
family O 0 9.448504556530679e-07
with O 0 1.6494480803430633e-07
three O 0 6.121535989223048e-07
siblings O 0 1.7054284171535983e-06
, O 0 3.0944875106797554e-07
one O 0 2.0591886595866526e-07
developed O 0 1.779602825990878e-06
classical O 0 3.3642158086877316e-05
late O 0 0.00022467263625003397
infantile O 1 0.9999649524688721
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.6472005629329942e-05
MLD B-Disease 1 1.0
) O 0 7.881131978138001e-07
, O 0 2.1190683696659107e-07
fatal O 0 1.7194868632941507e-05
at O 0 2.8665492664003978e-06
age O 0 8.45320528242155e-07
5 O 0 7.700571700297587e-07
years O 0 5.473897317642695e-07
, O 0 2.408907562312379e-07
with O 0 3.1380972131955787e-07
deficient O 0 0.0023296079598367214
arylsulfatase O 0 0.0017442659009248018
A O 0 0.0002440821990603581
( O 0 1.6890674032765673e-06
ARSA O 0 0.00028828828362748027
) O 0 1.686735231487546e-07
activity O 0 7.223366651487595e-07
and O 0 2.639679053118016e-07
increased O 0 1.0853696039703209e-05
galactosylsulfatide O 0 0.00034154453896917403
( O 0 1.0375289093644824e-05
GS O 1 0.9999926090240479
) O 0 2.5958913738577394e-06
excretion O 0 2.745809979387559e-05
. O 0 7.72699604567606e-06

The O 0 2.4621542252134532e-05
two O 0 2.0244963252480375e-06
other O 0 4.0708829374125344e-07
siblings O 0 2.3940765458974056e-06
, O 0 1.2532042319435277e-06
apparently O 0 4.933068794343853e-06
healthy O 0 1.8683329017221695e-06
at O 0 3.1244458114088047e-06
12 O 0 8.5327252463685e-07
( O 0 1.0468922795325852e-07
1 O 0 6.295299499470275e-07
/ O 0 7.330571634156513e-07
2 O 0 2.1834301833223435e-07
) O 0 3.637163814573796e-08
and O 0 5.788617229995907e-08
15 O 0 3.4352731859144114e-07
years O 0 1.5518023133154202e-07
, O 0 7.283118463874416e-08
respectively O 0 3.531088168529095e-07
, O 0 6.246011707844445e-08
and O 0 4.21600603317529e-08
their O 0 5.107345302235444e-08
father O 0 3.2899754387472058e-06
, O 0 4.55718122793769e-07
apparently O 0 5.241970939096063e-06
healthy O 0 8.593581810600881e-07
as O 0 3.722770713920909e-07
well O 0 1.7903664684126852e-07
, O 0 1.959937492301833e-07
presented O 0 2.4724197373870993e-06
ARSA O 0 0.05755513533949852
and O 0 2.622648707983899e-06
GS O 1 0.9999774694442749
values O 0 1.1899419405381195e-07
within O 0 6.566108368133428e-08
the O 0 2.459972847645986e-07
range O 0 1.7876178617370897e-06
of O 0 3.116580774076283e-05
MLD B-Disease 1 1.0
patients O 0 5.721775960410014e-05
. O 0 2.3714983399258927e-05

Mutation O 0 0.00010046028910437599
screening O 0 1.4648096112068743e-05
and O 0 8.456608497908746e-07
sequence O 0 1.464677438889339e-06
analysis O 0 1.1577673149076873e-06
disclosed O 0 2.598442279122537e-06
the O 0 6.719434963997628e-07
involvement O 0 2.6122122562810546e-06
of O 0 9.601984629625804e-07
three O 0 2.3723977449208178e-07
different O 0 6.961047915865493e-08
ARSA O 0 7.925313548184931e-05
mutations O 0 2.894727799684915e-07
being O 0 2.577613997800654e-07
the O 0 6.236964367190012e-08
molecular O 0 4.738750476462883e-07
basis O 0 3.119531299944356e-07
of O 0 2.8290598947933177e-06
intrafamilial O 0 6.794859655201435e-05
phenotypic O 0 1.5407149476232007e-05
heterogeneity O 0 9.089317609323189e-05
. O 0 2.449124622216914e-05

The O 0 0.00021347436995711178
late O 0 0.002895816694945097
infantile O 1 0.9999746084213257
patient O 0 0.1639239490032196
inherited O 1 0.9330191016197205
from O 0 3.3260883355978876e-05
his O 0 4.020254345959984e-05
mother O 0 1.138426159741357e-05
the O 0 2.69083329840214e-06
frequent O 0 3.4937836517201504e-06
0 O 0 3.2803104659251403e-06
- O 0 5.925719506194582e-06
type O 0 1.6100143511721399e-06
mutation O 0 2.4500484414602397e-06
459 O 0 0.00016107913688756526
+ O 0 1.604626959306188e-05
1G O 0 0.007392229977995157
> O 0 2.8432245926524047e-06
A O 0 3.7594222703773994e-06
, O 0 1.3409839993983041e-07
and O 0 1.0837355546300387e-07
from O 0 4.58226594446387e-07
his O 0 2.11480960388144e-06
father O 0 3.7937311390123796e-06
a O 0 2.0582926936185686e-06
novel O 0 1.8857467694033403e-06
, O 0 2.3520057368386915e-07
single O 0 1.6896893839657423e-06
basepair O 0 4.7093635657802224e-05
microdeletion O 0 2.2303387595457025e-05
of O 0 4.212062322039856e-06
guanine O 0 5.235046501184115e-06
at O 0 3.692331574711716e-06
nucleotide O 0 2.3081738618202507e-06
7 O 0 1.964139755727956e-06
in O 0 6.729220558554516e-07
exon O 0 3.118040240224218e-06
1 O 0 2.989932227137615e-06
( O 0 1.3007844472667784e-06
7delG O 0 2.52535810432164e-05
) O 0 4.508378424361581e-06
. O 0 8.313136277138256e-06

The O 0 6.028563802829012e-05
two O 0 1.532489295641426e-05
clinically O 0 0.46680575609207153
unaffected O 0 0.00018106969946529716
siblings O 0 3.238540102756815e-06
carried O 0 3.3055462154152337e-06
the O 0 8.18812054603768e-07
maternal O 0 2.6672878448152915e-05
mutation O 0 1.0435203876113519e-05
459 O 0 0.00020524903084151447
+ O 0 2.1221321730990894e-05
1G O 0 0.049296993762254715
> O 0 4.767875907418784e-06
A O 0 4.4839116526418366e-06
and O 0 2.221133001967246e-07
, O 0 1.6823784676489595e-07
on O 0 3.694511860885541e-07
their O 0 8.632255088514285e-08
paternal O 0 1.1669419109239243e-05
allele O 0 2.1461105461639818e-06
, O 0 3.657568470316619e-07
a O 0 9.365199957755976e-07
novel O 0 1.2255569572516833e-06
cytosine O 0 8.035071346057521e-07
to O 0 1.3108873986311664e-07
thymidine O 0 4.856287432630779e-06
transition O 0 2.4012654193938943e-06
at O 0 1.8430336012897897e-06
nucleotide O 0 2.397817070232122e-06
2435 O 0 1.1710993021551985e-05
in O 0 2.0821170210183482e-07
exon O 0 7.183165848800854e-07
8 O 0 6.307661237769935e-07
, O 0 1.0454755283717532e-07
resulting O 0 4.010140344234969e-07
in O 0 1.9849819921091694e-07
substitution O 0 1.8159521459892858e-06
of O 0 3.0988840080681257e-06
alanine O 0 7.339480362134054e-06
464 O 0 2.2312216970021836e-05
by O 0 5.1063743740087375e-06
valine O 0 0.00011359396739862859
( O 0 8.116840945149306e-06
A464V O 0 0.0003517440927680582
) O 0 9.193023288389668e-06
. O 0 1.956045707629528e-05

The O 0 9.066162601811811e-05
fathers O 0 5.8687059208750725e-05
genotype O 0 4.1046369005925953e-05
thus O 0 1.2102176697226241e-05
was O 0 0.00012374453945085406
7delG O 0 0.0005734209553338587
/ O 0 0.0003724033012986183
A464V O 0 0.0018967358628287911
. O 0 2.9465993065969087e-05

Mutation O 0 0.00033014011569321156
A464V O 0 0.0017865151166915894
was O 0 3.882388773490675e-05
not O 0 3.4736132192847435e-07
found O 0 1.8235502352581534e-07
in O 0 2.015268307786755e-07
18 O 0 4.874044407188194e-06
unrelated O 0 0.0001263377780560404
MLD B-Disease 1 1.0
patients O 0 5.931650775892194e-06
and O 0 2.6077270831592614e-06
50 O 0 1.339633217867231e-05
controls O 0 4.692302172770724e-05
. O 0 1.1692623957060277e-05

A464V O 0 0.004857504740357399
, O 0 1.3772861166216899e-05
although O 0 2.94947017209779e-06
clearly O 0 7.307214673346607e-06
modifying O 0 2.3251604943652637e-05
ARSA O 1 0.7922441363334656
and O 0 3.1733961805002764e-05
GS O 1 1.0
levels O 0 4.223425548843807e-06
, O 0 2.581759588338173e-07
apparently O 0 5.675323109244346e-07
bears O 0 3.0493927738461934e-07
little O 0 1.1862685056485134e-07
significance O 0 3.358128140007466e-07
for O 0 3.198748572685872e-07
clinical O 0 0.00036297706537880003
manifestation O 0 0.24661466479301453
of O 0 0.04815901443362236
MLD B-Disease 1 1.0
, O 0 4.713209364126669e-06
mimicking O 0 1.9215105567127466e-05
the O 0 6.1106679822842125e-06
frequent O 0 5.825036714668386e-05
ARSA O 1 0.9993209838867188
pseudodeficiency O 0 0.20359663665294647
allele O 0 0.0002040505496552214
. O 0 4.2775525798788294e-05

Our O 0 9.837784091359936e-06
results O 0 3.0201551908248803e-06
demonstrate O 0 1.377506009703211e-06
that O 0 1.1627561491422966e-07
in O 0 1.8073052387990174e-07
certain O 0 2.8486806513683405e-07
genetic O 0 3.204256063327193e-05
conditions O 1 0.8328255414962769
MLD B-Disease 1 1.0
- O 0 0.4977070987224579
like O 0 4.517903562373249e-06
ARSA O 1 0.557394802570343
and O 0 4.617800641426584e-06
GS O 1 0.9999641180038452
values O 0 2.1354074419832614e-07
need O 0 3.038749341044422e-08
not O 0 1.715010000680195e-08
be O 0 2.4524529962377528e-08
paralleled O 0 8.442465855296177e-07
by O 0 2.3814560279333818e-07
clinical O 0 0.10030496120452881
disease O 0 0.0056944238021969795
, O 0 2.529945675178169e-07
a O 0 2.9761642394987575e-07
finding O 0 1.1704394609068913e-07
with O 0 2.407495003353688e-07
serious O 0 7.713337981840596e-05
diagnostic O 0 0.00015619296755176038
and O 0 1.0561311682977248e-05
prognostic O 1 0.9991987347602844
implications O 0 0.0003934506676159799
. O 0 3.4180109651060775e-05

Moreover O 0 9.419672278454527e-05
, O 0 6.8701806412718724e-06
further O 0 1.1212950994377024e-05
ARSA O 0 0.0004560632514767349
alleles O 0 3.819964604190318e-06
functionally O 0 2.6787331535160774e-06
similar O 0 1.295342144658207e-07
to O 0 1.4580142249087658e-07
A464V O 0 1.2504688129411079e-05
might O 0 2.8523069772745657e-07
exist O 0 1.1823696866031241e-07
which O 0 1.3065454140814836e-07
, O 0 8.502980364255563e-08
together O 0 1.8526002065755165e-08
with O 0 5.0207553670134075e-08
0 O 0 1.984869641091791e-06
- O 0 7.84275198384421e-06
type O 0 4.3075415305793285e-06
mutations O 0 1.1235633792239241e-06
, O 0 5.058648184785852e-07
may O 0 3.686543550429633e-06
cause O 0 5.6023065553745255e-05
pathological O 1 0.999948263168335
ARSA O 1 0.9999833106994629
and O 0 1.4741665836481843e-05
GS O 1 1.0
levels O 0 1.5029758060336462e-06
, O 0 7.456842610054082e-08
but O 0 1.9991956534681776e-08
not O 0 4.0565819148241644e-08
clinical O 0 7.828569323464762e-06
outbreak O 0 1.9109536879113875e-05
of O 0 6.548763394675916e-06
the O 0 3.5699391446541995e-05
disease O 1 0.9768416285514832
. O 0 4.039583473058883e-06
. O 0 9.706384844321292e-06

Human O 0 0.2973242700099945
MLH1 O 1 0.9999995231628418
deficiency O 1 0.9999998807907104
predisposes O 0 0.08514778316020966
to O 0 2.451727596053388e-05
hematological B-Disease 1 0.9999983310699463
malignancy I-Disease 1 0.9999998807907104
and O 0 8.639354928163812e-05
neurofibromatosis B-Disease 1 0.9999992847442627
type I-Disease 1 0.7574694156646729
1 I-Disease 0 0.055699314922094345
. O 0 9.358958777738735e-05

Heterozygous O 0 0.0024251125287264585
germ O 1 0.9999074935913086
- O 0 0.0007317585404962301
line O 0 8.394340511586051e-06
mutations O 0 3.6631467992265243e-07
in O 0 1.699666256627097e-07
the O 0 3.745076355698984e-07
DNA O 0 2.7249730010225903e-06
mismatch O 0 0.010581206530332565
repair O 0 8.80267471075058e-05
genes O 0 4.2550600483082235e-06
lead O 0 1.8132619516109116e-05
to O 0 1.0327478776162025e-05
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.027103180065751076

The O 0 0.00025410213856957853
disease O 1 0.9662145376205444
susceptibility O 0 0.036929432302713394
of O 0 1.7807686162996106e-05
individuals O 0 6.557185088240658e-07
who O 0 1.4779933508179965e-06
constitutionally O 0 7.401094990200363e-06
lack O 0 3.6571991586242802e-06
both O 0 5.22470941177744e-07
wild O 0 6.45464206172619e-06
- O 0 2.0785071683349088e-05
type O 0 5.222077106736833e-06
alleles O 0 1.867157379820128e-06
is O 0 1.3966854339741985e-06
unknown O 0 1.0739244316937402e-05
. O 0 6.7275668698130175e-06

We O 0 5.7553043006919324e-06
have O 0 6.806841383877327e-07
identified O 0 1.0639591891958844e-06
three O 0 2.7542770908439707e-07
offspring O 0 8.013475962798111e-07
in O 0 1.1817355698440224e-06
a O 0 0.0002576897677499801
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.023072542622685432
who O 0 2.7838776077260263e-05
developed O 0 0.0009143069619312882
hematological B-Disease 1 0.9999936819076538
malignancy I-Disease 1 0.9999983310699463
at O 0 0.00015104726480785757
a O 0 1.2912920510643744e-06
very O 0 1.6177547479401255e-07
early O 0 4.0980484072861145e-07
age O 0 3.710977694026951e-07
, O 0 9.146775425961096e-08
and O 0 6.413699082941093e-08
at O 0 8.206797019738588e-07
least O 0 2.748813088260249e-08
two O 0 2.173163160534841e-08
of O 0 1.291911360112863e-07
them O 0 3.781929436286191e-08
displayed O 0 1.8130726857634727e-06
signs O 0 4.457321210793452e-06
of O 0 2.9667523904208792e-06
neurofibromatosis B-Disease 0 0.0689806342124939
type I-Disease 0 5.5054140830179676e-05
1 I-Disease 0 6.182462675496936e-05
( O 0 1.7338290490442887e-05
NF1 B-Disease 0 0.012147793546319008
) O 0 3.827560703939525e-06
. O 0 9.16587669053115e-06

DNA O 0 7.425920921377838e-05
sequence O 0 3.125966395600699e-05
analysis O 0 1.051822164299665e-05
and O 0 1.7401864624844166e-06
allele O 0 1.5852825526962988e-05
- O 0 1.30227672343608e-05
specific O 0 2.121942088706419e-07
amplification O 0 6.233483418327523e-06
in O 0 2.281986866137231e-07
two O 0 1.793509198932952e-07
siblings O 0 1.2203169035274186e-06
revealed O 0 5.092466381029226e-06
a O 0 5.1549027375585865e-06
homozygous O 0 3.1841638701735064e-05
MLH1 O 0 0.0018640707712620497
mutation O 0 1.1837786587420851e-05
( O 0 3.7176587284193374e-06
C676T O 0 0.0005490237381309271
- O 0 0.00011901041580131277
- O 0 0.00017639713769312948
> O 0 2.9713377443840727e-05
Arg226Stop O 0 0.00013865927758160979
) O 0 2.603090479169623e-06
. O 0 9.240726285497658e-06

Thus O 0 3.965200812672265e-05
, O 0 4.970052032149397e-06
a O 0 7.2483585427107755e-06
homozygous O 0 0.00012473066453821957
germ O 1 0.9999972581863403
- O 0 0.3197243809700012
line O 0 9.054109978023916e-05
MLH1 O 0 0.005211201962083578
mutation O 0 1.3105416201142361e-06
and O 0 6.083213293095469e-07
consequent O 1 0.9928338527679443
mismatch O 1 1.0
repair O 1 0.9999998807907104
deficiency O 1 1.0
results O 0 1.1272058145550545e-05
in O 0 1.658193468756508e-06
a O 0 4.5752643927698955e-05
mutator O 1 0.9999659061431885
phenotype O 0 0.08822566270828247
characterized O 0 6.029679570929147e-05
by O 0 5.983397841191618e-06
leukemia B-Disease 1 0.9999998807907104
and O 0 0.11196065694093704
/ O 1 0.9999997615814209
or O 1 0.9999505281448364
lymphoma B-Disease 1 1.0
associated O 1 0.9582023024559021
with O 0 1.0130531336471904e-05
neurofibromatosis B-Disease 1 0.9999996423721313
type I-Disease 0 0.15541991591453552
1 I-Disease 0 0.00030620399047620595
. O 0 4.008437372249318e-06
. O 0 1.1312475180602632e-05

Missense O 0 0.0007692108047194779
mutations O 0 4.5864737330703065e-05
in O 0 5.075815806776518e-06
the O 0 1.337848516413942e-06
most O 0 1.6593374141393724e-07
ancient O 0 4.661284549456468e-07
residues O 0 8.208510848817241e-07
of O 0 1.2359857919364003e-06
the O 0 5.696482276107417e-06
PAX6 O 0 0.036748629063367844
paired O 0 1.941175241881865e-06
domain O 0 2.535128942326992e-06
underlie O 0 8.975917808129452e-06
a O 0 1.0560066812104196e-06
spectrum O 0 6.6470643105276395e-06
of O 0 3.47708300978411e-05
human O 1 0.9995573163032532
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 0.030708156526088715

Mutations O 0 6.128694076323882e-05
of O 0 8.818953574518673e-06
the O 0 4.3296913645463064e-06
human O 0 1.8179263861384243e-05
PAX6 O 1 0.9971386194229126
gene O 0 0.0003576759481802583
underlie O 1 0.9998205304145813
aniridia B-Disease 1 1.0
( O 1 0.5532870292663574
congenital B-Disease 1 1.0
absence I-Disease 1 0.9751152992248535
of I-Disease 0 0.0001476676989113912
the I-Disease 0 1.1834479664685205e-05
iris I-Disease 0 0.009120468981564045
) O 0 4.527377939211874e-07
, O 0 1.3300537204941065e-07
a O 0 6.906494718350586e-07
rare O 0 1.1685478057188448e-05
dominant O 1 0.8243650197982788
malformation B-Disease 1 1.0
of I-Disease 1 0.918210506439209
the I-Disease 1 0.9711167812347412
eye I-Disease 1 0.9999990463256836
. O 0 0.00016148480062838644

The O 0 3.880733856931329e-05
spectrum O 0 2.6209680072497576e-05
of O 0 1.3464522453432437e-05
PAX6 O 0 0.18404485285282135
mutations O 0 2.6511621399549767e-05
in O 0 2.8269963877392e-05
aniridia B-Disease 1 1.0
patients O 0 7.4162217060802504e-06
is O 0 1.0405910870758817e-06
highly O 0 1.1612085017986828e-06
biased O 0 2.3186048565548845e-06
, O 0 8.19006658048238e-08
with O 0 4.1055113086940764e-08
92 O 0 1.4390462865776499e-06
% O 0 1.5717934331860306e-07
of O 0 4.256373244970746e-07
all O 0 1.0441542741546073e-07
reported O 0 1.9950377918576123e-06
mutations O 0 1.4370522194440127e-06
leading O 0 1.5223497939587105e-05
to O 0 4.5015590899311064e-07
premature O 0 5.6583932746434584e-05
truncation O 0 0.00010704393207561225
of O 0 4.7033990995259956e-06
the O 0 1.7778793335310183e-06
protein O 0 1.4411859865504084e-06
( O 0 5.082458756078267e-07
nonsense O 0 7.244502285175258e-06
, O 0 2.1126191995790577e-07
splicing O 0 4.2179487991234055e-07
, O 0 1.4691944727474038e-07
insertions O 0 7.327957973757293e-07
and O 0 2.761983921573119e-07
deletions O 0 4.0304016692971345e-06
) O 0 3.0103385029178753e-07
and O 0 1.8879190122333966e-07
just O 0 6.077611942600925e-07
2 O 0 9.465207426728739e-07
% O 0 3.7148478782000893e-07
leading O 0 2.3058107672113692e-06
to O 0 7.292403836345329e-08
substitution O 0 9.317893727711635e-07
of O 0 9.729095609145588e-07
one O 0 7.683208309572365e-07
amino O 0 7.043948357932095e-07
acid O 0 2.051780683132165e-07
by O 0 1.0865669963777691e-07
another O 0 5.333741341928544e-07
( O 0 1.203208057631855e-06
missense O 0 2.1684054445358925e-05
) O 0 3.864432983391453e-06
. O 0 8.99749829841312e-06

The O 0 1.8226794054498896e-05
extraordinary O 0 1.4070992619963363e-05
conservation O 0 5.7975066738436e-06
of O 0 4.422701749717817e-06
the O 0 1.1210299817321356e-05
PAX6 O 0 0.030696118250489235
protein O 0 2.0835577743127942e-05
at O 0 5.7775316236075014e-05
the O 0 6.945478162379004e-06
amino O 0 8.17897125671152e-06
acid O 0 1.8723301309364615e-06
level O 0 1.8620058881424484e-06
amongst O 0 9.94346237348509e-07
vertebrates O 0 5.6371554819634184e-06
predicts O 0 1.1986943491137936e-06
that O 0 5.8284790327434166e-08
pathological O 0 1.9136872651870362e-05
missense O 0 7.9765350164962e-06
mutations O 0 6.64548451823066e-07
should O 0 1.2975354479749512e-07
in O 0 1.3913131624576636e-07
fact O 0 7.955364367262518e-08
be O 0 4.661311336917606e-08
common O 0 4.719550972254183e-08
even O 0 4.603561976068704e-08
though O 0 3.677560300729965e-08
they O 0 1.3357759343080033e-08
are O 0 1.4414724525124711e-08
hardly O 0 1.9727718836293207e-07
ever O 0 3.209320880159794e-07
seen O 0 1.7332631614408456e-06
in O 0 2.686535935936263e-06
aniridia B-Disease 1 0.9999948740005493
patients O 0 3.6697310861200094e-05
. O 0 2.6796098609338515e-05

This O 0 1.0482071957085282e-05
indicates O 0 5.664855052600615e-06
that O 0 1.2684128591899935e-07
there O 0 1.2466406928979268e-07
is O 0 1.6775494771081867e-07
a O 0 5.913306608817948e-07
heavy O 0 4.026301030535251e-05
ascertainment O 1 0.7986319661140442
bias O 0 7.184240075730486e-06
in O 0 1.7528637386021728e-07
the O 0 1.8226704412427353e-07
selection O 0 1.8537815549279912e-07
of O 0 4.046474941787892e-07
patients O 0 3.9297168541452265e-07
for O 0 3.873876153193123e-07
PAX6 O 0 0.06236967071890831
mutation O 0 1.5486696156585822e-06
analysis O 0 4.364171957149665e-07
and O 0 1.7821795950112573e-07
that O 0 1.2280683847620821e-07
the O 0 1.0985561402776511e-06
missing O 0 9.064365258382168e-06
PAX6 O 0 0.0012202819343656301
missense O 0 3.526364889694378e-05
mutations O 0 7.235236353153596e-06
frequently O 0 3.3564676868991228e-06
may O 0 8.481731128995307e-06
underlie O 0 7.08270599716343e-05
phenotypes O 0 1.498678102507256e-05
distinct O 0 1.0086390602737083e-06
from O 0 1.3020010555919725e-05
textbook O 0 0.025847870856523514
aniridia B-Disease 1 0.9998800754547119
. O 0 2.9719982194365002e-05

Here O 0 4.073266245541163e-05
we O 0 1.6270984133370803e-06
present O 0 7.962876793499163e-07
four O 0 5.59117836473888e-07
novel O 0 5.448343472380657e-06
PAX6 O 0 0.00028240540996193886
missense O 0 2.0398012566147372e-05
mutations O 0 2.7333328489476116e-06
, O 0 4.515520117820415e-07
two O 0 1.2096793966520636e-07
in O 0 1.1093176226495416e-06
association O 0 1.6702651919331402e-06
with O 0 2.7771739041781984e-07
atypical O 1 0.5918800234794617
phenotypes O 0 0.23810875415802002
ectopia B-Disease 1 0.9611022472381592
pupillae I-Disease 0 0.13176369667053223
( O 0 9.259879902856483e-07
displaced B-Disease 0 8.754504392527451e-07
pupils I-Disease 0 2.3342017811955884e-06
) O 0 1.0564860986050917e-06
and O 0 8.198698196792975e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999022483825684
( O 0 4.483424163481686e-06
searching B-Disease 0 1.9737738057301613e-06
gaze I-Disease 0 0.0001050253922585398
) O 0 2.2116890363577113e-07
, O 0 6.230626325987032e-08
and O 0 4.339494452665349e-08
two O 0 6.43505657649257e-08
in O 0 6.853140348539455e-07
association O 0 1.3877289575248142e-06
with O 0 1.4908145828940178e-07
more O 0 8.377141966775525e-07
recognizable O 0 0.0001156069411081262
aniridia B-Disease 1 0.999997615814209
phenotypes O 0 0.0007977552013471723
. O 0 2.8735355954268016e-05

Strikingly O 0 0.00046840106369927526
, O 0 2.4863988983270247e-06
all O 0 1.8149152936075552e-07
four O 0 2.6975550326824305e-07
mutations O 0 3.5126157627018983e-07
are O 0 7.037019855715698e-08
located O 0 6.709382205372094e-07
within O 0 2.8836234378104564e-07
the O 0 1.9558854091883404e-06
PAX6 O 0 0.0003507601795718074
paired O 0 2.3610045900568366e-06
domain O 0 8.200748879971798e-07
and O 0 4.5717030161540606e-07
affect O 0 1.86811382718588e-06
amino O 0 1.471666905672464e-06
acids O 0 2.2279557754245616e-07
which O 0 6.243081429602171e-08
are O 0 2.16961808519045e-08
highly O 0 1.1664101862152165e-07
conserved O 0 1.8023446557435818e-07
in O 0 7.387278344594961e-08
all O 0 2.959887979159248e-08
known O 0 6.349777095238096e-07
paired O 0 3.010148702742299e-06
domain O 0 7.112679668352939e-06
proteins O 0 5.353603228286374e-06
. O 0 1.0767507774289697e-05

Our O 0 1.8243559679831378e-05
results O 0 3.867308805638459e-06
support O 0 1.052120410349744e-06
the O 0 6.899871891619114e-07
hypothesis O 0 5.981750064165681e-07
that O 0 6.849599287761521e-08
the O 0 1.5863464852827747e-07
under O 0 5.306794719217578e-07
- O 0 4.074805985965213e-07
representation O 0 1.039641261968427e-07
of O 0 2.3682180483319826e-07
missense O 0 4.890172021987382e-06
mutations O 0 8.389261552110838e-07
is O 0 4.839089342567604e-07
caused O 0 2.753509988906444e-06
by O 0 2.4789807184788515e-07
ascertainment O 0 0.005714283790439367
bias O 0 3.6427047689358005e-06
and O 0 5.602094077516995e-08
suggest O 0 1.0419479679057986e-07
that O 0 3.532279890805512e-08
a O 0 2.983791489441501e-07
substantial O 0 1.3626631698571146e-06
burden O 0 7.3388509918004274e-06
of O 0 9.070130909094587e-05
PAX6 B-Disease 1 0.9999990463256836
- I-Disease 0 0.28951090574264526
related I-Disease 0 0.00011007288412656635
disease I-Disease 0 0.15217898786067963
remains O 0 2.182604703193647e-06
to O 0 5.885519627213398e-08
be O 0 4.89281774207484e-07
uncovered O 0 4.916297984891571e-05
. O 0 1.6115689049911452e-06
. O 0 1.0132212992175482e-05

The O 0 4.772131433128379e-05
chromosomal O 0 0.00023233125102706254
order O 0 2.692537918846938e-06
of O 0 2.13492398870585e-06
genes O 0 1.420301941834623e-06
controlling O 0 2.754208708211081e-06
the O 0 1.5813905065442668e-06
major O 0 1.952988895936869e-05
histocompatibility O 0 0.005178149789571762
complex O 0 5.133023933012737e-06
, O 0 3.4935797543766967e-07
properdin O 0 2.3289996534003876e-05
factor O 0 5.568776032305323e-06
B O 0 1.0023505637946073e-05
, O 0 3.4264030546182767e-07
and O 0 1.0388725968368817e-06
deficiency B-Disease 0 0.2572658061981201
of I-Disease 0 2.05755463866808e-06
the I-Disease 0 1.7731008483679034e-06
second I-Disease 0 1.0983300853695255e-05
component I-Disease 0 4.231823822919978e-06
of I-Disease 0 4.14620672017918e-06
complement I-Disease 0 2.3149430489866063e-05
. O 0 1.6407408111263067e-05

The O 0 2.1977120923111215e-05
relationship O 0 5.028560735809151e-06
of O 0 4.7610601541236974e-06
the O 0 1.8478186802894925e-06
genes O 0 1.5515315681113862e-06
coding O 0 9.427808436157648e-06
for O 0 1.7810663166528684e-06
HLA O 0 9.495182894170284e-05
to O 0 2.122140330129696e-07
those O 0 1.7449877987019136e-07
coding O 0 2.4106639102683403e-06
for O 0 7.758000037938473e-07
properdin O 0 9.160600166069344e-05
Factor O 0 1.301159500144422e-05
B O 0 9.792583114176523e-06
allotypes O 0 1.0646123882906977e-05
and O 0 2.997887520450604e-07
for O 0 1.0921953617071267e-06
deficiency B-Disease 0 0.013157590292394161
of I-Disease 0 4.727673513116315e-06
the I-Disease 0 1.7712587805363e-06
second I-Disease 0 3.2975394788081758e-06
component I-Disease 0 1.1196410696356907e-06
of I-Disease 0 1.2789821539627155e-06
complement I-Disease 0 1.766892410159926e-06
( O 0 1.4489669410977513e-06
C2 O 0 4.010160773759708e-05
) O 0 6.715668376955364e-08
was O 0 9.663993978392682e-07
studied O 0 6.090231181588024e-07
in O 0 9.029286474060427e-08
families O 0 4.847838397381565e-08
of O 0 1.8503773162592552e-06
patients O 0 1.0783539437397849e-05
with O 0 0.000742426433134824
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.9864773750305176

Patients O 0 8.34762176964432e-05
were O 0 5.222176696406677e-06
selected O 0 1.6783894807304023e-06
because O 0 2.603164830361493e-07
they O 0 7.146256564283249e-08
were O 0 3.4249950431330944e-07
heterozygous O 0 1.4263462162489304e-06
or O 0 1.1604380460994435e-06
homozygous O 0 0.00011974771769018844
for O 0 0.003129403106868267
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00012021404836559668

12 O 0 5.3298652346711606e-05
families O 0 1.1610424053287716e-06
with O 0 3.519925826367398e-07
15 O 0 4.015025751868961e-06
matings O 0 3.6784796975553036e-05
informative O 0 4.2465977458050475e-05
for O 0 0.00018113772966898978
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.262142995983595e-05
found O 0 8.314356819028035e-06
. O 0 1.2163849532953463e-05

Of O 0 7.191161421360448e-05
57 O 0 5.953540312475525e-05
informative O 0 1.4469272173300851e-05
meioses O 0 8.271630213130265e-05
, O 0 4.803176807399723e-07
two O 0 8.256239425463718e-08
crossovers O 0 4.855417046201183e-07
were O 0 3.1194571192827425e-07
noted O 0 6.884510526106169e-07
between O 0 1.364848230878124e-06
the O 0 0.008905371651053429
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.711147655849345e-06
and O 0 1.955044353962876e-06
the O 0 4.3746385927079245e-05
HLA O 1 0.9999657869338989
- O 0 0.3094199001789093
B O 0 0.00022563201491720974
gene O 0 4.3643967728712596e-07
, O 0 1.0637131708790548e-07
with O 0 4.131339537138956e-08
a O 0 4.939141717841267e-07
recombinant O 0 1.7592690255696652e-06
fraction O 0 7.450841508216399e-07
of O 0 2.824449893523706e-06
0 O 0 1.1865635315189138e-05
. O 0 7.929910680104513e-06

035 O 1 0.5585512518882751
. O 0 0.001746818539686501

A O 0 0.0002966935862787068
lod O 0 0.0009134149877354503
score O 0 6.075118562876014e-06
of O 0 1.922851652125246e-06
13 O 0 3.1809904612600803e-06
was O 0 4.839260327571537e-06
calculated O 0 1.4537893093802268e-06
for O 0 4.570011640225857e-07
linkage O 0 0.0003012124798260629
between O 0 0.01800352707505226
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 9.390918421559036e-05
HLA O 1 0.9999939203262329
- O 0 0.0013636434450745583
B O 0 7.654753062524833e-06
at O 0 3.1948889045452233e-07
a O 0 4.0696789938010625e-08
maximum O 0 1.1088813067772207e-07
likelihood O 0 1.1121347398557191e-07
value O 0 4.177145385142467e-08
of O 0 1.9524082972566248e-07
the O 0 2.88392612901589e-07
recombinant O 0 2.0591112388501642e-06
fraction O 0 9.254202382180665e-07
of O 0 4.090632501174696e-06
0 O 0 9.879557183012366e-06
. O 0 1.0051168828795198e-05

04 O 0 0.05194980278611183
. O 0 0.0007941865478642285

18 O 0 9.467056224821135e-05
families O 0 2.862817382265348e-06
with O 0 7.588526500512671e-07
21 O 0 7.748138159513474e-06
informative O 0 4.272268142813118e-06
matings O 0 8.184043508663308e-06
for O 0 5.55205531327374e-07
both O 0 6.60193052226532e-07
properdin O 0 7.956049375934526e-05
Factor O 0 1.9628456357168034e-05
B O 0 2.0496856450336054e-05
allotype O 0 3.8334765122272074e-05
and O 0 4.121598067285959e-06
HLA O 1 0.9326775074005127
- O 0 0.00028594181640073657
B O 0 4.9678845243761316e-05
were O 0 2.954287083412055e-06
found O 0 4.027232080261456e-06
. O 0 6.1401788116199896e-06

Of O 0 0.00013937123003415763
72 O 0 0.00012807606253772974
informative O 0 4.4843152863904834e-05
meioses O 0 0.00023485506244469434
, O 0 2.6405050448374823e-06
three O 0 7.544898608102812e-07
recombinants O 0 2.0867593775619753e-05
were O 0 8.679537017997063e-07
found O 0 4.137719997743261e-07
, O 0 2.0291302860186988e-07
giving O 0 1.264356228602992e-07
a O 0 8.566277074351092e-07
recombinant O 0 2.476809186191531e-06
fraction O 0 1.2445647143977112e-06
of O 0 5.3970325097907335e-06
0 O 0 1.0267341167491395e-05
. O 0 8.500542207912076e-06

042 O 0 0.07360491901636124
. O 0 0.0023053938057273626

A O 0 0.0009760318207554519
lod O 0 0.0023300691973417997
score O 0 2.8691021725535393e-05
of O 0 1.6597265130258165e-05
16 O 0 2.0874422261840664e-05
between O 0 2.1198162357904948e-05
HLA O 1 0.866642951965332
- O 0 0.0001597273803781718
B O 0 2.2216629076865502e-05
and O 0 2.531432699015568e-07
Factor O 0 2.534193754399894e-06
B O 0 5.505673925654264e-06
allotypes O 0 6.354493962135166e-06
was O 0 1.8994531956195715e-06
calculated O 0 8.140974046000338e-07
at O 0 5.116213515066192e-07
a O 0 1.2524594694696134e-07
maximum O 0 2.3202495924579125e-07
likelihood O 0 4.263702351181564e-07
value O 0 1.9529520045580284e-07
of O 0 2.460434984641324e-07
the O 0 3.2658471127433586e-07
recombinant O 0 1.4389007674253662e-06
fraction O 0 7.43776467970747e-07
of O 0 2.5949284463422373e-06
0 O 0 8.387794878217392e-06
. O 0 6.977124485274544e-06

04 O 0 0.07138149440288544
. O 0 0.0016001671319827437

A O 0 8.981191058410332e-05
crossover O 0 1.5222379261103924e-05
was O 0 1.1241420907026622e-05
shown O 0 4.4276333710513427e-07
to O 0 1.1856916870556233e-07
have O 0 7.858648842784532e-08
occurred O 0 7.709072633588221e-07
between O 0 1.377729148543949e-07
genes O 0 2.1446034281780157e-07
for O 0 3.503722894038219e-07
Factor O 0 6.227096037036972e-06
B O 0 9.410283382749185e-06
and O 0 1.3791793662676355e-06
HLA O 0 0.1595873385667801
- O 0 0.00011863922554766759
D O 0 1.9116627299808897e-05
, O 0 1.7168353849683626e-07
in O 0 2.585857146186754e-07
which O 0 1.182412006528466e-06
HLA O 0 0.17172777652740479
- O 0 0.0005659657763317227
D O 0 0.00020575104281306267
segregared O 0 4.781392271979712e-05
with O 0 2.4274679617519723e-06
HLA O 1 0.9974435567855835
- O 0 0.0003322096890769899
A O 0 0.00015090503438841552
and O 0 7.570768957521068e-06
B O 0 0.0001459812483517453
. O 0 9.897691597871017e-06

These O 0 3.7801014514116105e-06
studies O 0 5.481144853547448e-06
suggest O 0 1.0905799854299403e-06
that O 0 1.3757806982539478e-07
the O 0 2.3153734218794852e-07
genes O 0 2.687966116354801e-07
for O 0 8.833860647428082e-07
Factor O 0 4.631237970897928e-05
B O 0 0.0018252745503559709
and O 0 0.0002569589123595506
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
are O 0 1.3498295459157816e-07
located O 0 1.1144019254061277e-06
outside O 0 3.505755046262493e-07
those O 0 4.705295708617996e-08
for O 0 2.462766133248806e-07
HLA O 0 7.870815170463175e-05
, O 0 1.293806377589135e-07
that O 0 5.345983566940049e-08
the O 0 2.472249605034449e-07
order O 0 1.719463540439392e-07
of O 0 2.5197559807565995e-06
genese O 0 9.760634566191584e-05
is O 0 6.254098025237909e-06
HLA O 0 0.0012917243875563145
- O 0 1.6924690498854034e-05
A O 0 3.9939106500241905e-05
, O 0 1.1946008271479513e-06
- O 0 1.236002026416827e-05
B O 0 1.2718344805762172e-05
, O 0 6.583916274394142e-07
- O 0 2.3604583475389518e-05
D O 0 1.7055461285053752e-05
, O 0 3.5591494906839216e-07
Factor O 0 5.401254838943714e-06
B O 0 6.312021287158132e-05
allotype O 0 0.02243519015610218
, O 0 0.0005159612046554685
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.2520008258197777e-07
that O 0 6.180630407470744e-08
the O 0 3.481552823814127e-07
genes O 0 8.912285807127773e-07
coding O 0 2.9586026357719675e-05
for O 0 5.833430986967869e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 6.5208123487536795e-06
Factor O 0 3.082635157625191e-05
B O 0 1.082666221918771e-05
allotypes O 0 5.271709596854635e-06
are O 0 1.968276031050209e-08
approximately O 0 4.3322754095243e-07
3 O 0 1.6067411934272968e-06
- O 0 3.273154561611591e-06
- O 0 2.182240450565587e-06
5 O 0 9.842427743933513e-07
centimorgans O 0 5.47040872334037e-06
from O 0 7.222602107503917e-07
the O 0 2.054946662610746e-06
HLA O 0 0.00020215584663674235
- O 0 1.0691990610212088e-05
A O 0 1.054489712259965e-05
and O 0 1.3746202967013232e-06
HLA O 0 0.03337349370121956
- O 0 6.957124423934147e-05
B O 0 9.742459042172413e-06
loci O 0 4.0300611203747394e-07
, O 0 4.890232929710692e-08
and O 0 2.0947394929748953e-08
that O 0 3.091174605174274e-08
the O 0 1.3527562714443775e-07
apparent O 0 2.4187513645301806e-06
lack O 0 9.97619395093352e-07
of O 0 1.7725700445225812e-06
recombinants O 0 9.372353815706447e-06
between O 0 4.094118821740267e-07
the O 0 8.136720452966983e-07
Factor O 0 4.368520876596449e-06
B O 0 1.7862043023342267e-05
gene O 0 1.1719517715391703e-05
and O 0 0.01503785327076912
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.52079246113135e-06
suggests O 0 4.735289849122637e-07
that O 0 3.4879192867265374e-08
these O 0 2.0022179469947332e-08
two O 0 3.8353508813315784e-08
genes O 0 2.2825658163583284e-07
lie O 0 1.682036440797674e-06
in O 0 7.949886366986902e-07
close O 0 1.956461801455589e-06
proximity O 0 1.9891785996151157e-06
to O 0 4.418867831645912e-07
one O 0 1.9514156974764774e-06
another O 0 1.031590363709256e-05
. O 0 2.0843051970587112e-05

Distribution O 0 4.934319804306142e-05
of O 0 2.1051122530479915e-05
emerin O 0 0.0004007974930573255
and O 0 3.0675923881062772e-06
lamins O 0 0.00012406731548253447
in O 0 1.523026185168419e-06
the O 0 2.000809217861388e-06
heart O 0 0.0004003087233286351
and O 0 8.005256972865027e-07
implications O 0 1.3429345926851965e-05
for O 0 5.464745754579781e-06
Emery B-Disease 1 0.9779286980628967
- I-Disease 1 0.9999996423721313
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0005953060463070869

Emerin O 0 0.004711989313364029
is O 0 3.14223398163449e-05
a O 0 1.9172273823642172e-05
nuclear O 0 7.16162467142567e-05
membrane O 0 3.479332008282654e-05
protein O 0 4.5568003770313226e-06
which O 0 5.795554329779407e-07
is O 0 6.025842935741821e-07
missing O 0 3.1841896088735666e-06
or O 0 1.5147204521781532e-06
defective O 0 0.0002014639030676335
in O 0 2.1488984202733263e-05
Emery B-Disease 1 0.9997351765632629
- I-Disease 1 0.9999997615814209
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.1712082475423813
EDMD B-Disease 1 1.0
) O 0 3.9334485336439684e-05
. O 0 3.17620906571392e-05

It O 0 1.1238077604502905e-05
is O 0 2.7855501230078517e-06
one O 0 8.046382049542444e-07
member O 0 1.4897530036250828e-06
of O 0 1.3530482192436466e-06
a O 0 8.984138730738778e-06
family O 0 4.058504600834567e-06
of O 0 0.0018212783616036177
lamina O 1 0.9999996423721313
- O 1 0.6709268689155579
associated O 0 4.855018687521806e-06
proteins O 0 3.857728358980239e-07
which O 0 4.353771316800703e-07
includes O 0 1.1267534318903927e-06
LAP1 O 0 0.00226507312618196
, O 0 3.6248475225875154e-06
LAP2 O 0 0.0013071347493678331
and O 0 3.615994728534133e-06
lamin O 0 0.00045137066626921296
B O 0 0.00016888770915102214
receptor O 0 0.00010175336501561105
( O 0 1.3742658666160423e-05
LBR O 0 0.0004780969466082752
) O 0 9.583309292793274e-06
. O 0 1.3947826118965168e-05

A O 0 0.0006268166471272707
panel O 0 5.256718213786371e-05
of O 0 7.56530653234222e-06
16 O 0 1.5053791685204487e-05
monoclonal O 0 3.262965037720278e-05
antibodies O 0 1.0018783541454468e-05
( O 0 2.40453096012061e-06
mAbs O 0 7.271365575434174e-06
) O 0 1.3755236238921498e-07
has O 0 8.613094593101778e-08
been O 0 7.87489824460863e-08
mapped O 0 2.418169344764465e-07
to O 0 3.259468073224525e-08
six O 0 3.986719221416024e-08
specific O 0 1.9408751938954083e-08
sites O 0 8.163554099382964e-08
throughout O 0 1.2453014619495661e-07
the O 0 5.687286375177791e-07
emerin O 0 6.178294825076591e-06
molecule O 0 6.823109401921101e-07
using O 0 2.9820648705936037e-07
phage O 0 3.862053290504264e-06
- O 0 1.4612884342568577e-06
displayed O 0 4.299380975680833e-07
peptide O 0 4.843457759307057e-07
libraries O 0 1.0466286681776182e-07
and O 0 5.0231214743234887e-08
has O 0 9.682946711109253e-08
been O 0 1.3164398637854902e-07
used O 0 7.655868472511429e-08
to O 0 1.2723599240871408e-07
localize O 0 1.1111378626083024e-05
emerin O 0 9.14378251763992e-05
in O 0 1.470384631829802e-06
human O 0 8.479943062411621e-06
and O 0 1.983461515919771e-05
rabbit O 0 0.13151441514492035
heart O 1 0.9997983574867249
. O 0 7.148400618461892e-05

Several O 0 3.1776267860550433e-05
mAbs O 0 0.0001440933847334236
against O 0 4.857496605836786e-06
different O 0 4.0701726788938686e-07
emerin O 0 4.222046845825389e-05
epitopes O 0 1.1200746484973934e-05
did O 0 4.308411121201061e-07
not O 0 1.1287889378763794e-07
recognize O 0 2.2457382442553353e-07
intercalated O 0 4.510090366238728e-05
discs O 0 1.233152852364583e-05
in O 0 1.3507442417903803e-06
the O 0 3.0381406759261154e-06
heart O 0 0.00018621954950504005
, O 0 1.6595525664797606e-07
though O 0 3.168943507603217e-08
they O 0 1.7210229685815648e-08
recognized O 0 1.9187909572337958e-07
cardiomyocyte O 0 1.0620123248372693e-05
nuclei O 0 3.5133969049638836e-06
strongly O 0 3.0441210583376233e-06
, O 0 4.0969976566884725e-07
both O 0 2.988005860515841e-07
at O 0 5.139004315424245e-06
the O 0 1.111479036808305e-06
rim O 0 4.312741111789364e-06
and O 0 1.5725970570201753e-07
in O 0 5.927806228100962e-07
intranuclear O 0 4.406727748573758e-05
spots O 0 3.3670603443169966e-06
or O 0 1.4277848094934598e-06
channels O 0 1.1001865459547844e-05
. O 0 1.449938372388715e-05

A O 0 0.0011629231739789248
polyclonal O 0 0.0024439445696771145
rabbit O 0 0.00025916515733115375
antiserum O 0 0.00020368664991110563
against O 0 1.1722479030140676e-05
emerin O 0 4.80155176774133e-05
did O 0 4.4236620055926323e-07
recognize O 0 1.548718273625127e-07
both O 0 3.4455689501555753e-07
nuclear O 0 8.975395758170635e-06
membrane O 0 4.730559794552391e-06
and O 0 5.975797421342577e-07
intercalated O 0 3.1643183319829404e-05
discs O 0 2.0619743281713454e-06
but O 0 6.583929490489027e-08
, O 0 5.616248444084704e-08
after O 0 7.313897043559336e-08
affinity O 0 2.5317223162346636e-07
purification O 0 2.0791255792573793e-06
against O 0 1.6645137748128036e-06
a O 0 4.064151653437875e-06
pure O 0 2.6190540665993467e-05
- O 0 1.2860913557233289e-05
emerin O 0 1.5106614227988757e-05
band O 0 1.2159708830949967e-06
on O 0 7.630152367710252e-07
a O 0 5.012163342144049e-07
western O 0 4.280022665170691e-07
blot O 0 1.1291758710285649e-05
, O 0 3.8815494463051436e-07
it O 0 1.4917930002411595e-07
stained O 0 2.7404495995142497e-05
only O 0 2.437451485093334e-07
the O 0 1.5260386589943664e-06
nuclear O 0 6.211704021552578e-05
membrane O 0 0.0004353320982772857
. O 0 2.9728344088653103e-05

These O 0 4.91304490424227e-06
results O 0 4.559416993288323e-06
would O 0 4.0651917743161903e-07
not O 0 2.4582936930528376e-07
be O 0 4.2886233586614253e-07
expected O 0 7.546640290456708e-07
if O 0 1.818571178091588e-07
immunostaining O 0 6.954598575248383e-06
at O 0 2.3361926650977693e-06
intercalated O 0 1.704006535874214e-05
discs O 0 2.2086294393375283e-06
were O 0 3.193094926245976e-07
due O 0 6.138793651189189e-07
to O 0 1.254635293435058e-07
a O 0 8.022827842069091e-07
product O 0 3.303128153220314e-07
of O 0 3.3673768484732136e-07
the O 0 8.818523724585248e-07
emerin O 0 1.0085687790706288e-05
gene O 0 3.095736076375033e-07
and O 0 1.6057562390869862e-07
, O 0 1.272119760642454e-07
therefore O 0 1.1807537703134585e-07
, O 0 3.7342125835948536e-08
cast O 0 5.332225683218894e-08
some O 0 2.1688650875262283e-08
doubt O 0 1.5607548675689031e-07
upon O 0 8.859747424594389e-08
the O 0 3.0800225658822455e-07
hypothesis O 0 1.985161134143709e-06
that O 0 1.6606766166660236e-06
cardiac B-Disease 1 1.0
defects I-Disease 1 0.9989338517189026
in O 0 3.9236252632690594e-05
EDMD B-Disease 1 1.0
are O 0 5.895270760447602e-07
caused O 0 4.177849768893793e-05
by O 0 1.1669636705846642e-06
absence O 0 1.203138344862964e-05
of O 0 1.2387243259581737e-05
emerin O 0 0.00036168520455248654
from O 0 1.059431815519929e-05
intercalated O 0 0.0008558540721423924
discs O 0 0.00014117021055426449
. O 0 2.2135332983452827e-05

Although O 0 3.608823681133799e-05
emerin O 0 0.0005859999801032245
was O 0 5.564211824093945e-05
abundant O 0 5.646097179123899e-06
in O 0 1.9350591173861176e-06
the O 0 1.0381803576819948e-06
membranes O 0 9.311159374192357e-06
of O 0 1.8233226001029834e-05
cardiomyocyte O 0 0.0003212793671991676
nuclei O 0 7.248198926390614e-06
, O 0 9.486064413977147e-07
it O 0 1.7104960647884582e-07
was O 0 2.1642466890625656e-05
absent O 0 2.1135354018042563e-06
from O 0 3.9812786667425826e-07
many O 0 1.451440994060249e-07
non O 0 7.115549578884384e-06
- O 0 9.186326497001573e-05
myocyte O 0 0.008954388089478016
cells O 0 4.432789410202531e-06
in O 0 1.5677020428483956e-06
the O 0 8.829969374346547e-06
heart O 0 0.003999277018010616
. O 0 2.270926779601723e-05

This O 0 4.447330411494477e-06
distribution O 0 2.815607331285719e-06
of O 0 4.555853138299426e-06
emerin O 0 5.224708729656413e-05
was O 0 8.440255442110356e-06
similar O 0 9.505356501904316e-08
to O 0 6.14196764558983e-08
that O 0 6.668631868933517e-08
of O 0 1.6387342611778877e-06
lamin O 0 0.00022856505529489368
A O 0 7.043531695671845e-06
, O 0 1.6078402609309705e-07
a O 0 4.84700137803884e-07
candidate O 0 5.393494575400837e-07
gene O 0 3.0854144483782875e-07
for O 0 1.1465102289776041e-07
an O 0 1.6338390196324326e-06
autosomal O 0 3.877848575939424e-05
form O 0 8.540478120266926e-06
of O 1 0.8237754702568054
EDMD B-Disease 1 1.0
. O 0 0.00018622948846314102

In O 0 7.48559323255904e-05
contrast O 0 5.925989171373658e-05
, O 0 4.507209814619273e-05
lamin O 1 0.5700542330741882
B1 O 1 0.9999827146530151
was O 0 0.000555420876480639
absent O 0 1.8852266293833964e-05
from O 0 2.3345444333244814e-06
cardiomyocyte O 0 0.00011873383482452482
nuclei O 0 7.788952643750235e-06
, O 0 8.609101200818259e-07
showing O 0 9.236964615411125e-06
that O 0 2.0488685095187975e-06
lamin O 0 0.14417093992233276
B1 O 1 0.9980497360229492
is O 0 3.6235749689694785e-07
not O 0 5.84075401377504e-08
essential O 0 2.578757403171039e-07
for O 0 2.0430624658729357e-07
localization O 0 1.423843150405446e-05
of O 0 1.0357218798162648e-06
emerin O 0 3.2086652936413884e-05
to O 0 7.662529242224991e-07
the O 0 1.428859650332015e-05
nuclear O 0 0.0007599869859404862
lamina O 1 0.9009735584259033
. O 0 5.375237014959566e-05

Lamin O 1 0.9993301630020142
B1 O 1 0.9999505281448364
is O 0 9.111216058954597e-06
also O 0 1.9348542537045432e-06
almost O 0 2.4497353479091544e-06
completely O 0 9.275778211303987e-06
absent O 0 2.4623774152132683e-05
from O 0 1.4724595530424267e-05
skeletal O 1 0.9984779953956604
muscle O 0 0.03739970922470093
nuclei O 0 0.0006091829854995012
. O 0 4.122839527553879e-05

In O 0 0.00023682756000198424
EDMD B-Disease 1 0.9999607801437378
, O 0 4.4261068978812546e-06
the O 0 1.1634322163445177e-06
additional O 0 9.9333874459262e-07
absence O 0 1.5293317119358107e-05
of O 0 7.824201748007908e-05
lamin O 1 0.9999758005142212
B1 O 1 1.0
from O 0 0.0003579273179639131
heart O 1 0.9999791383743286
and O 0 0.00867557991296053
skeletal O 1 1.0
muscle O 0 0.15790516138076782
nuclei O 0 1.4162375919113401e-05
which O 0 3.482834642909438e-07
already O 0 4.951974688083283e-07
lack O 0 2.7549624519451754e-06
emerin O 0 0.00018385010480415076
may O 0 4.927548502564605e-07
offer O 0 4.7565396954496464e-08
an O 0 1.5060879832162755e-07
alternative O 0 1.7893731296680926e-07
explanation O 0 2.0245454379619332e-07
of O 0 3.0453705335276027e-07
why O 0 1.1437526126201192e-07
these O 0 5.3919531950441524e-08
tissues O 0 2.883724846469704e-06
are O 0 1.054763103525147e-07
particularly O 0 7.860879804866272e-07
affected O 0 9.545759667162201e-07
. O 0 1.204904037876986e-06
. O 0 4.772879947267938e-06

Genetic O 0 0.000215011095860973
mapping O 0 0.00016419687017332762
of O 0 3.1884243071544915e-05
the O 0 3.1769446650287136e-05
copper B-Disease 0 0.10190609842538834
toxicosis I-Disease 0 0.029361872002482414
locus O 0 9.452280937694013e-05
in O 0 3.2129241844813805e-06
Bedlington O 0 0.00012732634786516428
terriers O 0 9.833207514020614e-06
to O 0 2.3474970589631994e-07
dog O 0 2.5752281089808093e-06
chromosome O 0 3.054930493817665e-05
10 O 0 1.5963172472766018e-06
, O 0 2.251172048772787e-07
in O 0 1.8563291348527855e-07
a O 0 5.517503041119198e-07
region O 0 8.203244306059787e-07
syntenic O 0 8.32176738185808e-06
to O 0 1.8049901484573638e-07
human O 0 2.8542710879264632e-06
chromosome O 0 0.0006291100871749222
region O 0 5.683778726961464e-05
2p13 O 1 0.9995607733726501
- O 1 0.5494969487190247
p16 O 0 0.0017039054073393345
. O 0 1.648875513637904e-05

Abnormal O 1 0.9999998807907104
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999929666519165
accumulation I-Disease 0 0.46361422538757324
is O 0 8.704338370080222e-07
recognized O 0 3.136550219551282e-07
as O 0 8.984026749203622e-07
an O 0 2.7509862775332294e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 1 0.6257691979408264
man O 1 0.9927893280982971
, O 0 1.3473821127263363e-05
mouse O 0 0.0019268611213192344
, O 0 9.600367775419727e-06
rat O 0 0.16286307573318481
and O 0 1.5547871953458525e-05
dog O 0 0.00697708036750555
. O 0 3.8523314287886024e-05

The O 0 5.673321720678359e-05
major O 0 9.851281356532127e-05
cause O 0 0.00012753193732351065
of O 0 0.006208131555467844
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999984502792358
accumulation I-Disease 1 0.9907213449478149
in O 0 6.470406788139371e-06
man O 0 1.5719713701400906e-05
is O 0 6.850277713965625e-07
a O 0 3.5131624827045016e-06
dysfunctional O 0 2.5857194486889057e-05
ATP7B O 0 0.1918865442276001
gene O 0 9.778203093446791e-06
, O 0 3.561468929547118e-06
causing O 0 0.006851894780993462
Wilson B-Disease 0 0.23463229835033417
disease I-Disease 1 0.998247504234314
( O 0 1.8779735910356976e-05
WD B-Disease 1 0.9689784049987793
) O 0 1.7792715880204923e-05
. O 0 1.1713082130881958e-05

Mutations O 0 6.579546607099473e-05
in O 0 5.0353319238638505e-06
the O 0 3.8888774724910036e-06
ATP7B O 0 7.759445725241676e-05
genes O 0 4.726505551388982e-07
have O 0 1.6881128317436378e-07
also O 0 2.1456713739098632e-07
been O 0 2.8727376388815173e-07
demonstrated O 0 1.3763124115939718e-06
in O 0 1.260263388758176e-06
mouse O 0 2.4185661459341645e-05
and O 0 1.1042249752790667e-05
rat O 0 0.12086561322212219
. O 0 2.7197360395803116e-05

The O 0 7.772577373543754e-05
ATP7B O 0 0.00104647153057158
gene O 0 4.2774458961503115e-06
has O 0 1.226864355885482e-06
been O 0 5.429434395409771e-07
excluded O 0 5.951171715423698e-07
in O 0 1.0327929800268976e-07
the O 0 1.2192113274522853e-07
much O 0 1.9713651511210628e-07
rarer O 0 1.441272434021812e-05
human O 0 0.00037085259100422263
copper B-Disease 1 0.9999998807907104
overload I-Disease 1 0.9999997615814209
disease O 1 0.9999929666519165
non B-Disease 0 0.04209413006901741
- I-Disease 0 0.005406469106674194
Indian I-Disease 0 6.800730261602439e-06
childhood I-Disease 0 0.000296100479317829
cirrhosis I-Disease 1 0.9999994039535522
, O 0 2.2338967937685084e-06
indicating O 0 4.887772956863046e-05
genetic O 0 2.8266298613743857e-05
heterogeneity O 0 0.0015788490418344736
. O 0 5.024251731811091e-05

By O 0 1.6596870409557596e-05
investigating O 0 1.2447945664462168e-05
the O 0 5.7381334954698104e-06
common O 0 1.3675601621798705e-05
autosomal O 1 0.9774706363677979
recessive O 1 0.9999954700469971
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 1.5822633940842934e-05
CT B-Disease 1 0.7033796310424805
) O 0 3.7599315305669734e-07
in O 0 4.2879895545411273e-07
Bedlington O 0 8.65866313688457e-05
terriers O 0 7.295321665878873e-06
, O 0 8.089725866966546e-08
we O 0 1.7600422452801467e-08
have O 0 2.1417251971911355e-08
identified O 0 8.225902803360441e-08
a O 0 1.2234789892318076e-07
new O 0 5.9310124811418063e-08
locus O 0 4.702143087342847e-06
involved O 0 7.698890271967684e-07
in O 0 3.934378764824942e-05
progressive O 1 0.9999998807907104
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.002286131028085947

We O 0 1.2293015061004553e-05
examined O 0 1.2515652997535653e-05
whether O 0 6.023205969540868e-07
the O 0 2.6015543426183285e-06
WD B-Disease 0 0.00044708052882924676
gene O 0 1.690091630734969e-05
ATP7B O 0 0.24629606306552887
was O 0 3.655445107142441e-05
also O 0 8.781848350736254e-07
causative O 0 9.722448339744005e-06
for O 0 9.67950882113655e-07
CT B-Disease 0 0.05239148065447807
by O 0 7.112009825505083e-07
investigating O 0 1.024184598463762e-06
the O 0 1.4806612398388097e-06
chromosomal O 1 0.9207710027694702
co O 1 0.6858933568000793
- O 0 0.023135999217629433
localization O 0 0.07155326753854752
of O 0 1.3498798580258153e-05
ATP7B O 0 0.006668201647698879
and O 0 5.391689796852006e-07
C04107 O 0 2.6101724870386533e-05
, O 0 1.635546311717917e-07
using O 0 8.601881518188748e-08
fluorescence O 0 1.5400300981127657e-06
in O 0 4.863165941060288e-07
situ O 0 1.2996427358302753e-05
hybridization O 0 3.52907204614894e-06
( O 0 1.24278790281096e-06
FISH O 0 8.208086910599377e-06
) O 0 1.243931023964251e-06
. O 0 5.4702413763152435e-06

C04107 O 0 0.0053246342577040195
is O 0 2.5368477508891374e-05
an O 0 6.2712329054193106e-06
anonymous O 0 2.0502371626207605e-05
microsatellite O 0 0.00023634078388568014
marker O 0 0.00015815909137018025
closely O 0 8.532646461389959e-06
linked O 0 7.899425690993667e-05
to O 0 1.2802054698113352e-05
CT B-Disease 1 0.998573899269104
. O 0 4.261425419826992e-05

However O 0 8.641488966532052e-05
, O 0 3.341061528772116e-05
BAC O 0 0.0005496808444149792
clones O 0 1.958100801857654e-05
containing O 0 4.654697477235459e-06
ATP7B O 0 0.0004080969956703484
and O 0 1.0218947181783733e-06
C04107 O 0 2.268005300720688e-05
mapped O 0 2.1209841634117765e-06
to O 0 3.033902657989529e-07
the O 0 1.8518991282689967e-06
canine O 0 5.364611206459813e-05
chromosome O 0 5.0714603275991976e-05
regions O 0 4.039941813971382e-06
CFA22q11 O 0 0.015301690436899662
and O 0 1.588118948347983e-06
CFA10q26 O 0 0.0005943393334746361
, O 0 3.7283987808223173e-07
respectively O 0 6.343736913549947e-07
, O 0 6.885108660981132e-08
demonstrating O 0 2.129103648940145e-07
that O 0 9.930700173299556e-08
WD B-Disease 0 1.6811427485663444e-05
cannot O 0 1.7629913884320558e-07
be O 0 2.607259546039131e-07
homologous O 0 1.686797759248293e-06
to O 0 3.931575065507786e-06
CT B-Disease 1 0.7801728248596191
. O 0 2.883615525206551e-05

The O 0 0.0001717383274808526
copper O 0 0.0010760572040453553
transport O 0 6.516386201838031e-05
genes O 0 2.6502570108277723e-05
CTR1 O 0 0.04627053812146187
and O 0 3.6071980957785854e-06
CTR2 O 0 0.0010339041473343968
were O 0 6.525469871121459e-07
also O 0 2.9849755378563714e-07
excluded O 0 5.695519575965591e-07
as O 0 1.8097337317612983e-07
candidate O 0 4.1058333977161965e-07
genes O 0 3.064353677473264e-07
for O 0 4.55250727782186e-07
CT B-Disease 0 0.0006408789195120335
since O 0 5.213192366682051e-07
they O 0 4.6874340853264584e-08
both O 0 8.94014107188923e-08
mapped O 0 1.4766858384973602e-06
to O 0 3.644438493211055e-07
canine O 0 0.0002310325944563374
chromosome O 0 0.03544013947248459
region O 0 0.00018082228780258447
CFA11q22 O 1 0.994647204875946
. O 0 5.105719537823461e-05

2 O 0 0.0008985054446384311
- O 0 0.0010878226021304727
22 O 0 0.00036783929681405425
. O 0 3.571566776372492e-05

5 O 0 0.0015185861848294735
. O 0 0.0003058786387555301

A O 0 0.00016542058438062668
transcribed O 0 4.06109138566535e-05
sequence O 0 9.593302820576355e-06
identified O 0 5.803906333312625e-06
from O 0 1.9708509171323385e-06
the O 0 2.982578962473781e-06
C04107 O 0 0.00016783042519818991
- O 0 1.1727612218237482e-05
containing O 0 1.692337491476792e-06
BAC O 0 3.255658157286234e-05
was O 0 3.123325541309896e-06
found O 0 8.203605972312289e-08
to O 0 2.545448296586983e-08
be O 0 3.164111817000048e-08
homologous O 0 8.541586282717617e-08
to O 0 5.6981882323725586e-08
a O 0 1.0414308917461312e-06
gene O 0 8.623506460025965e-07
expressed O 0 8.446572792308871e-07
from O 0 1.0312354561392567e-06
human O 0 2.8910244509461336e-06
chromosome O 0 0.22393058240413666
2p13 O 1 0.9605310559272766
- O 0 0.0016945531824603677
p16 O 0 3.412099613342434e-05
, O 0 1.0255553917204452e-07
a O 0 2.563559462487319e-07
region O 0 2.2648114850198908e-07
devoid O 0 1.1718931318682735e-06
of O 0 3.6141568671155255e-07
any O 0 2.647060171057092e-07
positional O 0 1.6911542843445204e-05
candidate O 0 1.0257671419822145e-05
genes O 0 1.0779939657368232e-05
. O 0 1.5117782822926529e-05

Molecular O 0 0.0014264854835346341
analysis O 0 2.0901810785289854e-05
of O 0 8.25827464723261e-06
the O 0 7.1110721364675555e-06
APC B-Disease 0 3.281229146523401e-05
gene O 0 9.838045116339345e-07
in O 0 7.569661875095335e-07
205 O 0 3.705672952492023e-06
families O 0 2.767455100638472e-07
: O 0 2.362810533895754e-07
extended O 0 3.066323188249953e-06
genotype O 0 1.32260656755534e-05
- O 0 1.7755559383658692e-05
phenotype O 0 9.31167414819356e-06
correlations O 0 2.076712235066225e-06
in O 0 4.845153398491675e-07
FAP B-Disease 0 4.975685897079529e-06
and O 0 3.7347042791679996e-08
evidence O 0 1.8947947921788e-07
for O 0 4.7085187304674037e-08
the O 0 1.92789613606692e-07
role O 0 7.175484597610193e-07
of O 0 6.013728580001043e-06
APC B-Disease 0 0.00018714694306254387
amino O 0 1.950556224983302e-06
acid O 0 7.602695859532105e-07
changes O 0 6.940153980394825e-07
in O 0 0.0002900983381550759
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999997615814209
. O 0 0.0004971985472366214

BACKGROUND O 0 0.002693132497370243
/ O 0 0.0005637669237330556
AIMS O 0 3.394803570699878e-05
The O 0 4.603677098202752e-06
development O 0 1.1031051144527737e-05
of O 0 0.0039836335927248
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.529213136564067e-06
a O 0 3.175943447786267e-06
variable O 0 1.6128111610669293e-06
range O 0 5.425127937996876e-07
of O 0 2.5647088932601037e-06
extracolonic O 0 0.004238605499267578
manifestations O 0 0.00025984039530158043
in O 0 7.77219065639656e-06
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9574418663978577
FAP B-Disease 1 0.9999550580978394
) O 0 6.107110266384552e-07
is O 0 1.9375839599433675e-07
the O 0 1.8619172692524444e-07
result O 0 1.880425912759165e-07
of O 0 4.923857090943784e-07
the O 0 1.2169801948402892e-06
dominant O 0 5.372706709749764e-06
inheritance O 0 1.6462374333059415e-05
of O 0 0.0008925547008402646
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.10932163894176483
APC B-Disease 1 0.9461286067962646
) O 0 4.1467919800197706e-06
gene O 0 1.4968841242080089e-05
mutations O 0 5.0753107643686235e-05
. O 0 3.759562605409883e-05

In O 0 9.599634722690098e-06
this O 0 4.6297765265990165e-07
study O 0 3.6859736951555533e-07
, O 0 9.258284450197607e-08
direct O 0 3.634203267210978e-07
mutation O 0 9.79956894298084e-07
analysis O 0 6.583514391422796e-07
of O 0 7.841733804525575e-07
the O 0 2.5857116270344704e-06
APC B-Disease 0 1.3978574315842707e-05
gene O 0 5.684271400241414e-07
was O 0 5.48547541256994e-06
performed O 0 7.266314696607878e-07
to O 0 1.6889116238871793e-07
determine O 0 7.700123774156964e-07
genotype O 0 0.000147066981298849
- O 0 0.002311372198164463
phenotype O 0 2.859598862414714e-05
correlations O 0 3.4966401472047437e-06
for O 0 4.479081496810977e-07
nine O 0 1.3218195817898959e-06
extracolonic O 0 2.1590540200122632e-05
manifestations O 0 7.614736205141526e-06
and O 0 1.642347058350424e-07
to O 0 7.348463526568594e-08
investigate O 0 3.3424052503505663e-07
the O 0 1.3496342035068665e-06
incidence O 0 0.0017569027841091156
of O 0 8.090301889751572e-06
APC B-Disease 0 2.0579629563144408e-05
mutations O 0 9.300209740104037e-07
in O 0 3.0212556794140255e-06
non O 0 0.22874484956264496
- O 1 0.999998927116394
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00016946664254646748

METHODS O 0 0.0002495282969903201
The O 0 3.499360536807217e-05
APC B-Disease 0 6.314826896414161e-05
gene O 0 2.0750335352204274e-06
was O 0 6.894346824992681e-06
analysed O 0 1.4830621921646525e-06
in O 0 4.2221461171720875e-07
190 O 0 2.214087089669192e-06
unrelated O 0 1.8901326939158025e-06
FAP B-Disease 0 1.378417346131755e-05
and O 0 3.1775081765772484e-07
15 O 0 6.337402737699449e-06
non O 0 0.022384358569979668
- O 1 0.999998927116394
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.6208809837698936e-05
using O 0 2.825349611157435e-06
denaturing O 0 0.0019872216507792473
gradient O 0 0.00403273431584239
gel O 0 2.3578821128467098e-05
electrophoresis O 0 9.05775414139498e-06
, O 0 3.666970656013291e-07
the O 0 2.642117067352956e-07
protein O 0 7.445656251547916e-07
truncation O 0 1.2596033229783643e-05
test O 0 3.638121768290148e-07
, O 0 1.5090094507286267e-07
and O 0 1.3162942025246593e-07
direct O 0 2.8349772946967278e-06
sequencing O 0 3.6127701605437323e-05
. O 0 1.073941803042544e-05

RESULTS O 0 0.0007264771265909076
Chain O 0 7.199628453236073e-05
terminating O 0 1.8443295630277134e-05
signals O 0 9.463634341955185e-06
were O 0 8.373403943551239e-07
only O 0 1.5484641835428192e-07
identified O 0 4.873165835306281e-07
in O 0 5.184451197237649e-07
patients O 0 5.482800133904675e-07
belonging O 0 1.1961717518715886e-06
to O 0 1.914867908681117e-07
the O 0 3.2250065942207584e-06
FAP B-Disease 0 0.00012012111983494833
group O 0 6.116248982834804e-07
( O 0 4.879625521425623e-07
105 O 0 7.296365765796509e-06
patients O 0 1.6438496004411718e-06
) O 0 3.247676431783475e-06
. O 0 9.469954420637805e-06

Amino O 0 0.00029142701532691717
acid O 0 1.7449794540880248e-05
changes O 0 1.1189098358954652e-06
were O 0 9.332942454420845e-07
identified O 0 4.5723263042418694e-07
in O 0 2.8788588224415435e-07
four O 0 3.6724929941556184e-07
patients O 0 4.5498424583456654e-07
, O 0 2.5390266955582774e-07
three O 0 2.358996624707288e-07
of O 0 1.2327202512096846e-06
whom O 0 4.988805812899955e-07
belonged O 0 2.152624574591755e-06
to O 0 1.5064644287576812e-07
the O 0 1.5793513057360542e-06
non O 0 0.0004451859276741743
- O 0 0.018453579396009445
FAP O 0 0.004982809070497751
group O 0 2.1758730781584745e-06
of O 0 0.15646253526210785
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.8282705545425415
. O 0 9.815190423978493e-05

Genotype O 0 0.07328058779239655
- O 0 0.0013378857402130961
phenotype O 0 0.00013284328451845795
correlations O 0 1.7091349945985712e-05
identified O 0 8.864908522809856e-07
significant O 0 1.7156389731098898e-07
differences O 0 1.09083423183165e-07
in O 0 1.4900811606821662e-07
the O 0 1.8915991972789925e-07
nature O 0 2.0506736575498508e-07
of O 0 7.959368986121262e-07
certain O 0 4.0229494402410637e-07
extracolonic O 0 0.0002984562888741493
manifestations O 0 9.233250602846965e-05
in O 0 4.705413175543072e-06
FAP B-Disease 0 0.0005509350448846817
patients O 0 2.0277296641779685e-07
belonging O 0 3.483824571048899e-07
to O 0 7.506402255330613e-08
three O 0 6.803771839258843e-07
mutation O 0 2.8378764909575693e-05
subgroups O 0 0.00019220879767090082
. O 0 2.999943717441056e-05

CONCLUSIONS O 0 0.0009382868302054703
Extended O 0 0.00023056648205965757
genotype O 0 0.000601542298682034
- O 0 0.00022841800819151103
phenotype O 0 5.379314097808674e-05
correlations O 0 7.109559646778507e-06
made O 0 4.910992856821395e-07
in O 0 1.7568903842857253e-07
this O 0 2.4244403817874627e-08
study O 0 9.726000627097164e-08
may O 0 6.029860344369808e-08
have O 0 1.463396248624349e-08
the O 0 3.612240107031539e-08
potential O 0 7.284313596755965e-08
to O 0 2.517751518382738e-08
determine O 0 5.2950205997603916e-08
the O 0 1.6813872605325741e-07
most O 0 3.8090618659225584e-08
appropriate O 0 1.0693234742120694e-07
surveillance O 0 5.636784408125095e-06
and O 0 1.149928152699431e-06
prophylactic O 1 0.9999872446060181
treatment O 0 0.4366108477115631
regimens O 0 2.423812293272931e-05
for O 0 1.433672309758549e-07
those O 0 7.588094064203688e-08
patients O 0 9.403597545087905e-08
with O 0 8.09446447647133e-08
mutations O 0 2.3516070086770924e-06
associated O 0 1.5939333479764173e-06
with O 0 2.6472775971342344e-07
life O 0 9.893028618535027e-06
threatening O 0 0.0001185268338304013
conditions O 0 0.00012139514001319185
. O 0 1.972630161617417e-05

This O 0 7.694377018196974e-06
study O 0 2.526676553316065e-06
also O 0 4.874109436059371e-07
provided O 0 3.3355112805111276e-07
evidence O 0 2.585790639386687e-07
for O 0 2.781398791285028e-07
the O 0 1.4013112377142534e-06
pathological O 0 0.10532068461179733
nature O 0 7.272128186741611e-06
of O 0 3.7783567677251995e-05
amino O 0 4.396137683215784e-06
acid O 0 1.4596477058148594e-06
changes O 0 1.784176077990196e-07
in O 0 8.382176019949839e-07
APC O 0 1.053570940712234e-05
associated O 0 2.0285034452172113e-07
with O 0 3.9552865871428367e-08
both O 0 2.1605293909487955e-07
FAP B-Disease 0 6.38910714769736e-05
and O 0 9.658484714236693e-07
non O 1 0.9859994053840637
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.003858459647744894
. O 0 3.0397811769944383e-06
. O 0 7.703158189542592e-06

Inherited B-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.993725597858429
cancer B-Disease 1 1.0
risk O 0 0.1678086370229721
of O 0 0.00031383478199131787
the O 0 0.00024058597045950592
APC O 0 0.0016411000397056341
I1307K O 0 0.000862675893586129
polymorphism O 0 0.000325010740198195
. O 0 3.157204628223553e-05

Germ O 1 0.9999842643737793
- O 0 0.010548979975283146
line O 0 3.267514694016427e-05
and O 0 7.464005875590374e-07
somatic O 0 1.238905042555416e-05
truncating O 0 1.0016615306085441e-05
mutations O 0 6.917885002621915e-07
of O 0 9.503604019300838e-07
the O 0 1.5631308087904472e-06
APC B-Disease 0 6.054441655578557e-06
gene O 0 1.0983878695469684e-07
are O 0 1.2336131227641545e-08
thought O 0 7.590178086047672e-08
to O 0 8.352223090923871e-08
initiate O 0 0.00010483506775926799
colorectal B-Disease 1 1.0
tumor I-Disease 1 1.0
formation O 0 0.0007657532696612179
in O 0 4.3073690903838724e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9999819993972778
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 0.0014703156193718314
respectively O 0 0.00036176550202071667
. O 0 2.0553507056320086e-05

Recently O 0 0.0006382287247106433
, O 0 2.913493699452374e-05
an O 0 4.43343524239026e-05
isoleucine O 0 0.3005247414112091
- O 0 0.003476581536233425
- O 0 0.001769213704392314
> O 0 4.381117469165474e-05
lysine O 0 5.425074050435796e-06
polymorphism O 0 2.166472768294625e-06
at O 0 2.936963028332684e-06
codon O 0 5.470700671139639e-06
1307 O 0 1.2388223694870248e-05
( O 0 5.872914812243835e-07
I1307K O 0 3.7107656680746004e-06
) O 0 6.588602730062121e-08
of O 0 2.814086030866747e-07
the O 0 8.463126732749515e-07
APC B-Disease 0 4.243903276801575e-06
gene O 0 1.759207464147039e-07
has O 0 1.5474662973247177e-07
been O 0 3.57923852334352e-07
identified O 0 2.443283904085547e-07
in O 0 2.0595518890331732e-07
6 O 0 1.3321829328560852e-06
% O 0 2.830201992765069e-07
- O 0 1.840174377321091e-06
7 O 0 8.654558314447058e-07
% O 0 1.4070074882965855e-07
of O 0 4.541995508589025e-07
the O 0 1.3654508848048863e-06
Ashkenazi O 0 5.656655503116781e-06
Jewish O 0 3.6923595416737953e-06
population O 0 1.8813027509168023e-06
. O 0 5.999316726956749e-06

To O 0 1.119312128139427e-05
assess O 0 1.0526068763283547e-05
the O 0 2.930357595687383e-06
risk O 0 3.273822585470043e-06
of O 0 8.168060503521701e-07
this O 0 5.353667233976012e-07
common O 0 1.5642403923266102e-06
APC B-Disease 0 2.0354911612230353e-05
allelic O 0 9.935862181009725e-06
variant O 0 5.496823177963961e-06
in O 0 7.30393321646261e-06
colorectal O 1 1.0
carcinogenesis O 1 0.9999842643737793
, O 0 4.709726795226743e-07
we O 0 4.668465081181239e-08
have O 0 1.789642212202125e-08
analyzed O 0 1.3858915792752668e-07
a O 0 1.6442244543668494e-07
large O 0 3.2536610206079786e-07
cohort O 0 9.079435585590545e-06
of O 0 1.0030065595856286e-06
unselected O 0 0.000244313181610778
Ashkenazi O 0 8.009266821318306e-06
Jewish O 0 1.6798819615360117e-06
subjects O 0 1.6046157043092535e-06
with O 0 7.007780595813529e-07
adenomatous B-Disease 1 0.9949789643287659
polyps I-Disease 1 0.9994885921478271
and O 0 2.100420260831015e-06
. O 0 2.0809191028092755e-06
or O 1 0.9966132044792175
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.3946522813057527e-05
for O 0 1.4880349681334337e-06
the O 0 2.91826236207271e-05
APC O 0 0.0005066943704150617
I1307K O 0 0.0008229821687564254
polymorphism O 0 0.00038211134960874915
. O 0 5.768959454144351e-05

The O 0 0.0002519026747904718
APC O 0 0.0008692730334587395
I1307K O 0 0.0003732732147909701
allele O 0 2.6833127776626498e-05
was O 0 2.17151809920324e-05
identified O 0 1.2952732504345477e-06
in O 0 7.882342174525547e-07
48 O 0 1.4689019280922366e-06
( O 0 2.2438416635850444e-07
10 O 0 1.7356536829993274e-07
. O 0 5.87058579526456e-08
1 O 0 2.912499894591747e-07
% O 0 1.8486227304492786e-07
) O 0 1.7042923161625367e-07
of O 0 1.7950610526895616e-06
476 O 0 0.00018362165428698063
patients O 0 1.1853941941808444e-05
. O 0 1.412488109053811e-05

Compared O 0 3.110938996542245e-05
with O 0 3.442317506596737e-07
the O 0 4.6772262862759817e-07
frequency O 0 5.032822514294821e-07
in O 0 6.542830277567191e-08
two O 0 1.541138594518543e-08
separate O 0 1.3156311595707848e-08
population O 0 2.869368920244142e-08
control O 0 2.819786573127203e-07
groups O 0 5.96166813693344e-08
, O 0 2.2636756114025047e-07
the O 0 1.5710037359895068e-06
APC O 0 5.1982591685373336e-05
I1307K O 0 3.498029400361702e-05
allele O 0 1.6279583405776066e-06
is O 0 2.1227455704320164e-07
associated O 0 1.3651160202243773e-07
with O 0 2.4746549698306808e-08
an O 0 2.3560467354855064e-07
estimated O 0 4.756172415909532e-07
relative O 0 2.473532731528394e-06
risk O 0 1.1006146678482764e-06
of O 0 3.682920805658796e-06
1 O 0 2.231732287327759e-05
. O 0 1.1832346899609547e-05

5 O 0 0.0008028310257941484
- O 0 0.0007086877594701946
1 O 0 0.0001451631251256913
. O 0 5.137955668033101e-05

7 O 0 0.00046764666331000626
for O 0 7.619702228112146e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999923706054688
( O 0 1.4658829059044365e-05
both O 0 4.5612305257236585e-06
P O 0 0.0016715131932869554
= O 0 1.337597132078372e-05
. O 0 1.5808055877641891e-06
01 O 0 9.018091805046424e-05
) O 0 3.887305410898989e-06
. O 0 1.1936799637624063e-05

Furthermore O 0 0.00018583695054985583
, O 0 6.66996947984444e-06
compared O 0 6.509776994789718e-06
with O 0 7.053628792164091e-07
noncarriers O 0 0.00045418553054332733
, O 0 5.736213097407017e-06
APC O 0 5.8285480918129906e-05
I1307K O 0 2.6224755856674165e-05
carriers O 0 3.2581201026005147e-07
had O 0 5.220799721428193e-07
increased O 0 8.388901733269449e-07
numbers O 0 4.604141849995358e-07
of O 0 4.8062515816127416e-06
adenomas B-Disease 1 0.9986639022827148
and O 0 1.787591645552311e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999984502792358
per O 0 6.28839188721031e-05
patient O 0 3.0123428587103263e-05
( O 0 2.3848908767831745e-06
P O 0 0.0002653787669260055
= O 0 2.231661028417875e-06
. O 0 2.0157314395419235e-07
03 O 0 1.4226513485482428e-05
) O 0 9.526937105874822e-08
, O 0 5.3153897283664264e-08
as O 0 8.404398954553471e-08
well O 0 8.093940095932339e-08
as O 0 2.887638856918784e-07
a O 0 1.1322720183670754e-06
younger O 0 2.0261188637960004e-06
age O 0 5.651090759783983e-06
at O 0 0.00020986248273402452
diagnosis O 0 0.2969372868537903
. O 0 2.5078552425839007e-05

We O 0 1.4175294381857384e-05
conclude O 0 1.800634345272556e-05
that O 0 1.99287183022534e-06
the O 0 7.803377229720354e-06
APC O 0 9.986953955376521e-05
I1307K O 0 6.810214836150408e-05
variant O 0 6.1809532780898735e-06
leads O 0 2.8048739295627456e-06
to O 0 5.538976211028057e-07
increased O 0 0.0008367230766452849
adenoma B-Disease 1 1.0
formation O 0 8.70930580276763e-06
and O 0 4.1924829474737635e-07
directly O 0 2.4045397140071145e-07
contributes O 0 3.081850366015715e-07
to O 0 5.451267526268566e-08
3 O 0 5.444076691674127e-07
% O 0 2.9881513796681247e-07
- O 0 1.3801030718241236e-06
4 O 0 4.982881591786281e-07
% O 0 8.954629748814114e-08
of O 0 2.721965302043827e-07
all O 0 4.290386357297393e-07
Ashkenazi O 0 0.014733410440385342
Jewish O 1 0.9952254295349121
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00017093453789129853

The O 0 1.892258478619624e-05
estimated O 0 5.380649781727698e-06
relative O 0 1.1177867236256134e-05
risk O 0 3.765428573387908e-06
for O 0 3.6227493183105253e-07
carriers O 0 7.849133680792875e-07
may O 0 6.98326914516656e-07
justify O 0 8.309897339131567e-07
specific O 0 9.798263533866702e-08
clinical O 0 3.367715635249624e-06
screening O 0 4.307441372475296e-07
for O 0 1.3797777853596926e-07
the O 0 5.53478912479477e-07
360 O 0 5.56122756734112e-07
, O 0 6.042997569011277e-08
000 O 0 5.240843279352703e-07
Americans O 0 6.148988518361875e-08
expected O 0 1.0150969842470658e-07
to O 0 3.488984035016074e-08
harbor O 0 4.464600351639092e-06
this O 0 5.658947799247471e-08
allele O 0 2.897904209930857e-07
, O 0 4.1982879395163764e-08
and O 0 1.8263603962509478e-08
genetic O 0 1.2134299254284997e-07
testing O 0 2.568860395513184e-07
in O 0 1.636106361502243e-07
the O 0 2.459470920257445e-07
setting O 0 4.4090344886171806e-07
of O 0 1.110864445763582e-06
long O 0 6.04183878749609e-06
- O 0 1.7687603758531623e-05
term O 0 6.041290816938272e-06
- O 0 8.287886998914473e-07
outcome O 0 1.0803179151253062e-07
studies O 0 2.3411566019149177e-07
may O 0 9.485921736995806e-08
impact O 0 3.24539286111758e-07
significantly O 0 1.558201347506838e-06
on O 0 0.010127246379852295
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.017372138798236847
in O 0 4.467379710604291e-07
this O 0 3.982740963692777e-07
population O 0 1.249702677341702e-06
. O 0 5.007318122807192e-06

Localization O 0 0.0018251053988933563
of O 0 1.974513907043729e-05
human O 0 4.498092948779231e-06
BRCA1 O 0 3.373625804670155e-05
and O 0 1.2877379731435212e-06
its O 0 1.2531623951872461e-06
loss O 0 3.0325451007229276e-05
in O 0 3.36529478772718e-06
high O 0 0.42614346742630005
- O 0 0.007713145576417446
grade O 0 0.002991334069520235
, O 0 2.280603894178057e-06
non B-Disease 0 0.49730515480041504
- I-Disease 1 0.9999244213104248
inherited I-Disease 1 0.9999996423721313
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.001163856708444655

Although O 0 7.957433808769565e-06
the O 0 3.189955350535456e-06
link O 0 4.9143191063194536e-06
between O 0 1.5949400449244422e-06
the O 0 1.0890295925491955e-05
BRCA1 O 1 0.9998526573181152
tumour B-Disease 1 1.0
- O 1 0.9999996423721313
suppressor O 1 1.0
gene O 0 1.4015266970091034e-05
and O 0 8.497146154695656e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 8.602014531788882e-06
established O 0 1.241655468220415e-06
, O 0 9.574061721195903e-08
the O 0 2.446632265673543e-07
role O 0 5.532519935513847e-07
, O 0 1.587999491903247e-07
if O 0 2.441280066989293e-08
any O 0 4.4154049305689114e-08
, O 0 1.224559866841446e-07
of O 0 7.191460440481023e-07
BRCA1 O 0 3.3252417779294774e-05
in O 0 5.2101881919952575e-06
non B-Disease 1 0.7698082327842712
- I-Disease 1 0.9942335486412048
familial I-Disease 1 0.9998818635940552
cancers I-Disease 1 1.0
is O 0 0.00034810378565452993
unclear O 0 2.2832218746771105e-05
. O 0 1.3902554201195017e-05

BRCA1 O 0 0.0010952189331874251
mutations O 0 1.6536941984668374e-05
are O 0 4.253670908838103e-07
rare O 0 8.039916110647027e-07
in O 0 6.344571943373012e-07
sporadic B-Disease 0 9.10840681171976e-05
cancers I-Disease 1 0.9961379170417786
, O 0 5.851246100974095e-07
but O 0 5.402720759661861e-08
loss O 0 2.416805273242062e-06
of O 0 2.300023652423988e-06
BRCA1 O 0 0.00010826263314811513
resulting O 0 1.7180051145260222e-05
from O 0 2.7647165552480146e-06
reduced O 0 2.30208434004453e-06
expression O 0 1.3908185110267368e-06
or O 0 7.970003252921742e-07
incorrect O 0 9.928709914674982e-06
subcellular O 0 0.00010585780546534806
localization O 0 1.239399080077419e-05
is O 0 1.1298519098090765e-07
postulated O 0 5.121495405546739e-07
to O 0 1.738538912832155e-08
be O 0 3.676648674399985e-08
important O 0 9.712560000707526e-08
in O 0 4.6579430090787355e-07
non B-Disease 0 7.410145917674527e-05
- I-Disease 1 0.5379077792167664
familial I-Disease 1 0.9999678134918213
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.8179380297660828

Epigenetic O 0 0.005709473509341478
loss O 0 0.00030624482315033674
, O 0 5.7449783525953535e-06
however O 0 9.326179792878975e-07
, O 0 1.9356262725978013e-07
has O 0 1.0307659437103212e-07
not O 0 3.200261389224579e-08
received O 0 2.9856104788450466e-07
general O 0 4.724649045328988e-07
acceptance O 0 8.433992206846597e-07
due O 0 1.1552923524504877e-06
to O 0 1.2631087997760915e-07
controversy O 0 1.9147596503898967e-06
regarding O 0 1.1595485602811095e-06
the O 0 1.4879667560308008e-06
subcellular O 0 7.688363257329911e-05
localization O 0 1.9943145161960274e-05
of O 0 1.3647570540342713e-06
BRCA1 O 0 6.223776836122852e-06
proteins O 0 5.42358691291156e-07
, O 0 2.466635180553567e-07
reports O 0 3.6640483358496567e-07
of O 0 3.077439032495022e-07
which O 0 1.4958659733110835e-07
have O 0 8.617055158310905e-08
ranged O 0 2.051095179922413e-06
from O 0 2.847539803951804e-07
exclusively O 0 2.851189151442668e-07
nuclear O 0 2.4225696506618988e-06
, O 0 1.2455889475404547e-07
to O 0 7.517104450016632e-08
conditionally O 0 2.0123425201745704e-06
nuclear O 0 2.4929665869422024e-06
, O 0 2.8936457852069e-07
to O 0 1.8377632216015627e-07
the O 0 3.9766259760654066e-06
ER O 1 0.9686092138290405
/ O 0 0.0005228100344538689
golgi O 0 0.27773967385292053
, O 0 9.883635812002467e-07
to O 0 6.556796847689839e-07
cytoplasmic O 0 2.1590643882518634e-05
invaginations O 0 0.00010105204273713753
into O 0 1.7512708154754364e-06
the O 0 7.444509719789494e-06
nucleus O 0 4.761830496136099e-05
. O 0 1.99991773115471e-05

In O 0 1.479860111430753e-05
an O 0 2.488315658411011e-06
attempt O 0 1.8927806877400144e-06
to O 0 3.00684689591435e-07
resolve O 0 8.281866712422925e-07
this O 0 1.970350069768756e-07
issue O 0 2.940478509572131e-07
, O 0 6.398133223228797e-08
we O 0 5.5983981894769386e-08
have O 0 9.09118682557164e-08
comprehensively O 0 4.311141765356297e-06
characterized O 0 7.728353011771105e-06
19 O 0 3.927817670046352e-05
anti O 0 0.0002518325636629015
- O 0 0.0003506180364638567
BRCA1 O 0 0.00013594400661531836
antibodies O 0 5.494561992236413e-05
. O 0 3.700784145621583e-05

These O 0 1.3805157323076855e-05
reagents O 0 6.433561793528497e-05
detect O 0 2.134041096724104e-05
a O 0 1.4899027519277297e-05
220 O 0 2.436790964566171e-05
- O 0 2.4820425096550025e-05
kD O 0 5.499930557562038e-05
protein O 0 1.2524037629191298e-06
localized O 0 7.513549462601077e-07
in O 0 1.9007238449830766e-07
discrete O 0 7.181405976552924e-07
nuclear O 0 2.4743585527176037e-06
foci O 0 6.168245363369351e-06
in O 0 1.2689476136529265e-07
all O 0 6.053044643294925e-08
epithelial O 0 0.00035215247771702707
cell O 0 0.00014523844583891332
lines O 0 6.136569936643355e-07
, O 0 4.256778751710044e-08
including O 0 4.408286002899331e-08
those O 0 6.354532899877086e-08
derived O 0 2.1386326807260048e-06
from O 0 1.640018126636278e-05
breast B-Disease 1 0.9996384382247925
malignancies I-Disease 1 0.9997662901878357
. O 0 9.801842679735273e-05

Immunohistochemical O 0 0.4797203242778778
staining O 0 0.002400841098278761
of O 0 3.425215618335642e-05
human O 0 4.196773443254642e-05
breast O 1 0.8316623568534851
specimens O 0 1.7925063730217516e-05
also O 0 2.3583986603625817e-06
revealed O 0 1.553429501655046e-05
BRCA1 O 0 0.0006405301974155009
nuclear O 0 0.0014050980098545551
foci O 1 0.7271652817726135
in O 0 1.3680676602234598e-05
benign O 1 0.9999982118606567
breast O 1 0.9999399185180664
, O 0 2.1634463337250054e-05
invasive B-Disease 1 0.9999985694885254
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 0.018603749573230743
low B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999370574951172
grade I-Disease 1 0.9997535347938538
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00022501949570141733

Conversely O 0 0.000281867163721472
, O 0 7.750828444841318e-06
BRCA1 O 0 4.291502045816742e-05
expression O 0 8.058945240918547e-06
was O 0 3.184971501468681e-05
reduced O 0 2.8386727990437066e-06
or O 0 2.8892640102640144e-07
undetectable O 0 4.358583737484878e-06
in O 0 1.20129172387351e-07
the O 0 1.3092906669953663e-07
majority O 0 3.9912613658543705e-08
of O 0 1.1663572649922571e-06
high O 0 0.010432442650198936
- O 0 0.000269438314717263
grade O 0 0.00014335523883346468
, O 0 2.6983807401848026e-06
ductal B-Disease 1 0.9999997615814209
carcinomas I-Disease 1 1.0
, O 0 1.7293796190642752e-06
suggesting O 0 1.1647089195321314e-06
that O 0 9.001687573118033e-08
absence O 0 9.04949104096886e-07
of O 0 8.724192639419925e-07
BRCA1 O 0 2.1255898900562897e-05
may O 0 1.1544200333446497e-06
contribute O 0 9.577130555271651e-08
to O 0 5.354443288752009e-08
the O 0 3.167487534483371e-07
pathogenesis O 0 1.7291740732616745e-05
of O 0 9.530499767151923e-08
a O 0 1.7774101479517412e-07
significant O 0 1.022434332753619e-07
percentage O 0 7.030593565104937e-07
of O 0 1.1965140629399684e-06
sporadic B-Disease 0 0.031105179339647293
breast I-Disease 1 0.999998927116394
cancers I-Disease 1 0.9999992847442627
. O 0 1.8271486624144018e-05
. O 0 2.5329220079584047e-05

